{"docstore/data": {"9861564a-b70a-45d1-a8d3-440b2bf43b82": {"__data__": {"id_": "9861564a-b70a-45d1-a8d3-440b2bf43b82", "embedding": null, "metadata": {"window": " \nPage 1 of 15 \n \nQ3 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 5 , 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Third  Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to  turn the \nconference over to Kevin Moran, Vice President of Investor Relations. ", "original_text": " \nPage 1 of 15 \n \nQ3 FY22 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3347ad46b125d39ae7d6ac6577ef96306bd677cbd518da4b3f5f10887f54fadb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6aab3612-657c-4607-a81f-37c18078577a", "node_type": "1", "metadata": {"window": " \nPage 1 of 15 \n \nQ3 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 5 , 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Third  Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to  turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n", "original_text": "Earnings \nConference Call  \nMay 5 , 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Third  Quarter Fiscal Year 2022 \nEarnings Conference Call. "}, "hash": "df5f21f48addffb6e28e6c7642d6013b642a43abe5e28c27cd51cff8ac0100a0", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 1 of 15 \n \nQ3 FY22 Cardinal Health, Inc. ", "start_char_idx": 0, "end_char_idx": 48, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6aab3612-657c-4607-a81f-37c18078577a": {"__data__": {"id_": "6aab3612-657c-4607-a81f-37c18078577a", "embedding": null, "metadata": {"window": " \nPage 1 of 15 \n \nQ3 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 5 , 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Third  Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to  turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n", "original_text": "Earnings \nConference Call  \nMay 5 , 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Third  Quarter Fiscal Year 2022 \nEarnings Conference Call. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3347ad46b125d39ae7d6ac6577ef96306bd677cbd518da4b3f5f10887f54fadb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9861564a-b70a-45d1-a8d3-440b2bf43b82", "node_type": "1", "metadata": {"window": " \nPage 1 of 15 \n \nQ3 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 5 , 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Third  Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to  turn the \nconference over to Kevin Moran, Vice President of Investor Relations. ", "original_text": " \nPage 1 of 15 \n \nQ3 FY22 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "896c4d285aa7ce61f1985027707432093454d76d12bf4cd8188d9394c287e2cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1e0f3ba3-6964-427c-bec0-c65bf3161363", "node_type": "1", "metadata": {"window": " \nPage 1 of 15 \n \nQ3 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 5 , 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Third  Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to  turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:   Good morning. ", "original_text": "Today's conference is being recorded. "}, "hash": "92ec9fbb775b94120e196964538a491bac0e3dd1c1c0b2f49bf705dd108dc40e", "class_name": "RelatedNodeInfo"}}, "text": "Earnings \nConference Call  \nMay 5 , 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Third  Quarter Fiscal Year 2022 \nEarnings Conference Call. ", "start_char_idx": 48, "end_char_idx": 232, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1e0f3ba3-6964-427c-bec0-c65bf3161363": {"__data__": {"id_": "1e0f3ba3-6964-427c-bec0-c65bf3161363", "embedding": null, "metadata": {"window": " \nPage 1 of 15 \n \nQ3 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 5 , 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Third  Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to  turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:   Good morning. ", "original_text": "Today's conference is being recorded. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3347ad46b125d39ae7d6ac6577ef96306bd677cbd518da4b3f5f10887f54fadb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6aab3612-657c-4607-a81f-37c18078577a", "node_type": "1", "metadata": {"window": " \nPage 1 of 15 \n \nQ3 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 5 , 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Third  Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to  turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n", "original_text": "Earnings \nConference Call  \nMay 5 , 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Third  Quarter Fiscal Year 2022 \nEarnings Conference Call. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f47fb36442ac3649331587b194a153dfd850454af4a8a5eb364cd6341a961cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5451f15-5a39-40a1-8060-d001bc39b9eb", "node_type": "1", "metadata": {"window": " \nPage 1 of 15 \n \nQ3 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 5 , 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Third  Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to  turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:   Good morning.  Today, we will discuss Cardinal Health  Third  Quarter Fiscal 2022 \nresults along with an update to our FY  \u201822 outlook. ", "original_text": "At this time, I would like to  turn the \nconference over to Kevin Moran, Vice President of Investor Relations. "}, "hash": "8d299b6aaaea2f45366053779d4a9a267b323e7a43f0bbf16857cf55e2407950", "class_name": "RelatedNodeInfo"}}, "text": "Today's conference is being recorded. ", "start_char_idx": 232, "end_char_idx": 270, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5451f15-5a39-40a1-8060-d001bc39b9eb": {"__data__": {"id_": "f5451f15-5a39-40a1-8060-d001bc39b9eb", "embedding": null, "metadata": {"window": " \nPage 1 of 15 \n \nQ3 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 5 , 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Third  Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to  turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:   Good morning.  Today, we will discuss Cardinal Health  Third  Quarter Fiscal 2022 \nresults along with an update to our FY  \u201822 outlook. ", "original_text": "At this time, I would like to  turn the \nconference over to Kevin Moran, Vice President of Investor Relations. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3347ad46b125d39ae7d6ac6577ef96306bd677cbd518da4b3f5f10887f54fadb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1e0f3ba3-6964-427c-bec0-c65bf3161363", "node_type": "1", "metadata": {"window": " \nPage 1 of 15 \n \nQ3 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 5 , 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Third  Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to  turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:   Good morning. ", "original_text": "Today's conference is being recorded. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ddca16fc98f853ec356973b592734084a60e4095483ecc4dec1c241bc5eb7ca8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b12e7571-47d5-4063-88a8-bec0885ac20a", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nMay 5 , 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Third  Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to  turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:   Good morning.  Today, we will discuss Cardinal Health  Third  Quarter Fiscal 2022 \nresults along with an update to our FY  \u201822 outlook.  You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com. ", "original_text": "Please go ahead.  \n \n"}, "hash": "d6d6df152cf395b83d602fbf4499fff79bbd1b6bcd50e43a9855dc40ac24c724", "class_name": "RelatedNodeInfo"}}, "text": "At this time, I would like to  turn the \nconference over to Kevin Moran, Vice President of Investor Relations. ", "start_char_idx": 270, "end_char_idx": 381, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b12e7571-47d5-4063-88a8-bec0885ac20a": {"__data__": {"id_": "b12e7571-47d5-4063-88a8-bec0885ac20a", "embedding": null, "metadata": {"window": "Earnings \nConference Call  \nMay 5 , 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Third  Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to  turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:   Good morning.  Today, we will discuss Cardinal Health  Third  Quarter Fiscal 2022 \nresults along with an update to our FY  \u201822 outlook.  You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com. ", "original_text": "Please go ahead.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3347ad46b125d39ae7d6ac6577ef96306bd677cbd518da4b3f5f10887f54fadb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5451f15-5a39-40a1-8060-d001bc39b9eb", "node_type": "1", "metadata": {"window": " \nPage 1 of 15 \n \nQ3 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 5 , 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Third  Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to  turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:   Good morning.  Today, we will discuss Cardinal Health  Third  Quarter Fiscal 2022 \nresults along with an update to our FY  \u201822 outlook. ", "original_text": "At this time, I would like to  turn the \nconference over to Kevin Moran, Vice President of Investor Relations. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "be3be9d8495a337032fcd476b76dbea6e53914033be0ff7e5526fbcb020a03a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "226dbb9b-725a-4dac-9307-f6fb78c81a4d", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  At this time, I would like to  turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:   Good morning.  Today, we will discuss Cardinal Health  Third  Quarter Fiscal 2022 \nresults along with an update to our FY  \u201822 outlook.  You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n", "original_text": "Kevin Moran:   Good morning. "}, "hash": "756e1060fbda82a063f1381555a520b645e744d64f37dbfa295a6a5f325c57c5", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead.  \n \n", "start_char_idx": 381, "end_char_idx": 402, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "226dbb9b-725a-4dac-9307-f6fb78c81a4d": {"__data__": {"id_": "226dbb9b-725a-4dac-9307-f6fb78c81a4d", "embedding": null, "metadata": {"window": "Today's conference is being recorded.  At this time, I would like to  turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:   Good morning.  Today, we will discuss Cardinal Health  Third  Quarter Fiscal 2022 \nresults along with an update to our FY  \u201822 outlook.  You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n", "original_text": "Kevin Moran:   Good morning. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3347ad46b125d39ae7d6ac6577ef96306bd677cbd518da4b3f5f10887f54fadb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b12e7571-47d5-4063-88a8-bec0885ac20a", "node_type": "1", "metadata": {"window": "Earnings \nConference Call  \nMay 5 , 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Third  Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to  turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:   Good morning.  Today, we will discuss Cardinal Health  Third  Quarter Fiscal 2022 \nresults along with an update to our FY  \u201822 outlook.  You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com. ", "original_text": "Please go ahead.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c55f68029feeb262be2b7899fda29e2725ddc01ef63c3685276b59963818c1eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61f2f479-b3ae-4113-a570-ddd7ec89e85c", "node_type": "1", "metadata": {"window": "At this time, I would like to  turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:   Good morning.  Today, we will discuss Cardinal Health  Third  Quarter Fiscal 2022 \nresults along with an update to our FY  \u201822 outlook.  You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements. ", "original_text": "Today, we will discuss Cardinal Health  Third  Quarter Fiscal 2022 \nresults along with an update to our FY  \u201822 outlook. "}, "hash": "69f2e8ebcd4b714872859fb68a0d1e79f498b614a91185b6064d9b9c0e68a725", "class_name": "RelatedNodeInfo"}}, "text": "Kevin Moran:   Good morning. ", "start_char_idx": 402, "end_char_idx": 431, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61f2f479-b3ae-4113-a570-ddd7ec89e85c": {"__data__": {"id_": "61f2f479-b3ae-4113-a570-ddd7ec89e85c", "embedding": null, "metadata": {"window": "At this time, I would like to  turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:   Good morning.  Today, we will discuss Cardinal Health  Third  Quarter Fiscal 2022 \nresults along with an update to our FY  \u201822 outlook.  You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements. ", "original_text": "Today, we will discuss Cardinal Health  Third  Quarter Fiscal 2022 \nresults along with an update to our FY  \u201822 outlook. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3347ad46b125d39ae7d6ac6577ef96306bd677cbd518da4b3f5f10887f54fadb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "226dbb9b-725a-4dac-9307-f6fb78c81a4d", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  At this time, I would like to  turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:   Good morning.  Today, we will discuss Cardinal Health  Third  Quarter Fiscal 2022 \nresults along with an update to our FY  \u201822 outlook.  You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n", "original_text": "Kevin Moran:   Good morning. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "21d59bba4892b63fc459059b6464bf9f49accb6899fde4cf8b7bdb3e66a0f69e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a04914f-e86b-4004-94e9-8e12dae0d039", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Kevin Moran:   Good morning.  Today, we will discuss Cardinal Health  Third  Quarter Fiscal 2022 \nresults along with an update to our FY  \u201822 outlook.  You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results t o differ materially \nfrom those projected or implied. ", "original_text": "You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com. "}, "hash": "5d0e6f1acec2b83600bb67dc6a10a324b129a46467cd9e3194d14970f01521b4", "class_name": "RelatedNodeInfo"}}, "text": "Today, we will discuss Cardinal Health  Third  Quarter Fiscal 2022 \nresults along with an update to our FY  \u201822 outlook. ", "start_char_idx": 431, "end_char_idx": 552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a04914f-e86b-4004-94e9-8e12dae0d039": {"__data__": {"id_": "2a04914f-e86b-4004-94e9-8e12dae0d039", "embedding": null, "metadata": {"window": "Please go ahead.  \n \n Kevin Moran:   Good morning.  Today, we will discuss Cardinal Health  Third  Quarter Fiscal 2022 \nresults along with an update to our FY  \u201822 outlook.  You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results t o differ materially \nfrom those projected or implied. ", "original_text": "You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3347ad46b125d39ae7d6ac6577ef96306bd677cbd518da4b3f5f10887f54fadb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61f2f479-b3ae-4113-a570-ddd7ec89e85c", "node_type": "1", "metadata": {"window": "At this time, I would like to  turn the \nconference over to Kevin Moran, Vice President of Investor Relations.  Please go ahead.  \n \n Kevin Moran:   Good morning.  Today, we will discuss Cardinal Health  Third  Quarter Fiscal 2022 \nresults along with an update to our FY  \u201822 outlook.  You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements. ", "original_text": "Today, we will discuss Cardinal Health  Third  Quarter Fiscal 2022 \nresults along with an update to our FY  \u201822 outlook. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e86080bda4ca23e42b59d57239dc58e9300fa4f1de7e0e8a83d6b624c51b1596", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3356a4e6-41ab-41b5-9b56-858737803b51", "node_type": "1", "metadata": {"window": "Kevin Moran:   Good morning.  Today, we will discuss Cardinal Health  Third  Quarter Fiscal 2022 \nresults along with an update to our FY  \u201822 outlook.  You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results t o differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties. ", "original_text": "Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n"}, "hash": "ad33e8c3e5e337f66dcfdf5a89fde7aa1aa4a6af3b22c20fef535e9d8e155d9e", "class_name": "RelatedNodeInfo"}}, "text": "You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com. ", "start_char_idx": 552, "end_char_idx": 664, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3356a4e6-41ab-41b5-9b56-858737803b51": {"__data__": {"id_": "3356a4e6-41ab-41b5-9b56-858737803b51", "embedding": null, "metadata": {"window": "Kevin Moran:   Good morning.  Today, we will discuss Cardinal Health  Third  Quarter Fiscal 2022 \nresults along with an update to our FY  \u201822 outlook.  You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results t o differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties. ", "original_text": "Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3347ad46b125d39ae7d6ac6577ef96306bd677cbd518da4b3f5f10887f54fadb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a04914f-e86b-4004-94e9-8e12dae0d039", "node_type": "1", "metadata": {"window": "Please go ahead.  \n \n Kevin Moran:   Good morning.  Today, we will discuss Cardinal Health  Third  Quarter Fiscal 2022 \nresults along with an update to our FY  \u201822 outlook.  You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results t o differ materially \nfrom those projected or implied. ", "original_text": "You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "42814a4953ee35a1ce65bd63b7b3d4298b44f5eb54fef6d4ed81a20ef8c25a5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b191f8a7-9b04-4e14-851b-e0fb69333558", "node_type": "1", "metadata": {"window": "Today, we will discuss Cardinal Health  Third  Quarter Fiscal 2022 \nresults along with an update to our FY  \u201822 outlook.  You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results t o differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  Please \nnote that during the discussion tod ay, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP. ", "original_text": "During the call, we will be making forward -looking statements. "}, "hash": "31c15d308b42c9cd0fd3306d377669b22e15df8d22c3ad3dccd990e249229377", "class_name": "RelatedNodeInfo"}}, "text": "Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n", "start_char_idx": 664, "end_char_idx": 773, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b191f8a7-9b04-4e14-851b-e0fb69333558": {"__data__": {"id_": "b191f8a7-9b04-4e14-851b-e0fb69333558", "embedding": null, "metadata": {"window": "Today, we will discuss Cardinal Health  Third  Quarter Fiscal 2022 \nresults along with an update to our FY  \u201822 outlook.  You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results t o differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  Please \nnote that during the discussion tod ay, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP. ", "original_text": "During the call, we will be making forward -looking statements. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3347ad46b125d39ae7d6ac6577ef96306bd677cbd518da4b3f5f10887f54fadb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3356a4e6-41ab-41b5-9b56-858737803b51", "node_type": "1", "metadata": {"window": "Kevin Moran:   Good morning.  Today, we will discuss Cardinal Health  Third  Quarter Fiscal 2022 \nresults along with an update to our FY  \u201822 outlook.  You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results t o differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties. ", "original_text": "Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c7001b523e63af492f7ff355d5345ef90ddcb884c5da186b0e2a39d0f24a418", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5d5942f-578e-4009-8a88-0d9fa4e23502", "node_type": "1", "metadata": {"window": "You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results t o differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  Please \nnote that during the discussion tod ay, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "original_text": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results t o differ materially \nfrom those projected or implied. "}, "hash": "a3bd6d40a62c4e53f85a696e1f1e677537a5e251bcc043b92a2d0b5abf4222ea", "class_name": "RelatedNodeInfo"}}, "text": "During the call, we will be making forward -looking statements. ", "start_char_idx": 773, "end_char_idx": 837, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5d5942f-578e-4009-8a88-0d9fa4e23502": {"__data__": {"id_": "d5d5942f-578e-4009-8a88-0d9fa4e23502", "embedding": null, "metadata": {"window": "You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results t o differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  Please \nnote that during the discussion tod ay, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "original_text": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results t o differ materially \nfrom those projected or implied. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3347ad46b125d39ae7d6ac6577ef96306bd677cbd518da4b3f5f10887f54fadb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b191f8a7-9b04-4e14-851b-e0fb69333558", "node_type": "1", "metadata": {"window": "Today, we will discuss Cardinal Health  Third  Quarter Fiscal 2022 \nresults along with an update to our FY  \u201822 outlook.  You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results t o differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  Please \nnote that during the discussion tod ay, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP. ", "original_text": "During the call, we will be making forward -looking statements. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "46eed298cbc5bb0cb44e12b08894b9cf86136d4d9661e4ff4a4a94ac5942a5d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c070cc17-29e1-4cc7-a97c-78a375db9e32", "node_type": "1", "metadata": {"window": "Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results t o differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  Please \nnote that during the discussion tod ay, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity . ", "original_text": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties. "}, "hash": "97600569c8aea1270eb11eb5290912eda46fa5f0e50cfa7a3c85417924a25bee", "class_name": "RelatedNodeInfo"}}, "text": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results t o differ materially \nfrom those projected or implied. ", "start_char_idx": 837, "end_char_idx": 1009, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c070cc17-29e1-4cc7-a97c-78a375db9e32": {"__data__": {"id_": "c070cc17-29e1-4cc7-a97c-78a375db9e32", "embedding": null, "metadata": {"window": "Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results t o differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  Please \nnote that during the discussion tod ay, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity . ", "original_text": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3347ad46b125d39ae7d6ac6577ef96306bd677cbd518da4b3f5f10887f54fadb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5d5942f-578e-4009-8a88-0d9fa4e23502", "node_type": "1", "metadata": {"window": "You can find today's press release and \npresentation on the IR section of our website at ir.cardinalhealth.com.  Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results t o differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  Please \nnote that during the discussion tod ay, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "original_text": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results t o differ materially \nfrom those projected or implied. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5f8847da9f5a578ce2db5aa1ae5ea55dbb0d709bccad19f14c2c13d0bc81de3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5953b510-bfa8-44c9-a1b6-9c11cf8a9f7b", "node_type": "1", "metadata": {"window": "During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results t o differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  Please \nnote that during the discussion tod ay, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n", "original_text": "Please \nnote that during the discussion tod ay, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP. "}, "hash": "57dde5bfe3b07c3f396ab6a09942b7826daaf751583c67f1b8c60a382b9c9b20", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties. ", "start_char_idx": 1009, "end_char_idx": 1172, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5953b510-bfa8-44c9-a1b6-9c11cf8a9f7b": {"__data__": {"id_": "5953b510-bfa8-44c9-a1b6-9c11cf8a9f7b", "embedding": null, "metadata": {"window": "During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results t o differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  Please \nnote that during the discussion tod ay, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n", "original_text": "Please \nnote that during the discussion tod ay, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3347ad46b125d39ae7d6ac6577ef96306bd677cbd518da4b3f5f10887f54fadb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c070cc17-29e1-4cc7-a97c-78a375db9e32", "node_type": "1", "metadata": {"window": "Joining me today are Mike \nKaufmann, Chief Executive Officer, and Jason Hollar, Chief Financial Officer.  \n \n During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results t o differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  Please \nnote that during the discussion tod ay, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity . ", "original_text": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "977431299182c299d94145e89b6a568313f4aaa27c11e412efa77b7fe2fcb69c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a88196ff-144c-4c7e-a901-8b54d0e35030", "node_type": "1", "metadata": {"window": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results t o differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  Please \nnote that during the discussion tod ay, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone. ", "original_text": "GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n"}, "hash": "49e7613136794d2026a60d4b671e741267b05fbaef350e56c995ad7d14fdedd5", "class_name": "RelatedNodeInfo"}}, "text": "Please \nnote that during the discussion tod ay, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP. ", "start_char_idx": 1172, "end_char_idx": 1312, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a88196ff-144c-4c7e-a901-8b54d0e35030": {"__data__": {"id_": "a88196ff-144c-4c7e-a901-8b54d0e35030", "embedding": null, "metadata": {"window": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results t o differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  Please \nnote that during the discussion tod ay, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone. ", "original_text": "GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3347ad46b125d39ae7d6ac6577ef96306bd677cbd518da4b3f5f10887f54fadb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5953b510-bfa8-44c9-a1b6-9c11cf8a9f7b", "node_type": "1", "metadata": {"window": "During the call, we will be making forward -looking statements.  The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results t o differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  Please \nnote that during the discussion tod ay, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n", "original_text": "Please \nnote that during the discussion tod ay, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "529a20d529e8b6e4100a8313008faa5b9236161d0131734708847db26301fee0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0498a176-4a8b-4378-8cbd-4ea71576bfee", "node_type": "1", "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  Please \nnote that during the discussion tod ay, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  Our third quarter results reflect \ncontinued inflationary impacts and global supply chain constraints. ", "original_text": "During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity . "}, "hash": "721fef2b8c943ca206f880b360f209f4e0cc335c2338092a506f61bc9b89504c", "class_name": "RelatedNodeInfo"}}, "text": "GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "start_char_idx": 1312, "end_char_idx": 1436, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0498a176-4a8b-4378-8cbd-4ea71576bfee": {"__data__": {"id_": "0498a176-4a8b-4378-8cbd-4ea71576bfee", "embedding": null, "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  Please \nnote that during the discussion tod ay, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  Our third quarter results reflect \ncontinued inflationary impacts and global supply chain constraints. ", "original_text": "During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity . ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3347ad46b125d39ae7d6ac6577ef96306bd677cbd518da4b3f5f10887f54fadb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a88196ff-144c-4c7e-a901-8b54d0e35030", "node_type": "1", "metadata": {"window": "The matters addressed in the \nstatements are subject to the risks and uncertainties that could cause actual results t o differ materially \nfrom those projected or implied.  Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  Please \nnote that during the discussion tod ay, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone. ", "original_text": "GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "40f251e3deac3c4d5ef692e1c2a29ae98e8be9894d685a4836e458ae54948a26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad088871-518c-4144-b4da-bfe6cf82e5a0", "node_type": "1", "metadata": {"window": "Please \nnote that during the discussion tod ay, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  Our third quarter results reflect \ncontinued inflationary impacts and global supply chain constraints.  As we continue to manage \nthrough the current macroeconomic environment, we remain focused on both near -term priorities and \nlong-term strategies to drive growth and momentum across our busin esses.  \n \n", "original_text": "With that, I'll now turn the call over to Mike.  \n \n"}, "hash": "4b519701407b83fe8eb8e8a5bcf3430fcf4b200a86b8454f29d1adbf7cdec9af", "class_name": "RelatedNodeInfo"}}, "text": "During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity . ", "start_char_idx": 1436, "end_char_idx": 1593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad088871-518c-4144-b4da-bfe6cf82e5a0": {"__data__": {"id_": "ad088871-518c-4144-b4da-bfe6cf82e5a0", "embedding": null, "metadata": {"window": "Please \nnote that during the discussion tod ay, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  Our third quarter results reflect \ncontinued inflationary impacts and global supply chain constraints.  As we continue to manage \nthrough the current macroeconomic environment, we remain focused on both near -term priorities and \nlong-term strategies to drive growth and momentum across our busin esses.  \n \n", "original_text": "With that, I'll now turn the call over to Mike.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3347ad46b125d39ae7d6ac6577ef96306bd677cbd518da4b3f5f10887f54fadb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0498a176-4a8b-4378-8cbd-4ea71576bfee", "node_type": "1", "metadata": {"window": "Please refer to our SEC filings and the forward -looking statement \nslide at the beginning of our presentation for a description of these risks and uncertainties.  Please \nnote that during the discussion tod ay, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  Our third quarter results reflect \ncontinued inflationary impacts and global supply chain constraints. ", "original_text": "During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity . ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1b019f142de14d13d41a3b182d15734cab3ec84f381a7a10f1ea3bb048d032f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82ef9e54-d236-4694-a3ad-0c632f7fa4ad", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  Our third quarter results reflect \ncontinued inflationary impacts and global supply chain constraints.  As we continue to manage \nthrough the current macroeconomic environment, we remain focused on both near -term priorities and \nlong-term strategies to drive growth and momentum across our busin esses.  \n \n At an enterprise level, we\u2019re maintaining our focus on our 3 strategic priorities: optimizing our core \nbusinesses; investing for growth and innovation; and deploying capital efficiently.  \n \n", "original_text": "Mike Kaufmann:  Thanks, Kevin, and good morning, everyone. "}, "hash": "2592c6d25723a3d5af116bfeab34b606f8e360956a1576503a3b5d0c761e9d75", "class_name": "RelatedNodeInfo"}}, "text": "With that, I'll now turn the call over to Mike.  \n \n", "start_char_idx": 1593, "end_char_idx": 1645, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82ef9e54-d236-4694-a3ad-0c632f7fa4ad": {"__data__": {"id_": "82ef9e54-d236-4694-a3ad-0c632f7fa4ad", "embedding": null, "metadata": {"window": "GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  Our third quarter results reflect \ncontinued inflationary impacts and global supply chain constraints.  As we continue to manage \nthrough the current macroeconomic environment, we remain focused on both near -term priorities and \nlong-term strategies to drive growth and momentum across our busin esses.  \n \n At an enterprise level, we\u2019re maintaining our focus on our 3 strategic priorities: optimizing our core \nbusinesses; investing for growth and innovation; and deploying capital efficiently.  \n \n", "original_text": "Mike Kaufmann:  Thanks, Kevin, and good morning, everyone. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3347ad46b125d39ae7d6ac6577ef96306bd677cbd518da4b3f5f10887f54fadb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad088871-518c-4144-b4da-bfe6cf82e5a0", "node_type": "1", "metadata": {"window": "Please \nnote that during the discussion tod ay, our comments will be on a non -GAAP basis unless they are \nspecifically called out as GAAP.  GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  Our third quarter results reflect \ncontinued inflationary impacts and global supply chain constraints.  As we continue to manage \nthrough the current macroeconomic environment, we remain focused on both near -term priorities and \nlong-term strategies to drive growth and momentum across our busin esses.  \n \n", "original_text": "With that, I'll now turn the call over to Mike.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "acf28117cf26cc5b630c1f86a4d4047fa587338256d5a197f2002a99e7fba048", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c69b1cf-7580-4578-bf13-acf0e6f84109", "node_type": "1", "metadata": {"window": "During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  Our third quarter results reflect \ncontinued inflationary impacts and global supply chain constraints.  As we continue to manage \nthrough the current macroeconomic environment, we remain focused on both near -term priorities and \nlong-term strategies to drive growth and momentum across our busin esses.  \n \n At an enterprise level, we\u2019re maintaining our focus on our 3 strategic priorities: optimizing our core \nbusinesses; investing for growth and innovation; and deploying capital efficiently.  \n \n In Pharma, despite the quarter being a little lower due to higher o perations costs, we remain \nencouraged by the trajectory of the business. ", "original_text": "Our third quarter results reflect \ncontinued inflationary impacts and global supply chain constraints. "}, "hash": "d664aa252927415d28b13ac3cbed1e5d71aa29a3723a94c305d921807d42fdc4", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Thanks, Kevin, and good morning, everyone. ", "start_char_idx": 1645, "end_char_idx": 1704, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c69b1cf-7580-4578-bf13-acf0e6f84109": {"__data__": {"id_": "2c69b1cf-7580-4578-bf13-acf0e6f84109", "embedding": null, "metadata": {"window": "During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  Our third quarter results reflect \ncontinued inflationary impacts and global supply chain constraints.  As we continue to manage \nthrough the current macroeconomic environment, we remain focused on both near -term priorities and \nlong-term strategies to drive growth and momentum across our busin esses.  \n \n At an enterprise level, we\u2019re maintaining our focus on our 3 strategic priorities: optimizing our core \nbusinesses; investing for growth and innovation; and deploying capital efficiently.  \n \n In Pharma, despite the quarter being a little lower due to higher o perations costs, we remain \nencouraged by the trajectory of the business. ", "original_text": "Our third quarter results reflect \ncontinued inflationary impacts and global supply chain constraints. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3347ad46b125d39ae7d6ac6577ef96306bd677cbd518da4b3f5f10887f54fadb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82ef9e54-d236-4694-a3ad-0c632f7fa4ad", "node_type": "1", "metadata": {"window": "GAAP to non -GAAP reconciliation for all relevant periods can be \nfound in the schedules attached to our press release.  \n \n During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  Our third quarter results reflect \ncontinued inflationary impacts and global supply chain constraints.  As we continue to manage \nthrough the current macroeconomic environment, we remain focused on both near -term priorities and \nlong-term strategies to drive growth and momentum across our busin esses.  \n \n At an enterprise level, we\u2019re maintaining our focus on our 3 strategic priorities: optimizing our core \nbusinesses; investing for growth and innovation; and deploying capital efficiently.  \n \n", "original_text": "Mike Kaufmann:  Thanks, Kevin, and good morning, everyone. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0c8d3918d58d2bdc25943d5677aa4bbc2046689103702fb50f757ca1a16667eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e62478f-8e60-4340-b645-15a550ea1ba5", "node_type": "1", "metadata": {"window": "With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  Our third quarter results reflect \ncontinued inflationary impacts and global supply chain constraints.  As we continue to manage \nthrough the current macroeconomic environment, we remain focused on both near -term priorities and \nlong-term strategies to drive growth and momentum across our busin esses.  \n \n At an enterprise level, we\u2019re maintaining our focus on our 3 strategic priorities: optimizing our core \nbusinesses; investing for growth and innovation; and deploying capital efficiently.  \n \n In Pharma, despite the quarter being a little lower due to higher o perations costs, we remain \nencouraged by the trajectory of the business.  We saw resiliency in overall pharmaceutical demand, \nstrong performance in our generics program, and continue to expect Pharma to realize mid -single \ndigit profit growth in FY  \u201822. \n \n", "original_text": "As we continue to manage \nthrough the current macroeconomic environment, we remain focused on both near -term priorities and \nlong-term strategies to drive growth and momentum across our busin esses.  \n \n"}, "hash": "7ee1d261a11daee0e4beae9574a6e1d0bde71b3492a71e89dd34eb6ce8aefa47", "class_name": "RelatedNodeInfo"}}, "text": "Our third quarter results reflect \ncontinued inflationary impacts and global supply chain constraints. ", "start_char_idx": 1704, "end_char_idx": 1807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e62478f-8e60-4340-b645-15a550ea1ba5": {"__data__": {"id_": "2e62478f-8e60-4340-b645-15a550ea1ba5", "embedding": null, "metadata": {"window": "With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  Our third quarter results reflect \ncontinued inflationary impacts and global supply chain constraints.  As we continue to manage \nthrough the current macroeconomic environment, we remain focused on both near -term priorities and \nlong-term strategies to drive growth and momentum across our busin esses.  \n \n At an enterprise level, we\u2019re maintaining our focus on our 3 strategic priorities: optimizing our core \nbusinesses; investing for growth and innovation; and deploying capital efficiently.  \n \n In Pharma, despite the quarter being a little lower due to higher o perations costs, we remain \nencouraged by the trajectory of the business.  We saw resiliency in overall pharmaceutical demand, \nstrong performance in our generics program, and continue to expect Pharma to realize mid -single \ndigit profit growth in FY  \u201822. \n \n", "original_text": "As we continue to manage \nthrough the current macroeconomic environment, we remain focused on both near -term priorities and \nlong-term strategies to drive growth and momentum across our busin esses.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3347ad46b125d39ae7d6ac6577ef96306bd677cbd518da4b3f5f10887f54fadb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c69b1cf-7580-4578-bf13-acf0e6f84109", "node_type": "1", "metadata": {"window": "During the Q&A portion of today's call, we please ask that you try and limit yourself to one question so \nthat we can try and give everyone an opportunity .  With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  Our third quarter results reflect \ncontinued inflationary impacts and global supply chain constraints.  As we continue to manage \nthrough the current macroeconomic environment, we remain focused on both near -term priorities and \nlong-term strategies to drive growth and momentum across our busin esses.  \n \n At an enterprise level, we\u2019re maintaining our focus on our 3 strategic priorities: optimizing our core \nbusinesses; investing for growth and innovation; and deploying capital efficiently.  \n \n In Pharma, despite the quarter being a little lower due to higher o perations costs, we remain \nencouraged by the trajectory of the business. ", "original_text": "Our third quarter results reflect \ncontinued inflationary impacts and global supply chain constraints. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "442313af5499f69960352a0439e1e6a8a3a3c8804d00575ef0685656c1231b21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5cb5b03-cf22-47ae-b102-1408e6d32026", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  Our third quarter results reflect \ncontinued inflationary impacts and global supply chain constraints.  As we continue to manage \nthrough the current macroeconomic environment, we remain focused on both near -term priorities and \nlong-term strategies to drive growth and momentum across our busin esses.  \n \n At an enterprise level, we\u2019re maintaining our focus on our 3 strategic priorities: optimizing our core \nbusinesses; investing for growth and innovation; and deploying capital efficiently.  \n \n In Pharma, despite the quarter being a little lower due to higher o perations costs, we remain \nencouraged by the trajectory of the business.  We saw resiliency in overall pharmaceutical demand, \nstrong performance in our generics program, and continue to expect Pharma to realize mid -single \ndigit profit growth in FY  \u201822. \n \n In Medical, our core US Medical Products and Distribution business continued to experience \nunprecedented inflationary impacts and global supply chain constraints. ", "original_text": "At an enterprise level, we\u2019re maintaining our focus on our 3 strategic priorities: optimizing our core \nbusinesses; investing for growth and innovation; and deploying capital efficiently.  \n \n"}, "hash": "949298311a142207ef28f3936bf91ba6a7a4c42e62c54305cc3badf80e03e83f", "class_name": "RelatedNodeInfo"}}, "text": "As we continue to manage \nthrough the current macroeconomic environment, we remain focused on both near -term priorities and \nlong-term strategies to drive growth and momentum across our busin esses.  \n \n", "start_char_idx": 1807, "end_char_idx": 2011, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5cb5b03-cf22-47ae-b102-1408e6d32026": {"__data__": {"id_": "b5cb5b03-cf22-47ae-b102-1408e6d32026", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  Our third quarter results reflect \ncontinued inflationary impacts and global supply chain constraints.  As we continue to manage \nthrough the current macroeconomic environment, we remain focused on both near -term priorities and \nlong-term strategies to drive growth and momentum across our busin esses.  \n \n At an enterprise level, we\u2019re maintaining our focus on our 3 strategic priorities: optimizing our core \nbusinesses; investing for growth and innovation; and deploying capital efficiently.  \n \n In Pharma, despite the quarter being a little lower due to higher o perations costs, we remain \nencouraged by the trajectory of the business.  We saw resiliency in overall pharmaceutical demand, \nstrong performance in our generics program, and continue to expect Pharma to realize mid -single \ndigit profit growth in FY  \u201822. \n \n In Medical, our core US Medical Products and Distribution business continued to experience \nunprecedented inflationary impacts and global supply chain constraints. ", "original_text": "At an enterprise level, we\u2019re maintaining our focus on our 3 strategic priorities: optimizing our core \nbusinesses; investing for growth and innovation; and deploying capital efficiently.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3347ad46b125d39ae7d6ac6577ef96306bd677cbd518da4b3f5f10887f54fadb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e62478f-8e60-4340-b645-15a550ea1ba5", "node_type": "1", "metadata": {"window": "With that, I'll now turn the call over to Mike.  \n \n Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  Our third quarter results reflect \ncontinued inflationary impacts and global supply chain constraints.  As we continue to manage \nthrough the current macroeconomic environment, we remain focused on both near -term priorities and \nlong-term strategies to drive growth and momentum across our busin esses.  \n \n At an enterprise level, we\u2019re maintaining our focus on our 3 strategic priorities: optimizing our core \nbusinesses; investing for growth and innovation; and deploying capital efficiently.  \n \n In Pharma, despite the quarter being a little lower due to higher o perations costs, we remain \nencouraged by the trajectory of the business.  We saw resiliency in overall pharmaceutical demand, \nstrong performance in our generics program, and continue to expect Pharma to realize mid -single \ndigit profit growth in FY  \u201822. \n \n", "original_text": "As we continue to manage \nthrough the current macroeconomic environment, we remain focused on both near -term priorities and \nlong-term strategies to drive growth and momentum across our busin esses.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7482515834d4922d100c3b41666013a1b604e3c9267d63a388c97af8a1edf089", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d59015fa-1f9f-4c8a-84d2-f8197a5795ed", "node_type": "1", "metadata": {"window": "Our third quarter results reflect \ncontinued inflationary impacts and global supply chain constraints.  As we continue to manage \nthrough the current macroeconomic environment, we remain focused on both near -term priorities and \nlong-term strategies to drive growth and momentum across our busin esses.  \n \n At an enterprise level, we\u2019re maintaining our focus on our 3 strategic priorities: optimizing our core \nbusinesses; investing for growth and innovation; and deploying capital efficiently.  \n \n In Pharma, despite the quarter being a little lower due to higher o perations costs, we remain \nencouraged by the trajectory of the business.  We saw resiliency in overall pharmaceutical demand, \nstrong performance in our generics program, and continue to expect Pharma to realize mid -single \ndigit profit growth in FY  \u201822. \n \n In Medical, our core US Medical Products and Distribution business continued to experience \nunprecedented inflationary impacts and global supply chain constraints.  We continue to take action to \nmitigate the effect of these global challenges on our business, in cluding taking pricing actions, \nevolving our commercial contracting strategies, and investing in additional supply chain capacity. \n", "original_text": "In Pharma, despite the quarter being a little lower due to higher o perations costs, we remain \nencouraged by the trajectory of the business. "}, "hash": "49d0071282bbddf2e20963318a6b1d30053f418d5eae2aeb9e8300610fb66b4f", "class_name": "RelatedNodeInfo"}}, "text": "At an enterprise level, we\u2019re maintaining our focus on our 3 strategic priorities: optimizing our core \nbusinesses; investing for growth and innovation; and deploying capital efficiently.  \n \n", "start_char_idx": 2011, "end_char_idx": 2203, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d59015fa-1f9f-4c8a-84d2-f8197a5795ed": {"__data__": {"id_": "d59015fa-1f9f-4c8a-84d2-f8197a5795ed", "embedding": null, "metadata": {"window": "Our third quarter results reflect \ncontinued inflationary impacts and global supply chain constraints.  As we continue to manage \nthrough the current macroeconomic environment, we remain focused on both near -term priorities and \nlong-term strategies to drive growth and momentum across our busin esses.  \n \n At an enterprise level, we\u2019re maintaining our focus on our 3 strategic priorities: optimizing our core \nbusinesses; investing for growth and innovation; and deploying capital efficiently.  \n \n In Pharma, despite the quarter being a little lower due to higher o perations costs, we remain \nencouraged by the trajectory of the business.  We saw resiliency in overall pharmaceutical demand, \nstrong performance in our generics program, and continue to expect Pharma to realize mid -single \ndigit profit growth in FY  \u201822. \n \n In Medical, our core US Medical Products and Distribution business continued to experience \nunprecedented inflationary impacts and global supply chain constraints.  We continue to take action to \nmitigate the effect of these global challenges on our business, in cluding taking pricing actions, \nevolving our commercial contracting strategies, and investing in additional supply chain capacity. \n", "original_text": "In Pharma, despite the quarter being a little lower due to higher o perations costs, we remain \nencouraged by the trajectory of the business. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3347ad46b125d39ae7d6ac6577ef96306bd677cbd518da4b3f5f10887f54fadb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5cb5b03-cf22-47ae-b102-1408e6d32026", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Thanks, Kevin, and good morning, everyone.  Our third quarter results reflect \ncontinued inflationary impacts and global supply chain constraints.  As we continue to manage \nthrough the current macroeconomic environment, we remain focused on both near -term priorities and \nlong-term strategies to drive growth and momentum across our busin esses.  \n \n At an enterprise level, we\u2019re maintaining our focus on our 3 strategic priorities: optimizing our core \nbusinesses; investing for growth and innovation; and deploying capital efficiently.  \n \n In Pharma, despite the quarter being a little lower due to higher o perations costs, we remain \nencouraged by the trajectory of the business.  We saw resiliency in overall pharmaceutical demand, \nstrong performance in our generics program, and continue to expect Pharma to realize mid -single \ndigit profit growth in FY  \u201822. \n \n In Medical, our core US Medical Products and Distribution business continued to experience \nunprecedented inflationary impacts and global supply chain constraints. ", "original_text": "At an enterprise level, we\u2019re maintaining our focus on our 3 strategic priorities: optimizing our core \nbusinesses; investing for growth and innovation; and deploying capital efficiently.  \n \n", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "782017f75c3d19f799c38a1b00fe91abd860a845ee8bd61dec66454932291c70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7cebd692-22e4-4e83-a105-39d39e4cf86a", "node_type": "1", "metadata": {"window": "As we continue to manage \nthrough the current macroeconomic environment, we remain focused on both near -term priorities and \nlong-term strategies to drive growth and momentum across our busin esses.  \n \n At an enterprise level, we\u2019re maintaining our focus on our 3 strategic priorities: optimizing our core \nbusinesses; investing for growth and innovation; and deploying capital efficiently.  \n \n In Pharma, despite the quarter being a little lower due to higher o perations costs, we remain \nencouraged by the trajectory of the business.  We saw resiliency in overall pharmaceutical demand, \nstrong performance in our generics program, and continue to expect Pharma to realize mid -single \ndigit profit growth in FY  \u201822. \n \n In Medical, our core US Medical Products and Distribution business continued to experience \nunprecedented inflationary impacts and global supply chain constraints.  We continue to take action to \nmitigate the effect of these global challenges on our business, in cluding taking pricing actions, \nevolving our commercial contracting strategies, and investing in additional supply chain capacity. \n While we remain confident these actions will deliver value, and are encouraged by the other areas of \nour Medical business and  our opportunities for long -term growth, the current environment remains \nhighly dynamic. ", "original_text": "We saw resiliency in overall pharmaceutical demand, \nstrong performance in our generics program, and continue to expect Pharma to realize mid -single \ndigit profit growth in FY  \u201822. \n \n"}, "hash": "a7376d9643362daa452d2cef8e95184330627e5deb8eebd85117efacff546ed4", "class_name": "RelatedNodeInfo"}}, "text": "In Pharma, despite the quarter being a little lower due to higher o perations costs, we remain \nencouraged by the trajectory of the business. ", "start_char_idx": 2203, "end_char_idx": 2345, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7cebd692-22e4-4e83-a105-39d39e4cf86a": {"__data__": {"id_": "7cebd692-22e4-4e83-a105-39d39e4cf86a", "embedding": null, "metadata": {"window": "As we continue to manage \nthrough the current macroeconomic environment, we remain focused on both near -term priorities and \nlong-term strategies to drive growth and momentum across our busin esses.  \n \n At an enterprise level, we\u2019re maintaining our focus on our 3 strategic priorities: optimizing our core \nbusinesses; investing for growth and innovation; and deploying capital efficiently.  \n \n In Pharma, despite the quarter being a little lower due to higher o perations costs, we remain \nencouraged by the trajectory of the business.  We saw resiliency in overall pharmaceutical demand, \nstrong performance in our generics program, and continue to expect Pharma to realize mid -single \ndigit profit growth in FY  \u201822. \n \n In Medical, our core US Medical Products and Distribution business continued to experience \nunprecedented inflationary impacts and global supply chain constraints.  We continue to take action to \nmitigate the effect of these global challenges on our business, in cluding taking pricing actions, \nevolving our commercial contracting strategies, and investing in additional supply chain capacity. \n While we remain confident these actions will deliver value, and are encouraged by the other areas of \nour Medical business and  our opportunities for long -term growth, the current environment remains \nhighly dynamic. ", "original_text": "We saw resiliency in overall pharmaceutical demand, \nstrong performance in our generics program, and continue to expect Pharma to realize mid -single \ndigit profit growth in FY  \u201822. \n \n", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3347ad46b125d39ae7d6ac6577ef96306bd677cbd518da4b3f5f10887f54fadb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d59015fa-1f9f-4c8a-84d2-f8197a5795ed", "node_type": "1", "metadata": {"window": "Our third quarter results reflect \ncontinued inflationary impacts and global supply chain constraints.  As we continue to manage \nthrough the current macroeconomic environment, we remain focused on both near -term priorities and \nlong-term strategies to drive growth and momentum across our busin esses.  \n \n At an enterprise level, we\u2019re maintaining our focus on our 3 strategic priorities: optimizing our core \nbusinesses; investing for growth and innovation; and deploying capital efficiently.  \n \n In Pharma, despite the quarter being a little lower due to higher o perations costs, we remain \nencouraged by the trajectory of the business.  We saw resiliency in overall pharmaceutical demand, \nstrong performance in our generics program, and continue to expect Pharma to realize mid -single \ndigit profit growth in FY  \u201822. \n \n In Medical, our core US Medical Products and Distribution business continued to experience \nunprecedented inflationary impacts and global supply chain constraints.  We continue to take action to \nmitigate the effect of these global challenges on our business, in cluding taking pricing actions, \nevolving our commercial contracting strategies, and investing in additional supply chain capacity. \n", "original_text": "In Pharma, despite the quarter being a little lower due to higher o perations costs, we remain \nencouraged by the trajectory of the business. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7fb30d01942380c4966d8663e9db82652049129bd8a1638624b364df6b3b0360", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7559097a-2603-40c2-969e-62a7586e23df", "node_type": "1", "metadata": {"window": "At an enterprise level, we\u2019re maintaining our focus on our 3 strategic priorities: optimizing our core \nbusinesses; investing for growth and innovation; and deploying capital efficiently.  \n \n In Pharma, despite the quarter being a little lower due to higher o perations costs, we remain \nencouraged by the trajectory of the business.  We saw resiliency in overall pharmaceutical demand, \nstrong performance in our generics program, and continue to expect Pharma to realize mid -single \ndigit profit growth in FY  \u201822. \n \n In Medical, our core US Medical Products and Distribution business continued to experience \nunprecedented inflationary impacts and global supply chain constraints.  We continue to take action to \nmitigate the effect of these global challenges on our business, in cluding taking pricing actions, \nevolving our commercial contracting strategies, and investing in additional supply chain capacity. \n While we remain confident these actions will deliver value, and are encouraged by the other areas of \nour Medical business and  our opportunities for long -term growth, the current environment remains \nhighly dynamic.  Our updated outlook for FY  \u201822 reflects our most current expectations.  ", "original_text": "In Medical, our core US Medical Products and Distribution business continued to experience \nunprecedented inflationary impacts and global supply chain constraints. "}, "hash": "aa57d43cfcfe0e5624663b1503451dee480c4193f2494355825b2f270b4190a9", "class_name": "RelatedNodeInfo"}}, "text": "We saw resiliency in overall pharmaceutical demand, \nstrong performance in our generics program, and continue to expect Pharma to realize mid -single \ndigit profit growth in FY  \u201822. \n \n", "start_char_idx": 2345, "end_char_idx": 2531, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7559097a-2603-40c2-969e-62a7586e23df": {"__data__": {"id_": "7559097a-2603-40c2-969e-62a7586e23df", "embedding": null, "metadata": {"window": "At an enterprise level, we\u2019re maintaining our focus on our 3 strategic priorities: optimizing our core \nbusinesses; investing for growth and innovation; and deploying capital efficiently.  \n \n In Pharma, despite the quarter being a little lower due to higher o perations costs, we remain \nencouraged by the trajectory of the business.  We saw resiliency in overall pharmaceutical demand, \nstrong performance in our generics program, and continue to expect Pharma to realize mid -single \ndigit profit growth in FY  \u201822. \n \n In Medical, our core US Medical Products and Distribution business continued to experience \nunprecedented inflationary impacts and global supply chain constraints.  We continue to take action to \nmitigate the effect of these global challenges on our business, in cluding taking pricing actions, \nevolving our commercial contracting strategies, and investing in additional supply chain capacity. \n While we remain confident these actions will deliver value, and are encouraged by the other areas of \nour Medical business and  our opportunities for long -term growth, the current environment remains \nhighly dynamic.  Our updated outlook for FY  \u201822 reflects our most current expectations.  ", "original_text": "In Medical, our core US Medical Products and Distribution business continued to experience \nunprecedented inflationary impacts and global supply chain constraints. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3347ad46b125d39ae7d6ac6577ef96306bd677cbd518da4b3f5f10887f54fadb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7cebd692-22e4-4e83-a105-39d39e4cf86a", "node_type": "1", "metadata": {"window": "As we continue to manage \nthrough the current macroeconomic environment, we remain focused on both near -term priorities and \nlong-term strategies to drive growth and momentum across our busin esses.  \n \n At an enterprise level, we\u2019re maintaining our focus on our 3 strategic priorities: optimizing our core \nbusinesses; investing for growth and innovation; and deploying capital efficiently.  \n \n In Pharma, despite the quarter being a little lower due to higher o perations costs, we remain \nencouraged by the trajectory of the business.  We saw resiliency in overall pharmaceutical demand, \nstrong performance in our generics program, and continue to expect Pharma to realize mid -single \ndigit profit growth in FY  \u201822. \n \n In Medical, our core US Medical Products and Distribution business continued to experience \nunprecedented inflationary impacts and global supply chain constraints.  We continue to take action to \nmitigate the effect of these global challenges on our business, in cluding taking pricing actions, \nevolving our commercial contracting strategies, and investing in additional supply chain capacity. \n While we remain confident these actions will deliver value, and are encouraged by the other areas of \nour Medical business and  our opportunities for long -term growth, the current environment remains \nhighly dynamic. ", "original_text": "We saw resiliency in overall pharmaceutical demand, \nstrong performance in our generics program, and continue to expect Pharma to realize mid -single \ndigit profit growth in FY  \u201822. \n \n", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b22a25e53ebd30634603ea25736dd959c24882b84a21764b34bddac645d980b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fc7b6a4a-0193-499f-89ae-3781930222e2", "node_type": "1", "metadata": {"window": "In Pharma, despite the quarter being a little lower due to higher o perations costs, we remain \nencouraged by the trajectory of the business.  We saw resiliency in overall pharmaceutical demand, \nstrong performance in our generics program, and continue to expect Pharma to realize mid -single \ndigit profit growth in FY  \u201822. \n \n In Medical, our core US Medical Products and Distribution business continued to experience \nunprecedented inflationary impacts and global supply chain constraints.  We continue to take action to \nmitigate the effect of these global challenges on our business, in cluding taking pricing actions, \nevolving our commercial contracting strategies, and investing in additional supply chain capacity. \n While we remain confident these actions will deliver value, and are encouraged by the other areas of \nour Medical business and  our opportunities for long -term growth, the current environment remains \nhighly dynamic.  Our updated outlook for FY  \u201822 reflects our most current expectations.  ", "original_text": "We continue to take action to \nmitigate the effect of these global challenges on our business, in cluding taking pricing actions, \nevolving our commercial contracting strategies, and investing in additional supply chain capacity. \n"}, "hash": "5a5e437f946e7e9980f5c886f870b8c983380ee8bd567e1fe720a68b84df3acc", "class_name": "RelatedNodeInfo"}}, "text": "In Medical, our core US Medical Products and Distribution business continued to experience \nunprecedented inflationary impacts and global supply chain constraints. ", "start_char_idx": 2531, "end_char_idx": 2695, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fc7b6a4a-0193-499f-89ae-3781930222e2": {"__data__": {"id_": "fc7b6a4a-0193-499f-89ae-3781930222e2", "embedding": null, "metadata": {"window": "In Pharma, despite the quarter being a little lower due to higher o perations costs, we remain \nencouraged by the trajectory of the business.  We saw resiliency in overall pharmaceutical demand, \nstrong performance in our generics program, and continue to expect Pharma to realize mid -single \ndigit profit growth in FY  \u201822. \n \n In Medical, our core US Medical Products and Distribution business continued to experience \nunprecedented inflationary impacts and global supply chain constraints.  We continue to take action to \nmitigate the effect of these global challenges on our business, in cluding taking pricing actions, \nevolving our commercial contracting strategies, and investing in additional supply chain capacity. \n While we remain confident these actions will deliver value, and are encouraged by the other areas of \nour Medical business and  our opportunities for long -term growth, the current environment remains \nhighly dynamic.  Our updated outlook for FY  \u201822 reflects our most current expectations.  ", "original_text": "We continue to take action to \nmitigate the effect of these global challenges on our business, in cluding taking pricing actions, \nevolving our commercial contracting strategies, and investing in additional supply chain capacity. \n", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3347ad46b125d39ae7d6ac6577ef96306bd677cbd518da4b3f5f10887f54fadb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7559097a-2603-40c2-969e-62a7586e23df", "node_type": "1", "metadata": {"window": "At an enterprise level, we\u2019re maintaining our focus on our 3 strategic priorities: optimizing our core \nbusinesses; investing for growth and innovation; and deploying capital efficiently.  \n \n In Pharma, despite the quarter being a little lower due to higher o perations costs, we remain \nencouraged by the trajectory of the business.  We saw resiliency in overall pharmaceutical demand, \nstrong performance in our generics program, and continue to expect Pharma to realize mid -single \ndigit profit growth in FY  \u201822. \n \n In Medical, our core US Medical Products and Distribution business continued to experience \nunprecedented inflationary impacts and global supply chain constraints.  We continue to take action to \nmitigate the effect of these global challenges on our business, in cluding taking pricing actions, \nevolving our commercial contracting strategies, and investing in additional supply chain capacity. \n While we remain confident these actions will deliver value, and are encouraged by the other areas of \nour Medical business and  our opportunities for long -term growth, the current environment remains \nhighly dynamic.  Our updated outlook for FY  \u201822 reflects our most current expectations.  ", "original_text": "In Medical, our core US Medical Products and Distribution business continued to experience \nunprecedented inflationary impacts and global supply chain constraints. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "35b2b80f8026b76a4431ba51167347ad121c87ff01bf3ba2088c72a078e530db", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "04154aa0-8f35-45e3-969d-00497c5aef08", "node_type": "1", "metadata": {"window": "We saw resiliency in overall pharmaceutical demand, \nstrong performance in our generics program, and continue to expect Pharma to realize mid -single \ndigit profit growth in FY  \u201822. \n \n In Medical, our core US Medical Products and Distribution business continued to experience \nunprecedented inflationary impacts and global supply chain constraints.  We continue to take action to \nmitigate the effect of these global challenges on our business, in cluding taking pricing actions, \nevolving our commercial contracting strategies, and investing in additional supply chain capacity. \n While we remain confident these actions will deliver value, and are encouraged by the other areas of \nour Medical business and  our opportunities for long -term growth, the current environment remains \nhighly dynamic.  Our updated outlook for FY  \u201822 reflects our most current expectations.  ", "original_text": "While we remain confident these actions will deliver value, and are encouraged by the other areas of \nour Medical business and  our opportunities for long -term growth, the current environment remains \nhighly dynamic. "}, "hash": "995280c68e8605bb629cd958678ff92800f55c1a053907b3b74c5d45f0892237", "class_name": "RelatedNodeInfo"}}, "text": "We continue to take action to \nmitigate the effect of these global challenges on our business, in cluding taking pricing actions, \nevolving our commercial contracting strategies, and investing in additional supply chain capacity. \n", "start_char_idx": 2695, "end_char_idx": 2926, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "04154aa0-8f35-45e3-969d-00497c5aef08": {"__data__": {"id_": "04154aa0-8f35-45e3-969d-00497c5aef08", "embedding": null, "metadata": {"window": "We saw resiliency in overall pharmaceutical demand, \nstrong performance in our generics program, and continue to expect Pharma to realize mid -single \ndigit profit growth in FY  \u201822. \n \n In Medical, our core US Medical Products and Distribution business continued to experience \nunprecedented inflationary impacts and global supply chain constraints.  We continue to take action to \nmitigate the effect of these global challenges on our business, in cluding taking pricing actions, \nevolving our commercial contracting strategies, and investing in additional supply chain capacity. \n While we remain confident these actions will deliver value, and are encouraged by the other areas of \nour Medical business and  our opportunities for long -term growth, the current environment remains \nhighly dynamic.  Our updated outlook for FY  \u201822 reflects our most current expectations.  ", "original_text": "While we remain confident these actions will deliver value, and are encouraged by the other areas of \nour Medical business and  our opportunities for long -term growth, the current environment remains \nhighly dynamic. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3347ad46b125d39ae7d6ac6577ef96306bd677cbd518da4b3f5f10887f54fadb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fc7b6a4a-0193-499f-89ae-3781930222e2", "node_type": "1", "metadata": {"window": "In Pharma, despite the quarter being a little lower due to higher o perations costs, we remain \nencouraged by the trajectory of the business.  We saw resiliency in overall pharmaceutical demand, \nstrong performance in our generics program, and continue to expect Pharma to realize mid -single \ndigit profit growth in FY  \u201822. \n \n In Medical, our core US Medical Products and Distribution business continued to experience \nunprecedented inflationary impacts and global supply chain constraints.  We continue to take action to \nmitigate the effect of these global challenges on our business, in cluding taking pricing actions, \nevolving our commercial contracting strategies, and investing in additional supply chain capacity. \n While we remain confident these actions will deliver value, and are encouraged by the other areas of \nour Medical business and  our opportunities for long -term growth, the current environment remains \nhighly dynamic.  Our updated outlook for FY  \u201822 reflects our most current expectations.  ", "original_text": "We continue to take action to \nmitigate the effect of these global challenges on our business, in cluding taking pricing actions, \nevolving our commercial contracting strategies, and investing in additional supply chain capacity. \n", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "888ea3f1e7c743da83fb90f1da1c83fec615a0a37b185e46834147b5f567a4bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31e3833c-1067-45dd-bc8d-57473732b783", "node_type": "1", "metadata": {"window": "In Medical, our core US Medical Products and Distribution business continued to experience \nunprecedented inflationary impacts and global supply chain constraints.  We continue to take action to \nmitigate the effect of these global challenges on our business, in cluding taking pricing actions, \nevolving our commercial contracting strategies, and investing in additional supply chain capacity. \n While we remain confident these actions will deliver value, and are encouraged by the other areas of \nour Medical business and  our opportunities for long -term growth, the current environment remains \nhighly dynamic.  Our updated outlook for FY  \u201822 reflects our most current expectations.  ", "original_text": "Our updated outlook for FY  \u201822 reflects our most current expectations.  "}, "hash": "01b5486051fdf74795403fe799f091c214217f4d0477a9de2d80cccb3a999f95", "class_name": "RelatedNodeInfo"}}, "text": "While we remain confident these actions will deliver value, and are encouraged by the other areas of \nour Medical business and  our opportunities for long -term growth, the current environment remains \nhighly dynamic. ", "start_char_idx": 2926, "end_char_idx": 3144, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31e3833c-1067-45dd-bc8d-57473732b783": {"__data__": {"id_": "31e3833c-1067-45dd-bc8d-57473732b783", "embedding": null, "metadata": {"window": "In Medical, our core US Medical Products and Distribution business continued to experience \nunprecedented inflationary impacts and global supply chain constraints.  We continue to take action to \nmitigate the effect of these global challenges on our business, in cluding taking pricing actions, \nevolving our commercial contracting strategies, and investing in additional supply chain capacity. \n While we remain confident these actions will deliver value, and are encouraged by the other areas of \nour Medical business and  our opportunities for long -term growth, the current environment remains \nhighly dynamic.  Our updated outlook for FY  \u201822 reflects our most current expectations.  ", "original_text": "Our updated outlook for FY  \u201822 reflects our most current expectations.  ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c", "node_type": "4", "metadata": {"page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3347ad46b125d39ae7d6ac6577ef96306bd677cbd518da4b3f5f10887f54fadb", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "04154aa0-8f35-45e3-969d-00497c5aef08", "node_type": "1", "metadata": {"window": "We saw resiliency in overall pharmaceutical demand, \nstrong performance in our generics program, and continue to expect Pharma to realize mid -single \ndigit profit growth in FY  \u201822. \n \n In Medical, our core US Medical Products and Distribution business continued to experience \nunprecedented inflationary impacts and global supply chain constraints.  We continue to take action to \nmitigate the effect of these global challenges on our business, in cluding taking pricing actions, \nevolving our commercial contracting strategies, and investing in additional supply chain capacity. \n While we remain confident these actions will deliver value, and are encouraged by the other areas of \nour Medical business and  our opportunities for long -term growth, the current environment remains \nhighly dynamic.  Our updated outlook for FY  \u201822 reflects our most current expectations.  ", "original_text": "While we remain confident these actions will deliver value, and are encouraged by the other areas of \nour Medical business and  our opportunities for long -term growth, the current environment remains \nhighly dynamic. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e6d563444da1fd8e10fd44ef7c614edb3e8a9b98a9ce755de2b7d503b67b67c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32d0cc58-70a4-4008-b106-7e6a01f509df", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nI\u2019ll elaborate on the actions we are taking to drive performance , particularly in Medical , after Jason \nreviews our third quarter results and updated outlook.  \n \n Before turning the discussion over to Jason, it\u2019s important to note that the opioid settlement \nagreement was finalized during the quarter and became effective on April 2nd.  This is an important  \nand significant step forward for our company.  We feel this settlement is the best way to deliver relief \nto communities across the United States and allow our company to move forward by putting \nthousands of lawsuits behind us. ", "original_text": " \nPage 2 of 15 \n \nI\u2019ll elaborate on the actions we are taking to drive performance , particularly in Medical , after Jason \nreviews our third quarter results and updated outlook.  \n \n"}, "hash": "a50302fb4fe74375a905282d9f7aa195591130a833049926e31a48c61a4731e1", "class_name": "RelatedNodeInfo"}}, "text": "Our updated outlook for FY  \u201822 reflects our most current expectations.  ", "start_char_idx": 3144, "end_char_idx": 3217, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32d0cc58-70a4-4008-b106-7e6a01f509df": {"__data__": {"id_": "32d0cc58-70a4-4008-b106-7e6a01f509df", "embedding": null, "metadata": {"window": " \nPage 2 of 15 \n \nI\u2019ll elaborate on the actions we are taking to drive performance , particularly in Medical , after Jason \nreviews our third quarter results and updated outlook.  \n \n Before turning the discussion over to Jason, it\u2019s important to note that the opioid settlement \nagreement was finalized during the quarter and became effective on April 2nd.  This is an important  \nand significant step forward for our company.  We feel this settlement is the best way to deliver relief \nto communities across the United States and allow our company to move forward by putting \nthousands of lawsuits behind us. ", "original_text": " \nPage 2 of 15 \n \nI\u2019ll elaborate on the actions we are taking to drive performance , particularly in Medical , after Jason \nreviews our third quarter results and updated outlook.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4498f1fdb78b4b44925acc3c493b8cea7ad3efe3a26cbe1a86b2b8a818fb9f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31e3833c-1067-45dd-bc8d-57473732b783", "node_type": "1", "metadata": {"window": "In Medical, our core US Medical Products and Distribution business continued to experience \nunprecedented inflationary impacts and global supply chain constraints.  We continue to take action to \nmitigate the effect of these global challenges on our business, in cluding taking pricing actions, \nevolving our commercial contracting strategies, and investing in additional supply chain capacity. \n While we remain confident these actions will deliver value, and are encouraged by the other areas of \nour Medical business and  our opportunities for long -term growth, the current environment remains \nhighly dynamic.  Our updated outlook for FY  \u201822 reflects our most current expectations.  ", "original_text": "Our updated outlook for FY  \u201822 reflects our most current expectations.  ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e9fba5ecf3c7352356a57d13f06a0d752c578de580bf72e5eb3ada8ce8b775b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "42721dda-8296-4c1b-ad3c-ee45b0e1914a", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nI\u2019ll elaborate on the actions we are taking to drive performance , particularly in Medical , after Jason \nreviews our third quarter results and updated outlook.  \n \n Before turning the discussion over to Jason, it\u2019s important to note that the opioid settlement \nagreement was finalized during the quarter and became effective on April 2nd.  This is an important  \nand significant step forward for our company.  We feel this settlement is the best way to deliver relief \nto communities across the United States and allow our company to move forward by putting \nthousands of lawsuits behind us.  46 of 49 eligible states, all  6 eligible territories, and over 98% of \nlitigating political subdivisions are part of the national agreement. ", "original_text": "Before turning the discussion over to Jason, it\u2019s important to note that the opioid settlement \nagreement was finalized during the quarter and became effective on April 2nd. "}, "hash": "f1099fe8c2420f0cdee3ba1d359954c2713eeb73092eb7d6ed50cda6697a0167", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 2 of 15 \n \nI\u2019ll elaborate on the actions we are taking to drive performance , particularly in Medical , after Jason \nreviews our third quarter results and updated outlook.  \n \n", "start_char_idx": 0, "end_char_idx": 183, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "42721dda-8296-4c1b-ad3c-ee45b0e1914a": {"__data__": {"id_": "42721dda-8296-4c1b-ad3c-ee45b0e1914a", "embedding": null, "metadata": {"window": " \nPage 2 of 15 \n \nI\u2019ll elaborate on the actions we are taking to drive performance , particularly in Medical , after Jason \nreviews our third quarter results and updated outlook.  \n \n Before turning the discussion over to Jason, it\u2019s important to note that the opioid settlement \nagreement was finalized during the quarter and became effective on April 2nd.  This is an important  \nand significant step forward for our company.  We feel this settlement is the best way to deliver relief \nto communities across the United States and allow our company to move forward by putting \nthousands of lawsuits behind us.  46 of 49 eligible states, all  6 eligible territories, and over 98% of \nlitigating political subdivisions are part of the national agreement. ", "original_text": "Before turning the discussion over to Jason, it\u2019s important to note that the opioid settlement \nagreement was finalized during the quarter and became effective on April 2nd. ", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4498f1fdb78b4b44925acc3c493b8cea7ad3efe3a26cbe1a86b2b8a818fb9f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32d0cc58-70a4-4008-b106-7e6a01f509df", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nI\u2019ll elaborate on the actions we are taking to drive performance , particularly in Medical , after Jason \nreviews our third quarter results and updated outlook.  \n \n Before turning the discussion over to Jason, it\u2019s important to note that the opioid settlement \nagreement was finalized during the quarter and became effective on April 2nd.  This is an important  \nand significant step forward for our company.  We feel this settlement is the best way to deliver relief \nto communities across the United States and allow our company to move forward by putting \nthousands of lawsuits behind us. ", "original_text": " \nPage 2 of 15 \n \nI\u2019ll elaborate on the actions we are taking to drive performance , particularly in Medical , after Jason \nreviews our third quarter results and updated outlook.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b09fa85e65565b420259af905c3e99db8dab2b4cbe77c49164c2d9e8fc8453a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54a9e66e-a12b-4d9d-aeca-b849838d45d7", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nI\u2019ll elaborate on the actions we are taking to drive performance , particularly in Medical , after Jason \nreviews our third quarter results and updated outlook.  \n \n Before turning the discussion over to Jason, it\u2019s important to note that the opioid settlement \nagreement was finalized during the quarter and became effective on April 2nd.  This is an important  \nand significant step forward for our company.  We feel this settlement is the best way to deliver relief \nto communities across the United States and allow our company to move forward by putting \nthousands of lawsuits behind us.  46 of 49 eligible states, all  6 eligible territories, and over 98% of \nlitigating political subdivisions are part of the national agreement.  This comprehensive agreement will \nsettle the vast majority of the opioid lawsuits filed by state and local governmental entities.  \n \n", "original_text": "This is an important  \nand significant step forward for our company. "}, "hash": "6f81aa9b3e580f0b922281ccd9ed0885bbefae350e552ff2bb44ffe2afdf377b", "class_name": "RelatedNodeInfo"}}, "text": "Before turning the discussion over to Jason, it\u2019s important to note that the opioid settlement \nagreement was finalized during the quarter and became effective on April 2nd. ", "start_char_idx": 183, "end_char_idx": 357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54a9e66e-a12b-4d9d-aeca-b849838d45d7": {"__data__": {"id_": "54a9e66e-a12b-4d9d-aeca-b849838d45d7", "embedding": null, "metadata": {"window": " \nPage 2 of 15 \n \nI\u2019ll elaborate on the actions we are taking to drive performance , particularly in Medical , after Jason \nreviews our third quarter results and updated outlook.  \n \n Before turning the discussion over to Jason, it\u2019s important to note that the opioid settlement \nagreement was finalized during the quarter and became effective on April 2nd.  This is an important  \nand significant step forward for our company.  We feel this settlement is the best way to deliver relief \nto communities across the United States and allow our company to move forward by putting \nthousands of lawsuits behind us.  46 of 49 eligible states, all  6 eligible territories, and over 98% of \nlitigating political subdivisions are part of the national agreement.  This comprehensive agreement will \nsettle the vast majority of the opioid lawsuits filed by state and local governmental entities.  \n \n", "original_text": "This is an important  \nand significant step forward for our company. ", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4498f1fdb78b4b44925acc3c493b8cea7ad3efe3a26cbe1a86b2b8a818fb9f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "42721dda-8296-4c1b-ad3c-ee45b0e1914a", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nI\u2019ll elaborate on the actions we are taking to drive performance , particularly in Medical , after Jason \nreviews our third quarter results and updated outlook.  \n \n Before turning the discussion over to Jason, it\u2019s important to note that the opioid settlement \nagreement was finalized during the quarter and became effective on April 2nd.  This is an important  \nand significant step forward for our company.  We feel this settlement is the best way to deliver relief \nto communities across the United States and allow our company to move forward by putting \nthousands of lawsuits behind us.  46 of 49 eligible states, all  6 eligible territories, and over 98% of \nlitigating political subdivisions are part of the national agreement. ", "original_text": "Before turning the discussion over to Jason, it\u2019s important to note that the opioid settlement \nagreement was finalized during the quarter and became effective on April 2nd. ", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a243d289de08c8e90d4196bc14529e5ffb5c7b6370a0ced23c8de275a4c8812", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0958599d-8eba-447a-83f6-bc31fe888a31", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nI\u2019ll elaborate on the actions we are taking to drive performance , particularly in Medical , after Jason \nreviews our third quarter results and updated outlook.  \n \n Before turning the discussion over to Jason, it\u2019s important to note that the opioid settlement \nagreement was finalized during the quarter and became effective on April 2nd.  This is an important  \nand significant step forward for our company.  We feel this settlement is the best way to deliver relief \nto communities across the United States and allow our company to move forward by putting \nthousands of lawsuits behind us.  46 of 49 eligible states, all  6 eligible territories, and over 98% of \nlitigating political subdivisions are part of the national agreement.  This comprehensive agreement will \nsettle the vast majority of the opioid lawsuits filed by state and local governmental entities.  \n \n Additionally,  we recently reached an agreement with the State of Washington and its participating \nsubdivisions to resolve opioid -related claims on similar terms to the broader settlement, bringing the \ntotal number of states with which we have settled to 47 out of 49.  \n \n", "original_text": "We feel this settlement is the best way to deliver relief \nto communities across the United States and allow our company to move forward by putting \nthousands of lawsuits behind us. "}, "hash": "91a4f5cdac8207692edb6c49cd63be0e85ed81fa3225b24c69bc8c1feec586c8", "class_name": "RelatedNodeInfo"}}, "text": "This is an important  \nand significant step forward for our company. ", "start_char_idx": 357, "end_char_idx": 426, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0958599d-8eba-447a-83f6-bc31fe888a31": {"__data__": {"id_": "0958599d-8eba-447a-83f6-bc31fe888a31", "embedding": null, "metadata": {"window": " \nPage 2 of 15 \n \nI\u2019ll elaborate on the actions we are taking to drive performance , particularly in Medical , after Jason \nreviews our third quarter results and updated outlook.  \n \n Before turning the discussion over to Jason, it\u2019s important to note that the opioid settlement \nagreement was finalized during the quarter and became effective on April 2nd.  This is an important  \nand significant step forward for our company.  We feel this settlement is the best way to deliver relief \nto communities across the United States and allow our company to move forward by putting \nthousands of lawsuits behind us.  46 of 49 eligible states, all  6 eligible territories, and over 98% of \nlitigating political subdivisions are part of the national agreement.  This comprehensive agreement will \nsettle the vast majority of the opioid lawsuits filed by state and local governmental entities.  \n \n Additionally,  we recently reached an agreement with the State of Washington and its participating \nsubdivisions to resolve opioid -related claims on similar terms to the broader settlement, bringing the \ntotal number of states with which we have settled to 47 out of 49.  \n \n", "original_text": "We feel this settlement is the best way to deliver relief \nto communities across the United States and allow our company to move forward by putting \nthousands of lawsuits behind us. ", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4498f1fdb78b4b44925acc3c493b8cea7ad3efe3a26cbe1a86b2b8a818fb9f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54a9e66e-a12b-4d9d-aeca-b849838d45d7", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nI\u2019ll elaborate on the actions we are taking to drive performance , particularly in Medical , after Jason \nreviews our third quarter results and updated outlook.  \n \n Before turning the discussion over to Jason, it\u2019s important to note that the opioid settlement \nagreement was finalized during the quarter and became effective on April 2nd.  This is an important  \nand significant step forward for our company.  We feel this settlement is the best way to deliver relief \nto communities across the United States and allow our company to move forward by putting \nthousands of lawsuits behind us.  46 of 49 eligible states, all  6 eligible territories, and over 98% of \nlitigating political subdivisions are part of the national agreement.  This comprehensive agreement will \nsettle the vast majority of the opioid lawsuits filed by state and local governmental entities.  \n \n", "original_text": "This is an important  \nand significant step forward for our company. ", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6fd396092ddcaf0cafce627454186cf7bce009838c2e965564f6c64b707e084c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2bb5b4c-3f5b-4325-a670-3213763ce4f2", "node_type": "1", "metadata": {"window": "Before turning the discussion over to Jason, it\u2019s important to note that the opioid settlement \nagreement was finalized during the quarter and became effective on April 2nd.  This is an important  \nand significant step forward for our company.  We feel this settlement is the best way to deliver relief \nto communities across the United States and allow our company to move forward by putting \nthousands of lawsuits behind us.  46 of 49 eligible states, all  6 eligible territories, and over 98% of \nlitigating political subdivisions are part of the national agreement.  This comprehensive agreement will \nsettle the vast majority of the opioid lawsuits filed by state and local governmental entities.  \n \n Additionally,  we recently reached an agreement with the State of Washington and its participating \nsubdivisions to resolve opioid -related claims on similar terms to the broader settlement, bringing the \ntotal number of states with which we have settled to 47 out of 49.  \n \n While these settlements do not cover all opioid -related claims, these comprehensive agreements are \na significant milestone toward achieving broad resolution of governmental opioid claims, and include \ninjunctive relief terms designed, in part, to increase transparency to the supply chain for these \nproducts and demonstrate our commitment to the safety of the pharmaceutical supply chain.  \n \n", "original_text": "46 of 49 eligible states, all  6 eligible territories, and over 98% of \nlitigating political subdivisions are part of the national agreement. "}, "hash": "419a39521cc6fb0ac5f3430cffac43f18b4a6a09aa0836af26e0e567cddda18d", "class_name": "RelatedNodeInfo"}}, "text": "We feel this settlement is the best way to deliver relief \nto communities across the United States and allow our company to move forward by putting \nthousands of lawsuits behind us. ", "start_char_idx": 426, "end_char_idx": 608, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2bb5b4c-3f5b-4325-a670-3213763ce4f2": {"__data__": {"id_": "b2bb5b4c-3f5b-4325-a670-3213763ce4f2", "embedding": null, "metadata": {"window": "Before turning the discussion over to Jason, it\u2019s important to note that the opioid settlement \nagreement was finalized during the quarter and became effective on April 2nd.  This is an important  \nand significant step forward for our company.  We feel this settlement is the best way to deliver relief \nto communities across the United States and allow our company to move forward by putting \nthousands of lawsuits behind us.  46 of 49 eligible states, all  6 eligible territories, and over 98% of \nlitigating political subdivisions are part of the national agreement.  This comprehensive agreement will \nsettle the vast majority of the opioid lawsuits filed by state and local governmental entities.  \n \n Additionally,  we recently reached an agreement with the State of Washington and its participating \nsubdivisions to resolve opioid -related claims on similar terms to the broader settlement, bringing the \ntotal number of states with which we have settled to 47 out of 49.  \n \n While these settlements do not cover all opioid -related claims, these comprehensive agreements are \na significant milestone toward achieving broad resolution of governmental opioid claims, and include \ninjunctive relief terms designed, in part, to increase transparency to the supply chain for these \nproducts and demonstrate our commitment to the safety of the pharmaceutical supply chain.  \n \n", "original_text": "46 of 49 eligible states, all  6 eligible territories, and over 98% of \nlitigating political subdivisions are part of the national agreement. ", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4498f1fdb78b4b44925acc3c493b8cea7ad3efe3a26cbe1a86b2b8a818fb9f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0958599d-8eba-447a-83f6-bc31fe888a31", "node_type": "1", "metadata": {"window": " \nPage 2 of 15 \n \nI\u2019ll elaborate on the actions we are taking to drive performance , particularly in Medical , after Jason \nreviews our third quarter results and updated outlook.  \n \n Before turning the discussion over to Jason, it\u2019s important to note that the opioid settlement \nagreement was finalized during the quarter and became effective on April 2nd.  This is an important  \nand significant step forward for our company.  We feel this settlement is the best way to deliver relief \nto communities across the United States and allow our company to move forward by putting \nthousands of lawsuits behind us.  46 of 49 eligible states, all  6 eligible territories, and over 98% of \nlitigating political subdivisions are part of the national agreement.  This comprehensive agreement will \nsettle the vast majority of the opioid lawsuits filed by state and local governmental entities.  \n \n Additionally,  we recently reached an agreement with the State of Washington and its participating \nsubdivisions to resolve opioid -related claims on similar terms to the broader settlement, bringing the \ntotal number of states with which we have settled to 47 out of 49.  \n \n", "original_text": "We feel this settlement is the best way to deliver relief \nto communities across the United States and allow our company to move forward by putting \nthousands of lawsuits behind us. ", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "12890e4766b442e2e285e8388302aa785d84ace491aa423aaf64a7b515ebd9bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d981d406-88cb-43e0-93b4-8682b2efbe08", "node_type": "1", "metadata": {"window": "This is an important  \nand significant step forward for our company.  We feel this settlement is the best way to deliver relief \nto communities across the United States and allow our company to move forward by putting \nthousands of lawsuits behind us.  46 of 49 eligible states, all  6 eligible territories, and over 98% of \nlitigating political subdivisions are part of the national agreement.  This comprehensive agreement will \nsettle the vast majority of the opioid lawsuits filed by state and local governmental entities.  \n \n Additionally,  we recently reached an agreement with the State of Washington and its participating \nsubdivisions to resolve opioid -related claims on similar terms to the broader settlement, bringing the \ntotal number of states with which we have settled to 47 out of 49.  \n \n While these settlements do not cover all opioid -related claims, these comprehensive agreements are \na significant milestone toward achieving broad resolution of governmental opioid claims, and include \ninjunctive relief terms designed, in part, to increase transparency to the supply chain for these \nproducts and demonstrate our commitment to the safety of the pharmaceutical supply chain.  \n \n With that, I\u2019ll turn it over to Jason.  \n \n", "original_text": "This comprehensive agreement will \nsettle the vast majority of the opioid lawsuits filed by state and local governmental entities.  \n \n"}, "hash": "01072326ee2154a84768fcefaf4cc25898a2ac329f9025999994d123238479ed", "class_name": "RelatedNodeInfo"}}, "text": "46 of 49 eligible states, all  6 eligible territories, and over 98% of \nlitigating political subdivisions are part of the national agreement. ", "start_char_idx": 608, "end_char_idx": 750, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d981d406-88cb-43e0-93b4-8682b2efbe08": {"__data__": {"id_": "d981d406-88cb-43e0-93b4-8682b2efbe08", "embedding": null, "metadata": {"window": "This is an important  \nand significant step forward for our company.  We feel this settlement is the best way to deliver relief \nto communities across the United States and allow our company to move forward by putting \nthousands of lawsuits behind us.  46 of 49 eligible states, all  6 eligible territories, and over 98% of \nlitigating political subdivisions are part of the national agreement.  This comprehensive agreement will \nsettle the vast majority of the opioid lawsuits filed by state and local governmental entities.  \n \n Additionally,  we recently reached an agreement with the State of Washington and its participating \nsubdivisions to resolve opioid -related claims on similar terms to the broader settlement, bringing the \ntotal number of states with which we have settled to 47 out of 49.  \n \n While these settlements do not cover all opioid -related claims, these comprehensive agreements are \na significant milestone toward achieving broad resolution of governmental opioid claims, and include \ninjunctive relief terms designed, in part, to increase transparency to the supply chain for these \nproducts and demonstrate our commitment to the safety of the pharmaceutical supply chain.  \n \n With that, I\u2019ll turn it over to Jason.  \n \n", "original_text": "This comprehensive agreement will \nsettle the vast majority of the opioid lawsuits filed by state and local governmental entities.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4498f1fdb78b4b44925acc3c493b8cea7ad3efe3a26cbe1a86b2b8a818fb9f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2bb5b4c-3f5b-4325-a670-3213763ce4f2", "node_type": "1", "metadata": {"window": "Before turning the discussion over to Jason, it\u2019s important to note that the opioid settlement \nagreement was finalized during the quarter and became effective on April 2nd.  This is an important  \nand significant step forward for our company.  We feel this settlement is the best way to deliver relief \nto communities across the United States and allow our company to move forward by putting \nthousands of lawsuits behind us.  46 of 49 eligible states, all  6 eligible territories, and over 98% of \nlitigating political subdivisions are part of the national agreement.  This comprehensive agreement will \nsettle the vast majority of the opioid lawsuits filed by state and local governmental entities.  \n \n Additionally,  we recently reached an agreement with the State of Washington and its participating \nsubdivisions to resolve opioid -related claims on similar terms to the broader settlement, bringing the \ntotal number of states with which we have settled to 47 out of 49.  \n \n While these settlements do not cover all opioid -related claims, these comprehensive agreements are \na significant milestone toward achieving broad resolution of governmental opioid claims, and include \ninjunctive relief terms designed, in part, to increase transparency to the supply chain for these \nproducts and demonstrate our commitment to the safety of the pharmaceutical supply chain.  \n \n", "original_text": "46 of 49 eligible states, all  6 eligible territories, and over 98% of \nlitigating political subdivisions are part of the national agreement. ", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec9fd06f032dc92be0c886058c3ab7b4fe773fa6dae2c0ab40a34723288edee9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65e69f90-4d3b-4920-8807-7fa36ffb0455", "node_type": "1", "metadata": {"window": "We feel this settlement is the best way to deliver relief \nto communities across the United States and allow our company to move forward by putting \nthousands of lawsuits behind us.  46 of 49 eligible states, all  6 eligible territories, and over 98% of \nlitigating political subdivisions are part of the national agreement.  This comprehensive agreement will \nsettle the vast majority of the opioid lawsuits filed by state and local governmental entities.  \n \n Additionally,  we recently reached an agreement with the State of Washington and its participating \nsubdivisions to resolve opioid -related claims on similar terms to the broader settlement, bringing the \ntotal number of states with which we have settled to 47 out of 49.  \n \n While these settlements do not cover all opioid -related claims, these comprehensive agreements are \na significant milestone toward achieving broad resolution of governmental opioid claims, and include \ninjunctive relief terms designed, in part, to increase transparency to the supply chain for these \nproducts and demonstrate our commitment to the safety of the pharmaceutical supply chain.  \n \n With that, I\u2019ll turn it over to Jason.  \n \n Jason Hollar:  Thanks Mike, and good morning, everyone.  \n \n", "original_text": "Additionally,  we recently reached an agreement with the State of Washington and its participating \nsubdivisions to resolve opioid -related claims on similar terms to the broader settlement, bringing the \ntotal number of states with which we have settled to 47 out of 49.  \n \n"}, "hash": "1845d3944446eb3218ef1a3b2c0aa00af42bf6be32de325e82c3377bdd9ec8e7", "class_name": "RelatedNodeInfo"}}, "text": "This comprehensive agreement will \nsettle the vast majority of the opioid lawsuits filed by state and local governmental entities.  \n \n", "start_char_idx": 750, "end_char_idx": 885, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65e69f90-4d3b-4920-8807-7fa36ffb0455": {"__data__": {"id_": "65e69f90-4d3b-4920-8807-7fa36ffb0455", "embedding": null, "metadata": {"window": "We feel this settlement is the best way to deliver relief \nto communities across the United States and allow our company to move forward by putting \nthousands of lawsuits behind us.  46 of 49 eligible states, all  6 eligible territories, and over 98% of \nlitigating political subdivisions are part of the national agreement.  This comprehensive agreement will \nsettle the vast majority of the opioid lawsuits filed by state and local governmental entities.  \n \n Additionally,  we recently reached an agreement with the State of Washington and its participating \nsubdivisions to resolve opioid -related claims on similar terms to the broader settlement, bringing the \ntotal number of states with which we have settled to 47 out of 49.  \n \n While these settlements do not cover all opioid -related claims, these comprehensive agreements are \na significant milestone toward achieving broad resolution of governmental opioid claims, and include \ninjunctive relief terms designed, in part, to increase transparency to the supply chain for these \nproducts and demonstrate our commitment to the safety of the pharmaceutical supply chain.  \n \n With that, I\u2019ll turn it over to Jason.  \n \n Jason Hollar:  Thanks Mike, and good morning, everyone.  \n \n", "original_text": "Additionally,  we recently reached an agreement with the State of Washington and its participating \nsubdivisions to resolve opioid -related claims on similar terms to the broader settlement, bringing the \ntotal number of states with which we have settled to 47 out of 49.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4498f1fdb78b4b44925acc3c493b8cea7ad3efe3a26cbe1a86b2b8a818fb9f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d981d406-88cb-43e0-93b4-8682b2efbe08", "node_type": "1", "metadata": {"window": "This is an important  \nand significant step forward for our company.  We feel this settlement is the best way to deliver relief \nto communities across the United States and allow our company to move forward by putting \nthousands of lawsuits behind us.  46 of 49 eligible states, all  6 eligible territories, and over 98% of \nlitigating political subdivisions are part of the national agreement.  This comprehensive agreement will \nsettle the vast majority of the opioid lawsuits filed by state and local governmental entities.  \n \n Additionally,  we recently reached an agreement with the State of Washington and its participating \nsubdivisions to resolve opioid -related claims on similar terms to the broader settlement, bringing the \ntotal number of states with which we have settled to 47 out of 49.  \n \n While these settlements do not cover all opioid -related claims, these comprehensive agreements are \na significant milestone toward achieving broad resolution of governmental opioid claims, and include \ninjunctive relief terms designed, in part, to increase transparency to the supply chain for these \nproducts and demonstrate our commitment to the safety of the pharmaceutical supply chain.  \n \n With that, I\u2019ll turn it over to Jason.  \n \n", "original_text": "This comprehensive agreement will \nsettle the vast majority of the opioid lawsuits filed by state and local governmental entities.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d05f5261b32c9e7b85aeb04145d30a47391b6343310d7bbe581abe8f0c97bfe2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b7e229f-4221-4be1-9994-ef2b44054550", "node_type": "1", "metadata": {"window": "46 of 49 eligible states, all  6 eligible territories, and over 98% of \nlitigating political subdivisions are part of the national agreement.  This comprehensive agreement will \nsettle the vast majority of the opioid lawsuits filed by state and local governmental entities.  \n \n Additionally,  we recently reached an agreement with the State of Washington and its participating \nsubdivisions to resolve opioid -related claims on similar terms to the broader settlement, bringing the \ntotal number of states with which we have settled to 47 out of 49.  \n \n While these settlements do not cover all opioid -related claims, these comprehensive agreements are \na significant milestone toward achieving broad resolution of governmental opioid claims, and include \ninjunctive relief terms designed, in part, to increase transparency to the supply chain for these \nproducts and demonstrate our commitment to the safety of the pharmaceutical supply chain.  \n \n With that, I\u2019ll turn it over to Jason.  \n \n Jason Hollar:  Thanks Mike, and good morning, everyone.  \n \n Beginning with total co mpany results, third quarter revenue increased 14% to $45 billion, driven by \nsales growth from existing and net new Pharma customers.  \n \n", "original_text": "While these settlements do not cover all opioid -related claims, these comprehensive agreements are \na significant milestone toward achieving broad resolution of governmental opioid claims, and include \ninjunctive relief terms designed, in part, to increase transparency to the supply chain for these \nproducts and demonstrate our commitment to the safety of the pharmaceutical supply chain.  \n \n"}, "hash": "e260eb18c84cb1206cbed2b5fcf7169c4c2eaf5af97d294801acb0ef34664eca", "class_name": "RelatedNodeInfo"}}, "text": "Additionally,  we recently reached an agreement with the State of Washington and its participating \nsubdivisions to resolve opioid -related claims on similar terms to the broader settlement, bringing the \ntotal number of states with which we have settled to 47 out of 49.  \n \n", "start_char_idx": 885, "end_char_idx": 1161, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b7e229f-4221-4be1-9994-ef2b44054550": {"__data__": {"id_": "1b7e229f-4221-4be1-9994-ef2b44054550", "embedding": null, "metadata": {"window": "46 of 49 eligible states, all  6 eligible territories, and over 98% of \nlitigating political subdivisions are part of the national agreement.  This comprehensive agreement will \nsettle the vast majority of the opioid lawsuits filed by state and local governmental entities.  \n \n Additionally,  we recently reached an agreement with the State of Washington and its participating \nsubdivisions to resolve opioid -related claims on similar terms to the broader settlement, bringing the \ntotal number of states with which we have settled to 47 out of 49.  \n \n While these settlements do not cover all opioid -related claims, these comprehensive agreements are \na significant milestone toward achieving broad resolution of governmental opioid claims, and include \ninjunctive relief terms designed, in part, to increase transparency to the supply chain for these \nproducts and demonstrate our commitment to the safety of the pharmaceutical supply chain.  \n \n With that, I\u2019ll turn it over to Jason.  \n \n Jason Hollar:  Thanks Mike, and good morning, everyone.  \n \n Beginning with total co mpany results, third quarter revenue increased 14% to $45 billion, driven by \nsales growth from existing and net new Pharma customers.  \n \n", "original_text": "While these settlements do not cover all opioid -related claims, these comprehensive agreements are \na significant milestone toward achieving broad resolution of governmental opioid claims, and include \ninjunctive relief terms designed, in part, to increase transparency to the supply chain for these \nproducts and demonstrate our commitment to the safety of the pharmaceutical supply chain.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4498f1fdb78b4b44925acc3c493b8cea7ad3efe3a26cbe1a86b2b8a818fb9f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65e69f90-4d3b-4920-8807-7fa36ffb0455", "node_type": "1", "metadata": {"window": "We feel this settlement is the best way to deliver relief \nto communities across the United States and allow our company to move forward by putting \nthousands of lawsuits behind us.  46 of 49 eligible states, all  6 eligible territories, and over 98% of \nlitigating political subdivisions are part of the national agreement.  This comprehensive agreement will \nsettle the vast majority of the opioid lawsuits filed by state and local governmental entities.  \n \n Additionally,  we recently reached an agreement with the State of Washington and its participating \nsubdivisions to resolve opioid -related claims on similar terms to the broader settlement, bringing the \ntotal number of states with which we have settled to 47 out of 49.  \n \n While these settlements do not cover all opioid -related claims, these comprehensive agreements are \na significant milestone toward achieving broad resolution of governmental opioid claims, and include \ninjunctive relief terms designed, in part, to increase transparency to the supply chain for these \nproducts and demonstrate our commitment to the safety of the pharmaceutical supply chain.  \n \n With that, I\u2019ll turn it over to Jason.  \n \n Jason Hollar:  Thanks Mike, and good morning, everyone.  \n \n", "original_text": "Additionally,  we recently reached an agreement with the State of Washington and its participating \nsubdivisions to resolve opioid -related claims on similar terms to the broader settlement, bringing the \ntotal number of states with which we have settled to 47 out of 49.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6de8f6cc3dd2fc21b0bf7627cf0f2a7186e6b4baafabc5f9b760dcf871916fa4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02b4e416-a019-491b-82c6-982b212afce2", "node_type": "1", "metadata": {"window": "This comprehensive agreement will \nsettle the vast majority of the opioid lawsuits filed by state and local governmental entities.  \n \n Additionally,  we recently reached an agreement with the State of Washington and its participating \nsubdivisions to resolve opioid -related claims on similar terms to the broader settlement, bringing the \ntotal number of states with which we have settled to 47 out of 49.  \n \n While these settlements do not cover all opioid -related claims, these comprehensive agreements are \na significant milestone toward achieving broad resolution of governmental opioid claims, and include \ninjunctive relief terms designed, in part, to increase transparency to the supply chain for these \nproducts and demonstrate our commitment to the safety of the pharmaceutical supply chain.  \n \n With that, I\u2019ll turn it over to Jason.  \n \n Jason Hollar:  Thanks Mike, and good morning, everyone.  \n \n Beginning with total co mpany results, third quarter revenue increased 14% to $45 billion, driven by \nsales growth from existing and net new Pharma customers.  \n \n Total gross margin was $1.7 billion, a decrease of 7%  due to the elevated supply chain costs in \nMedical and the Cordis divestiture, partially offset by generics program performance.  \n \n", "original_text": "With that, I\u2019ll turn it over to Jason.  \n \n"}, "hash": "7be4b980aa6c1f5e553f40dace6c1750fa38d440b4cd14c6073e30184a34d72f", "class_name": "RelatedNodeInfo"}}, "text": "While these settlements do not cover all opioid -related claims, these comprehensive agreements are \na significant milestone toward achieving broad resolution of governmental opioid claims, and include \ninjunctive relief terms designed, in part, to increase transparency to the supply chain for these \nproducts and demonstrate our commitment to the safety of the pharmaceutical supply chain.  \n \n", "start_char_idx": 1161, "end_char_idx": 1557, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02b4e416-a019-491b-82c6-982b212afce2": {"__data__": {"id_": "02b4e416-a019-491b-82c6-982b212afce2", "embedding": null, "metadata": {"window": "This comprehensive agreement will \nsettle the vast majority of the opioid lawsuits filed by state and local governmental entities.  \n \n Additionally,  we recently reached an agreement with the State of Washington and its participating \nsubdivisions to resolve opioid -related claims on similar terms to the broader settlement, bringing the \ntotal number of states with which we have settled to 47 out of 49.  \n \n While these settlements do not cover all opioid -related claims, these comprehensive agreements are \na significant milestone toward achieving broad resolution of governmental opioid claims, and include \ninjunctive relief terms designed, in part, to increase transparency to the supply chain for these \nproducts and demonstrate our commitment to the safety of the pharmaceutical supply chain.  \n \n With that, I\u2019ll turn it over to Jason.  \n \n Jason Hollar:  Thanks Mike, and good morning, everyone.  \n \n Beginning with total co mpany results, third quarter revenue increased 14% to $45 billion, driven by \nsales growth from existing and net new Pharma customers.  \n \n Total gross margin was $1.7 billion, a decrease of 7%  due to the elevated supply chain costs in \nMedical and the Cordis divestiture, partially offset by generics program performance.  \n \n", "original_text": "With that, I\u2019ll turn it over to Jason.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4498f1fdb78b4b44925acc3c493b8cea7ad3efe3a26cbe1a86b2b8a818fb9f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b7e229f-4221-4be1-9994-ef2b44054550", "node_type": "1", "metadata": {"window": "46 of 49 eligible states, all  6 eligible territories, and over 98% of \nlitigating political subdivisions are part of the national agreement.  This comprehensive agreement will \nsettle the vast majority of the opioid lawsuits filed by state and local governmental entities.  \n \n Additionally,  we recently reached an agreement with the State of Washington and its participating \nsubdivisions to resolve opioid -related claims on similar terms to the broader settlement, bringing the \ntotal number of states with which we have settled to 47 out of 49.  \n \n While these settlements do not cover all opioid -related claims, these comprehensive agreements are \na significant milestone toward achieving broad resolution of governmental opioid claims, and include \ninjunctive relief terms designed, in part, to increase transparency to the supply chain for these \nproducts and demonstrate our commitment to the safety of the pharmaceutical supply chain.  \n \n With that, I\u2019ll turn it over to Jason.  \n \n Jason Hollar:  Thanks Mike, and good morning, everyone.  \n \n Beginning with total co mpany results, third quarter revenue increased 14% to $45 billion, driven by \nsales growth from existing and net new Pharma customers.  \n \n", "original_text": "While these settlements do not cover all opioid -related claims, these comprehensive agreements are \na significant milestone toward achieving broad resolution of governmental opioid claims, and include \ninjunctive relief terms designed, in part, to increase transparency to the supply chain for these \nproducts and demonstrate our commitment to the safety of the pharmaceutical supply chain.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f0f515bf207a0121bd83e0d1b838e17259d7860a69d60442614f17e483103ef7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1c829d4-ebe8-408c-a577-524f42309f36", "node_type": "1", "metadata": {"window": "Additionally,  we recently reached an agreement with the State of Washington and its participating \nsubdivisions to resolve opioid -related claims on similar terms to the broader settlement, bringing the \ntotal number of states with which we have settled to 47 out of 49.  \n \n While these settlements do not cover all opioid -related claims, these comprehensive agreements are \na significant milestone toward achieving broad resolution of governmental opioid claims, and include \ninjunctive relief terms designed, in part, to increase transparency to the supply chain for these \nproducts and demonstrate our commitment to the safety of the pharmaceutical supply chain.  \n \n With that, I\u2019ll turn it over to Jason.  \n \n Jason Hollar:  Thanks Mike, and good morning, everyone.  \n \n Beginning with total co mpany results, third quarter revenue increased 14% to $45 billion, driven by \nsales growth from existing and net new Pharma customers.  \n \n Total gross margin was $1.7 billion, a decrease of 7%  due to the elevated supply chain costs in \nMedical and the Cordis divestiture, partially offset by generics program performance.  \n \n Consolidated SG&A increased 2% to $1.1 billion, reflecting higher operations expenses and \npreviously anticipated IT investment s, partially offset by the Cordis divestiture and cost savings \ninitiatives.  \n \n", "original_text": "Jason Hollar:  Thanks Mike, and good morning, everyone.  \n \n"}, "hash": "a9b2419027e065fc3838de72c1d5d2531c240a2c20ed335a188395f35841bd54", "class_name": "RelatedNodeInfo"}}, "text": "With that, I\u2019ll turn it over to Jason.  \n \n", "start_char_idx": 1557, "end_char_idx": 1600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1c829d4-ebe8-408c-a577-524f42309f36": {"__data__": {"id_": "d1c829d4-ebe8-408c-a577-524f42309f36", "embedding": null, "metadata": {"window": "Additionally,  we recently reached an agreement with the State of Washington and its participating \nsubdivisions to resolve opioid -related claims on similar terms to the broader settlement, bringing the \ntotal number of states with which we have settled to 47 out of 49.  \n \n While these settlements do not cover all opioid -related claims, these comprehensive agreements are \na significant milestone toward achieving broad resolution of governmental opioid claims, and include \ninjunctive relief terms designed, in part, to increase transparency to the supply chain for these \nproducts and demonstrate our commitment to the safety of the pharmaceutical supply chain.  \n \n With that, I\u2019ll turn it over to Jason.  \n \n Jason Hollar:  Thanks Mike, and good morning, everyone.  \n \n Beginning with total co mpany results, third quarter revenue increased 14% to $45 billion, driven by \nsales growth from existing and net new Pharma customers.  \n \n Total gross margin was $1.7 billion, a decrease of 7%  due to the elevated supply chain costs in \nMedical and the Cordis divestiture, partially offset by generics program performance.  \n \n Consolidated SG&A increased 2% to $1.1 billion, reflecting higher operations expenses and \npreviously anticipated IT investment s, partially offset by the Cordis divestiture and cost savings \ninitiatives.  \n \n", "original_text": "Jason Hollar:  Thanks Mike, and good morning, everyone.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4498f1fdb78b4b44925acc3c493b8cea7ad3efe3a26cbe1a86b2b8a818fb9f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02b4e416-a019-491b-82c6-982b212afce2", "node_type": "1", "metadata": {"window": "This comprehensive agreement will \nsettle the vast majority of the opioid lawsuits filed by state and local governmental entities.  \n \n Additionally,  we recently reached an agreement with the State of Washington and its participating \nsubdivisions to resolve opioid -related claims on similar terms to the broader settlement, bringing the \ntotal number of states with which we have settled to 47 out of 49.  \n \n While these settlements do not cover all opioid -related claims, these comprehensive agreements are \na significant milestone toward achieving broad resolution of governmental opioid claims, and include \ninjunctive relief terms designed, in part, to increase transparency to the supply chain for these \nproducts and demonstrate our commitment to the safety of the pharmaceutical supply chain.  \n \n With that, I\u2019ll turn it over to Jason.  \n \n Jason Hollar:  Thanks Mike, and good morning, everyone.  \n \n Beginning with total co mpany results, third quarter revenue increased 14% to $45 billion, driven by \nsales growth from existing and net new Pharma customers.  \n \n Total gross margin was $1.7 billion, a decrease of 7%  due to the elevated supply chain costs in \nMedical and the Cordis divestiture, partially offset by generics program performance.  \n \n", "original_text": "With that, I\u2019ll turn it over to Jason.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c5999a5be2d3448b128b1eb8c67b7c78e7ce6c3fac23f2fa78e872e453adb18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa1d083b-1725-4351-83b6-1293aa5e9099", "node_type": "1", "metadata": {"window": "While these settlements do not cover all opioid -related claims, these comprehensive agreements are \na significant milestone toward achieving broad resolution of governmental opioid claims, and include \ninjunctive relief terms designed, in part, to increase transparency to the supply chain for these \nproducts and demonstrate our commitment to the safety of the pharmaceutical supply chain.  \n \n With that, I\u2019ll turn it over to Jason.  \n \n Jason Hollar:  Thanks Mike, and good morning, everyone.  \n \n Beginning with total co mpany results, third quarter revenue increased 14% to $45 billion, driven by \nsales growth from existing and net new Pharma customers.  \n \n Total gross margin was $1.7 billion, a decrease of 7%  due to the elevated supply chain costs in \nMedical and the Cordis divestiture, partially offset by generics program performance.  \n \n Consolidated SG&A increased 2% to $1.1 billion, reflecting higher operations expenses and \npreviously anticipated IT investment s, partially offset by the Cordis divestiture and cost savings \ninitiatives.  \n \n Third quarter operating earnings decreased 21% to $545 million, primarily reflecting the elevated \nsupply chain costs in Medical.  \n \n", "original_text": "Beginning with total co mpany results, third quarter revenue increased 14% to $45 billion, driven by \nsales growth from existing and net new Pharma customers.  \n \n"}, "hash": "04406199a706f59f52ff12d99d0e37445320a6e81b07b295d6a172da02f0eec5", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Thanks Mike, and good morning, everyone.  \n \n", "start_char_idx": 1600, "end_char_idx": 1660, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa1d083b-1725-4351-83b6-1293aa5e9099": {"__data__": {"id_": "aa1d083b-1725-4351-83b6-1293aa5e9099", "embedding": null, "metadata": {"window": "While these settlements do not cover all opioid -related claims, these comprehensive agreements are \na significant milestone toward achieving broad resolution of governmental opioid claims, and include \ninjunctive relief terms designed, in part, to increase transparency to the supply chain for these \nproducts and demonstrate our commitment to the safety of the pharmaceutical supply chain.  \n \n With that, I\u2019ll turn it over to Jason.  \n \n Jason Hollar:  Thanks Mike, and good morning, everyone.  \n \n Beginning with total co mpany results, third quarter revenue increased 14% to $45 billion, driven by \nsales growth from existing and net new Pharma customers.  \n \n Total gross margin was $1.7 billion, a decrease of 7%  due to the elevated supply chain costs in \nMedical and the Cordis divestiture, partially offset by generics program performance.  \n \n Consolidated SG&A increased 2% to $1.1 billion, reflecting higher operations expenses and \npreviously anticipated IT investment s, partially offset by the Cordis divestiture and cost savings \ninitiatives.  \n \n Third quarter operating earnings decreased 21% to $545 million, primarily reflecting the elevated \nsupply chain costs in Medical.  \n \n", "original_text": "Beginning with total co mpany results, third quarter revenue increased 14% to $45 billion, driven by \nsales growth from existing and net new Pharma customers.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4498f1fdb78b4b44925acc3c493b8cea7ad3efe3a26cbe1a86b2b8a818fb9f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1c829d4-ebe8-408c-a577-524f42309f36", "node_type": "1", "metadata": {"window": "Additionally,  we recently reached an agreement with the State of Washington and its participating \nsubdivisions to resolve opioid -related claims on similar terms to the broader settlement, bringing the \ntotal number of states with which we have settled to 47 out of 49.  \n \n While these settlements do not cover all opioid -related claims, these comprehensive agreements are \na significant milestone toward achieving broad resolution of governmental opioid claims, and include \ninjunctive relief terms designed, in part, to increase transparency to the supply chain for these \nproducts and demonstrate our commitment to the safety of the pharmaceutical supply chain.  \n \n With that, I\u2019ll turn it over to Jason.  \n \n Jason Hollar:  Thanks Mike, and good morning, everyone.  \n \n Beginning with total co mpany results, third quarter revenue increased 14% to $45 billion, driven by \nsales growth from existing and net new Pharma customers.  \n \n Total gross margin was $1.7 billion, a decrease of 7%  due to the elevated supply chain costs in \nMedical and the Cordis divestiture, partially offset by generics program performance.  \n \n Consolidated SG&A increased 2% to $1.1 billion, reflecting higher operations expenses and \npreviously anticipated IT investment s, partially offset by the Cordis divestiture and cost savings \ninitiatives.  \n \n", "original_text": "Jason Hollar:  Thanks Mike, and good morning, everyone.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a255d34c1f9b72c871685ab57e113db39094ef600039bc53f62970795aafc786", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "094d0bb6-bfca-4e59-a0e9-e02a806e0b62", "node_type": "1", "metadata": {"window": "With that, I\u2019ll turn it over to Jason.  \n \n Jason Hollar:  Thanks Mike, and good morning, everyone.  \n \n Beginning with total co mpany results, third quarter revenue increased 14% to $45 billion, driven by \nsales growth from existing and net new Pharma customers.  \n \n Total gross margin was $1.7 billion, a decrease of 7%  due to the elevated supply chain costs in \nMedical and the Cordis divestiture, partially offset by generics program performance.  \n \n Consolidated SG&A increased 2% to $1.1 billion, reflecting higher operations expenses and \npreviously anticipated IT investment s, partially offset by the Cordis divestiture and cost savings \ninitiatives.  \n \n Third quarter operating earnings decreased 21% to $545 million, primarily reflecting the elevated \nsupply chain costs in Medical.  \n \n Moving below the line, Interest and Other incre ased by $8 million, which reflects one -time gains in \nOther income in the prior year, partially offset by lower interest expense from debt reduction actions.  \n \n", "original_text": "Total gross margin was $1.7 billion, a decrease of 7%  due to the elevated supply chain costs in \nMedical and the Cordis divestiture, partially offset by generics program performance.  \n \n"}, "hash": "cac51ed6c6f9aba2eeae0d43df28cea679caf2a99a7f746cb8ed56290879aaa3", "class_name": "RelatedNodeInfo"}}, "text": "Beginning with total co mpany results, third quarter revenue increased 14% to $45 billion, driven by \nsales growth from existing and net new Pharma customers.  \n \n", "start_char_idx": 1660, "end_char_idx": 1823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "094d0bb6-bfca-4e59-a0e9-e02a806e0b62": {"__data__": {"id_": "094d0bb6-bfca-4e59-a0e9-e02a806e0b62", "embedding": null, "metadata": {"window": "With that, I\u2019ll turn it over to Jason.  \n \n Jason Hollar:  Thanks Mike, and good morning, everyone.  \n \n Beginning with total co mpany results, third quarter revenue increased 14% to $45 billion, driven by \nsales growth from existing and net new Pharma customers.  \n \n Total gross margin was $1.7 billion, a decrease of 7%  due to the elevated supply chain costs in \nMedical and the Cordis divestiture, partially offset by generics program performance.  \n \n Consolidated SG&A increased 2% to $1.1 billion, reflecting higher operations expenses and \npreviously anticipated IT investment s, partially offset by the Cordis divestiture and cost savings \ninitiatives.  \n \n Third quarter operating earnings decreased 21% to $545 million, primarily reflecting the elevated \nsupply chain costs in Medical.  \n \n Moving below the line, Interest and Other incre ased by $8 million, which reflects one -time gains in \nOther income in the prior year, partially offset by lower interest expense from debt reduction actions.  \n \n", "original_text": "Total gross margin was $1.7 billion, a decrease of 7%  due to the elevated supply chain costs in \nMedical and the Cordis divestiture, partially offset by generics program performance.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4498f1fdb78b4b44925acc3c493b8cea7ad3efe3a26cbe1a86b2b8a818fb9f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa1d083b-1725-4351-83b6-1293aa5e9099", "node_type": "1", "metadata": {"window": "While these settlements do not cover all opioid -related claims, these comprehensive agreements are \na significant milestone toward achieving broad resolution of governmental opioid claims, and include \ninjunctive relief terms designed, in part, to increase transparency to the supply chain for these \nproducts and demonstrate our commitment to the safety of the pharmaceutical supply chain.  \n \n With that, I\u2019ll turn it over to Jason.  \n \n Jason Hollar:  Thanks Mike, and good morning, everyone.  \n \n Beginning with total co mpany results, third quarter revenue increased 14% to $45 billion, driven by \nsales growth from existing and net new Pharma customers.  \n \n Total gross margin was $1.7 billion, a decrease of 7%  due to the elevated supply chain costs in \nMedical and the Cordis divestiture, partially offset by generics program performance.  \n \n Consolidated SG&A increased 2% to $1.1 billion, reflecting higher operations expenses and \npreviously anticipated IT investment s, partially offset by the Cordis divestiture and cost savings \ninitiatives.  \n \n Third quarter operating earnings decreased 21% to $545 million, primarily reflecting the elevated \nsupply chain costs in Medical.  \n \n", "original_text": "Beginning with total co mpany results, third quarter revenue increased 14% to $45 billion, driven by \nsales growth from existing and net new Pharma customers.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6dec8e1ee5194e7de9d5c82dd609ad22b94c4d2e9e05f79f9ec1d78e20cd26e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "839af643-252c-4d9b-b9b8-ff26a787eb09", "node_type": "1", "metadata": {"window": "Jason Hollar:  Thanks Mike, and good morning, everyone.  \n \n Beginning with total co mpany results, third quarter revenue increased 14% to $45 billion, driven by \nsales growth from existing and net new Pharma customers.  \n \n Total gross margin was $1.7 billion, a decrease of 7%  due to the elevated supply chain costs in \nMedical and the Cordis divestiture, partially offset by generics program performance.  \n \n Consolidated SG&A increased 2% to $1.1 billion, reflecting higher operations expenses and \npreviously anticipated IT investment s, partially offset by the Cordis divestiture and cost savings \ninitiatives.  \n \n Third quarter operating earnings decreased 21% to $545 million, primarily reflecting the elevated \nsupply chain costs in Medical.  \n \n Moving below the line, Interest and Other incre ased by $8 million, which reflects one -time gains in \nOther income in the prior year, partially offset by lower interest expense from debt reduction actions.  \n \n Our third quarter effective tax rate finished at 20.1%, eleven percentage points lower than the p rior \nyear due to certain discrete items affecting both periods.  \n", "original_text": "Consolidated SG&A increased 2% to $1.1 billion, reflecting higher operations expenses and \npreviously anticipated IT investment s, partially offset by the Cordis divestiture and cost savings \ninitiatives.  \n \n"}, "hash": "33bc2f02b0f6bb1d6845800a6f8d9e7ddea623f7f223f3370da8af84add50cd1", "class_name": "RelatedNodeInfo"}}, "text": "Total gross margin was $1.7 billion, a decrease of 7%  due to the elevated supply chain costs in \nMedical and the Cordis divestiture, partially offset by generics program performance.  \n \n", "start_char_idx": 1823, "end_char_idx": 2011, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "839af643-252c-4d9b-b9b8-ff26a787eb09": {"__data__": {"id_": "839af643-252c-4d9b-b9b8-ff26a787eb09", "embedding": null, "metadata": {"window": "Jason Hollar:  Thanks Mike, and good morning, everyone.  \n \n Beginning with total co mpany results, third quarter revenue increased 14% to $45 billion, driven by \nsales growth from existing and net new Pharma customers.  \n \n Total gross margin was $1.7 billion, a decrease of 7%  due to the elevated supply chain costs in \nMedical and the Cordis divestiture, partially offset by generics program performance.  \n \n Consolidated SG&A increased 2% to $1.1 billion, reflecting higher operations expenses and \npreviously anticipated IT investment s, partially offset by the Cordis divestiture and cost savings \ninitiatives.  \n \n Third quarter operating earnings decreased 21% to $545 million, primarily reflecting the elevated \nsupply chain costs in Medical.  \n \n Moving below the line, Interest and Other incre ased by $8 million, which reflects one -time gains in \nOther income in the prior year, partially offset by lower interest expense from debt reduction actions.  \n \n Our third quarter effective tax rate finished at 20.1%, eleven percentage points lower than the p rior \nyear due to certain discrete items affecting both periods.  \n", "original_text": "Consolidated SG&A increased 2% to $1.1 billion, reflecting higher operations expenses and \npreviously anticipated IT investment s, partially offset by the Cordis divestiture and cost savings \ninitiatives.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4498f1fdb78b4b44925acc3c493b8cea7ad3efe3a26cbe1a86b2b8a818fb9f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "094d0bb6-bfca-4e59-a0e9-e02a806e0b62", "node_type": "1", "metadata": {"window": "With that, I\u2019ll turn it over to Jason.  \n \n Jason Hollar:  Thanks Mike, and good morning, everyone.  \n \n Beginning with total co mpany results, third quarter revenue increased 14% to $45 billion, driven by \nsales growth from existing and net new Pharma customers.  \n \n Total gross margin was $1.7 billion, a decrease of 7%  due to the elevated supply chain costs in \nMedical and the Cordis divestiture, partially offset by generics program performance.  \n \n Consolidated SG&A increased 2% to $1.1 billion, reflecting higher operations expenses and \npreviously anticipated IT investment s, partially offset by the Cordis divestiture and cost savings \ninitiatives.  \n \n Third quarter operating earnings decreased 21% to $545 million, primarily reflecting the elevated \nsupply chain costs in Medical.  \n \n Moving below the line, Interest and Other incre ased by $8 million, which reflects one -time gains in \nOther income in the prior year, partially offset by lower interest expense from debt reduction actions.  \n \n", "original_text": "Total gross margin was $1.7 billion, a decrease of 7%  due to the elevated supply chain costs in \nMedical and the Cordis divestiture, partially offset by generics program performance.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa6f288b773314cae1ffff461f3721a517fe7f7fc0cad6a2b47cc91bfbe24c7d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4831a1e1-4d97-4e6f-b374-8304dee7dce6", "node_type": "1", "metadata": {"window": "Beginning with total co mpany results, third quarter revenue increased 14% to $45 billion, driven by \nsales growth from existing and net new Pharma customers.  \n \n Total gross margin was $1.7 billion, a decrease of 7%  due to the elevated supply chain costs in \nMedical and the Cordis divestiture, partially offset by generics program performance.  \n \n Consolidated SG&A increased 2% to $1.1 billion, reflecting higher operations expenses and \npreviously anticipated IT investment s, partially offset by the Cordis divestiture and cost savings \ninitiatives.  \n \n Third quarter operating earnings decreased 21% to $545 million, primarily reflecting the elevated \nsupply chain costs in Medical.  \n \n Moving below the line, Interest and Other incre ased by $8 million, which reflects one -time gains in \nOther income in the prior year, partially offset by lower interest expense from debt reduction actions.  \n \n Our third quarter effective tax rate finished at 20.1%, eleven percentage points lower than the p rior \nyear due to certain discrete items affecting both periods.  \n Average diluted shares outstanding were 277 million, 6% lower than a year ago, due to share \nrepurchases. ", "original_text": "Third quarter operating earnings decreased 21% to $545 million, primarily reflecting the elevated \nsupply chain costs in Medical.  \n \n"}, "hash": "38bdff58ed273d4b7cb95be7b92501333a4a9f30dc66692ef05a2277b52b0e22", "class_name": "RelatedNodeInfo"}}, "text": "Consolidated SG&A increased 2% to $1.1 billion, reflecting higher operations expenses and \npreviously anticipated IT investment s, partially offset by the Cordis divestiture and cost savings \ninitiatives.  \n \n", "start_char_idx": 2011, "end_char_idx": 2220, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4831a1e1-4d97-4e6f-b374-8304dee7dce6": {"__data__": {"id_": "4831a1e1-4d97-4e6f-b374-8304dee7dce6", "embedding": null, "metadata": {"window": "Beginning with total co mpany results, third quarter revenue increased 14% to $45 billion, driven by \nsales growth from existing and net new Pharma customers.  \n \n Total gross margin was $1.7 billion, a decrease of 7%  due to the elevated supply chain costs in \nMedical and the Cordis divestiture, partially offset by generics program performance.  \n \n Consolidated SG&A increased 2% to $1.1 billion, reflecting higher operations expenses and \npreviously anticipated IT investment s, partially offset by the Cordis divestiture and cost savings \ninitiatives.  \n \n Third quarter operating earnings decreased 21% to $545 million, primarily reflecting the elevated \nsupply chain costs in Medical.  \n \n Moving below the line, Interest and Other incre ased by $8 million, which reflects one -time gains in \nOther income in the prior year, partially offset by lower interest expense from debt reduction actions.  \n \n Our third quarter effective tax rate finished at 20.1%, eleven percentage points lower than the p rior \nyear due to certain discrete items affecting both periods.  \n Average diluted shares outstanding were 277 million, 6% lower than a year ago, due to share \nrepurchases. ", "original_text": "Third quarter operating earnings decreased 21% to $545 million, primarily reflecting the elevated \nsupply chain costs in Medical.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4498f1fdb78b4b44925acc3c493b8cea7ad3efe3a26cbe1a86b2b8a818fb9f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "839af643-252c-4d9b-b9b8-ff26a787eb09", "node_type": "1", "metadata": {"window": "Jason Hollar:  Thanks Mike, and good morning, everyone.  \n \n Beginning with total co mpany results, third quarter revenue increased 14% to $45 billion, driven by \nsales growth from existing and net new Pharma customers.  \n \n Total gross margin was $1.7 billion, a decrease of 7%  due to the elevated supply chain costs in \nMedical and the Cordis divestiture, partially offset by generics program performance.  \n \n Consolidated SG&A increased 2% to $1.1 billion, reflecting higher operations expenses and \npreviously anticipated IT investment s, partially offset by the Cordis divestiture and cost savings \ninitiatives.  \n \n Third quarter operating earnings decreased 21% to $545 million, primarily reflecting the elevated \nsupply chain costs in Medical.  \n \n Moving below the line, Interest and Other incre ased by $8 million, which reflects one -time gains in \nOther income in the prior year, partially offset by lower interest expense from debt reduction actions.  \n \n Our third quarter effective tax rate finished at 20.1%, eleven percentage points lower than the p rior \nyear due to certain discrete items affecting both periods.  \n", "original_text": "Consolidated SG&A increased 2% to $1.1 billion, reflecting higher operations expenses and \npreviously anticipated IT investment s, partially offset by the Cordis divestiture and cost savings \ninitiatives.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c5f8dcf80393bb2ce8fec99b23631dd928577c84892185f951e68b39713150d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e90fadb-caab-441e-957f-cdc5653f558f", "node_type": "1", "metadata": {"window": "Total gross margin was $1.7 billion, a decrease of 7%  due to the elevated supply chain costs in \nMedical and the Cordis divestiture, partially offset by generics program performance.  \n \n Consolidated SG&A increased 2% to $1.1 billion, reflecting higher operations expenses and \npreviously anticipated IT investment s, partially offset by the Cordis divestiture and cost savings \ninitiatives.  \n \n Third quarter operating earnings decreased 21% to $545 million, primarily reflecting the elevated \nsupply chain costs in Medical.  \n \n Moving below the line, Interest and Other incre ased by $8 million, which reflects one -time gains in \nOther income in the prior year, partially offset by lower interest expense from debt reduction actions.  \n \n Our third quarter effective tax rate finished at 20.1%, eleven percentage points lower than the p rior \nyear due to certain discrete items affecting both periods.  \n Average diluted shares outstanding were 277 million, 6% lower than a year ago, due to share \nrepurchases.  During the quarter, we initiated a $200 million share repurchase program, which was \ncompleted in April and brings our year -to-date repurchases to $1 billion.  ", "original_text": "Moving below the line, Interest and Other incre ased by $8 million, which reflects one -time gains in \nOther income in the prior year, partially offset by lower interest expense from debt reduction actions.  \n \n"}, "hash": "d3b27c26028edcedb1710d73822e8f6e2229ca6df99f6ee03480c60f7cbc8546", "class_name": "RelatedNodeInfo"}}, "text": "Third quarter operating earnings decreased 21% to $545 million, primarily reflecting the elevated \nsupply chain costs in Medical.  \n \n", "start_char_idx": 2220, "end_char_idx": 2354, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e90fadb-caab-441e-957f-cdc5653f558f": {"__data__": {"id_": "4e90fadb-caab-441e-957f-cdc5653f558f", "embedding": null, "metadata": {"window": "Total gross margin was $1.7 billion, a decrease of 7%  due to the elevated supply chain costs in \nMedical and the Cordis divestiture, partially offset by generics program performance.  \n \n Consolidated SG&A increased 2% to $1.1 billion, reflecting higher operations expenses and \npreviously anticipated IT investment s, partially offset by the Cordis divestiture and cost savings \ninitiatives.  \n \n Third quarter operating earnings decreased 21% to $545 million, primarily reflecting the elevated \nsupply chain costs in Medical.  \n \n Moving below the line, Interest and Other incre ased by $8 million, which reflects one -time gains in \nOther income in the prior year, partially offset by lower interest expense from debt reduction actions.  \n \n Our third quarter effective tax rate finished at 20.1%, eleven percentage points lower than the p rior \nyear due to certain discrete items affecting both periods.  \n Average diluted shares outstanding were 277 million, 6% lower than a year ago, due to share \nrepurchases.  During the quarter, we initiated a $200 million share repurchase program, which was \ncompleted in April and brings our year -to-date repurchases to $1 billion.  ", "original_text": "Moving below the line, Interest and Other incre ased by $8 million, which reflects one -time gains in \nOther income in the prior year, partially offset by lower interest expense from debt reduction actions.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4498f1fdb78b4b44925acc3c493b8cea7ad3efe3a26cbe1a86b2b8a818fb9f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4831a1e1-4d97-4e6f-b374-8304dee7dce6", "node_type": "1", "metadata": {"window": "Beginning with total co mpany results, third quarter revenue increased 14% to $45 billion, driven by \nsales growth from existing and net new Pharma customers.  \n \n Total gross margin was $1.7 billion, a decrease of 7%  due to the elevated supply chain costs in \nMedical and the Cordis divestiture, partially offset by generics program performance.  \n \n Consolidated SG&A increased 2% to $1.1 billion, reflecting higher operations expenses and \npreviously anticipated IT investment s, partially offset by the Cordis divestiture and cost savings \ninitiatives.  \n \n Third quarter operating earnings decreased 21% to $545 million, primarily reflecting the elevated \nsupply chain costs in Medical.  \n \n Moving below the line, Interest and Other incre ased by $8 million, which reflects one -time gains in \nOther income in the prior year, partially offset by lower interest expense from debt reduction actions.  \n \n Our third quarter effective tax rate finished at 20.1%, eleven percentage points lower than the p rior \nyear due to certain discrete items affecting both periods.  \n Average diluted shares outstanding were 277 million, 6% lower than a year ago, due to share \nrepurchases. ", "original_text": "Third quarter operating earnings decreased 21% to $545 million, primarily reflecting the elevated \nsupply chain costs in Medical.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4e554f4b2941fcda18b00fe6699dc4d15417d30d789c9d9a2aab61eb5ba516ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "108ab7a0-30d8-47b6-ad79-7ef2d40cbc2d", "node_type": "1", "metadata": {"window": "Consolidated SG&A increased 2% to $1.1 billion, reflecting higher operations expenses and \npreviously anticipated IT investment s, partially offset by the Cordis divestiture and cost savings \ninitiatives.  \n \n Third quarter operating earnings decreased 21% to $545 million, primarily reflecting the elevated \nsupply chain costs in Medical.  \n \n Moving below the line, Interest and Other incre ased by $8 million, which reflects one -time gains in \nOther income in the prior year, partially offset by lower interest expense from debt reduction actions.  \n \n Our third quarter effective tax rate finished at 20.1%, eleven percentage points lower than the p rior \nyear due to certain discrete items affecting both periods.  \n Average diluted shares outstanding were 277 million, 6% lower than a year ago, due to share \nrepurchases.  During the quarter, we initiated a $200 million share repurchase program, which was \ncompleted in April and brings our year -to-date repurchases to $1 billion.  ", "original_text": "Our third quarter effective tax rate finished at 20.1%, eleven percentage points lower than the p rior \nyear due to certain discrete items affecting both periods.  \n"}, "hash": "56aa7093fdae4760eb3fad7d2dbddefb13473f3edcd8a445b6d45124d6037ab8", "class_name": "RelatedNodeInfo"}}, "text": "Moving below the line, Interest and Other incre ased by $8 million, which reflects one -time gains in \nOther income in the prior year, partially offset by lower interest expense from debt reduction actions.  \n \n", "start_char_idx": 2354, "end_char_idx": 2565, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "108ab7a0-30d8-47b6-ad79-7ef2d40cbc2d": {"__data__": {"id_": "108ab7a0-30d8-47b6-ad79-7ef2d40cbc2d", "embedding": null, "metadata": {"window": "Consolidated SG&A increased 2% to $1.1 billion, reflecting higher operations expenses and \npreviously anticipated IT investment s, partially offset by the Cordis divestiture and cost savings \ninitiatives.  \n \n Third quarter operating earnings decreased 21% to $545 million, primarily reflecting the elevated \nsupply chain costs in Medical.  \n \n Moving below the line, Interest and Other incre ased by $8 million, which reflects one -time gains in \nOther income in the prior year, partially offset by lower interest expense from debt reduction actions.  \n \n Our third quarter effective tax rate finished at 20.1%, eleven percentage points lower than the p rior \nyear due to certain discrete items affecting both periods.  \n Average diluted shares outstanding were 277 million, 6% lower than a year ago, due to share \nrepurchases.  During the quarter, we initiated a $200 million share repurchase program, which was \ncompleted in April and brings our year -to-date repurchases to $1 billion.  ", "original_text": "Our third quarter effective tax rate finished at 20.1%, eleven percentage points lower than the p rior \nyear due to certain discrete items affecting both periods.  \n", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4498f1fdb78b4b44925acc3c493b8cea7ad3efe3a26cbe1a86b2b8a818fb9f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e90fadb-caab-441e-957f-cdc5653f558f", "node_type": "1", "metadata": {"window": "Total gross margin was $1.7 billion, a decrease of 7%  due to the elevated supply chain costs in \nMedical and the Cordis divestiture, partially offset by generics program performance.  \n \n Consolidated SG&A increased 2% to $1.1 billion, reflecting higher operations expenses and \npreviously anticipated IT investment s, partially offset by the Cordis divestiture and cost savings \ninitiatives.  \n \n Third quarter operating earnings decreased 21% to $545 million, primarily reflecting the elevated \nsupply chain costs in Medical.  \n \n Moving below the line, Interest and Other incre ased by $8 million, which reflects one -time gains in \nOther income in the prior year, partially offset by lower interest expense from debt reduction actions.  \n \n Our third quarter effective tax rate finished at 20.1%, eleven percentage points lower than the p rior \nyear due to certain discrete items affecting both periods.  \n Average diluted shares outstanding were 277 million, 6% lower than a year ago, due to share \nrepurchases.  During the quarter, we initiated a $200 million share repurchase program, which was \ncompleted in April and brings our year -to-date repurchases to $1 billion.  ", "original_text": "Moving below the line, Interest and Other incre ased by $8 million, which reflects one -time gains in \nOther income in the prior year, partially offset by lower interest expense from debt reduction actions.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe954f62d3ab3c83c130f8217f748bc61c408e86df8ae915587707e0ea82250c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89fa0cae-9246-4d29-924a-64e5c3f107b0", "node_type": "1", "metadata": {"window": "Third quarter operating earnings decreased 21% to $545 million, primarily reflecting the elevated \nsupply chain costs in Medical.  \n \n Moving below the line, Interest and Other incre ased by $8 million, which reflects one -time gains in \nOther income in the prior year, partially offset by lower interest expense from debt reduction actions.  \n \n Our third quarter effective tax rate finished at 20.1%, eleven percentage points lower than the p rior \nyear due to certain discrete items affecting both periods.  \n Average diluted shares outstanding were 277 million, 6% lower than a year ago, due to share \nrepurchases.  During the quarter, we initiated a $200 million share repurchase program, which was \ncompleted in April and brings our year -to-date repurchases to $1 billion.  ", "original_text": "Average diluted shares outstanding were 277 million, 6% lower than a year ago, due to share \nrepurchases. "}, "hash": "805931d854d8c6b9938ac6d58f0da71c29c1ceb1ef2a589afb54581066f6e628", "class_name": "RelatedNodeInfo"}}, "text": "Our third quarter effective tax rate finished at 20.1%, eleven percentage points lower than the p rior \nyear due to certain discrete items affecting both periods.  \n", "start_char_idx": 2565, "end_char_idx": 2730, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89fa0cae-9246-4d29-924a-64e5c3f107b0": {"__data__": {"id_": "89fa0cae-9246-4d29-924a-64e5c3f107b0", "embedding": null, "metadata": {"window": "Third quarter operating earnings decreased 21% to $545 million, primarily reflecting the elevated \nsupply chain costs in Medical.  \n \n Moving below the line, Interest and Other incre ased by $8 million, which reflects one -time gains in \nOther income in the prior year, partially offset by lower interest expense from debt reduction actions.  \n \n Our third quarter effective tax rate finished at 20.1%, eleven percentage points lower than the p rior \nyear due to certain discrete items affecting both periods.  \n Average diluted shares outstanding were 277 million, 6% lower than a year ago, due to share \nrepurchases.  During the quarter, we initiated a $200 million share repurchase program, which was \ncompleted in April and brings our year -to-date repurchases to $1 billion.  ", "original_text": "Average diluted shares outstanding were 277 million, 6% lower than a year ago, due to share \nrepurchases. ", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4498f1fdb78b4b44925acc3c493b8cea7ad3efe3a26cbe1a86b2b8a818fb9f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "108ab7a0-30d8-47b6-ad79-7ef2d40cbc2d", "node_type": "1", "metadata": {"window": "Consolidated SG&A increased 2% to $1.1 billion, reflecting higher operations expenses and \npreviously anticipated IT investment s, partially offset by the Cordis divestiture and cost savings \ninitiatives.  \n \n Third quarter operating earnings decreased 21% to $545 million, primarily reflecting the elevated \nsupply chain costs in Medical.  \n \n Moving below the line, Interest and Other incre ased by $8 million, which reflects one -time gains in \nOther income in the prior year, partially offset by lower interest expense from debt reduction actions.  \n \n Our third quarter effective tax rate finished at 20.1%, eleven percentage points lower than the p rior \nyear due to certain discrete items affecting both periods.  \n Average diluted shares outstanding were 277 million, 6% lower than a year ago, due to share \nrepurchases.  During the quarter, we initiated a $200 million share repurchase program, which was \ncompleted in April and brings our year -to-date repurchases to $1 billion.  ", "original_text": "Our third quarter effective tax rate finished at 20.1%, eleven percentage points lower than the p rior \nyear due to certain discrete items affecting both periods.  \n", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bd4f0727ce2c0dbdd41f6507adadb3017257b0228072e1719836ff6a97f84c6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a5a8843-c88a-42ed-9e28-c2bc1a86e6b0", "node_type": "1", "metadata": {"window": "Moving below the line, Interest and Other incre ased by $8 million, which reflects one -time gains in \nOther income in the prior year, partially offset by lower interest expense from debt reduction actions.  \n \n Our third quarter effective tax rate finished at 20.1%, eleven percentage points lower than the p rior \nyear due to certain discrete items affecting both periods.  \n Average diluted shares outstanding were 277 million, 6% lower than a year ago, due to share \nrepurchases.  During the quarter, we initiated a $200 million share repurchase program, which was \ncompleted in April and brings our year -to-date repurchases to $1 billion.  ", "original_text": "During the quarter, we initiated a $200 million share repurchase program, which was \ncompleted in April and brings our year -to-date repurchases to $1 billion.  "}, "hash": "0a381499c1b25307b7a0a50cc73f7a43e50bdbaa3912056ba2fc163fe93b8ceb", "class_name": "RelatedNodeInfo"}}, "text": "Average diluted shares outstanding were 277 million, 6% lower than a year ago, due to share \nrepurchases. ", "start_char_idx": 2730, "end_char_idx": 2836, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a5a8843-c88a-42ed-9e28-c2bc1a86e6b0": {"__data__": {"id_": "0a5a8843-c88a-42ed-9e28-c2bc1a86e6b0", "embedding": null, "metadata": {"window": "Moving below the line, Interest and Other incre ased by $8 million, which reflects one -time gains in \nOther income in the prior year, partially offset by lower interest expense from debt reduction actions.  \n \n Our third quarter effective tax rate finished at 20.1%, eleven percentage points lower than the p rior \nyear due to certain discrete items affecting both periods.  \n Average diluted shares outstanding were 277 million, 6% lower than a year ago, due to share \nrepurchases.  During the quarter, we initiated a $200 million share repurchase program, which was \ncompleted in April and brings our year -to-date repurchases to $1 billion.  ", "original_text": "During the quarter, we initiated a $200 million share repurchase program, which was \ncompleted in April and brings our year -to-date repurchases to $1 billion.  ", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a4498f1fdb78b4b44925acc3c493b8cea7ad3efe3a26cbe1a86b2b8a818fb9f1", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89fa0cae-9246-4d29-924a-64e5c3f107b0", "node_type": "1", "metadata": {"window": "Third quarter operating earnings decreased 21% to $545 million, primarily reflecting the elevated \nsupply chain costs in Medical.  \n \n Moving below the line, Interest and Other incre ased by $8 million, which reflects one -time gains in \nOther income in the prior year, partially offset by lower interest expense from debt reduction actions.  \n \n Our third quarter effective tax rate finished at 20.1%, eleven percentage points lower than the p rior \nyear due to certain discrete items affecting both periods.  \n Average diluted shares outstanding were 277 million, 6% lower than a year ago, due to share \nrepurchases.  During the quarter, we initiated a $200 million share repurchase program, which was \ncompleted in April and brings our year -to-date repurchases to $1 billion.  ", "original_text": "Average diluted shares outstanding were 277 million, 6% lower than a year ago, due to share \nrepurchases. ", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "481c8b7e778d1afe15e122753521ecac22593ba84b2f8985881ffe228b6fbf36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8113da84-d516-46da-8331-ad4d997fffa3", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \nThe net result for the quarter was EPS of $1.45, a decline of 5%.  \n \n In the quarter, we also recorded a $474 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results.  This accounting charge \nreflects an increase in the discount rate used in our goodwill impairment analysis.  \n \n Third quarter operating cash flow was a use of $419 million, and we ended the quarter with a cash \nbalance of $2.4 billion and no outstanding borrowings under our credit facilities.  \n \n", "original_text": " \nPage 3 of 15 \n \nThe net result for the quarter was EPS of $1.45, a decline of 5%.  \n \n"}, "hash": "44a56bd2263f11d41fbc7b2761912faecde02b476da24e4839153d06ae6ef4c9", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, we initiated a $200 million share repurchase program, which was \ncompleted in April and brings our year -to-date repurchases to $1 billion.  ", "start_char_idx": 2836, "end_char_idx": 2997, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8113da84-d516-46da-8331-ad4d997fffa3": {"__data__": {"id_": "8113da84-d516-46da-8331-ad4d997fffa3", "embedding": null, "metadata": {"window": " \nPage 3 of 15 \n \nThe net result for the quarter was EPS of $1.45, a decline of 5%.  \n \n In the quarter, we also recorded a $474 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results.  This accounting charge \nreflects an increase in the discount rate used in our goodwill impairment analysis.  \n \n Third quarter operating cash flow was a use of $419 million, and we ended the quarter with a cash \nbalance of $2.4 billion and no outstanding borrowings under our credit facilities.  \n \n", "original_text": " \nPage 3 of 15 \n \nThe net result for the quarter was EPS of $1.45, a decline of 5%.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a2fb01e8c59aca0b10b021f9d5f1a87b49d799702414d8e4228fe800d635f30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a5a8843-c88a-42ed-9e28-c2bc1a86e6b0", "node_type": "1", "metadata": {"window": "Moving below the line, Interest and Other incre ased by $8 million, which reflects one -time gains in \nOther income in the prior year, partially offset by lower interest expense from debt reduction actions.  \n \n Our third quarter effective tax rate finished at 20.1%, eleven percentage points lower than the p rior \nyear due to certain discrete items affecting both periods.  \n Average diluted shares outstanding were 277 million, 6% lower than a year ago, due to share \nrepurchases.  During the quarter, we initiated a $200 million share repurchase program, which was \ncompleted in April and brings our year -to-date repurchases to $1 billion.  ", "original_text": "During the quarter, we initiated a $200 million share repurchase program, which was \ncompleted in April and brings our year -to-date repurchases to $1 billion.  ", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f4fcbcc84f1c1c9238f17e088db71da075dba50bb3f2da2c0b5b6cae7cf2dc4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5dcb6d96-85fb-422a-8714-42e825b549ca", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \nThe net result for the quarter was EPS of $1.45, a decline of 5%.  \n \n In the quarter, we also recorded a $474 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results.  This accounting charge \nreflects an increase in the discount rate used in our goodwill impairment analysis.  \n \n Third quarter operating cash flow was a use of $419 million, and we ended the quarter with a cash \nbalance of $2.4 billion and no outstanding borrowings under our credit facilities.  \n \n Looking ahead to the fourth quarter, in addition t o expecting strong operating cash flow generation, \nwe received the previously -defined tax receivable of approximately $1 billion in April. ", "original_text": "In the quarter, we also recorded a $474 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results. "}, "hash": "cb1bc069e2c47311f5958d1a529150760c8e3938b8b600bda438e08ffe8218e1", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 3 of 15 \n \nThe net result for the quarter was EPS of $1.45, a decline of 5%.  \n \n", "start_char_idx": 0, "end_char_idx": 88, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5dcb6d96-85fb-422a-8714-42e825b549ca": {"__data__": {"id_": "5dcb6d96-85fb-422a-8714-42e825b549ca", "embedding": null, "metadata": {"window": " \nPage 3 of 15 \n \nThe net result for the quarter was EPS of $1.45, a decline of 5%.  \n \n In the quarter, we also recorded a $474 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results.  This accounting charge \nreflects an increase in the discount rate used in our goodwill impairment analysis.  \n \n Third quarter operating cash flow was a use of $419 million, and we ended the quarter with a cash \nbalance of $2.4 billion and no outstanding borrowings under our credit facilities.  \n \n Looking ahead to the fourth quarter, in addition t o expecting strong operating cash flow generation, \nwe received the previously -defined tax receivable of approximately $1 billion in April. ", "original_text": "In the quarter, we also recorded a $474 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results. ", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a2fb01e8c59aca0b10b021f9d5f1a87b49d799702414d8e4228fe800d635f30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8113da84-d516-46da-8331-ad4d997fffa3", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \nThe net result for the quarter was EPS of $1.45, a decline of 5%.  \n \n In the quarter, we also recorded a $474 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results.  This accounting charge \nreflects an increase in the discount rate used in our goodwill impairment analysis.  \n \n Third quarter operating cash flow was a use of $419 million, and we ended the quarter with a cash \nbalance of $2.4 billion and no outstanding borrowings under our credit facilities.  \n \n", "original_text": " \nPage 3 of 15 \n \nThe net result for the quarter was EPS of $1.45, a decline of 5%.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5c1c7291f7fe9f7ce101af11f311e2d0a12c22f1342d3915c47bd3ada775dc46", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "080cf7ee-82ef-4bf2-bfb3-5ac287442c0a", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \nThe net result for the quarter was EPS of $1.45, a decline of 5%.  \n \n In the quarter, we also recorded a $474 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results.  This accounting charge \nreflects an increase in the discount rate used in our goodwill impairment analysis.  \n \n Third quarter operating cash flow was a use of $419 million, and we ended the quarter with a cash \nbalance of $2.4 billion and no outstanding borrowings under our credit facilities.  \n \n Looking ahead to the fourth quarter, in addition t o expecting strong operating cash flow generation, \nwe received the previously -defined tax receivable of approximately $1 billion in April.  Timing, \nincluding the day of the week in which any period ends, affects point -in-time cash flows, and fiscal \u201822 \nis unfavorabl y affected by this dynamic. ", "original_text": "This accounting charge \nreflects an increase in the discount rate used in our goodwill impairment analysis.  \n \n"}, "hash": "e02f4b8bbdbd6e7376a002ed9506b5f60071caad33c66185a55ce90e3be945f6", "class_name": "RelatedNodeInfo"}}, "text": "In the quarter, we also recorded a $474 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results. ", "start_char_idx": 88, "end_char_idx": 262, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "080cf7ee-82ef-4bf2-bfb3-5ac287442c0a": {"__data__": {"id_": "080cf7ee-82ef-4bf2-bfb3-5ac287442c0a", "embedding": null, "metadata": {"window": " \nPage 3 of 15 \n \nThe net result for the quarter was EPS of $1.45, a decline of 5%.  \n \n In the quarter, we also recorded a $474 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results.  This accounting charge \nreflects an increase in the discount rate used in our goodwill impairment analysis.  \n \n Third quarter operating cash flow was a use of $419 million, and we ended the quarter with a cash \nbalance of $2.4 billion and no outstanding borrowings under our credit facilities.  \n \n Looking ahead to the fourth quarter, in addition t o expecting strong operating cash flow generation, \nwe received the previously -defined tax receivable of approximately $1 billion in April.  Timing, \nincluding the day of the week in which any period ends, affects point -in-time cash flows, and fiscal \u201822 \nis unfavorabl y affected by this dynamic. ", "original_text": "This accounting charge \nreflects an increase in the discount rate used in our goodwill impairment analysis.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a2fb01e8c59aca0b10b021f9d5f1a87b49d799702414d8e4228fe800d635f30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5dcb6d96-85fb-422a-8714-42e825b549ca", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \nThe net result for the quarter was EPS of $1.45, a decline of 5%.  \n \n In the quarter, we also recorded a $474 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results.  This accounting charge \nreflects an increase in the discount rate used in our goodwill impairment analysis.  \n \n Third quarter operating cash flow was a use of $419 million, and we ended the quarter with a cash \nbalance of $2.4 billion and no outstanding borrowings under our credit facilities.  \n \n Looking ahead to the fourth quarter, in addition t o expecting strong operating cash flow generation, \nwe received the previously -defined tax receivable of approximately $1 billion in April. ", "original_text": "In the quarter, we also recorded a $474 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results. ", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a2130881ee5950ba3d0d3166676dfdede4b6ea7aa27220394ed9b61c305f0e07", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b03ab9f8-98df-42ef-9919-a6aebd2afa4a", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \nThe net result for the quarter was EPS of $1.45, a decline of 5%.  \n \n In the quarter, we also recorded a $474 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results.  This accounting charge \nreflects an increase in the discount rate used in our goodwill impairment analysis.  \n \n Third quarter operating cash flow was a use of $419 million, and we ended the quarter with a cash \nbalance of $2.4 billion and no outstanding borrowings under our credit facilities.  \n \n Looking ahead to the fourth quarter, in addition t o expecting strong operating cash flow generation, \nwe received the previously -defined tax receivable of approximately $1 billion in April.  Timing, \nincluding the day of the week in which any period ends, affects point -in-time cash flows, and fiscal \u201822 \nis unfavorabl y affected by this dynamic.  Additionally, we expect approximately $550 million in total \nlitigation payments this year, primarily related to opioid settlements, which includes the initial payment \nfor the national settlement already made.  \n \n", "original_text": "Third quarter operating cash flow was a use of $419 million, and we ended the quarter with a cash \nbalance of $2.4 billion and no outstanding borrowings under our credit facilities.  \n \n"}, "hash": "089a5cd08824de7485296776ea4c02ad49526c7575a366776151fde92e847627", "class_name": "RelatedNodeInfo"}}, "text": "This accounting charge \nreflects an increase in the discount rate used in our goodwill impairment analysis.  \n \n", "start_char_idx": 262, "end_char_idx": 374, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b03ab9f8-98df-42ef-9919-a6aebd2afa4a": {"__data__": {"id_": "b03ab9f8-98df-42ef-9919-a6aebd2afa4a", "embedding": null, "metadata": {"window": " \nPage 3 of 15 \n \nThe net result for the quarter was EPS of $1.45, a decline of 5%.  \n \n In the quarter, we also recorded a $474 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results.  This accounting charge \nreflects an increase in the discount rate used in our goodwill impairment analysis.  \n \n Third quarter operating cash flow was a use of $419 million, and we ended the quarter with a cash \nbalance of $2.4 billion and no outstanding borrowings under our credit facilities.  \n \n Looking ahead to the fourth quarter, in addition t o expecting strong operating cash flow generation, \nwe received the previously -defined tax receivable of approximately $1 billion in April.  Timing, \nincluding the day of the week in which any period ends, affects point -in-time cash flows, and fiscal \u201822 \nis unfavorabl y affected by this dynamic.  Additionally, we expect approximately $550 million in total \nlitigation payments this year, primarily related to opioid settlements, which includes the initial payment \nfor the national settlement already made.  \n \n", "original_text": "Third quarter operating cash flow was a use of $419 million, and we ended the quarter with a cash \nbalance of $2.4 billion and no outstanding borrowings under our credit facilities.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a2fb01e8c59aca0b10b021f9d5f1a87b49d799702414d8e4228fe800d635f30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "080cf7ee-82ef-4bf2-bfb3-5ac287442c0a", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \nThe net result for the quarter was EPS of $1.45, a decline of 5%.  \n \n In the quarter, we also recorded a $474 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results.  This accounting charge \nreflects an increase in the discount rate used in our goodwill impairment analysis.  \n \n Third quarter operating cash flow was a use of $419 million, and we ended the quarter with a cash \nbalance of $2.4 billion and no outstanding borrowings under our credit facilities.  \n \n Looking ahead to the fourth quarter, in addition t o expecting strong operating cash flow generation, \nwe received the previously -defined tax receivable of approximately $1 billion in April.  Timing, \nincluding the day of the week in which any period ends, affects point -in-time cash flows, and fiscal \u201822 \nis unfavorabl y affected by this dynamic. ", "original_text": "This accounting charge \nreflects an increase in the discount rate used in our goodwill impairment analysis.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "575b088246343ba530763441ddbb764096d526c165cb22ead4508e83b486b2af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "501dc48d-c75e-484a-a273-11432264f642", "node_type": "1", "metadata": {"window": "In the quarter, we also recorded a $474 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results.  This accounting charge \nreflects an increase in the discount rate used in our goodwill impairment analysis.  \n \n Third quarter operating cash flow was a use of $419 million, and we ended the quarter with a cash \nbalance of $2.4 billion and no outstanding borrowings under our credit facilities.  \n \n Looking ahead to the fourth quarter, in addition t o expecting strong operating cash flow generation, \nwe received the previously -defined tax receivable of approximately $1 billion in April.  Timing, \nincluding the day of the week in which any period ends, affects point -in-time cash flows, and fiscal \u201822 \nis unfavorabl y affected by this dynamic.  Additionally, we expect approximately $550 million in total \nlitigation payments this year, primarily related to opioid settlements, which includes the initial payment \nfor the national settlement already made.  \n \n Now turni ng to the segments, beginning with Pharma on slide 5\u2026  \n \nRevenue increased 17% to $41 billion, driven by branded pharmaceutical sales growth from existing \nand net new Pharmaceutical Distribution and Specialty customers.  \n \n", "original_text": "Looking ahead to the fourth quarter, in addition t o expecting strong operating cash flow generation, \nwe received the previously -defined tax receivable of approximately $1 billion in April. "}, "hash": "f3ac16c62a579ccfbf98bce8986d589e77922d6c4ce473b4bd410be41aefe04d", "class_name": "RelatedNodeInfo"}}, "text": "Third quarter operating cash flow was a use of $419 million, and we ended the quarter with a cash \nbalance of $2.4 billion and no outstanding borrowings under our credit facilities.  \n \n", "start_char_idx": 374, "end_char_idx": 560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "501dc48d-c75e-484a-a273-11432264f642": {"__data__": {"id_": "501dc48d-c75e-484a-a273-11432264f642", "embedding": null, "metadata": {"window": "In the quarter, we also recorded a $474 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results.  This accounting charge \nreflects an increase in the discount rate used in our goodwill impairment analysis.  \n \n Third quarter operating cash flow was a use of $419 million, and we ended the quarter with a cash \nbalance of $2.4 billion and no outstanding borrowings under our credit facilities.  \n \n Looking ahead to the fourth quarter, in addition t o expecting strong operating cash flow generation, \nwe received the previously -defined tax receivable of approximately $1 billion in April.  Timing, \nincluding the day of the week in which any period ends, affects point -in-time cash flows, and fiscal \u201822 \nis unfavorabl y affected by this dynamic.  Additionally, we expect approximately $550 million in total \nlitigation payments this year, primarily related to opioid settlements, which includes the initial payment \nfor the national settlement already made.  \n \n Now turni ng to the segments, beginning with Pharma on slide 5\u2026  \n \nRevenue increased 17% to $41 billion, driven by branded pharmaceutical sales growth from existing \nand net new Pharmaceutical Distribution and Specialty customers.  \n \n", "original_text": "Looking ahead to the fourth quarter, in addition t o expecting strong operating cash flow generation, \nwe received the previously -defined tax receivable of approximately $1 billion in April. ", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a2fb01e8c59aca0b10b021f9d5f1a87b49d799702414d8e4228fe800d635f30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b03ab9f8-98df-42ef-9919-a6aebd2afa4a", "node_type": "1", "metadata": {"window": " \nPage 3 of 15 \n \nThe net result for the quarter was EPS of $1.45, a decline of 5%.  \n \n In the quarter, we also recorded a $474 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results.  This accounting charge \nreflects an increase in the discount rate used in our goodwill impairment analysis.  \n \n Third quarter operating cash flow was a use of $419 million, and we ended the quarter with a cash \nbalance of $2.4 billion and no outstanding borrowings under our credit facilities.  \n \n Looking ahead to the fourth quarter, in addition t o expecting strong operating cash flow generation, \nwe received the previously -defined tax receivable of approximately $1 billion in April.  Timing, \nincluding the day of the week in which any period ends, affects point -in-time cash flows, and fiscal \u201822 \nis unfavorabl y affected by this dynamic.  Additionally, we expect approximately $550 million in total \nlitigation payments this year, primarily related to opioid settlements, which includes the initial payment \nfor the national settlement already made.  \n \n", "original_text": "Third quarter operating cash flow was a use of $419 million, and we ended the quarter with a cash \nbalance of $2.4 billion and no outstanding borrowings under our credit facilities.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1acd63fef4f5711a736f2297b2fbeada5631e74750d8ebdfe6f9c3add1e2e2a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb05aaa1-8187-4bc7-8f74-97b4a4a6cace", "node_type": "1", "metadata": {"window": "This accounting charge \nreflects an increase in the discount rate used in our goodwill impairment analysis.  \n \n Third quarter operating cash flow was a use of $419 million, and we ended the quarter with a cash \nbalance of $2.4 billion and no outstanding borrowings under our credit facilities.  \n \n Looking ahead to the fourth quarter, in addition t o expecting strong operating cash flow generation, \nwe received the previously -defined tax receivable of approximately $1 billion in April.  Timing, \nincluding the day of the week in which any period ends, affects point -in-time cash flows, and fiscal \u201822 \nis unfavorabl y affected by this dynamic.  Additionally, we expect approximately $550 million in total \nlitigation payments this year, primarily related to opioid settlements, which includes the initial payment \nfor the national settlement already made.  \n \n Now turni ng to the segments, beginning with Pharma on slide 5\u2026  \n \nRevenue increased 17% to $41 billion, driven by branded pharmaceutical sales growth from existing \nand net new Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit decreased 5% to $487  million driven by higher operations expenses and previously \nanticipated investments in technology enhancements, partially offset by generics program \nperformance.  \n \n", "original_text": "Timing, \nincluding the day of the week in which any period ends, affects point -in-time cash flows, and fiscal \u201822 \nis unfavorabl y affected by this dynamic. "}, "hash": "53db60cf88cc85524650bf18b8b2a9fb3de2435b3b39edc7029783bb00ab932b", "class_name": "RelatedNodeInfo"}}, "text": "Looking ahead to the fourth quarter, in addition t o expecting strong operating cash flow generation, \nwe received the previously -defined tax receivable of approximately $1 billion in April. ", "start_char_idx": 560, "end_char_idx": 752, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb05aaa1-8187-4bc7-8f74-97b4a4a6cace": {"__data__": {"id_": "cb05aaa1-8187-4bc7-8f74-97b4a4a6cace", "embedding": null, "metadata": {"window": "This accounting charge \nreflects an increase in the discount rate used in our goodwill impairment analysis.  \n \n Third quarter operating cash flow was a use of $419 million, and we ended the quarter with a cash \nbalance of $2.4 billion and no outstanding borrowings under our credit facilities.  \n \n Looking ahead to the fourth quarter, in addition t o expecting strong operating cash flow generation, \nwe received the previously -defined tax receivable of approximately $1 billion in April.  Timing, \nincluding the day of the week in which any period ends, affects point -in-time cash flows, and fiscal \u201822 \nis unfavorabl y affected by this dynamic.  Additionally, we expect approximately $550 million in total \nlitigation payments this year, primarily related to opioid settlements, which includes the initial payment \nfor the national settlement already made.  \n \n Now turni ng to the segments, beginning with Pharma on slide 5\u2026  \n \nRevenue increased 17% to $41 billion, driven by branded pharmaceutical sales growth from existing \nand net new Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit decreased 5% to $487  million driven by higher operations expenses and previously \nanticipated investments in technology enhancements, partially offset by generics program \nperformance.  \n \n", "original_text": "Timing, \nincluding the day of the week in which any period ends, affects point -in-time cash flows, and fiscal \u201822 \nis unfavorabl y affected by this dynamic. ", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a2fb01e8c59aca0b10b021f9d5f1a87b49d799702414d8e4228fe800d635f30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "501dc48d-c75e-484a-a273-11432264f642", "node_type": "1", "metadata": {"window": "In the quarter, we also recorded a $474 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results.  This accounting charge \nreflects an increase in the discount rate used in our goodwill impairment analysis.  \n \n Third quarter operating cash flow was a use of $419 million, and we ended the quarter with a cash \nbalance of $2.4 billion and no outstanding borrowings under our credit facilities.  \n \n Looking ahead to the fourth quarter, in addition t o expecting strong operating cash flow generation, \nwe received the previously -defined tax receivable of approximately $1 billion in April.  Timing, \nincluding the day of the week in which any period ends, affects point -in-time cash flows, and fiscal \u201822 \nis unfavorabl y affected by this dynamic.  Additionally, we expect approximately $550 million in total \nlitigation payments this year, primarily related to opioid settlements, which includes the initial payment \nfor the national settlement already made.  \n \n Now turni ng to the segments, beginning with Pharma on slide 5\u2026  \n \nRevenue increased 17% to $41 billion, driven by branded pharmaceutical sales growth from existing \nand net new Pharmaceutical Distribution and Specialty customers.  \n \n", "original_text": "Looking ahead to the fourth quarter, in addition t o expecting strong operating cash flow generation, \nwe received the previously -defined tax receivable of approximately $1 billion in April. ", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4c2f6123b0c5cbce5229a2fd61e5fd6d68f48c7150058b242022b808848dbc33", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3857ea75-02f1-441a-bec2-710521da85e8", "node_type": "1", "metadata": {"window": "Third quarter operating cash flow was a use of $419 million, and we ended the quarter with a cash \nbalance of $2.4 billion and no outstanding borrowings under our credit facilities.  \n \n Looking ahead to the fourth quarter, in addition t o expecting strong operating cash flow generation, \nwe received the previously -defined tax receivable of approximately $1 billion in April.  Timing, \nincluding the day of the week in which any period ends, affects point -in-time cash flows, and fiscal \u201822 \nis unfavorabl y affected by this dynamic.  Additionally, we expect approximately $550 million in total \nlitigation payments this year, primarily related to opioid settlements, which includes the initial payment \nfor the national settlement already made.  \n \n Now turni ng to the segments, beginning with Pharma on slide 5\u2026  \n \nRevenue increased 17% to $41 billion, driven by branded pharmaceutical sales growth from existing \nand net new Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit decreased 5% to $487  million driven by higher operations expenses and previously \nanticipated investments in technology enhancements, partially offset by generics program \nperformance.  \n \n During the quarter, we incurred higher costs supporting sales growth, including some initia l customer \nonboarding costs, and inflationary impacts in areas like transportation and labor. ", "original_text": "Additionally, we expect approximately $550 million in total \nlitigation payments this year, primarily related to opioid settlements, which includes the initial payment \nfor the national settlement already made.  \n \n"}, "hash": "88755cdbec52611146e959b67ad5cd40d11014e4c77dfef96eef36f3b0ef77f0", "class_name": "RelatedNodeInfo"}}, "text": "Timing, \nincluding the day of the week in which any period ends, affects point -in-time cash flows, and fiscal \u201822 \nis unfavorabl y affected by this dynamic. ", "start_char_idx": 752, "end_char_idx": 910, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3857ea75-02f1-441a-bec2-710521da85e8": {"__data__": {"id_": "3857ea75-02f1-441a-bec2-710521da85e8", "embedding": null, "metadata": {"window": "Third quarter operating cash flow was a use of $419 million, and we ended the quarter with a cash \nbalance of $2.4 billion and no outstanding borrowings under our credit facilities.  \n \n Looking ahead to the fourth quarter, in addition t o expecting strong operating cash flow generation, \nwe received the previously -defined tax receivable of approximately $1 billion in April.  Timing, \nincluding the day of the week in which any period ends, affects point -in-time cash flows, and fiscal \u201822 \nis unfavorabl y affected by this dynamic.  Additionally, we expect approximately $550 million in total \nlitigation payments this year, primarily related to opioid settlements, which includes the initial payment \nfor the national settlement already made.  \n \n Now turni ng to the segments, beginning with Pharma on slide 5\u2026  \n \nRevenue increased 17% to $41 billion, driven by branded pharmaceutical sales growth from existing \nand net new Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit decreased 5% to $487  million driven by higher operations expenses and previously \nanticipated investments in technology enhancements, partially offset by generics program \nperformance.  \n \n During the quarter, we incurred higher costs supporting sales growth, including some initia l customer \nonboarding costs, and inflationary impacts in areas like transportation and labor. ", "original_text": "Additionally, we expect approximately $550 million in total \nlitigation payments this year, primarily related to opioid settlements, which includes the initial payment \nfor the national settlement already made.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a2fb01e8c59aca0b10b021f9d5f1a87b49d799702414d8e4228fe800d635f30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb05aaa1-8187-4bc7-8f74-97b4a4a6cace", "node_type": "1", "metadata": {"window": "This accounting charge \nreflects an increase in the discount rate used in our goodwill impairment analysis.  \n \n Third quarter operating cash flow was a use of $419 million, and we ended the quarter with a cash \nbalance of $2.4 billion and no outstanding borrowings under our credit facilities.  \n \n Looking ahead to the fourth quarter, in addition t o expecting strong operating cash flow generation, \nwe received the previously -defined tax receivable of approximately $1 billion in April.  Timing, \nincluding the day of the week in which any period ends, affects point -in-time cash flows, and fiscal \u201822 \nis unfavorabl y affected by this dynamic.  Additionally, we expect approximately $550 million in total \nlitigation payments this year, primarily related to opioid settlements, which includes the initial payment \nfor the national settlement already made.  \n \n Now turni ng to the segments, beginning with Pharma on slide 5\u2026  \n \nRevenue increased 17% to $41 billion, driven by branded pharmaceutical sales growth from existing \nand net new Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit decreased 5% to $487  million driven by higher operations expenses and previously \nanticipated investments in technology enhancements, partially offset by generics program \nperformance.  \n \n", "original_text": "Timing, \nincluding the day of the week in which any period ends, affects point -in-time cash flows, and fiscal \u201822 \nis unfavorabl y affected by this dynamic. ", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f00318913f0136c255bdfe73773f5ee0b46f575b0c7ba269ce025bcacc406035", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e709a4c8-3c59-4887-bfa8-4dd4bcad1129", "node_type": "1", "metadata": {"window": "Looking ahead to the fourth quarter, in addition t o expecting strong operating cash flow generation, \nwe received the previously -defined tax receivable of approximately $1 billion in April.  Timing, \nincluding the day of the week in which any period ends, affects point -in-time cash flows, and fiscal \u201822 \nis unfavorabl y affected by this dynamic.  Additionally, we expect approximately $550 million in total \nlitigation payments this year, primarily related to opioid settlements, which includes the initial payment \nfor the national settlement already made.  \n \n Now turni ng to the segments, beginning with Pharma on slide 5\u2026  \n \nRevenue increased 17% to $41 billion, driven by branded pharmaceutical sales growth from existing \nand net new Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit decreased 5% to $487  million driven by higher operations expenses and previously \nanticipated investments in technology enhancements, partially offset by generics program \nperformance.  \n \n During the quarter, we incurred higher costs supporting sales growth, including some initia l customer \nonboarding costs, and inflationary impacts in areas like transportation and labor.  Importantly, we also \ncompleted the launch of our planned technology enhancements.  \n \n", "original_text": "Now turni ng to the segments, beginning with Pharma on slide 5\u2026  \n \nRevenue increased 17% to $41 billion, driven by branded pharmaceutical sales growth from existing \nand net new Pharmaceutical Distribution and Specialty customers.  \n \n"}, "hash": "9a981897931066dfc8859eda077acefffd99df528ef955fc17fb0d5bc3650aff", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, we expect approximately $550 million in total \nlitigation payments this year, primarily related to opioid settlements, which includes the initial payment \nfor the national settlement already made.  \n \n", "start_char_idx": 910, "end_char_idx": 1125, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e709a4c8-3c59-4887-bfa8-4dd4bcad1129": {"__data__": {"id_": "e709a4c8-3c59-4887-bfa8-4dd4bcad1129", "embedding": null, "metadata": {"window": "Looking ahead to the fourth quarter, in addition t o expecting strong operating cash flow generation, \nwe received the previously -defined tax receivable of approximately $1 billion in April.  Timing, \nincluding the day of the week in which any period ends, affects point -in-time cash flows, and fiscal \u201822 \nis unfavorabl y affected by this dynamic.  Additionally, we expect approximately $550 million in total \nlitigation payments this year, primarily related to opioid settlements, which includes the initial payment \nfor the national settlement already made.  \n \n Now turni ng to the segments, beginning with Pharma on slide 5\u2026  \n \nRevenue increased 17% to $41 billion, driven by branded pharmaceutical sales growth from existing \nand net new Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit decreased 5% to $487  million driven by higher operations expenses and previously \nanticipated investments in technology enhancements, partially offset by generics program \nperformance.  \n \n During the quarter, we incurred higher costs supporting sales growth, including some initia l customer \nonboarding costs, and inflationary impacts in areas like transportation and labor.  Importantly, we also \ncompleted the launch of our planned technology enhancements.  \n \n", "original_text": "Now turni ng to the segments, beginning with Pharma on slide 5\u2026  \n \nRevenue increased 17% to $41 billion, driven by branded pharmaceutical sales growth from existing \nand net new Pharmaceutical Distribution and Specialty customers.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a2fb01e8c59aca0b10b021f9d5f1a87b49d799702414d8e4228fe800d635f30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3857ea75-02f1-441a-bec2-710521da85e8", "node_type": "1", "metadata": {"window": "Third quarter operating cash flow was a use of $419 million, and we ended the quarter with a cash \nbalance of $2.4 billion and no outstanding borrowings under our credit facilities.  \n \n Looking ahead to the fourth quarter, in addition t o expecting strong operating cash flow generation, \nwe received the previously -defined tax receivable of approximately $1 billion in April.  Timing, \nincluding the day of the week in which any period ends, affects point -in-time cash flows, and fiscal \u201822 \nis unfavorabl y affected by this dynamic.  Additionally, we expect approximately $550 million in total \nlitigation payments this year, primarily related to opioid settlements, which includes the initial payment \nfor the national settlement already made.  \n \n Now turni ng to the segments, beginning with Pharma on slide 5\u2026  \n \nRevenue increased 17% to $41 billion, driven by branded pharmaceutical sales growth from existing \nand net new Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit decreased 5% to $487  million driven by higher operations expenses and previously \nanticipated investments in technology enhancements, partially offset by generics program \nperformance.  \n \n During the quarter, we incurred higher costs supporting sales growth, including some initia l customer \nonboarding costs, and inflationary impacts in areas like transportation and labor. ", "original_text": "Additionally, we expect approximately $550 million in total \nlitigation payments this year, primarily related to opioid settlements, which includes the initial payment \nfor the national settlement already made.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c13546cec519ca3afa89099e72a4cb2b8e5267eae4a77c32ddd82a9012750c63", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9fb0a74f-8b1a-47fe-aa29-9f446dc32900", "node_type": "1", "metadata": {"window": "Timing, \nincluding the day of the week in which any period ends, affects point -in-time cash flows, and fiscal \u201822 \nis unfavorabl y affected by this dynamic.  Additionally, we expect approximately $550 million in total \nlitigation payments this year, primarily related to opioid settlements, which includes the initial payment \nfor the national settlement already made.  \n \n Now turni ng to the segments, beginning with Pharma on slide 5\u2026  \n \nRevenue increased 17% to $41 billion, driven by branded pharmaceutical sales growth from existing \nand net new Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit decreased 5% to $487  million driven by higher operations expenses and previously \nanticipated investments in technology enhancements, partially offset by generics program \nperformance.  \n \n During the quarter, we incurred higher costs supporting sales growth, including some initia l customer \nonboarding costs, and inflationary impacts in areas like transportation and labor.  Importantly, we also \ncompleted the launch of our planned technology enhancements.  \n \n As Mike mentioned, we continued to see resiliency in pharmaceutical demand. ", "original_text": "Segment profit decreased 5% to $487  million driven by higher operations expenses and previously \nanticipated investments in technology enhancements, partially offset by generics program \nperformance.  \n \n"}, "hash": "61fdb10e283d8971d118fcd8b633bddca30e170b6ebe0d7bae93cf5b7b1e274e", "class_name": "RelatedNodeInfo"}}, "text": "Now turni ng to the segments, beginning with Pharma on slide 5\u2026  \n \nRevenue increased 17% to $41 billion, driven by branded pharmaceutical sales growth from existing \nand net new Pharmaceutical Distribution and Specialty customers.  \n \n", "start_char_idx": 1125, "end_char_idx": 1361, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9fb0a74f-8b1a-47fe-aa29-9f446dc32900": {"__data__": {"id_": "9fb0a74f-8b1a-47fe-aa29-9f446dc32900", "embedding": null, "metadata": {"window": "Timing, \nincluding the day of the week in which any period ends, affects point -in-time cash flows, and fiscal \u201822 \nis unfavorabl y affected by this dynamic.  Additionally, we expect approximately $550 million in total \nlitigation payments this year, primarily related to opioid settlements, which includes the initial payment \nfor the national settlement already made.  \n \n Now turni ng to the segments, beginning with Pharma on slide 5\u2026  \n \nRevenue increased 17% to $41 billion, driven by branded pharmaceutical sales growth from existing \nand net new Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit decreased 5% to $487  million driven by higher operations expenses and previously \nanticipated investments in technology enhancements, partially offset by generics program \nperformance.  \n \n During the quarter, we incurred higher costs supporting sales growth, including some initia l customer \nonboarding costs, and inflationary impacts in areas like transportation and labor.  Importantly, we also \ncompleted the launch of our planned technology enhancements.  \n \n As Mike mentioned, we continued to see resiliency in pharmaceutical demand. ", "original_text": "Segment profit decreased 5% to $487  million driven by higher operations expenses and previously \nanticipated investments in technology enhancements, partially offset by generics program \nperformance.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a2fb01e8c59aca0b10b021f9d5f1a87b49d799702414d8e4228fe800d635f30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e709a4c8-3c59-4887-bfa8-4dd4bcad1129", "node_type": "1", "metadata": {"window": "Looking ahead to the fourth quarter, in addition t o expecting strong operating cash flow generation, \nwe received the previously -defined tax receivable of approximately $1 billion in April.  Timing, \nincluding the day of the week in which any period ends, affects point -in-time cash flows, and fiscal \u201822 \nis unfavorabl y affected by this dynamic.  Additionally, we expect approximately $550 million in total \nlitigation payments this year, primarily related to opioid settlements, which includes the initial payment \nfor the national settlement already made.  \n \n Now turni ng to the segments, beginning with Pharma on slide 5\u2026  \n \nRevenue increased 17% to $41 billion, driven by branded pharmaceutical sales growth from existing \nand net new Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit decreased 5% to $487  million driven by higher operations expenses and previously \nanticipated investments in technology enhancements, partially offset by generics program \nperformance.  \n \n During the quarter, we incurred higher costs supporting sales growth, including some initia l customer \nonboarding costs, and inflationary impacts in areas like transportation and labor.  Importantly, we also \ncompleted the launch of our planned technology enhancements.  \n \n", "original_text": "Now turni ng to the segments, beginning with Pharma on slide 5\u2026  \n \nRevenue increased 17% to $41 billion, driven by branded pharmaceutical sales growth from existing \nand net new Pharmaceutical Distribution and Specialty customers.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a2888d4922681c735c2739972a325873c9caa0ab6e4677f74e59c3af2d77a62a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18d5860e-81bd-4772-acb2-18dee7e45c67", "node_type": "1", "metadata": {"window": "Additionally, we expect approximately $550 million in total \nlitigation payments this year, primarily related to opioid settlements, which includes the initial payment \nfor the national settlement already made.  \n \n Now turni ng to the segments, beginning with Pharma on slide 5\u2026  \n \nRevenue increased 17% to $41 billion, driven by branded pharmaceutical sales growth from existing \nand net new Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit decreased 5% to $487  million driven by higher operations expenses and previously \nanticipated investments in technology enhancements, partially offset by generics program \nperformance.  \n \n During the quarter, we incurred higher costs supporting sales growth, including some initia l customer \nonboarding costs, and inflationary impacts in areas like transportation and labor.  Importantly, we also \ncompleted the launch of our planned technology enhancements.  \n \n As Mike mentioned, we continued to see resiliency in pharmaceutical demand.  An d, our generics \nprogram continued to experience generally consistent market dynamics, including strong \nperformance from Red Oak.  \n \n", "original_text": "During the quarter, we incurred higher costs supporting sales growth, including some initia l customer \nonboarding costs, and inflationary impacts in areas like transportation and labor. "}, "hash": "c977208b6e624356a37084526ab5c80d3b996430fa219a7f6ec60dfa425119ac", "class_name": "RelatedNodeInfo"}}, "text": "Segment profit decreased 5% to $487  million driven by higher operations expenses and previously \nanticipated investments in technology enhancements, partially offset by generics program \nperformance.  \n \n", "start_char_idx": 1361, "end_char_idx": 1566, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18d5860e-81bd-4772-acb2-18dee7e45c67": {"__data__": {"id_": "18d5860e-81bd-4772-acb2-18dee7e45c67", "embedding": null, "metadata": {"window": "Additionally, we expect approximately $550 million in total \nlitigation payments this year, primarily related to opioid settlements, which includes the initial payment \nfor the national settlement already made.  \n \n Now turni ng to the segments, beginning with Pharma on slide 5\u2026  \n \nRevenue increased 17% to $41 billion, driven by branded pharmaceutical sales growth from existing \nand net new Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit decreased 5% to $487  million driven by higher operations expenses and previously \nanticipated investments in technology enhancements, partially offset by generics program \nperformance.  \n \n During the quarter, we incurred higher costs supporting sales growth, including some initia l customer \nonboarding costs, and inflationary impacts in areas like transportation and labor.  Importantly, we also \ncompleted the launch of our planned technology enhancements.  \n \n As Mike mentioned, we continued to see resiliency in pharmaceutical demand.  An d, our generics \nprogram continued to experience generally consistent market dynamics, including strong \nperformance from Red Oak.  \n \n", "original_text": "During the quarter, we incurred higher costs supporting sales growth, including some initia l customer \nonboarding costs, and inflationary impacts in areas like transportation and labor. ", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a2fb01e8c59aca0b10b021f9d5f1a87b49d799702414d8e4228fe800d635f30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9fb0a74f-8b1a-47fe-aa29-9f446dc32900", "node_type": "1", "metadata": {"window": "Timing, \nincluding the day of the week in which any period ends, affects point -in-time cash flows, and fiscal \u201822 \nis unfavorabl y affected by this dynamic.  Additionally, we expect approximately $550 million in total \nlitigation payments this year, primarily related to opioid settlements, which includes the initial payment \nfor the national settlement already made.  \n \n Now turni ng to the segments, beginning with Pharma on slide 5\u2026  \n \nRevenue increased 17% to $41 billion, driven by branded pharmaceutical sales growth from existing \nand net new Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit decreased 5% to $487  million driven by higher operations expenses and previously \nanticipated investments in technology enhancements, partially offset by generics program \nperformance.  \n \n During the quarter, we incurred higher costs supporting sales growth, including some initia l customer \nonboarding costs, and inflationary impacts in areas like transportation and labor.  Importantly, we also \ncompleted the launch of our planned technology enhancements.  \n \n As Mike mentioned, we continued to see resiliency in pharmaceutical demand. ", "original_text": "Segment profit decreased 5% to $487  million driven by higher operations expenses and previously \nanticipated investments in technology enhancements, partially offset by generics program \nperformance.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb6c9526bdf1b2176c9ae6fb520238631dedeea7335b7a0d21eb313cc662e246", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0db1529a-4f62-4b88-a1a1-0862a29384c8", "node_type": "1", "metadata": {"window": "Now turni ng to the segments, beginning with Pharma on slide 5\u2026  \n \nRevenue increased 17% to $41 billion, driven by branded pharmaceutical sales growth from existing \nand net new Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit decreased 5% to $487  million driven by higher operations expenses and previously \nanticipated investments in technology enhancements, partially offset by generics program \nperformance.  \n \n During the quarter, we incurred higher costs supporting sales growth, including some initia l customer \nonboarding costs, and inflationary impacts in areas like transportation and labor.  Importantly, we also \ncompleted the launch of our planned technology enhancements.  \n \n As Mike mentioned, we continued to see resiliency in pharmaceutical demand.  An d, our generics \nprogram continued to experience generally consistent market dynamics, including strong \nperformance from Red Oak.  \n \n Turning to Medical on slide 6\u2026  \n \nThird -quarter revenue decreased 7% to $3.9 billion due to the divestiture of the Cordis busi ness and \nlower products and distribution volumes, which includes the impact of global supply chain constraints.  \n", "original_text": "Importantly, we also \ncompleted the launch of our planned technology enhancements.  \n \n"}, "hash": "7ffc49492339d96fc736bf100dc7a321dde0a5de2a665ff48c755b606b4cbdda", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, we incurred higher costs supporting sales growth, including some initia l customer \nonboarding costs, and inflationary impacts in areas like transportation and labor. ", "start_char_idx": 1566, "end_char_idx": 1753, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0db1529a-4f62-4b88-a1a1-0862a29384c8": {"__data__": {"id_": "0db1529a-4f62-4b88-a1a1-0862a29384c8", "embedding": null, "metadata": {"window": "Now turni ng to the segments, beginning with Pharma on slide 5\u2026  \n \nRevenue increased 17% to $41 billion, driven by branded pharmaceutical sales growth from existing \nand net new Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit decreased 5% to $487  million driven by higher operations expenses and previously \nanticipated investments in technology enhancements, partially offset by generics program \nperformance.  \n \n During the quarter, we incurred higher costs supporting sales growth, including some initia l customer \nonboarding costs, and inflationary impacts in areas like transportation and labor.  Importantly, we also \ncompleted the launch of our planned technology enhancements.  \n \n As Mike mentioned, we continued to see resiliency in pharmaceutical demand.  An d, our generics \nprogram continued to experience generally consistent market dynamics, including strong \nperformance from Red Oak.  \n \n Turning to Medical on slide 6\u2026  \n \nThird -quarter revenue decreased 7% to $3.9 billion due to the divestiture of the Cordis busi ness and \nlower products and distribution volumes, which includes the impact of global supply chain constraints.  \n", "original_text": "Importantly, we also \ncompleted the launch of our planned technology enhancements.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a2fb01e8c59aca0b10b021f9d5f1a87b49d799702414d8e4228fe800d635f30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18d5860e-81bd-4772-acb2-18dee7e45c67", "node_type": "1", "metadata": {"window": "Additionally, we expect approximately $550 million in total \nlitigation payments this year, primarily related to opioid settlements, which includes the initial payment \nfor the national settlement already made.  \n \n Now turni ng to the segments, beginning with Pharma on slide 5\u2026  \n \nRevenue increased 17% to $41 billion, driven by branded pharmaceutical sales growth from existing \nand net new Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit decreased 5% to $487  million driven by higher operations expenses and previously \nanticipated investments in technology enhancements, partially offset by generics program \nperformance.  \n \n During the quarter, we incurred higher costs supporting sales growth, including some initia l customer \nonboarding costs, and inflationary impacts in areas like transportation and labor.  Importantly, we also \ncompleted the launch of our planned technology enhancements.  \n \n As Mike mentioned, we continued to see resiliency in pharmaceutical demand.  An d, our generics \nprogram continued to experience generally consistent market dynamics, including strong \nperformance from Red Oak.  \n \n", "original_text": "During the quarter, we incurred higher costs supporting sales growth, including some initia l customer \nonboarding costs, and inflationary impacts in areas like transportation and labor. ", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b6ad0583050176f0722d0829100308870dae178e82cdecb50080fa19287c599c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e09c3658-5a19-4455-9848-1e3c31b8bcca", "node_type": "1", "metadata": {"window": "Segment profit decreased 5% to $487  million driven by higher operations expenses and previously \nanticipated investments in technology enhancements, partially offset by generics program \nperformance.  \n \n During the quarter, we incurred higher costs supporting sales growth, including some initia l customer \nonboarding costs, and inflationary impacts in areas like transportation and labor.  Importantly, we also \ncompleted the launch of our planned technology enhancements.  \n \n As Mike mentioned, we continued to see resiliency in pharmaceutical demand.  An d, our generics \nprogram continued to experience generally consistent market dynamics, including strong \nperformance from Red Oak.  \n \n Turning to Medical on slide 6\u2026  \n \nThird -quarter revenue decreased 7% to $3.9 billion due to the divestiture of the Cordis busi ness and \nlower products and distribution volumes, which includes the impact of global supply chain constraints.  \n Segment profit decreased 66% to $59 million, primarily due to net inflationary impacts and global \nsupply chain constraints in products and dist ribution.  \n", "original_text": "As Mike mentioned, we continued to see resiliency in pharmaceutical demand. "}, "hash": "c0f96d11c7a157186cc40c55d8e91cf083d320de5cf5542c3a9a961855814d61", "class_name": "RelatedNodeInfo"}}, "text": "Importantly, we also \ncompleted the launch of our planned technology enhancements.  \n \n", "start_char_idx": 1753, "end_char_idx": 1840, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e09c3658-5a19-4455-9848-1e3c31b8bcca": {"__data__": {"id_": "e09c3658-5a19-4455-9848-1e3c31b8bcca", "embedding": null, "metadata": {"window": "Segment profit decreased 5% to $487  million driven by higher operations expenses and previously \nanticipated investments in technology enhancements, partially offset by generics program \nperformance.  \n \n During the quarter, we incurred higher costs supporting sales growth, including some initia l customer \nonboarding costs, and inflationary impacts in areas like transportation and labor.  Importantly, we also \ncompleted the launch of our planned technology enhancements.  \n \n As Mike mentioned, we continued to see resiliency in pharmaceutical demand.  An d, our generics \nprogram continued to experience generally consistent market dynamics, including strong \nperformance from Red Oak.  \n \n Turning to Medical on slide 6\u2026  \n \nThird -quarter revenue decreased 7% to $3.9 billion due to the divestiture of the Cordis busi ness and \nlower products and distribution volumes, which includes the impact of global supply chain constraints.  \n Segment profit decreased 66% to $59 million, primarily due to net inflationary impacts and global \nsupply chain constraints in products and dist ribution.  \n", "original_text": "As Mike mentioned, we continued to see resiliency in pharmaceutical demand. ", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a2fb01e8c59aca0b10b021f9d5f1a87b49d799702414d8e4228fe800d635f30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0db1529a-4f62-4b88-a1a1-0862a29384c8", "node_type": "1", "metadata": {"window": "Now turni ng to the segments, beginning with Pharma on slide 5\u2026  \n \nRevenue increased 17% to $41 billion, driven by branded pharmaceutical sales growth from existing \nand net new Pharmaceutical Distribution and Specialty customers.  \n \n Segment profit decreased 5% to $487  million driven by higher operations expenses and previously \nanticipated investments in technology enhancements, partially offset by generics program \nperformance.  \n \n During the quarter, we incurred higher costs supporting sales growth, including some initia l customer \nonboarding costs, and inflationary impacts in areas like transportation and labor.  Importantly, we also \ncompleted the launch of our planned technology enhancements.  \n \n As Mike mentioned, we continued to see resiliency in pharmaceutical demand.  An d, our generics \nprogram continued to experience generally consistent market dynamics, including strong \nperformance from Red Oak.  \n \n Turning to Medical on slide 6\u2026  \n \nThird -quarter revenue decreased 7% to $3.9 billion due to the divestiture of the Cordis busi ness and \nlower products and distribution volumes, which includes the impact of global supply chain constraints.  \n", "original_text": "Importantly, we also \ncompleted the launch of our planned technology enhancements.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb88c2bc9f4d463aaa505067c39c6220fbc2f036582697c3aafaa82361936675", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56ca1fc6-3a0c-4722-bf70-073e48a9e59e", "node_type": "1", "metadata": {"window": "During the quarter, we incurred higher costs supporting sales growth, including some initia l customer \nonboarding costs, and inflationary impacts in areas like transportation and labor.  Importantly, we also \ncompleted the launch of our planned technology enhancements.  \n \n As Mike mentioned, we continued to see resiliency in pharmaceutical demand.  An d, our generics \nprogram continued to experience generally consistent market dynamics, including strong \nperformance from Red Oak.  \n \n Turning to Medical on slide 6\u2026  \n \nThird -quarter revenue decreased 7% to $3.9 billion due to the divestiture of the Cordis busi ness and \nlower products and distribution volumes, which includes the impact of global supply chain constraints.  \n Segment profit decreased 66% to $59 million, primarily due to net inflationary impacts and global \nsupply chain constraints in products and dist ribution.  \n During the quarter, our U.S. ", "original_text": "An d, our generics \nprogram continued to experience generally consistent market dynamics, including strong \nperformance from Red Oak.  \n \n"}, "hash": "9a7a14fef429c2f9e033f26b17d74c957e9b3d3e0ccd203108aa0f7ffb80d2be", "class_name": "RelatedNodeInfo"}}, "text": "As Mike mentioned, we continued to see resiliency in pharmaceutical demand. ", "start_char_idx": 1840, "end_char_idx": 1916, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56ca1fc6-3a0c-4722-bf70-073e48a9e59e": {"__data__": {"id_": "56ca1fc6-3a0c-4722-bf70-073e48a9e59e", "embedding": null, "metadata": {"window": "During the quarter, we incurred higher costs supporting sales growth, including some initia l customer \nonboarding costs, and inflationary impacts in areas like transportation and labor.  Importantly, we also \ncompleted the launch of our planned technology enhancements.  \n \n As Mike mentioned, we continued to see resiliency in pharmaceutical demand.  An d, our generics \nprogram continued to experience generally consistent market dynamics, including strong \nperformance from Red Oak.  \n \n Turning to Medical on slide 6\u2026  \n \nThird -quarter revenue decreased 7% to $3.9 billion due to the divestiture of the Cordis busi ness and \nlower products and distribution volumes, which includes the impact of global supply chain constraints.  \n Segment profit decreased 66% to $59 million, primarily due to net inflationary impacts and global \nsupply chain constraints in products and dist ribution.  \n During the quarter, our U.S. ", "original_text": "An d, our generics \nprogram continued to experience generally consistent market dynamics, including strong \nperformance from Red Oak.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a2fb01e8c59aca0b10b021f9d5f1a87b49d799702414d8e4228fe800d635f30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e09c3658-5a19-4455-9848-1e3c31b8bcca", "node_type": "1", "metadata": {"window": "Segment profit decreased 5% to $487  million driven by higher operations expenses and previously \nanticipated investments in technology enhancements, partially offset by generics program \nperformance.  \n \n During the quarter, we incurred higher costs supporting sales growth, including some initia l customer \nonboarding costs, and inflationary impacts in areas like transportation and labor.  Importantly, we also \ncompleted the launch of our planned technology enhancements.  \n \n As Mike mentioned, we continued to see resiliency in pharmaceutical demand.  An d, our generics \nprogram continued to experience generally consistent market dynamics, including strong \nperformance from Red Oak.  \n \n Turning to Medical on slide 6\u2026  \n \nThird -quarter revenue decreased 7% to $3.9 billion due to the divestiture of the Cordis busi ness and \nlower products and distribution volumes, which includes the impact of global supply chain constraints.  \n Segment profit decreased 66% to $59 million, primarily due to net inflationary impacts and global \nsupply chain constraints in products and dist ribution.  \n", "original_text": "As Mike mentioned, we continued to see resiliency in pharmaceutical demand. ", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e448090b4a00beed16665eaad16320606d6e708c7325a1534fc36e02d521556e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d9ae547-ee60-4220-a19c-27e118511cf3", "node_type": "1", "metadata": {"window": "Importantly, we also \ncompleted the launch of our planned technology enhancements.  \n \n As Mike mentioned, we continued to see resiliency in pharmaceutical demand.  An d, our generics \nprogram continued to experience generally consistent market dynamics, including strong \nperformance from Red Oak.  \n \n Turning to Medical on slide 6\u2026  \n \nThird -quarter revenue decreased 7% to $3.9 billion due to the divestiture of the Cordis busi ness and \nlower products and distribution volumes, which includes the impact of global supply chain constraints.  \n Segment profit decreased 66% to $59 million, primarily due to net inflationary impacts and global \nsupply chain constraints in products and dist ribution.  \n During the quarter, our U.S.  Medical Products and Distribution business continued to experience \nsignificant inflationary impacts across the global supply chain, particularly in the areas of international \nand domestic transportation and commoditie s. Additionally, increased pressures from global supply \nchain constraints affected the volume of some of our higher margin Cardinal Health brand products.  ", "original_text": "Turning to Medical on slide 6\u2026  \n \nThird -quarter revenue decreased 7% to $3.9 billion due to the divestiture of the Cordis busi ness and \nlower products and distribution volumes, which includes the impact of global supply chain constraints.  \n"}, "hash": "81b765725974ef9a68a244f5f4748aa403356c6892a00879a3d625fc351200c5", "class_name": "RelatedNodeInfo"}}, "text": "An d, our generics \nprogram continued to experience generally consistent market dynamics, including strong \nperformance from Red Oak.  \n \n", "start_char_idx": 1916, "end_char_idx": 2054, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d9ae547-ee60-4220-a19c-27e118511cf3": {"__data__": {"id_": "7d9ae547-ee60-4220-a19c-27e118511cf3", "embedding": null, "metadata": {"window": "Importantly, we also \ncompleted the launch of our planned technology enhancements.  \n \n As Mike mentioned, we continued to see resiliency in pharmaceutical demand.  An d, our generics \nprogram continued to experience generally consistent market dynamics, including strong \nperformance from Red Oak.  \n \n Turning to Medical on slide 6\u2026  \n \nThird -quarter revenue decreased 7% to $3.9 billion due to the divestiture of the Cordis busi ness and \nlower products and distribution volumes, which includes the impact of global supply chain constraints.  \n Segment profit decreased 66% to $59 million, primarily due to net inflationary impacts and global \nsupply chain constraints in products and dist ribution.  \n During the quarter, our U.S.  Medical Products and Distribution business continued to experience \nsignificant inflationary impacts across the global supply chain, particularly in the areas of international \nand domestic transportation and commoditie s. Additionally, increased pressures from global supply \nchain constraints affected the volume of some of our higher margin Cardinal Health brand products.  ", "original_text": "Turning to Medical on slide 6\u2026  \n \nThird -quarter revenue decreased 7% to $3.9 billion due to the divestiture of the Cordis busi ness and \nlower products and distribution volumes, which includes the impact of global supply chain constraints.  \n", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a2fb01e8c59aca0b10b021f9d5f1a87b49d799702414d8e4228fe800d635f30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56ca1fc6-3a0c-4722-bf70-073e48a9e59e", "node_type": "1", "metadata": {"window": "During the quarter, we incurred higher costs supporting sales growth, including some initia l customer \nonboarding costs, and inflationary impacts in areas like transportation and labor.  Importantly, we also \ncompleted the launch of our planned technology enhancements.  \n \n As Mike mentioned, we continued to see resiliency in pharmaceutical demand.  An d, our generics \nprogram continued to experience generally consistent market dynamics, including strong \nperformance from Red Oak.  \n \n Turning to Medical on slide 6\u2026  \n \nThird -quarter revenue decreased 7% to $3.9 billion due to the divestiture of the Cordis busi ness and \nlower products and distribution volumes, which includes the impact of global supply chain constraints.  \n Segment profit decreased 66% to $59 million, primarily due to net inflationary impacts and global \nsupply chain constraints in products and dist ribution.  \n During the quarter, our U.S. ", "original_text": "An d, our generics \nprogram continued to experience generally consistent market dynamics, including strong \nperformance from Red Oak.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d62e579275103809e4700686837a2fc25e55578cb1fba941997517410f2fd024", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f272a3fa-544f-4361-80a9-9182a2e68d66", "node_type": "1", "metadata": {"window": "As Mike mentioned, we continued to see resiliency in pharmaceutical demand.  An d, our generics \nprogram continued to experience generally consistent market dynamics, including strong \nperformance from Red Oak.  \n \n Turning to Medical on slide 6\u2026  \n \nThird -quarter revenue decreased 7% to $3.9 billion due to the divestiture of the Cordis busi ness and \nlower products and distribution volumes, which includes the impact of global supply chain constraints.  \n Segment profit decreased 66% to $59 million, primarily due to net inflationary impacts and global \nsupply chain constraints in products and dist ribution.  \n During the quarter, our U.S.  Medical Products and Distribution business continued to experience \nsignificant inflationary impacts across the global supply chain, particularly in the areas of international \nand domestic transportation and commoditie s. Additionally, increased pressures from global supply \nchain constraints affected the volume of some of our higher margin Cardinal Health brand products.  ", "original_text": "Segment profit decreased 66% to $59 million, primarily due to net inflationary impacts and global \nsupply chain constraints in products and dist ribution.  \n"}, "hash": "ef8223653db0e627ea54ee8b98e0e0f9ea4c37c1d50a51508ad1437ced85d96b", "class_name": "RelatedNodeInfo"}}, "text": "Turning to Medical on slide 6\u2026  \n \nThird -quarter revenue decreased 7% to $3.9 billion due to the divestiture of the Cordis busi ness and \nlower products and distribution volumes, which includes the impact of global supply chain constraints.  \n", "start_char_idx": 2054, "end_char_idx": 2298, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f272a3fa-544f-4361-80a9-9182a2e68d66": {"__data__": {"id_": "f272a3fa-544f-4361-80a9-9182a2e68d66", "embedding": null, "metadata": {"window": "As Mike mentioned, we continued to see resiliency in pharmaceutical demand.  An d, our generics \nprogram continued to experience generally consistent market dynamics, including strong \nperformance from Red Oak.  \n \n Turning to Medical on slide 6\u2026  \n \nThird -quarter revenue decreased 7% to $3.9 billion due to the divestiture of the Cordis busi ness and \nlower products and distribution volumes, which includes the impact of global supply chain constraints.  \n Segment profit decreased 66% to $59 million, primarily due to net inflationary impacts and global \nsupply chain constraints in products and dist ribution.  \n During the quarter, our U.S.  Medical Products and Distribution business continued to experience \nsignificant inflationary impacts across the global supply chain, particularly in the areas of international \nand domestic transportation and commoditie s. Additionally, increased pressures from global supply \nchain constraints affected the volume of some of our higher margin Cardinal Health brand products.  ", "original_text": "Segment profit decreased 66% to $59 million, primarily due to net inflationary impacts and global \nsupply chain constraints in products and dist ribution.  \n", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a2fb01e8c59aca0b10b021f9d5f1a87b49d799702414d8e4228fe800d635f30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d9ae547-ee60-4220-a19c-27e118511cf3", "node_type": "1", "metadata": {"window": "Importantly, we also \ncompleted the launch of our planned technology enhancements.  \n \n As Mike mentioned, we continued to see resiliency in pharmaceutical demand.  An d, our generics \nprogram continued to experience generally consistent market dynamics, including strong \nperformance from Red Oak.  \n \n Turning to Medical on slide 6\u2026  \n \nThird -quarter revenue decreased 7% to $3.9 billion due to the divestiture of the Cordis busi ness and \nlower products and distribution volumes, which includes the impact of global supply chain constraints.  \n Segment profit decreased 66% to $59 million, primarily due to net inflationary impacts and global \nsupply chain constraints in products and dist ribution.  \n During the quarter, our U.S.  Medical Products and Distribution business continued to experience \nsignificant inflationary impacts across the global supply chain, particularly in the areas of international \nand domestic transportation and commoditie s. Additionally, increased pressures from global supply \nchain constraints affected the volume of some of our higher margin Cardinal Health brand products.  ", "original_text": "Turning to Medical on slide 6\u2026  \n \nThird -quarter revenue decreased 7% to $3.9 billion due to the divestiture of the Cordis busi ness and \nlower products and distribution volumes, which includes the impact of global supply chain constraints.  \n", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3bc62633eb74562568ed0cf98df97d95670dca1e033da7eb38885ee46cfd71c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7229ae2d-0630-4d11-af07-4d725bbea20d", "node_type": "1", "metadata": {"window": "An d, our generics \nprogram continued to experience generally consistent market dynamics, including strong \nperformance from Red Oak.  \n \n Turning to Medical on slide 6\u2026  \n \nThird -quarter revenue decreased 7% to $3.9 billion due to the divestiture of the Cordis busi ness and \nlower products and distribution volumes, which includes the impact of global supply chain constraints.  \n Segment profit decreased 66% to $59 million, primarily due to net inflationary impacts and global \nsupply chain constraints in products and dist ribution.  \n During the quarter, our U.S.  Medical Products and Distribution business continued to experience \nsignificant inflationary impacts across the global supply chain, particularly in the areas of international \nand domestic transportation and commoditie s. Additionally, increased pressures from global supply \nchain constraints affected the volume of some of our higher margin Cardinal Health brand products.  ", "original_text": "During the quarter, our U.S. "}, "hash": "9397c937554a4a44351f09b6f9d40c13efea82901562f8580205a94f3b33125b", "class_name": "RelatedNodeInfo"}}, "text": "Segment profit decreased 66% to $59 million, primarily due to net inflationary impacts and global \nsupply chain constraints in products and dist ribution.  \n", "start_char_idx": 2298, "end_char_idx": 2455, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7229ae2d-0630-4d11-af07-4d725bbea20d": {"__data__": {"id_": "7229ae2d-0630-4d11-af07-4d725bbea20d", "embedding": null, "metadata": {"window": "An d, our generics \nprogram continued to experience generally consistent market dynamics, including strong \nperformance from Red Oak.  \n \n Turning to Medical on slide 6\u2026  \n \nThird -quarter revenue decreased 7% to $3.9 billion due to the divestiture of the Cordis busi ness and \nlower products and distribution volumes, which includes the impact of global supply chain constraints.  \n Segment profit decreased 66% to $59 million, primarily due to net inflationary impacts and global \nsupply chain constraints in products and dist ribution.  \n During the quarter, our U.S.  Medical Products and Distribution business continued to experience \nsignificant inflationary impacts across the global supply chain, particularly in the areas of international \nand domestic transportation and commoditie s. Additionally, increased pressures from global supply \nchain constraints affected the volume of some of our higher margin Cardinal Health brand products.  ", "original_text": "During the quarter, our U.S. ", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a2fb01e8c59aca0b10b021f9d5f1a87b49d799702414d8e4228fe800d635f30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f272a3fa-544f-4361-80a9-9182a2e68d66", "node_type": "1", "metadata": {"window": "As Mike mentioned, we continued to see resiliency in pharmaceutical demand.  An d, our generics \nprogram continued to experience generally consistent market dynamics, including strong \nperformance from Red Oak.  \n \n Turning to Medical on slide 6\u2026  \n \nThird -quarter revenue decreased 7% to $3.9 billion due to the divestiture of the Cordis busi ness and \nlower products and distribution volumes, which includes the impact of global supply chain constraints.  \n Segment profit decreased 66% to $59 million, primarily due to net inflationary impacts and global \nsupply chain constraints in products and dist ribution.  \n During the quarter, our U.S.  Medical Products and Distribution business continued to experience \nsignificant inflationary impacts across the global supply chain, particularly in the areas of international \nand domestic transportation and commoditie s. Additionally, increased pressures from global supply \nchain constraints affected the volume of some of our higher margin Cardinal Health brand products.  ", "original_text": "Segment profit decreased 66% to $59 million, primarily due to net inflationary impacts and global \nsupply chain constraints in products and dist ribution.  \n", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed42de7812120e185cbe1b5bc439bcb1a3e5f7cc0782c583b33404591f93acf4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "967132a2-bb30-4ec7-bb8a-c10c6dbc397e", "node_type": "1", "metadata": {"window": "Turning to Medical on slide 6\u2026  \n \nThird -quarter revenue decreased 7% to $3.9 billion due to the divestiture of the Cordis busi ness and \nlower products and distribution volumes, which includes the impact of global supply chain constraints.  \n Segment profit decreased 66% to $59 million, primarily due to net inflationary impacts and global \nsupply chain constraints in products and dist ribution.  \n During the quarter, our U.S.  Medical Products and Distribution business continued to experience \nsignificant inflationary impacts across the global supply chain, particularly in the areas of international \nand domestic transportation and commoditie s. Additionally, increased pressures from global supply \nchain constraints affected the volume of some of our higher margin Cardinal Health brand products.  ", "original_text": "Medical Products and Distribution business continued to experience \nsignificant inflationary impacts across the global supply chain, particularly in the areas of international \nand domestic transportation and commoditie s. Additionally, increased pressures from global supply \nchain constraints affected the volume of some of our higher margin Cardinal Health brand products.  "}, "hash": "f6b391382cedfb0a3aa8c53451be56d4966b4fcee5fade9608aa23cdd15eebd4", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, our U.S. ", "start_char_idx": 2455, "end_char_idx": 2484, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "967132a2-bb30-4ec7-bb8a-c10c6dbc397e": {"__data__": {"id_": "967132a2-bb30-4ec7-bb8a-c10c6dbc397e", "embedding": null, "metadata": {"window": "Turning to Medical on slide 6\u2026  \n \nThird -quarter revenue decreased 7% to $3.9 billion due to the divestiture of the Cordis busi ness and \nlower products and distribution volumes, which includes the impact of global supply chain constraints.  \n Segment profit decreased 66% to $59 million, primarily due to net inflationary impacts and global \nsupply chain constraints in products and dist ribution.  \n During the quarter, our U.S.  Medical Products and Distribution business continued to experience \nsignificant inflationary impacts across the global supply chain, particularly in the areas of international \nand domestic transportation and commoditie s. Additionally, increased pressures from global supply \nchain constraints affected the volume of some of our higher margin Cardinal Health brand products.  ", "original_text": "Medical Products and Distribution business continued to experience \nsignificant inflationary impacts across the global supply chain, particularly in the areas of international \nand domestic transportation and commoditie s. Additionally, increased pressures from global supply \nchain constraints affected the volume of some of our higher margin Cardinal Health brand products.  ", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428", "node_type": "4", "metadata": {"page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5a2fb01e8c59aca0b10b021f9d5f1a87b49d799702414d8e4228fe800d635f30", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7229ae2d-0630-4d11-af07-4d725bbea20d", "node_type": "1", "metadata": {"window": "An d, our generics \nprogram continued to experience generally consistent market dynamics, including strong \nperformance from Red Oak.  \n \n Turning to Medical on slide 6\u2026  \n \nThird -quarter revenue decreased 7% to $3.9 billion due to the divestiture of the Cordis busi ness and \nlower products and distribution volumes, which includes the impact of global supply chain constraints.  \n Segment profit decreased 66% to $59 million, primarily due to net inflationary impacts and global \nsupply chain constraints in products and dist ribution.  \n During the quarter, our U.S.  Medical Products and Distribution business continued to experience \nsignificant inflationary impacts across the global supply chain, particularly in the areas of international \nand domestic transportation and commoditie s. Additionally, increased pressures from global supply \nchain constraints affected the volume of some of our higher margin Cardinal Health brand products.  ", "original_text": "During the quarter, our U.S. ", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d28618e5fe6535f5c24e56b24649af39d4a53e08946809a062cae04df584b7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a85ab10-a64a-4150-9f87-972ed3be1638", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \nTo a lesser extent, the third -quarter decline in segment profit also reflected a lower contribution from \nPPE, as well as the Cordis divestiture.  On PPE, we saw unfavorable price -cost timing in the quarter, \nas well as lower volumes as we exited the quarter.  \n \n We were encouraged, however, by the resiliency in surgical product demand related to elective \nprocedures, which was generally consistent with recent quarters and improved from a year ago.  And, \nwe continued to see strong performance from our Lab business.   \n \n", "original_text": " \nPage 4 of 15 \n \nTo a lesser extent, the third -quarter decline in segment profit also reflected a lower contribution from \nPPE, as well as the Cordis divestiture. "}, "hash": "dbab04248d7a83df344728b7b13d9829611062e06319cac683cba61b49773ccd", "class_name": "RelatedNodeInfo"}}, "text": "Medical Products and Distribution business continued to experience \nsignificant inflationary impacts across the global supply chain, particularly in the areas of international \nand domestic transportation and commoditie s. Additionally, increased pressures from global supply \nchain constraints affected the volume of some of our higher margin Cardinal Health brand products.  ", "start_char_idx": 2484, "end_char_idx": 2861, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a85ab10-a64a-4150-9f87-972ed3be1638": {"__data__": {"id_": "4a85ab10-a64a-4150-9f87-972ed3be1638", "embedding": null, "metadata": {"window": " \nPage 4 of 15 \n \nTo a lesser extent, the third -quarter decline in segment profit also reflected a lower contribution from \nPPE, as well as the Cordis divestiture.  On PPE, we saw unfavorable price -cost timing in the quarter, \nas well as lower volumes as we exited the quarter.  \n \n We were encouraged, however, by the resiliency in surgical product demand related to elective \nprocedures, which was generally consistent with recent quarters and improved from a year ago.  And, \nwe continued to see strong performance from our Lab business.   \n \n", "original_text": " \nPage 4 of 15 \n \nTo a lesser extent, the third -quarter decline in segment profit also reflected a lower contribution from \nPPE, as well as the Cordis divestiture. ", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83870c13955ae97a1035138f8e3e4bf1c92fb1a0eaef87ba9f190428c8659c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "967132a2-bb30-4ec7-bb8a-c10c6dbc397e", "node_type": "1", "metadata": {"window": "Turning to Medical on slide 6\u2026  \n \nThird -quarter revenue decreased 7% to $3.9 billion due to the divestiture of the Cordis busi ness and \nlower products and distribution volumes, which includes the impact of global supply chain constraints.  \n Segment profit decreased 66% to $59 million, primarily due to net inflationary impacts and global \nsupply chain constraints in products and dist ribution.  \n During the quarter, our U.S.  Medical Products and Distribution business continued to experience \nsignificant inflationary impacts across the global supply chain, particularly in the areas of international \nand domestic transportation and commoditie s. Additionally, increased pressures from global supply \nchain constraints affected the volume of some of our higher margin Cardinal Health brand products.  ", "original_text": "Medical Products and Distribution business continued to experience \nsignificant inflationary impacts across the global supply chain, particularly in the areas of international \nand domestic transportation and commoditie s. Additionally, increased pressures from global supply \nchain constraints affected the volume of some of our higher margin Cardinal Health brand products.  ", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "49b618006812d5c66caeae66ca7a9ea53b481fcdb4538d956938275b59dd08a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce5b11fe-765e-4cea-9bea-22d2aa6ac937", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \nTo a lesser extent, the third -quarter decline in segment profit also reflected a lower contribution from \nPPE, as well as the Cordis divestiture.  On PPE, we saw unfavorable price -cost timing in the quarter, \nas well as lower volumes as we exited the quarter.  \n \n We were encouraged, however, by the resiliency in surgical product demand related to elective \nprocedures, which was generally consistent with recent quarters and improved from a year ago.  And, \nwe continued to see strong performance from our Lab business.   \n \n We continue to take action to address the inflationary cost challenges and manage through the \ntemporary supply disruptions, including pricing adjustments, cutting costs throughout the \norganization, and investing in our supply chain network, which Mike will  elaborate on momentarily.  \n \n", "original_text": "On PPE, we saw unfavorable price -cost timing in the quarter, \nas well as lower volumes as we exited the quarter.  \n \n"}, "hash": "09da7d44563b21e66a7af00adbe08f53617800ef8618aa7cb7d359bbfa473100", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 4 of 15 \n \nTo a lesser extent, the third -quarter decline in segment profit also reflected a lower contribution from \nPPE, as well as the Cordis divestiture. ", "start_char_idx": 0, "end_char_idx": 165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce5b11fe-765e-4cea-9bea-22d2aa6ac937": {"__data__": {"id_": "ce5b11fe-765e-4cea-9bea-22d2aa6ac937", "embedding": null, "metadata": {"window": " \nPage 4 of 15 \n \nTo a lesser extent, the third -quarter decline in segment profit also reflected a lower contribution from \nPPE, as well as the Cordis divestiture.  On PPE, we saw unfavorable price -cost timing in the quarter, \nas well as lower volumes as we exited the quarter.  \n \n We were encouraged, however, by the resiliency in surgical product demand related to elective \nprocedures, which was generally consistent with recent quarters and improved from a year ago.  And, \nwe continued to see strong performance from our Lab business.   \n \n We continue to take action to address the inflationary cost challenges and manage through the \ntemporary supply disruptions, including pricing adjustments, cutting costs throughout the \norganization, and investing in our supply chain network, which Mike will  elaborate on momentarily.  \n \n", "original_text": "On PPE, we saw unfavorable price -cost timing in the quarter, \nas well as lower volumes as we exited the quarter.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83870c13955ae97a1035138f8e3e4bf1c92fb1a0eaef87ba9f190428c8659c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a85ab10-a64a-4150-9f87-972ed3be1638", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \nTo a lesser extent, the third -quarter decline in segment profit also reflected a lower contribution from \nPPE, as well as the Cordis divestiture.  On PPE, we saw unfavorable price -cost timing in the quarter, \nas well as lower volumes as we exited the quarter.  \n \n We were encouraged, however, by the resiliency in surgical product demand related to elective \nprocedures, which was generally consistent with recent quarters and improved from a year ago.  And, \nwe continued to see strong performance from our Lab business.   \n \n", "original_text": " \nPage 4 of 15 \n \nTo a lesser extent, the third -quarter decline in segment profit also reflected a lower contribution from \nPPE, as well as the Cordis divestiture. ", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "56a33a6cd19ec3d52df59e99933195cfbc9571c4250f80b688158aa5270acf04", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e05a428-97c4-4220-8fcc-c55ff18471f4", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \nTo a lesser extent, the third -quarter decline in segment profit also reflected a lower contribution from \nPPE, as well as the Cordis divestiture.  On PPE, we saw unfavorable price -cost timing in the quarter, \nas well as lower volumes as we exited the quarter.  \n \n We were encouraged, however, by the resiliency in surgical product demand related to elective \nprocedures, which was generally consistent with recent quarters and improved from a year ago.  And, \nwe continued to see strong performance from our Lab business.   \n \n We continue to take action to address the inflationary cost challenges and manage through the \ntemporary supply disruptions, including pricing adjustments, cutting costs throughout the \norganization, and investing in our supply chain network, which Mike will  elaborate on momentarily.  \n \n Now, transitioning to our updated fiscal \u201822 outlook on slide 8\u2026  \n \nWe now expect EPS in the range of $5.15 to $5.25 per share, reflecting updated expectations for \nMedical and a few of our corporate assumptions.  \n \n", "original_text": "We were encouraged, however, by the resiliency in surgical product demand related to elective \nprocedures, which was generally consistent with recent quarters and improved from a year ago. "}, "hash": "62301b1cbdd7253cca3b510c80fe76ee2a0e72fccd38aef917590e0af845c501", "class_name": "RelatedNodeInfo"}}, "text": "On PPE, we saw unfavorable price -cost timing in the quarter, \nas well as lower volumes as we exited the quarter.  \n \n", "start_char_idx": 165, "end_char_idx": 283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e05a428-97c4-4220-8fcc-c55ff18471f4": {"__data__": {"id_": "3e05a428-97c4-4220-8fcc-c55ff18471f4", "embedding": null, "metadata": {"window": " \nPage 4 of 15 \n \nTo a lesser extent, the third -quarter decline in segment profit also reflected a lower contribution from \nPPE, as well as the Cordis divestiture.  On PPE, we saw unfavorable price -cost timing in the quarter, \nas well as lower volumes as we exited the quarter.  \n \n We were encouraged, however, by the resiliency in surgical product demand related to elective \nprocedures, which was generally consistent with recent quarters and improved from a year ago.  And, \nwe continued to see strong performance from our Lab business.   \n \n We continue to take action to address the inflationary cost challenges and manage through the \ntemporary supply disruptions, including pricing adjustments, cutting costs throughout the \norganization, and investing in our supply chain network, which Mike will  elaborate on momentarily.  \n \n Now, transitioning to our updated fiscal \u201822 outlook on slide 8\u2026  \n \nWe now expect EPS in the range of $5.15 to $5.25 per share, reflecting updated expectations for \nMedical and a few of our corporate assumptions.  \n \n", "original_text": "We were encouraged, however, by the resiliency in surgical product demand related to elective \nprocedures, which was generally consistent with recent quarters and improved from a year ago. ", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83870c13955ae97a1035138f8e3e4bf1c92fb1a0eaef87ba9f190428c8659c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce5b11fe-765e-4cea-9bea-22d2aa6ac937", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \nTo a lesser extent, the third -quarter decline in segment profit also reflected a lower contribution from \nPPE, as well as the Cordis divestiture.  On PPE, we saw unfavorable price -cost timing in the quarter, \nas well as lower volumes as we exited the quarter.  \n \n We were encouraged, however, by the resiliency in surgical product demand related to elective \nprocedures, which was generally consistent with recent quarters and improved from a year ago.  And, \nwe continued to see strong performance from our Lab business.   \n \n We continue to take action to address the inflationary cost challenges and manage through the \ntemporary supply disruptions, including pricing adjustments, cutting costs throughout the \norganization, and investing in our supply chain network, which Mike will  elaborate on momentarily.  \n \n", "original_text": "On PPE, we saw unfavorable price -cost timing in the quarter, \nas well as lower volumes as we exited the quarter.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "46644c92d7fd3522c058fddcfe4f31c2a355fabeee265f8ac2317b534d4ade6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93924e37-6ee9-4f56-a46f-c0715c587de3", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \nTo a lesser extent, the third -quarter decline in segment profit also reflected a lower contribution from \nPPE, as well as the Cordis divestiture.  On PPE, we saw unfavorable price -cost timing in the quarter, \nas well as lower volumes as we exited the quarter.  \n \n We were encouraged, however, by the resiliency in surgical product demand related to elective \nprocedures, which was generally consistent with recent quarters and improved from a year ago.  And, \nwe continued to see strong performance from our Lab business.   \n \n We continue to take action to address the inflationary cost challenges and manage through the \ntemporary supply disruptions, including pricing adjustments, cutting costs throughout the \norganization, and investing in our supply chain network, which Mike will  elaborate on momentarily.  \n \n Now, transitioning to our updated fiscal \u201822 outlook on slide 8\u2026  \n \nWe now expect EPS in the range of $5.15 to $5.25 per share, reflecting updated expectations for \nMedical and a few of our corporate assumptions.  \n \n With the favorability seen to date from discrete items, we now expect our annual effective tax rate to \nbe in t he range of 22% to 23%. ", "original_text": "And, \nwe continued to see strong performance from our Lab business.   \n \n"}, "hash": "77466b1b0892ab8ad8f19a9e9c723e2e521d0e0fd9860ed549bebd728d317d1a", "class_name": "RelatedNodeInfo"}}, "text": "We were encouraged, however, by the resiliency in surgical product demand related to elective \nprocedures, which was generally consistent with recent quarters and improved from a year ago. ", "start_char_idx": 283, "end_char_idx": 472, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93924e37-6ee9-4f56-a46f-c0715c587de3": {"__data__": {"id_": "93924e37-6ee9-4f56-a46f-c0715c587de3", "embedding": null, "metadata": {"window": " \nPage 4 of 15 \n \nTo a lesser extent, the third -quarter decline in segment profit also reflected a lower contribution from \nPPE, as well as the Cordis divestiture.  On PPE, we saw unfavorable price -cost timing in the quarter, \nas well as lower volumes as we exited the quarter.  \n \n We were encouraged, however, by the resiliency in surgical product demand related to elective \nprocedures, which was generally consistent with recent quarters and improved from a year ago.  And, \nwe continued to see strong performance from our Lab business.   \n \n We continue to take action to address the inflationary cost challenges and manage through the \ntemporary supply disruptions, including pricing adjustments, cutting costs throughout the \norganization, and investing in our supply chain network, which Mike will  elaborate on momentarily.  \n \n Now, transitioning to our updated fiscal \u201822 outlook on slide 8\u2026  \n \nWe now expect EPS in the range of $5.15 to $5.25 per share, reflecting updated expectations for \nMedical and a few of our corporate assumptions.  \n \n With the favorability seen to date from discrete items, we now expect our annual effective tax rate to \nbe in t he range of 22% to 23%. ", "original_text": "And, \nwe continued to see strong performance from our Lab business.   \n \n", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83870c13955ae97a1035138f8e3e4bf1c92fb1a0eaef87ba9f190428c8659c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e05a428-97c4-4220-8fcc-c55ff18471f4", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \nTo a lesser extent, the third -quarter decline in segment profit also reflected a lower contribution from \nPPE, as well as the Cordis divestiture.  On PPE, we saw unfavorable price -cost timing in the quarter, \nas well as lower volumes as we exited the quarter.  \n \n We were encouraged, however, by the resiliency in surgical product demand related to elective \nprocedures, which was generally consistent with recent quarters and improved from a year ago.  And, \nwe continued to see strong performance from our Lab business.   \n \n We continue to take action to address the inflationary cost challenges and manage through the \ntemporary supply disruptions, including pricing adjustments, cutting costs throughout the \norganization, and investing in our supply chain network, which Mike will  elaborate on momentarily.  \n \n Now, transitioning to our updated fiscal \u201822 outlook on slide 8\u2026  \n \nWe now expect EPS in the range of $5.15 to $5.25 per share, reflecting updated expectations for \nMedical and a few of our corporate assumptions.  \n \n", "original_text": "We were encouraged, however, by the resiliency in surgical product demand related to elective \nprocedures, which was generally consistent with recent quarters and improved from a year ago. ", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "893ca48f838d3ee8551c7a102eb8b08c477628b15d4e1dfb2b1e0909148f57e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f4b64fc-3b42-41ad-ad5b-6a1059b5630b", "node_type": "1", "metadata": {"window": "On PPE, we saw unfavorable price -cost timing in the quarter, \nas well as lower volumes as we exited the quarter.  \n \n We were encouraged, however, by the resiliency in surgical product demand related to elective \nprocedures, which was generally consistent with recent quarters and improved from a year ago.  And, \nwe continued to see strong performance from our Lab business.   \n \n We continue to take action to address the inflationary cost challenges and manage through the \ntemporary supply disruptions, including pricing adjustments, cutting costs throughout the \norganization, and investing in our supply chain network, which Mike will  elaborate on momentarily.  \n \n Now, transitioning to our updated fiscal \u201822 outlook on slide 8\u2026  \n \nWe now expect EPS in the range of $5.15 to $5.25 per share, reflecting updated expectations for \nMedical and a few of our corporate assumptions.  \n \n With the favorability seen to date from discrete items, we now expect our annual effective tax rate to \nbe in t he range of 22% to 23%.  We expect diluted weighted average shares outstanding of \napproximately 281 million, which reflects the  $1 billion in share repurchases completed to date. ", "original_text": "We continue to take action to address the inflationary cost challenges and manage through the \ntemporary supply disruptions, including pricing adjustments, cutting costs throughout the \norganization, and investing in our supply chain network, which Mike will  elaborate on momentarily.  \n \n"}, "hash": "5005e5eafa1d3a4c13ba2bcf7ae9ab29412cecbfcd8a9bf1d45bd10e3a55e3e4", "class_name": "RelatedNodeInfo"}}, "text": "And, \nwe continued to see strong performance from our Lab business.   \n \n", "start_char_idx": 472, "end_char_idx": 545, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f4b64fc-3b42-41ad-ad5b-6a1059b5630b": {"__data__": {"id_": "1f4b64fc-3b42-41ad-ad5b-6a1059b5630b", "embedding": null, "metadata": {"window": "On PPE, we saw unfavorable price -cost timing in the quarter, \nas well as lower volumes as we exited the quarter.  \n \n We were encouraged, however, by the resiliency in surgical product demand related to elective \nprocedures, which was generally consistent with recent quarters and improved from a year ago.  And, \nwe continued to see strong performance from our Lab business.   \n \n We continue to take action to address the inflationary cost challenges and manage through the \ntemporary supply disruptions, including pricing adjustments, cutting costs throughout the \norganization, and investing in our supply chain network, which Mike will  elaborate on momentarily.  \n \n Now, transitioning to our updated fiscal \u201822 outlook on slide 8\u2026  \n \nWe now expect EPS in the range of $5.15 to $5.25 per share, reflecting updated expectations for \nMedical and a few of our corporate assumptions.  \n \n With the favorability seen to date from discrete items, we now expect our annual effective tax rate to \nbe in t he range of 22% to 23%.  We expect diluted weighted average shares outstanding of \napproximately 281 million, which reflects the  $1 billion in share repurchases completed to date. ", "original_text": "We continue to take action to address the inflationary cost challenges and manage through the \ntemporary supply disruptions, including pricing adjustments, cutting costs throughout the \norganization, and investing in our supply chain network, which Mike will  elaborate on momentarily.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83870c13955ae97a1035138f8e3e4bf1c92fb1a0eaef87ba9f190428c8659c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93924e37-6ee9-4f56-a46f-c0715c587de3", "node_type": "1", "metadata": {"window": " \nPage 4 of 15 \n \nTo a lesser extent, the third -quarter decline in segment profit also reflected a lower contribution from \nPPE, as well as the Cordis divestiture.  On PPE, we saw unfavorable price -cost timing in the quarter, \nas well as lower volumes as we exited the quarter.  \n \n We were encouraged, however, by the resiliency in surgical product demand related to elective \nprocedures, which was generally consistent with recent quarters and improved from a year ago.  And, \nwe continued to see strong performance from our Lab business.   \n \n We continue to take action to address the inflationary cost challenges and manage through the \ntemporary supply disruptions, including pricing adjustments, cutting costs throughout the \norganization, and investing in our supply chain network, which Mike will  elaborate on momentarily.  \n \n Now, transitioning to our updated fiscal \u201822 outlook on slide 8\u2026  \n \nWe now expect EPS in the range of $5.15 to $5.25 per share, reflecting updated expectations for \nMedical and a few of our corporate assumptions.  \n \n With the favorability seen to date from discrete items, we now expect our annual effective tax rate to \nbe in t he range of 22% to 23%. ", "original_text": "And, \nwe continued to see strong performance from our Lab business.   \n \n", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "54bc5b4a5e4a751a92878ea859ac3ae4838264993150a3ab1f3176155d7f50f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d15799ae-b1f8-4f7c-83e8-5f1d1c41cb14", "node_type": "1", "metadata": {"window": "We were encouraged, however, by the resiliency in surgical product demand related to elective \nprocedures, which was generally consistent with recent quarters and improved from a year ago.  And, \nwe continued to see strong performance from our Lab business.   \n \n We continue to take action to address the inflationary cost challenges and manage through the \ntemporary supply disruptions, including pricing adjustments, cutting costs throughout the \norganization, and investing in our supply chain network, which Mike will  elaborate on momentarily.  \n \n Now, transitioning to our updated fiscal \u201822 outlook on slide 8\u2026  \n \nWe now expect EPS in the range of $5.15 to $5.25 per share, reflecting updated expectations for \nMedical and a few of our corporate assumptions.  \n \n With the favorability seen to date from discrete items, we now expect our annual effective tax rate to \nbe in t he range of 22% to 23%.  We expect diluted weighted average shares outstanding of \napproximately 281 million, which reflects the  $1 billion in share repurchases completed to date.  And \nwith one quarter to go, we expect capex of approximately $400 million. ", "original_text": "Now, transitioning to our updated fiscal \u201822 outlook on slide 8\u2026  \n \nWe now expect EPS in the range of $5.15 to $5.25 per share, reflecting updated expectations for \nMedical and a few of our corporate assumptions.  \n \n"}, "hash": "4927c4445178ad9ddd37540d570c787fcf6766ffaf3d882f03e2928be5668d9a", "class_name": "RelatedNodeInfo"}}, "text": "We continue to take action to address the inflationary cost challenges and manage through the \ntemporary supply disruptions, including pricing adjustments, cutting costs throughout the \norganization, and investing in our supply chain network, which Mike will  elaborate on momentarily.  \n \n", "start_char_idx": 545, "end_char_idx": 835, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d15799ae-b1f8-4f7c-83e8-5f1d1c41cb14": {"__data__": {"id_": "d15799ae-b1f8-4f7c-83e8-5f1d1c41cb14", "embedding": null, "metadata": {"window": "We were encouraged, however, by the resiliency in surgical product demand related to elective \nprocedures, which was generally consistent with recent quarters and improved from a year ago.  And, \nwe continued to see strong performance from our Lab business.   \n \n We continue to take action to address the inflationary cost challenges and manage through the \ntemporary supply disruptions, including pricing adjustments, cutting costs throughout the \norganization, and investing in our supply chain network, which Mike will  elaborate on momentarily.  \n \n Now, transitioning to our updated fiscal \u201822 outlook on slide 8\u2026  \n \nWe now expect EPS in the range of $5.15 to $5.25 per share, reflecting updated expectations for \nMedical and a few of our corporate assumptions.  \n \n With the favorability seen to date from discrete items, we now expect our annual effective tax rate to \nbe in t he range of 22% to 23%.  We expect diluted weighted average shares outstanding of \napproximately 281 million, which reflects the  $1 billion in share repurchases completed to date.  And \nwith one quarter to go, we expect capex of approximately $400 million. ", "original_text": "Now, transitioning to our updated fiscal \u201822 outlook on slide 8\u2026  \n \nWe now expect EPS in the range of $5.15 to $5.25 per share, reflecting updated expectations for \nMedical and a few of our corporate assumptions.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83870c13955ae97a1035138f8e3e4bf1c92fb1a0eaef87ba9f190428c8659c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f4b64fc-3b42-41ad-ad5b-6a1059b5630b", "node_type": "1", "metadata": {"window": "On PPE, we saw unfavorable price -cost timing in the quarter, \nas well as lower volumes as we exited the quarter.  \n \n We were encouraged, however, by the resiliency in surgical product demand related to elective \nprocedures, which was generally consistent with recent quarters and improved from a year ago.  And, \nwe continued to see strong performance from our Lab business.   \n \n We continue to take action to address the inflationary cost challenges and manage through the \ntemporary supply disruptions, including pricing adjustments, cutting costs throughout the \norganization, and investing in our supply chain network, which Mike will  elaborate on momentarily.  \n \n Now, transitioning to our updated fiscal \u201822 outlook on slide 8\u2026  \n \nWe now expect EPS in the range of $5.15 to $5.25 per share, reflecting updated expectations for \nMedical and a few of our corporate assumptions.  \n \n With the favorability seen to date from discrete items, we now expect our annual effective tax rate to \nbe in t he range of 22% to 23%.  We expect diluted weighted average shares outstanding of \napproximately 281 million, which reflects the  $1 billion in share repurchases completed to date. ", "original_text": "We continue to take action to address the inflationary cost challenges and manage through the \ntemporary supply disruptions, including pricing adjustments, cutting costs throughout the \norganization, and investing in our supply chain network, which Mike will  elaborate on momentarily.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5dec63c986ec2ecdcda0f8290197731c703aec511a516235195a02205fb85eca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17839fd1-a058-44f8-8662-51909ca3db58", "node_type": "1", "metadata": {"window": "And, \nwe continued to see strong performance from our Lab business.   \n \n We continue to take action to address the inflationary cost challenges and manage through the \ntemporary supply disruptions, including pricing adjustments, cutting costs throughout the \norganization, and investing in our supply chain network, which Mike will  elaborate on momentarily.  \n \n Now, transitioning to our updated fiscal \u201822 outlook on slide 8\u2026  \n \nWe now expect EPS in the range of $5.15 to $5.25 per share, reflecting updated expectations for \nMedical and a few of our corporate assumptions.  \n \n With the favorability seen to date from discrete items, we now expect our annual effective tax rate to \nbe in t he range of 22% to 23%.  We expect diluted weighted average shares outstanding of \napproximately 281 million, which reflects the  $1 billion in share repurchases completed to date.  And \nwith one quarter to go, we expect capex of approximately $400 million.  We continue to expect Interest \nand Other in the range of $140 to $160 million.  \n \n", "original_text": "With the favorability seen to date from discrete items, we now expect our annual effective tax rate to \nbe in t he range of 22% to 23%. "}, "hash": "61f4de01b7a26df64e4799be5b7d35077b3a022f8b0bb32bec7d634f0823a068", "class_name": "RelatedNodeInfo"}}, "text": "Now, transitioning to our updated fiscal \u201822 outlook on slide 8\u2026  \n \nWe now expect EPS in the range of $5.15 to $5.25 per share, reflecting updated expectations for \nMedical and a few of our corporate assumptions.  \n \n", "start_char_idx": 835, "end_char_idx": 1053, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17839fd1-a058-44f8-8662-51909ca3db58": {"__data__": {"id_": "17839fd1-a058-44f8-8662-51909ca3db58", "embedding": null, "metadata": {"window": "And, \nwe continued to see strong performance from our Lab business.   \n \n We continue to take action to address the inflationary cost challenges and manage through the \ntemporary supply disruptions, including pricing adjustments, cutting costs throughout the \norganization, and investing in our supply chain network, which Mike will  elaborate on momentarily.  \n \n Now, transitioning to our updated fiscal \u201822 outlook on slide 8\u2026  \n \nWe now expect EPS in the range of $5.15 to $5.25 per share, reflecting updated expectations for \nMedical and a few of our corporate assumptions.  \n \n With the favorability seen to date from discrete items, we now expect our annual effective tax rate to \nbe in t he range of 22% to 23%.  We expect diluted weighted average shares outstanding of \napproximately 281 million, which reflects the  $1 billion in share repurchases completed to date.  And \nwith one quarter to go, we expect capex of approximately $400 million.  We continue to expect Interest \nand Other in the range of $140 to $160 million.  \n \n", "original_text": "With the favorability seen to date from discrete items, we now expect our annual effective tax rate to \nbe in t he range of 22% to 23%. ", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83870c13955ae97a1035138f8e3e4bf1c92fb1a0eaef87ba9f190428c8659c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d15799ae-b1f8-4f7c-83e8-5f1d1c41cb14", "node_type": "1", "metadata": {"window": "We were encouraged, however, by the resiliency in surgical product demand related to elective \nprocedures, which was generally consistent with recent quarters and improved from a year ago.  And, \nwe continued to see strong performance from our Lab business.   \n \n We continue to take action to address the inflationary cost challenges and manage through the \ntemporary supply disruptions, including pricing adjustments, cutting costs throughout the \norganization, and investing in our supply chain network, which Mike will  elaborate on momentarily.  \n \n Now, transitioning to our updated fiscal \u201822 outlook on slide 8\u2026  \n \nWe now expect EPS in the range of $5.15 to $5.25 per share, reflecting updated expectations for \nMedical and a few of our corporate assumptions.  \n \n With the favorability seen to date from discrete items, we now expect our annual effective tax rate to \nbe in t he range of 22% to 23%.  We expect diluted weighted average shares outstanding of \napproximately 281 million, which reflects the  $1 billion in share repurchases completed to date.  And \nwith one quarter to go, we expect capex of approximately $400 million. ", "original_text": "Now, transitioning to our updated fiscal \u201822 outlook on slide 8\u2026  \n \nWe now expect EPS in the range of $5.15 to $5.25 per share, reflecting updated expectations for \nMedical and a few of our corporate assumptions.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11588cdfc0bea4d05a4a1faa0d86ce734f4061f2414d40dba5271f70a1a20b4b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43957dcb-6239-45ef-b608-0b0230654bfb", "node_type": "1", "metadata": {"window": "We continue to take action to address the inflationary cost challenges and manage through the \ntemporary supply disruptions, including pricing adjustments, cutting costs throughout the \norganization, and investing in our supply chain network, which Mike will  elaborate on momentarily.  \n \n Now, transitioning to our updated fiscal \u201822 outlook on slide 8\u2026  \n \nWe now expect EPS in the range of $5.15 to $5.25 per share, reflecting updated expectations for \nMedical and a few of our corporate assumptions.  \n \n With the favorability seen to date from discrete items, we now expect our annual effective tax rate to \nbe in t he range of 22% to 23%.  We expect diluted weighted average shares outstanding of \napproximately 281 million, which reflects the  $1 billion in share repurchases completed to date.  And \nwith one quarter to go, we expect capex of approximately $400 million.  We continue to expect Interest \nand Other in the range of $140 to $160 million.  \n \n As for the segments on slide 9\u2026  \n \nFor Pharma, no changes to our outlook, we continue to expect low -double digit revenue growth, mid -\nsingle digit segment profit growth, and as prev iously indicated, strong fourth quarter segment profit \ngrowth. ", "original_text": "We expect diluted weighted average shares outstanding of \napproximately 281 million, which reflects the  $1 billion in share repurchases completed to date. "}, "hash": "c402c75af9d8b8f6b00708ed57bf10f120bdb0e2522b5d3e3e596d19432e76b2", "class_name": "RelatedNodeInfo"}}, "text": "With the favorability seen to date from discrete items, we now expect our annual effective tax rate to \nbe in t he range of 22% to 23%. ", "start_char_idx": 1053, "end_char_idx": 1189, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43957dcb-6239-45ef-b608-0b0230654bfb": {"__data__": {"id_": "43957dcb-6239-45ef-b608-0b0230654bfb", "embedding": null, "metadata": {"window": "We continue to take action to address the inflationary cost challenges and manage through the \ntemporary supply disruptions, including pricing adjustments, cutting costs throughout the \norganization, and investing in our supply chain network, which Mike will  elaborate on momentarily.  \n \n Now, transitioning to our updated fiscal \u201822 outlook on slide 8\u2026  \n \nWe now expect EPS in the range of $5.15 to $5.25 per share, reflecting updated expectations for \nMedical and a few of our corporate assumptions.  \n \n With the favorability seen to date from discrete items, we now expect our annual effective tax rate to \nbe in t he range of 22% to 23%.  We expect diluted weighted average shares outstanding of \napproximately 281 million, which reflects the  $1 billion in share repurchases completed to date.  And \nwith one quarter to go, we expect capex of approximately $400 million.  We continue to expect Interest \nand Other in the range of $140 to $160 million.  \n \n As for the segments on slide 9\u2026  \n \nFor Pharma, no changes to our outlook, we continue to expect low -double digit revenue growth, mid -\nsingle digit segment profit growth, and as prev iously indicated, strong fourth quarter segment profit \ngrowth. ", "original_text": "We expect diluted weighted average shares outstanding of \napproximately 281 million, which reflects the  $1 billion in share repurchases completed to date. ", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83870c13955ae97a1035138f8e3e4bf1c92fb1a0eaef87ba9f190428c8659c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17839fd1-a058-44f8-8662-51909ca3db58", "node_type": "1", "metadata": {"window": "And, \nwe continued to see strong performance from our Lab business.   \n \n We continue to take action to address the inflationary cost challenges and manage through the \ntemporary supply disruptions, including pricing adjustments, cutting costs throughout the \norganization, and investing in our supply chain network, which Mike will  elaborate on momentarily.  \n \n Now, transitioning to our updated fiscal \u201822 outlook on slide 8\u2026  \n \nWe now expect EPS in the range of $5.15 to $5.25 per share, reflecting updated expectations for \nMedical and a few of our corporate assumptions.  \n \n With the favorability seen to date from discrete items, we now expect our annual effective tax rate to \nbe in t he range of 22% to 23%.  We expect diluted weighted average shares outstanding of \napproximately 281 million, which reflects the  $1 billion in share repurchases completed to date.  And \nwith one quarter to go, we expect capex of approximately $400 million.  We continue to expect Interest \nand Other in the range of $140 to $160 million.  \n \n", "original_text": "With the favorability seen to date from discrete items, we now expect our annual effective tax rate to \nbe in t he range of 22% to 23%. ", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30b42052227553ffd6b66406456315304c399f8840add4fa694441b61cb8a9a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ed86934-c1be-4007-a442-28c531e54ab6", "node_type": "1", "metadata": {"window": "Now, transitioning to our updated fiscal \u201822 outlook on slide 8\u2026  \n \nWe now expect EPS in the range of $5.15 to $5.25 per share, reflecting updated expectations for \nMedical and a few of our corporate assumptions.  \n \n With the favorability seen to date from discrete items, we now expect our annual effective tax rate to \nbe in t he range of 22% to 23%.  We expect diluted weighted average shares outstanding of \napproximately 281 million, which reflects the  $1 billion in share repurchases completed to date.  And \nwith one quarter to go, we expect capex of approximately $400 million.  We continue to expect Interest \nand Other in the range of $140 to $160 million.  \n \n As for the segments on slide 9\u2026  \n \nFor Pharma, no changes to our outlook, we continue to expect low -double digit revenue growth, mid -\nsingle digit segment profit growth, and as prev iously indicated, strong fourth quarter segment profit \ngrowth.  With the culmination of our planned technology enhancements, we will now be lapping \nelevated expense levels from the initial deployment a year ago, which has been a year -over-year \nheadwind the last several quarters. ", "original_text": "And \nwith one quarter to go, we expect capex of approximately $400 million. "}, "hash": "dd7b5bac12f88f61f908e5c0c0bb53fb5aac2c3b97a9ae2062ffa6b1402ce053", "class_name": "RelatedNodeInfo"}}, "text": "We expect diluted weighted average shares outstanding of \napproximately 281 million, which reflects the  $1 billion in share repurchases completed to date. ", "start_char_idx": 1189, "end_char_idx": 1345, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ed86934-c1be-4007-a442-28c531e54ab6": {"__data__": {"id_": "9ed86934-c1be-4007-a442-28c531e54ab6", "embedding": null, "metadata": {"window": "Now, transitioning to our updated fiscal \u201822 outlook on slide 8\u2026  \n \nWe now expect EPS in the range of $5.15 to $5.25 per share, reflecting updated expectations for \nMedical and a few of our corporate assumptions.  \n \n With the favorability seen to date from discrete items, we now expect our annual effective tax rate to \nbe in t he range of 22% to 23%.  We expect diluted weighted average shares outstanding of \napproximately 281 million, which reflects the  $1 billion in share repurchases completed to date.  And \nwith one quarter to go, we expect capex of approximately $400 million.  We continue to expect Interest \nand Other in the range of $140 to $160 million.  \n \n As for the segments on slide 9\u2026  \n \nFor Pharma, no changes to our outlook, we continue to expect low -double digit revenue growth, mid -\nsingle digit segment profit growth, and as prev iously indicated, strong fourth quarter segment profit \ngrowth.  With the culmination of our planned technology enhancements, we will now be lapping \nelevated expense levels from the initial deployment a year ago, which has been a year -over-year \nheadwind the last several quarters. ", "original_text": "And \nwith one quarter to go, we expect capex of approximately $400 million. ", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83870c13955ae97a1035138f8e3e4bf1c92fb1a0eaef87ba9f190428c8659c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43957dcb-6239-45ef-b608-0b0230654bfb", "node_type": "1", "metadata": {"window": "We continue to take action to address the inflationary cost challenges and manage through the \ntemporary supply disruptions, including pricing adjustments, cutting costs throughout the \norganization, and investing in our supply chain network, which Mike will  elaborate on momentarily.  \n \n Now, transitioning to our updated fiscal \u201822 outlook on slide 8\u2026  \n \nWe now expect EPS in the range of $5.15 to $5.25 per share, reflecting updated expectations for \nMedical and a few of our corporate assumptions.  \n \n With the favorability seen to date from discrete items, we now expect our annual effective tax rate to \nbe in t he range of 22% to 23%.  We expect diluted weighted average shares outstanding of \napproximately 281 million, which reflects the  $1 billion in share repurchases completed to date.  And \nwith one quarter to go, we expect capex of approximately $400 million.  We continue to expect Interest \nand Other in the range of $140 to $160 million.  \n \n As for the segments on slide 9\u2026  \n \nFor Pharma, no changes to our outlook, we continue to expect low -double digit revenue growth, mid -\nsingle digit segment profit growth, and as prev iously indicated, strong fourth quarter segment profit \ngrowth. ", "original_text": "We expect diluted weighted average shares outstanding of \napproximately 281 million, which reflects the  $1 billion in share repurchases completed to date. ", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d9312362b4ca522a862aa0db0a84882dae63e98be1ec8cbe8117baf97016ae0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0a90130-8552-4ed6-8f9c-e007b61935f4", "node_type": "1", "metadata": {"window": "With the favorability seen to date from discrete items, we now expect our annual effective tax rate to \nbe in t he range of 22% to 23%.  We expect diluted weighted average shares outstanding of \napproximately 281 million, which reflects the  $1 billion in share repurchases completed to date.  And \nwith one quarter to go, we expect capex of approximately $400 million.  We continue to expect Interest \nand Other in the range of $140 to $160 million.  \n \n As for the segments on slide 9\u2026  \n \nFor Pharma, no changes to our outlook, we continue to expect low -double digit revenue growth, mid -\nsingle digit segment profit growth, and as prev iously indicated, strong fourth quarter segment profit \ngrowth.  With the culmination of our planned technology enhancements, we will now be lapping \nelevated expense levels from the initial deployment a year ago, which has been a year -over-year \nheadwind the last several quarters.  We are also lapping a few one -time items that we called out last \nyear, which will create a favorable fourth -quarter comparison, and we expect strong underlying \nperformance in the quarter.  \n \n", "original_text": "We continue to expect Interest \nand Other in the range of $140 to $160 million.  \n \n"}, "hash": "8b0c7ad4c66ba48befe77bd66d4f6f1bed3eca6d1d3cd1d67e9c4b683792585a", "class_name": "RelatedNodeInfo"}}, "text": "And \nwith one quarter to go, we expect capex of approximately $400 million. ", "start_char_idx": 1345, "end_char_idx": 1421, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0a90130-8552-4ed6-8f9c-e007b61935f4": {"__data__": {"id_": "d0a90130-8552-4ed6-8f9c-e007b61935f4", "embedding": null, "metadata": {"window": "With the favorability seen to date from discrete items, we now expect our annual effective tax rate to \nbe in t he range of 22% to 23%.  We expect diluted weighted average shares outstanding of \napproximately 281 million, which reflects the  $1 billion in share repurchases completed to date.  And \nwith one quarter to go, we expect capex of approximately $400 million.  We continue to expect Interest \nand Other in the range of $140 to $160 million.  \n \n As for the segments on slide 9\u2026  \n \nFor Pharma, no changes to our outlook, we continue to expect low -double digit revenue growth, mid -\nsingle digit segment profit growth, and as prev iously indicated, strong fourth quarter segment profit \ngrowth.  With the culmination of our planned technology enhancements, we will now be lapping \nelevated expense levels from the initial deployment a year ago, which has been a year -over-year \nheadwind the last several quarters.  We are also lapping a few one -time items that we called out last \nyear, which will create a favorable fourth -quarter comparison, and we expect strong underlying \nperformance in the quarter.  \n \n", "original_text": "We continue to expect Interest \nand Other in the range of $140 to $160 million.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83870c13955ae97a1035138f8e3e4bf1c92fb1a0eaef87ba9f190428c8659c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ed86934-c1be-4007-a442-28c531e54ab6", "node_type": "1", "metadata": {"window": "Now, transitioning to our updated fiscal \u201822 outlook on slide 8\u2026  \n \nWe now expect EPS in the range of $5.15 to $5.25 per share, reflecting updated expectations for \nMedical and a few of our corporate assumptions.  \n \n With the favorability seen to date from discrete items, we now expect our annual effective tax rate to \nbe in t he range of 22% to 23%.  We expect diluted weighted average shares outstanding of \napproximately 281 million, which reflects the  $1 billion in share repurchases completed to date.  And \nwith one quarter to go, we expect capex of approximately $400 million.  We continue to expect Interest \nand Other in the range of $140 to $160 million.  \n \n As for the segments on slide 9\u2026  \n \nFor Pharma, no changes to our outlook, we continue to expect low -double digit revenue growth, mid -\nsingle digit segment profit growth, and as prev iously indicated, strong fourth quarter segment profit \ngrowth.  With the culmination of our planned technology enhancements, we will now be lapping \nelevated expense levels from the initial deployment a year ago, which has been a year -over-year \nheadwind the last several quarters. ", "original_text": "And \nwith one quarter to go, we expect capex of approximately $400 million. ", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b80dcde59f5a3f7e9eaed5a00a10f580ef2c3030bf7a7f563548f8dbd0d355bb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5235ea24-9b80-48c0-9394-8054a9b6d888", "node_type": "1", "metadata": {"window": "We expect diluted weighted average shares outstanding of \napproximately 281 million, which reflects the  $1 billion in share repurchases completed to date.  And \nwith one quarter to go, we expect capex of approximately $400 million.  We continue to expect Interest \nand Other in the range of $140 to $160 million.  \n \n As for the segments on slide 9\u2026  \n \nFor Pharma, no changes to our outlook, we continue to expect low -double digit revenue growth, mid -\nsingle digit segment profit growth, and as prev iously indicated, strong fourth quarter segment profit \ngrowth.  With the culmination of our planned technology enhancements, we will now be lapping \nelevated expense levels from the initial deployment a year ago, which has been a year -over-year \nheadwind the last several quarters.  We are also lapping a few one -time items that we called out last \nyear, which will create a favorable fourth -quarter comparison, and we expect strong underlying \nperformance in the quarter.  \n \n For Medical, we now expect revenue at the l ow end of our previous range, down mid -single digits, \nand segment profit to be down 45% to 55% in fiscal \u201822, which includes a net incremental headwind \nof nearly $300 million due to inflationary and global supply chain constraints. ", "original_text": "As for the segments on slide 9\u2026  \n \nFor Pharma, no changes to our outlook, we continue to expect low -double digit revenue growth, mid -\nsingle digit segment profit growth, and as prev iously indicated, strong fourth quarter segment profit \ngrowth. "}, "hash": "122457d783fa1a281d63e39e92201f9738bd79aa0688ceed0d3f4466621ab56e", "class_name": "RelatedNodeInfo"}}, "text": "We continue to expect Interest \nand Other in the range of $140 to $160 million.  \n \n", "start_char_idx": 1421, "end_char_idx": 1505, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5235ea24-9b80-48c0-9394-8054a9b6d888": {"__data__": {"id_": "5235ea24-9b80-48c0-9394-8054a9b6d888", "embedding": null, "metadata": {"window": "We expect diluted weighted average shares outstanding of \napproximately 281 million, which reflects the  $1 billion in share repurchases completed to date.  And \nwith one quarter to go, we expect capex of approximately $400 million.  We continue to expect Interest \nand Other in the range of $140 to $160 million.  \n \n As for the segments on slide 9\u2026  \n \nFor Pharma, no changes to our outlook, we continue to expect low -double digit revenue growth, mid -\nsingle digit segment profit growth, and as prev iously indicated, strong fourth quarter segment profit \ngrowth.  With the culmination of our planned technology enhancements, we will now be lapping \nelevated expense levels from the initial deployment a year ago, which has been a year -over-year \nheadwind the last several quarters.  We are also lapping a few one -time items that we called out last \nyear, which will create a favorable fourth -quarter comparison, and we expect strong underlying \nperformance in the quarter.  \n \n For Medical, we now expect revenue at the l ow end of our previous range, down mid -single digits, \nand segment profit to be down 45% to 55% in fiscal \u201822, which includes a net incremental headwind \nof nearly $300 million due to inflationary and global supply chain constraints. ", "original_text": "As for the segments on slide 9\u2026  \n \nFor Pharma, no changes to our outlook, we continue to expect low -double digit revenue growth, mid -\nsingle digit segment profit growth, and as prev iously indicated, strong fourth quarter segment profit \ngrowth. ", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83870c13955ae97a1035138f8e3e4bf1c92fb1a0eaef87ba9f190428c8659c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0a90130-8552-4ed6-8f9c-e007b61935f4", "node_type": "1", "metadata": {"window": "With the favorability seen to date from discrete items, we now expect our annual effective tax rate to \nbe in t he range of 22% to 23%.  We expect diluted weighted average shares outstanding of \napproximately 281 million, which reflects the  $1 billion in share repurchases completed to date.  And \nwith one quarter to go, we expect capex of approximately $400 million.  We continue to expect Interest \nand Other in the range of $140 to $160 million.  \n \n As for the segments on slide 9\u2026  \n \nFor Pharma, no changes to our outlook, we continue to expect low -double digit revenue growth, mid -\nsingle digit segment profit growth, and as prev iously indicated, strong fourth quarter segment profit \ngrowth.  With the culmination of our planned technology enhancements, we will now be lapping \nelevated expense levels from the initial deployment a year ago, which has been a year -over-year \nheadwind the last several quarters.  We are also lapping a few one -time items that we called out last \nyear, which will create a favorable fourth -quarter comparison, and we expect strong underlying \nperformance in the quarter.  \n \n", "original_text": "We continue to expect Interest \nand Other in the range of $140 to $160 million.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ca5b59b12547fe27bd9554e522622eb3a4bea8fdb0cc3dc7492d3686d8b280d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d4233c3-c624-45e1-ad85-9120a667415b", "node_type": "1", "metadata": {"window": "And \nwith one quarter to go, we expect capex of approximately $400 million.  We continue to expect Interest \nand Other in the range of $140 to $160 million.  \n \n As for the segments on slide 9\u2026  \n \nFor Pharma, no changes to our outlook, we continue to expect low -double digit revenue growth, mid -\nsingle digit segment profit growth, and as prev iously indicated, strong fourth quarter segment profit \ngrowth.  With the culmination of our planned technology enhancements, we will now be lapping \nelevated expense levels from the initial deployment a year ago, which has been a year -over-year \nheadwind the last several quarters.  We are also lapping a few one -time items that we called out last \nyear, which will create a favorable fourth -quarter comparison, and we expect strong underlying \nperformance in the quarter.  \n \n For Medical, we now expect revenue at the l ow end of our previous range, down mid -single digits, \nand segment profit to be down 45% to 55% in fiscal \u201822, which includes a net incremental headwind \nof nearly $300 million due to inflationary and global supply chain constraints.  Additionally, based on \nvolume trends, the update from our previous Medical outlook primarily reflects a lower contribution \nfrom PPE.  \n \n", "original_text": "With the culmination of our planned technology enhancements, we will now be lapping \nelevated expense levels from the initial deployment a year ago, which has been a year -over-year \nheadwind the last several quarters. "}, "hash": "4d91daf34021e16bcfef78df52e1850d9be3928e6104aad989bc7a49799efaf4", "class_name": "RelatedNodeInfo"}}, "text": "As for the segments on slide 9\u2026  \n \nFor Pharma, no changes to our outlook, we continue to expect low -double digit revenue growth, mid -\nsingle digit segment profit growth, and as prev iously indicated, strong fourth quarter segment profit \ngrowth. ", "start_char_idx": 1505, "end_char_idx": 1754, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d4233c3-c624-45e1-ad85-9120a667415b": {"__data__": {"id_": "0d4233c3-c624-45e1-ad85-9120a667415b", "embedding": null, "metadata": {"window": "And \nwith one quarter to go, we expect capex of approximately $400 million.  We continue to expect Interest \nand Other in the range of $140 to $160 million.  \n \n As for the segments on slide 9\u2026  \n \nFor Pharma, no changes to our outlook, we continue to expect low -double digit revenue growth, mid -\nsingle digit segment profit growth, and as prev iously indicated, strong fourth quarter segment profit \ngrowth.  With the culmination of our planned technology enhancements, we will now be lapping \nelevated expense levels from the initial deployment a year ago, which has been a year -over-year \nheadwind the last several quarters.  We are also lapping a few one -time items that we called out last \nyear, which will create a favorable fourth -quarter comparison, and we expect strong underlying \nperformance in the quarter.  \n \n For Medical, we now expect revenue at the l ow end of our previous range, down mid -single digits, \nand segment profit to be down 45% to 55% in fiscal \u201822, which includes a net incremental headwind \nof nearly $300 million due to inflationary and global supply chain constraints.  Additionally, based on \nvolume trends, the update from our previous Medical outlook primarily reflects a lower contribution \nfrom PPE.  \n \n", "original_text": "With the culmination of our planned technology enhancements, we will now be lapping \nelevated expense levels from the initial deployment a year ago, which has been a year -over-year \nheadwind the last several quarters. ", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83870c13955ae97a1035138f8e3e4bf1c92fb1a0eaef87ba9f190428c8659c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5235ea24-9b80-48c0-9394-8054a9b6d888", "node_type": "1", "metadata": {"window": "We expect diluted weighted average shares outstanding of \napproximately 281 million, which reflects the  $1 billion in share repurchases completed to date.  And \nwith one quarter to go, we expect capex of approximately $400 million.  We continue to expect Interest \nand Other in the range of $140 to $160 million.  \n \n As for the segments on slide 9\u2026  \n \nFor Pharma, no changes to our outlook, we continue to expect low -double digit revenue growth, mid -\nsingle digit segment profit growth, and as prev iously indicated, strong fourth quarter segment profit \ngrowth.  With the culmination of our planned technology enhancements, we will now be lapping \nelevated expense levels from the initial deployment a year ago, which has been a year -over-year \nheadwind the last several quarters.  We are also lapping a few one -time items that we called out last \nyear, which will create a favorable fourth -quarter comparison, and we expect strong underlying \nperformance in the quarter.  \n \n For Medical, we now expect revenue at the l ow end of our previous range, down mid -single digits, \nand segment profit to be down 45% to 55% in fiscal \u201822, which includes a net incremental headwind \nof nearly $300 million due to inflationary and global supply chain constraints. ", "original_text": "As for the segments on slide 9\u2026  \n \nFor Pharma, no changes to our outlook, we continue to expect low -double digit revenue growth, mid -\nsingle digit segment profit growth, and as prev iously indicated, strong fourth quarter segment profit \ngrowth. ", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a2b016b806f8d9db0e0f2c50db10d6b574a71d19d3cb158f88edfb0221facf0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3bf3d11d-b797-402f-bbab-78a092925771", "node_type": "1", "metadata": {"window": "We continue to expect Interest \nand Other in the range of $140 to $160 million.  \n \n As for the segments on slide 9\u2026  \n \nFor Pharma, no changes to our outlook, we continue to expect low -double digit revenue growth, mid -\nsingle digit segment profit growth, and as prev iously indicated, strong fourth quarter segment profit \ngrowth.  With the culmination of our planned technology enhancements, we will now be lapping \nelevated expense levels from the initial deployment a year ago, which has been a year -over-year \nheadwind the last several quarters.  We are also lapping a few one -time items that we called out last \nyear, which will create a favorable fourth -quarter comparison, and we expect strong underlying \nperformance in the quarter.  \n \n For Medical, we now expect revenue at the l ow end of our previous range, down mid -single digits, \nand segment profit to be down 45% to 55% in fiscal \u201822, which includes a net incremental headwind \nof nearly $300 million due to inflationary and global supply chain constraints.  Additionally, based on \nvolume trends, the update from our previous Medical outlook primarily reflects a lower contribution \nfrom PPE.  \n \n Now, let me spend some time sharing a few high -level thoughts on fiscal \u201823 from our vantage point \ntoday ahead of providing our usual guidance in early August.  \n \n", "original_text": "We are also lapping a few one -time items that we called out last \nyear, which will create a favorable fourth -quarter comparison, and we expect strong underlying \nperformance in the quarter.  \n \n"}, "hash": "67a433ba1acac02cf23c2767a77f6da3b265f873a4c7d5f70dfcc3e1143f0c08", "class_name": "RelatedNodeInfo"}}, "text": "With the culmination of our planned technology enhancements, we will now be lapping \nelevated expense levels from the initial deployment a year ago, which has been a year -over-year \nheadwind the last several quarters. ", "start_char_idx": 1754, "end_char_idx": 1973, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3bf3d11d-b797-402f-bbab-78a092925771": {"__data__": {"id_": "3bf3d11d-b797-402f-bbab-78a092925771", "embedding": null, "metadata": {"window": "We continue to expect Interest \nand Other in the range of $140 to $160 million.  \n \n As for the segments on slide 9\u2026  \n \nFor Pharma, no changes to our outlook, we continue to expect low -double digit revenue growth, mid -\nsingle digit segment profit growth, and as prev iously indicated, strong fourth quarter segment profit \ngrowth.  With the culmination of our planned technology enhancements, we will now be lapping \nelevated expense levels from the initial deployment a year ago, which has been a year -over-year \nheadwind the last several quarters.  We are also lapping a few one -time items that we called out last \nyear, which will create a favorable fourth -quarter comparison, and we expect strong underlying \nperformance in the quarter.  \n \n For Medical, we now expect revenue at the l ow end of our previous range, down mid -single digits, \nand segment profit to be down 45% to 55% in fiscal \u201822, which includes a net incremental headwind \nof nearly $300 million due to inflationary and global supply chain constraints.  Additionally, based on \nvolume trends, the update from our previous Medical outlook primarily reflects a lower contribution \nfrom PPE.  \n \n Now, let me spend some time sharing a few high -level thoughts on fiscal \u201823 from our vantage point \ntoday ahead of providing our usual guidance in early August.  \n \n", "original_text": "We are also lapping a few one -time items that we called out last \nyear, which will create a favorable fourth -quarter comparison, and we expect strong underlying \nperformance in the quarter.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83870c13955ae97a1035138f8e3e4bf1c92fb1a0eaef87ba9f190428c8659c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d4233c3-c624-45e1-ad85-9120a667415b", "node_type": "1", "metadata": {"window": "And \nwith one quarter to go, we expect capex of approximately $400 million.  We continue to expect Interest \nand Other in the range of $140 to $160 million.  \n \n As for the segments on slide 9\u2026  \n \nFor Pharma, no changes to our outlook, we continue to expect low -double digit revenue growth, mid -\nsingle digit segment profit growth, and as prev iously indicated, strong fourth quarter segment profit \ngrowth.  With the culmination of our planned technology enhancements, we will now be lapping \nelevated expense levels from the initial deployment a year ago, which has been a year -over-year \nheadwind the last several quarters.  We are also lapping a few one -time items that we called out last \nyear, which will create a favorable fourth -quarter comparison, and we expect strong underlying \nperformance in the quarter.  \n \n For Medical, we now expect revenue at the l ow end of our previous range, down mid -single digits, \nand segment profit to be down 45% to 55% in fiscal \u201822, which includes a net incremental headwind \nof nearly $300 million due to inflationary and global supply chain constraints.  Additionally, based on \nvolume trends, the update from our previous Medical outlook primarily reflects a lower contribution \nfrom PPE.  \n \n", "original_text": "With the culmination of our planned technology enhancements, we will now be lapping \nelevated expense levels from the initial deployment a year ago, which has been a year -over-year \nheadwind the last several quarters. ", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dbf220aaf37769a276da3acd42a5ed32cca771846d5e8d6fb5e70bcf5e5574d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ea82698d-8c6a-441e-81e8-f80fc4fa01f8", "node_type": "1", "metadata": {"window": "As for the segments on slide 9\u2026  \n \nFor Pharma, no changes to our outlook, we continue to expect low -double digit revenue growth, mid -\nsingle digit segment profit growth, and as prev iously indicated, strong fourth quarter segment profit \ngrowth.  With the culmination of our planned technology enhancements, we will now be lapping \nelevated expense levels from the initial deployment a year ago, which has been a year -over-year \nheadwind the last several quarters.  We are also lapping a few one -time items that we called out last \nyear, which will create a favorable fourth -quarter comparison, and we expect strong underlying \nperformance in the quarter.  \n \n For Medical, we now expect revenue at the l ow end of our previous range, down mid -single digits, \nand segment profit to be down 45% to 55% in fiscal \u201822, which includes a net incremental headwind \nof nearly $300 million due to inflationary and global supply chain constraints.  Additionally, based on \nvolume trends, the update from our previous Medical outlook primarily reflects a lower contribution \nfrom PPE.  \n \n Now, let me spend some time sharing a few high -level thoughts on fiscal \u201823 from our vantage point \ntoday ahead of providing our usual guidance in early August.  \n \n In Pharma, the business is tracking consistent with our long -term target of low to mid -single digit \nsegment profit growth. ", "original_text": "For Medical, we now expect revenue at the l ow end of our previous range, down mid -single digits, \nand segment profit to be down 45% to 55% in fiscal \u201822, which includes a net incremental headwind \nof nearly $300 million due to inflationary and global supply chain constraints. "}, "hash": "59a444ac1ab69df0f37e52090bb549695e78e3059df224d7631299ee5713b66c", "class_name": "RelatedNodeInfo"}}, "text": "We are also lapping a few one -time items that we called out last \nyear, which will create a favorable fourth -quarter comparison, and we expect strong underlying \nperformance in the quarter.  \n \n", "start_char_idx": 1973, "end_char_idx": 2169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ea82698d-8c6a-441e-81e8-f80fc4fa01f8": {"__data__": {"id_": "ea82698d-8c6a-441e-81e8-f80fc4fa01f8", "embedding": null, "metadata": {"window": "As for the segments on slide 9\u2026  \n \nFor Pharma, no changes to our outlook, we continue to expect low -double digit revenue growth, mid -\nsingle digit segment profit growth, and as prev iously indicated, strong fourth quarter segment profit \ngrowth.  With the culmination of our planned technology enhancements, we will now be lapping \nelevated expense levels from the initial deployment a year ago, which has been a year -over-year \nheadwind the last several quarters.  We are also lapping a few one -time items that we called out last \nyear, which will create a favorable fourth -quarter comparison, and we expect strong underlying \nperformance in the quarter.  \n \n For Medical, we now expect revenue at the l ow end of our previous range, down mid -single digits, \nand segment profit to be down 45% to 55% in fiscal \u201822, which includes a net incremental headwind \nof nearly $300 million due to inflationary and global supply chain constraints.  Additionally, based on \nvolume trends, the update from our previous Medical outlook primarily reflects a lower contribution \nfrom PPE.  \n \n Now, let me spend some time sharing a few high -level thoughts on fiscal \u201823 from our vantage point \ntoday ahead of providing our usual guidance in early August.  \n \n In Pharma, the business is tracking consistent with our long -term target of low to mid -single digit \nsegment profit growth. ", "original_text": "For Medical, we now expect revenue at the l ow end of our previous range, down mid -single digits, \nand segment profit to be down 45% to 55% in fiscal \u201822, which includes a net incremental headwind \nof nearly $300 million due to inflationary and global supply chain constraints. ", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83870c13955ae97a1035138f8e3e4bf1c92fb1a0eaef87ba9f190428c8659c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3bf3d11d-b797-402f-bbab-78a092925771", "node_type": "1", "metadata": {"window": "We continue to expect Interest \nand Other in the range of $140 to $160 million.  \n \n As for the segments on slide 9\u2026  \n \nFor Pharma, no changes to our outlook, we continue to expect low -double digit revenue growth, mid -\nsingle digit segment profit growth, and as prev iously indicated, strong fourth quarter segment profit \ngrowth.  With the culmination of our planned technology enhancements, we will now be lapping \nelevated expense levels from the initial deployment a year ago, which has been a year -over-year \nheadwind the last several quarters.  We are also lapping a few one -time items that we called out last \nyear, which will create a favorable fourth -quarter comparison, and we expect strong underlying \nperformance in the quarter.  \n \n For Medical, we now expect revenue at the l ow end of our previous range, down mid -single digits, \nand segment profit to be down 45% to 55% in fiscal \u201822, which includes a net incremental headwind \nof nearly $300 million due to inflationary and global supply chain constraints.  Additionally, based on \nvolume trends, the update from our previous Medical outlook primarily reflects a lower contribution \nfrom PPE.  \n \n Now, let me spend some time sharing a few high -level thoughts on fiscal \u201823 from our vantage point \ntoday ahead of providing our usual guidance in early August.  \n \n", "original_text": "We are also lapping a few one -time items that we called out last \nyear, which will create a favorable fourth -quarter comparison, and we expect strong underlying \nperformance in the quarter.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d105be8680faad0505b3da33baddc293d6883ce4a65deb69ac7f1ce43eacd229", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f63c2ae-a369-48bd-8dde-a40870c8a860", "node_type": "1", "metadata": {"window": "With the culmination of our planned technology enhancements, we will now be lapping \nelevated expense levels from the initial deployment a year ago, which has been a year -over-year \nheadwind the last several quarters.  We are also lapping a few one -time items that we called out last \nyear, which will create a favorable fourth -quarter comparison, and we expect strong underlying \nperformance in the quarter.  \n \n For Medical, we now expect revenue at the l ow end of our previous range, down mid -single digits, \nand segment profit to be down 45% to 55% in fiscal \u201822, which includes a net incremental headwind \nof nearly $300 million due to inflationary and global supply chain constraints.  Additionally, based on \nvolume trends, the update from our previous Medical outlook primarily reflects a lower contribution \nfrom PPE.  \n \n Now, let me spend some time sharing a few high -level thoughts on fiscal \u201823 from our vantage point \ntoday ahead of providing our usual guidance in early August.  \n \n In Pharma, the business is tracking consistent with our long -term target of low to mid -single digit \nsegment profit growth.  With respect to a couple other notable Pharma puts and takes for next year, \nwe do anticipate higher operations expens es based on recent inflationary trends, particularly in the ", "original_text": "Additionally, based on \nvolume trends, the update from our previous Medical outlook primarily reflects a lower contribution \nfrom PPE.  \n \n"}, "hash": "10ea14594a23bc67c95d3d9e109752ad397fae3b3d0803745d8bb97e96eef110", "class_name": "RelatedNodeInfo"}}, "text": "For Medical, we now expect revenue at the l ow end of our previous range, down mid -single digits, \nand segment profit to be down 45% to 55% in fiscal \u201822, which includes a net incremental headwind \nof nearly $300 million due to inflationary and global supply chain constraints. ", "start_char_idx": 2169, "end_char_idx": 2448, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f63c2ae-a369-48bd-8dde-a40870c8a860": {"__data__": {"id_": "5f63c2ae-a369-48bd-8dde-a40870c8a860", "embedding": null, "metadata": {"window": "With the culmination of our planned technology enhancements, we will now be lapping \nelevated expense levels from the initial deployment a year ago, which has been a year -over-year \nheadwind the last several quarters.  We are also lapping a few one -time items that we called out last \nyear, which will create a favorable fourth -quarter comparison, and we expect strong underlying \nperformance in the quarter.  \n \n For Medical, we now expect revenue at the l ow end of our previous range, down mid -single digits, \nand segment profit to be down 45% to 55% in fiscal \u201822, which includes a net incremental headwind \nof nearly $300 million due to inflationary and global supply chain constraints.  Additionally, based on \nvolume trends, the update from our previous Medical outlook primarily reflects a lower contribution \nfrom PPE.  \n \n Now, let me spend some time sharing a few high -level thoughts on fiscal \u201823 from our vantage point \ntoday ahead of providing our usual guidance in early August.  \n \n In Pharma, the business is tracking consistent with our long -term target of low to mid -single digit \nsegment profit growth.  With respect to a couple other notable Pharma puts and takes for next year, \nwe do anticipate higher operations expens es based on recent inflationary trends, particularly in the ", "original_text": "Additionally, based on \nvolume trends, the update from our previous Medical outlook primarily reflects a lower contribution \nfrom PPE.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83870c13955ae97a1035138f8e3e4bf1c92fb1a0eaef87ba9f190428c8659c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ea82698d-8c6a-441e-81e8-f80fc4fa01f8", "node_type": "1", "metadata": {"window": "As for the segments on slide 9\u2026  \n \nFor Pharma, no changes to our outlook, we continue to expect low -double digit revenue growth, mid -\nsingle digit segment profit growth, and as prev iously indicated, strong fourth quarter segment profit \ngrowth.  With the culmination of our planned technology enhancements, we will now be lapping \nelevated expense levels from the initial deployment a year ago, which has been a year -over-year \nheadwind the last several quarters.  We are also lapping a few one -time items that we called out last \nyear, which will create a favorable fourth -quarter comparison, and we expect strong underlying \nperformance in the quarter.  \n \n For Medical, we now expect revenue at the l ow end of our previous range, down mid -single digits, \nand segment profit to be down 45% to 55% in fiscal \u201822, which includes a net incremental headwind \nof nearly $300 million due to inflationary and global supply chain constraints.  Additionally, based on \nvolume trends, the update from our previous Medical outlook primarily reflects a lower contribution \nfrom PPE.  \n \n Now, let me spend some time sharing a few high -level thoughts on fiscal \u201823 from our vantage point \ntoday ahead of providing our usual guidance in early August.  \n \n In Pharma, the business is tracking consistent with our long -term target of low to mid -single digit \nsegment profit growth. ", "original_text": "For Medical, we now expect revenue at the l ow end of our previous range, down mid -single digits, \nand segment profit to be down 45% to 55% in fiscal \u201822, which includes a net incremental headwind \nof nearly $300 million due to inflationary and global supply chain constraints. ", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5fad2641cc5b36bb40693406c543cb481ed70bb43ff0389ee38263ad498289ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0cc4a662-1fca-4698-9576-41816536bf48", "node_type": "1", "metadata": {"window": "We are also lapping a few one -time items that we called out last \nyear, which will create a favorable fourth -quarter comparison, and we expect strong underlying \nperformance in the quarter.  \n \n For Medical, we now expect revenue at the l ow end of our previous range, down mid -single digits, \nand segment profit to be down 45% to 55% in fiscal \u201822, which includes a net incremental headwind \nof nearly $300 million due to inflationary and global supply chain constraints.  Additionally, based on \nvolume trends, the update from our previous Medical outlook primarily reflects a lower contribution \nfrom PPE.  \n \n Now, let me spend some time sharing a few high -level thoughts on fiscal \u201823 from our vantage point \ntoday ahead of providing our usual guidance in early August.  \n \n In Pharma, the business is tracking consistent with our long -term target of low to mid -single digit \nsegment profit growth.  With respect to a couple other notable Pharma puts and takes for next year, \nwe do anticipate higher operations expens es based on recent inflationary trends, particularly in the ", "original_text": "Now, let me spend some time sharing a few high -level thoughts on fiscal \u201823 from our vantage point \ntoday ahead of providing our usual guidance in early August.  \n \n"}, "hash": "6e700a4c7a03023d551a67021cee286b3fa79ddafc59c71fee53d449740e1f90", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, based on \nvolume trends, the update from our previous Medical outlook primarily reflects a lower contribution \nfrom PPE.  \n \n", "start_char_idx": 2448, "end_char_idx": 2587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0cc4a662-1fca-4698-9576-41816536bf48": {"__data__": {"id_": "0cc4a662-1fca-4698-9576-41816536bf48", "embedding": null, "metadata": {"window": "We are also lapping a few one -time items that we called out last \nyear, which will create a favorable fourth -quarter comparison, and we expect strong underlying \nperformance in the quarter.  \n \n For Medical, we now expect revenue at the l ow end of our previous range, down mid -single digits, \nand segment profit to be down 45% to 55% in fiscal \u201822, which includes a net incremental headwind \nof nearly $300 million due to inflationary and global supply chain constraints.  Additionally, based on \nvolume trends, the update from our previous Medical outlook primarily reflects a lower contribution \nfrom PPE.  \n \n Now, let me spend some time sharing a few high -level thoughts on fiscal \u201823 from our vantage point \ntoday ahead of providing our usual guidance in early August.  \n \n In Pharma, the business is tracking consistent with our long -term target of low to mid -single digit \nsegment profit growth.  With respect to a couple other notable Pharma puts and takes for next year, \nwe do anticipate higher operations expens es based on recent inflationary trends, particularly in the ", "original_text": "Now, let me spend some time sharing a few high -level thoughts on fiscal \u201823 from our vantage point \ntoday ahead of providing our usual guidance in early August.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83870c13955ae97a1035138f8e3e4bf1c92fb1a0eaef87ba9f190428c8659c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f63c2ae-a369-48bd-8dde-a40870c8a860", "node_type": "1", "metadata": {"window": "With the culmination of our planned technology enhancements, we will now be lapping \nelevated expense levels from the initial deployment a year ago, which has been a year -over-year \nheadwind the last several quarters.  We are also lapping a few one -time items that we called out last \nyear, which will create a favorable fourth -quarter comparison, and we expect strong underlying \nperformance in the quarter.  \n \n For Medical, we now expect revenue at the l ow end of our previous range, down mid -single digits, \nand segment profit to be down 45% to 55% in fiscal \u201822, which includes a net incremental headwind \nof nearly $300 million due to inflationary and global supply chain constraints.  Additionally, based on \nvolume trends, the update from our previous Medical outlook primarily reflects a lower contribution \nfrom PPE.  \n \n Now, let me spend some time sharing a few high -level thoughts on fiscal \u201823 from our vantage point \ntoday ahead of providing our usual guidance in early August.  \n \n In Pharma, the business is tracking consistent with our long -term target of low to mid -single digit \nsegment profit growth.  With respect to a couple other notable Pharma puts and takes for next year, \nwe do anticipate higher operations expens es based on recent inflationary trends, particularly in the ", "original_text": "Additionally, based on \nvolume trends, the update from our previous Medical outlook primarily reflects a lower contribution \nfrom PPE.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "18eb8d91efdcc1acc9996ccd8f2d2b2d7e40d3d791ba51481b63229aef50c80a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "261954c1-3e5c-4f90-9c31-bd54d99c9381", "node_type": "1", "metadata": {"window": "For Medical, we now expect revenue at the l ow end of our previous range, down mid -single digits, \nand segment profit to be down 45% to 55% in fiscal \u201822, which includes a net incremental headwind \nof nearly $300 million due to inflationary and global supply chain constraints.  Additionally, based on \nvolume trends, the update from our previous Medical outlook primarily reflects a lower contribution \nfrom PPE.  \n \n Now, let me spend some time sharing a few high -level thoughts on fiscal \u201823 from our vantage point \ntoday ahead of providing our usual guidance in early August.  \n \n In Pharma, the business is tracking consistent with our long -term target of low to mid -single digit \nsegment profit growth.  With respect to a couple other notable Pharma puts and takes for next year, \nwe do anticipate higher operations expens es based on recent inflationary trends, particularly in the ", "original_text": "In Pharma, the business is tracking consistent with our long -term target of low to mid -single digit \nsegment profit growth. "}, "hash": "fbcb04c9bb0bee986d8ed6ba65b6c03154fa1ac8c18596e63b373fb57efcbc1e", "class_name": "RelatedNodeInfo"}}, "text": "Now, let me spend some time sharing a few high -level thoughts on fiscal \u201823 from our vantage point \ntoday ahead of providing our usual guidance in early August.  \n \n", "start_char_idx": 2587, "end_char_idx": 2753, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "261954c1-3e5c-4f90-9c31-bd54d99c9381": {"__data__": {"id_": "261954c1-3e5c-4f90-9c31-bd54d99c9381", "embedding": null, "metadata": {"window": "For Medical, we now expect revenue at the l ow end of our previous range, down mid -single digits, \nand segment profit to be down 45% to 55% in fiscal \u201822, which includes a net incremental headwind \nof nearly $300 million due to inflationary and global supply chain constraints.  Additionally, based on \nvolume trends, the update from our previous Medical outlook primarily reflects a lower contribution \nfrom PPE.  \n \n Now, let me spend some time sharing a few high -level thoughts on fiscal \u201823 from our vantage point \ntoday ahead of providing our usual guidance in early August.  \n \n In Pharma, the business is tracking consistent with our long -term target of low to mid -single digit \nsegment profit growth.  With respect to a couple other notable Pharma puts and takes for next year, \nwe do anticipate higher operations expens es based on recent inflationary trends, particularly in the ", "original_text": "In Pharma, the business is tracking consistent with our long -term target of low to mid -single digit \nsegment profit growth. ", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83870c13955ae97a1035138f8e3e4bf1c92fb1a0eaef87ba9f190428c8659c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0cc4a662-1fca-4698-9576-41816536bf48", "node_type": "1", "metadata": {"window": "We are also lapping a few one -time items that we called out last \nyear, which will create a favorable fourth -quarter comparison, and we expect strong underlying \nperformance in the quarter.  \n \n For Medical, we now expect revenue at the l ow end of our previous range, down mid -single digits, \nand segment profit to be down 45% to 55% in fiscal \u201822, which includes a net incremental headwind \nof nearly $300 million due to inflationary and global supply chain constraints.  Additionally, based on \nvolume trends, the update from our previous Medical outlook primarily reflects a lower contribution \nfrom PPE.  \n \n Now, let me spend some time sharing a few high -level thoughts on fiscal \u201823 from our vantage point \ntoday ahead of providing our usual guidance in early August.  \n \n In Pharma, the business is tracking consistent with our long -term target of low to mid -single digit \nsegment profit growth.  With respect to a couple other notable Pharma puts and takes for next year, \nwe do anticipate higher operations expens es based on recent inflationary trends, particularly in the ", "original_text": "Now, let me spend some time sharing a few high -level thoughts on fiscal \u201823 from our vantage point \ntoday ahead of providing our usual guidance in early August.  \n \n", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825ed16a592c9dd6e563f55c7ebbf20d3c804706f447e6985af8ba0802b786a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70eeb967-5220-417b-bc67-e7bdfd9b3830", "node_type": "1", "metadata": {"window": "Additionally, based on \nvolume trends, the update from our previous Medical outlook primarily reflects a lower contribution \nfrom PPE.  \n \n Now, let me spend some time sharing a few high -level thoughts on fiscal \u201823 from our vantage point \ntoday ahead of providing our usual guidance in early August.  \n \n In Pharma, the business is tracking consistent with our long -term target of low to mid -single digit \nsegment profit growth.  With respect to a couple other notable Pharma puts and takes for next year, \nwe do anticipate higher operations expens es based on recent inflationary trends, particularly in the ", "original_text": "With respect to a couple other notable Pharma puts and takes for next year, \nwe do anticipate higher operations expens es based on recent inflationary trends, particularly in the "}, "hash": "afbbf92e5b6a2841de0d9ce23670cd717287a2eb5619b14a604748fd666f4d22", "class_name": "RelatedNodeInfo"}}, "text": "In Pharma, the business is tracking consistent with our long -term target of low to mid -single digit \nsegment profit growth. ", "start_char_idx": 2753, "end_char_idx": 2879, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70eeb967-5220-417b-bc67-e7bdfd9b3830": {"__data__": {"id_": "70eeb967-5220-417b-bc67-e7bdfd9b3830", "embedding": null, "metadata": {"window": "Additionally, based on \nvolume trends, the update from our previous Medical outlook primarily reflects a lower contribution \nfrom PPE.  \n \n Now, let me spend some time sharing a few high -level thoughts on fiscal \u201823 from our vantage point \ntoday ahead of providing our usual guidance in early August.  \n \n In Pharma, the business is tracking consistent with our long -term target of low to mid -single digit \nsegment profit growth.  With respect to a couple other notable Pharma puts and takes for next year, \nwe do anticipate higher operations expens es based on recent inflationary trends, particularly in the ", "original_text": "With respect to a couple other notable Pharma puts and takes for next year, \nwe do anticipate higher operations expens es based on recent inflationary trends, particularly in the ", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8", "node_type": "4", "metadata": {"page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83870c13955ae97a1035138f8e3e4bf1c92fb1a0eaef87ba9f190428c8659c56", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "261954c1-3e5c-4f90-9c31-bd54d99c9381", "node_type": "1", "metadata": {"window": "For Medical, we now expect revenue at the l ow end of our previous range, down mid -single digits, \nand segment profit to be down 45% to 55% in fiscal \u201822, which includes a net incremental headwind \nof nearly $300 million due to inflationary and global supply chain constraints.  Additionally, based on \nvolume trends, the update from our previous Medical outlook primarily reflects a lower contribution \nfrom PPE.  \n \n Now, let me spend some time sharing a few high -level thoughts on fiscal \u201823 from our vantage point \ntoday ahead of providing our usual guidance in early August.  \n \n In Pharma, the business is tracking consistent with our long -term target of low to mid -single digit \nsegment profit growth.  With respect to a couple other notable Pharma puts and takes for next year, \nwe do anticipate higher operations expens es based on recent inflationary trends, particularly in the ", "original_text": "In Pharma, the business is tracking consistent with our long -term target of low to mid -single digit \nsegment profit growth. ", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d31018f84039ea4c0b6223ab9ca926332dea6ea6c565da4045f082bb14aa21e3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "430a1f3f-aefd-473a-abd1-b5f71790776e", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nfirst half of the fiscal year.  Additionally, with the finalization of the global opioid settlement, we \nanticipate lower opioid -related legal costs, partially offset by higher costs for implementat ion of the \nsettlement\u2019s injunctive relief terms.  Together, we expect these litigation items to be a modest net \ntailwind in fiscal \u201823.  For reference, we are currently estimating opioid -related legal costs of \napproximately $115 million in fiscal \u201822. ", "original_text": " \nPage 5 of 15 \n \nfirst half of the fiscal year. "}, "hash": "245bd8e033c0ee15f69b20cb20a47379ee1ebb0e462891df304f4e2a7acfa604", "class_name": "RelatedNodeInfo"}}, "text": "With respect to a couple other notable Pharma puts and takes for next year, \nwe do anticipate higher operations expens es based on recent inflationary trends, particularly in the ", "start_char_idx": 2879, "end_char_idx": 3058, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "430a1f3f-aefd-473a-abd1-b5f71790776e": {"__data__": {"id_": "430a1f3f-aefd-473a-abd1-b5f71790776e", "embedding": null, "metadata": {"window": " \nPage 5 of 15 \n \nfirst half of the fiscal year.  Additionally, with the finalization of the global opioid settlement, we \nanticipate lower opioid -related legal costs, partially offset by higher costs for implementat ion of the \nsettlement\u2019s injunctive relief terms.  Together, we expect these litigation items to be a modest net \ntailwind in fiscal \u201823.  For reference, we are currently estimating opioid -related legal costs of \napproximately $115 million in fiscal \u201822. ", "original_text": " \nPage 5 of 15 \n \nfirst half of the fiscal year. ", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76b354ab6872c0357a4cf258effe78f89bfac987ad4754b52f45e59c1bf5896c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70eeb967-5220-417b-bc67-e7bdfd9b3830", "node_type": "1", "metadata": {"window": "Additionally, based on \nvolume trends, the update from our previous Medical outlook primarily reflects a lower contribution \nfrom PPE.  \n \n Now, let me spend some time sharing a few high -level thoughts on fiscal \u201823 from our vantage point \ntoday ahead of providing our usual guidance in early August.  \n \n In Pharma, the business is tracking consistent with our long -term target of low to mid -single digit \nsegment profit growth.  With respect to a couple other notable Pharma puts and takes for next year, \nwe do anticipate higher operations expens es based on recent inflationary trends, particularly in the ", "original_text": "With respect to a couple other notable Pharma puts and takes for next year, \nwe do anticipate higher operations expens es based on recent inflationary trends, particularly in the ", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "52031687c596a3cf8223d5538abcc1ee2f52f6742177655c1ba072e2db938f94", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b51c219-8a31-412e-9406-0cbb598e6777", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nfirst half of the fiscal year.  Additionally, with the finalization of the global opioid settlement, we \nanticipate lower opioid -related legal costs, partially offset by higher costs for implementat ion of the \nsettlement\u2019s injunctive relief terms.  Together, we expect these litigation items to be a modest net \ntailwind in fiscal \u201823.  For reference, we are currently estimating opioid -related legal costs of \napproximately $115 million in fiscal \u201822.  We exp ect a further reduction in opioid -related legal costs in \nsubsequent years.  \n \n", "original_text": "Additionally, with the finalization of the global opioid settlement, we \nanticipate lower opioid -related legal costs, partially offset by higher costs for implementat ion of the \nsettlement\u2019s injunctive relief terms. "}, "hash": "80169ae80ab99494913774549eb1b79ad72ac1ba845dfa5216b541b1734302c6", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 5 of 15 \n \nfirst half of the fiscal year. ", "start_char_idx": 0, "end_char_idx": 49, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b51c219-8a31-412e-9406-0cbb598e6777": {"__data__": {"id_": "9b51c219-8a31-412e-9406-0cbb598e6777", "embedding": null, "metadata": {"window": " \nPage 5 of 15 \n \nfirst half of the fiscal year.  Additionally, with the finalization of the global opioid settlement, we \nanticipate lower opioid -related legal costs, partially offset by higher costs for implementat ion of the \nsettlement\u2019s injunctive relief terms.  Together, we expect these litigation items to be a modest net \ntailwind in fiscal \u201823.  For reference, we are currently estimating opioid -related legal costs of \napproximately $115 million in fiscal \u201822.  We exp ect a further reduction in opioid -related legal costs in \nsubsequent years.  \n \n", "original_text": "Additionally, with the finalization of the global opioid settlement, we \nanticipate lower opioid -related legal costs, partially offset by higher costs for implementat ion of the \nsettlement\u2019s injunctive relief terms. ", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76b354ab6872c0357a4cf258effe78f89bfac987ad4754b52f45e59c1bf5896c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "430a1f3f-aefd-473a-abd1-b5f71790776e", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nfirst half of the fiscal year.  Additionally, with the finalization of the global opioid settlement, we \nanticipate lower opioid -related legal costs, partially offset by higher costs for implementat ion of the \nsettlement\u2019s injunctive relief terms.  Together, we expect these litigation items to be a modest net \ntailwind in fiscal \u201823.  For reference, we are currently estimating opioid -related legal costs of \napproximately $115 million in fiscal \u201822. ", "original_text": " \nPage 5 of 15 \n \nfirst half of the fiscal year. ", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "038c2cf15449063b7b1ed4a2e268ba90a1e742e999a890cb3f54009d63233e7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7108691d-6288-46b3-97b7-ce281cf24d07", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nfirst half of the fiscal year.  Additionally, with the finalization of the global opioid settlement, we \nanticipate lower opioid -related legal costs, partially offset by higher costs for implementat ion of the \nsettlement\u2019s injunctive relief terms.  Together, we expect these litigation items to be a modest net \ntailwind in fiscal \u201823.  For reference, we are currently estimating opioid -related legal costs of \napproximately $115 million in fiscal \u201822.  We exp ect a further reduction in opioid -related legal costs in \nsubsequent years.  \n \n In Medical, we are highly focused on the inflationary impacts and global supply chain constraints \naffecting our U.S. ", "original_text": "Together, we expect these litigation items to be a modest net \ntailwind in fiscal \u201823. "}, "hash": "8631b6852a9422e30ec95c29733b256c3839a57358510c87c869340d6e887f51", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, with the finalization of the global opioid settlement, we \nanticipate lower opioid -related legal costs, partially offset by higher costs for implementat ion of the \nsettlement\u2019s injunctive relief terms. ", "start_char_idx": 49, "end_char_idx": 267, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7108691d-6288-46b3-97b7-ce281cf24d07": {"__data__": {"id_": "7108691d-6288-46b3-97b7-ce281cf24d07", "embedding": null, "metadata": {"window": " \nPage 5 of 15 \n \nfirst half of the fiscal year.  Additionally, with the finalization of the global opioid settlement, we \nanticipate lower opioid -related legal costs, partially offset by higher costs for implementat ion of the \nsettlement\u2019s injunctive relief terms.  Together, we expect these litigation items to be a modest net \ntailwind in fiscal \u201823.  For reference, we are currently estimating opioid -related legal costs of \napproximately $115 million in fiscal \u201822.  We exp ect a further reduction in opioid -related legal costs in \nsubsequent years.  \n \n In Medical, we are highly focused on the inflationary impacts and global supply chain constraints \naffecting our U.S. ", "original_text": "Together, we expect these litigation items to be a modest net \ntailwind in fiscal \u201823. ", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76b354ab6872c0357a4cf258effe78f89bfac987ad4754b52f45e59c1bf5896c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b51c219-8a31-412e-9406-0cbb598e6777", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nfirst half of the fiscal year.  Additionally, with the finalization of the global opioid settlement, we \nanticipate lower opioid -related legal costs, partially offset by higher costs for implementat ion of the \nsettlement\u2019s injunctive relief terms.  Together, we expect these litigation items to be a modest net \ntailwind in fiscal \u201823.  For reference, we are currently estimating opioid -related legal costs of \napproximately $115 million in fiscal \u201822.  We exp ect a further reduction in opioid -related legal costs in \nsubsequent years.  \n \n", "original_text": "Additionally, with the finalization of the global opioid settlement, we \nanticipate lower opioid -related legal costs, partially offset by higher costs for implementat ion of the \nsettlement\u2019s injunctive relief terms. ", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cb6f56015ecfe196ac69ed927cb8eacf39416ca99ac2fa8f33c1f638d9ff4b98", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "581d546e-cc9b-4cc6-8b01-944a4be9a342", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nfirst half of the fiscal year.  Additionally, with the finalization of the global opioid settlement, we \nanticipate lower opioid -related legal costs, partially offset by higher costs for implementat ion of the \nsettlement\u2019s injunctive relief terms.  Together, we expect these litigation items to be a modest net \ntailwind in fiscal \u201823.  For reference, we are currently estimating opioid -related legal costs of \napproximately $115 million in fiscal \u201822.  We exp ect a further reduction in opioid -related legal costs in \nsubsequent years.  \n \n In Medical, we are highly focused on the inflationary impacts and global supply chain constraints \naffecting our U.S.  Medical Products and Distribution business.  \n \n", "original_text": "For reference, we are currently estimating opioid -related legal costs of \napproximately $115 million in fiscal \u201822. "}, "hash": "dd0238f16c9d82d51c464c0373b02c6eec178a5c4dc37aa1ea5485fb31f23d21", "class_name": "RelatedNodeInfo"}}, "text": "Together, we expect these litigation items to be a modest net \ntailwind in fiscal \u201823. ", "start_char_idx": 267, "end_char_idx": 354, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "581d546e-cc9b-4cc6-8b01-944a4be9a342": {"__data__": {"id_": "581d546e-cc9b-4cc6-8b01-944a4be9a342", "embedding": null, "metadata": {"window": " \nPage 5 of 15 \n \nfirst half of the fiscal year.  Additionally, with the finalization of the global opioid settlement, we \nanticipate lower opioid -related legal costs, partially offset by higher costs for implementat ion of the \nsettlement\u2019s injunctive relief terms.  Together, we expect these litigation items to be a modest net \ntailwind in fiscal \u201823.  For reference, we are currently estimating opioid -related legal costs of \napproximately $115 million in fiscal \u201822.  We exp ect a further reduction in opioid -related legal costs in \nsubsequent years.  \n \n In Medical, we are highly focused on the inflationary impacts and global supply chain constraints \naffecting our U.S.  Medical Products and Distribution business.  \n \n", "original_text": "For reference, we are currently estimating opioid -related legal costs of \napproximately $115 million in fiscal \u201822. ", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76b354ab6872c0357a4cf258effe78f89bfac987ad4754b52f45e59c1bf5896c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7108691d-6288-46b3-97b7-ce281cf24d07", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nfirst half of the fiscal year.  Additionally, with the finalization of the global opioid settlement, we \nanticipate lower opioid -related legal costs, partially offset by higher costs for implementat ion of the \nsettlement\u2019s injunctive relief terms.  Together, we expect these litigation items to be a modest net \ntailwind in fiscal \u201823.  For reference, we are currently estimating opioid -related legal costs of \napproximately $115 million in fiscal \u201822.  We exp ect a further reduction in opioid -related legal costs in \nsubsequent years.  \n \n In Medical, we are highly focused on the inflationary impacts and global supply chain constraints \naffecting our U.S. ", "original_text": "Together, we expect these litigation items to be a modest net \ntailwind in fiscal \u201823. ", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da2ae57bbe671b2bb7468e34de0deb879fdc28c807c2fec10238549d6e9f1cc1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6d148ce-59c3-4bc0-8481-00116f610f6d", "node_type": "1", "metadata": {"window": "Additionally, with the finalization of the global opioid settlement, we \nanticipate lower opioid -related legal costs, partially offset by higher costs for implementat ion of the \nsettlement\u2019s injunctive relief terms.  Together, we expect these litigation items to be a modest net \ntailwind in fiscal \u201823.  For reference, we are currently estimating opioid -related legal costs of \napproximately $115 million in fiscal \u201822.  We exp ect a further reduction in opioid -related legal costs in \nsubsequent years.  \n \n In Medical, we are highly focused on the inflationary impacts and global supply chain constraints \naffecting our U.S.  Medical Products and Distribution business.  \n \n At this time, we expect a similar to modestly higher net impact from inflation and global supply chain \nconstraints in fiscal \u201823 as in fiscal \u201822. ", "original_text": "We exp ect a further reduction in opioid -related legal costs in \nsubsequent years.  \n \n"}, "hash": "0e6b962d4bb88e5d1e17d30de3227f2ccba9b54aed0ec85f1437f77f946a9f1a", "class_name": "RelatedNodeInfo"}}, "text": "For reference, we are currently estimating opioid -related legal costs of \napproximately $115 million in fiscal \u201822. ", "start_char_idx": 354, "end_char_idx": 471, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6d148ce-59c3-4bc0-8481-00116f610f6d": {"__data__": {"id_": "b6d148ce-59c3-4bc0-8481-00116f610f6d", "embedding": null, "metadata": {"window": "Additionally, with the finalization of the global opioid settlement, we \nanticipate lower opioid -related legal costs, partially offset by higher costs for implementat ion of the \nsettlement\u2019s injunctive relief terms.  Together, we expect these litigation items to be a modest net \ntailwind in fiscal \u201823.  For reference, we are currently estimating opioid -related legal costs of \napproximately $115 million in fiscal \u201822.  We exp ect a further reduction in opioid -related legal costs in \nsubsequent years.  \n \n In Medical, we are highly focused on the inflationary impacts and global supply chain constraints \naffecting our U.S.  Medical Products and Distribution business.  \n \n At this time, we expect a similar to modestly higher net impact from inflation and global supply chain \nconstraints in fiscal \u201823 as in fiscal \u201822. ", "original_text": "We exp ect a further reduction in opioid -related legal costs in \nsubsequent years.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76b354ab6872c0357a4cf258effe78f89bfac987ad4754b52f45e59c1bf5896c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "581d546e-cc9b-4cc6-8b01-944a4be9a342", "node_type": "1", "metadata": {"window": " \nPage 5 of 15 \n \nfirst half of the fiscal year.  Additionally, with the finalization of the global opioid settlement, we \nanticipate lower opioid -related legal costs, partially offset by higher costs for implementat ion of the \nsettlement\u2019s injunctive relief terms.  Together, we expect these litigation items to be a modest net \ntailwind in fiscal \u201823.  For reference, we are currently estimating opioid -related legal costs of \napproximately $115 million in fiscal \u201822.  We exp ect a further reduction in opioid -related legal costs in \nsubsequent years.  \n \n In Medical, we are highly focused on the inflationary impacts and global supply chain constraints \naffecting our U.S.  Medical Products and Distribution business.  \n \n", "original_text": "For reference, we are currently estimating opioid -related legal costs of \napproximately $115 million in fiscal \u201822. ", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9acdb3a8919b6cfde81116ba37010a7d9682cff6ada71474dafc33a7d133655e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da2a0182-687f-4045-8126-37ea0b05dab5", "node_type": "1", "metadata": {"window": "Together, we expect these litigation items to be a modest net \ntailwind in fiscal \u201823.  For reference, we are currently estimating opioid -related legal costs of \napproximately $115 million in fiscal \u201822.  We exp ect a further reduction in opioid -related legal costs in \nsubsequent years.  \n \n In Medical, we are highly focused on the inflationary impacts and global supply chain constraints \naffecting our U.S.  Medical Products and Distribution business.  \n \n At this time, we expect a similar to modestly higher net impact from inflation and global supply chain \nconstraints in fiscal \u201823 as in fiscal \u201822.  Embedded in this are two key assumptions:  \n \nFirst, with visibility generally limited to the first half of the year, we are assu ming key cost drivers such \nas international freight and commodities have flattened and will begin to decrease slowly over the \ncourse of next fiscal year, affecting our results on a one to two quarter delay. ", "original_text": "In Medical, we are highly focused on the inflationary impacts and global supply chain constraints \naffecting our U.S. "}, "hash": "0cacb04ec5b37978248b6c86e9245f206d16e88fc0dc3f89462561dd55b82124", "class_name": "RelatedNodeInfo"}}, "text": "We exp ect a further reduction in opioid -related legal costs in \nsubsequent years.  \n \n", "start_char_idx": 471, "end_char_idx": 559, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da2a0182-687f-4045-8126-37ea0b05dab5": {"__data__": {"id_": "da2a0182-687f-4045-8126-37ea0b05dab5", "embedding": null, "metadata": {"window": "Together, we expect these litigation items to be a modest net \ntailwind in fiscal \u201823.  For reference, we are currently estimating opioid -related legal costs of \napproximately $115 million in fiscal \u201822.  We exp ect a further reduction in opioid -related legal costs in \nsubsequent years.  \n \n In Medical, we are highly focused on the inflationary impacts and global supply chain constraints \naffecting our U.S.  Medical Products and Distribution business.  \n \n At this time, we expect a similar to modestly higher net impact from inflation and global supply chain \nconstraints in fiscal \u201823 as in fiscal \u201822.  Embedded in this are two key assumptions:  \n \nFirst, with visibility generally limited to the first half of the year, we are assu ming key cost drivers such \nas international freight and commodities have flattened and will begin to decrease slowly over the \ncourse of next fiscal year, affecting our results on a one to two quarter delay. ", "original_text": "In Medical, we are highly focused on the inflationary impacts and global supply chain constraints \naffecting our U.S. ", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76b354ab6872c0357a4cf258effe78f89bfac987ad4754b52f45e59c1bf5896c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6d148ce-59c3-4bc0-8481-00116f610f6d", "node_type": "1", "metadata": {"window": "Additionally, with the finalization of the global opioid settlement, we \nanticipate lower opioid -related legal costs, partially offset by higher costs for implementat ion of the \nsettlement\u2019s injunctive relief terms.  Together, we expect these litigation items to be a modest net \ntailwind in fiscal \u201823.  For reference, we are currently estimating opioid -related legal costs of \napproximately $115 million in fiscal \u201822.  We exp ect a further reduction in opioid -related legal costs in \nsubsequent years.  \n \n In Medical, we are highly focused on the inflationary impacts and global supply chain constraints \naffecting our U.S.  Medical Products and Distribution business.  \n \n At this time, we expect a similar to modestly higher net impact from inflation and global supply chain \nconstraints in fiscal \u201823 as in fiscal \u201822. ", "original_text": "We exp ect a further reduction in opioid -related legal costs in \nsubsequent years.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4a8b3e6e19568a32ea2d99fb6ab8aa7ece3c3f290de882ca387b34730f7c7ef4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85407112-c2aa-4931-a043-020974083122", "node_type": "1", "metadata": {"window": "For reference, we are currently estimating opioid -related legal costs of \napproximately $115 million in fiscal \u201822.  We exp ect a further reduction in opioid -related legal costs in \nsubsequent years.  \n \n In Medical, we are highly focused on the inflationary impacts and global supply chain constraints \naffecting our U.S.  Medical Products and Distribution business.  \n \n At this time, we expect a similar to modestly higher net impact from inflation and global supply chain \nconstraints in fiscal \u201823 as in fiscal \u201822.  Embedded in this are two key assumptions:  \n \nFirst, with visibility generally limited to the first half of the year, we are assu ming key cost drivers such \nas international freight and commodities have flattened and will begin to decrease slowly over the \ncourse of next fiscal year, affecting our results on a one to two quarter delay.  This would result in a \ngreater absolute impact from inflation and global supply chain constraints in fiscal \u201823 due to the \nannualization of the higher costs seen in the second half of fiscal \u201822.  \n \n", "original_text": "Medical Products and Distribution business.  \n \n"}, "hash": "9a74ca53030150d0ea552bb5de2e5859b1efd113ca5e02e68a4584c479b151f3", "class_name": "RelatedNodeInfo"}}, "text": "In Medical, we are highly focused on the inflationary impacts and global supply chain constraints \naffecting our U.S. ", "start_char_idx": 559, "end_char_idx": 677, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85407112-c2aa-4931-a043-020974083122": {"__data__": {"id_": "85407112-c2aa-4931-a043-020974083122", "embedding": null, "metadata": {"window": "For reference, we are currently estimating opioid -related legal costs of \napproximately $115 million in fiscal \u201822.  We exp ect a further reduction in opioid -related legal costs in \nsubsequent years.  \n \n In Medical, we are highly focused on the inflationary impacts and global supply chain constraints \naffecting our U.S.  Medical Products and Distribution business.  \n \n At this time, we expect a similar to modestly higher net impact from inflation and global supply chain \nconstraints in fiscal \u201823 as in fiscal \u201822.  Embedded in this are two key assumptions:  \n \nFirst, with visibility generally limited to the first half of the year, we are assu ming key cost drivers such \nas international freight and commodities have flattened and will begin to decrease slowly over the \ncourse of next fiscal year, affecting our results on a one to two quarter delay.  This would result in a \ngreater absolute impact from inflation and global supply chain constraints in fiscal \u201823 due to the \nannualization of the higher costs seen in the second half of fiscal \u201822.  \n \n", "original_text": "Medical Products and Distribution business.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76b354ab6872c0357a4cf258effe78f89bfac987ad4754b52f45e59c1bf5896c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da2a0182-687f-4045-8126-37ea0b05dab5", "node_type": "1", "metadata": {"window": "Together, we expect these litigation items to be a modest net \ntailwind in fiscal \u201823.  For reference, we are currently estimating opioid -related legal costs of \napproximately $115 million in fiscal \u201822.  We exp ect a further reduction in opioid -related legal costs in \nsubsequent years.  \n \n In Medical, we are highly focused on the inflationary impacts and global supply chain constraints \naffecting our U.S.  Medical Products and Distribution business.  \n \n At this time, we expect a similar to modestly higher net impact from inflation and global supply chain \nconstraints in fiscal \u201823 as in fiscal \u201822.  Embedded in this are two key assumptions:  \n \nFirst, with visibility generally limited to the first half of the year, we are assu ming key cost drivers such \nas international freight and commodities have flattened and will begin to decrease slowly over the \ncourse of next fiscal year, affecting our results on a one to two quarter delay. ", "original_text": "In Medical, we are highly focused on the inflationary impacts and global supply chain constraints \naffecting our U.S. ", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "21e02cd6a03f46b28f66fe7c098ee6a3285ce3d6baaa364b886b12f6e4f63c66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76590a9c-6493-460e-85fe-0e5f7fd691ab", "node_type": "1", "metadata": {"window": "We exp ect a further reduction in opioid -related legal costs in \nsubsequent years.  \n \n In Medical, we are highly focused on the inflationary impacts and global supply chain constraints \naffecting our U.S.  Medical Products and Distribution business.  \n \n At this time, we expect a similar to modestly higher net impact from inflation and global supply chain \nconstraints in fiscal \u201823 as in fiscal \u201822.  Embedded in this are two key assumptions:  \n \nFirst, with visibility generally limited to the first half of the year, we are assu ming key cost drivers such \nas international freight and commodities have flattened and will begin to decrease slowly over the \ncourse of next fiscal year, affecting our results on a one to two quarter delay.  This would result in a \ngreater absolute impact from inflation and global supply chain constraints in fiscal \u201823 due to the \nannualization of the higher costs seen in the second half of fiscal \u201822.  \n \n Second, we also expect a greater impact fro m mitigation initiatives, with various waves of price \nincreases going into effect throughout the year.  \n \n", "original_text": "At this time, we expect a similar to modestly higher net impact from inflation and global supply chain \nconstraints in fiscal \u201823 as in fiscal \u201822. "}, "hash": "1f1fe09341ae33639843c080c1586eabc895b3e1d660721e34a9e2378cac77a3", "class_name": "RelatedNodeInfo"}}, "text": "Medical Products and Distribution business.  \n \n", "start_char_idx": 677, "end_char_idx": 725, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76590a9c-6493-460e-85fe-0e5f7fd691ab": {"__data__": {"id_": "76590a9c-6493-460e-85fe-0e5f7fd691ab", "embedding": null, "metadata": {"window": "We exp ect a further reduction in opioid -related legal costs in \nsubsequent years.  \n \n In Medical, we are highly focused on the inflationary impacts and global supply chain constraints \naffecting our U.S.  Medical Products and Distribution business.  \n \n At this time, we expect a similar to modestly higher net impact from inflation and global supply chain \nconstraints in fiscal \u201823 as in fiscal \u201822.  Embedded in this are two key assumptions:  \n \nFirst, with visibility generally limited to the first half of the year, we are assu ming key cost drivers such \nas international freight and commodities have flattened and will begin to decrease slowly over the \ncourse of next fiscal year, affecting our results on a one to two quarter delay.  This would result in a \ngreater absolute impact from inflation and global supply chain constraints in fiscal \u201823 due to the \nannualization of the higher costs seen in the second half of fiscal \u201822.  \n \n Second, we also expect a greater impact fro m mitigation initiatives, with various waves of price \nincreases going into effect throughout the year.  \n \n", "original_text": "At this time, we expect a similar to modestly higher net impact from inflation and global supply chain \nconstraints in fiscal \u201823 as in fiscal \u201822. ", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76b354ab6872c0357a4cf258effe78f89bfac987ad4754b52f45e59c1bf5896c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85407112-c2aa-4931-a043-020974083122", "node_type": "1", "metadata": {"window": "For reference, we are currently estimating opioid -related legal costs of \napproximately $115 million in fiscal \u201822.  We exp ect a further reduction in opioid -related legal costs in \nsubsequent years.  \n \n In Medical, we are highly focused on the inflationary impacts and global supply chain constraints \naffecting our U.S.  Medical Products and Distribution business.  \n \n At this time, we expect a similar to modestly higher net impact from inflation and global supply chain \nconstraints in fiscal \u201823 as in fiscal \u201822.  Embedded in this are two key assumptions:  \n \nFirst, with visibility generally limited to the first half of the year, we are assu ming key cost drivers such \nas international freight and commodities have flattened and will begin to decrease slowly over the \ncourse of next fiscal year, affecting our results on a one to two quarter delay.  This would result in a \ngreater absolute impact from inflation and global supply chain constraints in fiscal \u201823 due to the \nannualization of the higher costs seen in the second half of fiscal \u201822.  \n \n", "original_text": "Medical Products and Distribution business.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b43f346ea501f6ba5a09f6c5398ad8b8e8ca3b768ca308bb977800750748a26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a8e33d0-9976-46a5-8f04-7c3ef24c36a1", "node_type": "1", "metadata": {"window": "In Medical, we are highly focused on the inflationary impacts and global supply chain constraints \naffecting our U.S.  Medical Products and Distribution business.  \n \n At this time, we expect a similar to modestly higher net impact from inflation and global supply chain \nconstraints in fiscal \u201823 as in fiscal \u201822.  Embedded in this are two key assumptions:  \n \nFirst, with visibility generally limited to the first half of the year, we are assu ming key cost drivers such \nas international freight and commodities have flattened and will begin to decrease slowly over the \ncourse of next fiscal year, affecting our results on a one to two quarter delay.  This would result in a \ngreater absolute impact from inflation and global supply chain constraints in fiscal \u201823 due to the \nannualization of the higher costs seen in the second half of fiscal \u201822.  \n \n Second, we also expect a greater impact fro m mitigation initiatives, with various waves of price \nincreases going into effect throughout the year.  \n \n In total, these two assumptions result in a similar to modestly higher net impact from inflation and \nglobal supply chain constraints as in the current year. ", "original_text": "Embedded in this are two key assumptions:  \n \nFirst, with visibility generally limited to the first half of the year, we are assu ming key cost drivers such \nas international freight and commodities have flattened and will begin to decrease slowly over the \ncourse of next fiscal year, affecting our results on a one to two quarter delay. "}, "hash": "a7ddf858c8dcdfe8829e48764a53c9aa096d4b8fb26faf7c4097363d9cc08b5b", "class_name": "RelatedNodeInfo"}}, "text": "At this time, we expect a similar to modestly higher net impact from inflation and global supply chain \nconstraints in fiscal \u201823 as in fiscal \u201822. ", "start_char_idx": 725, "end_char_idx": 873, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a8e33d0-9976-46a5-8f04-7c3ef24c36a1": {"__data__": {"id_": "3a8e33d0-9976-46a5-8f04-7c3ef24c36a1", "embedding": null, "metadata": {"window": "In Medical, we are highly focused on the inflationary impacts and global supply chain constraints \naffecting our U.S.  Medical Products and Distribution business.  \n \n At this time, we expect a similar to modestly higher net impact from inflation and global supply chain \nconstraints in fiscal \u201823 as in fiscal \u201822.  Embedded in this are two key assumptions:  \n \nFirst, with visibility generally limited to the first half of the year, we are assu ming key cost drivers such \nas international freight and commodities have flattened and will begin to decrease slowly over the \ncourse of next fiscal year, affecting our results on a one to two quarter delay.  This would result in a \ngreater absolute impact from inflation and global supply chain constraints in fiscal \u201823 due to the \nannualization of the higher costs seen in the second half of fiscal \u201822.  \n \n Second, we also expect a greater impact fro m mitigation initiatives, with various waves of price \nincreases going into effect throughout the year.  \n \n In total, these two assumptions result in a similar to modestly higher net impact from inflation and \nglobal supply chain constraints as in the current year. ", "original_text": "Embedded in this are two key assumptions:  \n \nFirst, with visibility generally limited to the first half of the year, we are assu ming key cost drivers such \nas international freight and commodities have flattened and will begin to decrease slowly over the \ncourse of next fiscal year, affecting our results on a one to two quarter delay. ", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76b354ab6872c0357a4cf258effe78f89bfac987ad4754b52f45e59c1bf5896c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76590a9c-6493-460e-85fe-0e5f7fd691ab", "node_type": "1", "metadata": {"window": "We exp ect a further reduction in opioid -related legal costs in \nsubsequent years.  \n \n In Medical, we are highly focused on the inflationary impacts and global supply chain constraints \naffecting our U.S.  Medical Products and Distribution business.  \n \n At this time, we expect a similar to modestly higher net impact from inflation and global supply chain \nconstraints in fiscal \u201823 as in fiscal \u201822.  Embedded in this are two key assumptions:  \n \nFirst, with visibility generally limited to the first half of the year, we are assu ming key cost drivers such \nas international freight and commodities have flattened and will begin to decrease slowly over the \ncourse of next fiscal year, affecting our results on a one to two quarter delay.  This would result in a \ngreater absolute impact from inflation and global supply chain constraints in fiscal \u201823 due to the \nannualization of the higher costs seen in the second half of fiscal \u201822.  \n \n Second, we also expect a greater impact fro m mitigation initiatives, with various waves of price \nincreases going into effect throughout the year.  \n \n", "original_text": "At this time, we expect a similar to modestly higher net impact from inflation and global supply chain \nconstraints in fiscal \u201823 as in fiscal \u201822. ", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa2218dc56c9ee619fae21a304169c0e50f843841a0c16ef052a6c99a7563ee0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3750c08-2d5e-4847-a73d-ec230d52f4f7", "node_type": "1", "metadata": {"window": "Medical Products and Distribution business.  \n \n At this time, we expect a similar to modestly higher net impact from inflation and global supply chain \nconstraints in fiscal \u201823 as in fiscal \u201822.  Embedded in this are two key assumptions:  \n \nFirst, with visibility generally limited to the first half of the year, we are assu ming key cost drivers such \nas international freight and commodities have flattened and will begin to decrease slowly over the \ncourse of next fiscal year, affecting our results on a one to two quarter delay.  This would result in a \ngreater absolute impact from inflation and global supply chain constraints in fiscal \u201823 due to the \nannualization of the higher costs seen in the second half of fiscal \u201822.  \n \n Second, we also expect a greater impact fro m mitigation initiatives, with various waves of price \nincreases going into effect throughout the year.  \n \n In total, these two assumptions result in a similar to modestly higher net impact from inflation and \nglobal supply chain constraints as in the current year.  As we exit fiscal \u201823, we anticipate a run rate \nwhere our pricing actions will offset approximately half of the gross impact.  \n \n", "original_text": "This would result in a \ngreater absolute impact from inflation and global supply chain constraints in fiscal \u201823 due to the \nannualization of the higher costs seen in the second half of fiscal \u201822.  \n \n"}, "hash": "9c9550591861ca9e0ca4c8a446e6078a7f9f158dfa70f3532c14e437b7e4ce5b", "class_name": "RelatedNodeInfo"}}, "text": "Embedded in this are two key assumptions:  \n \nFirst, with visibility generally limited to the first half of the year, we are assu ming key cost drivers such \nas international freight and commodities have flattened and will begin to decrease slowly over the \ncourse of next fiscal year, affecting our results on a one to two quarter delay. ", "start_char_idx": 873, "end_char_idx": 1212, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3750c08-2d5e-4847-a73d-ec230d52f4f7": {"__data__": {"id_": "b3750c08-2d5e-4847-a73d-ec230d52f4f7", "embedding": null, "metadata": {"window": "Medical Products and Distribution business.  \n \n At this time, we expect a similar to modestly higher net impact from inflation and global supply chain \nconstraints in fiscal \u201823 as in fiscal \u201822.  Embedded in this are two key assumptions:  \n \nFirst, with visibility generally limited to the first half of the year, we are assu ming key cost drivers such \nas international freight and commodities have flattened and will begin to decrease slowly over the \ncourse of next fiscal year, affecting our results on a one to two quarter delay.  This would result in a \ngreater absolute impact from inflation and global supply chain constraints in fiscal \u201823 due to the \nannualization of the higher costs seen in the second half of fiscal \u201822.  \n \n Second, we also expect a greater impact fro m mitigation initiatives, with various waves of price \nincreases going into effect throughout the year.  \n \n In total, these two assumptions result in a similar to modestly higher net impact from inflation and \nglobal supply chain constraints as in the current year.  As we exit fiscal \u201823, we anticipate a run rate \nwhere our pricing actions will offset approximately half of the gross impact.  \n \n", "original_text": "This would result in a \ngreater absolute impact from inflation and global supply chain constraints in fiscal \u201823 due to the \nannualization of the higher costs seen in the second half of fiscal \u201822.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76b354ab6872c0357a4cf258effe78f89bfac987ad4754b52f45e59c1bf5896c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a8e33d0-9976-46a5-8f04-7c3ef24c36a1", "node_type": "1", "metadata": {"window": "In Medical, we are highly focused on the inflationary impacts and global supply chain constraints \naffecting our U.S.  Medical Products and Distribution business.  \n \n At this time, we expect a similar to modestly higher net impact from inflation and global supply chain \nconstraints in fiscal \u201823 as in fiscal \u201822.  Embedded in this are two key assumptions:  \n \nFirst, with visibility generally limited to the first half of the year, we are assu ming key cost drivers such \nas international freight and commodities have flattened and will begin to decrease slowly over the \ncourse of next fiscal year, affecting our results on a one to two quarter delay.  This would result in a \ngreater absolute impact from inflation and global supply chain constraints in fiscal \u201823 due to the \nannualization of the higher costs seen in the second half of fiscal \u201822.  \n \n Second, we also expect a greater impact fro m mitigation initiatives, with various waves of price \nincreases going into effect throughout the year.  \n \n In total, these two assumptions result in a similar to modestly higher net impact from inflation and \nglobal supply chain constraints as in the current year. ", "original_text": "Embedded in this are two key assumptions:  \n \nFirst, with visibility generally limited to the first half of the year, we are assu ming key cost drivers such \nas international freight and commodities have flattened and will begin to decrease slowly over the \ncourse of next fiscal year, affecting our results on a one to two quarter delay. ", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70f44660588c406e23617bd2a5025d69a89e6e44d24555ad1a57652ef244e7e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "844edd1f-0b2d-45e4-baf3-78fd6a0395f6", "node_type": "1", "metadata": {"window": "At this time, we expect a similar to modestly higher net impact from inflation and global supply chain \nconstraints in fiscal \u201823 as in fiscal \u201822.  Embedded in this are two key assumptions:  \n \nFirst, with visibility generally limited to the first half of the year, we are assu ming key cost drivers such \nas international freight and commodities have flattened and will begin to decrease slowly over the \ncourse of next fiscal year, affecting our results on a one to two quarter delay.  This would result in a \ngreater absolute impact from inflation and global supply chain constraints in fiscal \u201823 due to the \nannualization of the higher costs seen in the second half of fiscal \u201822.  \n \n Second, we also expect a greater impact fro m mitigation initiatives, with various waves of price \nincreases going into effect throughout the year.  \n \n In total, these two assumptions result in a similar to modestly higher net impact from inflation and \nglobal supply chain constraints as in the current year.  As we exit fiscal \u201823, we anticipate a run rate \nwhere our pricing actions will offset approximately half of the gross impact.  \n \n Though these inflationary impacts are persisting for much longer than originally anticipated, we \nremain committed to mitig ating the effects on our Medical business over time. ", "original_text": "Second, we also expect a greater impact fro m mitigation initiatives, with various waves of price \nincreases going into effect throughout the year.  \n \n"}, "hash": "6f0c8011cf0d472d70f54a6e7eccce164a56141d0955481774e9abe58db72356", "class_name": "RelatedNodeInfo"}}, "text": "This would result in a \ngreater absolute impact from inflation and global supply chain constraints in fiscal \u201823 due to the \nannualization of the higher costs seen in the second half of fiscal \u201822.  \n \n", "start_char_idx": 1212, "end_char_idx": 1414, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "844edd1f-0b2d-45e4-baf3-78fd6a0395f6": {"__data__": {"id_": "844edd1f-0b2d-45e4-baf3-78fd6a0395f6", "embedding": null, "metadata": {"window": "At this time, we expect a similar to modestly higher net impact from inflation and global supply chain \nconstraints in fiscal \u201823 as in fiscal \u201822.  Embedded in this are two key assumptions:  \n \nFirst, with visibility generally limited to the first half of the year, we are assu ming key cost drivers such \nas international freight and commodities have flattened and will begin to decrease slowly over the \ncourse of next fiscal year, affecting our results on a one to two quarter delay.  This would result in a \ngreater absolute impact from inflation and global supply chain constraints in fiscal \u201823 due to the \nannualization of the higher costs seen in the second half of fiscal \u201822.  \n \n Second, we also expect a greater impact fro m mitigation initiatives, with various waves of price \nincreases going into effect throughout the year.  \n \n In total, these two assumptions result in a similar to modestly higher net impact from inflation and \nglobal supply chain constraints as in the current year.  As we exit fiscal \u201823, we anticipate a run rate \nwhere our pricing actions will offset approximately half of the gross impact.  \n \n Though these inflationary impacts are persisting for much longer than originally anticipated, we \nremain committed to mitig ating the effects on our Medical business over time. ", "original_text": "Second, we also expect a greater impact fro m mitigation initiatives, with various waves of price \nincreases going into effect throughout the year.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76b354ab6872c0357a4cf258effe78f89bfac987ad4754b52f45e59c1bf5896c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3750c08-2d5e-4847-a73d-ec230d52f4f7", "node_type": "1", "metadata": {"window": "Medical Products and Distribution business.  \n \n At this time, we expect a similar to modestly higher net impact from inflation and global supply chain \nconstraints in fiscal \u201823 as in fiscal \u201822.  Embedded in this are two key assumptions:  \n \nFirst, with visibility generally limited to the first half of the year, we are assu ming key cost drivers such \nas international freight and commodities have flattened and will begin to decrease slowly over the \ncourse of next fiscal year, affecting our results on a one to two quarter delay.  This would result in a \ngreater absolute impact from inflation and global supply chain constraints in fiscal \u201823 due to the \nannualization of the higher costs seen in the second half of fiscal \u201822.  \n \n Second, we also expect a greater impact fro m mitigation initiatives, with various waves of price \nincreases going into effect throughout the year.  \n \n In total, these two assumptions result in a similar to modestly higher net impact from inflation and \nglobal supply chain constraints as in the current year.  As we exit fiscal \u201823, we anticipate a run rate \nwhere our pricing actions will offset approximately half of the gross impact.  \n \n", "original_text": "This would result in a \ngreater absolute impact from inflation and global supply chain constraints in fiscal \u201823 due to the \nannualization of the higher costs seen in the second half of fiscal \u201822.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66a6fc010d6c5cd828336b8161f1557233a0766a00c04b39fa654e77ddb01222", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9ee4045-ef6d-4ff0-a9f1-e62f319454b2", "node_type": "1", "metadata": {"window": "Embedded in this are two key assumptions:  \n \nFirst, with visibility generally limited to the first half of the year, we are assu ming key cost drivers such \nas international freight and commodities have flattened and will begin to decrease slowly over the \ncourse of next fiscal year, affecting our results on a one to two quarter delay.  This would result in a \ngreater absolute impact from inflation and global supply chain constraints in fiscal \u201823 due to the \nannualization of the higher costs seen in the second half of fiscal \u201822.  \n \n Second, we also expect a greater impact fro m mitigation initiatives, with various waves of price \nincreases going into effect throughout the year.  \n \n In total, these two assumptions result in a similar to modestly higher net impact from inflation and \nglobal supply chain constraints as in the current year.  As we exit fiscal \u201823, we anticipate a run rate \nwhere our pricing actions will offset approximately half of the gross impact.  \n \n Though these inflationary impacts are persisting for much longer than originally anticipated, we \nremain committed to mitig ating the effects on our Medical business over time.  We continue to believe \nthe majority of these impacts will prove temporary once global supply chain pressures eventually \nabate, or pricing will adjust accordingly.  \n \n", "original_text": "In total, these two assumptions result in a similar to modestly higher net impact from inflation and \nglobal supply chain constraints as in the current year. "}, "hash": "ba918d0e3d7a2a53da52f2054db245f3acad709fae32727d3bc4598864a69aef", "class_name": "RelatedNodeInfo"}}, "text": "Second, we also expect a greater impact fro m mitigation initiatives, with various waves of price \nincreases going into effect throughout the year.  \n \n", "start_char_idx": 1414, "end_char_idx": 1566, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9ee4045-ef6d-4ff0-a9f1-e62f319454b2": {"__data__": {"id_": "b9ee4045-ef6d-4ff0-a9f1-e62f319454b2", "embedding": null, "metadata": {"window": "Embedded in this are two key assumptions:  \n \nFirst, with visibility generally limited to the first half of the year, we are assu ming key cost drivers such \nas international freight and commodities have flattened and will begin to decrease slowly over the \ncourse of next fiscal year, affecting our results on a one to two quarter delay.  This would result in a \ngreater absolute impact from inflation and global supply chain constraints in fiscal \u201823 due to the \nannualization of the higher costs seen in the second half of fiscal \u201822.  \n \n Second, we also expect a greater impact fro m mitigation initiatives, with various waves of price \nincreases going into effect throughout the year.  \n \n In total, these two assumptions result in a similar to modestly higher net impact from inflation and \nglobal supply chain constraints as in the current year.  As we exit fiscal \u201823, we anticipate a run rate \nwhere our pricing actions will offset approximately half of the gross impact.  \n \n Though these inflationary impacts are persisting for much longer than originally anticipated, we \nremain committed to mitig ating the effects on our Medical business over time.  We continue to believe \nthe majority of these impacts will prove temporary once global supply chain pressures eventually \nabate, or pricing will adjust accordingly.  \n \n", "original_text": "In total, these two assumptions result in a similar to modestly higher net impact from inflation and \nglobal supply chain constraints as in the current year. ", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76b354ab6872c0357a4cf258effe78f89bfac987ad4754b52f45e59c1bf5896c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "844edd1f-0b2d-45e4-baf3-78fd6a0395f6", "node_type": "1", "metadata": {"window": "At this time, we expect a similar to modestly higher net impact from inflation and global supply chain \nconstraints in fiscal \u201823 as in fiscal \u201822.  Embedded in this are two key assumptions:  \n \nFirst, with visibility generally limited to the first half of the year, we are assu ming key cost drivers such \nas international freight and commodities have flattened and will begin to decrease slowly over the \ncourse of next fiscal year, affecting our results on a one to two quarter delay.  This would result in a \ngreater absolute impact from inflation and global supply chain constraints in fiscal \u201823 due to the \nannualization of the higher costs seen in the second half of fiscal \u201822.  \n \n Second, we also expect a greater impact fro m mitigation initiatives, with various waves of price \nincreases going into effect throughout the year.  \n \n In total, these two assumptions result in a similar to modestly higher net impact from inflation and \nglobal supply chain constraints as in the current year.  As we exit fiscal \u201823, we anticipate a run rate \nwhere our pricing actions will offset approximately half of the gross impact.  \n \n Though these inflationary impacts are persisting for much longer than originally anticipated, we \nremain committed to mitig ating the effects on our Medical business over time. ", "original_text": "Second, we also expect a greater impact fro m mitigation initiatives, with various waves of price \nincreases going into effect throughout the year.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3d03d7207c81c0758c043abf99a8288625339e10711b5bf5b44ff88f67fd0e4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f44438ce-2bd8-4996-b2da-94fad6042d67", "node_type": "1", "metadata": {"window": "This would result in a \ngreater absolute impact from inflation and global supply chain constraints in fiscal \u201823 due to the \nannualization of the higher costs seen in the second half of fiscal \u201822.  \n \n Second, we also expect a greater impact fro m mitigation initiatives, with various waves of price \nincreases going into effect throughout the year.  \n \n In total, these two assumptions result in a similar to modestly higher net impact from inflation and \nglobal supply chain constraints as in the current year.  As we exit fiscal \u201823, we anticipate a run rate \nwhere our pricing actions will offset approximately half of the gross impact.  \n \n Though these inflationary impacts are persisting for much longer than originally anticipated, we \nremain committed to mitig ating the effects on our Medical business over time.  We continue to believe \nthe majority of these impacts will prove temporary once global supply chain pressures eventually \nabate, or pricing will adjust accordingly.  \n \n Below the line, we anticipate a year -over-year headwind in our fiscal \u201823 effective tax rate with the \ndiscrete favorability seen in fiscal \u201822 not expected to repeat. ", "original_text": "As we exit fiscal \u201823, we anticipate a run rate \nwhere our pricing actions will offset approximately half of the gross impact.  \n \n"}, "hash": "77747a949187d96c758bd7154e4ca7d020a76c0f08fa5e855d0c377a92de73f5", "class_name": "RelatedNodeInfo"}}, "text": "In total, these two assumptions result in a similar to modestly higher net impact from inflation and \nglobal supply chain constraints as in the current year. ", "start_char_idx": 1566, "end_char_idx": 1724, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f44438ce-2bd8-4996-b2da-94fad6042d67": {"__data__": {"id_": "f44438ce-2bd8-4996-b2da-94fad6042d67", "embedding": null, "metadata": {"window": "This would result in a \ngreater absolute impact from inflation and global supply chain constraints in fiscal \u201823 due to the \nannualization of the higher costs seen in the second half of fiscal \u201822.  \n \n Second, we also expect a greater impact fro m mitigation initiatives, with various waves of price \nincreases going into effect throughout the year.  \n \n In total, these two assumptions result in a similar to modestly higher net impact from inflation and \nglobal supply chain constraints as in the current year.  As we exit fiscal \u201823, we anticipate a run rate \nwhere our pricing actions will offset approximately half of the gross impact.  \n \n Though these inflationary impacts are persisting for much longer than originally anticipated, we \nremain committed to mitig ating the effects on our Medical business over time.  We continue to believe \nthe majority of these impacts will prove temporary once global supply chain pressures eventually \nabate, or pricing will adjust accordingly.  \n \n Below the line, we anticipate a year -over-year headwind in our fiscal \u201823 effective tax rate with the \ndiscrete favorability seen in fiscal \u201822 not expected to repeat. ", "original_text": "As we exit fiscal \u201823, we anticipate a run rate \nwhere our pricing actions will offset approximately half of the gross impact.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76b354ab6872c0357a4cf258effe78f89bfac987ad4754b52f45e59c1bf5896c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9ee4045-ef6d-4ff0-a9f1-e62f319454b2", "node_type": "1", "metadata": {"window": "Embedded in this are two key assumptions:  \n \nFirst, with visibility generally limited to the first half of the year, we are assu ming key cost drivers such \nas international freight and commodities have flattened and will begin to decrease slowly over the \ncourse of next fiscal year, affecting our results on a one to two quarter delay.  This would result in a \ngreater absolute impact from inflation and global supply chain constraints in fiscal \u201823 due to the \nannualization of the higher costs seen in the second half of fiscal \u201822.  \n \n Second, we also expect a greater impact fro m mitigation initiatives, with various waves of price \nincreases going into effect throughout the year.  \n \n In total, these two assumptions result in a similar to modestly higher net impact from inflation and \nglobal supply chain constraints as in the current year.  As we exit fiscal \u201823, we anticipate a run rate \nwhere our pricing actions will offset approximately half of the gross impact.  \n \n Though these inflationary impacts are persisting for much longer than originally anticipated, we \nremain committed to mitig ating the effects on our Medical business over time.  We continue to believe \nthe majority of these impacts will prove temporary once global supply chain pressures eventually \nabate, or pricing will adjust accordingly.  \n \n", "original_text": "In total, these two assumptions result in a similar to modestly higher net impact from inflation and \nglobal supply chain constraints as in the current year. ", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "55d74b9d734700463b9c18552b957858c2b967f5ea21b7612bedc624970e1aee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f256a355-3301-4d9e-b132-7611abf6c51c", "node_type": "1", "metadata": {"window": "Second, we also expect a greater impact fro m mitigation initiatives, with various waves of price \nincreases going into effect throughout the year.  \n \n In total, these two assumptions result in a similar to modestly higher net impact from inflation and \nglobal supply chain constraints as in the current year.  As we exit fiscal \u201823, we anticipate a run rate \nwhere our pricing actions will offset approximately half of the gross impact.  \n \n Though these inflationary impacts are persisting for much longer than originally anticipated, we \nremain committed to mitig ating the effects on our Medical business over time.  We continue to believe \nthe majority of these impacts will prove temporary once global supply chain pressures eventually \nabate, or pricing will adjust accordingly.  \n \n Below the line, we anticipate a year -over-year headwind in our fiscal \u201823 effective tax rate with the \ndiscrete favorability seen in fiscal \u201822 not expected to repeat.  And with our strong balance sheet, we \nsee the potential for accretive capital deployment through a similar level of share repurchases over \nthe course of the year, supported by the $2.7 billion of authorization remaining on our existing share \nrepurchase program expiring at the end of 2024.  \n \n", "original_text": "Though these inflationary impacts are persisting for much longer than originally anticipated, we \nremain committed to mitig ating the effects on our Medical business over time. "}, "hash": "71d44a5327fd05d52123912ecdd7b152b7c68f52bb4461fbc9ad8b77397ddf2c", "class_name": "RelatedNodeInfo"}}, "text": "As we exit fiscal \u201823, we anticipate a run rate \nwhere our pricing actions will offset approximately half of the gross impact.  \n \n", "start_char_idx": 1724, "end_char_idx": 1855, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f256a355-3301-4d9e-b132-7611abf6c51c": {"__data__": {"id_": "f256a355-3301-4d9e-b132-7611abf6c51c", "embedding": null, "metadata": {"window": "Second, we also expect a greater impact fro m mitigation initiatives, with various waves of price \nincreases going into effect throughout the year.  \n \n In total, these two assumptions result in a similar to modestly higher net impact from inflation and \nglobal supply chain constraints as in the current year.  As we exit fiscal \u201823, we anticipate a run rate \nwhere our pricing actions will offset approximately half of the gross impact.  \n \n Though these inflationary impacts are persisting for much longer than originally anticipated, we \nremain committed to mitig ating the effects on our Medical business over time.  We continue to believe \nthe majority of these impacts will prove temporary once global supply chain pressures eventually \nabate, or pricing will adjust accordingly.  \n \n Below the line, we anticipate a year -over-year headwind in our fiscal \u201823 effective tax rate with the \ndiscrete favorability seen in fiscal \u201822 not expected to repeat.  And with our strong balance sheet, we \nsee the potential for accretive capital deployment through a similar level of share repurchases over \nthe course of the year, supported by the $2.7 billion of authorization remaining on our existing share \nrepurchase program expiring at the end of 2024.  \n \n", "original_text": "Though these inflationary impacts are persisting for much longer than originally anticipated, we \nremain committed to mitig ating the effects on our Medical business over time. ", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76b354ab6872c0357a4cf258effe78f89bfac987ad4754b52f45e59c1bf5896c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f44438ce-2bd8-4996-b2da-94fad6042d67", "node_type": "1", "metadata": {"window": "This would result in a \ngreater absolute impact from inflation and global supply chain constraints in fiscal \u201823 due to the \nannualization of the higher costs seen in the second half of fiscal \u201822.  \n \n Second, we also expect a greater impact fro m mitigation initiatives, with various waves of price \nincreases going into effect throughout the year.  \n \n In total, these two assumptions result in a similar to modestly higher net impact from inflation and \nglobal supply chain constraints as in the current year.  As we exit fiscal \u201823, we anticipate a run rate \nwhere our pricing actions will offset approximately half of the gross impact.  \n \n Though these inflationary impacts are persisting for much longer than originally anticipated, we \nremain committed to mitig ating the effects on our Medical business over time.  We continue to believe \nthe majority of these impacts will prove temporary once global supply chain pressures eventually \nabate, or pricing will adjust accordingly.  \n \n Below the line, we anticipate a year -over-year headwind in our fiscal \u201823 effective tax rate with the \ndiscrete favorability seen in fiscal \u201822 not expected to repeat. ", "original_text": "As we exit fiscal \u201823, we anticipate a run rate \nwhere our pricing actions will offset approximately half of the gross impact.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae806ff588d8249de7eff43fe1f593fd2018d8bcb3f7d2e4450897fd876328d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7dd0e815-f9f1-4496-bd29-e6c00badf645", "node_type": "1", "metadata": {"window": "In total, these two assumptions result in a similar to modestly higher net impact from inflation and \nglobal supply chain constraints as in the current year.  As we exit fiscal \u201823, we anticipate a run rate \nwhere our pricing actions will offset approximately half of the gross impact.  \n \n Though these inflationary impacts are persisting for much longer than originally anticipated, we \nremain committed to mitig ating the effects on our Medical business over time.  We continue to believe \nthe majority of these impacts will prove temporary once global supply chain pressures eventually \nabate, or pricing will adjust accordingly.  \n \n Below the line, we anticipate a year -over-year headwind in our fiscal \u201823 effective tax rate with the \ndiscrete favorability seen in fiscal \u201822 not expected to repeat.  And with our strong balance sheet, we \nsee the potential for accretive capital deployment through a similar level of share repurchases over \nthe course of the year, supported by the $2.7 billion of authorization remaining on our existing share \nrepurchase program expiring at the end of 2024.  \n \n In summary, while there\u2019s obviously moving parts for f iscal \u201823, or any particular year, we continue to \nbelieve our previously -announced long -term targets for our businesses and for double -digit combined \nEPS growth and dividend yield are achievable over normalized, longer periods.  \n \n", "original_text": "We continue to believe \nthe majority of these impacts will prove temporary once global supply chain pressures eventually \nabate, or pricing will adjust accordingly.  \n \n"}, "hash": "8a7a515b97dfcdcf687fee71d00af0574521b8b7d3f9f730427b29f7454527fe", "class_name": "RelatedNodeInfo"}}, "text": "Though these inflationary impacts are persisting for much longer than originally anticipated, we \nremain committed to mitig ating the effects on our Medical business over time. ", "start_char_idx": 1855, "end_char_idx": 2032, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7dd0e815-f9f1-4496-bd29-e6c00badf645": {"__data__": {"id_": "7dd0e815-f9f1-4496-bd29-e6c00badf645", "embedding": null, "metadata": {"window": "In total, these two assumptions result in a similar to modestly higher net impact from inflation and \nglobal supply chain constraints as in the current year.  As we exit fiscal \u201823, we anticipate a run rate \nwhere our pricing actions will offset approximately half of the gross impact.  \n \n Though these inflationary impacts are persisting for much longer than originally anticipated, we \nremain committed to mitig ating the effects on our Medical business over time.  We continue to believe \nthe majority of these impacts will prove temporary once global supply chain pressures eventually \nabate, or pricing will adjust accordingly.  \n \n Below the line, we anticipate a year -over-year headwind in our fiscal \u201823 effective tax rate with the \ndiscrete favorability seen in fiscal \u201822 not expected to repeat.  And with our strong balance sheet, we \nsee the potential for accretive capital deployment through a similar level of share repurchases over \nthe course of the year, supported by the $2.7 billion of authorization remaining on our existing share \nrepurchase program expiring at the end of 2024.  \n \n In summary, while there\u2019s obviously moving parts for f iscal \u201823, or any particular year, we continue to \nbelieve our previously -announced long -term targets for our businesses and for double -digit combined \nEPS growth and dividend yield are achievable over normalized, longer periods.  \n \n", "original_text": "We continue to believe \nthe majority of these impacts will prove temporary once global supply chain pressures eventually \nabate, or pricing will adjust accordingly.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76b354ab6872c0357a4cf258effe78f89bfac987ad4754b52f45e59c1bf5896c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f256a355-3301-4d9e-b132-7611abf6c51c", "node_type": "1", "metadata": {"window": "Second, we also expect a greater impact fro m mitigation initiatives, with various waves of price \nincreases going into effect throughout the year.  \n \n In total, these two assumptions result in a similar to modestly higher net impact from inflation and \nglobal supply chain constraints as in the current year.  As we exit fiscal \u201823, we anticipate a run rate \nwhere our pricing actions will offset approximately half of the gross impact.  \n \n Though these inflationary impacts are persisting for much longer than originally anticipated, we \nremain committed to mitig ating the effects on our Medical business over time.  We continue to believe \nthe majority of these impacts will prove temporary once global supply chain pressures eventually \nabate, or pricing will adjust accordingly.  \n \n Below the line, we anticipate a year -over-year headwind in our fiscal \u201823 effective tax rate with the \ndiscrete favorability seen in fiscal \u201822 not expected to repeat.  And with our strong balance sheet, we \nsee the potential for accretive capital deployment through a similar level of share repurchases over \nthe course of the year, supported by the $2.7 billion of authorization remaining on our existing share \nrepurchase program expiring at the end of 2024.  \n \n", "original_text": "Though these inflationary impacts are persisting for much longer than originally anticipated, we \nremain committed to mitig ating the effects on our Medical business over time. ", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4cbde8d4472ef7607aee44a424ad0e461858899d11f5bb8987af65bd035f232", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "95188c0a-9dd5-44c0-92a0-83397e297501", "node_type": "1", "metadata": {"window": "As we exit fiscal \u201823, we anticipate a run rate \nwhere our pricing actions will offset approximately half of the gross impact.  \n \n Though these inflationary impacts are persisting for much longer than originally anticipated, we \nremain committed to mitig ating the effects on our Medical business over time.  We continue to believe \nthe majority of these impacts will prove temporary once global supply chain pressures eventually \nabate, or pricing will adjust accordingly.  \n \n Below the line, we anticipate a year -over-year headwind in our fiscal \u201823 effective tax rate with the \ndiscrete favorability seen in fiscal \u201822 not expected to repeat.  And with our strong balance sheet, we \nsee the potential for accretive capital deployment through a similar level of share repurchases over \nthe course of the year, supported by the $2.7 billion of authorization remaining on our existing share \nrepurchase program expiring at the end of 2024.  \n \n In summary, while there\u2019s obviously moving parts for f iscal \u201823, or any particular year, we continue to \nbelieve our previously -announced long -term targets for our businesses and for double -digit combined \nEPS growth and dividend yield are achievable over normalized, longer periods.  \n \n With that, I\u2019ll turn it bac k over to Mike.  \n \n", "original_text": "Below the line, we anticipate a year -over-year headwind in our fiscal \u201823 effective tax rate with the \ndiscrete favorability seen in fiscal \u201822 not expected to repeat. "}, "hash": "8e82e3c72a44e1b6d347bcf3592409b37b2b0739018c5b097ff83c32f44ab901", "class_name": "RelatedNodeInfo"}}, "text": "We continue to believe \nthe majority of these impacts will prove temporary once global supply chain pressures eventually \nabate, or pricing will adjust accordingly.  \n \n", "start_char_idx": 2032, "end_char_idx": 2201, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "95188c0a-9dd5-44c0-92a0-83397e297501": {"__data__": {"id_": "95188c0a-9dd5-44c0-92a0-83397e297501", "embedding": null, "metadata": {"window": "As we exit fiscal \u201823, we anticipate a run rate \nwhere our pricing actions will offset approximately half of the gross impact.  \n \n Though these inflationary impacts are persisting for much longer than originally anticipated, we \nremain committed to mitig ating the effects on our Medical business over time.  We continue to believe \nthe majority of these impacts will prove temporary once global supply chain pressures eventually \nabate, or pricing will adjust accordingly.  \n \n Below the line, we anticipate a year -over-year headwind in our fiscal \u201823 effective tax rate with the \ndiscrete favorability seen in fiscal \u201822 not expected to repeat.  And with our strong balance sheet, we \nsee the potential for accretive capital deployment through a similar level of share repurchases over \nthe course of the year, supported by the $2.7 billion of authorization remaining on our existing share \nrepurchase program expiring at the end of 2024.  \n \n In summary, while there\u2019s obviously moving parts for f iscal \u201823, or any particular year, we continue to \nbelieve our previously -announced long -term targets for our businesses and for double -digit combined \nEPS growth and dividend yield are achievable over normalized, longer periods.  \n \n With that, I\u2019ll turn it bac k over to Mike.  \n \n", "original_text": "Below the line, we anticipate a year -over-year headwind in our fiscal \u201823 effective tax rate with the \ndiscrete favorability seen in fiscal \u201822 not expected to repeat. ", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76b354ab6872c0357a4cf258effe78f89bfac987ad4754b52f45e59c1bf5896c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7dd0e815-f9f1-4496-bd29-e6c00badf645", "node_type": "1", "metadata": {"window": "In total, these two assumptions result in a similar to modestly higher net impact from inflation and \nglobal supply chain constraints as in the current year.  As we exit fiscal \u201823, we anticipate a run rate \nwhere our pricing actions will offset approximately half of the gross impact.  \n \n Though these inflationary impacts are persisting for much longer than originally anticipated, we \nremain committed to mitig ating the effects on our Medical business over time.  We continue to believe \nthe majority of these impacts will prove temporary once global supply chain pressures eventually \nabate, or pricing will adjust accordingly.  \n \n Below the line, we anticipate a year -over-year headwind in our fiscal \u201823 effective tax rate with the \ndiscrete favorability seen in fiscal \u201822 not expected to repeat.  And with our strong balance sheet, we \nsee the potential for accretive capital deployment through a similar level of share repurchases over \nthe course of the year, supported by the $2.7 billion of authorization remaining on our existing share \nrepurchase program expiring at the end of 2024.  \n \n In summary, while there\u2019s obviously moving parts for f iscal \u201823, or any particular year, we continue to \nbelieve our previously -announced long -term targets for our businesses and for double -digit combined \nEPS growth and dividend yield are achievable over normalized, longer periods.  \n \n", "original_text": "We continue to believe \nthe majority of these impacts will prove temporary once global supply chain pressures eventually \nabate, or pricing will adjust accordingly.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c06404c3d7154c1ed47cc0c65ed06fa1fbf5863b522fcb3dfabfd937db91382b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc4e14e6-b3b4-4036-a7c0-5e7368002a85", "node_type": "1", "metadata": {"window": "Though these inflationary impacts are persisting for much longer than originally anticipated, we \nremain committed to mitig ating the effects on our Medical business over time.  We continue to believe \nthe majority of these impacts will prove temporary once global supply chain pressures eventually \nabate, or pricing will adjust accordingly.  \n \n Below the line, we anticipate a year -over-year headwind in our fiscal \u201823 effective tax rate with the \ndiscrete favorability seen in fiscal \u201822 not expected to repeat.  And with our strong balance sheet, we \nsee the potential for accretive capital deployment through a similar level of share repurchases over \nthe course of the year, supported by the $2.7 billion of authorization remaining on our existing share \nrepurchase program expiring at the end of 2024.  \n \n In summary, while there\u2019s obviously moving parts for f iscal \u201823, or any particular year, we continue to \nbelieve our previously -announced long -term targets for our businesses and for double -digit combined \nEPS growth and dividend yield are achievable over normalized, longer periods.  \n \n With that, I\u2019ll turn it bac k over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.  \n ", "original_text": "And with our strong balance sheet, we \nsee the potential for accretive capital deployment through a similar level of share repurchases over \nthe course of the year, supported by the $2.7 billion of authorization remaining on our existing share \nrepurchase program expiring at the end of 2024.  \n \n"}, "hash": "e63aa7b2d3d6c9edff073c6856bc295bfeb937d1bc44d36145d8f07d5584e906", "class_name": "RelatedNodeInfo"}}, "text": "Below the line, we anticipate a year -over-year headwind in our fiscal \u201823 effective tax rate with the \ndiscrete favorability seen in fiscal \u201822 not expected to repeat. ", "start_char_idx": 2201, "end_char_idx": 2370, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc4e14e6-b3b4-4036-a7c0-5e7368002a85": {"__data__": {"id_": "bc4e14e6-b3b4-4036-a7c0-5e7368002a85", "embedding": null, "metadata": {"window": "Though these inflationary impacts are persisting for much longer than originally anticipated, we \nremain committed to mitig ating the effects on our Medical business over time.  We continue to believe \nthe majority of these impacts will prove temporary once global supply chain pressures eventually \nabate, or pricing will adjust accordingly.  \n \n Below the line, we anticipate a year -over-year headwind in our fiscal \u201823 effective tax rate with the \ndiscrete favorability seen in fiscal \u201822 not expected to repeat.  And with our strong balance sheet, we \nsee the potential for accretive capital deployment through a similar level of share repurchases over \nthe course of the year, supported by the $2.7 billion of authorization remaining on our existing share \nrepurchase program expiring at the end of 2024.  \n \n In summary, while there\u2019s obviously moving parts for f iscal \u201823, or any particular year, we continue to \nbelieve our previously -announced long -term targets for our businesses and for double -digit combined \nEPS growth and dividend yield are achievable over normalized, longer periods.  \n \n With that, I\u2019ll turn it bac k over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.  \n ", "original_text": "And with our strong balance sheet, we \nsee the potential for accretive capital deployment through a similar level of share repurchases over \nthe course of the year, supported by the $2.7 billion of authorization remaining on our existing share \nrepurchase program expiring at the end of 2024.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76b354ab6872c0357a4cf258effe78f89bfac987ad4754b52f45e59c1bf5896c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "95188c0a-9dd5-44c0-92a0-83397e297501", "node_type": "1", "metadata": {"window": "As we exit fiscal \u201823, we anticipate a run rate \nwhere our pricing actions will offset approximately half of the gross impact.  \n \n Though these inflationary impacts are persisting for much longer than originally anticipated, we \nremain committed to mitig ating the effects on our Medical business over time.  We continue to believe \nthe majority of these impacts will prove temporary once global supply chain pressures eventually \nabate, or pricing will adjust accordingly.  \n \n Below the line, we anticipate a year -over-year headwind in our fiscal \u201823 effective tax rate with the \ndiscrete favorability seen in fiscal \u201822 not expected to repeat.  And with our strong balance sheet, we \nsee the potential for accretive capital deployment through a similar level of share repurchases over \nthe course of the year, supported by the $2.7 billion of authorization remaining on our existing share \nrepurchase program expiring at the end of 2024.  \n \n In summary, while there\u2019s obviously moving parts for f iscal \u201823, or any particular year, we continue to \nbelieve our previously -announced long -term targets for our businesses and for double -digit combined \nEPS growth and dividend yield are achievable over normalized, longer periods.  \n \n With that, I\u2019ll turn it bac k over to Mike.  \n \n", "original_text": "Below the line, we anticipate a year -over-year headwind in our fiscal \u201823 effective tax rate with the \ndiscrete favorability seen in fiscal \u201822 not expected to repeat. ", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "dc2bf8d3801c0da9915103536d7f3fee54bb6b296f4c7a7ee233e5f39527bd23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70f8eccf-3cd6-41fc-931a-41a8bd8f0cfb", "node_type": "1", "metadata": {"window": "We continue to believe \nthe majority of these impacts will prove temporary once global supply chain pressures eventually \nabate, or pricing will adjust accordingly.  \n \n Below the line, we anticipate a year -over-year headwind in our fiscal \u201823 effective tax rate with the \ndiscrete favorability seen in fiscal \u201822 not expected to repeat.  And with our strong balance sheet, we \nsee the potential for accretive capital deployment through a similar level of share repurchases over \nthe course of the year, supported by the $2.7 billion of authorization remaining on our existing share \nrepurchase program expiring at the end of 2024.  \n \n In summary, while there\u2019s obviously moving parts for f iscal \u201823, or any particular year, we continue to \nbelieve our previously -announced long -term targets for our businesses and for double -digit combined \nEPS growth and dividend yield are achievable over normalized, longer periods.  \n \n With that, I\u2019ll turn it bac k over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.  \n ", "original_text": "In summary, while there\u2019s obviously moving parts for f iscal \u201823, or any particular year, we continue to \nbelieve our previously -announced long -term targets for our businesses and for double -digit combined \nEPS growth and dividend yield are achievable over normalized, longer periods.  \n \n"}, "hash": "ab6c1fe7a688e6a56afbf164ae980a55242da1c23f20d65eafd65cf0870d33e3", "class_name": "RelatedNodeInfo"}}, "text": "And with our strong balance sheet, we \nsee the potential for accretive capital deployment through a similar level of share repurchases over \nthe course of the year, supported by the $2.7 billion of authorization remaining on our existing share \nrepurchase program expiring at the end of 2024.  \n \n", "start_char_idx": 2370, "end_char_idx": 2667, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70f8eccf-3cd6-41fc-931a-41a8bd8f0cfb": {"__data__": {"id_": "70f8eccf-3cd6-41fc-931a-41a8bd8f0cfb", "embedding": null, "metadata": {"window": "We continue to believe \nthe majority of these impacts will prove temporary once global supply chain pressures eventually \nabate, or pricing will adjust accordingly.  \n \n Below the line, we anticipate a year -over-year headwind in our fiscal \u201823 effective tax rate with the \ndiscrete favorability seen in fiscal \u201822 not expected to repeat.  And with our strong balance sheet, we \nsee the potential for accretive capital deployment through a similar level of share repurchases over \nthe course of the year, supported by the $2.7 billion of authorization remaining on our existing share \nrepurchase program expiring at the end of 2024.  \n \n In summary, while there\u2019s obviously moving parts for f iscal \u201823, or any particular year, we continue to \nbelieve our previously -announced long -term targets for our businesses and for double -digit combined \nEPS growth and dividend yield are achievable over normalized, longer periods.  \n \n With that, I\u2019ll turn it bac k over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.  \n ", "original_text": "In summary, while there\u2019s obviously moving parts for f iscal \u201823, or any particular year, we continue to \nbelieve our previously -announced long -term targets for our businesses and for double -digit combined \nEPS growth and dividend yield are achievable over normalized, longer periods.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76b354ab6872c0357a4cf258effe78f89bfac987ad4754b52f45e59c1bf5896c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc4e14e6-b3b4-4036-a7c0-5e7368002a85", "node_type": "1", "metadata": {"window": "Though these inflationary impacts are persisting for much longer than originally anticipated, we \nremain committed to mitig ating the effects on our Medical business over time.  We continue to believe \nthe majority of these impacts will prove temporary once global supply chain pressures eventually \nabate, or pricing will adjust accordingly.  \n \n Below the line, we anticipate a year -over-year headwind in our fiscal \u201823 effective tax rate with the \ndiscrete favorability seen in fiscal \u201822 not expected to repeat.  And with our strong balance sheet, we \nsee the potential for accretive capital deployment through a similar level of share repurchases over \nthe course of the year, supported by the $2.7 billion of authorization remaining on our existing share \nrepurchase program expiring at the end of 2024.  \n \n In summary, while there\u2019s obviously moving parts for f iscal \u201823, or any particular year, we continue to \nbelieve our previously -announced long -term targets for our businesses and for double -digit combined \nEPS growth and dividend yield are achievable over normalized, longer periods.  \n \n With that, I\u2019ll turn it bac k over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.  \n ", "original_text": "And with our strong balance sheet, we \nsee the potential for accretive capital deployment through a similar level of share repurchases over \nthe course of the year, supported by the $2.7 billion of authorization remaining on our existing share \nrepurchase program expiring at the end of 2024.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1b388089b210bfd9177f82fd94e6cea12c8285bd171683bac0a3a0e5927e4cb1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a4c5154-0f73-450a-8145-ffeb11640f9b", "node_type": "1", "metadata": {"window": "Below the line, we anticipate a year -over-year headwind in our fiscal \u201823 effective tax rate with the \ndiscrete favorability seen in fiscal \u201822 not expected to repeat.  And with our strong balance sheet, we \nsee the potential for accretive capital deployment through a similar level of share repurchases over \nthe course of the year, supported by the $2.7 billion of authorization remaining on our existing share \nrepurchase program expiring at the end of 2024.  \n \n In summary, while there\u2019s obviously moving parts for f iscal \u201823, or any particular year, we continue to \nbelieve our previously -announced long -term targets for our businesses and for double -digit combined \nEPS growth and dividend yield are achievable over normalized, longer periods.  \n \n With that, I\u2019ll turn it bac k over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.  \n ", "original_text": "With that, I\u2019ll turn it bac k over to Mike.  \n \n"}, "hash": "e353c59b2f562f48d1763ae472456b29ffadcdae7309048c09e2b5410de537bb", "class_name": "RelatedNodeInfo"}}, "text": "In summary, while there\u2019s obviously moving parts for f iscal \u201823, or any particular year, we continue to \nbelieve our previously -announced long -term targets for our businesses and for double -digit combined \nEPS growth and dividend yield are achievable over normalized, longer periods.  \n \n", "start_char_idx": 2667, "end_char_idx": 2959, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a4c5154-0f73-450a-8145-ffeb11640f9b": {"__data__": {"id_": "1a4c5154-0f73-450a-8145-ffeb11640f9b", "embedding": null, "metadata": {"window": "Below the line, we anticipate a year -over-year headwind in our fiscal \u201823 effective tax rate with the \ndiscrete favorability seen in fiscal \u201822 not expected to repeat.  And with our strong balance sheet, we \nsee the potential for accretive capital deployment through a similar level of share repurchases over \nthe course of the year, supported by the $2.7 billion of authorization remaining on our existing share \nrepurchase program expiring at the end of 2024.  \n \n In summary, while there\u2019s obviously moving parts for f iscal \u201823, or any particular year, we continue to \nbelieve our previously -announced long -term targets for our businesses and for double -digit combined \nEPS growth and dividend yield are achievable over normalized, longer periods.  \n \n With that, I\u2019ll turn it bac k over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.  \n ", "original_text": "With that, I\u2019ll turn it bac k over to Mike.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76b354ab6872c0357a4cf258effe78f89bfac987ad4754b52f45e59c1bf5896c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70f8eccf-3cd6-41fc-931a-41a8bd8f0cfb", "node_type": "1", "metadata": {"window": "We continue to believe \nthe majority of these impacts will prove temporary once global supply chain pressures eventually \nabate, or pricing will adjust accordingly.  \n \n Below the line, we anticipate a year -over-year headwind in our fiscal \u201823 effective tax rate with the \ndiscrete favorability seen in fiscal \u201822 not expected to repeat.  And with our strong balance sheet, we \nsee the potential for accretive capital deployment through a similar level of share repurchases over \nthe course of the year, supported by the $2.7 billion of authorization remaining on our existing share \nrepurchase program expiring at the end of 2024.  \n \n In summary, while there\u2019s obviously moving parts for f iscal \u201823, or any particular year, we continue to \nbelieve our previously -announced long -term targets for our businesses and for double -digit combined \nEPS growth and dividend yield are achievable over normalized, longer periods.  \n \n With that, I\u2019ll turn it bac k over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.  \n ", "original_text": "In summary, while there\u2019s obviously moving parts for f iscal \u201823, or any particular year, we continue to \nbelieve our previously -announced long -term targets for our businesses and for double -digit combined \nEPS growth and dividend yield are achievable over normalized, longer periods.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f3455d3ff37ae6a36755ef53a372c5ca3d20f573be074497d250d10d80de488", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc3ffc41-5602-4435-b2ac-697626c13b61", "node_type": "1", "metadata": {"window": "And with our strong balance sheet, we \nsee the potential for accretive capital deployment through a similar level of share repurchases over \nthe course of the year, supported by the $2.7 billion of authorization remaining on our existing share \nrepurchase program expiring at the end of 2024.  \n \n In summary, while there\u2019s obviously moving parts for f iscal \u201823, or any particular year, we continue to \nbelieve our previously -announced long -term targets for our businesses and for double -digit combined \nEPS growth and dividend yield are achievable over normalized, longer periods.  \n \n With that, I\u2019ll turn it bac k over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.  \n ", "original_text": "Mike Kaufmann:  Thanks, Jason.  \n "}, "hash": "e632868ca0fbfd675a2378584e8d3283cb551ddeec48c445e9b4924c517aaa36", "class_name": "RelatedNodeInfo"}}, "text": "With that, I\u2019ll turn it bac k over to Mike.  \n \n", "start_char_idx": 2959, "end_char_idx": 3007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc3ffc41-5602-4435-b2ac-697626c13b61": {"__data__": {"id_": "bc3ffc41-5602-4435-b2ac-697626c13b61", "embedding": null, "metadata": {"window": "And with our strong balance sheet, we \nsee the potential for accretive capital deployment through a similar level of share repurchases over \nthe course of the year, supported by the $2.7 billion of authorization remaining on our existing share \nrepurchase program expiring at the end of 2024.  \n \n In summary, while there\u2019s obviously moving parts for f iscal \u201823, or any particular year, we continue to \nbelieve our previously -announced long -term targets for our businesses and for double -digit combined \nEPS growth and dividend yield are achievable over normalized, longer periods.  \n \n With that, I\u2019ll turn it bac k over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.  \n ", "original_text": "Mike Kaufmann:  Thanks, Jason.  \n ", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5", "node_type": "4", "metadata": {"page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "76b354ab6872c0357a4cf258effe78f89bfac987ad4754b52f45e59c1bf5896c", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a4c5154-0f73-450a-8145-ffeb11640f9b", "node_type": "1", "metadata": {"window": "Below the line, we anticipate a year -over-year headwind in our fiscal \u201823 effective tax rate with the \ndiscrete favorability seen in fiscal \u201822 not expected to repeat.  And with our strong balance sheet, we \nsee the potential for accretive capital deployment through a similar level of share repurchases over \nthe course of the year, supported by the $2.7 billion of authorization remaining on our existing share \nrepurchase program expiring at the end of 2024.  \n \n In summary, while there\u2019s obviously moving parts for f iscal \u201823, or any particular year, we continue to \nbelieve our previously -announced long -term targets for our businesses and for double -digit combined \nEPS growth and dividend yield are achievable over normalized, longer periods.  \n \n With that, I\u2019ll turn it bac k over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.  \n ", "original_text": "With that, I\u2019ll turn it bac k over to Mike.  \n \n", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e56f217824b243c5b95d174b9c5c8e19e57a51041f23c99e39b2423b23d47b0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "605bb7fe-0bfd-4ac0-9bda-f81bd93e6273", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \nLet me elaborate on the actions we are taking to drive Medical performance and maximize our \ndifferentiated strengths:  \n \nFirst,  we\u2019re taking pricing actions, evolving our commercial contracting strategies, and  focusing on \ndriving mix across our global business.  We have implemented a series of initial customer price \nincreases on nine Cardinal Health brand product categories.  \n \n We\u2019ve also implemented fee increases for certain Medical National brand suppliers to o ffset some of \nthe elevated supply chain costs.  We provide the most efficient and effective way for manufacturers to \nreach our customers and believe these increases help compensate us for the increased cost of \nproviding this value. ", "original_text": " \nPage 6 of 15 \n \nLet me elaborate on the actions we are taking to drive Medical performance and maximize our \ndifferentiated strengths:  \n \nFirst,  we\u2019re taking pricing actions, evolving our commercial contracting strategies, and  focusing on \ndriving mix across our global business. "}, "hash": "0a8d8cef9fca2acaf85b4af60932f5a9a94c8071d1ba8140b8166d93803ec1af", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Thanks, Jason.  \n ", "start_char_idx": 3007, "end_char_idx": 3041, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "605bb7fe-0bfd-4ac0-9bda-f81bd93e6273": {"__data__": {"id_": "605bb7fe-0bfd-4ac0-9bda-f81bd93e6273", "embedding": null, "metadata": {"window": " \nPage 6 of 15 \n \nLet me elaborate on the actions we are taking to drive Medical performance and maximize our \ndifferentiated strengths:  \n \nFirst,  we\u2019re taking pricing actions, evolving our commercial contracting strategies, and  focusing on \ndriving mix across our global business.  We have implemented a series of initial customer price \nincreases on nine Cardinal Health brand product categories.  \n \n We\u2019ve also implemented fee increases for certain Medical National brand suppliers to o ffset some of \nthe elevated supply chain costs.  We provide the most efficient and effective way for manufacturers to \nreach our customers and believe these increases help compensate us for the increased cost of \nproviding this value. ", "original_text": " \nPage 6 of 15 \n \nLet me elaborate on the actions we are taking to drive Medical performance and maximize our \ndifferentiated strengths:  \n \nFirst,  we\u2019re taking pricing actions, evolving our commercial contracting strategies, and  focusing on \ndriving mix across our global business. ", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78757932bc47d6cef15e552e0b512bbce0dce4779869fa90b30d0d21d3dba90e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc3ffc41-5602-4435-b2ac-697626c13b61", "node_type": "1", "metadata": {"window": "And with our strong balance sheet, we \nsee the potential for accretive capital deployment through a similar level of share repurchases over \nthe course of the year, supported by the $2.7 billion of authorization remaining on our existing share \nrepurchase program expiring at the end of 2024.  \n \n In summary, while there\u2019s obviously moving parts for f iscal \u201823, or any particular year, we continue to \nbelieve our previously -announced long -term targets for our businesses and for double -digit combined \nEPS growth and dividend yield are achievable over normalized, longer periods.  \n \n With that, I\u2019ll turn it bac k over to Mike.  \n \n Mike Kaufmann:  Thanks, Jason.  \n ", "original_text": "Mike Kaufmann:  Thanks, Jason.  \n ", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "842f31c223c76d25adbd78d9cb448ee212ca20c754cc032c53bd910816c1c10d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e2a8f21-decd-405c-9226-2acf33a7b7fb", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \nLet me elaborate on the actions we are taking to drive Medical performance and maximize our \ndifferentiated strengths:  \n \nFirst,  we\u2019re taking pricing actions, evolving our commercial contracting strategies, and  focusing on \ndriving mix across our global business.  We have implemented a series of initial customer price \nincreases on nine Cardinal Health brand product categories.  \n \n We\u2019ve also implemented fee increases for certain Medical National brand suppliers to o ffset some of \nthe elevated supply chain costs.  We provide the most efficient and effective way for manufacturers to \nreach our customers and believe these increases help compensate us for the increased cost of \nproviding this value.  We have and will continue  to be transparent and fair with customers and \nsuppliers, and focused on delivering on our service. ", "original_text": "We have implemented a series of initial customer price \nincreases on nine Cardinal Health brand product categories.  \n \n"}, "hash": "fe5e3a8d953f43761c50482c88e4df7ae144b10c0ada77f7088b24ed55064f06", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 6 of 15 \n \nLet me elaborate on the actions we are taking to drive Medical performance and maximize our \ndifferentiated strengths:  \n \nFirst,  we\u2019re taking pricing actions, evolving our commercial contracting strategies, and  focusing on \ndriving mix across our global business. ", "start_char_idx": 0, "end_char_idx": 285, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e2a8f21-decd-405c-9226-2acf33a7b7fb": {"__data__": {"id_": "2e2a8f21-decd-405c-9226-2acf33a7b7fb", "embedding": null, "metadata": {"window": " \nPage 6 of 15 \n \nLet me elaborate on the actions we are taking to drive Medical performance and maximize our \ndifferentiated strengths:  \n \nFirst,  we\u2019re taking pricing actions, evolving our commercial contracting strategies, and  focusing on \ndriving mix across our global business.  We have implemented a series of initial customer price \nincreases on nine Cardinal Health brand product categories.  \n \n We\u2019ve also implemented fee increases for certain Medical National brand suppliers to o ffset some of \nthe elevated supply chain costs.  We provide the most efficient and effective way for manufacturers to \nreach our customers and believe these increases help compensate us for the increased cost of \nproviding this value.  We have and will continue  to be transparent and fair with customers and \nsuppliers, and focused on delivering on our service. ", "original_text": "We have implemented a series of initial customer price \nincreases on nine Cardinal Health brand product categories.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78757932bc47d6cef15e552e0b512bbce0dce4779869fa90b30d0d21d3dba90e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "605bb7fe-0bfd-4ac0-9bda-f81bd93e6273", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \nLet me elaborate on the actions we are taking to drive Medical performance and maximize our \ndifferentiated strengths:  \n \nFirst,  we\u2019re taking pricing actions, evolving our commercial contracting strategies, and  focusing on \ndriving mix across our global business.  We have implemented a series of initial customer price \nincreases on nine Cardinal Health brand product categories.  \n \n We\u2019ve also implemented fee increases for certain Medical National brand suppliers to o ffset some of \nthe elevated supply chain costs.  We provide the most efficient and effective way for manufacturers to \nreach our customers and believe these increases help compensate us for the increased cost of \nproviding this value. ", "original_text": " \nPage 6 of 15 \n \nLet me elaborate on the actions we are taking to drive Medical performance and maximize our \ndifferentiated strengths:  \n \nFirst,  we\u2019re taking pricing actions, evolving our commercial contracting strategies, and  focusing on \ndriving mix across our global business. ", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "395104c8a329ba5eaaaacae604e515f9aa7aea145fd953c873b4bd5bce5b29f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c2529853-f67a-48c5-bc55-b09174b24e8e", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \nLet me elaborate on the actions we are taking to drive Medical performance and maximize our \ndifferentiated strengths:  \n \nFirst,  we\u2019re taking pricing actions, evolving our commercial contracting strategies, and  focusing on \ndriving mix across our global business.  We have implemented a series of initial customer price \nincreases on nine Cardinal Health brand product categories.  \n \n We\u2019ve also implemented fee increases for certain Medical National brand suppliers to o ffset some of \nthe elevated supply chain costs.  We provide the most efficient and effective way for manufacturers to \nreach our customers and believe these increases help compensate us for the increased cost of \nproviding this value.  We have and will continue  to be transparent and fair with customers and \nsuppliers, and focused on delivering on our service.  As it relates to our products and distribution \ncontracts, we are focusing on future pricing flexibility for factors beyond our control.  \n \n", "original_text": "We\u2019ve also implemented fee increases for certain Medical National brand suppliers to o ffset some of \nthe elevated supply chain costs. "}, "hash": "3074c5d0a6c7df03af5907f4d5daa0c3d5142221dc97ad9e41840f6e7d10d308", "class_name": "RelatedNodeInfo"}}, "text": "We have implemented a series of initial customer price \nincreases on nine Cardinal Health brand product categories.  \n \n", "start_char_idx": 285, "end_char_idx": 405, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c2529853-f67a-48c5-bc55-b09174b24e8e": {"__data__": {"id_": "c2529853-f67a-48c5-bc55-b09174b24e8e", "embedding": null, "metadata": {"window": " \nPage 6 of 15 \n \nLet me elaborate on the actions we are taking to drive Medical performance and maximize our \ndifferentiated strengths:  \n \nFirst,  we\u2019re taking pricing actions, evolving our commercial contracting strategies, and  focusing on \ndriving mix across our global business.  We have implemented a series of initial customer price \nincreases on nine Cardinal Health brand product categories.  \n \n We\u2019ve also implemented fee increases for certain Medical National brand suppliers to o ffset some of \nthe elevated supply chain costs.  We provide the most efficient and effective way for manufacturers to \nreach our customers and believe these increases help compensate us for the increased cost of \nproviding this value.  We have and will continue  to be transparent and fair with customers and \nsuppliers, and focused on delivering on our service.  As it relates to our products and distribution \ncontracts, we are focusing on future pricing flexibility for factors beyond our control.  \n \n", "original_text": "We\u2019ve also implemented fee increases for certain Medical National brand suppliers to o ffset some of \nthe elevated supply chain costs. ", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78757932bc47d6cef15e552e0b512bbce0dce4779869fa90b30d0d21d3dba90e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e2a8f21-decd-405c-9226-2acf33a7b7fb", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \nLet me elaborate on the actions we are taking to drive Medical performance and maximize our \ndifferentiated strengths:  \n \nFirst,  we\u2019re taking pricing actions, evolving our commercial contracting strategies, and  focusing on \ndriving mix across our global business.  We have implemented a series of initial customer price \nincreases on nine Cardinal Health brand product categories.  \n \n We\u2019ve also implemented fee increases for certain Medical National brand suppliers to o ffset some of \nthe elevated supply chain costs.  We provide the most efficient and effective way for manufacturers to \nreach our customers and believe these increases help compensate us for the increased cost of \nproviding this value.  We have and will continue  to be transparent and fair with customers and \nsuppliers, and focused on delivering on our service. ", "original_text": "We have implemented a series of initial customer price \nincreases on nine Cardinal Health brand product categories.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5bcae296f98f41157d3362c6cd8e6d10f4ba3bb17a5fd944f7e2d4464e4abac4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "027e8c4b-bcd3-43fc-973c-2014dae2583f", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \nLet me elaborate on the actions we are taking to drive Medical performance and maximize our \ndifferentiated strengths:  \n \nFirst,  we\u2019re taking pricing actions, evolving our commercial contracting strategies, and  focusing on \ndriving mix across our global business.  We have implemented a series of initial customer price \nincreases on nine Cardinal Health brand product categories.  \n \n We\u2019ve also implemented fee increases for certain Medical National brand suppliers to o ffset some of \nthe elevated supply chain costs.  We provide the most efficient and effective way for manufacturers to \nreach our customers and believe these increases help compensate us for the increased cost of \nproviding this value.  We have and will continue  to be transparent and fair with customers and \nsuppliers, and focused on delivering on our service.  As it relates to our products and distribution \ncontracts, we are focusing on future pricing flexibility for factors beyond our control.  \n \n To drive changes in mix , we\u2019re investing in new and innovative products to increase the breadth of \nour Cardinal Health Brand product portfolio.  \n \n", "original_text": "We provide the most efficient and effective way for manufacturers to \nreach our customers and believe these increases help compensate us for the increased cost of \nproviding this value. "}, "hash": "be2fb24ca94a633ad602ccd9411c17da5ffe444080bb22edf182cdcccf9d34df", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019ve also implemented fee increases for certain Medical National brand suppliers to o ffset some of \nthe elevated supply chain costs. ", "start_char_idx": 405, "end_char_idx": 540, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "027e8c4b-bcd3-43fc-973c-2014dae2583f": {"__data__": {"id_": "027e8c4b-bcd3-43fc-973c-2014dae2583f", "embedding": null, "metadata": {"window": " \nPage 6 of 15 \n \nLet me elaborate on the actions we are taking to drive Medical performance and maximize our \ndifferentiated strengths:  \n \nFirst,  we\u2019re taking pricing actions, evolving our commercial contracting strategies, and  focusing on \ndriving mix across our global business.  We have implemented a series of initial customer price \nincreases on nine Cardinal Health brand product categories.  \n \n We\u2019ve also implemented fee increases for certain Medical National brand suppliers to o ffset some of \nthe elevated supply chain costs.  We provide the most efficient and effective way for manufacturers to \nreach our customers and believe these increases help compensate us for the increased cost of \nproviding this value.  We have and will continue  to be transparent and fair with customers and \nsuppliers, and focused on delivering on our service.  As it relates to our products and distribution \ncontracts, we are focusing on future pricing flexibility for factors beyond our control.  \n \n To drive changes in mix , we\u2019re investing in new and innovative products to increase the breadth of \nour Cardinal Health Brand product portfolio.  \n \n", "original_text": "We provide the most efficient and effective way for manufacturers to \nreach our customers and believe these increases help compensate us for the increased cost of \nproviding this value. ", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78757932bc47d6cef15e552e0b512bbce0dce4779869fa90b30d0d21d3dba90e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c2529853-f67a-48c5-bc55-b09174b24e8e", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \nLet me elaborate on the actions we are taking to drive Medical performance and maximize our \ndifferentiated strengths:  \n \nFirst,  we\u2019re taking pricing actions, evolving our commercial contracting strategies, and  focusing on \ndriving mix across our global business.  We have implemented a series of initial customer price \nincreases on nine Cardinal Health brand product categories.  \n \n We\u2019ve also implemented fee increases for certain Medical National brand suppliers to o ffset some of \nthe elevated supply chain costs.  We provide the most efficient and effective way for manufacturers to \nreach our customers and believe these increases help compensate us for the increased cost of \nproviding this value.  We have and will continue  to be transparent and fair with customers and \nsuppliers, and focused on delivering on our service.  As it relates to our products and distribution \ncontracts, we are focusing on future pricing flexibility for factors beyond our control.  \n \n", "original_text": "We\u2019ve also implemented fee increases for certain Medical National brand suppliers to o ffset some of \nthe elevated supply chain costs. ", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2c59531130c7bcb88c9a39e1f2a9e8675b03a4e8dfa0b41f86de92174d5892b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c089ef74-fc8e-40fa-b18d-57c384e0e374", "node_type": "1", "metadata": {"window": "We have implemented a series of initial customer price \nincreases on nine Cardinal Health brand product categories.  \n \n We\u2019ve also implemented fee increases for certain Medical National brand suppliers to o ffset some of \nthe elevated supply chain costs.  We provide the most efficient and effective way for manufacturers to \nreach our customers and believe these increases help compensate us for the increased cost of \nproviding this value.  We have and will continue  to be transparent and fair with customers and \nsuppliers, and focused on delivering on our service.  As it relates to our products and distribution \ncontracts, we are focusing on future pricing flexibility for factors beyond our control.  \n \n To drive changes in mix , we\u2019re investing in new and innovative products to increase the breadth of \nour Cardinal Health Brand product portfolio.  \n \n One example of increased breadth is our recent launch of the first surgical incise drape using Avery \nDennison\u2019s patented  BeneHold CHG adhesive, which reduces risk of surgical site contamination yet \nstill removes easily after surgery without harming a patient\u2019s skin.  \n \n", "original_text": "We have and will continue  to be transparent and fair with customers and \nsuppliers, and focused on delivering on our service. "}, "hash": "33ba4da121c798122d7d189804e6c29474d5ec16e9ae4f4d6ae89fe6e63290f9", "class_name": "RelatedNodeInfo"}}, "text": "We provide the most efficient and effective way for manufacturers to \nreach our customers and believe these increases help compensate us for the increased cost of \nproviding this value. ", "start_char_idx": 540, "end_char_idx": 726, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c089ef74-fc8e-40fa-b18d-57c384e0e374": {"__data__": {"id_": "c089ef74-fc8e-40fa-b18d-57c384e0e374", "embedding": null, "metadata": {"window": "We have implemented a series of initial customer price \nincreases on nine Cardinal Health brand product categories.  \n \n We\u2019ve also implemented fee increases for certain Medical National brand suppliers to o ffset some of \nthe elevated supply chain costs.  We provide the most efficient and effective way for manufacturers to \nreach our customers and believe these increases help compensate us for the increased cost of \nproviding this value.  We have and will continue  to be transparent and fair with customers and \nsuppliers, and focused on delivering on our service.  As it relates to our products and distribution \ncontracts, we are focusing on future pricing flexibility for factors beyond our control.  \n \n To drive changes in mix , we\u2019re investing in new and innovative products to increase the breadth of \nour Cardinal Health Brand product portfolio.  \n \n One example of increased breadth is our recent launch of the first surgical incise drape using Avery \nDennison\u2019s patented  BeneHold CHG adhesive, which reduces risk of surgical site contamination yet \nstill removes easily after surgery without harming a patient\u2019s skin.  \n \n", "original_text": "We have and will continue  to be transparent and fair with customers and \nsuppliers, and focused on delivering on our service. ", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78757932bc47d6cef15e552e0b512bbce0dce4779869fa90b30d0d21d3dba90e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "027e8c4b-bcd3-43fc-973c-2014dae2583f", "node_type": "1", "metadata": {"window": " \nPage 6 of 15 \n \nLet me elaborate on the actions we are taking to drive Medical performance and maximize our \ndifferentiated strengths:  \n \nFirst,  we\u2019re taking pricing actions, evolving our commercial contracting strategies, and  focusing on \ndriving mix across our global business.  We have implemented a series of initial customer price \nincreases on nine Cardinal Health brand product categories.  \n \n We\u2019ve also implemented fee increases for certain Medical National brand suppliers to o ffset some of \nthe elevated supply chain costs.  We provide the most efficient and effective way for manufacturers to \nreach our customers and believe these increases help compensate us for the increased cost of \nproviding this value.  We have and will continue  to be transparent and fair with customers and \nsuppliers, and focused on delivering on our service.  As it relates to our products and distribution \ncontracts, we are focusing on future pricing flexibility for factors beyond our control.  \n \n To drive changes in mix , we\u2019re investing in new and innovative products to increase the breadth of \nour Cardinal Health Brand product portfolio.  \n \n", "original_text": "We provide the most efficient and effective way for manufacturers to \nreach our customers and believe these increases help compensate us for the increased cost of \nproviding this value. ", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "774ccd2c42d4d994eedf472e15352cf556ce3f9dc5c2a93cdddbd720c4246be0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "070e3616-a37f-42e7-92cc-84f3c9c73398", "node_type": "1", "metadata": {"window": "We\u2019ve also implemented fee increases for certain Medical National brand suppliers to o ffset some of \nthe elevated supply chain costs.  We provide the most efficient and effective way for manufacturers to \nreach our customers and believe these increases help compensate us for the increased cost of \nproviding this value.  We have and will continue  to be transparent and fair with customers and \nsuppliers, and focused on delivering on our service.  As it relates to our products and distribution \ncontracts, we are focusing on future pricing flexibility for factors beyond our control.  \n \n To drive changes in mix , we\u2019re investing in new and innovative products to increase the breadth of \nour Cardinal Health Brand product portfolio.  \n \n One example of increased breadth is our recent launch of the first surgical incise drape using Avery \nDennison\u2019s patented  BeneHold CHG adhesive, which reduces risk of surgical site contamination yet \nstill removes easily after surgery without harming a patient\u2019s skin.  \n \n Another example is our recently announced collaboration with Innara Health, the industry leader in \nfeeding development for newborns and premature infants, to design Innara\u2019s next generation N -\nTrainer System, making it smaller, more intuitive, and eas ier to integrate into NICU feeding protocols.  \n \n", "original_text": "As it relates to our products and distribution \ncontracts, we are focusing on future pricing flexibility for factors beyond our control.  \n \n"}, "hash": "20dc9c44c46a050fc4cc628ae860db1ed5191182969640b1a86591b0b34b4a12", "class_name": "RelatedNodeInfo"}}, "text": "We have and will continue  to be transparent and fair with customers and \nsuppliers, and focused on delivering on our service. ", "start_char_idx": 726, "end_char_idx": 853, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "070e3616-a37f-42e7-92cc-84f3c9c73398": {"__data__": {"id_": "070e3616-a37f-42e7-92cc-84f3c9c73398", "embedding": null, "metadata": {"window": "We\u2019ve also implemented fee increases for certain Medical National brand suppliers to o ffset some of \nthe elevated supply chain costs.  We provide the most efficient and effective way for manufacturers to \nreach our customers and believe these increases help compensate us for the increased cost of \nproviding this value.  We have and will continue  to be transparent and fair with customers and \nsuppliers, and focused on delivering on our service.  As it relates to our products and distribution \ncontracts, we are focusing on future pricing flexibility for factors beyond our control.  \n \n To drive changes in mix , we\u2019re investing in new and innovative products to increase the breadth of \nour Cardinal Health Brand product portfolio.  \n \n One example of increased breadth is our recent launch of the first surgical incise drape using Avery \nDennison\u2019s patented  BeneHold CHG adhesive, which reduces risk of surgical site contamination yet \nstill removes easily after surgery without harming a patient\u2019s skin.  \n \n Another example is our recently announced collaboration with Innara Health, the industry leader in \nfeeding development for newborns and premature infants, to design Innara\u2019s next generation N -\nTrainer System, making it smaller, more intuitive, and eas ier to integrate into NICU feeding protocols.  \n \n", "original_text": "As it relates to our products and distribution \ncontracts, we are focusing on future pricing flexibility for factors beyond our control.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78757932bc47d6cef15e552e0b512bbce0dce4779869fa90b30d0d21d3dba90e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c089ef74-fc8e-40fa-b18d-57c384e0e374", "node_type": "1", "metadata": {"window": "We have implemented a series of initial customer price \nincreases on nine Cardinal Health brand product categories.  \n \n We\u2019ve also implemented fee increases for certain Medical National brand suppliers to o ffset some of \nthe elevated supply chain costs.  We provide the most efficient and effective way for manufacturers to \nreach our customers and believe these increases help compensate us for the increased cost of \nproviding this value.  We have and will continue  to be transparent and fair with customers and \nsuppliers, and focused on delivering on our service.  As it relates to our products and distribution \ncontracts, we are focusing on future pricing flexibility for factors beyond our control.  \n \n To drive changes in mix , we\u2019re investing in new and innovative products to increase the breadth of \nour Cardinal Health Brand product portfolio.  \n \n One example of increased breadth is our recent launch of the first surgical incise drape using Avery \nDennison\u2019s patented  BeneHold CHG adhesive, which reduces risk of surgical site contamination yet \nstill removes easily after surgery without harming a patient\u2019s skin.  \n \n", "original_text": "We have and will continue  to be transparent and fair with customers and \nsuppliers, and focused on delivering on our service. ", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6008bc1c7df6060ab537185993f8991c39c2e3b758c5ae4796cfd4fc30bc083d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a2ecad2-7787-482e-9207-2d508b90051a", "node_type": "1", "metadata": {"window": "We provide the most efficient and effective way for manufacturers to \nreach our customers and believe these increases help compensate us for the increased cost of \nproviding this value.  We have and will continue  to be transparent and fair with customers and \nsuppliers, and focused on delivering on our service.  As it relates to our products and distribution \ncontracts, we are focusing on future pricing flexibility for factors beyond our control.  \n \n To drive changes in mix , we\u2019re investing in new and innovative products to increase the breadth of \nour Cardinal Health Brand product portfolio.  \n \n One example of increased breadth is our recent launch of the first surgical incise drape using Avery \nDennison\u2019s patented  BeneHold CHG adhesive, which reduces risk of surgical site contamination yet \nstill removes easily after surgery without harming a patient\u2019s skin.  \n \n Another example is our recently announced collaboration with Innara Health, the industry leader in \nfeeding development for newborns and premature infants, to design Innara\u2019s next generation N -\nTrainer System, making it smaller, more intuitive, and eas ier to integrate into NICU feeding protocols.  \n \n We are also investing to increase supply capacity, particularly w ithin our ProtexisTM Surgical Glove \nline where we have increased our existing capacity by over 30% with a focus on long -term growth. \n", "original_text": "To drive changes in mix , we\u2019re investing in new and innovative products to increase the breadth of \nour Cardinal Health Brand product portfolio.  \n \n"}, "hash": "25e66955162d7020516d3c7efb2c163340b603ded8f9d33f5774398c65b50f1f", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to our products and distribution \ncontracts, we are focusing on future pricing flexibility for factors beyond our control.  \n \n", "start_char_idx": 853, "end_char_idx": 994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a2ecad2-7787-482e-9207-2d508b90051a": {"__data__": {"id_": "1a2ecad2-7787-482e-9207-2d508b90051a", "embedding": null, "metadata": {"window": "We provide the most efficient and effective way for manufacturers to \nreach our customers and believe these increases help compensate us for the increased cost of \nproviding this value.  We have and will continue  to be transparent and fair with customers and \nsuppliers, and focused on delivering on our service.  As it relates to our products and distribution \ncontracts, we are focusing on future pricing flexibility for factors beyond our control.  \n \n To drive changes in mix , we\u2019re investing in new and innovative products to increase the breadth of \nour Cardinal Health Brand product portfolio.  \n \n One example of increased breadth is our recent launch of the first surgical incise drape using Avery \nDennison\u2019s patented  BeneHold CHG adhesive, which reduces risk of surgical site contamination yet \nstill removes easily after surgery without harming a patient\u2019s skin.  \n \n Another example is our recently announced collaboration with Innara Health, the industry leader in \nfeeding development for newborns and premature infants, to design Innara\u2019s next generation N -\nTrainer System, making it smaller, more intuitive, and eas ier to integrate into NICU feeding protocols.  \n \n We are also investing to increase supply capacity, particularly w ithin our ProtexisTM Surgical Glove \nline where we have increased our existing capacity by over 30% with a focus on long -term growth. \n", "original_text": "To drive changes in mix , we\u2019re investing in new and innovative products to increase the breadth of \nour Cardinal Health Brand product portfolio.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78757932bc47d6cef15e552e0b512bbce0dce4779869fa90b30d0d21d3dba90e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "070e3616-a37f-42e7-92cc-84f3c9c73398", "node_type": "1", "metadata": {"window": "We\u2019ve also implemented fee increases for certain Medical National brand suppliers to o ffset some of \nthe elevated supply chain costs.  We provide the most efficient and effective way for manufacturers to \nreach our customers and believe these increases help compensate us for the increased cost of \nproviding this value.  We have and will continue  to be transparent and fair with customers and \nsuppliers, and focused on delivering on our service.  As it relates to our products and distribution \ncontracts, we are focusing on future pricing flexibility for factors beyond our control.  \n \n To drive changes in mix , we\u2019re investing in new and innovative products to increase the breadth of \nour Cardinal Health Brand product portfolio.  \n \n One example of increased breadth is our recent launch of the first surgical incise drape using Avery \nDennison\u2019s patented  BeneHold CHG adhesive, which reduces risk of surgical site contamination yet \nstill removes easily after surgery without harming a patient\u2019s skin.  \n \n Another example is our recently announced collaboration with Innara Health, the industry leader in \nfeeding development for newborns and premature infants, to design Innara\u2019s next generation N -\nTrainer System, making it smaller, more intuitive, and eas ier to integrate into NICU feeding protocols.  \n \n", "original_text": "As it relates to our products and distribution \ncontracts, we are focusing on future pricing flexibility for factors beyond our control.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0edb4abace1b301592aff6286ddeb71813279fc3d6a16ac55666398e8d4711d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "40151aaa-aff3-4b8e-8a7e-daafac2c0930", "node_type": "1", "metadata": {"window": "We have and will continue  to be transparent and fair with customers and \nsuppliers, and focused on delivering on our service.  As it relates to our products and distribution \ncontracts, we are focusing on future pricing flexibility for factors beyond our control.  \n \n To drive changes in mix , we\u2019re investing in new and innovative products to increase the breadth of \nour Cardinal Health Brand product portfolio.  \n \n One example of increased breadth is our recent launch of the first surgical incise drape using Avery \nDennison\u2019s patented  BeneHold CHG adhesive, which reduces risk of surgical site contamination yet \nstill removes easily after surgery without harming a patient\u2019s skin.  \n \n Another example is our recently announced collaboration with Innara Health, the industry leader in \nfeeding development for newborns and premature infants, to design Innara\u2019s next generation N -\nTrainer System, making it smaller, more intuitive, and eas ier to integrate into NICU feeding protocols.  \n \n We are also investing to increase supply capacity, particularly w ithin our ProtexisTM Surgical Glove \nline where we have increased our existing capacity by over 30% with a focus on long -term growth. \n We expect to invest over $125 million to expand our manufacturing footprint with the construction of a \nnew facility dedicat ed to increase supply of our Protexis\u2122 brand gloves and drive innovation in this \nimportant product portfolio.  \n \n", "original_text": "One example of increased breadth is our recent launch of the first surgical incise drape using Avery \nDennison\u2019s patented  BeneHold CHG adhesive, which reduces risk of surgical site contamination yet \nstill removes easily after surgery without harming a patient\u2019s skin.  \n \n"}, "hash": "246f8766e9c7c25c0936258e7808774b3598da65e9fbc15aa747a179e904ffb6", "class_name": "RelatedNodeInfo"}}, "text": "To drive changes in mix , we\u2019re investing in new and innovative products to increase the breadth of \nour Cardinal Health Brand product portfolio.  \n \n", "start_char_idx": 994, "end_char_idx": 1144, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "40151aaa-aff3-4b8e-8a7e-daafac2c0930": {"__data__": {"id_": "40151aaa-aff3-4b8e-8a7e-daafac2c0930", "embedding": null, "metadata": {"window": "We have and will continue  to be transparent and fair with customers and \nsuppliers, and focused on delivering on our service.  As it relates to our products and distribution \ncontracts, we are focusing on future pricing flexibility for factors beyond our control.  \n \n To drive changes in mix , we\u2019re investing in new and innovative products to increase the breadth of \nour Cardinal Health Brand product portfolio.  \n \n One example of increased breadth is our recent launch of the first surgical incise drape using Avery \nDennison\u2019s patented  BeneHold CHG adhesive, which reduces risk of surgical site contamination yet \nstill removes easily after surgery without harming a patient\u2019s skin.  \n \n Another example is our recently announced collaboration with Innara Health, the industry leader in \nfeeding development for newborns and premature infants, to design Innara\u2019s next generation N -\nTrainer System, making it smaller, more intuitive, and eas ier to integrate into NICU feeding protocols.  \n \n We are also investing to increase supply capacity, particularly w ithin our ProtexisTM Surgical Glove \nline where we have increased our existing capacity by over 30% with a focus on long -term growth. \n We expect to invest over $125 million to expand our manufacturing footprint with the construction of a \nnew facility dedicat ed to increase supply of our Protexis\u2122 brand gloves and drive innovation in this \nimportant product portfolio.  \n \n", "original_text": "One example of increased breadth is our recent launch of the first surgical incise drape using Avery \nDennison\u2019s patented  BeneHold CHG adhesive, which reduces risk of surgical site contamination yet \nstill removes easily after surgery without harming a patient\u2019s skin.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78757932bc47d6cef15e552e0b512bbce0dce4779869fa90b30d0d21d3dba90e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a2ecad2-7787-482e-9207-2d508b90051a", "node_type": "1", "metadata": {"window": "We provide the most efficient and effective way for manufacturers to \nreach our customers and believe these increases help compensate us for the increased cost of \nproviding this value.  We have and will continue  to be transparent and fair with customers and \nsuppliers, and focused on delivering on our service.  As it relates to our products and distribution \ncontracts, we are focusing on future pricing flexibility for factors beyond our control.  \n \n To drive changes in mix , we\u2019re investing in new and innovative products to increase the breadth of \nour Cardinal Health Brand product portfolio.  \n \n One example of increased breadth is our recent launch of the first surgical incise drape using Avery \nDennison\u2019s patented  BeneHold CHG adhesive, which reduces risk of surgical site contamination yet \nstill removes easily after surgery without harming a patient\u2019s skin.  \n \n Another example is our recently announced collaboration with Innara Health, the industry leader in \nfeeding development for newborns and premature infants, to design Innara\u2019s next generation N -\nTrainer System, making it smaller, more intuitive, and eas ier to integrate into NICU feeding protocols.  \n \n We are also investing to increase supply capacity, particularly w ithin our ProtexisTM Surgical Glove \nline where we have increased our existing capacity by over 30% with a focus on long -term growth. \n", "original_text": "To drive changes in mix , we\u2019re investing in new and innovative products to increase the breadth of \nour Cardinal Health Brand product portfolio.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb9bb09285c933e76efd83f18544ddcb2b6c7d453fcbc37ca35be37424acbf43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f226b963-5385-469d-9f1f-071d5d8edd06", "node_type": "1", "metadata": {"window": "As it relates to our products and distribution \ncontracts, we are focusing on future pricing flexibility for factors beyond our control.  \n \n To drive changes in mix , we\u2019re investing in new and innovative products to increase the breadth of \nour Cardinal Health Brand product portfolio.  \n \n One example of increased breadth is our recent launch of the first surgical incise drape using Avery \nDennison\u2019s patented  BeneHold CHG adhesive, which reduces risk of surgical site contamination yet \nstill removes easily after surgery without harming a patient\u2019s skin.  \n \n Another example is our recently announced collaboration with Innara Health, the industry leader in \nfeeding development for newborns and premature infants, to design Innara\u2019s next generation N -\nTrainer System, making it smaller, more intuitive, and eas ier to integrate into NICU feeding protocols.  \n \n We are also investing to increase supply capacity, particularly w ithin our ProtexisTM Surgical Glove \nline where we have increased our existing capacity by over 30% with a focus on long -term growth. \n We expect to invest over $125 million to expand our manufacturing footprint with the construction of a \nnew facility dedicat ed to increase supply of our Protexis\u2122 brand gloves and drive innovation in this \nimportant product portfolio.  \n \n Second, we  are simplifying our operating model, and optimizing our international footprint.  \n \n", "original_text": "Another example is our recently announced collaboration with Innara Health, the industry leader in \nfeeding development for newborns and premature infants, to design Innara\u2019s next generation N -\nTrainer System, making it smaller, more intuitive, and eas ier to integrate into NICU feeding protocols.  \n \n"}, "hash": "424c118ffb254bb95cfc2c38622690aa5c0a6f0a43d4af180e920099b25db5f9", "class_name": "RelatedNodeInfo"}}, "text": "One example of increased breadth is our recent launch of the first surgical incise drape using Avery \nDennison\u2019s patented  BeneHold CHG adhesive, which reduces risk of surgical site contamination yet \nstill removes easily after surgery without harming a patient\u2019s skin.  \n \n", "start_char_idx": 1144, "end_char_idx": 1418, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f226b963-5385-469d-9f1f-071d5d8edd06": {"__data__": {"id_": "f226b963-5385-469d-9f1f-071d5d8edd06", "embedding": null, "metadata": {"window": "As it relates to our products and distribution \ncontracts, we are focusing on future pricing flexibility for factors beyond our control.  \n \n To drive changes in mix , we\u2019re investing in new and innovative products to increase the breadth of \nour Cardinal Health Brand product portfolio.  \n \n One example of increased breadth is our recent launch of the first surgical incise drape using Avery \nDennison\u2019s patented  BeneHold CHG adhesive, which reduces risk of surgical site contamination yet \nstill removes easily after surgery without harming a patient\u2019s skin.  \n \n Another example is our recently announced collaboration with Innara Health, the industry leader in \nfeeding development for newborns and premature infants, to design Innara\u2019s next generation N -\nTrainer System, making it smaller, more intuitive, and eas ier to integrate into NICU feeding protocols.  \n \n We are also investing to increase supply capacity, particularly w ithin our ProtexisTM Surgical Glove \nline where we have increased our existing capacity by over 30% with a focus on long -term growth. \n We expect to invest over $125 million to expand our manufacturing footprint with the construction of a \nnew facility dedicat ed to increase supply of our Protexis\u2122 brand gloves and drive innovation in this \nimportant product portfolio.  \n \n Second, we  are simplifying our operating model, and optimizing our international footprint.  \n \n", "original_text": "Another example is our recently announced collaboration with Innara Health, the industry leader in \nfeeding development for newborns and premature infants, to design Innara\u2019s next generation N -\nTrainer System, making it smaller, more intuitive, and eas ier to integrate into NICU feeding protocols.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78757932bc47d6cef15e552e0b512bbce0dce4779869fa90b30d0d21d3dba90e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "40151aaa-aff3-4b8e-8a7e-daafac2c0930", "node_type": "1", "metadata": {"window": "We have and will continue  to be transparent and fair with customers and \nsuppliers, and focused on delivering on our service.  As it relates to our products and distribution \ncontracts, we are focusing on future pricing flexibility for factors beyond our control.  \n \n To drive changes in mix , we\u2019re investing in new and innovative products to increase the breadth of \nour Cardinal Health Brand product portfolio.  \n \n One example of increased breadth is our recent launch of the first surgical incise drape using Avery \nDennison\u2019s patented  BeneHold CHG adhesive, which reduces risk of surgical site contamination yet \nstill removes easily after surgery without harming a patient\u2019s skin.  \n \n Another example is our recently announced collaboration with Innara Health, the industry leader in \nfeeding development for newborns and premature infants, to design Innara\u2019s next generation N -\nTrainer System, making it smaller, more intuitive, and eas ier to integrate into NICU feeding protocols.  \n \n We are also investing to increase supply capacity, particularly w ithin our ProtexisTM Surgical Glove \nline where we have increased our existing capacity by over 30% with a focus on long -term growth. \n We expect to invest over $125 million to expand our manufacturing footprint with the construction of a \nnew facility dedicat ed to increase supply of our Protexis\u2122 brand gloves and drive innovation in this \nimportant product portfolio.  \n \n", "original_text": "One example of increased breadth is our recent launch of the first surgical incise drape using Avery \nDennison\u2019s patented  BeneHold CHG adhesive, which reduces risk of surgical site contamination yet \nstill removes easily after surgery without harming a patient\u2019s skin.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a29ba079da6b54d68945b8e06d6ee3e05bc6ca48ce2b65378e2078ca2a81f55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5414619a-04e2-4331-ae8c-f9298754a890", "node_type": "1", "metadata": {"window": "To drive changes in mix , we\u2019re investing in new and innovative products to increase the breadth of \nour Cardinal Health Brand product portfolio.  \n \n One example of increased breadth is our recent launch of the first surgical incise drape using Avery \nDennison\u2019s patented  BeneHold CHG adhesive, which reduces risk of surgical site contamination yet \nstill removes easily after surgery without harming a patient\u2019s skin.  \n \n Another example is our recently announced collaboration with Innara Health, the industry leader in \nfeeding development for newborns and premature infants, to design Innara\u2019s next generation N -\nTrainer System, making it smaller, more intuitive, and eas ier to integrate into NICU feeding protocols.  \n \n We are also investing to increase supply capacity, particularly w ithin our ProtexisTM Surgical Glove \nline where we have increased our existing capacity by over 30% with a focus on long -term growth. \n We expect to invest over $125 million to expand our manufacturing footprint with the construction of a \nnew facility dedicat ed to increase supply of our Protexis\u2122 brand gloves and drive innovation in this \nimportant product portfolio.  \n \n Second, we  are simplifying our operating model, and optimizing our international footprint.  \n \n A year ago, we announced our intention to exit 36 ma rkets, and those exits are now complete. ", "original_text": "We are also investing to increase supply capacity, particularly w ithin our ProtexisTM Surgical Glove \nline where we have increased our existing capacity by over 30% with a focus on long -term growth. \n"}, "hash": "f114041fdcdf342765308dddbc248e034d7b15608ef5ec3cac072ed7e60398ad", "class_name": "RelatedNodeInfo"}}, "text": "Another example is our recently announced collaboration with Innara Health, the industry leader in \nfeeding development for newborns and premature infants, to design Innara\u2019s next generation N -\nTrainer System, making it smaller, more intuitive, and eas ier to integrate into NICU feeding protocols.  \n \n", "start_char_idx": 1418, "end_char_idx": 1722, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5414619a-04e2-4331-ae8c-f9298754a890": {"__data__": {"id_": "5414619a-04e2-4331-ae8c-f9298754a890", "embedding": null, "metadata": {"window": "To drive changes in mix , we\u2019re investing in new and innovative products to increase the breadth of \nour Cardinal Health Brand product portfolio.  \n \n One example of increased breadth is our recent launch of the first surgical incise drape using Avery \nDennison\u2019s patented  BeneHold CHG adhesive, which reduces risk of surgical site contamination yet \nstill removes easily after surgery without harming a patient\u2019s skin.  \n \n Another example is our recently announced collaboration with Innara Health, the industry leader in \nfeeding development for newborns and premature infants, to design Innara\u2019s next generation N -\nTrainer System, making it smaller, more intuitive, and eas ier to integrate into NICU feeding protocols.  \n \n We are also investing to increase supply capacity, particularly w ithin our ProtexisTM Surgical Glove \nline where we have increased our existing capacity by over 30% with a focus on long -term growth. \n We expect to invest over $125 million to expand our manufacturing footprint with the construction of a \nnew facility dedicat ed to increase supply of our Protexis\u2122 brand gloves and drive innovation in this \nimportant product portfolio.  \n \n Second, we  are simplifying our operating model, and optimizing our international footprint.  \n \n A year ago, we announced our intention to exit 36 ma rkets, and those exits are now complete. ", "original_text": "We are also investing to increase supply capacity, particularly w ithin our ProtexisTM Surgical Glove \nline where we have increased our existing capacity by over 30% with a focus on long -term growth. \n", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78757932bc47d6cef15e552e0b512bbce0dce4779869fa90b30d0d21d3dba90e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f226b963-5385-469d-9f1f-071d5d8edd06", "node_type": "1", "metadata": {"window": "As it relates to our products and distribution \ncontracts, we are focusing on future pricing flexibility for factors beyond our control.  \n \n To drive changes in mix , we\u2019re investing in new and innovative products to increase the breadth of \nour Cardinal Health Brand product portfolio.  \n \n One example of increased breadth is our recent launch of the first surgical incise drape using Avery \nDennison\u2019s patented  BeneHold CHG adhesive, which reduces risk of surgical site contamination yet \nstill removes easily after surgery without harming a patient\u2019s skin.  \n \n Another example is our recently announced collaboration with Innara Health, the industry leader in \nfeeding development for newborns and premature infants, to design Innara\u2019s next generation N -\nTrainer System, making it smaller, more intuitive, and eas ier to integrate into NICU feeding protocols.  \n \n We are also investing to increase supply capacity, particularly w ithin our ProtexisTM Surgical Glove \nline where we have increased our existing capacity by over 30% with a focus on long -term growth. \n We expect to invest over $125 million to expand our manufacturing footprint with the construction of a \nnew facility dedicat ed to increase supply of our Protexis\u2122 brand gloves and drive innovation in this \nimportant product portfolio.  \n \n Second, we  are simplifying our operating model, and optimizing our international footprint.  \n \n", "original_text": "Another example is our recently announced collaboration with Innara Health, the industry leader in \nfeeding development for newborns and premature infants, to design Innara\u2019s next generation N -\nTrainer System, making it smaller, more intuitive, and eas ier to integrate into NICU feeding protocols.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c22f6761bdc380e226575cf96dae060f4661f52f835a8f875faf2f8a7197898c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f6ca02b-fde3-4949-8abd-d9145328ec9a", "node_type": "1", "metadata": {"window": "One example of increased breadth is our recent launch of the first surgical incise drape using Avery \nDennison\u2019s patented  BeneHold CHG adhesive, which reduces risk of surgical site contamination yet \nstill removes easily after surgery without harming a patient\u2019s skin.  \n \n Another example is our recently announced collaboration with Innara Health, the industry leader in \nfeeding development for newborns and premature infants, to design Innara\u2019s next generation N -\nTrainer System, making it smaller, more intuitive, and eas ier to integrate into NICU feeding protocols.  \n \n We are also investing to increase supply capacity, particularly w ithin our ProtexisTM Surgical Glove \nline where we have increased our existing capacity by over 30% with a focus on long -term growth. \n We expect to invest over $125 million to expand our manufacturing footprint with the construction of a \nnew facility dedicat ed to increase supply of our Protexis\u2122 brand gloves and drive innovation in this \nimportant product portfolio.  \n \n Second, we  are simplifying our operating model, and optimizing our international footprint.  \n \n A year ago, we announced our intention to exit 36 ma rkets, and those exits are now complete.  We \nhave also decided to exit another 10 markets where we see limited opportunity for long -term growth. \n", "original_text": "We expect to invest over $125 million to expand our manufacturing footprint with the construction of a \nnew facility dedicat ed to increase supply of our Protexis\u2122 brand gloves and drive innovation in this \nimportant product portfolio.  \n \n"}, "hash": "5ff088fc656946edb55dfbb709429061697d2bbe30558f391531f393849ee7fb", "class_name": "RelatedNodeInfo"}}, "text": "We are also investing to increase supply capacity, particularly w ithin our ProtexisTM Surgical Glove \nline where we have increased our existing capacity by over 30% with a focus on long -term growth. \n", "start_char_idx": 1722, "end_char_idx": 1924, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f6ca02b-fde3-4949-8abd-d9145328ec9a": {"__data__": {"id_": "0f6ca02b-fde3-4949-8abd-d9145328ec9a", "embedding": null, "metadata": {"window": "One example of increased breadth is our recent launch of the first surgical incise drape using Avery \nDennison\u2019s patented  BeneHold CHG adhesive, which reduces risk of surgical site contamination yet \nstill removes easily after surgery without harming a patient\u2019s skin.  \n \n Another example is our recently announced collaboration with Innara Health, the industry leader in \nfeeding development for newborns and premature infants, to design Innara\u2019s next generation N -\nTrainer System, making it smaller, more intuitive, and eas ier to integrate into NICU feeding protocols.  \n \n We are also investing to increase supply capacity, particularly w ithin our ProtexisTM Surgical Glove \nline where we have increased our existing capacity by over 30% with a focus on long -term growth. \n We expect to invest over $125 million to expand our manufacturing footprint with the construction of a \nnew facility dedicat ed to increase supply of our Protexis\u2122 brand gloves and drive innovation in this \nimportant product portfolio.  \n \n Second, we  are simplifying our operating model, and optimizing our international footprint.  \n \n A year ago, we announced our intention to exit 36 ma rkets, and those exits are now complete.  We \nhave also decided to exit another 10 markets where we see limited opportunity for long -term growth. \n", "original_text": "We expect to invest over $125 million to expand our manufacturing footprint with the construction of a \nnew facility dedicat ed to increase supply of our Protexis\u2122 brand gloves and drive innovation in this \nimportant product portfolio.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78757932bc47d6cef15e552e0b512bbce0dce4779869fa90b30d0d21d3dba90e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5414619a-04e2-4331-ae8c-f9298754a890", "node_type": "1", "metadata": {"window": "To drive changes in mix , we\u2019re investing in new and innovative products to increase the breadth of \nour Cardinal Health Brand product portfolio.  \n \n One example of increased breadth is our recent launch of the first surgical incise drape using Avery \nDennison\u2019s patented  BeneHold CHG adhesive, which reduces risk of surgical site contamination yet \nstill removes easily after surgery without harming a patient\u2019s skin.  \n \n Another example is our recently announced collaboration with Innara Health, the industry leader in \nfeeding development for newborns and premature infants, to design Innara\u2019s next generation N -\nTrainer System, making it smaller, more intuitive, and eas ier to integrate into NICU feeding protocols.  \n \n We are also investing to increase supply capacity, particularly w ithin our ProtexisTM Surgical Glove \nline where we have increased our existing capacity by over 30% with a focus on long -term growth. \n We expect to invest over $125 million to expand our manufacturing footprint with the construction of a \nnew facility dedicat ed to increase supply of our Protexis\u2122 brand gloves and drive innovation in this \nimportant product portfolio.  \n \n Second, we  are simplifying our operating model, and optimizing our international footprint.  \n \n A year ago, we announced our intention to exit 36 ma rkets, and those exits are now complete. ", "original_text": "We are also investing to increase supply capacity, particularly w ithin our ProtexisTM Surgical Glove \nline where we have increased our existing capacity by over 30% with a focus on long -term growth. \n", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f4230f0e4c8b8076a1e943f2ba0e7cd999ff9c19a29e65822bba8a9cf24bace7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e05ac319-81c1-4405-9db8-68c32655f164", "node_type": "1", "metadata": {"window": "Another example is our recently announced collaboration with Innara Health, the industry leader in \nfeeding development for newborns and premature infants, to design Innara\u2019s next generation N -\nTrainer System, making it smaller, more intuitive, and eas ier to integrate into NICU feeding protocols.  \n \n We are also investing to increase supply capacity, particularly w ithin our ProtexisTM Surgical Glove \nline where we have increased our existing capacity by over 30% with a focus on long -term growth. \n We expect to invest over $125 million to expand our manufacturing footprint with the construction of a \nnew facility dedicat ed to increase supply of our Protexis\u2122 brand gloves and drive innovation in this \nimportant product portfolio.  \n \n Second, we  are simplifying our operating model, and optimizing our international footprint.  \n \n A year ago, we announced our intention to exit 36 ma rkets, and those exits are now complete.  We \nhave also decided to exit another 10 markets where we see limited opportunity for long -term growth. \n Once complete, these actions will reduce our international commercial footprint by 50%, allowing us \nto focus on approximately 45 remaining markets where we are best positioned to serve.   \n", "original_text": "Second, we  are simplifying our operating model, and optimizing our international footprint.  \n \n"}, "hash": "e405aca77250e4d6519e53faa805e0328e1069d0a0b51b12abeaad9550af10b7", "class_name": "RelatedNodeInfo"}}, "text": "We expect to invest over $125 million to expand our manufacturing footprint with the construction of a \nnew facility dedicat ed to increase supply of our Protexis\u2122 brand gloves and drive innovation in this \nimportant product portfolio.  \n \n", "start_char_idx": 1924, "end_char_idx": 2164, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e05ac319-81c1-4405-9db8-68c32655f164": {"__data__": {"id_": "e05ac319-81c1-4405-9db8-68c32655f164", "embedding": null, "metadata": {"window": "Another example is our recently announced collaboration with Innara Health, the industry leader in \nfeeding development for newborns and premature infants, to design Innara\u2019s next generation N -\nTrainer System, making it smaller, more intuitive, and eas ier to integrate into NICU feeding protocols.  \n \n We are also investing to increase supply capacity, particularly w ithin our ProtexisTM Surgical Glove \nline where we have increased our existing capacity by over 30% with a focus on long -term growth. \n We expect to invest over $125 million to expand our manufacturing footprint with the construction of a \nnew facility dedicat ed to increase supply of our Protexis\u2122 brand gloves and drive innovation in this \nimportant product portfolio.  \n \n Second, we  are simplifying our operating model, and optimizing our international footprint.  \n \n A year ago, we announced our intention to exit 36 ma rkets, and those exits are now complete.  We \nhave also decided to exit another 10 markets where we see limited opportunity for long -term growth. \n Once complete, these actions will reduce our international commercial footprint by 50%, allowing us \nto focus on approximately 45 remaining markets where we are best positioned to serve.   \n", "original_text": "Second, we  are simplifying our operating model, and optimizing our international footprint.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78757932bc47d6cef15e552e0b512bbce0dce4779869fa90b30d0d21d3dba90e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f6ca02b-fde3-4949-8abd-d9145328ec9a", "node_type": "1", "metadata": {"window": "One example of increased breadth is our recent launch of the first surgical incise drape using Avery \nDennison\u2019s patented  BeneHold CHG adhesive, which reduces risk of surgical site contamination yet \nstill removes easily after surgery without harming a patient\u2019s skin.  \n \n Another example is our recently announced collaboration with Innara Health, the industry leader in \nfeeding development for newborns and premature infants, to design Innara\u2019s next generation N -\nTrainer System, making it smaller, more intuitive, and eas ier to integrate into NICU feeding protocols.  \n \n We are also investing to increase supply capacity, particularly w ithin our ProtexisTM Surgical Glove \nline where we have increased our existing capacity by over 30% with a focus on long -term growth. \n We expect to invest over $125 million to expand our manufacturing footprint with the construction of a \nnew facility dedicat ed to increase supply of our Protexis\u2122 brand gloves and drive innovation in this \nimportant product portfolio.  \n \n Second, we  are simplifying our operating model, and optimizing our international footprint.  \n \n A year ago, we announced our intention to exit 36 ma rkets, and those exits are now complete.  We \nhave also decided to exit another 10 markets where we see limited opportunity for long -term growth. \n", "original_text": "We expect to invest over $125 million to expand our manufacturing footprint with the construction of a \nnew facility dedicat ed to increase supply of our Protexis\u2122 brand gloves and drive innovation in this \nimportant product portfolio.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "06014e808be9489d3646206481c406253e5458737febbef58fe73c7082df49c7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec09fd3b-550c-45ce-b2f8-6ac4d13f832c", "node_type": "1", "metadata": {"window": "We are also investing to increase supply capacity, particularly w ithin our ProtexisTM Surgical Glove \nline where we have increased our existing capacity by over 30% with a focus on long -term growth. \n We expect to invest over $125 million to expand our manufacturing footprint with the construction of a \nnew facility dedicat ed to increase supply of our Protexis\u2122 brand gloves and drive innovation in this \nimportant product portfolio.  \n \n Second, we  are simplifying our operating model, and optimizing our international footprint.  \n \n A year ago, we announced our intention to exit 36 ma rkets, and those exits are now complete.  We \nhave also decided to exit another 10 markets where we see limited opportunity for long -term growth. \n Once complete, these actions will reduce our international commercial footprint by 50%, allowing us \nto focus on approximately 45 remaining markets where we are best positioned to serve.   \n We are also optimizing our distribution network by consolidating less efficient facilities into larger, \nmodern, more efficient distribution centers to deliver improved service to o ur customers. ", "original_text": "A year ago, we announced our intention to exit 36 ma rkets, and those exits are now complete. "}, "hash": "192526cd56ab85b8c030296043bfbda7af8fe4664168ff80f64f603be45319fa", "class_name": "RelatedNodeInfo"}}, "text": "Second, we  are simplifying our operating model, and optimizing our international footprint.  \n \n", "start_char_idx": 2164, "end_char_idx": 2261, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec09fd3b-550c-45ce-b2f8-6ac4d13f832c": {"__data__": {"id_": "ec09fd3b-550c-45ce-b2f8-6ac4d13f832c", "embedding": null, "metadata": {"window": "We are also investing to increase supply capacity, particularly w ithin our ProtexisTM Surgical Glove \nline where we have increased our existing capacity by over 30% with a focus on long -term growth. \n We expect to invest over $125 million to expand our manufacturing footprint with the construction of a \nnew facility dedicat ed to increase supply of our Protexis\u2122 brand gloves and drive innovation in this \nimportant product portfolio.  \n \n Second, we  are simplifying our operating model, and optimizing our international footprint.  \n \n A year ago, we announced our intention to exit 36 ma rkets, and those exits are now complete.  We \nhave also decided to exit another 10 markets where we see limited opportunity for long -term growth. \n Once complete, these actions will reduce our international commercial footprint by 50%, allowing us \nto focus on approximately 45 remaining markets where we are best positioned to serve.   \n We are also optimizing our distribution network by consolidating less efficient facilities into larger, \nmodern, more efficient distribution centers to deliver improved service to o ur customers. ", "original_text": "A year ago, we announced our intention to exit 36 ma rkets, and those exits are now complete. ", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78757932bc47d6cef15e552e0b512bbce0dce4779869fa90b30d0d21d3dba90e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e05ac319-81c1-4405-9db8-68c32655f164", "node_type": "1", "metadata": {"window": "Another example is our recently announced collaboration with Innara Health, the industry leader in \nfeeding development for newborns and premature infants, to design Innara\u2019s next generation N -\nTrainer System, making it smaller, more intuitive, and eas ier to integrate into NICU feeding protocols.  \n \n We are also investing to increase supply capacity, particularly w ithin our ProtexisTM Surgical Glove \nline where we have increased our existing capacity by over 30% with a focus on long -term growth. \n We expect to invest over $125 million to expand our manufacturing footprint with the construction of a \nnew facility dedicat ed to increase supply of our Protexis\u2122 brand gloves and drive innovation in this \nimportant product portfolio.  \n \n Second, we  are simplifying our operating model, and optimizing our international footprint.  \n \n A year ago, we announced our intention to exit 36 ma rkets, and those exits are now complete.  We \nhave also decided to exit another 10 markets where we see limited opportunity for long -term growth. \n Once complete, these actions will reduce our international commercial footprint by 50%, allowing us \nto focus on approximately 45 remaining markets where we are best positioned to serve.   \n", "original_text": "Second, we  are simplifying our operating model, and optimizing our international footprint.  \n \n", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eb724c5e22e78b2c5f08542bf109a9e24a902f17dcac92b0a9f71e2df78456fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d916785-c4d2-4407-b562-55cc80253357", "node_type": "1", "metadata": {"window": "We expect to invest over $125 million to expand our manufacturing footprint with the construction of a \nnew facility dedicat ed to increase supply of our Protexis\u2122 brand gloves and drive innovation in this \nimportant product portfolio.  \n \n Second, we  are simplifying our operating model, and optimizing our international footprint.  \n \n A year ago, we announced our intention to exit 36 ma rkets, and those exits are now complete.  We \nhave also decided to exit another 10 markets where we see limited opportunity for long -term growth. \n Once complete, these actions will reduce our international commercial footprint by 50%, allowing us \nto focus on approximately 45 remaining markets where we are best positioned to serve.   \n We are also optimizing our distribution network by consolidating less efficient facilities into larger, \nmodern, more efficient distribution centers to deliver improved service to o ur customers.  For example, \nwe recently announced plans to build a new approximately 600,000 square foot medical distribution \ncenter in central Ohio, replacing a smaller facility nearby. ", "original_text": "We \nhave also decided to exit another 10 markets where we see limited opportunity for long -term growth. \n"}, "hash": "07d455d02f340573873c0233c224abe9cd8569391bc5fde94d1b0f1908b3a363", "class_name": "RelatedNodeInfo"}}, "text": "A year ago, we announced our intention to exit 36 ma rkets, and those exits are now complete. ", "start_char_idx": 2261, "end_char_idx": 2355, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d916785-c4d2-4407-b562-55cc80253357": {"__data__": {"id_": "6d916785-c4d2-4407-b562-55cc80253357", "embedding": null, "metadata": {"window": "We expect to invest over $125 million to expand our manufacturing footprint with the construction of a \nnew facility dedicat ed to increase supply of our Protexis\u2122 brand gloves and drive innovation in this \nimportant product portfolio.  \n \n Second, we  are simplifying our operating model, and optimizing our international footprint.  \n \n A year ago, we announced our intention to exit 36 ma rkets, and those exits are now complete.  We \nhave also decided to exit another 10 markets where we see limited opportunity for long -term growth. \n Once complete, these actions will reduce our international commercial footprint by 50%, allowing us \nto focus on approximately 45 remaining markets where we are best positioned to serve.   \n We are also optimizing our distribution network by consolidating less efficient facilities into larger, \nmodern, more efficient distribution centers to deliver improved service to o ur customers.  For example, \nwe recently announced plans to build a new approximately 600,000 square foot medical distribution \ncenter in central Ohio, replacing a smaller facility nearby. ", "original_text": "We \nhave also decided to exit another 10 markets where we see limited opportunity for long -term growth. \n", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78757932bc47d6cef15e552e0b512bbce0dce4779869fa90b30d0d21d3dba90e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec09fd3b-550c-45ce-b2f8-6ac4d13f832c", "node_type": "1", "metadata": {"window": "We are also investing to increase supply capacity, particularly w ithin our ProtexisTM Surgical Glove \nline where we have increased our existing capacity by over 30% with a focus on long -term growth. \n We expect to invest over $125 million to expand our manufacturing footprint with the construction of a \nnew facility dedicat ed to increase supply of our Protexis\u2122 brand gloves and drive innovation in this \nimportant product portfolio.  \n \n Second, we  are simplifying our operating model, and optimizing our international footprint.  \n \n A year ago, we announced our intention to exit 36 ma rkets, and those exits are now complete.  We \nhave also decided to exit another 10 markets where we see limited opportunity for long -term growth. \n Once complete, these actions will reduce our international commercial footprint by 50%, allowing us \nto focus on approximately 45 remaining markets where we are best positioned to serve.   \n We are also optimizing our distribution network by consolidating less efficient facilities into larger, \nmodern, more efficient distribution centers to deliver improved service to o ur customers. ", "original_text": "A year ago, we announced our intention to exit 36 ma rkets, and those exits are now complete. ", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad2c3ba194be5ec4a32faf455a03ece38ef6028499f46a1d2ba278a586f70ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3d8d0f1-0aeb-437e-ab3b-326cc243dcd0", "node_type": "1", "metadata": {"window": "Second, we  are simplifying our operating model, and optimizing our international footprint.  \n \n A year ago, we announced our intention to exit 36 ma rkets, and those exits are now complete.  We \nhave also decided to exit another 10 markets where we see limited opportunity for long -term growth. \n Once complete, these actions will reduce our international commercial footprint by 50%, allowing us \nto focus on approximately 45 remaining markets where we are best positioned to serve.   \n We are also optimizing our distribution network by consolidating less efficient facilities into larger, \nmodern, more efficient distribution centers to deliver improved service to o ur customers.  For example, \nwe recently announced plans to build a new approximately 600,000 square foot medical distribution \ncenter in central Ohio, replacing a smaller facility nearby.  This new facility \u2013 along with others we \nhave planned \u2013 will improve s ervice and quality; deliver operational efficiencies; and better support \nfluctuations in volume and labor.  \n ", "original_text": "Once complete, these actions will reduce our international commercial footprint by 50%, allowing us \nto focus on approximately 45 remaining markets where we are best positioned to serve.   \n"}, "hash": "332bedf94f4015f2a7e191d2c15cc67c256561f669fe2009e1d6e1679b6b7e16", "class_name": "RelatedNodeInfo"}}, "text": "We \nhave also decided to exit another 10 markets where we see limited opportunity for long -term growth. \n", "start_char_idx": 2355, "end_char_idx": 2461, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3d8d0f1-0aeb-437e-ab3b-326cc243dcd0": {"__data__": {"id_": "d3d8d0f1-0aeb-437e-ab3b-326cc243dcd0", "embedding": null, "metadata": {"window": "Second, we  are simplifying our operating model, and optimizing our international footprint.  \n \n A year ago, we announced our intention to exit 36 ma rkets, and those exits are now complete.  We \nhave also decided to exit another 10 markets where we see limited opportunity for long -term growth. \n Once complete, these actions will reduce our international commercial footprint by 50%, allowing us \nto focus on approximately 45 remaining markets where we are best positioned to serve.   \n We are also optimizing our distribution network by consolidating less efficient facilities into larger, \nmodern, more efficient distribution centers to deliver improved service to o ur customers.  For example, \nwe recently announced plans to build a new approximately 600,000 square foot medical distribution \ncenter in central Ohio, replacing a smaller facility nearby.  This new facility \u2013 along with others we \nhave planned \u2013 will improve s ervice and quality; deliver operational efficiencies; and better support \nfluctuations in volume and labor.  \n ", "original_text": "Once complete, these actions will reduce our international commercial footprint by 50%, allowing us \nto focus on approximately 45 remaining markets where we are best positioned to serve.   \n", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78757932bc47d6cef15e552e0b512bbce0dce4779869fa90b30d0d21d3dba90e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d916785-c4d2-4407-b562-55cc80253357", "node_type": "1", "metadata": {"window": "We expect to invest over $125 million to expand our manufacturing footprint with the construction of a \nnew facility dedicat ed to increase supply of our Protexis\u2122 brand gloves and drive innovation in this \nimportant product portfolio.  \n \n Second, we  are simplifying our operating model, and optimizing our international footprint.  \n \n A year ago, we announced our intention to exit 36 ma rkets, and those exits are now complete.  We \nhave also decided to exit another 10 markets where we see limited opportunity for long -term growth. \n Once complete, these actions will reduce our international commercial footprint by 50%, allowing us \nto focus on approximately 45 remaining markets where we are best positioned to serve.   \n We are also optimizing our distribution network by consolidating less efficient facilities into larger, \nmodern, more efficient distribution centers to deliver improved service to o ur customers.  For example, \nwe recently announced plans to build a new approximately 600,000 square foot medical distribution \ncenter in central Ohio, replacing a smaller facility nearby. ", "original_text": "We \nhave also decided to exit another 10 markets where we see limited opportunity for long -term growth. \n", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f64a5a4879cd866a37aa0695b8495a8211419971914977ff906ce7a72f70ba89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b0e4d8d-13ab-448b-8367-83c4af4ee5e6", "node_type": "1", "metadata": {"window": "A year ago, we announced our intention to exit 36 ma rkets, and those exits are now complete.  We \nhave also decided to exit another 10 markets where we see limited opportunity for long -term growth. \n Once complete, these actions will reduce our international commercial footprint by 50%, allowing us \nto focus on approximately 45 remaining markets where we are best positioned to serve.   \n We are also optimizing our distribution network by consolidating less efficient facilities into larger, \nmodern, more efficient distribution centers to deliver improved service to o ur customers.  For example, \nwe recently announced plans to build a new approximately 600,000 square foot medical distribution \ncenter in central Ohio, replacing a smaller facility nearby.  This new facility \u2013 along with others we \nhave planned \u2013 will improve s ervice and quality; deliver operational efficiencies; and better support \nfluctuations in volume and labor.  \n ", "original_text": "We are also optimizing our distribution network by consolidating less efficient facilities into larger, \nmodern, more efficient distribution centers to deliver improved service to o ur customers. "}, "hash": "eaaeb3165a642129f8e83b5c8d801f75ea7d1321d3cae0c5eb0278dbd3a1ea39", "class_name": "RelatedNodeInfo"}}, "text": "Once complete, these actions will reduce our international commercial footprint by 50%, allowing us \nto focus on approximately 45 remaining markets where we are best positioned to serve.   \n", "start_char_idx": 2461, "end_char_idx": 2651, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b0e4d8d-13ab-448b-8367-83c4af4ee5e6": {"__data__": {"id_": "7b0e4d8d-13ab-448b-8367-83c4af4ee5e6", "embedding": null, "metadata": {"window": "A year ago, we announced our intention to exit 36 ma rkets, and those exits are now complete.  We \nhave also decided to exit another 10 markets where we see limited opportunity for long -term growth. \n Once complete, these actions will reduce our international commercial footprint by 50%, allowing us \nto focus on approximately 45 remaining markets where we are best positioned to serve.   \n We are also optimizing our distribution network by consolidating less efficient facilities into larger, \nmodern, more efficient distribution centers to deliver improved service to o ur customers.  For example, \nwe recently announced plans to build a new approximately 600,000 square foot medical distribution \ncenter in central Ohio, replacing a smaller facility nearby.  This new facility \u2013 along with others we \nhave planned \u2013 will improve s ervice and quality; deliver operational efficiencies; and better support \nfluctuations in volume and labor.  \n ", "original_text": "We are also optimizing our distribution network by consolidating less efficient facilities into larger, \nmodern, more efficient distribution centers to deliver improved service to o ur customers. ", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78757932bc47d6cef15e552e0b512bbce0dce4779869fa90b30d0d21d3dba90e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3d8d0f1-0aeb-437e-ab3b-326cc243dcd0", "node_type": "1", "metadata": {"window": "Second, we  are simplifying our operating model, and optimizing our international footprint.  \n \n A year ago, we announced our intention to exit 36 ma rkets, and those exits are now complete.  We \nhave also decided to exit another 10 markets where we see limited opportunity for long -term growth. \n Once complete, these actions will reduce our international commercial footprint by 50%, allowing us \nto focus on approximately 45 remaining markets where we are best positioned to serve.   \n We are also optimizing our distribution network by consolidating less efficient facilities into larger, \nmodern, more efficient distribution centers to deliver improved service to o ur customers.  For example, \nwe recently announced plans to build a new approximately 600,000 square foot medical distribution \ncenter in central Ohio, replacing a smaller facility nearby.  This new facility \u2013 along with others we \nhave planned \u2013 will improve s ervice and quality; deliver operational efficiencies; and better support \nfluctuations in volume and labor.  \n ", "original_text": "Once complete, these actions will reduce our international commercial footprint by 50%, allowing us \nto focus on approximately 45 remaining markets where we are best positioned to serve.   \n", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8c18a66db200e675a7937119a41d0bdaaaaab1652ce8d19df8465386a8cde8f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b47b381-f505-4337-ae37-92b5caa91be9", "node_type": "1", "metadata": {"window": "We \nhave also decided to exit another 10 markets where we see limited opportunity for long -term growth. \n Once complete, these actions will reduce our international commercial footprint by 50%, allowing us \nto focus on approximately 45 remaining markets where we are best positioned to serve.   \n We are also optimizing our distribution network by consolidating less efficient facilities into larger, \nmodern, more efficient distribution centers to deliver improved service to o ur customers.  For example, \nwe recently announced plans to build a new approximately 600,000 square foot medical distribution \ncenter in central Ohio, replacing a smaller facility nearby.  This new facility \u2013 along with others we \nhave planned \u2013 will improve s ervice and quality; deliver operational efficiencies; and better support \nfluctuations in volume and labor.  \n ", "original_text": "For example, \nwe recently announced plans to build a new approximately 600,000 square foot medical distribution \ncenter in central Ohio, replacing a smaller facility nearby. "}, "hash": "740b2426ab206b9107b746fdd270a759edb40c8aa4064b08ee02a6938f02944d", "class_name": "RelatedNodeInfo"}}, "text": "We are also optimizing our distribution network by consolidating less efficient facilities into larger, \nmodern, more efficient distribution centers to deliver improved service to o ur customers. ", "start_char_idx": 2651, "end_char_idx": 2847, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b47b381-f505-4337-ae37-92b5caa91be9": {"__data__": {"id_": "6b47b381-f505-4337-ae37-92b5caa91be9", "embedding": null, "metadata": {"window": "We \nhave also decided to exit another 10 markets where we see limited opportunity for long -term growth. \n Once complete, these actions will reduce our international commercial footprint by 50%, allowing us \nto focus on approximately 45 remaining markets where we are best positioned to serve.   \n We are also optimizing our distribution network by consolidating less efficient facilities into larger, \nmodern, more efficient distribution centers to deliver improved service to o ur customers.  For example, \nwe recently announced plans to build a new approximately 600,000 square foot medical distribution \ncenter in central Ohio, replacing a smaller facility nearby.  This new facility \u2013 along with others we \nhave planned \u2013 will improve s ervice and quality; deliver operational efficiencies; and better support \nfluctuations in volume and labor.  \n ", "original_text": "For example, \nwe recently announced plans to build a new approximately 600,000 square foot medical distribution \ncenter in central Ohio, replacing a smaller facility nearby. ", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78757932bc47d6cef15e552e0b512bbce0dce4779869fa90b30d0d21d3dba90e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b0e4d8d-13ab-448b-8367-83c4af4ee5e6", "node_type": "1", "metadata": {"window": "A year ago, we announced our intention to exit 36 ma rkets, and those exits are now complete.  We \nhave also decided to exit another 10 markets where we see limited opportunity for long -term growth. \n Once complete, these actions will reduce our international commercial footprint by 50%, allowing us \nto focus on approximately 45 remaining markets where we are best positioned to serve.   \n We are also optimizing our distribution network by consolidating less efficient facilities into larger, \nmodern, more efficient distribution centers to deliver improved service to o ur customers.  For example, \nwe recently announced plans to build a new approximately 600,000 square foot medical distribution \ncenter in central Ohio, replacing a smaller facility nearby.  This new facility \u2013 along with others we \nhave planned \u2013 will improve s ervice and quality; deliver operational efficiencies; and better support \nfluctuations in volume and labor.  \n ", "original_text": "We are also optimizing our distribution network by consolidating less efficient facilities into larger, \nmodern, more efficient distribution centers to deliver improved service to o ur customers. ", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fc171b7efc93aec342524a90b6680d6b5caa2021a9c59a3e6941867e13a6204f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76b98b59-e7c1-4ef2-a0ca-c38c769e0fe1", "node_type": "1", "metadata": {"window": "Once complete, these actions will reduce our international commercial footprint by 50%, allowing us \nto focus on approximately 45 remaining markets where we are best positioned to serve.   \n We are also optimizing our distribution network by consolidating less efficient facilities into larger, \nmodern, more efficient distribution centers to deliver improved service to o ur customers.  For example, \nwe recently announced plans to build a new approximately 600,000 square foot medical distribution \ncenter in central Ohio, replacing a smaller facility nearby.  This new facility \u2013 along with others we \nhave planned \u2013 will improve s ervice and quality; deliver operational efficiencies; and better support \nfluctuations in volume and labor.  \n ", "original_text": "This new facility \u2013 along with others we \nhave planned \u2013 will improve s ervice and quality; deliver operational efficiencies; and better support \nfluctuations in volume and labor.  \n "}, "hash": "c48dfad1fc0644d32539f5728561e7c20488582ad61ed624c18a52210051ed96", "class_name": "RelatedNodeInfo"}}, "text": "For example, \nwe recently announced plans to build a new approximately 600,000 square foot medical distribution \ncenter in central Ohio, replacing a smaller facility nearby. ", "start_char_idx": 2847, "end_char_idx": 3021, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76b98b59-e7c1-4ef2-a0ca-c38c769e0fe1": {"__data__": {"id_": "76b98b59-e7c1-4ef2-a0ca-c38c769e0fe1", "embedding": null, "metadata": {"window": "Once complete, these actions will reduce our international commercial footprint by 50%, allowing us \nto focus on approximately 45 remaining markets where we are best positioned to serve.   \n We are also optimizing our distribution network by consolidating less efficient facilities into larger, \nmodern, more efficient distribution centers to deliver improved service to o ur customers.  For example, \nwe recently announced plans to build a new approximately 600,000 square foot medical distribution \ncenter in central Ohio, replacing a smaller facility nearby.  This new facility \u2013 along with others we \nhave planned \u2013 will improve s ervice and quality; deliver operational efficiencies; and better support \nfluctuations in volume and labor.  \n ", "original_text": "This new facility \u2013 along with others we \nhave planned \u2013 will improve s ervice and quality; deliver operational efficiencies; and better support \nfluctuations in volume and labor.  \n ", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9", "node_type": "4", "metadata": {"page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "78757932bc47d6cef15e552e0b512bbce0dce4779869fa90b30d0d21d3dba90e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b47b381-f505-4337-ae37-92b5caa91be9", "node_type": "1", "metadata": {"window": "We \nhave also decided to exit another 10 markets where we see limited opportunity for long -term growth. \n Once complete, these actions will reduce our international commercial footprint by 50%, allowing us \nto focus on approximately 45 remaining markets where we are best positioned to serve.   \n We are also optimizing our distribution network by consolidating less efficient facilities into larger, \nmodern, more efficient distribution centers to deliver improved service to o ur customers.  For example, \nwe recently announced plans to build a new approximately 600,000 square foot medical distribution \ncenter in central Ohio, replacing a smaller facility nearby.  This new facility \u2013 along with others we \nhave planned \u2013 will improve s ervice and quality; deliver operational efficiencies; and better support \nfluctuations in volume and labor.  \n ", "original_text": "For example, \nwe recently announced plans to build a new approximately 600,000 square foot medical distribution \ncenter in central Ohio, replacing a smaller facility nearby. ", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24b573c9aaa56312aebfdab57a8d5b40160b6cd2be7ce33eeeea2b86a41521b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "485fcd1d-ee29-411e-8806-1f79d3552621", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nAdditionally, our Lab business is consolidating manufacturing and warehouse space into a new, \nlarger 100,000 square foot facility.  This move centra lizes our high -growth lab kitting services and \nsupports significant expansion of our direct -to-consumer kitting capabilities.  \n \n Third,  in addition to investing in our core Medical business, we continue to invest in our growth \nbusinesses, at -Home Solutions and Medical Services, which are aligned with industry trends.  \n \n In at-Home Solutions, we continue to see strong demand as care continue s to shift into the home. ", "original_text": " \nPage 7 of 15 \n \nAdditionally, our Lab business is consolidating manufacturing and warehouse space into a new, \nlarger 100,000 square foot facility. "}, "hash": "e2f325796cbeec20c3eef9e544b86d2a3af066afc2a540b65b85394c73e869d4", "class_name": "RelatedNodeInfo"}}, "text": "This new facility \u2013 along with others we \nhave planned \u2013 will improve s ervice and quality; deliver operational efficiencies; and better support \nfluctuations in volume and labor.  \n ", "start_char_idx": 3021, "end_char_idx": 3204, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "485fcd1d-ee29-411e-8806-1f79d3552621": {"__data__": {"id_": "485fcd1d-ee29-411e-8806-1f79d3552621", "embedding": null, "metadata": {"window": " \nPage 7 of 15 \n \nAdditionally, our Lab business is consolidating manufacturing and warehouse space into a new, \nlarger 100,000 square foot facility.  This move centra lizes our high -growth lab kitting services and \nsupports significant expansion of our direct -to-consumer kitting capabilities.  \n \n Third,  in addition to investing in our core Medical business, we continue to invest in our growth \nbusinesses, at -Home Solutions and Medical Services, which are aligned with industry trends.  \n \n In at-Home Solutions, we continue to see strong demand as care continue s to shift into the home. ", "original_text": " \nPage 7 of 15 \n \nAdditionally, our Lab business is consolidating manufacturing and warehouse space into a new, \nlarger 100,000 square foot facility. ", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b950ea21a1b6cb34fd9fd54b6f7062ab2e908e786bd237a86896e277923e4563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76b98b59-e7c1-4ef2-a0ca-c38c769e0fe1", "node_type": "1", "metadata": {"window": "Once complete, these actions will reduce our international commercial footprint by 50%, allowing us \nto focus on approximately 45 remaining markets where we are best positioned to serve.   \n We are also optimizing our distribution network by consolidating less efficient facilities into larger, \nmodern, more efficient distribution centers to deliver improved service to o ur customers.  For example, \nwe recently announced plans to build a new approximately 600,000 square foot medical distribution \ncenter in central Ohio, replacing a smaller facility nearby.  This new facility \u2013 along with others we \nhave planned \u2013 will improve s ervice and quality; deliver operational efficiencies; and better support \nfluctuations in volume and labor.  \n ", "original_text": "This new facility \u2013 along with others we \nhave planned \u2013 will improve s ervice and quality; deliver operational efficiencies; and better support \nfluctuations in volume and labor.  \n ", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0a7dca56a6c3ea751b4bf9b7d2c2927ccf586f8a7139be69e3784d2a6c808e99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ffaeead9-2797-4a33-b6d7-403e1b7528c7", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nAdditionally, our Lab business is consolidating manufacturing and warehouse space into a new, \nlarger 100,000 square foot facility.  This move centra lizes our high -growth lab kitting services and \nsupports significant expansion of our direct -to-consumer kitting capabilities.  \n \n Third,  in addition to investing in our core Medical business, we continue to invest in our growth \nbusinesses, at -Home Solutions and Medical Services, which are aligned with industry trends.  \n \n In at-Home Solutions, we continue to see strong demand as care continue s to shift into the home.  We \nrecently partnered with Kinaxis to optimize digital supply chain planning, increase medical product \nvisibility and supply chain agility. ", "original_text": "This move centra lizes our high -growth lab kitting services and \nsupports significant expansion of our direct -to-consumer kitting capabilities.  \n \n"}, "hash": "a2afbf63811f25180bb5aa439a0e0d1677275ca11d7dc7aba3271e1dc35b906f", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 7 of 15 \n \nAdditionally, our Lab business is consolidating manufacturing and warehouse space into a new, \nlarger 100,000 square foot facility. ", "start_char_idx": 0, "end_char_idx": 150, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ffaeead9-2797-4a33-b6d7-403e1b7528c7": {"__data__": {"id_": "ffaeead9-2797-4a33-b6d7-403e1b7528c7", "embedding": null, "metadata": {"window": " \nPage 7 of 15 \n \nAdditionally, our Lab business is consolidating manufacturing and warehouse space into a new, \nlarger 100,000 square foot facility.  This move centra lizes our high -growth lab kitting services and \nsupports significant expansion of our direct -to-consumer kitting capabilities.  \n \n Third,  in addition to investing in our core Medical business, we continue to invest in our growth \nbusinesses, at -Home Solutions and Medical Services, which are aligned with industry trends.  \n \n In at-Home Solutions, we continue to see strong demand as care continue s to shift into the home.  We \nrecently partnered with Kinaxis to optimize digital supply chain planning, increase medical product \nvisibility and supply chain agility. ", "original_text": "This move centra lizes our high -growth lab kitting services and \nsupports significant expansion of our direct -to-consumer kitting capabilities.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b950ea21a1b6cb34fd9fd54b6f7062ab2e908e786bd237a86896e277923e4563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "485fcd1d-ee29-411e-8806-1f79d3552621", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nAdditionally, our Lab business is consolidating manufacturing and warehouse space into a new, \nlarger 100,000 square foot facility.  This move centra lizes our high -growth lab kitting services and \nsupports significant expansion of our direct -to-consumer kitting capabilities.  \n \n Third,  in addition to investing in our core Medical business, we continue to invest in our growth \nbusinesses, at -Home Solutions and Medical Services, which are aligned with industry trends.  \n \n In at-Home Solutions, we continue to see strong demand as care continue s to shift into the home. ", "original_text": " \nPage 7 of 15 \n \nAdditionally, our Lab business is consolidating manufacturing and warehouse space into a new, \nlarger 100,000 square foot facility. ", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cccb54cd75e45b6b468ebfb51416dff6cbd0c02a3f397641796e28d526aa8968", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c33e6f22-c8c1-437e-a9b9-1b567be2e47e", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nAdditionally, our Lab business is consolidating manufacturing and warehouse space into a new, \nlarger 100,000 square foot facility.  This move centra lizes our high -growth lab kitting services and \nsupports significant expansion of our direct -to-consumer kitting capabilities.  \n \n Third,  in addition to investing in our core Medical business, we continue to invest in our growth \nbusinesses, at -Home Solutions and Medical Services, which are aligned with industry trends.  \n \n In at-Home Solutions, we continue to see strong demand as care continue s to shift into the home.  We \nrecently partnered with Kinaxis to optimize digital supply chain planning, increase medical product \nvisibility and supply chain agility.  We\u2019re focusing initial implementation of Kinaxis\u2019 RapidResponse \nplatform within at -Home So lutions with an expected completion date this summer. ", "original_text": "Third,  in addition to investing in our core Medical business, we continue to invest in our growth \nbusinesses, at -Home Solutions and Medical Services, which are aligned with industry trends.  \n \n"}, "hash": "683c6f9e490c8e893c0e57ff6fc01a7bae594c33bd892f0fcc8b8dc9283e08a9", "class_name": "RelatedNodeInfo"}}, "text": "This move centra lizes our high -growth lab kitting services and \nsupports significant expansion of our direct -to-consumer kitting capabilities.  \n \n", "start_char_idx": 150, "end_char_idx": 300, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c33e6f22-c8c1-437e-a9b9-1b567be2e47e": {"__data__": {"id_": "c33e6f22-c8c1-437e-a9b9-1b567be2e47e", "embedding": null, "metadata": {"window": " \nPage 7 of 15 \n \nAdditionally, our Lab business is consolidating manufacturing and warehouse space into a new, \nlarger 100,000 square foot facility.  This move centra lizes our high -growth lab kitting services and \nsupports significant expansion of our direct -to-consumer kitting capabilities.  \n \n Third,  in addition to investing in our core Medical business, we continue to invest in our growth \nbusinesses, at -Home Solutions and Medical Services, which are aligned with industry trends.  \n \n In at-Home Solutions, we continue to see strong demand as care continue s to shift into the home.  We \nrecently partnered with Kinaxis to optimize digital supply chain planning, increase medical product \nvisibility and supply chain agility.  We\u2019re focusing initial implementation of Kinaxis\u2019 RapidResponse \nplatform within at -Home So lutions with an expected completion date this summer. ", "original_text": "Third,  in addition to investing in our core Medical business, we continue to invest in our growth \nbusinesses, at -Home Solutions and Medical Services, which are aligned with industry trends.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b950ea21a1b6cb34fd9fd54b6f7062ab2e908e786bd237a86896e277923e4563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ffaeead9-2797-4a33-b6d7-403e1b7528c7", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nAdditionally, our Lab business is consolidating manufacturing and warehouse space into a new, \nlarger 100,000 square foot facility.  This move centra lizes our high -growth lab kitting services and \nsupports significant expansion of our direct -to-consumer kitting capabilities.  \n \n Third,  in addition to investing in our core Medical business, we continue to invest in our growth \nbusinesses, at -Home Solutions and Medical Services, which are aligned with industry trends.  \n \n In at-Home Solutions, we continue to see strong demand as care continue s to shift into the home.  We \nrecently partnered with Kinaxis to optimize digital supply chain planning, increase medical product \nvisibility and supply chain agility. ", "original_text": "This move centra lizes our high -growth lab kitting services and \nsupports significant expansion of our direct -to-consumer kitting capabilities.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa64a34fa77c3c6ccad883d3d1501843c72850070401a81bb74f42a3cc7cb56c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c392311-48ed-4495-81b4-b05150443507", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nAdditionally, our Lab business is consolidating manufacturing and warehouse space into a new, \nlarger 100,000 square foot facility.  This move centra lizes our high -growth lab kitting services and \nsupports significant expansion of our direct -to-consumer kitting capabilities.  \n \n Third,  in addition to investing in our core Medical business, we continue to invest in our growth \nbusinesses, at -Home Solutions and Medical Services, which are aligned with industry trends.  \n \n In at-Home Solutions, we continue to see strong demand as care continue s to shift into the home.  We \nrecently partnered with Kinaxis to optimize digital supply chain planning, increase medical product \nvisibility and supply chain agility.  We\u2019re focusing initial implementation of Kinaxis\u2019 RapidResponse \nplatform within at -Home So lutions with an expected completion date this summer.  Furthermore, we\u2019ve \ninvested in a new warehouse management system across our at -Home Solutions network, which we \nexpect to roll out next week. ", "original_text": "In at-Home Solutions, we continue to see strong demand as care continue s to shift into the home. "}, "hash": "43f7c013f70e78503a10b0e2323d1a7a58e95627224aaa688fc20deb249f30d5", "class_name": "RelatedNodeInfo"}}, "text": "Third,  in addition to investing in our core Medical business, we continue to invest in our growth \nbusinesses, at -Home Solutions and Medical Services, which are aligned with industry trends.  \n \n", "start_char_idx": 300, "end_char_idx": 497, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c392311-48ed-4495-81b4-b05150443507": {"__data__": {"id_": "9c392311-48ed-4495-81b4-b05150443507", "embedding": null, "metadata": {"window": " \nPage 7 of 15 \n \nAdditionally, our Lab business is consolidating manufacturing and warehouse space into a new, \nlarger 100,000 square foot facility.  This move centra lizes our high -growth lab kitting services and \nsupports significant expansion of our direct -to-consumer kitting capabilities.  \n \n Third,  in addition to investing in our core Medical business, we continue to invest in our growth \nbusinesses, at -Home Solutions and Medical Services, which are aligned with industry trends.  \n \n In at-Home Solutions, we continue to see strong demand as care continue s to shift into the home.  We \nrecently partnered with Kinaxis to optimize digital supply chain planning, increase medical product \nvisibility and supply chain agility.  We\u2019re focusing initial implementation of Kinaxis\u2019 RapidResponse \nplatform within at -Home So lutions with an expected completion date this summer.  Furthermore, we\u2019ve \ninvested in a new warehouse management system across our at -Home Solutions network, which we \nexpect to roll out next week. ", "original_text": "In at-Home Solutions, we continue to see strong demand as care continue s to shift into the home. ", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b950ea21a1b6cb34fd9fd54b6f7062ab2e908e786bd237a86896e277923e4563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c33e6f22-c8c1-437e-a9b9-1b567be2e47e", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nAdditionally, our Lab business is consolidating manufacturing and warehouse space into a new, \nlarger 100,000 square foot facility.  This move centra lizes our high -growth lab kitting services and \nsupports significant expansion of our direct -to-consumer kitting capabilities.  \n \n Third,  in addition to investing in our core Medical business, we continue to invest in our growth \nbusinesses, at -Home Solutions and Medical Services, which are aligned with industry trends.  \n \n In at-Home Solutions, we continue to see strong demand as care continue s to shift into the home.  We \nrecently partnered with Kinaxis to optimize digital supply chain planning, increase medical product \nvisibility and supply chain agility.  We\u2019re focusing initial implementation of Kinaxis\u2019 RapidResponse \nplatform within at -Home So lutions with an expected completion date this summer. ", "original_text": "Third,  in addition to investing in our core Medical business, we continue to invest in our growth \nbusinesses, at -Home Solutions and Medical Services, which are aligned with industry trends.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bc707c0e3a796ea5d8a3b21c4d609d50e04c48c1db087fdc27866a8b422b3996", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19934eeb-9f06-470d-8db3-a703dec1e5c6", "node_type": "1", "metadata": {"window": "This move centra lizes our high -growth lab kitting services and \nsupports significant expansion of our direct -to-consumer kitting capabilities.  \n \n Third,  in addition to investing in our core Medical business, we continue to invest in our growth \nbusinesses, at -Home Solutions and Medical Services, which are aligned with industry trends.  \n \n In at-Home Solutions, we continue to see strong demand as care continue s to shift into the home.  We \nrecently partnered with Kinaxis to optimize digital supply chain planning, increase medical product \nvisibility and supply chain agility.  We\u2019re focusing initial implementation of Kinaxis\u2019 RapidResponse \nplatform within at -Home So lutions with an expected completion date this summer.  Furthermore, we\u2019ve \ninvested in a new warehouse management system across our at -Home Solutions network, which we \nexpect to roll out next week.  This new infrastructure will improve labor planning based on  demand, \nincrease operating efficiencies to deliver on our commitments, and streamline and standardize \nprocesses across our at -Home network. ", "original_text": "We \nrecently partnered with Kinaxis to optimize digital supply chain planning, increase medical product \nvisibility and supply chain agility. "}, "hash": "8486da2bca67ad9b14b4b03d813cc4ef1289e40451a29373dc99e663f8bd03fa", "class_name": "RelatedNodeInfo"}}, "text": "In at-Home Solutions, we continue to see strong demand as care continue s to shift into the home. ", "start_char_idx": 497, "end_char_idx": 595, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19934eeb-9f06-470d-8db3-a703dec1e5c6": {"__data__": {"id_": "19934eeb-9f06-470d-8db3-a703dec1e5c6", "embedding": null, "metadata": {"window": "This move centra lizes our high -growth lab kitting services and \nsupports significant expansion of our direct -to-consumer kitting capabilities.  \n \n Third,  in addition to investing in our core Medical business, we continue to invest in our growth \nbusinesses, at -Home Solutions and Medical Services, which are aligned with industry trends.  \n \n In at-Home Solutions, we continue to see strong demand as care continue s to shift into the home.  We \nrecently partnered with Kinaxis to optimize digital supply chain planning, increase medical product \nvisibility and supply chain agility.  We\u2019re focusing initial implementation of Kinaxis\u2019 RapidResponse \nplatform within at -Home So lutions with an expected completion date this summer.  Furthermore, we\u2019ve \ninvested in a new warehouse management system across our at -Home Solutions network, which we \nexpect to roll out next week.  This new infrastructure will improve labor planning based on  demand, \nincrease operating efficiencies to deliver on our commitments, and streamline and standardize \nprocesses across our at -Home network. ", "original_text": "We \nrecently partnered with Kinaxis to optimize digital supply chain planning, increase medical product \nvisibility and supply chain agility. ", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b950ea21a1b6cb34fd9fd54b6f7062ab2e908e786bd237a86896e277923e4563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c392311-48ed-4495-81b4-b05150443507", "node_type": "1", "metadata": {"window": " \nPage 7 of 15 \n \nAdditionally, our Lab business is consolidating manufacturing and warehouse space into a new, \nlarger 100,000 square foot facility.  This move centra lizes our high -growth lab kitting services and \nsupports significant expansion of our direct -to-consumer kitting capabilities.  \n \n Third,  in addition to investing in our core Medical business, we continue to invest in our growth \nbusinesses, at -Home Solutions and Medical Services, which are aligned with industry trends.  \n \n In at-Home Solutions, we continue to see strong demand as care continue s to shift into the home.  We \nrecently partnered with Kinaxis to optimize digital supply chain planning, increase medical product \nvisibility and supply chain agility.  We\u2019re focusing initial implementation of Kinaxis\u2019 RapidResponse \nplatform within at -Home So lutions with an expected completion date this summer.  Furthermore, we\u2019ve \ninvested in a new warehouse management system across our at -Home Solutions network, which we \nexpect to roll out next week. ", "original_text": "In at-Home Solutions, we continue to see strong demand as care continue s to shift into the home. ", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "29e59c1543798fa8f887fb8379e7b35e01176d0bbb7a23b31b0c0dd94281d87a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75e80953-b548-4afa-8766-3efbddba1cfc", "node_type": "1", "metadata": {"window": "Third,  in addition to investing in our core Medical business, we continue to invest in our growth \nbusinesses, at -Home Solutions and Medical Services, which are aligned with industry trends.  \n \n In at-Home Solutions, we continue to see strong demand as care continue s to shift into the home.  We \nrecently partnered with Kinaxis to optimize digital supply chain planning, increase medical product \nvisibility and supply chain agility.  We\u2019re focusing initial implementation of Kinaxis\u2019 RapidResponse \nplatform within at -Home So lutions with an expected completion date this summer.  Furthermore, we\u2019ve \ninvested in a new warehouse management system across our at -Home Solutions network, which we \nexpect to roll out next week.  This new infrastructure will improve labor planning based on  demand, \nincrease operating efficiencies to deliver on our commitments, and streamline and standardize \nprocesses across our at -Home network.  We\u2019re initiating a multi -year strategy to grow our warehouse \nfootprint for at -Home Solutions in target markets, and  will announce details for a new warehouse \nopening later this calendar year.  \n \n", "original_text": "We\u2019re focusing initial implementation of Kinaxis\u2019 RapidResponse \nplatform within at -Home So lutions with an expected completion date this summer. "}, "hash": "2a85de489b4eb63bd0bce4ef4db5e9b9b98a438d897d7985cb54657234ee3993", "class_name": "RelatedNodeInfo"}}, "text": "We \nrecently partnered with Kinaxis to optimize digital supply chain planning, increase medical product \nvisibility and supply chain agility. ", "start_char_idx": 595, "end_char_idx": 737, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75e80953-b548-4afa-8766-3efbddba1cfc": {"__data__": {"id_": "75e80953-b548-4afa-8766-3efbddba1cfc", "embedding": null, "metadata": {"window": "Third,  in addition to investing in our core Medical business, we continue to invest in our growth \nbusinesses, at -Home Solutions and Medical Services, which are aligned with industry trends.  \n \n In at-Home Solutions, we continue to see strong demand as care continue s to shift into the home.  We \nrecently partnered with Kinaxis to optimize digital supply chain planning, increase medical product \nvisibility and supply chain agility.  We\u2019re focusing initial implementation of Kinaxis\u2019 RapidResponse \nplatform within at -Home So lutions with an expected completion date this summer.  Furthermore, we\u2019ve \ninvested in a new warehouse management system across our at -Home Solutions network, which we \nexpect to roll out next week.  This new infrastructure will improve labor planning based on  demand, \nincrease operating efficiencies to deliver on our commitments, and streamline and standardize \nprocesses across our at -Home network.  We\u2019re initiating a multi -year strategy to grow our warehouse \nfootprint for at -Home Solutions in target markets, and  will announce details for a new warehouse \nopening later this calendar year.  \n \n", "original_text": "We\u2019re focusing initial implementation of Kinaxis\u2019 RapidResponse \nplatform within at -Home So lutions with an expected completion date this summer. ", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b950ea21a1b6cb34fd9fd54b6f7062ab2e908e786bd237a86896e277923e4563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19934eeb-9f06-470d-8db3-a703dec1e5c6", "node_type": "1", "metadata": {"window": "This move centra lizes our high -growth lab kitting services and \nsupports significant expansion of our direct -to-consumer kitting capabilities.  \n \n Third,  in addition to investing in our core Medical business, we continue to invest in our growth \nbusinesses, at -Home Solutions and Medical Services, which are aligned with industry trends.  \n \n In at-Home Solutions, we continue to see strong demand as care continue s to shift into the home.  We \nrecently partnered with Kinaxis to optimize digital supply chain planning, increase medical product \nvisibility and supply chain agility.  We\u2019re focusing initial implementation of Kinaxis\u2019 RapidResponse \nplatform within at -Home So lutions with an expected completion date this summer.  Furthermore, we\u2019ve \ninvested in a new warehouse management system across our at -Home Solutions network, which we \nexpect to roll out next week.  This new infrastructure will improve labor planning based on  demand, \nincrease operating efficiencies to deliver on our commitments, and streamline and standardize \nprocesses across our at -Home network. ", "original_text": "We \nrecently partnered with Kinaxis to optimize digital supply chain planning, increase medical product \nvisibility and supply chain agility. ", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a49bf025f7dc322a15e54df88b699c7653fe34eb74c6d5bb918091a9dc404a5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ba627ec-7812-4e20-8fc9-5117d3495605", "node_type": "1", "metadata": {"window": "In at-Home Solutions, we continue to see strong demand as care continue s to shift into the home.  We \nrecently partnered with Kinaxis to optimize digital supply chain planning, increase medical product \nvisibility and supply chain agility.  We\u2019re focusing initial implementation of Kinaxis\u2019 RapidResponse \nplatform within at -Home So lutions with an expected completion date this summer.  Furthermore, we\u2019ve \ninvested in a new warehouse management system across our at -Home Solutions network, which we \nexpect to roll out next week.  This new infrastructure will improve labor planning based on  demand, \nincrease operating efficiencies to deliver on our commitments, and streamline and standardize \nprocesses across our at -Home network.  We\u2019re initiating a multi -year strategy to grow our warehouse \nfootprint for at -Home Solutions in target markets, and  will announce details for a new warehouse \nopening later this calendar year.  \n \n And in our higher -margin, technology -enabled Medical Services businesses OptiFreight\u00ae Logistics \nand WaveMark, we\u2019ve invested in additional technology capabilities to expand our o fferings in both \nbusinesses.  \n \n", "original_text": "Furthermore, we\u2019ve \ninvested in a new warehouse management system across our at -Home Solutions network, which we \nexpect to roll out next week. "}, "hash": "853cdcdb8934d2c190976fc09989470bea59f8d33314ee271a1380a2f3abac4d", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re focusing initial implementation of Kinaxis\u2019 RapidResponse \nplatform within at -Home So lutions with an expected completion date this summer. ", "start_char_idx": 737, "end_char_idx": 884, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ba627ec-7812-4e20-8fc9-5117d3495605": {"__data__": {"id_": "3ba627ec-7812-4e20-8fc9-5117d3495605", "embedding": null, "metadata": {"window": "In at-Home Solutions, we continue to see strong demand as care continue s to shift into the home.  We \nrecently partnered with Kinaxis to optimize digital supply chain planning, increase medical product \nvisibility and supply chain agility.  We\u2019re focusing initial implementation of Kinaxis\u2019 RapidResponse \nplatform within at -Home So lutions with an expected completion date this summer.  Furthermore, we\u2019ve \ninvested in a new warehouse management system across our at -Home Solutions network, which we \nexpect to roll out next week.  This new infrastructure will improve labor planning based on  demand, \nincrease operating efficiencies to deliver on our commitments, and streamline and standardize \nprocesses across our at -Home network.  We\u2019re initiating a multi -year strategy to grow our warehouse \nfootprint for at -Home Solutions in target markets, and  will announce details for a new warehouse \nopening later this calendar year.  \n \n And in our higher -margin, technology -enabled Medical Services businesses OptiFreight\u00ae Logistics \nand WaveMark, we\u2019ve invested in additional technology capabilities to expand our o fferings in both \nbusinesses.  \n \n", "original_text": "Furthermore, we\u2019ve \ninvested in a new warehouse management system across our at -Home Solutions network, which we \nexpect to roll out next week. ", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b950ea21a1b6cb34fd9fd54b6f7062ab2e908e786bd237a86896e277923e4563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75e80953-b548-4afa-8766-3efbddba1cfc", "node_type": "1", "metadata": {"window": "Third,  in addition to investing in our core Medical business, we continue to invest in our growth \nbusinesses, at -Home Solutions and Medical Services, which are aligned with industry trends.  \n \n In at-Home Solutions, we continue to see strong demand as care continue s to shift into the home.  We \nrecently partnered with Kinaxis to optimize digital supply chain planning, increase medical product \nvisibility and supply chain agility.  We\u2019re focusing initial implementation of Kinaxis\u2019 RapidResponse \nplatform within at -Home So lutions with an expected completion date this summer.  Furthermore, we\u2019ve \ninvested in a new warehouse management system across our at -Home Solutions network, which we \nexpect to roll out next week.  This new infrastructure will improve labor planning based on  demand, \nincrease operating efficiencies to deliver on our commitments, and streamline and standardize \nprocesses across our at -Home network.  We\u2019re initiating a multi -year strategy to grow our warehouse \nfootprint for at -Home Solutions in target markets, and  will announce details for a new warehouse \nopening later this calendar year.  \n \n", "original_text": "We\u2019re focusing initial implementation of Kinaxis\u2019 RapidResponse \nplatform within at -Home So lutions with an expected completion date this summer. ", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba20fee77a45fa89465df914c926e01162ed04feccb2adf66f8e43876845e282", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d957f2d5-1247-4735-8d0f-97747db3432c", "node_type": "1", "metadata": {"window": "We \nrecently partnered with Kinaxis to optimize digital supply chain planning, increase medical product \nvisibility and supply chain agility.  We\u2019re focusing initial implementation of Kinaxis\u2019 RapidResponse \nplatform within at -Home So lutions with an expected completion date this summer.  Furthermore, we\u2019ve \ninvested in a new warehouse management system across our at -Home Solutions network, which we \nexpect to roll out next week.  This new infrastructure will improve labor planning based on  demand, \nincrease operating efficiencies to deliver on our commitments, and streamline and standardize \nprocesses across our at -Home network.  We\u2019re initiating a multi -year strategy to grow our warehouse \nfootprint for at -Home Solutions in target markets, and  will announce details for a new warehouse \nopening later this calendar year.  \n \n And in our higher -margin, technology -enabled Medical Services businesses OptiFreight\u00ae Logistics \nand WaveMark, we\u2019ve invested in additional technology capabilities to expand our o fferings in both \nbusinesses.  \n \n Turning to Pharma, we continue to make progress on our two primary objectives:  \n \nFirst, strengthening our core Pharma Distribution business.  \n \n", "original_text": "This new infrastructure will improve labor planning based on  demand, \nincrease operating efficiencies to deliver on our commitments, and streamline and standardize \nprocesses across our at -Home network. "}, "hash": "e4ec4d59786448e8a9faf7955e03d8be8d2b698ad41fbef87a71d7c23e15677c", "class_name": "RelatedNodeInfo"}}, "text": "Furthermore, we\u2019ve \ninvested in a new warehouse management system across our at -Home Solutions network, which we \nexpect to roll out next week. ", "start_char_idx": 884, "end_char_idx": 1029, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d957f2d5-1247-4735-8d0f-97747db3432c": {"__data__": {"id_": "d957f2d5-1247-4735-8d0f-97747db3432c", "embedding": null, "metadata": {"window": "We \nrecently partnered with Kinaxis to optimize digital supply chain planning, increase medical product \nvisibility and supply chain agility.  We\u2019re focusing initial implementation of Kinaxis\u2019 RapidResponse \nplatform within at -Home So lutions with an expected completion date this summer.  Furthermore, we\u2019ve \ninvested in a new warehouse management system across our at -Home Solutions network, which we \nexpect to roll out next week.  This new infrastructure will improve labor planning based on  demand, \nincrease operating efficiencies to deliver on our commitments, and streamline and standardize \nprocesses across our at -Home network.  We\u2019re initiating a multi -year strategy to grow our warehouse \nfootprint for at -Home Solutions in target markets, and  will announce details for a new warehouse \nopening later this calendar year.  \n \n And in our higher -margin, technology -enabled Medical Services businesses OptiFreight\u00ae Logistics \nand WaveMark, we\u2019ve invested in additional technology capabilities to expand our o fferings in both \nbusinesses.  \n \n Turning to Pharma, we continue to make progress on our two primary objectives:  \n \nFirst, strengthening our core Pharma Distribution business.  \n \n", "original_text": "This new infrastructure will improve labor planning based on  demand, \nincrease operating efficiencies to deliver on our commitments, and streamline and standardize \nprocesses across our at -Home network. ", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b950ea21a1b6cb34fd9fd54b6f7062ab2e908e786bd237a86896e277923e4563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ba627ec-7812-4e20-8fc9-5117d3495605", "node_type": "1", "metadata": {"window": "In at-Home Solutions, we continue to see strong demand as care continue s to shift into the home.  We \nrecently partnered with Kinaxis to optimize digital supply chain planning, increase medical product \nvisibility and supply chain agility.  We\u2019re focusing initial implementation of Kinaxis\u2019 RapidResponse \nplatform within at -Home So lutions with an expected completion date this summer.  Furthermore, we\u2019ve \ninvested in a new warehouse management system across our at -Home Solutions network, which we \nexpect to roll out next week.  This new infrastructure will improve labor planning based on  demand, \nincrease operating efficiencies to deliver on our commitments, and streamline and standardize \nprocesses across our at -Home network.  We\u2019re initiating a multi -year strategy to grow our warehouse \nfootprint for at -Home Solutions in target markets, and  will announce details for a new warehouse \nopening later this calendar year.  \n \n And in our higher -margin, technology -enabled Medical Services businesses OptiFreight\u00ae Logistics \nand WaveMark, we\u2019ve invested in additional technology capabilities to expand our o fferings in both \nbusinesses.  \n \n", "original_text": "Furthermore, we\u2019ve \ninvested in a new warehouse management system across our at -Home Solutions network, which we \nexpect to roll out next week. ", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b333ca4f86351d949f3970ac30393eafc2c086ade7b2a8996bfe63de2e111a86", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c80b159-113b-4b58-9e08-eb3d9ea55149", "node_type": "1", "metadata": {"window": "We\u2019re focusing initial implementation of Kinaxis\u2019 RapidResponse \nplatform within at -Home So lutions with an expected completion date this summer.  Furthermore, we\u2019ve \ninvested in a new warehouse management system across our at -Home Solutions network, which we \nexpect to roll out next week.  This new infrastructure will improve labor planning based on  demand, \nincrease operating efficiencies to deliver on our commitments, and streamline and standardize \nprocesses across our at -Home network.  We\u2019re initiating a multi -year strategy to grow our warehouse \nfootprint for at -Home Solutions in target markets, and  will announce details for a new warehouse \nopening later this calendar year.  \n \n And in our higher -margin, technology -enabled Medical Services businesses OptiFreight\u00ae Logistics \nand WaveMark, we\u2019ve invested in additional technology capabilities to expand our o fferings in both \nbusinesses.  \n \n Turning to Pharma, we continue to make progress on our two primary objectives:  \n \nFirst, strengthening our core Pharma Distribution business.  \n \n We have completed all deployments of our multi -year investment to modernize our pharmaceutical IT \ninfrastructure in order to standardize operations, drive efficiencies and enhance the customer \nexperience. ", "original_text": "We\u2019re initiating a multi -year strategy to grow our warehouse \nfootprint for at -Home Solutions in target markets, and  will announce details for a new warehouse \nopening later this calendar year.  \n \n"}, "hash": "9268a38aba5c5faf209617be7f9683f6352c463fa81ca499d45468ddbd0d957e", "class_name": "RelatedNodeInfo"}}, "text": "This new infrastructure will improve labor planning based on  demand, \nincrease operating efficiencies to deliver on our commitments, and streamline and standardize \nprocesses across our at -Home network. ", "start_char_idx": 1029, "end_char_idx": 1234, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c80b159-113b-4b58-9e08-eb3d9ea55149": {"__data__": {"id_": "1c80b159-113b-4b58-9e08-eb3d9ea55149", "embedding": null, "metadata": {"window": "We\u2019re focusing initial implementation of Kinaxis\u2019 RapidResponse \nplatform within at -Home So lutions with an expected completion date this summer.  Furthermore, we\u2019ve \ninvested in a new warehouse management system across our at -Home Solutions network, which we \nexpect to roll out next week.  This new infrastructure will improve labor planning based on  demand, \nincrease operating efficiencies to deliver on our commitments, and streamline and standardize \nprocesses across our at -Home network.  We\u2019re initiating a multi -year strategy to grow our warehouse \nfootprint for at -Home Solutions in target markets, and  will announce details for a new warehouse \nopening later this calendar year.  \n \n And in our higher -margin, technology -enabled Medical Services businesses OptiFreight\u00ae Logistics \nand WaveMark, we\u2019ve invested in additional technology capabilities to expand our o fferings in both \nbusinesses.  \n \n Turning to Pharma, we continue to make progress on our two primary objectives:  \n \nFirst, strengthening our core Pharma Distribution business.  \n \n We have completed all deployments of our multi -year investment to modernize our pharmaceutical IT \ninfrastructure in order to standardize operations, drive efficiencies and enhance the customer \nexperience. ", "original_text": "We\u2019re initiating a multi -year strategy to grow our warehouse \nfootprint for at -Home Solutions in target markets, and  will announce details for a new warehouse \nopening later this calendar year.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b950ea21a1b6cb34fd9fd54b6f7062ab2e908e786bd237a86896e277923e4563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d957f2d5-1247-4735-8d0f-97747db3432c", "node_type": "1", "metadata": {"window": "We \nrecently partnered with Kinaxis to optimize digital supply chain planning, increase medical product \nvisibility and supply chain agility.  We\u2019re focusing initial implementation of Kinaxis\u2019 RapidResponse \nplatform within at -Home So lutions with an expected completion date this summer.  Furthermore, we\u2019ve \ninvested in a new warehouse management system across our at -Home Solutions network, which we \nexpect to roll out next week.  This new infrastructure will improve labor planning based on  demand, \nincrease operating efficiencies to deliver on our commitments, and streamline and standardize \nprocesses across our at -Home network.  We\u2019re initiating a multi -year strategy to grow our warehouse \nfootprint for at -Home Solutions in target markets, and  will announce details for a new warehouse \nopening later this calendar year.  \n \n And in our higher -margin, technology -enabled Medical Services businesses OptiFreight\u00ae Logistics \nand WaveMark, we\u2019ve invested in additional technology capabilities to expand our o fferings in both \nbusinesses.  \n \n Turning to Pharma, we continue to make progress on our two primary objectives:  \n \nFirst, strengthening our core Pharma Distribution business.  \n \n", "original_text": "This new infrastructure will improve labor planning based on  demand, \nincrease operating efficiencies to deliver on our commitments, and streamline and standardize \nprocesses across our at -Home network. ", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "09c5083570de746a949a22073ca3fde34e647e81bfecfccb06b06709a6cfdb24", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ed03923-6fb4-4799-9b59-e4687bd881b0", "node_type": "1", "metadata": {"window": "Furthermore, we\u2019ve \ninvested in a new warehouse management system across our at -Home Solutions network, which we \nexpect to roll out next week.  This new infrastructure will improve labor planning based on  demand, \nincrease operating efficiencies to deliver on our commitments, and streamline and standardize \nprocesses across our at -Home network.  We\u2019re initiating a multi -year strategy to grow our warehouse \nfootprint for at -Home Solutions in target markets, and  will announce details for a new warehouse \nopening later this calendar year.  \n \n And in our higher -margin, technology -enabled Medical Services businesses OptiFreight\u00ae Logistics \nand WaveMark, we\u2019ve invested in additional technology capabilities to expand our o fferings in both \nbusinesses.  \n \n Turning to Pharma, we continue to make progress on our two primary objectives:  \n \nFirst, strengthening our core Pharma Distribution business.  \n \n We have completed all deployments of our multi -year investment to modernize our pharmaceutical IT \ninfrastructure in order to standardize operations, drive efficiencies and enhance the customer \nexperience.  These investments, including the automation of business procedures and real -time line of \nsight transparency for our e mployees and customers, will result in operational efficiencies and a more \nconnected pharmaceutical distribution supply chain. ", "original_text": "And in our higher -margin, technology -enabled Medical Services businesses OptiFreight\u00ae Logistics \nand WaveMark, we\u2019ve invested in additional technology capabilities to expand our o fferings in both \nbusinesses.  \n \n"}, "hash": "e003006896846029ff2addfbfd3268a3603ea56dcb8278f7f15ff33ac189f466", "class_name": "RelatedNodeInfo"}}, "text": "We\u2019re initiating a multi -year strategy to grow our warehouse \nfootprint for at -Home Solutions in target markets, and  will announce details for a new warehouse \nopening later this calendar year.  \n \n", "start_char_idx": 1234, "end_char_idx": 1435, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ed03923-6fb4-4799-9b59-e4687bd881b0": {"__data__": {"id_": "5ed03923-6fb4-4799-9b59-e4687bd881b0", "embedding": null, "metadata": {"window": "Furthermore, we\u2019ve \ninvested in a new warehouse management system across our at -Home Solutions network, which we \nexpect to roll out next week.  This new infrastructure will improve labor planning based on  demand, \nincrease operating efficiencies to deliver on our commitments, and streamline and standardize \nprocesses across our at -Home network.  We\u2019re initiating a multi -year strategy to grow our warehouse \nfootprint for at -Home Solutions in target markets, and  will announce details for a new warehouse \nopening later this calendar year.  \n \n And in our higher -margin, technology -enabled Medical Services businesses OptiFreight\u00ae Logistics \nand WaveMark, we\u2019ve invested in additional technology capabilities to expand our o fferings in both \nbusinesses.  \n \n Turning to Pharma, we continue to make progress on our two primary objectives:  \n \nFirst, strengthening our core Pharma Distribution business.  \n \n We have completed all deployments of our multi -year investment to modernize our pharmaceutical IT \ninfrastructure in order to standardize operations, drive efficiencies and enhance the customer \nexperience.  These investments, including the automation of business procedures and real -time line of \nsight transparency for our e mployees and customers, will result in operational efficiencies and a more \nconnected pharmaceutical distribution supply chain. ", "original_text": "And in our higher -margin, technology -enabled Medical Services businesses OptiFreight\u00ae Logistics \nand WaveMark, we\u2019ve invested in additional technology capabilities to expand our o fferings in both \nbusinesses.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b950ea21a1b6cb34fd9fd54b6f7062ab2e908e786bd237a86896e277923e4563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c80b159-113b-4b58-9e08-eb3d9ea55149", "node_type": "1", "metadata": {"window": "We\u2019re focusing initial implementation of Kinaxis\u2019 RapidResponse \nplatform within at -Home So lutions with an expected completion date this summer.  Furthermore, we\u2019ve \ninvested in a new warehouse management system across our at -Home Solutions network, which we \nexpect to roll out next week.  This new infrastructure will improve labor planning based on  demand, \nincrease operating efficiencies to deliver on our commitments, and streamline and standardize \nprocesses across our at -Home network.  We\u2019re initiating a multi -year strategy to grow our warehouse \nfootprint for at -Home Solutions in target markets, and  will announce details for a new warehouse \nopening later this calendar year.  \n \n And in our higher -margin, technology -enabled Medical Services businesses OptiFreight\u00ae Logistics \nand WaveMark, we\u2019ve invested in additional technology capabilities to expand our o fferings in both \nbusinesses.  \n \n Turning to Pharma, we continue to make progress on our two primary objectives:  \n \nFirst, strengthening our core Pharma Distribution business.  \n \n We have completed all deployments of our multi -year investment to modernize our pharmaceutical IT \ninfrastructure in order to standardize operations, drive efficiencies and enhance the customer \nexperience. ", "original_text": "We\u2019re initiating a multi -year strategy to grow our warehouse \nfootprint for at -Home Solutions in target markets, and  will announce details for a new warehouse \nopening later this calendar year.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1de7a705b207ffe7d24109a285d18b9c222f1c1498bd7c5c8a738ec295585188", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b3aeb28-18d2-433c-861d-93c630467028", "node_type": "1", "metadata": {"window": "This new infrastructure will improve labor planning based on  demand, \nincrease operating efficiencies to deliver on our commitments, and streamline and standardize \nprocesses across our at -Home network.  We\u2019re initiating a multi -year strategy to grow our warehouse \nfootprint for at -Home Solutions in target markets, and  will announce details for a new warehouse \nopening later this calendar year.  \n \n And in our higher -margin, technology -enabled Medical Services businesses OptiFreight\u00ae Logistics \nand WaveMark, we\u2019ve invested in additional technology capabilities to expand our o fferings in both \nbusinesses.  \n \n Turning to Pharma, we continue to make progress on our two primary objectives:  \n \nFirst, strengthening our core Pharma Distribution business.  \n \n We have completed all deployments of our multi -year investment to modernize our pharmaceutical IT \ninfrastructure in order to standardize operations, drive efficiencies and enhance the customer \nexperience.  These investments, including the automation of business procedures and real -time line of \nsight transparency for our e mployees and customers, will result in operational efficiencies and a more \nconnected pharmaceutical distribution supply chain.  We expect to benefit from the conversion in FY  \n\u201823 and beyond.  \n \n", "original_text": "Turning to Pharma, we continue to make progress on our two primary objectives:  \n \nFirst, strengthening our core Pharma Distribution business.  \n \n"}, "hash": "221704817e1a634c420f79c43f9f5502c4359c826b656cd5764d3e6365c23659", "class_name": "RelatedNodeInfo"}}, "text": "And in our higher -margin, technology -enabled Medical Services businesses OptiFreight\u00ae Logistics \nand WaveMark, we\u2019ve invested in additional technology capabilities to expand our o fferings in both \nbusinesses.  \n \n", "start_char_idx": 1435, "end_char_idx": 1651, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b3aeb28-18d2-433c-861d-93c630467028": {"__data__": {"id_": "2b3aeb28-18d2-433c-861d-93c630467028", "embedding": null, "metadata": {"window": "This new infrastructure will improve labor planning based on  demand, \nincrease operating efficiencies to deliver on our commitments, and streamline and standardize \nprocesses across our at -Home network.  We\u2019re initiating a multi -year strategy to grow our warehouse \nfootprint for at -Home Solutions in target markets, and  will announce details for a new warehouse \nopening later this calendar year.  \n \n And in our higher -margin, technology -enabled Medical Services businesses OptiFreight\u00ae Logistics \nand WaveMark, we\u2019ve invested in additional technology capabilities to expand our o fferings in both \nbusinesses.  \n \n Turning to Pharma, we continue to make progress on our two primary objectives:  \n \nFirst, strengthening our core Pharma Distribution business.  \n \n We have completed all deployments of our multi -year investment to modernize our pharmaceutical IT \ninfrastructure in order to standardize operations, drive efficiencies and enhance the customer \nexperience.  These investments, including the automation of business procedures and real -time line of \nsight transparency for our e mployees and customers, will result in operational efficiencies and a more \nconnected pharmaceutical distribution supply chain.  We expect to benefit from the conversion in FY  \n\u201823 and beyond.  \n \n", "original_text": "Turning to Pharma, we continue to make progress on our two primary objectives:  \n \nFirst, strengthening our core Pharma Distribution business.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b950ea21a1b6cb34fd9fd54b6f7062ab2e908e786bd237a86896e277923e4563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ed03923-6fb4-4799-9b59-e4687bd881b0", "node_type": "1", "metadata": {"window": "Furthermore, we\u2019ve \ninvested in a new warehouse management system across our at -Home Solutions network, which we \nexpect to roll out next week.  This new infrastructure will improve labor planning based on  demand, \nincrease operating efficiencies to deliver on our commitments, and streamline and standardize \nprocesses across our at -Home network.  We\u2019re initiating a multi -year strategy to grow our warehouse \nfootprint for at -Home Solutions in target markets, and  will announce details for a new warehouse \nopening later this calendar year.  \n \n And in our higher -margin, technology -enabled Medical Services businesses OptiFreight\u00ae Logistics \nand WaveMark, we\u2019ve invested in additional technology capabilities to expand our o fferings in both \nbusinesses.  \n \n Turning to Pharma, we continue to make progress on our two primary objectives:  \n \nFirst, strengthening our core Pharma Distribution business.  \n \n We have completed all deployments of our multi -year investment to modernize our pharmaceutical IT \ninfrastructure in order to standardize operations, drive efficiencies and enhance the customer \nexperience.  These investments, including the automation of business procedures and real -time line of \nsight transparency for our e mployees and customers, will result in operational efficiencies and a more \nconnected pharmaceutical distribution supply chain. ", "original_text": "And in our higher -margin, technology -enabled Medical Services businesses OptiFreight\u00ae Logistics \nand WaveMark, we\u2019ve invested in additional technology capabilities to expand our o fferings in both \nbusinesses.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b9dfdb6f1018b938efda3e07e9a4cb06a3b82bf7b0d8ec0064b008cfae5a7bca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9e9f703-72f5-45db-a312-68b6c9a58241", "node_type": "1", "metadata": {"window": "We\u2019re initiating a multi -year strategy to grow our warehouse \nfootprint for at -Home Solutions in target markets, and  will announce details for a new warehouse \nopening later this calendar year.  \n \n And in our higher -margin, technology -enabled Medical Services businesses OptiFreight\u00ae Logistics \nand WaveMark, we\u2019ve invested in additional technology capabilities to expand our o fferings in both \nbusinesses.  \n \n Turning to Pharma, we continue to make progress on our two primary objectives:  \n \nFirst, strengthening our core Pharma Distribution business.  \n \n We have completed all deployments of our multi -year investment to modernize our pharmaceutical IT \ninfrastructure in order to standardize operations, drive efficiencies and enhance the customer \nexperience.  These investments, including the automation of business procedures and real -time line of \nsight transparency for our e mployees and customers, will result in operational efficiencies and a more \nconnected pharmaceutical distribution supply chain.  We expect to benefit from the conversion in FY  \n\u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n", "original_text": "We have completed all deployments of our multi -year investment to modernize our pharmaceutical IT \ninfrastructure in order to standardize operations, drive efficiencies and enhance the customer \nexperience. "}, "hash": "50aaf77a06ea36489374ef91e62929e5eb5ff2554756d1ab87bd2a73c99276bf", "class_name": "RelatedNodeInfo"}}, "text": "Turning to Pharma, we continue to make progress on our two primary objectives:  \n \nFirst, strengthening our core Pharma Distribution business.  \n \n", "start_char_idx": 1651, "end_char_idx": 1798, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9e9f703-72f5-45db-a312-68b6c9a58241": {"__data__": {"id_": "a9e9f703-72f5-45db-a312-68b6c9a58241", "embedding": null, "metadata": {"window": "We\u2019re initiating a multi -year strategy to grow our warehouse \nfootprint for at -Home Solutions in target markets, and  will announce details for a new warehouse \nopening later this calendar year.  \n \n And in our higher -margin, technology -enabled Medical Services businesses OptiFreight\u00ae Logistics \nand WaveMark, we\u2019ve invested in additional technology capabilities to expand our o fferings in both \nbusinesses.  \n \n Turning to Pharma, we continue to make progress on our two primary objectives:  \n \nFirst, strengthening our core Pharma Distribution business.  \n \n We have completed all deployments of our multi -year investment to modernize our pharmaceutical IT \ninfrastructure in order to standardize operations, drive efficiencies and enhance the customer \nexperience.  These investments, including the automation of business procedures and real -time line of \nsight transparency for our e mployees and customers, will result in operational efficiencies and a more \nconnected pharmaceutical distribution supply chain.  We expect to benefit from the conversion in FY  \n\u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n", "original_text": "We have completed all deployments of our multi -year investment to modernize our pharmaceutical IT \ninfrastructure in order to standardize operations, drive efficiencies and enhance the customer \nexperience. ", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b950ea21a1b6cb34fd9fd54b6f7062ab2e908e786bd237a86896e277923e4563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b3aeb28-18d2-433c-861d-93c630467028", "node_type": "1", "metadata": {"window": "This new infrastructure will improve labor planning based on  demand, \nincrease operating efficiencies to deliver on our commitments, and streamline and standardize \nprocesses across our at -Home network.  We\u2019re initiating a multi -year strategy to grow our warehouse \nfootprint for at -Home Solutions in target markets, and  will announce details for a new warehouse \nopening later this calendar year.  \n \n And in our higher -margin, technology -enabled Medical Services businesses OptiFreight\u00ae Logistics \nand WaveMark, we\u2019ve invested in additional technology capabilities to expand our o fferings in both \nbusinesses.  \n \n Turning to Pharma, we continue to make progress on our two primary objectives:  \n \nFirst, strengthening our core Pharma Distribution business.  \n \n We have completed all deployments of our multi -year investment to modernize our pharmaceutical IT \ninfrastructure in order to standardize operations, drive efficiencies and enhance the customer \nexperience.  These investments, including the automation of business procedures and real -time line of \nsight transparency for our e mployees and customers, will result in operational efficiencies and a more \nconnected pharmaceutical distribution supply chain.  We expect to benefit from the conversion in FY  \n\u201823 and beyond.  \n \n", "original_text": "Turning to Pharma, we continue to make progress on our two primary objectives:  \n \nFirst, strengthening our core Pharma Distribution business.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fa5ee44ff47400f4d6f49bedb8a7629f7ca484aa6b004677352799627f69556b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2aa3006b-50b9-42ce-8db8-0f6473cd71d1", "node_type": "1", "metadata": {"window": "And in our higher -margin, technology -enabled Medical Services businesses OptiFreight\u00ae Logistics \nand WaveMark, we\u2019ve invested in additional technology capabilities to expand our o fferings in both \nbusinesses.  \n \n Turning to Pharma, we continue to make progress on our two primary objectives:  \n \nFirst, strengthening our core Pharma Distribution business.  \n \n We have completed all deployments of our multi -year investment to modernize our pharmaceutical IT \ninfrastructure in order to standardize operations, drive efficiencies and enhance the customer \nexperience.  These investments, including the automation of business procedures and real -time line of \nsight transparency for our e mployees and customers, will result in operational efficiencies and a more \nconnected pharmaceutical distribution supply chain.  We expect to benefit from the conversion in FY  \n\u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care. ", "original_text": "These investments, including the automation of business procedures and real -time line of \nsight transparency for our e mployees and customers, will result in operational efficiencies and a more \nconnected pharmaceutical distribution supply chain. "}, "hash": "e467e25811bf30ffcb4311e0af2a334d7fa79dca4f9d8d2058c1208c591754b5", "class_name": "RelatedNodeInfo"}}, "text": "We have completed all deployments of our multi -year investment to modernize our pharmaceutical IT \ninfrastructure in order to standardize operations, drive efficiencies and enhance the customer \nexperience. ", "start_char_idx": 1798, "end_char_idx": 2006, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2aa3006b-50b9-42ce-8db8-0f6473cd71d1": {"__data__": {"id_": "2aa3006b-50b9-42ce-8db8-0f6473cd71d1", "embedding": null, "metadata": {"window": "And in our higher -margin, technology -enabled Medical Services businesses OptiFreight\u00ae Logistics \nand WaveMark, we\u2019ve invested in additional technology capabilities to expand our o fferings in both \nbusinesses.  \n \n Turning to Pharma, we continue to make progress on our two primary objectives:  \n \nFirst, strengthening our core Pharma Distribution business.  \n \n We have completed all deployments of our multi -year investment to modernize our pharmaceutical IT \ninfrastructure in order to standardize operations, drive efficiencies and enhance the customer \nexperience.  These investments, including the automation of business procedures and real -time line of \nsight transparency for our e mployees and customers, will result in operational efficiencies and a more \nconnected pharmaceutical distribution supply chain.  We expect to benefit from the conversion in FY  \n\u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care. ", "original_text": "These investments, including the automation of business procedures and real -time line of \nsight transparency for our e mployees and customers, will result in operational efficiencies and a more \nconnected pharmaceutical distribution supply chain. ", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b950ea21a1b6cb34fd9fd54b6f7062ab2e908e786bd237a86896e277923e4563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9e9f703-72f5-45db-a312-68b6c9a58241", "node_type": "1", "metadata": {"window": "We\u2019re initiating a multi -year strategy to grow our warehouse \nfootprint for at -Home Solutions in target markets, and  will announce details for a new warehouse \nopening later this calendar year.  \n \n And in our higher -margin, technology -enabled Medical Services businesses OptiFreight\u00ae Logistics \nand WaveMark, we\u2019ve invested in additional technology capabilities to expand our o fferings in both \nbusinesses.  \n \n Turning to Pharma, we continue to make progress on our two primary objectives:  \n \nFirst, strengthening our core Pharma Distribution business.  \n \n We have completed all deployments of our multi -year investment to modernize our pharmaceutical IT \ninfrastructure in order to standardize operations, drive efficiencies and enhance the customer \nexperience.  These investments, including the automation of business procedures and real -time line of \nsight transparency for our e mployees and customers, will result in operational efficiencies and a more \nconnected pharmaceutical distribution supply chain.  We expect to benefit from the conversion in FY  \n\u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n", "original_text": "We have completed all deployments of our multi -year investment to modernize our pharmaceutical IT \ninfrastructure in order to standardize operations, drive efficiencies and enhance the customer \nexperience. ", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "052c59925c37430fa556ca7e173bf7b9f8d773b881f70d97a9a83ed053e52a75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9236038b-0316-469c-8ba2-b00fc7e1a32b", "node_type": "1", "metadata": {"window": "Turning to Pharma, we continue to make progress on our two primary objectives:  \n \nFirst, strengthening our core Pharma Distribution business.  \n \n We have completed all deployments of our multi -year investment to modernize our pharmaceutical IT \ninfrastructure in order to standardize operations, drive efficiencies and enhance the customer \nexperience.  These investments, including the automation of business procedures and real -time line of \nsight transparency for our e mployees and customers, will result in operational efficiencies and a more \nconnected pharmaceutical distribution supply chain.  We expect to benefit from the conversion in FY  \n\u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  In March, we further expanded \nour Navista TS offering with the launch of Decision Path, a digital solution to help oncology practices \nlower costs, improve patient care and drive success in transitioning to value -based care. ", "original_text": "We expect to benefit from the conversion in FY  \n\u201823 and beyond.  \n \n"}, "hash": "bf022b9e97d72f801768cc9a0adced886eca35d50cb0f0ccda5d5229f74b9fa1", "class_name": "RelatedNodeInfo"}}, "text": "These investments, including the automation of business procedures and real -time line of \nsight transparency for our e mployees and customers, will result in operational efficiencies and a more \nconnected pharmaceutical distribution supply chain. ", "start_char_idx": 2006, "end_char_idx": 2254, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9236038b-0316-469c-8ba2-b00fc7e1a32b": {"__data__": {"id_": "9236038b-0316-469c-8ba2-b00fc7e1a32b", "embedding": null, "metadata": {"window": "Turning to Pharma, we continue to make progress on our two primary objectives:  \n \nFirst, strengthening our core Pharma Distribution business.  \n \n We have completed all deployments of our multi -year investment to modernize our pharmaceutical IT \ninfrastructure in order to standardize operations, drive efficiencies and enhance the customer \nexperience.  These investments, including the automation of business procedures and real -time line of \nsight transparency for our e mployees and customers, will result in operational efficiencies and a more \nconnected pharmaceutical distribution supply chain.  We expect to benefit from the conversion in FY  \n\u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  In March, we further expanded \nour Navista TS offering with the launch of Decision Path, a digital solution to help oncology practices \nlower costs, improve patient care and drive success in transitioning to value -based care. ", "original_text": "We expect to benefit from the conversion in FY  \n\u201823 and beyond.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b950ea21a1b6cb34fd9fd54b6f7062ab2e908e786bd237a86896e277923e4563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2aa3006b-50b9-42ce-8db8-0f6473cd71d1", "node_type": "1", "metadata": {"window": "And in our higher -margin, technology -enabled Medical Services businesses OptiFreight\u00ae Logistics \nand WaveMark, we\u2019ve invested in additional technology capabilities to expand our o fferings in both \nbusinesses.  \n \n Turning to Pharma, we continue to make progress on our two primary objectives:  \n \nFirst, strengthening our core Pharma Distribution business.  \n \n We have completed all deployments of our multi -year investment to modernize our pharmaceutical IT \ninfrastructure in order to standardize operations, drive efficiencies and enhance the customer \nexperience.  These investments, including the automation of business procedures and real -time line of \nsight transparency for our e mployees and customers, will result in operational efficiencies and a more \nconnected pharmaceutical distribution supply chain.  We expect to benefit from the conversion in FY  \n\u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care. ", "original_text": "These investments, including the automation of business procedures and real -time line of \nsight transparency for our e mployees and customers, will result in operational efficiencies and a more \nconnected pharmaceutical distribution supply chain. ", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cfadbfee9bd9a9f741c8cdb5b2eae94f346ba1783ba0005712de2d24e4683612", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4255d71f-0a71-4733-8fe0-8815dc7ce453", "node_type": "1", "metadata": {"window": "We have completed all deployments of our multi -year investment to modernize our pharmaceutical IT \ninfrastructure in order to standardize operations, drive efficiencies and enhance the customer \nexperience.  These investments, including the automation of business procedures and real -time line of \nsight transparency for our e mployees and customers, will result in operational efficiencies and a more \nconnected pharmaceutical distribution supply chain.  We expect to benefit from the conversion in FY  \n\u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  In March, we further expanded \nour Navista TS offering with the launch of Decision Path, a digital solution to help oncology practices \nlower costs, improve patient care and drive success in transitioning to value -based care.  Created by \nFuse, our internal innovation engine, Decision Path is built into electronic health record wor kflow, \nallowing oncologists to easily compare cancer treatment options, both by clinical indication and cost, \nat the point of care.  \n \n", "original_text": "Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n"}, "hash": "2907033c0d4b64da15fc4a37e70f60812a56a27d28315d37b02dfe63f69451db", "class_name": "RelatedNodeInfo"}}, "text": "We expect to benefit from the conversion in FY  \n\u201823 and beyond.  \n \n", "start_char_idx": 2254, "end_char_idx": 2323, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4255d71f-0a71-4733-8fe0-8815dc7ce453": {"__data__": {"id_": "4255d71f-0a71-4733-8fe0-8815dc7ce453", "embedding": null, "metadata": {"window": "We have completed all deployments of our multi -year investment to modernize our pharmaceutical IT \ninfrastructure in order to standardize operations, drive efficiencies and enhance the customer \nexperience.  These investments, including the automation of business procedures and real -time line of \nsight transparency for our e mployees and customers, will result in operational efficiencies and a more \nconnected pharmaceutical distribution supply chain.  We expect to benefit from the conversion in FY  \n\u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  In March, we further expanded \nour Navista TS offering with the launch of Decision Path, a digital solution to help oncology practices \nlower costs, improve patient care and drive success in transitioning to value -based care.  Created by \nFuse, our internal innovation engine, Decision Path is built into electronic health record wor kflow, \nallowing oncologists to easily compare cancer treatment options, both by clinical indication and cost, \nat the point of care.  \n \n", "original_text": "Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b950ea21a1b6cb34fd9fd54b6f7062ab2e908e786bd237a86896e277923e4563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9236038b-0316-469c-8ba2-b00fc7e1a32b", "node_type": "1", "metadata": {"window": "Turning to Pharma, we continue to make progress on our two primary objectives:  \n \nFirst, strengthening our core Pharma Distribution business.  \n \n We have completed all deployments of our multi -year investment to modernize our pharmaceutical IT \ninfrastructure in order to standardize operations, drive efficiencies and enhance the customer \nexperience.  These investments, including the automation of business procedures and real -time line of \nsight transparency for our e mployees and customers, will result in operational efficiencies and a more \nconnected pharmaceutical distribution supply chain.  We expect to benefit from the conversion in FY  \n\u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  In March, we further expanded \nour Navista TS offering with the launch of Decision Path, a digital solution to help oncology practices \nlower costs, improve patient care and drive success in transitioning to value -based care. ", "original_text": "We expect to benefit from the conversion in FY  \n\u201823 and beyond.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b663fe37b56251f12cf55e4cdbba548af41869aacfacf3f170283aac55b18643", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aec36554-5df3-428b-be01-75721d468144", "node_type": "1", "metadata": {"window": "These investments, including the automation of business procedures and real -time line of \nsight transparency for our e mployees and customers, will result in operational efficiencies and a more \nconnected pharmaceutical distribution supply chain.  We expect to benefit from the conversion in FY  \n\u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  In March, we further expanded \nour Navista TS offering with the launch of Decision Path, a digital solution to help oncology practices \nlower costs, improve patient care and drive success in transitioning to value -based care.  Created by \nFuse, our internal innovation engine, Decision Path is built into electronic health record wor kflow, \nallowing oncologists to easily compare cancer treatment options, both by clinical indication and cost, \nat the point of care.  \n \n And with biosimilars, we are well positioned to support the next phase of growth over the next several \nyears as biosimilars  expand into new therapeutic areas and sites of care. ", "original_text": "In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care. "}, "hash": "ddcd93b3c276713d01ec019b1211adf552c104f541d6a9ed54b501176de7e2f2", "class_name": "RelatedNodeInfo"}}, "text": "Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n", "start_char_idx": 2323, "end_char_idx": 2406, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aec36554-5df3-428b-be01-75721d468144": {"__data__": {"id_": "aec36554-5df3-428b-be01-75721d468144", "embedding": null, "metadata": {"window": "These investments, including the automation of business procedures and real -time line of \nsight transparency for our e mployees and customers, will result in operational efficiencies and a more \nconnected pharmaceutical distribution supply chain.  We expect to benefit from the conversion in FY  \n\u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  In March, we further expanded \nour Navista TS offering with the launch of Decision Path, a digital solution to help oncology practices \nlower costs, improve patient care and drive success in transitioning to value -based care.  Created by \nFuse, our internal innovation engine, Decision Path is built into electronic health record wor kflow, \nallowing oncologists to easily compare cancer treatment options, both by clinical indication and cost, \nat the point of care.  \n \n And with biosimilars, we are well positioned to support the next phase of growth over the next several \nyears as biosimilars  expand into new therapeutic areas and sites of care. ", "original_text": "In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care. ", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b950ea21a1b6cb34fd9fd54b6f7062ab2e908e786bd237a86896e277923e4563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4255d71f-0a71-4733-8fe0-8815dc7ce453", "node_type": "1", "metadata": {"window": "We have completed all deployments of our multi -year investment to modernize our pharmaceutical IT \ninfrastructure in order to standardize operations, drive efficiencies and enhance the customer \nexperience.  These investments, including the automation of business procedures and real -time line of \nsight transparency for our e mployees and customers, will result in operational efficiencies and a more \nconnected pharmaceutical distribution supply chain.  We expect to benefit from the conversion in FY  \n\u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  In March, we further expanded \nour Navista TS offering with the launch of Decision Path, a digital solution to help oncology practices \nlower costs, improve patient care and drive success in transitioning to value -based care.  Created by \nFuse, our internal innovation engine, Decision Path is built into electronic health record wor kflow, \nallowing oncologists to easily compare cancer treatment options, both by clinical indication and cost, \nat the point of care.  \n \n", "original_text": "Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5de3761ceae96bc7266090572f30e5dacaa1d1a6d27d019f7f5d04aa6e0cc93c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c22ceccb-da3d-49e7-b90a-80d1c3351431", "node_type": "1", "metadata": {"window": "We expect to benefit from the conversion in FY  \n\u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  In March, we further expanded \nour Navista TS offering with the launch of Decision Path, a digital solution to help oncology practices \nlower costs, improve patient care and drive success in transitioning to value -based care.  Created by \nFuse, our internal innovation engine, Decision Path is built into electronic health record wor kflow, \nallowing oncologists to easily compare cancer treatment options, both by clinical indication and cost, \nat the point of care.  \n \n And with biosimilars, we are well positioned to support the next phase of growth over the next several \nyears as biosimilars  expand into new therapeutic areas and sites of care.  We believe the next phase ", "original_text": "In March, we further expanded \nour Navista TS offering with the launch of Decision Path, a digital solution to help oncology practices \nlower costs, improve patient care and drive success in transitioning to value -based care. "}, "hash": "d216567a1c794190fb25efada9787aa27ecb1aacebab5357aa77b29195605bf6", "class_name": "RelatedNodeInfo"}}, "text": "In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care. ", "start_char_idx": 2406, "end_char_idx": 2576, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c22ceccb-da3d-49e7-b90a-80d1c3351431": {"__data__": {"id_": "c22ceccb-da3d-49e7-b90a-80d1c3351431", "embedding": null, "metadata": {"window": "We expect to benefit from the conversion in FY  \n\u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  In March, we further expanded \nour Navista TS offering with the launch of Decision Path, a digital solution to help oncology practices \nlower costs, improve patient care and drive success in transitioning to value -based care.  Created by \nFuse, our internal innovation engine, Decision Path is built into electronic health record wor kflow, \nallowing oncologists to easily compare cancer treatment options, both by clinical indication and cost, \nat the point of care.  \n \n And with biosimilars, we are well positioned to support the next phase of growth over the next several \nyears as biosimilars  expand into new therapeutic areas and sites of care.  We believe the next phase ", "original_text": "In March, we further expanded \nour Navista TS offering with the launch of Decision Path, a digital solution to help oncology practices \nlower costs, improve patient care and drive success in transitioning to value -based care. ", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b950ea21a1b6cb34fd9fd54b6f7062ab2e908e786bd237a86896e277923e4563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aec36554-5df3-428b-be01-75721d468144", "node_type": "1", "metadata": {"window": "These investments, including the automation of business procedures and real -time line of \nsight transparency for our e mployees and customers, will result in operational efficiencies and a more \nconnected pharmaceutical distribution supply chain.  We expect to benefit from the conversion in FY  \n\u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  In March, we further expanded \nour Navista TS offering with the launch of Decision Path, a digital solution to help oncology practices \nlower costs, improve patient care and drive success in transitioning to value -based care.  Created by \nFuse, our internal innovation engine, Decision Path is built into electronic health record wor kflow, \nallowing oncologists to easily compare cancer treatment options, both by clinical indication and cost, \nat the point of care.  \n \n And with biosimilars, we are well positioned to support the next phase of growth over the next several \nyears as biosimilars  expand into new therapeutic areas and sites of care. ", "original_text": "In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care. ", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9b0aa65811136547c028c7d3ca596485d89f0a57cbee3fc4d2fba10066a94d34", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "86a56f91-d08d-46b6-89d5-f23b6c617af1", "node_type": "1", "metadata": {"window": "Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  In March, we further expanded \nour Navista TS offering with the launch of Decision Path, a digital solution to help oncology practices \nlower costs, improve patient care and drive success in transitioning to value -based care.  Created by \nFuse, our internal innovation engine, Decision Path is built into electronic health record wor kflow, \nallowing oncologists to easily compare cancer treatment options, both by clinical indication and cost, \nat the point of care.  \n \n And with biosimilars, we are well positioned to support the next phase of growth over the next several \nyears as biosimilars  expand into new therapeutic areas and sites of care.  We believe the next phase ", "original_text": "Created by \nFuse, our internal innovation engine, Decision Path is built into electronic health record wor kflow, \nallowing oncologists to easily compare cancer treatment options, both by clinical indication and cost, \nat the point of care.  \n \n"}, "hash": "2f58d9ff3691beb7b0b6975a282a3015b6b2bdac5851d46661eb2ec5d7447848", "class_name": "RelatedNodeInfo"}}, "text": "In March, we further expanded \nour Navista TS offering with the launch of Decision Path, a digital solution to help oncology practices \nlower costs, improve patient care and drive success in transitioning to value -based care. ", "start_char_idx": 2576, "end_char_idx": 2803, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "86a56f91-d08d-46b6-89d5-f23b6c617af1": {"__data__": {"id_": "86a56f91-d08d-46b6-89d5-f23b6c617af1", "embedding": null, "metadata": {"window": "Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  In March, we further expanded \nour Navista TS offering with the launch of Decision Path, a digital solution to help oncology practices \nlower costs, improve patient care and drive success in transitioning to value -based care.  Created by \nFuse, our internal innovation engine, Decision Path is built into electronic health record wor kflow, \nallowing oncologists to easily compare cancer treatment options, both by clinical indication and cost, \nat the point of care.  \n \n And with biosimilars, we are well positioned to support the next phase of growth over the next several \nyears as biosimilars  expand into new therapeutic areas and sites of care.  We believe the next phase ", "original_text": "Created by \nFuse, our internal innovation engine, Decision Path is built into electronic health record wor kflow, \nallowing oncologists to easily compare cancer treatment options, both by clinical indication and cost, \nat the point of care.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b950ea21a1b6cb34fd9fd54b6f7062ab2e908e786bd237a86896e277923e4563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c22ceccb-da3d-49e7-b90a-80d1c3351431", "node_type": "1", "metadata": {"window": "We expect to benefit from the conversion in FY  \n\u201823 and beyond.  \n \n Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  In March, we further expanded \nour Navista TS offering with the launch of Decision Path, a digital solution to help oncology practices \nlower costs, improve patient care and drive success in transitioning to value -based care.  Created by \nFuse, our internal innovation engine, Decision Path is built into electronic health record wor kflow, \nallowing oncologists to easily compare cancer treatment options, both by clinical indication and cost, \nat the point of care.  \n \n And with biosimilars, we are well positioned to support the next phase of growth over the next several \nyears as biosimilars  expand into new therapeutic areas and sites of care.  We believe the next phase ", "original_text": "In March, we further expanded \nour Navista TS offering with the launch of Decision Path, a digital solution to help oncology practices \nlower costs, improve patient care and drive success in transitioning to value -based care. ", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4d31d9aeab74f3d86a53daa45a6a138f002a7322e88479e4db52736c5bea5bb9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2606b8c4-dd6a-4607-96e9-f3fd176eb08c", "node_type": "1", "metadata": {"window": "In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  In March, we further expanded \nour Navista TS offering with the launch of Decision Path, a digital solution to help oncology practices \nlower costs, improve patient care and drive success in transitioning to value -based care.  Created by \nFuse, our internal innovation engine, Decision Path is built into electronic health record wor kflow, \nallowing oncologists to easily compare cancer treatment options, both by clinical indication and cost, \nat the point of care.  \n \n And with biosimilars, we are well positioned to support the next phase of growth over the next several \nyears as biosimilars  expand into new therapeutic areas and sites of care.  We believe the next phase ", "original_text": "And with biosimilars, we are well positioned to support the next phase of growth over the next several \nyears as biosimilars  expand into new therapeutic areas and sites of care. "}, "hash": "43aadeb8aa6cd54f63580f9c1e60bb7554ae9133805aa93859f1301d94c08d52", "class_name": "RelatedNodeInfo"}}, "text": "Created by \nFuse, our internal innovation engine, Decision Path is built into electronic health record wor kflow, \nallowing oncologists to easily compare cancer treatment options, both by clinical indication and cost, \nat the point of care.  \n \n", "start_char_idx": 2803, "end_char_idx": 3048, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2606b8c4-dd6a-4607-96e9-f3fd176eb08c": {"__data__": {"id_": "2606b8c4-dd6a-4607-96e9-f3fd176eb08c", "embedding": null, "metadata": {"window": "In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  In March, we further expanded \nour Navista TS offering with the launch of Decision Path, a digital solution to help oncology practices \nlower costs, improve patient care and drive success in transitioning to value -based care.  Created by \nFuse, our internal innovation engine, Decision Path is built into electronic health record wor kflow, \nallowing oncologists to easily compare cancer treatment options, both by clinical indication and cost, \nat the point of care.  \n \n And with biosimilars, we are well positioned to support the next phase of growth over the next several \nyears as biosimilars  expand into new therapeutic areas and sites of care.  We believe the next phase ", "original_text": "And with biosimilars, we are well positioned to support the next phase of growth over the next several \nyears as biosimilars  expand into new therapeutic areas and sites of care. ", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b950ea21a1b6cb34fd9fd54b6f7062ab2e908e786bd237a86896e277923e4563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "86a56f91-d08d-46b6-89d5-f23b6c617af1", "node_type": "1", "metadata": {"window": "Second, we\u2019re fueling our growth businesses: Specialty, Nuclear, and Outcomes.  \n \n In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  In March, we further expanded \nour Navista TS offering with the launch of Decision Path, a digital solution to help oncology practices \nlower costs, improve patient care and drive success in transitioning to value -based care.  Created by \nFuse, our internal innovation engine, Decision Path is built into electronic health record wor kflow, \nallowing oncologists to easily compare cancer treatment options, both by clinical indication and cost, \nat the point of care.  \n \n And with biosimilars, we are well positioned to support the next phase of growth over the next several \nyears as biosimilars  expand into new therapeutic areas and sites of care.  We believe the next phase ", "original_text": "Created by \nFuse, our internal innovation engine, Decision Path is built into electronic health record wor kflow, \nallowing oncologists to easily compare cancer treatment options, both by clinical indication and cost, \nat the point of care.  \n \n", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6900978ba9d1eb6f3b6f8796643fdf4649ade835dfecacc9a0a7b4621e62cb14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62685d00-6522-488c-b946-3ff8c33ab0d6", "node_type": "1", "metadata": {"window": "In March, we further expanded \nour Navista TS offering with the launch of Decision Path, a digital solution to help oncology practices \nlower costs, improve patient care and drive success in transitioning to value -based care.  Created by \nFuse, our internal innovation engine, Decision Path is built into electronic health record wor kflow, \nallowing oncologists to easily compare cancer treatment options, both by clinical indication and cost, \nat the point of care.  \n \n And with biosimilars, we are well positioned to support the next phase of growth over the next several \nyears as biosimilars  expand into new therapeutic areas and sites of care.  We believe the next phase ", "original_text": "We believe the next phase "}, "hash": "d77943d91a57d1eae9158815b247518ca4c0640f5f2ea3f7dcd9356e48dc4365", "class_name": "RelatedNodeInfo"}}, "text": "And with biosimilars, we are well positioned to support the next phase of growth over the next several \nyears as biosimilars  expand into new therapeutic areas and sites of care. ", "start_char_idx": 3048, "end_char_idx": 3227, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62685d00-6522-488c-b946-3ff8c33ab0d6": {"__data__": {"id_": "62685d00-6522-488c-b946-3ff8c33ab0d6", "embedding": null, "metadata": {"window": "In March, we further expanded \nour Navista TS offering with the launch of Decision Path, a digital solution to help oncology practices \nlower costs, improve patient care and drive success in transitioning to value -based care.  Created by \nFuse, our internal innovation engine, Decision Path is built into electronic health record wor kflow, \nallowing oncologists to easily compare cancer treatment options, both by clinical indication and cost, \nat the point of care.  \n \n And with biosimilars, we are well positioned to support the next phase of growth over the next several \nyears as biosimilars  expand into new therapeutic areas and sites of care.  We believe the next phase ", "original_text": "We believe the next phase ", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042", "node_type": "4", "metadata": {"page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b950ea21a1b6cb34fd9fd54b6f7062ab2e908e786bd237a86896e277923e4563", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2606b8c4-dd6a-4607-96e9-f3fd176eb08c", "node_type": "1", "metadata": {"window": "In Specialty, we continue to experience momentum in our oncology physician office business, driven \nin part by Navista TS, our technology platform for value -based care.  In March, we further expanded \nour Navista TS offering with the launch of Decision Path, a digital solution to help oncology practices \nlower costs, improve patient care and drive success in transitioning to value -based care.  Created by \nFuse, our internal innovation engine, Decision Path is built into electronic health record wor kflow, \nallowing oncologists to easily compare cancer treatment options, both by clinical indication and cost, \nat the point of care.  \n \n And with biosimilars, we are well positioned to support the next phase of growth over the next several \nyears as biosimilars  expand into new therapeutic areas and sites of care.  We believe the next phase ", "original_text": "And with biosimilars, we are well positioned to support the next phase of growth over the next several \nyears as biosimilars  expand into new therapeutic areas and sites of care. ", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6941f8aa1ce73342afe100ad365b05adfb40d2b6791e86afc9ffc30e8ced3dae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e9a39ad-2e5b-405e-9727-a9af2d191ecb", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \nof growth in the biosimilars market will predominantly come from products with a greater retail or \nspecialty pharmacy presence.  As more retail products with interchangeability come to market, our \nsignificant scale and capabilities designed to support retail pharmacies uniquely positions us to \nsupport and empower those pharmacists as they navigate the important operational complexities of \nmanaging multiple biosimilar launches aga inst major reference products.  \n \n Our Sonexus digital services portal offers tailored solutions to help patients get on, and stay on, \ntherapy.  Patients who interact with our Sonexus portal experience shorter time to therapy for new \npatients and no gaps in th erapy for existing patients. ", "original_text": " \nPage 8 of 15 \n \nof growth in the biosimilars market will predominantly come from products with a greater retail or \nspecialty pharmacy presence. "}, "hash": "268ec38ee9ee8aa62d39ad497f86ae7ff1910e1351f696f1fabaa2598924ab4d", "class_name": "RelatedNodeInfo"}}, "text": "We believe the next phase ", "start_char_idx": 3227, "end_char_idx": 3253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e9a39ad-2e5b-405e-9727-a9af2d191ecb": {"__data__": {"id_": "2e9a39ad-2e5b-405e-9727-a9af2d191ecb", "embedding": null, "metadata": {"window": " \nPage 8 of 15 \n \nof growth in the biosimilars market will predominantly come from products with a greater retail or \nspecialty pharmacy presence.  As more retail products with interchangeability come to market, our \nsignificant scale and capabilities designed to support retail pharmacies uniquely positions us to \nsupport and empower those pharmacists as they navigate the important operational complexities of \nmanaging multiple biosimilar launches aga inst major reference products.  \n \n Our Sonexus digital services portal offers tailored solutions to help patients get on, and stay on, \ntherapy.  Patients who interact with our Sonexus portal experience shorter time to therapy for new \npatients and no gaps in th erapy for existing patients. ", "original_text": " \nPage 8 of 15 \n \nof growth in the biosimilars market will predominantly come from products with a greater retail or \nspecialty pharmacy presence. ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1d0e21bb32acf0620a5e9501cf7e3b3cce031bf56a7948ca87bcbe9237f1db0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62685d00-6522-488c-b946-3ff8c33ab0d6", "node_type": "1", "metadata": {"window": "In March, we further expanded \nour Navista TS offering with the launch of Decision Path, a digital solution to help oncology practices \nlower costs, improve patient care and drive success in transitioning to value -based care.  Created by \nFuse, our internal innovation engine, Decision Path is built into electronic health record wor kflow, \nallowing oncologists to easily compare cancer treatment options, both by clinical indication and cost, \nat the point of care.  \n \n And with biosimilars, we are well positioned to support the next phase of growth over the next several \nyears as biosimilars  expand into new therapeutic areas and sites of care.  We believe the next phase ", "original_text": "We believe the next phase ", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1ab7500c9bfa2e5a058ff999f7d651f76e8ebe33872c6a7a0e114e58799ce473", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c22dc5e4-13f0-47ce-ba45-be1ea0ab60f8", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \nof growth in the biosimilars market will predominantly come from products with a greater retail or \nspecialty pharmacy presence.  As more retail products with interchangeability come to market, our \nsignificant scale and capabilities designed to support retail pharmacies uniquely positions us to \nsupport and empower those pharmacists as they navigate the important operational complexities of \nmanaging multiple biosimilar launches aga inst major reference products.  \n \n Our Sonexus digital services portal offers tailored solutions to help patients get on, and stay on, \ntherapy.  Patients who interact with our Sonexus portal experience shorter time to therapy for new \npatients and no gaps in th erapy for existing patients.  Digital re -enrollment via the patient portal \nincreased approvals within the first 30 days by 10%, and delivered a retention rate greater than 90%.  \n \n", "original_text": "As more retail products with interchangeability come to market, our \nsignificant scale and capabilities designed to support retail pharmacies uniquely positions us to \nsupport and empower those pharmacists as they navigate the important operational complexities of \nmanaging multiple biosimilar launches aga inst major reference products.  \n \n"}, "hash": "a0f020a701e1790e5c1eeef0d77e53f252c51b11d539a71ba34f3ab9f6a187c3", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 8 of 15 \n \nof growth in the biosimilars market will predominantly come from products with a greater retail or \nspecialty pharmacy presence. ", "start_char_idx": 0, "end_char_idx": 147, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c22dc5e4-13f0-47ce-ba45-be1ea0ab60f8": {"__data__": {"id_": "c22dc5e4-13f0-47ce-ba45-be1ea0ab60f8", "embedding": null, "metadata": {"window": " \nPage 8 of 15 \n \nof growth in the biosimilars market will predominantly come from products with a greater retail or \nspecialty pharmacy presence.  As more retail products with interchangeability come to market, our \nsignificant scale and capabilities designed to support retail pharmacies uniquely positions us to \nsupport and empower those pharmacists as they navigate the important operational complexities of \nmanaging multiple biosimilar launches aga inst major reference products.  \n \n Our Sonexus digital services portal offers tailored solutions to help patients get on, and stay on, \ntherapy.  Patients who interact with our Sonexus portal experience shorter time to therapy for new \npatients and no gaps in th erapy for existing patients.  Digital re -enrollment via the patient portal \nincreased approvals within the first 30 days by 10%, and delivered a retention rate greater than 90%.  \n \n", "original_text": "As more retail products with interchangeability come to market, our \nsignificant scale and capabilities designed to support retail pharmacies uniquely positions us to \nsupport and empower those pharmacists as they navigate the important operational complexities of \nmanaging multiple biosimilar launches aga inst major reference products.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1d0e21bb32acf0620a5e9501cf7e3b3cce031bf56a7948ca87bcbe9237f1db0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e9a39ad-2e5b-405e-9727-a9af2d191ecb", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \nof growth in the biosimilars market will predominantly come from products with a greater retail or \nspecialty pharmacy presence.  As more retail products with interchangeability come to market, our \nsignificant scale and capabilities designed to support retail pharmacies uniquely positions us to \nsupport and empower those pharmacists as they navigate the important operational complexities of \nmanaging multiple biosimilar launches aga inst major reference products.  \n \n Our Sonexus digital services portal offers tailored solutions to help patients get on, and stay on, \ntherapy.  Patients who interact with our Sonexus portal experience shorter time to therapy for new \npatients and no gaps in th erapy for existing patients. ", "original_text": " \nPage 8 of 15 \n \nof growth in the biosimilars market will predominantly come from products with a greater retail or \nspecialty pharmacy presence. ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d3b87c173e0dff167e71a4ef89abc39bfd1a09cb16fb42680b8814b9657af4af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15e44632-45b9-4c32-8287-133ccc99385a", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \nof growth in the biosimilars market will predominantly come from products with a greater retail or \nspecialty pharmacy presence.  As more retail products with interchangeability come to market, our \nsignificant scale and capabilities designed to support retail pharmacies uniquely positions us to \nsupport and empower those pharmacists as they navigate the important operational complexities of \nmanaging multiple biosimilar launches aga inst major reference products.  \n \n Our Sonexus digital services portal offers tailored solutions to help patients get on, and stay on, \ntherapy.  Patients who interact with our Sonexus portal experience shorter time to therapy for new \npatients and no gaps in th erapy for existing patients.  Digital re -enrollment via the patient portal \nincreased approvals within the first 30 days by 10%, and delivered a retention rate greater than 90%.  \n \n In our Third Party Logistics business, we have won 66 manufacturer contracts t his fiscal year. ", "original_text": "Our Sonexus digital services portal offers tailored solutions to help patients get on, and stay on, \ntherapy. "}, "hash": "b171bc877c3d0c7cd07d8f33dabbf3b79f90cd8898c410a1670dfa753e040732", "class_name": "RelatedNodeInfo"}}, "text": "As more retail products with interchangeability come to market, our \nsignificant scale and capabilities designed to support retail pharmacies uniquely positions us to \nsupport and empower those pharmacists as they navigate the important operational complexities of \nmanaging multiple biosimilar launches aga inst major reference products.  \n \n", "start_char_idx": 147, "end_char_idx": 490, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15e44632-45b9-4c32-8287-133ccc99385a": {"__data__": {"id_": "15e44632-45b9-4c32-8287-133ccc99385a", "embedding": null, "metadata": {"window": " \nPage 8 of 15 \n \nof growth in the biosimilars market will predominantly come from products with a greater retail or \nspecialty pharmacy presence.  As more retail products with interchangeability come to market, our \nsignificant scale and capabilities designed to support retail pharmacies uniquely positions us to \nsupport and empower those pharmacists as they navigate the important operational complexities of \nmanaging multiple biosimilar launches aga inst major reference products.  \n \n Our Sonexus digital services portal offers tailored solutions to help patients get on, and stay on, \ntherapy.  Patients who interact with our Sonexus portal experience shorter time to therapy for new \npatients and no gaps in th erapy for existing patients.  Digital re -enrollment via the patient portal \nincreased approvals within the first 30 days by 10%, and delivered a retention rate greater than 90%.  \n \n In our Third Party Logistics business, we have won 66 manufacturer contracts t his fiscal year. ", "original_text": "Our Sonexus digital services portal offers tailored solutions to help patients get on, and stay on, \ntherapy. ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1d0e21bb32acf0620a5e9501cf7e3b3cce031bf56a7948ca87bcbe9237f1db0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c22dc5e4-13f0-47ce-ba45-be1ea0ab60f8", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \nof growth in the biosimilars market will predominantly come from products with a greater retail or \nspecialty pharmacy presence.  As more retail products with interchangeability come to market, our \nsignificant scale and capabilities designed to support retail pharmacies uniquely positions us to \nsupport and empower those pharmacists as they navigate the important operational complexities of \nmanaging multiple biosimilar launches aga inst major reference products.  \n \n Our Sonexus digital services portal offers tailored solutions to help patients get on, and stay on, \ntherapy.  Patients who interact with our Sonexus portal experience shorter time to therapy for new \npatients and no gaps in th erapy for existing patients.  Digital re -enrollment via the patient portal \nincreased approvals within the first 30 days by 10%, and delivered a retention rate greater than 90%.  \n \n", "original_text": "As more retail products with interchangeability come to market, our \nsignificant scale and capabilities designed to support retail pharmacies uniquely positions us to \nsupport and empower those pharmacists as they navigate the important operational complexities of \nmanaging multiple biosimilar launches aga inst major reference products.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "acca227864b770c0aaf4bdd4ffe245d3034a12555bea9ad7e5c2fcfc72684c2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "90c3bdbc-03a0-4c73-884a-c27f1afac135", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \nof growth in the biosimilars market will predominantly come from products with a greater retail or \nspecialty pharmacy presence.  As more retail products with interchangeability come to market, our \nsignificant scale and capabilities designed to support retail pharmacies uniquely positions us to \nsupport and empower those pharmacists as they navigate the important operational complexities of \nmanaging multiple biosimilar launches aga inst major reference products.  \n \n Our Sonexus digital services portal offers tailored solutions to help patients get on, and stay on, \ntherapy.  Patients who interact with our Sonexus portal experience shorter time to therapy for new \npatients and no gaps in th erapy for existing patients.  Digital re -enrollment via the patient portal \nincreased approvals within the first 30 days by 10%, and delivered a retention rate greater than 90%.  \n \n In our Third Party Logistics business, we have won 66 manufacturer contracts t his fiscal year.  So far \nwe have successfully launched 27 manufacturers, and we expect 5 -8 additional launches by the end \nof the fiscal year. ", "original_text": "Patients who interact with our Sonexus portal experience shorter time to therapy for new \npatients and no gaps in th erapy for existing patients. "}, "hash": "33037814834348e786bd0b101b9d15abc396291649531167e7ebf3ab800cd406", "class_name": "RelatedNodeInfo"}}, "text": "Our Sonexus digital services portal offers tailored solutions to help patients get on, and stay on, \ntherapy. ", "start_char_idx": 490, "end_char_idx": 600, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "90c3bdbc-03a0-4c73-884a-c27f1afac135": {"__data__": {"id_": "90c3bdbc-03a0-4c73-884a-c27f1afac135", "embedding": null, "metadata": {"window": " \nPage 8 of 15 \n \nof growth in the biosimilars market will predominantly come from products with a greater retail or \nspecialty pharmacy presence.  As more retail products with interchangeability come to market, our \nsignificant scale and capabilities designed to support retail pharmacies uniquely positions us to \nsupport and empower those pharmacists as they navigate the important operational complexities of \nmanaging multiple biosimilar launches aga inst major reference products.  \n \n Our Sonexus digital services portal offers tailored solutions to help patients get on, and stay on, \ntherapy.  Patients who interact with our Sonexus portal experience shorter time to therapy for new \npatients and no gaps in th erapy for existing patients.  Digital re -enrollment via the patient portal \nincreased approvals within the first 30 days by 10%, and delivered a retention rate greater than 90%.  \n \n In our Third Party Logistics business, we have won 66 manufacturer contracts t his fiscal year.  So far \nwe have successfully launched 27 manufacturers, and we expect 5 -8 additional launches by the end \nof the fiscal year. ", "original_text": "Patients who interact with our Sonexus portal experience shorter time to therapy for new \npatients and no gaps in th erapy for existing patients. ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1d0e21bb32acf0620a5e9501cf7e3b3cce031bf56a7948ca87bcbe9237f1db0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15e44632-45b9-4c32-8287-133ccc99385a", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \nof growth in the biosimilars market will predominantly come from products with a greater retail or \nspecialty pharmacy presence.  As more retail products with interchangeability come to market, our \nsignificant scale and capabilities designed to support retail pharmacies uniquely positions us to \nsupport and empower those pharmacists as they navigate the important operational complexities of \nmanaging multiple biosimilar launches aga inst major reference products.  \n \n Our Sonexus digital services portal offers tailored solutions to help patients get on, and stay on, \ntherapy.  Patients who interact with our Sonexus portal experience shorter time to therapy for new \npatients and no gaps in th erapy for existing patients.  Digital re -enrollment via the patient portal \nincreased approvals within the first 30 days by 10%, and delivered a retention rate greater than 90%.  \n \n In our Third Party Logistics business, we have won 66 manufacturer contracts t his fiscal year. ", "original_text": "Our Sonexus digital services portal offers tailored solutions to help patients get on, and stay on, \ntherapy. ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "362459e636da60ca756496e54453ac1b2e0f2eaa70f823904759eb68b71ff4f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9036003b-7dc6-486f-95bf-383611221c93", "node_type": "1", "metadata": {"window": "As more retail products with interchangeability come to market, our \nsignificant scale and capabilities designed to support retail pharmacies uniquely positions us to \nsupport and empower those pharmacists as they navigate the important operational complexities of \nmanaging multiple biosimilar launches aga inst major reference products.  \n \n Our Sonexus digital services portal offers tailored solutions to help patients get on, and stay on, \ntherapy.  Patients who interact with our Sonexus portal experience shorter time to therapy for new \npatients and no gaps in th erapy for existing patients.  Digital re -enrollment via the patient portal \nincreased approvals within the first 30 days by 10%, and delivered a retention rate greater than 90%.  \n \n In our Third Party Logistics business, we have won 66 manufacturer contracts t his fiscal year.  So far \nwe have successfully launched 27 manufacturers, and we expect 5 -8 additional launches by the end \nof the fiscal year.  And specific to cell and gene therapy, we continue to win opportunities and have \nplans to launch 5 manufacturers in  the coming years, based on FDA approval and manufacturer \nreadiness.  \n \n", "original_text": "Digital re -enrollment via the patient portal \nincreased approvals within the first 30 days by 10%, and delivered a retention rate greater than 90%.  \n \n"}, "hash": "81db2b19b95079573f871b7186da064bcf9056240b59511ea818fe5e84bc4fdf", "class_name": "RelatedNodeInfo"}}, "text": "Patients who interact with our Sonexus portal experience shorter time to therapy for new \npatients and no gaps in th erapy for existing patients. ", "start_char_idx": 600, "end_char_idx": 746, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9036003b-7dc6-486f-95bf-383611221c93": {"__data__": {"id_": "9036003b-7dc6-486f-95bf-383611221c93", "embedding": null, "metadata": {"window": "As more retail products with interchangeability come to market, our \nsignificant scale and capabilities designed to support retail pharmacies uniquely positions us to \nsupport and empower those pharmacists as they navigate the important operational complexities of \nmanaging multiple biosimilar launches aga inst major reference products.  \n \n Our Sonexus digital services portal offers tailored solutions to help patients get on, and stay on, \ntherapy.  Patients who interact with our Sonexus portal experience shorter time to therapy for new \npatients and no gaps in th erapy for existing patients.  Digital re -enrollment via the patient portal \nincreased approvals within the first 30 days by 10%, and delivered a retention rate greater than 90%.  \n \n In our Third Party Logistics business, we have won 66 manufacturer contracts t his fiscal year.  So far \nwe have successfully launched 27 manufacturers, and we expect 5 -8 additional launches by the end \nof the fiscal year.  And specific to cell and gene therapy, we continue to win opportunities and have \nplans to launch 5 manufacturers in  the coming years, based on FDA approval and manufacturer \nreadiness.  \n \n", "original_text": "Digital re -enrollment via the patient portal \nincreased approvals within the first 30 days by 10%, and delivered a retention rate greater than 90%.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1d0e21bb32acf0620a5e9501cf7e3b3cce031bf56a7948ca87bcbe9237f1db0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "90c3bdbc-03a0-4c73-884a-c27f1afac135", "node_type": "1", "metadata": {"window": " \nPage 8 of 15 \n \nof growth in the biosimilars market will predominantly come from products with a greater retail or \nspecialty pharmacy presence.  As more retail products with interchangeability come to market, our \nsignificant scale and capabilities designed to support retail pharmacies uniquely positions us to \nsupport and empower those pharmacists as they navigate the important operational complexities of \nmanaging multiple biosimilar launches aga inst major reference products.  \n \n Our Sonexus digital services portal offers tailored solutions to help patients get on, and stay on, \ntherapy.  Patients who interact with our Sonexus portal experience shorter time to therapy for new \npatients and no gaps in th erapy for existing patients.  Digital re -enrollment via the patient portal \nincreased approvals within the first 30 days by 10%, and delivered a retention rate greater than 90%.  \n \n In our Third Party Logistics business, we have won 66 manufacturer contracts t his fiscal year.  So far \nwe have successfully launched 27 manufacturers, and we expect 5 -8 additional launches by the end \nof the fiscal year. ", "original_text": "Patients who interact with our Sonexus portal experience shorter time to therapy for new \npatients and no gaps in th erapy for existing patients. ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4da03ca20beff07ebec99cfdfb21076421751c83e3ceda45802f055adbb2bb23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f04198a6-1173-4de4-8f0c-6bf60d5cc451", "node_type": "1", "metadata": {"window": "Our Sonexus digital services portal offers tailored solutions to help patients get on, and stay on, \ntherapy.  Patients who interact with our Sonexus portal experience shorter time to therapy for new \npatients and no gaps in th erapy for existing patients.  Digital re -enrollment via the patient portal \nincreased approvals within the first 30 days by 10%, and delivered a retention rate greater than 90%.  \n \n In our Third Party Logistics business, we have won 66 manufacturer contracts t his fiscal year.  So far \nwe have successfully launched 27 manufacturers, and we expect 5 -8 additional launches by the end \nof the fiscal year.  And specific to cell and gene therapy, we continue to win opportunities and have \nplans to launch 5 manufacturers in  the coming years, based on FDA approval and manufacturer \nreadiness.  \n \n In Nuclear, we continue to see the benefits of our investments in theranostics. ", "original_text": "In our Third Party Logistics business, we have won 66 manufacturer contracts t his fiscal year. "}, "hash": "1e21d8d3308a041646968dff586dac939eeb486cfdf7fe32ffdb5b887d0a8878", "class_name": "RelatedNodeInfo"}}, "text": "Digital re -enrollment via the patient portal \nincreased approvals within the first 30 days by 10%, and delivered a retention rate greater than 90%.  \n \n", "start_char_idx": 746, "end_char_idx": 899, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f04198a6-1173-4de4-8f0c-6bf60d5cc451": {"__data__": {"id_": "f04198a6-1173-4de4-8f0c-6bf60d5cc451", "embedding": null, "metadata": {"window": "Our Sonexus digital services portal offers tailored solutions to help patients get on, and stay on, \ntherapy.  Patients who interact with our Sonexus portal experience shorter time to therapy for new \npatients and no gaps in th erapy for existing patients.  Digital re -enrollment via the patient portal \nincreased approvals within the first 30 days by 10%, and delivered a retention rate greater than 90%.  \n \n In our Third Party Logistics business, we have won 66 manufacturer contracts t his fiscal year.  So far \nwe have successfully launched 27 manufacturers, and we expect 5 -8 additional launches by the end \nof the fiscal year.  And specific to cell and gene therapy, we continue to win opportunities and have \nplans to launch 5 manufacturers in  the coming years, based on FDA approval and manufacturer \nreadiness.  \n \n In Nuclear, we continue to see the benefits of our investments in theranostics. ", "original_text": "In our Third Party Logistics business, we have won 66 manufacturer contracts t his fiscal year. ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1d0e21bb32acf0620a5e9501cf7e3b3cce031bf56a7948ca87bcbe9237f1db0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9036003b-7dc6-486f-95bf-383611221c93", "node_type": "1", "metadata": {"window": "As more retail products with interchangeability come to market, our \nsignificant scale and capabilities designed to support retail pharmacies uniquely positions us to \nsupport and empower those pharmacists as they navigate the important operational complexities of \nmanaging multiple biosimilar launches aga inst major reference products.  \n \n Our Sonexus digital services portal offers tailored solutions to help patients get on, and stay on, \ntherapy.  Patients who interact with our Sonexus portal experience shorter time to therapy for new \npatients and no gaps in th erapy for existing patients.  Digital re -enrollment via the patient portal \nincreased approvals within the first 30 days by 10%, and delivered a retention rate greater than 90%.  \n \n In our Third Party Logistics business, we have won 66 manufacturer contracts t his fiscal year.  So far \nwe have successfully launched 27 manufacturers, and we expect 5 -8 additional launches by the end \nof the fiscal year.  And specific to cell and gene therapy, we continue to win opportunities and have \nplans to launch 5 manufacturers in  the coming years, based on FDA approval and manufacturer \nreadiness.  \n \n", "original_text": "Digital re -enrollment via the patient portal \nincreased approvals within the first 30 days by 10%, and delivered a retention rate greater than 90%.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e33f5b07926d278a486602d20822d1b91d59f25211b4315df31d310419e86205", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b0e5b47-aacb-4765-9eff-4f5973919264", "node_type": "1", "metadata": {"window": "Patients who interact with our Sonexus portal experience shorter time to therapy for new \npatients and no gaps in th erapy for existing patients.  Digital re -enrollment via the patient portal \nincreased approvals within the first 30 days by 10%, and delivered a retention rate greater than 90%.  \n \n In our Third Party Logistics business, we have won 66 manufacturer contracts t his fiscal year.  So far \nwe have successfully launched 27 manufacturers, and we expect 5 -8 additional launches by the end \nof the fiscal year.  And specific to cell and gene therapy, we continue to win opportunities and have \nplans to launch 5 manufacturers in  the coming years, based on FDA approval and manufacturer \nreadiness.  \n \n In Nuclear, we continue to see the benefits of our investments in theranostics.  Our Center for \nTheranostics Advancement in Indianapolis continues to be in high demand with the number of new \ninnovators and products we are collaborating with doubling in FY  \u201822 versus the prior year.  \n \n", "original_text": "So far \nwe have successfully launched 27 manufacturers, and we expect 5 -8 additional launches by the end \nof the fiscal year. "}, "hash": "e087817ef3a4e7925abb1a6ed748b3ea0bf6bf5ce489b3c15631ff03148cbf98", "class_name": "RelatedNodeInfo"}}, "text": "In our Third Party Logistics business, we have won 66 manufacturer contracts t his fiscal year. ", "start_char_idx": 899, "end_char_idx": 995, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b0e5b47-aacb-4765-9eff-4f5973919264": {"__data__": {"id_": "9b0e5b47-aacb-4765-9eff-4f5973919264", "embedding": null, "metadata": {"window": "Patients who interact with our Sonexus portal experience shorter time to therapy for new \npatients and no gaps in th erapy for existing patients.  Digital re -enrollment via the patient portal \nincreased approvals within the first 30 days by 10%, and delivered a retention rate greater than 90%.  \n \n In our Third Party Logistics business, we have won 66 manufacturer contracts t his fiscal year.  So far \nwe have successfully launched 27 manufacturers, and we expect 5 -8 additional launches by the end \nof the fiscal year.  And specific to cell and gene therapy, we continue to win opportunities and have \nplans to launch 5 manufacturers in  the coming years, based on FDA approval and manufacturer \nreadiness.  \n \n In Nuclear, we continue to see the benefits of our investments in theranostics.  Our Center for \nTheranostics Advancement in Indianapolis continues to be in high demand with the number of new \ninnovators and products we are collaborating with doubling in FY  \u201822 versus the prior year.  \n \n", "original_text": "So far \nwe have successfully launched 27 manufacturers, and we expect 5 -8 additional launches by the end \nof the fiscal year. ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1d0e21bb32acf0620a5e9501cf7e3b3cce031bf56a7948ca87bcbe9237f1db0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f04198a6-1173-4de4-8f0c-6bf60d5cc451", "node_type": "1", "metadata": {"window": "Our Sonexus digital services portal offers tailored solutions to help patients get on, and stay on, \ntherapy.  Patients who interact with our Sonexus portal experience shorter time to therapy for new \npatients and no gaps in th erapy for existing patients.  Digital re -enrollment via the patient portal \nincreased approvals within the first 30 days by 10%, and delivered a retention rate greater than 90%.  \n \n In our Third Party Logistics business, we have won 66 manufacturer contracts t his fiscal year.  So far \nwe have successfully launched 27 manufacturers, and we expect 5 -8 additional launches by the end \nof the fiscal year.  And specific to cell and gene therapy, we continue to win opportunities and have \nplans to launch 5 manufacturers in  the coming years, based on FDA approval and manufacturer \nreadiness.  \n \n In Nuclear, we continue to see the benefits of our investments in theranostics. ", "original_text": "In our Third Party Logistics business, we have won 66 manufacturer contracts t his fiscal year. ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "23e31620c392e74c2d08cdf1261a86f486622a0a34f469f9d7e0d2b07fdc6021", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31617823-033b-4bca-9eb4-ec6a93b390e5", "node_type": "1", "metadata": {"window": "Digital re -enrollment via the patient portal \nincreased approvals within the first 30 days by 10%, and delivered a retention rate greater than 90%.  \n \n In our Third Party Logistics business, we have won 66 manufacturer contracts t his fiscal year.  So far \nwe have successfully launched 27 manufacturers, and we expect 5 -8 additional launches by the end \nof the fiscal year.  And specific to cell and gene therapy, we continue to win opportunities and have \nplans to launch 5 manufacturers in  the coming years, based on FDA approval and manufacturer \nreadiness.  \n \n In Nuclear, we continue to see the benefits of our investments in theranostics.  Our Center for \nTheranostics Advancement in Indianapolis continues to be in high demand with the number of new \ninnovators and products we are collaborating with doubling in FY  \u201822 versus the prior year.  \n \n Our Outcomes business continues to add new payers, PBMs, pharmaceutical manufacturers, and \nexpand clinical solutions for both independent pharmacies and retai l chains. ", "original_text": "And specific to cell and gene therapy, we continue to win opportunities and have \nplans to launch 5 manufacturers in  the coming years, based on FDA approval and manufacturer \nreadiness.  \n \n"}, "hash": "511829b9df1d181831ce382a083148ac4ba8828471fde424f4e7b0756eb00971", "class_name": "RelatedNodeInfo"}}, "text": "So far \nwe have successfully launched 27 manufacturers, and we expect 5 -8 additional launches by the end \nof the fiscal year. ", "start_char_idx": 995, "end_char_idx": 1122, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31617823-033b-4bca-9eb4-ec6a93b390e5": {"__data__": {"id_": "31617823-033b-4bca-9eb4-ec6a93b390e5", "embedding": null, "metadata": {"window": "Digital re -enrollment via the patient portal \nincreased approvals within the first 30 days by 10%, and delivered a retention rate greater than 90%.  \n \n In our Third Party Logistics business, we have won 66 manufacturer contracts t his fiscal year.  So far \nwe have successfully launched 27 manufacturers, and we expect 5 -8 additional launches by the end \nof the fiscal year.  And specific to cell and gene therapy, we continue to win opportunities and have \nplans to launch 5 manufacturers in  the coming years, based on FDA approval and manufacturer \nreadiness.  \n \n In Nuclear, we continue to see the benefits of our investments in theranostics.  Our Center for \nTheranostics Advancement in Indianapolis continues to be in high demand with the number of new \ninnovators and products we are collaborating with doubling in FY  \u201822 versus the prior year.  \n \n Our Outcomes business continues to add new payers, PBMs, pharmaceutical manufacturers, and \nexpand clinical solutions for both independent pharmacies and retai l chains. ", "original_text": "And specific to cell and gene therapy, we continue to win opportunities and have \nplans to launch 5 manufacturers in  the coming years, based on FDA approval and manufacturer \nreadiness.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1d0e21bb32acf0620a5e9501cf7e3b3cce031bf56a7948ca87bcbe9237f1db0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b0e5b47-aacb-4765-9eff-4f5973919264", "node_type": "1", "metadata": {"window": "Patients who interact with our Sonexus portal experience shorter time to therapy for new \npatients and no gaps in th erapy for existing patients.  Digital re -enrollment via the patient portal \nincreased approvals within the first 30 days by 10%, and delivered a retention rate greater than 90%.  \n \n In our Third Party Logistics business, we have won 66 manufacturer contracts t his fiscal year.  So far \nwe have successfully launched 27 manufacturers, and we expect 5 -8 additional launches by the end \nof the fiscal year.  And specific to cell and gene therapy, we continue to win opportunities and have \nplans to launch 5 manufacturers in  the coming years, based on FDA approval and manufacturer \nreadiness.  \n \n In Nuclear, we continue to see the benefits of our investments in theranostics.  Our Center for \nTheranostics Advancement in Indianapolis continues to be in high demand with the number of new \ninnovators and products we are collaborating with doubling in FY  \u201822 versus the prior year.  \n \n", "original_text": "So far \nwe have successfully launched 27 manufacturers, and we expect 5 -8 additional launches by the end \nof the fiscal year. ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "975f1dd6a67b132eeab4dcd99b89594b83c69e37716787343781ff3c80d02b6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b0230f9-8a5f-4fc0-ab0e-72c821945ca2", "node_type": "1", "metadata": {"window": "In our Third Party Logistics business, we have won 66 manufacturer contracts t his fiscal year.  So far \nwe have successfully launched 27 manufacturers, and we expect 5 -8 additional launches by the end \nof the fiscal year.  And specific to cell and gene therapy, we continue to win opportunities and have \nplans to launch 5 manufacturers in  the coming years, based on FDA approval and manufacturer \nreadiness.  \n \n In Nuclear, we continue to see the benefits of our investments in theranostics.  Our Center for \nTheranostics Advancement in Indianapolis continues to be in high demand with the number of new \ninnovators and products we are collaborating with doubling in FY  \u201822 versus the prior year.  \n \n Our Outcomes business continues to add new payers, PBMs, pharmaceutical manufacturers, and \nexpand clinical solutions for both independent pharmacies and retai l chains.  We have combined our \nReimbursement Consulting Solutions and Outcomes Connect platforms into a single, unified platform \nthat offers reimbursement assistance, decision support and scheduling to identify and complete \nclinical opportunities.  \n \n", "original_text": "In Nuclear, we continue to see the benefits of our investments in theranostics. "}, "hash": "e7c111fa8cc9bc508acd00548f47e4b6b755f342a94afdaff629f44d8e24093a", "class_name": "RelatedNodeInfo"}}, "text": "And specific to cell and gene therapy, we continue to win opportunities and have \nplans to launch 5 manufacturers in  the coming years, based on FDA approval and manufacturer \nreadiness.  \n \n", "start_char_idx": 1122, "end_char_idx": 1313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b0230f9-8a5f-4fc0-ab0e-72c821945ca2": {"__data__": {"id_": "3b0230f9-8a5f-4fc0-ab0e-72c821945ca2", "embedding": null, "metadata": {"window": "In our Third Party Logistics business, we have won 66 manufacturer contracts t his fiscal year.  So far \nwe have successfully launched 27 manufacturers, and we expect 5 -8 additional launches by the end \nof the fiscal year.  And specific to cell and gene therapy, we continue to win opportunities and have \nplans to launch 5 manufacturers in  the coming years, based on FDA approval and manufacturer \nreadiness.  \n \n In Nuclear, we continue to see the benefits of our investments in theranostics.  Our Center for \nTheranostics Advancement in Indianapolis continues to be in high demand with the number of new \ninnovators and products we are collaborating with doubling in FY  \u201822 versus the prior year.  \n \n Our Outcomes business continues to add new payers, PBMs, pharmaceutical manufacturers, and \nexpand clinical solutions for both independent pharmacies and retai l chains.  We have combined our \nReimbursement Consulting Solutions and Outcomes Connect platforms into a single, unified platform \nthat offers reimbursement assistance, decision support and scheduling to identify and complete \nclinical opportunities.  \n \n", "original_text": "In Nuclear, we continue to see the benefits of our investments in theranostics. ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1d0e21bb32acf0620a5e9501cf7e3b3cce031bf56a7948ca87bcbe9237f1db0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31617823-033b-4bca-9eb4-ec6a93b390e5", "node_type": "1", "metadata": {"window": "Digital re -enrollment via the patient portal \nincreased approvals within the first 30 days by 10%, and delivered a retention rate greater than 90%.  \n \n In our Third Party Logistics business, we have won 66 manufacturer contracts t his fiscal year.  So far \nwe have successfully launched 27 manufacturers, and we expect 5 -8 additional launches by the end \nof the fiscal year.  And specific to cell and gene therapy, we continue to win opportunities and have \nplans to launch 5 manufacturers in  the coming years, based on FDA approval and manufacturer \nreadiness.  \n \n In Nuclear, we continue to see the benefits of our investments in theranostics.  Our Center for \nTheranostics Advancement in Indianapolis continues to be in high demand with the number of new \ninnovators and products we are collaborating with doubling in FY  \u201822 versus the prior year.  \n \n Our Outcomes business continues to add new payers, PBMs, pharmaceutical manufacturers, and \nexpand clinical solutions for both independent pharmacies and retai l chains. ", "original_text": "And specific to cell and gene therapy, we continue to win opportunities and have \nplans to launch 5 manufacturers in  the coming years, based on FDA approval and manufacturer \nreadiness.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c3bc118e6088b0ce04b393d94ff7e335c1dcd7e624c691fd295ec215cd40a367", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b391213c-79d2-40a3-8eb3-de3bf348730f", "node_type": "1", "metadata": {"window": "So far \nwe have successfully launched 27 manufacturers, and we expect 5 -8 additional launches by the end \nof the fiscal year.  And specific to cell and gene therapy, we continue to win opportunities and have \nplans to launch 5 manufacturers in  the coming years, based on FDA approval and manufacturer \nreadiness.  \n \n In Nuclear, we continue to see the benefits of our investments in theranostics.  Our Center for \nTheranostics Advancement in Indianapolis continues to be in high demand with the number of new \ninnovators and products we are collaborating with doubling in FY  \u201822 versus the prior year.  \n \n Our Outcomes business continues to add new payers, PBMs, pharmaceutical manufacturers, and \nexpand clinical solutions for both independent pharmacies and retai l chains.  We have combined our \nReimbursement Consulting Solutions and Outcomes Connect platforms into a single, unified platform \nthat offers reimbursement assistance, decision support and scheduling to identify and complete \nclinical opportunities.  \n \n Across the enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformation. ", "original_text": "Our Center for \nTheranostics Advancement in Indianapolis continues to be in high demand with the number of new \ninnovators and products we are collaborating with doubling in FY  \u201822 versus the prior year.  \n \n"}, "hash": "325d6a26a37df3c133a1a3c40428b99d04cc5dcd2da541672f3e2d4e9a06c9f6", "class_name": "RelatedNodeInfo"}}, "text": "In Nuclear, we continue to see the benefits of our investments in theranostics. ", "start_char_idx": 1313, "end_char_idx": 1393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b391213c-79d2-40a3-8eb3-de3bf348730f": {"__data__": {"id_": "b391213c-79d2-40a3-8eb3-de3bf348730f", "embedding": null, "metadata": {"window": "So far \nwe have successfully launched 27 manufacturers, and we expect 5 -8 additional launches by the end \nof the fiscal year.  And specific to cell and gene therapy, we continue to win opportunities and have \nplans to launch 5 manufacturers in  the coming years, based on FDA approval and manufacturer \nreadiness.  \n \n In Nuclear, we continue to see the benefits of our investments in theranostics.  Our Center for \nTheranostics Advancement in Indianapolis continues to be in high demand with the number of new \ninnovators and products we are collaborating with doubling in FY  \u201822 versus the prior year.  \n \n Our Outcomes business continues to add new payers, PBMs, pharmaceutical manufacturers, and \nexpand clinical solutions for both independent pharmacies and retai l chains.  We have combined our \nReimbursement Consulting Solutions and Outcomes Connect platforms into a single, unified platform \nthat offers reimbursement assistance, decision support and scheduling to identify and complete \nclinical opportunities.  \n \n Across the enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformation. ", "original_text": "Our Center for \nTheranostics Advancement in Indianapolis continues to be in high demand with the number of new \ninnovators and products we are collaborating with doubling in FY  \u201822 versus the prior year.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1d0e21bb32acf0620a5e9501cf7e3b3cce031bf56a7948ca87bcbe9237f1db0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b0230f9-8a5f-4fc0-ab0e-72c821945ca2", "node_type": "1", "metadata": {"window": "In our Third Party Logistics business, we have won 66 manufacturer contracts t his fiscal year.  So far \nwe have successfully launched 27 manufacturers, and we expect 5 -8 additional launches by the end \nof the fiscal year.  And specific to cell and gene therapy, we continue to win opportunities and have \nplans to launch 5 manufacturers in  the coming years, based on FDA approval and manufacturer \nreadiness.  \n \n In Nuclear, we continue to see the benefits of our investments in theranostics.  Our Center for \nTheranostics Advancement in Indianapolis continues to be in high demand with the number of new \ninnovators and products we are collaborating with doubling in FY  \u201822 versus the prior year.  \n \n Our Outcomes business continues to add new payers, PBMs, pharmaceutical manufacturers, and \nexpand clinical solutions for both independent pharmacies and retai l chains.  We have combined our \nReimbursement Consulting Solutions and Outcomes Connect platforms into a single, unified platform \nthat offers reimbursement assistance, decision support and scheduling to identify and complete \nclinical opportunities.  \n \n", "original_text": "In Nuclear, we continue to see the benefits of our investments in theranostics. ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "295e79b82a32651510c112f35a464ea97f1bd9b3a74db30cf4048b61baec2da6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b81448c4-6431-468d-a70b-d5b01956f5e7", "node_type": "1", "metadata": {"window": "And specific to cell and gene therapy, we continue to win opportunities and have \nplans to launch 5 manufacturers in  the coming years, based on FDA approval and manufacturer \nreadiness.  \n \n In Nuclear, we continue to see the benefits of our investments in theranostics.  Our Center for \nTheranostics Advancement in Indianapolis continues to be in high demand with the number of new \ninnovators and products we are collaborating with doubling in FY  \u201822 versus the prior year.  \n \n Our Outcomes business continues to add new payers, PBMs, pharmaceutical manufacturers, and \nexpand clinical solutions for both independent pharmacies and retai l chains.  We have combined our \nReimbursement Consulting Solutions and Outcomes Connect platforms into a single, unified platform \nthat offers reimbursement assistance, decision support and scheduling to identify and complete \nclinical opportunities.  \n \n Across the enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformation.  We're \npairing these cost reduction efforts with balanced, disciplined, and shareh older -friendly capital \nallocation according to our priorities. ", "original_text": "Our Outcomes business continues to add new payers, PBMs, pharmaceutical manufacturers, and \nexpand clinical solutions for both independent pharmacies and retai l chains. "}, "hash": "879f6fb2f781d63d114203d3ef1ab544cb7745200463df14e2ac5a501bd8c1c0", "class_name": "RelatedNodeInfo"}}, "text": "Our Center for \nTheranostics Advancement in Indianapolis continues to be in high demand with the number of new \ninnovators and products we are collaborating with doubling in FY  \u201822 versus the prior year.  \n \n", "start_char_idx": 1393, "end_char_idx": 1602, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b81448c4-6431-468d-a70b-d5b01956f5e7": {"__data__": {"id_": "b81448c4-6431-468d-a70b-d5b01956f5e7", "embedding": null, "metadata": {"window": "And specific to cell and gene therapy, we continue to win opportunities and have \nplans to launch 5 manufacturers in  the coming years, based on FDA approval and manufacturer \nreadiness.  \n \n In Nuclear, we continue to see the benefits of our investments in theranostics.  Our Center for \nTheranostics Advancement in Indianapolis continues to be in high demand with the number of new \ninnovators and products we are collaborating with doubling in FY  \u201822 versus the prior year.  \n \n Our Outcomes business continues to add new payers, PBMs, pharmaceutical manufacturers, and \nexpand clinical solutions for both independent pharmacies and retai l chains.  We have combined our \nReimbursement Consulting Solutions and Outcomes Connect platforms into a single, unified platform \nthat offers reimbursement assistance, decision support and scheduling to identify and complete \nclinical opportunities.  \n \n Across the enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformation.  We're \npairing these cost reduction efforts with balanced, disciplined, and shareh older -friendly capital \nallocation according to our priorities. ", "original_text": "Our Outcomes business continues to add new payers, PBMs, pharmaceutical manufacturers, and \nexpand clinical solutions for both independent pharmacies and retai l chains. ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1d0e21bb32acf0620a5e9501cf7e3b3cce031bf56a7948ca87bcbe9237f1db0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b391213c-79d2-40a3-8eb3-de3bf348730f", "node_type": "1", "metadata": {"window": "So far \nwe have successfully launched 27 manufacturers, and we expect 5 -8 additional launches by the end \nof the fiscal year.  And specific to cell and gene therapy, we continue to win opportunities and have \nplans to launch 5 manufacturers in  the coming years, based on FDA approval and manufacturer \nreadiness.  \n \n In Nuclear, we continue to see the benefits of our investments in theranostics.  Our Center for \nTheranostics Advancement in Indianapolis continues to be in high demand with the number of new \ninnovators and products we are collaborating with doubling in FY  \u201822 versus the prior year.  \n \n Our Outcomes business continues to add new payers, PBMs, pharmaceutical manufacturers, and \nexpand clinical solutions for both independent pharmacies and retai l chains.  We have combined our \nReimbursement Consulting Solutions and Outcomes Connect platforms into a single, unified platform \nthat offers reimbursement assistance, decision support and scheduling to identify and complete \nclinical opportunities.  \n \n Across the enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformation. ", "original_text": "Our Center for \nTheranostics Advancement in Indianapolis continues to be in high demand with the number of new \ninnovators and products we are collaborating with doubling in FY  \u201822 versus the prior year.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5fbdb95e6c543da6c6c28e6f2be62df1757ce4560a52a0220f32088efc902252", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b95e763b-f60f-41aa-98a8-710303a85cdd", "node_type": "1", "metadata": {"window": "In Nuclear, we continue to see the benefits of our investments in theranostics.  Our Center for \nTheranostics Advancement in Indianapolis continues to be in high demand with the number of new \ninnovators and products we are collaborating with doubling in FY  \u201822 versus the prior year.  \n \n Our Outcomes business continues to add new payers, PBMs, pharmaceutical manufacturers, and \nexpand clinical solutions for both independent pharmacies and retai l chains.  We have combined our \nReimbursement Consulting Solutions and Outcomes Connect platforms into a single, unified platform \nthat offers reimbursement assistance, decision support and scheduling to identify and complete \nclinical opportunities.  \n \n Across the enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformation.  We're \npairing these cost reduction efforts with balanced, disciplined, and shareh older -friendly capital \nallocation according to our priorities.  Looking ahead, we're confident in our ability to achieve our long -\nterm targets.  \n \n", "original_text": "We have combined our \nReimbursement Consulting Solutions and Outcomes Connect platforms into a single, unified platform \nthat offers reimbursement assistance, decision support and scheduling to identify and complete \nclinical opportunities.  \n \n"}, "hash": "9afca94331459f96fdb536ac81ed53b68b656b4fb224b6f24c0e2c80229de97d", "class_name": "RelatedNodeInfo"}}, "text": "Our Outcomes business continues to add new payers, PBMs, pharmaceutical manufacturers, and \nexpand clinical solutions for both independent pharmacies and retai l chains. ", "start_char_idx": 1602, "end_char_idx": 1772, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b95e763b-f60f-41aa-98a8-710303a85cdd": {"__data__": {"id_": "b95e763b-f60f-41aa-98a8-710303a85cdd", "embedding": null, "metadata": {"window": "In Nuclear, we continue to see the benefits of our investments in theranostics.  Our Center for \nTheranostics Advancement in Indianapolis continues to be in high demand with the number of new \ninnovators and products we are collaborating with doubling in FY  \u201822 versus the prior year.  \n \n Our Outcomes business continues to add new payers, PBMs, pharmaceutical manufacturers, and \nexpand clinical solutions for both independent pharmacies and retai l chains.  We have combined our \nReimbursement Consulting Solutions and Outcomes Connect platforms into a single, unified platform \nthat offers reimbursement assistance, decision support and scheduling to identify and complete \nclinical opportunities.  \n \n Across the enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformation.  We're \npairing these cost reduction efforts with balanced, disciplined, and shareh older -friendly capital \nallocation according to our priorities.  Looking ahead, we're confident in our ability to achieve our long -\nterm targets.  \n \n", "original_text": "We have combined our \nReimbursement Consulting Solutions and Outcomes Connect platforms into a single, unified platform \nthat offers reimbursement assistance, decision support and scheduling to identify and complete \nclinical opportunities.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1d0e21bb32acf0620a5e9501cf7e3b3cce031bf56a7948ca87bcbe9237f1db0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b81448c4-6431-468d-a70b-d5b01956f5e7", "node_type": "1", "metadata": {"window": "And specific to cell and gene therapy, we continue to win opportunities and have \nplans to launch 5 manufacturers in  the coming years, based on FDA approval and manufacturer \nreadiness.  \n \n In Nuclear, we continue to see the benefits of our investments in theranostics.  Our Center for \nTheranostics Advancement in Indianapolis continues to be in high demand with the number of new \ninnovators and products we are collaborating with doubling in FY  \u201822 versus the prior year.  \n \n Our Outcomes business continues to add new payers, PBMs, pharmaceutical manufacturers, and \nexpand clinical solutions for both independent pharmacies and retai l chains.  We have combined our \nReimbursement Consulting Solutions and Outcomes Connect platforms into a single, unified platform \nthat offers reimbursement assistance, decision support and scheduling to identify and complete \nclinical opportunities.  \n \n Across the enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformation.  We're \npairing these cost reduction efforts with balanced, disciplined, and shareh older -friendly capital \nallocation according to our priorities. ", "original_text": "Our Outcomes business continues to add new payers, PBMs, pharmaceutical manufacturers, and \nexpand clinical solutions for both independent pharmacies and retai l chains. ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0813a41ff620f799e5c680240ae077fb7542c5afe1623afee14e1ca8d36701d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d8ff9f9-3f77-4385-bd65-32f4bc24020b", "node_type": "1", "metadata": {"window": "Our Center for \nTheranostics Advancement in Indianapolis continues to be in high demand with the number of new \ninnovators and products we are collaborating with doubling in FY  \u201822 versus the prior year.  \n \n Our Outcomes business continues to add new payers, PBMs, pharmaceutical manufacturers, and \nexpand clinical solutions for both independent pharmacies and retai l chains.  We have combined our \nReimbursement Consulting Solutions and Outcomes Connect platforms into a single, unified platform \nthat offers reimbursement assistance, decision support and scheduling to identify and complete \nclinical opportunities.  \n \n Across the enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformation.  We're \npairing these cost reduction efforts with balanced, disciplined, and shareh older -friendly capital \nallocation according to our priorities.  Looking ahead, we're confident in our ability to achieve our long -\nterm targets.  \n \n Now let me give a little color on injunctive relief as part of the national opioid settlement. ", "original_text": "Across the enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformation. "}, "hash": "f30ba4be7266b089edee8bcf4482459b3fef9c16185da21c0fd09146df9eb8a6", "class_name": "RelatedNodeInfo"}}, "text": "We have combined our \nReimbursement Consulting Solutions and Outcomes Connect platforms into a single, unified platform \nthat offers reimbursement assistance, decision support and scheduling to identify and complete \nclinical opportunities.  \n \n", "start_char_idx": 1772, "end_char_idx": 2017, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d8ff9f9-3f77-4385-bd65-32f4bc24020b": {"__data__": {"id_": "0d8ff9f9-3f77-4385-bd65-32f4bc24020b", "embedding": null, "metadata": {"window": "Our Center for \nTheranostics Advancement in Indianapolis continues to be in high demand with the number of new \ninnovators and products we are collaborating with doubling in FY  \u201822 versus the prior year.  \n \n Our Outcomes business continues to add new payers, PBMs, pharmaceutical manufacturers, and \nexpand clinical solutions for both independent pharmacies and retai l chains.  We have combined our \nReimbursement Consulting Solutions and Outcomes Connect platforms into a single, unified platform \nthat offers reimbursement assistance, decision support and scheduling to identify and complete \nclinical opportunities.  \n \n Across the enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformation.  We're \npairing these cost reduction efforts with balanced, disciplined, and shareh older -friendly capital \nallocation according to our priorities.  Looking ahead, we're confident in our ability to achieve our long -\nterm targets.  \n \n Now let me give a little color on injunctive relief as part of the national opioid settlement. ", "original_text": "Across the enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformation. ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1d0e21bb32acf0620a5e9501cf7e3b3cce031bf56a7948ca87bcbe9237f1db0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b95e763b-f60f-41aa-98a8-710303a85cdd", "node_type": "1", "metadata": {"window": "In Nuclear, we continue to see the benefits of our investments in theranostics.  Our Center for \nTheranostics Advancement in Indianapolis continues to be in high demand with the number of new \ninnovators and products we are collaborating with doubling in FY  \u201822 versus the prior year.  \n \n Our Outcomes business continues to add new payers, PBMs, pharmaceutical manufacturers, and \nexpand clinical solutions for both independent pharmacies and retai l chains.  We have combined our \nReimbursement Consulting Solutions and Outcomes Connect platforms into a single, unified platform \nthat offers reimbursement assistance, decision support and scheduling to identify and complete \nclinical opportunities.  \n \n Across the enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformation.  We're \npairing these cost reduction efforts with balanced, disciplined, and shareh older -friendly capital \nallocation according to our priorities.  Looking ahead, we're confident in our ability to achieve our long -\nterm targets.  \n \n", "original_text": "We have combined our \nReimbursement Consulting Solutions and Outcomes Connect platforms into a single, unified platform \nthat offers reimbursement assistance, decision support and scheduling to identify and complete \nclinical opportunities.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed5d0234e9151fad2930a1f209187e432dbe93795af62bac05f0488a491b995d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e8baa435-44a4-40aa-91c1-d5b7cc6ed784", "node_type": "1", "metadata": {"window": "Our Outcomes business continues to add new payers, PBMs, pharmaceutical manufacturers, and \nexpand clinical solutions for both independent pharmacies and retai l chains.  We have combined our \nReimbursement Consulting Solutions and Outcomes Connect platforms into a single, unified platform \nthat offers reimbursement assistance, decision support and scheduling to identify and complete \nclinical opportunities.  \n \n Across the enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformation.  We're \npairing these cost reduction efforts with balanced, disciplined, and shareh older -friendly capital \nallocation according to our priorities.  Looking ahead, we're confident in our ability to achieve our long -\nterm targets.  \n \n Now let me give a little color on injunctive relief as part of the national opioid settlement.  Injunctive \nrelief relates to controlled substance anti -diversion efforts and includes enhancements to governance, \nindependence and training of personnel, due diligence for new and existing customers, ordering limits \nfor certain products, and suspicious order monitoring. ", "original_text": "We're \npairing these cost reduction efforts with balanced, disciplined, and shareh older -friendly capital \nallocation according to our priorities. "}, "hash": "3be2f4c74f3096c8102a4632b49cdd4e0945f8421f37957916a66f1341005ea7", "class_name": "RelatedNodeInfo"}}, "text": "Across the enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformation. ", "start_char_idx": 2017, "end_char_idx": 2200, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e8baa435-44a4-40aa-91c1-d5b7cc6ed784": {"__data__": {"id_": "e8baa435-44a4-40aa-91c1-d5b7cc6ed784", "embedding": null, "metadata": {"window": "Our Outcomes business continues to add new payers, PBMs, pharmaceutical manufacturers, and \nexpand clinical solutions for both independent pharmacies and retai l chains.  We have combined our \nReimbursement Consulting Solutions and Outcomes Connect platforms into a single, unified platform \nthat offers reimbursement assistance, decision support and scheduling to identify and complete \nclinical opportunities.  \n \n Across the enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformation.  We're \npairing these cost reduction efforts with balanced, disciplined, and shareh older -friendly capital \nallocation according to our priorities.  Looking ahead, we're confident in our ability to achieve our long -\nterm targets.  \n \n Now let me give a little color on injunctive relief as part of the national opioid settlement.  Injunctive \nrelief relates to controlled substance anti -diversion efforts and includes enhancements to governance, \nindependence and training of personnel, due diligence for new and existing customers, ordering limits \nfor certain products, and suspicious order monitoring. ", "original_text": "We're \npairing these cost reduction efforts with balanced, disciplined, and shareh older -friendly capital \nallocation according to our priorities. ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1d0e21bb32acf0620a5e9501cf7e3b3cce031bf56a7948ca87bcbe9237f1db0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d8ff9f9-3f77-4385-bd65-32f4bc24020b", "node_type": "1", "metadata": {"window": "Our Center for \nTheranostics Advancement in Indianapolis continues to be in high demand with the number of new \ninnovators and products we are collaborating with doubling in FY  \u201822 versus the prior year.  \n \n Our Outcomes business continues to add new payers, PBMs, pharmaceutical manufacturers, and \nexpand clinical solutions for both independent pharmacies and retai l chains.  We have combined our \nReimbursement Consulting Solutions and Outcomes Connect platforms into a single, unified platform \nthat offers reimbursement assistance, decision support and scheduling to identify and complete \nclinical opportunities.  \n \n Across the enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformation.  We're \npairing these cost reduction efforts with balanced, disciplined, and shareh older -friendly capital \nallocation according to our priorities.  Looking ahead, we're confident in our ability to achieve our long -\nterm targets.  \n \n Now let me give a little color on injunctive relief as part of the national opioid settlement. ", "original_text": "Across the enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformation. ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc128795c656659060db016f4762940b486f6bf26d4160a71ef0f7b910d3ac35", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "abdeaa26-759e-4242-9e81-8b3a94035ae4", "node_type": "1", "metadata": {"window": "We have combined our \nReimbursement Consulting Solutions and Outcomes Connect platforms into a single, unified platform \nthat offers reimbursement assistance, decision support and scheduling to identify and complete \nclinical opportunities.  \n \n Across the enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformation.  We're \npairing these cost reduction efforts with balanced, disciplined, and shareh older -friendly capital \nallocation according to our priorities.  Looking ahead, we're confident in our ability to achieve our long -\nterm targets.  \n \n Now let me give a little color on injunctive relief as part of the national opioid settlement.  Injunctive \nrelief relates to controlled substance anti -diversion efforts and includes enhancements to governance, \nindependence and training of personnel, due diligence for new and existing customers, ordering limits \nfor certain products, and suspicious order monitoring.  I n addition, we and the two other settling \ndistributors will engage a third -party vendor to act as a clearinghouse for data aggregation and \nreporting, which the distributors will fund for ten years. ", "original_text": "Looking ahead, we're confident in our ability to achieve our long -\nterm targets.  \n \n"}, "hash": "29939d2b97cfbeda3a0c9a228ca355d9798fa5a22c339e4519b64a02923fc64f", "class_name": "RelatedNodeInfo"}}, "text": "We're \npairing these cost reduction efforts with balanced, disciplined, and shareh older -friendly capital \nallocation according to our priorities. ", "start_char_idx": 2200, "end_char_idx": 2348, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "abdeaa26-759e-4242-9e81-8b3a94035ae4": {"__data__": {"id_": "abdeaa26-759e-4242-9e81-8b3a94035ae4", "embedding": null, "metadata": {"window": "We have combined our \nReimbursement Consulting Solutions and Outcomes Connect platforms into a single, unified platform \nthat offers reimbursement assistance, decision support and scheduling to identify and complete \nclinical opportunities.  \n \n Across the enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformation.  We're \npairing these cost reduction efforts with balanced, disciplined, and shareh older -friendly capital \nallocation according to our priorities.  Looking ahead, we're confident in our ability to achieve our long -\nterm targets.  \n \n Now let me give a little color on injunctive relief as part of the national opioid settlement.  Injunctive \nrelief relates to controlled substance anti -diversion efforts and includes enhancements to governance, \nindependence and training of personnel, due diligence for new and existing customers, ordering limits \nfor certain products, and suspicious order monitoring.  I n addition, we and the two other settling \ndistributors will engage a third -party vendor to act as a clearinghouse for data aggregation and \nreporting, which the distributors will fund for ten years. ", "original_text": "Looking ahead, we're confident in our ability to achieve our long -\nterm targets.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1d0e21bb32acf0620a5e9501cf7e3b3cce031bf56a7948ca87bcbe9237f1db0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e8baa435-44a4-40aa-91c1-d5b7cc6ed784", "node_type": "1", "metadata": {"window": "Our Outcomes business continues to add new payers, PBMs, pharmaceutical manufacturers, and \nexpand clinical solutions for both independent pharmacies and retai l chains.  We have combined our \nReimbursement Consulting Solutions and Outcomes Connect platforms into a single, unified platform \nthat offers reimbursement assistance, decision support and scheduling to identify and complete \nclinical opportunities.  \n \n Across the enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformation.  We're \npairing these cost reduction efforts with balanced, disciplined, and shareh older -friendly capital \nallocation according to our priorities.  Looking ahead, we're confident in our ability to achieve our long -\nterm targets.  \n \n Now let me give a little color on injunctive relief as part of the national opioid settlement.  Injunctive \nrelief relates to controlled substance anti -diversion efforts and includes enhancements to governance, \nindependence and training of personnel, due diligence for new and existing customers, ordering limits \nfor certain products, and suspicious order monitoring. ", "original_text": "We're \npairing these cost reduction efforts with balanced, disciplined, and shareh older -friendly capital \nallocation according to our priorities. ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5e91df2f2c55da013725c19cb38fbefc0e564fcffd01c769358833d134f9c91b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6667823f-b768-4396-8a17-89fc8eca647c", "node_type": "1", "metadata": {"window": "Across the enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformation.  We're \npairing these cost reduction efforts with balanced, disciplined, and shareh older -friendly capital \nallocation according to our priorities.  Looking ahead, we're confident in our ability to achieve our long -\nterm targets.  \n \n Now let me give a little color on injunctive relief as part of the national opioid settlement.  Injunctive \nrelief relates to controlled substance anti -diversion efforts and includes enhancements to governance, \nindependence and training of personnel, due diligence for new and existing customers, ordering limits \nfor certain products, and suspicious order monitoring.  I n addition, we and the two other settling \ndistributors will engage a third -party vendor to act as a clearinghouse for data aggregation and \nreporting, which the distributors will fund for ten years.  These relief measures are intended to create \nadditional tr ansparency, and while there is additional cost, these initiatives demonstrate our \ncommitment to being part of the solution to the U.S. ", "original_text": "Now let me give a little color on injunctive relief as part of the national opioid settlement. "}, "hash": "edd99e6e4646ecd3df45a29727aea444ae283385366ce355b70a2df3947400e1", "class_name": "RelatedNodeInfo"}}, "text": "Looking ahead, we're confident in our ability to achieve our long -\nterm targets.  \n \n", "start_char_idx": 2348, "end_char_idx": 2434, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6667823f-b768-4396-8a17-89fc8eca647c": {"__data__": {"id_": "6667823f-b768-4396-8a17-89fc8eca647c", "embedding": null, "metadata": {"window": "Across the enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformation.  We're \npairing these cost reduction efforts with balanced, disciplined, and shareh older -friendly capital \nallocation according to our priorities.  Looking ahead, we're confident in our ability to achieve our long -\nterm targets.  \n \n Now let me give a little color on injunctive relief as part of the national opioid settlement.  Injunctive \nrelief relates to controlled substance anti -diversion efforts and includes enhancements to governance, \nindependence and training of personnel, due diligence for new and existing customers, ordering limits \nfor certain products, and suspicious order monitoring.  I n addition, we and the two other settling \ndistributors will engage a third -party vendor to act as a clearinghouse for data aggregation and \nreporting, which the distributors will fund for ten years.  These relief measures are intended to create \nadditional tr ansparency, and while there is additional cost, these initiatives demonstrate our \ncommitment to being part of the solution to the U.S. ", "original_text": "Now let me give a little color on injunctive relief as part of the national opioid settlement. ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1d0e21bb32acf0620a5e9501cf7e3b3cce031bf56a7948ca87bcbe9237f1db0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "abdeaa26-759e-4242-9e81-8b3a94035ae4", "node_type": "1", "metadata": {"window": "We have combined our \nReimbursement Consulting Solutions and Outcomes Connect platforms into a single, unified platform \nthat offers reimbursement assistance, decision support and scheduling to identify and complete \nclinical opportunities.  \n \n Across the enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformation.  We're \npairing these cost reduction efforts with balanced, disciplined, and shareh older -friendly capital \nallocation according to our priorities.  Looking ahead, we're confident in our ability to achieve our long -\nterm targets.  \n \n Now let me give a little color on injunctive relief as part of the national opioid settlement.  Injunctive \nrelief relates to controlled substance anti -diversion efforts and includes enhancements to governance, \nindependence and training of personnel, due diligence for new and existing customers, ordering limits \nfor certain products, and suspicious order monitoring.  I n addition, we and the two other settling \ndistributors will engage a third -party vendor to act as a clearinghouse for data aggregation and \nreporting, which the distributors will fund for ten years. ", "original_text": "Looking ahead, we're confident in our ability to achieve our long -\nterm targets.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "04860fc71e028002b8cc436894f60c1553b9ccb92ec23e633dbf596534909b7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62d6ac93-7909-4633-92aa-3d643083656e", "node_type": "1", "metadata": {"window": "We're \npairing these cost reduction efforts with balanced, disciplined, and shareh older -friendly capital \nallocation according to our priorities.  Looking ahead, we're confident in our ability to achieve our long -\nterm targets.  \n \n Now let me give a little color on injunctive relief as part of the national opioid settlement.  Injunctive \nrelief relates to controlled substance anti -diversion efforts and includes enhancements to governance, \nindependence and training of personnel, due diligence for new and existing customers, ordering limits \nfor certain products, and suspicious order monitoring.  I n addition, we and the two other settling \ndistributors will engage a third -party vendor to act as a clearinghouse for data aggregation and \nreporting, which the distributors will fund for ten years.  These relief measures are intended to create \nadditional tr ansparency, and while there is additional cost, these initiatives demonstrate our \ncommitment to being part of the solution to the U.S.  opioid epidemic.  \n \n", "original_text": "Injunctive \nrelief relates to controlled substance anti -diversion efforts and includes enhancements to governance, \nindependence and training of personnel, due diligence for new and existing customers, ordering limits \nfor certain products, and suspicious order monitoring. "}, "hash": "87075a5cac1f069c7ee6588a79b800b4a6920b26b05bfe1d38dd8c28f65f60ac", "class_name": "RelatedNodeInfo"}}, "text": "Now let me give a little color on injunctive relief as part of the national opioid settlement. ", "start_char_idx": 2434, "end_char_idx": 2529, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62d6ac93-7909-4633-92aa-3d643083656e": {"__data__": {"id_": "62d6ac93-7909-4633-92aa-3d643083656e", "embedding": null, "metadata": {"window": "We're \npairing these cost reduction efforts with balanced, disciplined, and shareh older -friendly capital \nallocation according to our priorities.  Looking ahead, we're confident in our ability to achieve our long -\nterm targets.  \n \n Now let me give a little color on injunctive relief as part of the national opioid settlement.  Injunctive \nrelief relates to controlled substance anti -diversion efforts and includes enhancements to governance, \nindependence and training of personnel, due diligence for new and existing customers, ordering limits \nfor certain products, and suspicious order monitoring.  I n addition, we and the two other settling \ndistributors will engage a third -party vendor to act as a clearinghouse for data aggregation and \nreporting, which the distributors will fund for ten years.  These relief measures are intended to create \nadditional tr ansparency, and while there is additional cost, these initiatives demonstrate our \ncommitment to being part of the solution to the U.S.  opioid epidemic.  \n \n", "original_text": "Injunctive \nrelief relates to controlled substance anti -diversion efforts and includes enhancements to governance, \nindependence and training of personnel, due diligence for new and existing customers, ordering limits \nfor certain products, and suspicious order monitoring. ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1d0e21bb32acf0620a5e9501cf7e3b3cce031bf56a7948ca87bcbe9237f1db0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6667823f-b768-4396-8a17-89fc8eca647c", "node_type": "1", "metadata": {"window": "Across the enterprise, we continue to aggressively review our cost structure as we work to \nstreamline, simplify and strengthen our operations and execute our digital transformation.  We're \npairing these cost reduction efforts with balanced, disciplined, and shareh older -friendly capital \nallocation according to our priorities.  Looking ahead, we're confident in our ability to achieve our long -\nterm targets.  \n \n Now let me give a little color on injunctive relief as part of the national opioid settlement.  Injunctive \nrelief relates to controlled substance anti -diversion efforts and includes enhancements to governance, \nindependence and training of personnel, due diligence for new and existing customers, ordering limits \nfor certain products, and suspicious order monitoring.  I n addition, we and the two other settling \ndistributors will engage a third -party vendor to act as a clearinghouse for data aggregation and \nreporting, which the distributors will fund for ten years.  These relief measures are intended to create \nadditional tr ansparency, and while there is additional cost, these initiatives demonstrate our \ncommitment to being part of the solution to the U.S. ", "original_text": "Now let me give a little color on injunctive relief as part of the national opioid settlement. ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "425d37644e4e46b95c0c232f8cfbdceec8f71f81bf8bda1204740658412859cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cdfc8e8d-548e-49c0-84d3-2ee8b5015ded", "node_type": "1", "metadata": {"window": "Looking ahead, we're confident in our ability to achieve our long -\nterm targets.  \n \n Now let me give a little color on injunctive relief as part of the national opioid settlement.  Injunctive \nrelief relates to controlled substance anti -diversion efforts and includes enhancements to governance, \nindependence and training of personnel, due diligence for new and existing customers, ordering limits \nfor certain products, and suspicious order monitoring.  I n addition, we and the two other settling \ndistributors will engage a third -party vendor to act as a clearinghouse for data aggregation and \nreporting, which the distributors will fund for ten years.  These relief measures are intended to create \nadditional tr ansparency, and while there is additional cost, these initiatives demonstrate our \ncommitment to being part of the solution to the U.S.  opioid epidemic.  \n \n In closing, what we do matters.  ", "original_text": "I n addition, we and the two other settling \ndistributors will engage a third -party vendor to act as a clearinghouse for data aggregation and \nreporting, which the distributors will fund for ten years. "}, "hash": "8782577f2971f0a9ae0f35399e5b3c32557e80fc7bd76d0350c23472b84c7633", "class_name": "RelatedNodeInfo"}}, "text": "Injunctive \nrelief relates to controlled substance anti -diversion efforts and includes enhancements to governance, \nindependence and training of personnel, due diligence for new and existing customers, ordering limits \nfor certain products, and suspicious order monitoring. ", "start_char_idx": 2529, "end_char_idx": 2804, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cdfc8e8d-548e-49c0-84d3-2ee8b5015ded": {"__data__": {"id_": "cdfc8e8d-548e-49c0-84d3-2ee8b5015ded", "embedding": null, "metadata": {"window": "Looking ahead, we're confident in our ability to achieve our long -\nterm targets.  \n \n Now let me give a little color on injunctive relief as part of the national opioid settlement.  Injunctive \nrelief relates to controlled substance anti -diversion efforts and includes enhancements to governance, \nindependence and training of personnel, due diligence for new and existing customers, ordering limits \nfor certain products, and suspicious order monitoring.  I n addition, we and the two other settling \ndistributors will engage a third -party vendor to act as a clearinghouse for data aggregation and \nreporting, which the distributors will fund for ten years.  These relief measures are intended to create \nadditional tr ansparency, and while there is additional cost, these initiatives demonstrate our \ncommitment to being part of the solution to the U.S.  opioid epidemic.  \n \n In closing, what we do matters.  ", "original_text": "I n addition, we and the two other settling \ndistributors will engage a third -party vendor to act as a clearinghouse for data aggregation and \nreporting, which the distributors will fund for ten years. ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1d0e21bb32acf0620a5e9501cf7e3b3cce031bf56a7948ca87bcbe9237f1db0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62d6ac93-7909-4633-92aa-3d643083656e", "node_type": "1", "metadata": {"window": "We're \npairing these cost reduction efforts with balanced, disciplined, and shareh older -friendly capital \nallocation according to our priorities.  Looking ahead, we're confident in our ability to achieve our long -\nterm targets.  \n \n Now let me give a little color on injunctive relief as part of the national opioid settlement.  Injunctive \nrelief relates to controlled substance anti -diversion efforts and includes enhancements to governance, \nindependence and training of personnel, due diligence for new and existing customers, ordering limits \nfor certain products, and suspicious order monitoring.  I n addition, we and the two other settling \ndistributors will engage a third -party vendor to act as a clearinghouse for data aggregation and \nreporting, which the distributors will fund for ten years.  These relief measures are intended to create \nadditional tr ansparency, and while there is additional cost, these initiatives demonstrate our \ncommitment to being part of the solution to the U.S.  opioid epidemic.  \n \n", "original_text": "Injunctive \nrelief relates to controlled substance anti -diversion efforts and includes enhancements to governance, \nindependence and training of personnel, due diligence for new and existing customers, ordering limits \nfor certain products, and suspicious order monitoring. ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ed64299430829046f71e8330fe4bad9fc3dbb57567b772f7616e1ff6889e8a3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "661b2526-b098-4d8f-bf78-7259217f5b8d", "node_type": "1", "metadata": {"window": "Now let me give a little color on injunctive relief as part of the national opioid settlement.  Injunctive \nrelief relates to controlled substance anti -diversion efforts and includes enhancements to governance, \nindependence and training of personnel, due diligence for new and existing customers, ordering limits \nfor certain products, and suspicious order monitoring.  I n addition, we and the two other settling \ndistributors will engage a third -party vendor to act as a clearinghouse for data aggregation and \nreporting, which the distributors will fund for ten years.  These relief measures are intended to create \nadditional tr ansparency, and while there is additional cost, these initiatives demonstrate our \ncommitment to being part of the solution to the U.S.  opioid epidemic.  \n \n In closing, what we do matters.   We aspire to be healthcare's most trusted partner, by delivering the \nproducts and solutions our customers need, advancing healthcare and improving lives.  \n ", "original_text": "These relief measures are intended to create \nadditional tr ansparency, and while there is additional cost, these initiatives demonstrate our \ncommitment to being part of the solution to the U.S. "}, "hash": "de39489128395bcb48e19b47c33e76e90b01594cae279f46370b1c5dbbc64dae", "class_name": "RelatedNodeInfo"}}, "text": "I n addition, we and the two other settling \ndistributors will engage a third -party vendor to act as a clearinghouse for data aggregation and \nreporting, which the distributors will fund for ten years. ", "start_char_idx": 2804, "end_char_idx": 3007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "661b2526-b098-4d8f-bf78-7259217f5b8d": {"__data__": {"id_": "661b2526-b098-4d8f-bf78-7259217f5b8d", "embedding": null, "metadata": {"window": "Now let me give a little color on injunctive relief as part of the national opioid settlement.  Injunctive \nrelief relates to controlled substance anti -diversion efforts and includes enhancements to governance, \nindependence and training of personnel, due diligence for new and existing customers, ordering limits \nfor certain products, and suspicious order monitoring.  I n addition, we and the two other settling \ndistributors will engage a third -party vendor to act as a clearinghouse for data aggregation and \nreporting, which the distributors will fund for ten years.  These relief measures are intended to create \nadditional tr ansparency, and while there is additional cost, these initiatives demonstrate our \ncommitment to being part of the solution to the U.S.  opioid epidemic.  \n \n In closing, what we do matters.   We aspire to be healthcare's most trusted partner, by delivering the \nproducts and solutions our customers need, advancing healthcare and improving lives.  \n ", "original_text": "These relief measures are intended to create \nadditional tr ansparency, and while there is additional cost, these initiatives demonstrate our \ncommitment to being part of the solution to the U.S. ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1d0e21bb32acf0620a5e9501cf7e3b3cce031bf56a7948ca87bcbe9237f1db0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cdfc8e8d-548e-49c0-84d3-2ee8b5015ded", "node_type": "1", "metadata": {"window": "Looking ahead, we're confident in our ability to achieve our long -\nterm targets.  \n \n Now let me give a little color on injunctive relief as part of the national opioid settlement.  Injunctive \nrelief relates to controlled substance anti -diversion efforts and includes enhancements to governance, \nindependence and training of personnel, due diligence for new and existing customers, ordering limits \nfor certain products, and suspicious order monitoring.  I n addition, we and the two other settling \ndistributors will engage a third -party vendor to act as a clearinghouse for data aggregation and \nreporting, which the distributors will fund for ten years.  These relief measures are intended to create \nadditional tr ansparency, and while there is additional cost, these initiatives demonstrate our \ncommitment to being part of the solution to the U.S.  opioid epidemic.  \n \n In closing, what we do matters.  ", "original_text": "I n addition, we and the two other settling \ndistributors will engage a third -party vendor to act as a clearinghouse for data aggregation and \nreporting, which the distributors will fund for ten years. ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80a34d797e0ea5ac78d079dc4869ff1da5e8c7ae260a5241335e04182fbbb09c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a96a8bf-ac67-41b2-8081-bf8a8ad9963d", "node_type": "1", "metadata": {"window": "Injunctive \nrelief relates to controlled substance anti -diversion efforts and includes enhancements to governance, \nindependence and training of personnel, due diligence for new and existing customers, ordering limits \nfor certain products, and suspicious order monitoring.  I n addition, we and the two other settling \ndistributors will engage a third -party vendor to act as a clearinghouse for data aggregation and \nreporting, which the distributors will fund for ten years.  These relief measures are intended to create \nadditional tr ansparency, and while there is additional cost, these initiatives demonstrate our \ncommitment to being part of the solution to the U.S.  opioid epidemic.  \n \n In closing, what we do matters.   We aspire to be healthcare's most trusted partner, by delivering the \nproducts and solutions our customers need, advancing healthcare and improving lives.  \n ", "original_text": "opioid epidemic.  \n \n"}, "hash": "6c66b223b7c56702de21c2728dfbf5236826d076cbe531edb99cd83b30141ec2", "class_name": "RelatedNodeInfo"}}, "text": "These relief measures are intended to create \nadditional tr ansparency, and while there is additional cost, these initiatives demonstrate our \ncommitment to being part of the solution to the U.S. ", "start_char_idx": 3007, "end_char_idx": 3203, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a96a8bf-ac67-41b2-8081-bf8a8ad9963d": {"__data__": {"id_": "8a96a8bf-ac67-41b2-8081-bf8a8ad9963d", "embedding": null, "metadata": {"window": "Injunctive \nrelief relates to controlled substance anti -diversion efforts and includes enhancements to governance, \nindependence and training of personnel, due diligence for new and existing customers, ordering limits \nfor certain products, and suspicious order monitoring.  I n addition, we and the two other settling \ndistributors will engage a third -party vendor to act as a clearinghouse for data aggregation and \nreporting, which the distributors will fund for ten years.  These relief measures are intended to create \nadditional tr ansparency, and while there is additional cost, these initiatives demonstrate our \ncommitment to being part of the solution to the U.S.  opioid epidemic.  \n \n In closing, what we do matters.   We aspire to be healthcare's most trusted partner, by delivering the \nproducts and solutions our customers need, advancing healthcare and improving lives.  \n ", "original_text": "opioid epidemic.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1d0e21bb32acf0620a5e9501cf7e3b3cce031bf56a7948ca87bcbe9237f1db0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "661b2526-b098-4d8f-bf78-7259217f5b8d", "node_type": "1", "metadata": {"window": "Now let me give a little color on injunctive relief as part of the national opioid settlement.  Injunctive \nrelief relates to controlled substance anti -diversion efforts and includes enhancements to governance, \nindependence and training of personnel, due diligence for new and existing customers, ordering limits \nfor certain products, and suspicious order monitoring.  I n addition, we and the two other settling \ndistributors will engage a third -party vendor to act as a clearinghouse for data aggregation and \nreporting, which the distributors will fund for ten years.  These relief measures are intended to create \nadditional tr ansparency, and while there is additional cost, these initiatives demonstrate our \ncommitment to being part of the solution to the U.S.  opioid epidemic.  \n \n In closing, what we do matters.   We aspire to be healthcare's most trusted partner, by delivering the \nproducts and solutions our customers need, advancing healthcare and improving lives.  \n ", "original_text": "These relief measures are intended to create \nadditional tr ansparency, and while there is additional cost, these initiatives demonstrate our \ncommitment to being part of the solution to the U.S. ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1fe0cadc87c258b6f633452015781cdcb04464b85bd530b53993d38f6786ba9d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8109d82-ffe2-4964-822b-23e52c64d118", "node_type": "1", "metadata": {"window": "I n addition, we and the two other settling \ndistributors will engage a third -party vendor to act as a clearinghouse for data aggregation and \nreporting, which the distributors will fund for ten years.  These relief measures are intended to create \nadditional tr ansparency, and while there is additional cost, these initiatives demonstrate our \ncommitment to being part of the solution to the U.S.  opioid epidemic.  \n \n In closing, what we do matters.   We aspire to be healthcare's most trusted partner, by delivering the \nproducts and solutions our customers need, advancing healthcare and improving lives.  \n ", "original_text": "In closing, what we do matters.  "}, "hash": "91463ee8c9c13167e75bd57a836c7ceb4d7089a73f5157ba0b36c5d579dcb5f1", "class_name": "RelatedNodeInfo"}}, "text": "opioid epidemic.  \n \n", "start_char_idx": 3203, "end_char_idx": 3224, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8109d82-ffe2-4964-822b-23e52c64d118": {"__data__": {"id_": "d8109d82-ffe2-4964-822b-23e52c64d118", "embedding": null, "metadata": {"window": "I n addition, we and the two other settling \ndistributors will engage a third -party vendor to act as a clearinghouse for data aggregation and \nreporting, which the distributors will fund for ten years.  These relief measures are intended to create \nadditional tr ansparency, and while there is additional cost, these initiatives demonstrate our \ncommitment to being part of the solution to the U.S.  opioid epidemic.  \n \n In closing, what we do matters.   We aspire to be healthcare's most trusted partner, by delivering the \nproducts and solutions our customers need, advancing healthcare and improving lives.  \n ", "original_text": "In closing, what we do matters.  ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1d0e21bb32acf0620a5e9501cf7e3b3cce031bf56a7948ca87bcbe9237f1db0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a96a8bf-ac67-41b2-8081-bf8a8ad9963d", "node_type": "1", "metadata": {"window": "Injunctive \nrelief relates to controlled substance anti -diversion efforts and includes enhancements to governance, \nindependence and training of personnel, due diligence for new and existing customers, ordering limits \nfor certain products, and suspicious order monitoring.  I n addition, we and the two other settling \ndistributors will engage a third -party vendor to act as a clearinghouse for data aggregation and \nreporting, which the distributors will fund for ten years.  These relief measures are intended to create \nadditional tr ansparency, and while there is additional cost, these initiatives demonstrate our \ncommitment to being part of the solution to the U.S.  opioid epidemic.  \n \n In closing, what we do matters.   We aspire to be healthcare's most trusted partner, by delivering the \nproducts and solutions our customers need, advancing healthcare and improving lives.  \n ", "original_text": "opioid epidemic.  \n \n", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79ec5418af979e131d67fd5c1a5d7173c1098a6187e3dce10a0a293d73b0f895", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "594187ff-4f0c-4a59-8bef-463e8e6e503c", "node_type": "1", "metadata": {"window": "These relief measures are intended to create \nadditional tr ansparency, and while there is additional cost, these initiatives demonstrate our \ncommitment to being part of the solution to the U.S.  opioid epidemic.  \n \n In closing, what we do matters.   We aspire to be healthcare's most trusted partner, by delivering the \nproducts and solutions our customers need, advancing healthcare and improving lives.  \n ", "original_text": "We aspire to be healthcare's most trusted partner, by delivering the \nproducts and solutions our customers need, advancing healthcare and improving lives.  \n "}, "hash": "a795796d959231fc886535f72f3f6151fdbde849daa1e00ef82eada8073a66b8", "class_name": "RelatedNodeInfo"}}, "text": "In closing, what we do matters.  ", "start_char_idx": 3224, "end_char_idx": 3257, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "594187ff-4f0c-4a59-8bef-463e8e6e503c": {"__data__": {"id_": "594187ff-4f0c-4a59-8bef-463e8e6e503c", "embedding": null, "metadata": {"window": "These relief measures are intended to create \nadditional tr ansparency, and while there is additional cost, these initiatives demonstrate our \ncommitment to being part of the solution to the U.S.  opioid epidemic.  \n \n In closing, what we do matters.   We aspire to be healthcare's most trusted partner, by delivering the \nproducts and solutions our customers need, advancing healthcare and improving lives.  \n ", "original_text": "We aspire to be healthcare's most trusted partner, by delivering the \nproducts and solutions our customers need, advancing healthcare and improving lives.  \n ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e", "node_type": "4", "metadata": {"page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1d0e21bb32acf0620a5e9501cf7e3b3cce031bf56a7948ca87bcbe9237f1db0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8109d82-ffe2-4964-822b-23e52c64d118", "node_type": "1", "metadata": {"window": "I n addition, we and the two other settling \ndistributors will engage a third -party vendor to act as a clearinghouse for data aggregation and \nreporting, which the distributors will fund for ten years.  These relief measures are intended to create \nadditional tr ansparency, and while there is additional cost, these initiatives demonstrate our \ncommitment to being part of the solution to the U.S.  opioid epidemic.  \n \n In closing, what we do matters.   We aspire to be healthcare's most trusted partner, by delivering the \nproducts and solutions our customers need, advancing healthcare and improving lives.  \n ", "original_text": "In closing, what we do matters.  ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8335758968ef60267fc1365372d67daa6703677d04df9a126233e859003b6789", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e448cbb6-2a50-40b1-8baa-885ee5c2e998", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \nAnd now, Jason and I will take your questions.  \n \n Operator:  Thank you.   If you would like to ask a qu estion, please signal by pressing star 1 on your \ntelephone keypad.  If you're using a speakerphone, please make sure your mute function is turned off \nto allow your signal to reach our equipment. ", "original_text": " \nPage 9 of 15 \n \nAnd now, Jason and I will take your questions.  \n \n"}, "hash": "b308b2c3df30d60dc206baf5d151370808fffae2525e808db728a1b6e0922830", "class_name": "RelatedNodeInfo"}}, "text": "We aspire to be healthcare's most trusted partner, by delivering the \nproducts and solutions our customers need, advancing healthcare and improving lives.  \n ", "start_char_idx": 3257, "end_char_idx": 3415, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e448cbb6-2a50-40b1-8baa-885ee5c2e998": {"__data__": {"id_": "e448cbb6-2a50-40b1-8baa-885ee5c2e998", "embedding": null, "metadata": {"window": " \nPage 9 of 15 \n \nAnd now, Jason and I will take your questions.  \n \n Operator:  Thank you.   If you would like to ask a qu estion, please signal by pressing star 1 on your \ntelephone keypad.  If you're using a speakerphone, please make sure your mute function is turned off \nto allow your signal to reach our equipment. ", "original_text": " \nPage 9 of 15 \n \nAnd now, Jason and I will take your questions.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "594187ff-4f0c-4a59-8bef-463e8e6e503c", "node_type": "1", "metadata": {"window": "These relief measures are intended to create \nadditional tr ansparency, and while there is additional cost, these initiatives demonstrate our \ncommitment to being part of the solution to the U.S.  opioid epidemic.  \n \n In closing, what we do matters.   We aspire to be healthcare's most trusted partner, by delivering the \nproducts and solutions our customers need, advancing healthcare and improving lives.  \n ", "original_text": "We aspire to be healthcare's most trusted partner, by delivering the \nproducts and solutions our customers need, advancing healthcare and improving lives.  \n ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d709764fab42df70c15eddc973f6776f5e309fb5d86808bdc0cbf08977b4eb8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ce0134d-b301-46c4-af45-6c2a28303ede", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \nAnd now, Jason and I will take your questions.  \n \n Operator:  Thank you.   If you would like to ask a qu estion, please signal by pressing star 1 on your \ntelephone keypad.  If you're using a speakerphone, please make sure your mute function is turned off \nto allow your signal to reach our equipment.  Again, press star 1 to ask a question. ", "original_text": "Operator:  Thank you.  "}, "hash": "cc7c8ded6f7ec4da13b54278a04f5887e79b2f8a9d18f01aebd12b3c4a34ad25", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 9 of 15 \n \nAnd now, Jason and I will take your questions.  \n \n", "start_char_idx": 0, "end_char_idx": 69, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ce0134d-b301-46c4-af45-6c2a28303ede": {"__data__": {"id_": "0ce0134d-b301-46c4-af45-6c2a28303ede", "embedding": null, "metadata": {"window": " \nPage 9 of 15 \n \nAnd now, Jason and I will take your questions.  \n \n Operator:  Thank you.   If you would like to ask a qu estion, please signal by pressing star 1 on your \ntelephone keypad.  If you're using a speakerphone, please make sure your mute function is turned off \nto allow your signal to reach our equipment.  Again, press star 1 to ask a question. ", "original_text": "Operator:  Thank you.  ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e448cbb6-2a50-40b1-8baa-885ee5c2e998", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \nAnd now, Jason and I will take your questions.  \n \n Operator:  Thank you.   If you would like to ask a qu estion, please signal by pressing star 1 on your \ntelephone keypad.  If you're using a speakerphone, please make sure your mute function is turned off \nto allow your signal to reach our equipment. ", "original_text": " \nPage 9 of 15 \n \nAnd now, Jason and I will take your questions.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9c261333ae32044032bf2429750325333ca57ff22a45dd90446b5b5629cf6fa1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4aaccbef-af09-46fd-a8f5-58f5f0b98fe7", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \nAnd now, Jason and I will take your questions.  \n \n Operator:  Thank you.   If you would like to ask a qu estion, please signal by pressing star 1 on your \ntelephone keypad.  If you're using a speakerphone, please make sure your mute function is turned off \nto allow your signal to reach our equipment.  Again, press star 1 to ask a question.  W e'll go ahead and \ntake our first question from Charles Rhyee , with Cowen . \n \n", "original_text": "If you would like to ask a qu estion, please signal by pressing star 1 on your \ntelephone keypad. "}, "hash": "d6ac3a67a90760537464159c1cc69cdad6876c0f70bf476f29ecd9c8f79af9c9", "class_name": "RelatedNodeInfo"}}, "text": "Operator:  Thank you.  ", "start_char_idx": 69, "end_char_idx": 92, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4aaccbef-af09-46fd-a8f5-58f5f0b98fe7": {"__data__": {"id_": "4aaccbef-af09-46fd-a8f5-58f5f0b98fe7", "embedding": null, "metadata": {"window": " \nPage 9 of 15 \n \nAnd now, Jason and I will take your questions.  \n \n Operator:  Thank you.   If you would like to ask a qu estion, please signal by pressing star 1 on your \ntelephone keypad.  If you're using a speakerphone, please make sure your mute function is turned off \nto allow your signal to reach our equipment.  Again, press star 1 to ask a question.  W e'll go ahead and \ntake our first question from Charles Rhyee , with Cowen . \n \n", "original_text": "If you would like to ask a qu estion, please signal by pressing star 1 on your \ntelephone keypad. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ce0134d-b301-46c4-af45-6c2a28303ede", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \nAnd now, Jason and I will take your questions.  \n \n Operator:  Thank you.   If you would like to ask a qu estion, please signal by pressing star 1 on your \ntelephone keypad.  If you're using a speakerphone, please make sure your mute function is turned off \nto allow your signal to reach our equipment.  Again, press star 1 to ask a question. ", "original_text": "Operator:  Thank you.  ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cde038f292b9de8b745d190e781d1ca5043c66362dbc2b46eb2f8c88db22125c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d47c6ff-8970-43ba-8bf7-d3c60c1dd883", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \nAnd now, Jason and I will take your questions.  \n \n Operator:  Thank you.   If you would like to ask a qu estion, please signal by pressing star 1 on your \ntelephone keypad.  If you're using a speakerphone, please make sure your mute function is turned off \nto allow your signal to reach our equipment.  Again, press star 1 to ask a question.  W e'll go ahead and \ntake our first question from Charles Rhyee , with Cowen . \n \n Charles  Rhyee:   Yeah. ", "original_text": "If you're using a speakerphone, please make sure your mute function is turned off \nto allow your signal to reach our equipment. "}, "hash": "386f39df931c3c70ff4ea40333d0d9d40c8bf7ff77e4e97d3e27a2dc7e99b54b", "class_name": "RelatedNodeInfo"}}, "text": "If you would like to ask a qu estion, please signal by pressing star 1 on your \ntelephone keypad. ", "start_char_idx": 92, "end_char_idx": 190, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d47c6ff-8970-43ba-8bf7-d3c60c1dd883": {"__data__": {"id_": "5d47c6ff-8970-43ba-8bf7-d3c60c1dd883", "embedding": null, "metadata": {"window": " \nPage 9 of 15 \n \nAnd now, Jason and I will take your questions.  \n \n Operator:  Thank you.   If you would like to ask a qu estion, please signal by pressing star 1 on your \ntelephone keypad.  If you're using a speakerphone, please make sure your mute function is turned off \nto allow your signal to reach our equipment.  Again, press star 1 to ask a question.  W e'll go ahead and \ntake our first question from Charles Rhyee , with Cowen . \n \n Charles  Rhyee:   Yeah. ", "original_text": "If you're using a speakerphone, please make sure your mute function is turned off \nto allow your signal to reach our equipment. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4aaccbef-af09-46fd-a8f5-58f5f0b98fe7", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \nAnd now, Jason and I will take your questions.  \n \n Operator:  Thank you.   If you would like to ask a qu estion, please signal by pressing star 1 on your \ntelephone keypad.  If you're using a speakerphone, please make sure your mute function is turned off \nto allow your signal to reach our equipment.  Again, press star 1 to ask a question.  W e'll go ahead and \ntake our first question from Charles Rhyee , with Cowen . \n \n", "original_text": "If you would like to ask a qu estion, please signal by pressing star 1 on your \ntelephone keypad. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "adabd06eb62e4a6c6e7741fb279dc43e588d5bba82a795610d46ec95db871c4e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ceb9de7-ae65-4f20-bd19-90e19e317ebe", "node_type": "1", "metadata": {"window": "Operator:  Thank you.   If you would like to ask a qu estion, please signal by pressing star 1 on your \ntelephone keypad.  If you're using a speakerphone, please make sure your mute function is turned off \nto allow your signal to reach our equipment.  Again, press star 1 to ask a question.  W e'll go ahead and \ntake our first question from Charles Rhyee , with Cowen . \n \n Charles  Rhyee:   Yeah.  Thanks for taking the question, guys. ", "original_text": "Again, press star 1 to ask a question. "}, "hash": "abf62234abc7720fdc9a38be71b6f13ab46a679ba9ec2c563fb8ee1ba439ba80", "class_name": "RelatedNodeInfo"}}, "text": "If you're using a speakerphone, please make sure your mute function is turned off \nto allow your signal to reach our equipment. ", "start_char_idx": 190, "end_char_idx": 318, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ceb9de7-ae65-4f20-bd19-90e19e317ebe": {"__data__": {"id_": "6ceb9de7-ae65-4f20-bd19-90e19e317ebe", "embedding": null, "metadata": {"window": "Operator:  Thank you.   If you would like to ask a qu estion, please signal by pressing star 1 on your \ntelephone keypad.  If you're using a speakerphone, please make sure your mute function is turned off \nto allow your signal to reach our equipment.  Again, press star 1 to ask a question.  W e'll go ahead and \ntake our first question from Charles Rhyee , with Cowen . \n \n Charles  Rhyee:   Yeah.  Thanks for taking the question, guys. ", "original_text": "Again, press star 1 to ask a question. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d47c6ff-8970-43ba-8bf7-d3c60c1dd883", "node_type": "1", "metadata": {"window": " \nPage 9 of 15 \n \nAnd now, Jason and I will take your questions.  \n \n Operator:  Thank you.   If you would like to ask a qu estion, please signal by pressing star 1 on your \ntelephone keypad.  If you're using a speakerphone, please make sure your mute function is turned off \nto allow your signal to reach our equipment.  Again, press star 1 to ask a question.  W e'll go ahead and \ntake our first question from Charles Rhyee , with Cowen . \n \n Charles  Rhyee:   Yeah. ", "original_text": "If you're using a speakerphone, please make sure your mute function is turned off \nto allow your signal to reach our equipment. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "db710e121b22ab2ad7ac38fa32c9ec32835d2c518dda762b5a685a72b0e0345c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28cf4a31-14c7-4436-9ff1-9795e257c7ac", "node_type": "1", "metadata": {"window": "If you would like to ask a qu estion, please signal by pressing star 1 on your \ntelephone keypad.  If you're using a speakerphone, please make sure your mute function is turned off \nto allow your signal to reach our equipment.  Again, press star 1 to ask a question.  W e'll go ahead and \ntake our first question from Charles Rhyee , with Cowen . \n \n Charles  Rhyee:   Yeah.  Thanks for taking the question, guys.  Mike, obviously it looks like there were a  \nnumber of items here in the fiscal third quarter, particularly the pharma segment, and you highligh ted  \nthat we're going to be lapping a number of these as in the fourth quarter and you're maintaining the  \nfiscal \u201822 guide in that segment. ", "original_text": "W e'll go ahead and \ntake our first question from Charles Rhyee , with Cowen . \n \n"}, "hash": "87d03186f7751cb093f9977c159b065b458289def8425f84d5568fd26ddd679c", "class_name": "RelatedNodeInfo"}}, "text": "Again, press star 1 to ask a question. ", "start_char_idx": 318, "end_char_idx": 357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28cf4a31-14c7-4436-9ff1-9795e257c7ac": {"__data__": {"id_": "28cf4a31-14c7-4436-9ff1-9795e257c7ac", "embedding": null, "metadata": {"window": "If you would like to ask a qu estion, please signal by pressing star 1 on your \ntelephone keypad.  If you're using a speakerphone, please make sure your mute function is turned off \nto allow your signal to reach our equipment.  Again, press star 1 to ask a question.  W e'll go ahead and \ntake our first question from Charles Rhyee , with Cowen . \n \n Charles  Rhyee:   Yeah.  Thanks for taking the question, guys.  Mike, obviously it looks like there were a  \nnumber of items here in the fiscal third quarter, particularly the pharma segment, and you highligh ted  \nthat we're going to be lapping a number of these as in the fourth quarter and you're maintaining the  \nfiscal \u201822 guide in that segment. ", "original_text": "W e'll go ahead and \ntake our first question from Charles Rhyee , with Cowen . \n \n", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ceb9de7-ae65-4f20-bd19-90e19e317ebe", "node_type": "1", "metadata": {"window": "Operator:  Thank you.   If you would like to ask a qu estion, please signal by pressing star 1 on your \ntelephone keypad.  If you're using a speakerphone, please make sure your mute function is turned off \nto allow your signal to reach our equipment.  Again, press star 1 to ask a question.  W e'll go ahead and \ntake our first question from Charles Rhyee , with Cowen . \n \n Charles  Rhyee:   Yeah.  Thanks for taking the question, guys. ", "original_text": "Again, press star 1 to ask a question. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "eb04850d7b4d8c0dea26b0ac25f0c0596481058a186c5f61aeaffce7b09d2191", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43ff150e-4c03-4ca6-ae20-c3f742b1e2c7", "node_type": "1", "metadata": {"window": "If you're using a speakerphone, please make sure your mute function is turned off \nto allow your signal to reach our equipment.  Again, press star 1 to ask a question.  W e'll go ahead and \ntake our first question from Charles Rhyee , with Cowen . \n \n Charles  Rhyee:   Yeah.  Thanks for taking the question, guys.  Mike, obviously it looks like there were a  \nnumber of items here in the fiscal third quarter, particularly the pharma segment, and you highligh ted  \nthat we're going to be lapping a number of these as in the fourth quarter and you're maintaining the  \nfiscal \u201822 guide in that segment.  Can you just remind us what those items are that we're lapping now?  \n", "original_text": "Charles  Rhyee:   Yeah. "}, "hash": "4d12256ae6f31abc16ac628496279d07324caad65342277be7bbc3b8e6497b36", "class_name": "RelatedNodeInfo"}}, "text": "W e'll go ahead and \ntake our first question from Charles Rhyee , with Cowen . \n \n", "start_char_idx": 357, "end_char_idx": 439, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43ff150e-4c03-4ca6-ae20-c3f742b1e2c7": {"__data__": {"id_": "43ff150e-4c03-4ca6-ae20-c3f742b1e2c7", "embedding": null, "metadata": {"window": "If you're using a speakerphone, please make sure your mute function is turned off \nto allow your signal to reach our equipment.  Again, press star 1 to ask a question.  W e'll go ahead and \ntake our first question from Charles Rhyee , with Cowen . \n \n Charles  Rhyee:   Yeah.  Thanks for taking the question, guys.  Mike, obviously it looks like there were a  \nnumber of items here in the fiscal third quarter, particularly the pharma segment, and you highligh ted  \nthat we're going to be lapping a number of these as in the fourth quarter and you're maintaining the  \nfiscal \u201822 guide in that segment.  Can you just remind us what those items are that we're lapping now?  \n", "original_text": "Charles  Rhyee:   Yeah. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28cf4a31-14c7-4436-9ff1-9795e257c7ac", "node_type": "1", "metadata": {"window": "If you would like to ask a qu estion, please signal by pressing star 1 on your \ntelephone keypad.  If you're using a speakerphone, please make sure your mute function is turned off \nto allow your signal to reach our equipment.  Again, press star 1 to ask a question.  W e'll go ahead and \ntake our first question from Charles Rhyee , with Cowen . \n \n Charles  Rhyee:   Yeah.  Thanks for taking the question, guys.  Mike, obviously it looks like there were a  \nnumber of items here in the fiscal third quarter, particularly the pharma segment, and you highligh ted  \nthat we're going to be lapping a number of these as in the fourth quarter and you're maintaining the  \nfiscal \u201822 guide in that segment. ", "original_text": "W e'll go ahead and \ntake our first question from Charles Rhyee , with Cowen . \n \n", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c5cc4dae4c68f0b857a29e3de58ae3323d819d86a9b9d2df9f3aae6e2f947f75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df42005d-e2b8-49c7-a1ea-7725d413df6a", "node_type": "1", "metadata": {"window": "Again, press star 1 to ask a question.  W e'll go ahead and \ntake our first question from Charles Rhyee , with Cowen . \n \n Charles  Rhyee:   Yeah.  Thanks for taking the question, guys.  Mike, obviously it looks like there were a  \nnumber of items here in the fiscal third quarter, particularly the pharma segment, and you highligh ted  \nthat we're going to be lapping a number of these as in the fourth quarter and you're maintaining the  \nfiscal \u201822 guide in that segment.  Can you just remind us what those items are that we're lapping now?  \n I know the technology investments you mentione d is one, but could you kind of help us size those so  \nwe get better sense? ", "original_text": "Thanks for taking the question, guys. "}, "hash": "7266566fedf65921101e2f8a1a8a0f28c5eef4b366e5ab48dd42583a34a875a2", "class_name": "RelatedNodeInfo"}}, "text": "Charles  Rhyee:   Yeah. ", "start_char_idx": 439, "end_char_idx": 463, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df42005d-e2b8-49c7-a1ea-7725d413df6a": {"__data__": {"id_": "df42005d-e2b8-49c7-a1ea-7725d413df6a", "embedding": null, "metadata": {"window": "Again, press star 1 to ask a question.  W e'll go ahead and \ntake our first question from Charles Rhyee , with Cowen . \n \n Charles  Rhyee:   Yeah.  Thanks for taking the question, guys.  Mike, obviously it looks like there were a  \nnumber of items here in the fiscal third quarter, particularly the pharma segment, and you highligh ted  \nthat we're going to be lapping a number of these as in the fourth quarter and you're maintaining the  \nfiscal \u201822 guide in that segment.  Can you just remind us what those items are that we're lapping now?  \n I know the technology investments you mentione d is one, but could you kind of help us size those so  \nwe get better sense? ", "original_text": "Thanks for taking the question, guys. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43ff150e-4c03-4ca6-ae20-c3f742b1e2c7", "node_type": "1", "metadata": {"window": "If you're using a speakerphone, please make sure your mute function is turned off \nto allow your signal to reach our equipment.  Again, press star 1 to ask a question.  W e'll go ahead and \ntake our first question from Charles Rhyee , with Cowen . \n \n Charles  Rhyee:   Yeah.  Thanks for taking the question, guys.  Mike, obviously it looks like there were a  \nnumber of items here in the fiscal third quarter, particularly the pharma segment, and you highligh ted  \nthat we're going to be lapping a number of these as in the fourth quarter and you're maintaining the  \nfiscal \u201822 guide in that segment.  Can you just remind us what those items are that we're lapping now?  \n", "original_text": "Charles  Rhyee:   Yeah. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed14a36288871805681cde0f59b8cf12fc88ec6b99a90c4594ee2c11b6dda9b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5f12e8a1-3440-4115-a305-8759fbe39eea", "node_type": "1", "metadata": {"window": "W e'll go ahead and \ntake our first question from Charles Rhyee , with Cowen . \n \n Charles  Rhyee:   Yeah.  Thanks for taking the question, guys.  Mike, obviously it looks like there were a  \nnumber of items here in the fiscal third quarter, particularly the pharma segment, and you highligh ted  \nthat we're going to be lapping a number of these as in the fourth quarter and you're maintaining the  \nfiscal \u201822 guide in that segment.  Can you just remind us what those items are that we're lapping now?  \n I know the technology investments you mentione d is one, but could you kind of help us size those so  \nwe get better sense?  And is that then the right kind of jump -off point in the Pharma segment as we look  \ninto \u201823? ", "original_text": "Mike, obviously it looks like there were a  \nnumber of items here in the fiscal third quarter, particularly the pharma segment, and you highligh ted  \nthat we're going to be lapping a number of these as in the fourth quarter and you're maintaining the  \nfiscal \u201822 guide in that segment. "}, "hash": "3e75636ac24ca18ad1f720f34e527fd1cad1d4442d69d9ffbf6f0b868d73311c", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question, guys. ", "start_char_idx": 463, "end_char_idx": 501, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5f12e8a1-3440-4115-a305-8759fbe39eea": {"__data__": {"id_": "5f12e8a1-3440-4115-a305-8759fbe39eea", "embedding": null, "metadata": {"window": "W e'll go ahead and \ntake our first question from Charles Rhyee , with Cowen . \n \n Charles  Rhyee:   Yeah.  Thanks for taking the question, guys.  Mike, obviously it looks like there were a  \nnumber of items here in the fiscal third quarter, particularly the pharma segment, and you highligh ted  \nthat we're going to be lapping a number of these as in the fourth quarter and you're maintaining the  \nfiscal \u201822 guide in that segment.  Can you just remind us what those items are that we're lapping now?  \n I know the technology investments you mentione d is one, but could you kind of help us size those so  \nwe get better sense?  And is that then the right kind of jump -off point in the Pharma segment as we look  \ninto \u201823? ", "original_text": "Mike, obviously it looks like there were a  \nnumber of items here in the fiscal third quarter, particularly the pharma segment, and you highligh ted  \nthat we're going to be lapping a number of these as in the fourth quarter and you're maintaining the  \nfiscal \u201822 guide in that segment. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df42005d-e2b8-49c7-a1ea-7725d413df6a", "node_type": "1", "metadata": {"window": "Again, press star 1 to ask a question.  W e'll go ahead and \ntake our first question from Charles Rhyee , with Cowen . \n \n Charles  Rhyee:   Yeah.  Thanks for taking the question, guys.  Mike, obviously it looks like there were a  \nnumber of items here in the fiscal third quarter, particularly the pharma segment, and you highligh ted  \nthat we're going to be lapping a number of these as in the fourth quarter and you're maintaining the  \nfiscal \u201822 guide in that segment.  Can you just remind us what those items are that we're lapping now?  \n I know the technology investments you mentione d is one, but could you kind of help us size those so  \nwe get better sense? ", "original_text": "Thanks for taking the question, guys. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a95b431017c9afaac03b644f8212ddc67e94bce6d06c445afb032e1a27d63ba7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2dcdce6-d897-4358-9eb3-36df32bdc2df", "node_type": "1", "metadata": {"window": "Charles  Rhyee:   Yeah.  Thanks for taking the question, guys.  Mike, obviously it looks like there were a  \nnumber of items here in the fiscal third quarter, particularly the pharma segment, and you highligh ted  \nthat we're going to be lapping a number of these as in the fourth quarter and you're maintaining the  \nfiscal \u201822 guide in that segment.  Can you just remind us what those items are that we're lapping now?  \n I know the technology investments you mentione d is one, but could you kind of help us size those so  \nwe get better sense?  And is that then the right kind of jump -off point in the Pharma segment as we look  \ninto \u201823?  And part of that you mentioned higher sort of operational expense and you kind of mayb e  \nhighlighted inflation as in wage inflation, you kind of mentioned that should mostly just be in the first  \nhalf of the year. ", "original_text": "Can you just remind us what those items are that we're lapping now?  \n"}, "hash": "6ec904509be939e3b4db745209e6a84ca8066c23350594464fca0054183e76c3", "class_name": "RelatedNodeInfo"}}, "text": "Mike, obviously it looks like there were a  \nnumber of items here in the fiscal third quarter, particularly the pharma segment, and you highligh ted  \nthat we're going to be lapping a number of these as in the fourth quarter and you're maintaining the  \nfiscal \u201822 guide in that segment. ", "start_char_idx": 501, "end_char_idx": 789, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2dcdce6-d897-4358-9eb3-36df32bdc2df": {"__data__": {"id_": "f2dcdce6-d897-4358-9eb3-36df32bdc2df", "embedding": null, "metadata": {"window": "Charles  Rhyee:   Yeah.  Thanks for taking the question, guys.  Mike, obviously it looks like there were a  \nnumber of items here in the fiscal third quarter, particularly the pharma segment, and you highligh ted  \nthat we're going to be lapping a number of these as in the fourth quarter and you're maintaining the  \nfiscal \u201822 guide in that segment.  Can you just remind us what those items are that we're lapping now?  \n I know the technology investments you mentione d is one, but could you kind of help us size those so  \nwe get better sense?  And is that then the right kind of jump -off point in the Pharma segment as we look  \ninto \u201823?  And part of that you mentioned higher sort of operational expense and you kind of mayb e  \nhighlighted inflation as in wage inflation, you kind of mentioned that should mostly just be in the first  \nhalf of the year. ", "original_text": "Can you just remind us what those items are that we're lapping now?  \n", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5f12e8a1-3440-4115-a305-8759fbe39eea", "node_type": "1", "metadata": {"window": "W e'll go ahead and \ntake our first question from Charles Rhyee , with Cowen . \n \n Charles  Rhyee:   Yeah.  Thanks for taking the question, guys.  Mike, obviously it looks like there were a  \nnumber of items here in the fiscal third quarter, particularly the pharma segment, and you highligh ted  \nthat we're going to be lapping a number of these as in the fourth quarter and you're maintaining the  \nfiscal \u201822 guide in that segment.  Can you just remind us what those items are that we're lapping now?  \n I know the technology investments you mentione d is one, but could you kind of help us size those so  \nwe get better sense?  And is that then the right kind of jump -off point in the Pharma segment as we look  \ninto \u201823? ", "original_text": "Mike, obviously it looks like there were a  \nnumber of items here in the fiscal third quarter, particularly the pharma segment, and you highligh ted  \nthat we're going to be lapping a number of these as in the fourth quarter and you're maintaining the  \nfiscal \u201822 guide in that segment. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "144afacce85e16fb40b879c3ff56172df1adceec1edf8debb0458d5a298e7ec4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "628f0460-858f-49f0-afd3-9511f9ec5e8b", "node_type": "1", "metadata": {"window": "Thanks for taking the question, guys.  Mike, obviously it looks like there were a  \nnumber of items here in the fiscal third quarter, particularly the pharma segment, and you highligh ted  \nthat we're going to be lapping a number of these as in the fourth quarter and you're maintaining the  \nfiscal \u201822 guide in that segment.  Can you just remind us what those items are that we're lapping now?  \n I know the technology investments you mentione d is one, but could you kind of help us size those so  \nwe get better sense?  And is that then the right kind of jump -off point in the Pharma segment as we look  \ninto \u201823?  And part of that you mentioned higher sort of operational expense and you kind of mayb e  \nhighlighted inflation as in wage inflation, you kind of mentioned that should mostly just be in the first  \nhalf of the year.  Can you touch on why that might only be a half -year impact and not just a new baseline?  \n", "original_text": "I know the technology investments you mentione d is one, but could you kind of help us size those so  \nwe get better sense? "}, "hash": "0afae0d0859c75fc683641310af6546b9300d8652d265fd1fb0e9f37c921a311", "class_name": "RelatedNodeInfo"}}, "text": "Can you just remind us what those items are that we're lapping now?  \n", "start_char_idx": 789, "end_char_idx": 859, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "628f0460-858f-49f0-afd3-9511f9ec5e8b": {"__data__": {"id_": "628f0460-858f-49f0-afd3-9511f9ec5e8b", "embedding": null, "metadata": {"window": "Thanks for taking the question, guys.  Mike, obviously it looks like there were a  \nnumber of items here in the fiscal third quarter, particularly the pharma segment, and you highligh ted  \nthat we're going to be lapping a number of these as in the fourth quarter and you're maintaining the  \nfiscal \u201822 guide in that segment.  Can you just remind us what those items are that we're lapping now?  \n I know the technology investments you mentione d is one, but could you kind of help us size those so  \nwe get better sense?  And is that then the right kind of jump -off point in the Pharma segment as we look  \ninto \u201823?  And part of that you mentioned higher sort of operational expense and you kind of mayb e  \nhighlighted inflation as in wage inflation, you kind of mentioned that should mostly just be in the first  \nhalf of the year.  Can you touch on why that might only be a half -year impact and not just a new baseline?  \n", "original_text": "I know the technology investments you mentione d is one, but could you kind of help us size those so  \nwe get better sense? ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2dcdce6-d897-4358-9eb3-36df32bdc2df", "node_type": "1", "metadata": {"window": "Charles  Rhyee:   Yeah.  Thanks for taking the question, guys.  Mike, obviously it looks like there were a  \nnumber of items here in the fiscal third quarter, particularly the pharma segment, and you highligh ted  \nthat we're going to be lapping a number of these as in the fourth quarter and you're maintaining the  \nfiscal \u201822 guide in that segment.  Can you just remind us what those items are that we're lapping now?  \n I know the technology investments you mentione d is one, but could you kind of help us size those so  \nwe get better sense?  And is that then the right kind of jump -off point in the Pharma segment as we look  \ninto \u201823?  And part of that you mentioned higher sort of operational expense and you kind of mayb e  \nhighlighted inflation as in wage inflation, you kind of mentioned that should mostly just be in the first  \nhalf of the year. ", "original_text": "Can you just remind us what those items are that we're lapping now?  \n", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84fe1f7fdb70a32560cfcf6d1dc609cc8a8d8e484d8e988468bf863c7618b729", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1389b1b8-61bd-4d69-9fe1-2888f3775879", "node_type": "1", "metadata": {"window": "Mike, obviously it looks like there were a  \nnumber of items here in the fiscal third quarter, particularly the pharma segment, and you highligh ted  \nthat we're going to be lapping a number of these as in the fourth quarter and you're maintaining the  \nfiscal \u201822 guide in that segment.  Can you just remind us what those items are that we're lapping now?  \n I know the technology investments you mentione d is one, but could you kind of help us size those so  \nwe get better sense?  And is that then the right kind of jump -off point in the Pharma segment as we look  \ninto \u201823?  And part of that you mentioned higher sort of operational expense and you kind of mayb e  \nhighlighted inflation as in wage inflation, you kind of mentioned that should mostly just be in the first  \nhalf of the year.  Can you touch on why that might only be a half -year impact and not just a new baseline?  \n Thanks.  \n \n", "original_text": "And is that then the right kind of jump -off point in the Pharma segment as we look  \ninto \u201823? "}, "hash": "e7ae624c5b7721c0eec722ab41ac37ffffabcafd739808e6e1b773edf2dbf87a", "class_name": "RelatedNodeInfo"}}, "text": "I know the technology investments you mentione d is one, but could you kind of help us size those so  \nwe get better sense? ", "start_char_idx": 859, "end_char_idx": 983, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1389b1b8-61bd-4d69-9fe1-2888f3775879": {"__data__": {"id_": "1389b1b8-61bd-4d69-9fe1-2888f3775879", "embedding": null, "metadata": {"window": "Mike, obviously it looks like there were a  \nnumber of items here in the fiscal third quarter, particularly the pharma segment, and you highligh ted  \nthat we're going to be lapping a number of these as in the fourth quarter and you're maintaining the  \nfiscal \u201822 guide in that segment.  Can you just remind us what those items are that we're lapping now?  \n I know the technology investments you mentione d is one, but could you kind of help us size those so  \nwe get better sense?  And is that then the right kind of jump -off point in the Pharma segment as we look  \ninto \u201823?  And part of that you mentioned higher sort of operational expense and you kind of mayb e  \nhighlighted inflation as in wage inflation, you kind of mentioned that should mostly just be in the first  \nhalf of the year.  Can you touch on why that might only be a half -year impact and not just a new baseline?  \n Thanks.  \n \n", "original_text": "And is that then the right kind of jump -off point in the Pharma segment as we look  \ninto \u201823? ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "628f0460-858f-49f0-afd3-9511f9ec5e8b", "node_type": "1", "metadata": {"window": "Thanks for taking the question, guys.  Mike, obviously it looks like there were a  \nnumber of items here in the fiscal third quarter, particularly the pharma segment, and you highligh ted  \nthat we're going to be lapping a number of these as in the fourth quarter and you're maintaining the  \nfiscal \u201822 guide in that segment.  Can you just remind us what those items are that we're lapping now?  \n I know the technology investments you mentione d is one, but could you kind of help us size those so  \nwe get better sense?  And is that then the right kind of jump -off point in the Pharma segment as we look  \ninto \u201823?  And part of that you mentioned higher sort of operational expense and you kind of mayb e  \nhighlighted inflation as in wage inflation, you kind of mentioned that should mostly just be in the first  \nhalf of the year.  Can you touch on why that might only be a half -year impact and not just a new baseline?  \n", "original_text": "I know the technology investments you mentione d is one, but could you kind of help us size those so  \nwe get better sense? ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f4c1a0697e257016dc0ff1d66db40c4d7582ce84e6f656ffb542f6daf5c1938", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd9b935b-2d04-403d-b20d-afdb722b8269", "node_type": "1", "metadata": {"window": "Can you just remind us what those items are that we're lapping now?  \n I know the technology investments you mentione d is one, but could you kind of help us size those so  \nwe get better sense?  And is that then the right kind of jump -off point in the Pharma segment as we look  \ninto \u201823?  And part of that you mentioned higher sort of operational expense and you kind of mayb e  \nhighlighted inflation as in wage inflation, you kind of mentioned that should mostly just be in the first  \nhalf of the year.  Can you touch on why that might only be a half -year impact and not just a new baseline?  \n Thanks.  \n \n Jason Hollar:  Yeah, this is Jason, let me go ahead and start. ", "original_text": "And part of that you mentioned higher sort of operational expense and you kind of mayb e  \nhighlighted inflation as in wage inflation, you kind of mentioned that should mostly just be in the first  \nhalf of the year. "}, "hash": "37f6d158d53e66fe3d40f7a846dc721d7968288b70e83feb3a3219fdb47aa29e", "class_name": "RelatedNodeInfo"}}, "text": "And is that then the right kind of jump -off point in the Pharma segment as we look  \ninto \u201823? ", "start_char_idx": 983, "end_char_idx": 1079, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd9b935b-2d04-403d-b20d-afdb722b8269": {"__data__": {"id_": "dd9b935b-2d04-403d-b20d-afdb722b8269", "embedding": null, "metadata": {"window": "Can you just remind us what those items are that we're lapping now?  \n I know the technology investments you mentione d is one, but could you kind of help us size those so  \nwe get better sense?  And is that then the right kind of jump -off point in the Pharma segment as we look  \ninto \u201823?  And part of that you mentioned higher sort of operational expense and you kind of mayb e  \nhighlighted inflation as in wage inflation, you kind of mentioned that should mostly just be in the first  \nhalf of the year.  Can you touch on why that might only be a half -year impact and not just a new baseline?  \n Thanks.  \n \n Jason Hollar:  Yeah, this is Jason, let me go ahead and start. ", "original_text": "And part of that you mentioned higher sort of operational expense and you kind of mayb e  \nhighlighted inflation as in wage inflation, you kind of mentioned that should mostly just be in the first  \nhalf of the year. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1389b1b8-61bd-4d69-9fe1-2888f3775879", "node_type": "1", "metadata": {"window": "Mike, obviously it looks like there were a  \nnumber of items here in the fiscal third quarter, particularly the pharma segment, and you highligh ted  \nthat we're going to be lapping a number of these as in the fourth quarter and you're maintaining the  \nfiscal \u201822 guide in that segment.  Can you just remind us what those items are that we're lapping now?  \n I know the technology investments you mentione d is one, but could you kind of help us size those so  \nwe get better sense?  And is that then the right kind of jump -off point in the Pharma segment as we look  \ninto \u201823?  And part of that you mentioned higher sort of operational expense and you kind of mayb e  \nhighlighted inflation as in wage inflation, you kind of mentioned that should mostly just be in the first  \nhalf of the year.  Can you touch on why that might only be a half -year impact and not just a new baseline?  \n Thanks.  \n \n", "original_text": "And is that then the right kind of jump -off point in the Pharma segment as we look  \ninto \u201823? ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bbe5ddb11b8071a51e1b615b8ed373577e6022721fccf037a19b89d6ab762c9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac9735c3-b291-4c6d-beea-a07ffaa803ee", "node_type": "1", "metadata": {"window": "I know the technology investments you mentione d is one, but could you kind of help us size those so  \nwe get better sense?  And is that then the right kind of jump -off point in the Pharma segment as we look  \ninto \u201823?  And part of that you mentioned higher sort of operational expense and you kind of mayb e  \nhighlighted inflation as in wage inflation, you kind of mentioned that should mostly just be in the first  \nhalf of the year.  Can you touch on why that might only be a half -year impact and not just a new baseline?  \n Thanks.  \n \n Jason Hollar:  Yeah, this is Jason, let me go ahead and start.  There's a number of questions there, so  \nhopefully, you can catch them all. ", "original_text": "Can you touch on why that might only be a half -year impact and not just a new baseline?  \n"}, "hash": "44b172ca1acf6ac6414508cfea6e7b4a6a937cfaa0aab9dbdea5199b9e984239", "class_name": "RelatedNodeInfo"}}, "text": "And part of that you mentioned higher sort of operational expense and you kind of mayb e  \nhighlighted inflation as in wage inflation, you kind of mentioned that should mostly just be in the first  \nhalf of the year. ", "start_char_idx": 1079, "end_char_idx": 1296, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac9735c3-b291-4c6d-beea-a07ffaa803ee": {"__data__": {"id_": "ac9735c3-b291-4c6d-beea-a07ffaa803ee", "embedding": null, "metadata": {"window": "I know the technology investments you mentione d is one, but could you kind of help us size those so  \nwe get better sense?  And is that then the right kind of jump -off point in the Pharma segment as we look  \ninto \u201823?  And part of that you mentioned higher sort of operational expense and you kind of mayb e  \nhighlighted inflation as in wage inflation, you kind of mentioned that should mostly just be in the first  \nhalf of the year.  Can you touch on why that might only be a half -year impact and not just a new baseline?  \n Thanks.  \n \n Jason Hollar:  Yeah, this is Jason, let me go ahead and start.  There's a number of questions there, so  \nhopefully, you can catch them all. ", "original_text": "Can you touch on why that might only be a half -year impact and not just a new baseline?  \n", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd9b935b-2d04-403d-b20d-afdb722b8269", "node_type": "1", "metadata": {"window": "Can you just remind us what those items are that we're lapping now?  \n I know the technology investments you mentione d is one, but could you kind of help us size those so  \nwe get better sense?  And is that then the right kind of jump -off point in the Pharma segment as we look  \ninto \u201823?  And part of that you mentioned higher sort of operational expense and you kind of mayb e  \nhighlighted inflation as in wage inflation, you kind of mentioned that should mostly just be in the first  \nhalf of the year.  Can you touch on why that might only be a half -year impact and not just a new baseline?  \n Thanks.  \n \n Jason Hollar:  Yeah, this is Jason, let me go ahead and start. ", "original_text": "And part of that you mentioned higher sort of operational expense and you kind of mayb e  \nhighlighted inflation as in wage inflation, you kind of mentioned that should mostly just be in the first  \nhalf of the year. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "181231c14fe912f3a48b09223207ffe3ebf6d9a3cabf9264ed6bdf0616ab3fd3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "861358e3-2c87-4d02-b3de-884b41db3086", "node_type": "1", "metadata": {"window": "And is that then the right kind of jump -off point in the Pharma segment as we look  \ninto \u201823?  And part of that you mentioned higher sort of operational expense and you kind of mayb e  \nhighlighted inflation as in wage inflation, you kind of mentioned that should mostly just be in the first  \nhalf of the year.  Can you touch on why that might only be a half -year impact and not just a new baseline?  \n Thanks.  \n \n Jason Hollar:  Yeah, this is Jason, let me go ahead and start.  There's a number of questions there, so  \nhopefully, you can catch them all.  So in terms of the IT enhancements, what we mentioned at the  \nbeginning of the year and is still very consistent with what we've seen roll out is about $80 million of  \nincremental costs that we saw in \u201822 versus \u201821. ", "original_text": "Thanks.  \n \n"}, "hash": "7ed6120fed88aecd427cb7f7f3f3b4af0ba45065892282cc4e34132c69a3919a", "class_name": "RelatedNodeInfo"}}, "text": "Can you touch on why that might only be a half -year impact and not just a new baseline?  \n", "start_char_idx": 1296, "end_char_idx": 1387, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "861358e3-2c87-4d02-b3de-884b41db3086": {"__data__": {"id_": "861358e3-2c87-4d02-b3de-884b41db3086", "embedding": null, "metadata": {"window": "And is that then the right kind of jump -off point in the Pharma segment as we look  \ninto \u201823?  And part of that you mentioned higher sort of operational expense and you kind of mayb e  \nhighlighted inflation as in wage inflation, you kind of mentioned that should mostly just be in the first  \nhalf of the year.  Can you touch on why that might only be a half -year impact and not just a new baseline?  \n Thanks.  \n \n Jason Hollar:  Yeah, this is Jason, let me go ahead and start.  There's a number of questions there, so  \nhopefully, you can catch them all.  So in terms of the IT enhancements, what we mentioned at the  \nbeginning of the year and is still very consistent with what we've seen roll out is about $80 million of  \nincremental costs that we saw in \u201822 versus \u201821. ", "original_text": "Thanks.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac9735c3-b291-4c6d-beea-a07ffaa803ee", "node_type": "1", "metadata": {"window": "I know the technology investments you mentione d is one, but could you kind of help us size those so  \nwe get better sense?  And is that then the right kind of jump -off point in the Pharma segment as we look  \ninto \u201823?  And part of that you mentioned higher sort of operational expense and you kind of mayb e  \nhighlighted inflation as in wage inflation, you kind of mentioned that should mostly just be in the first  \nhalf of the year.  Can you touch on why that might only be a half -year impact and not just a new baseline?  \n Thanks.  \n \n Jason Hollar:  Yeah, this is Jason, let me go ahead and start.  There's a number of questions there, so  \nhopefully, you can catch them all. ", "original_text": "Can you touch on why that might only be a half -year impact and not just a new baseline?  \n", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2a35e24dfb50c3b73ea849a88c7667dd1067d5ce473cda4388e7aa67621f71c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c239b1fb-1aaa-491d-a56b-6dde29e8b502", "node_type": "1", "metadata": {"window": "And part of that you mentioned higher sort of operational expense and you kind of mayb e  \nhighlighted inflation as in wage inflation, you kind of mentioned that should mostly just be in the first  \nhalf of the year.  Can you touch on why that might only be a half -year impact and not just a new baseline?  \n Thanks.  \n \n Jason Hollar:  Yeah, this is Jason, let me go ahead and start.  There's a number of questions there, so  \nhopefully, you can catch them all.  So in terms of the IT enhancements, what we mentioned at the  \nbeginning of the year and is still very consistent with what we've seen roll out is about $80 million of  \nincremental costs that we saw in \u201822 versus \u201821.  And we indicated that would be spread somewhat  \nevenly over the first three quarters of the fiscal year. ", "original_text": "Jason Hollar:  Yeah, this is Jason, let me go ahead and start. "}, "hash": "218079cb45970734144c26c72d5bddd1ce5e5677728f7177e3699bb2910bdd23", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 1387, "end_char_idx": 1399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c239b1fb-1aaa-491d-a56b-6dde29e8b502": {"__data__": {"id_": "c239b1fb-1aaa-491d-a56b-6dde29e8b502", "embedding": null, "metadata": {"window": "And part of that you mentioned higher sort of operational expense and you kind of mayb e  \nhighlighted inflation as in wage inflation, you kind of mentioned that should mostly just be in the first  \nhalf of the year.  Can you touch on why that might only be a half -year impact and not just a new baseline?  \n Thanks.  \n \n Jason Hollar:  Yeah, this is Jason, let me go ahead and start.  There's a number of questions there, so  \nhopefully, you can catch them all.  So in terms of the IT enhancements, what we mentioned at the  \nbeginning of the year and is still very consistent with what we've seen roll out is about $80 million of  \nincremental costs that we saw in \u201822 versus \u201821.  And we indicated that would be spread somewhat  \nevenly over the first three quarters of the fiscal year. ", "original_text": "Jason Hollar:  Yeah, this is Jason, let me go ahead and start. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "861358e3-2c87-4d02-b3de-884b41db3086", "node_type": "1", "metadata": {"window": "And is that then the right kind of jump -off point in the Pharma segment as we look  \ninto \u201823?  And part of that you mentioned higher sort of operational expense and you kind of mayb e  \nhighlighted inflation as in wage inflation, you kind of mentioned that should mostly just be in the first  \nhalf of the year.  Can you touch on why that might only be a half -year impact and not just a new baseline?  \n Thanks.  \n \n Jason Hollar:  Yeah, this is Jason, let me go ahead and start.  There's a number of questions there, so  \nhopefully, you can catch them all.  So in terms of the IT enhancements, what we mentioned at the  \nbeginning of the year and is still very consistent with what we've seen roll out is about $80 million of  \nincremental costs that we saw in \u201822 versus \u201821. ", "original_text": "Thanks.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4210586df62ac834824f8ecef1ad3e0bbdbdcaf42bf5935a6e4e2d0ca1991752", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5489fb19-b6f2-4087-97ef-9b4731f6cb0e", "node_type": "1", "metadata": {"window": "Can you touch on why that might only be a half -year impact and not just a new baseline?  \n Thanks.  \n \n Jason Hollar:  Yeah, this is Jason, let me go ahead and start.  There's a number of questions there, so  \nhopefully, you can catch them all.  So in terms of the IT enhancements, what we mentioned at the  \nbeginning of the year and is still very consistent with what we've seen roll out is about $80 million of  \nincremental costs that we saw in \u201822 versus \u201821.  And we indicated that would be spread somewhat  \nevenly over the first three quarters of the fiscal year.  So you can kind of think of roughly that one third  \nper quarter is what we've be en experiencing all year.  \n \n", "original_text": "There's a number of questions there, so  \nhopefully, you can catch them all. "}, "hash": "7adb37e7cc1a054f500f8534cad144aae6bbb1fabee5b81b68c510d715f3355f", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yeah, this is Jason, let me go ahead and start. ", "start_char_idx": 1399, "end_char_idx": 1462, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5489fb19-b6f2-4087-97ef-9b4731f6cb0e": {"__data__": {"id_": "5489fb19-b6f2-4087-97ef-9b4731f6cb0e", "embedding": null, "metadata": {"window": "Can you touch on why that might only be a half -year impact and not just a new baseline?  \n Thanks.  \n \n Jason Hollar:  Yeah, this is Jason, let me go ahead and start.  There's a number of questions there, so  \nhopefully, you can catch them all.  So in terms of the IT enhancements, what we mentioned at the  \nbeginning of the year and is still very consistent with what we've seen roll out is about $80 million of  \nincremental costs that we saw in \u201822 versus \u201821.  And we indicated that would be spread somewhat  \nevenly over the first three quarters of the fiscal year.  So you can kind of think of roughly that one third  \nper quarter is what we've be en experiencing all year.  \n \n", "original_text": "There's a number of questions there, so  \nhopefully, you can catch them all. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c239b1fb-1aaa-491d-a56b-6dde29e8b502", "node_type": "1", "metadata": {"window": "And part of that you mentioned higher sort of operational expense and you kind of mayb e  \nhighlighted inflation as in wage inflation, you kind of mentioned that should mostly just be in the first  \nhalf of the year.  Can you touch on why that might only be a half -year impact and not just a new baseline?  \n Thanks.  \n \n Jason Hollar:  Yeah, this is Jason, let me go ahead and start.  There's a number of questions there, so  \nhopefully, you can catch them all.  So in terms of the IT enhancements, what we mentioned at the  \nbeginning of the year and is still very consistent with what we've seen roll out is about $80 million of  \nincremental costs that we saw in \u201822 versus \u201821.  And we indicated that would be spread somewhat  \nevenly over the first three quarters of the fiscal year. ", "original_text": "Jason Hollar:  Yeah, this is Jason, let me go ahead and start. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8e86bb9314b9b2bd3493bcf9feabd842cd394148acbf5b14d837d1fefdf3d300", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc02fa27-d1bb-4964-8133-c2eba7f297db", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Hollar:  Yeah, this is Jason, let me go ahead and start.  There's a number of questions there, so  \nhopefully, you can catch them all.  So in terms of the IT enhancements, what we mentioned at the  \nbeginning of the year and is still very consistent with what we've seen roll out is about $80 million of  \nincremental costs that we saw in \u201822 versus \u201821.  And we indicated that would be spread somewhat  \nevenly over the first three quarters of the fiscal year.  So you can kind of think of roughly that one third  \nper quarter is what we've be en experiencing all year.  \n \n First two quarters, we had other actions that drove growth above and beyond that headwind, but that  \nwas with the inflation included in the third quarter, drove that 5% reduction. ", "original_text": "So in terms of the IT enhancements, what we mentioned at the  \nbeginning of the year and is still very consistent with what we've seen roll out is about $80 million of  \nincremental costs that we saw in \u201822 versus \u201821. "}, "hash": "f5e4511dec9c546f03dc7187f0db189f487057a2126f1f5330dce92a52ec7b23", "class_name": "RelatedNodeInfo"}}, "text": "There's a number of questions there, so  \nhopefully, you can catch them all. ", "start_char_idx": 1462, "end_char_idx": 1539, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc02fa27-d1bb-4964-8133-c2eba7f297db": {"__data__": {"id_": "cc02fa27-d1bb-4964-8133-c2eba7f297db", "embedding": null, "metadata": {"window": "Thanks.  \n \n Jason Hollar:  Yeah, this is Jason, let me go ahead and start.  There's a number of questions there, so  \nhopefully, you can catch them all.  So in terms of the IT enhancements, what we mentioned at the  \nbeginning of the year and is still very consistent with what we've seen roll out is about $80 million of  \nincremental costs that we saw in \u201822 versus \u201821.  And we indicated that would be spread somewhat  \nevenly over the first three quarters of the fiscal year.  So you can kind of think of roughly that one third  \nper quarter is what we've be en experiencing all year.  \n \n First two quarters, we had other actions that drove growth above and beyond that headwind, but that  \nwas with the inflation included in the third quarter, drove that 5% reduction. ", "original_text": "So in terms of the IT enhancements, what we mentioned at the  \nbeginning of the year and is still very consistent with what we've seen roll out is about $80 million of  \nincremental costs that we saw in \u201822 versus \u201821. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5489fb19-b6f2-4087-97ef-9b4731f6cb0e", "node_type": "1", "metadata": {"window": "Can you touch on why that might only be a half -year impact and not just a new baseline?  \n Thanks.  \n \n Jason Hollar:  Yeah, this is Jason, let me go ahead and start.  There's a number of questions there, so  \nhopefully, you can catch them all.  So in terms of the IT enhancements, what we mentioned at the  \nbeginning of the year and is still very consistent with what we've seen roll out is about $80 million of  \nincremental costs that we saw in \u201822 versus \u201821.  And we indicated that would be spread somewhat  \nevenly over the first three quarters of the fiscal year.  So you can kind of think of roughly that one third  \nper quarter is what we've be en experiencing all year.  \n \n", "original_text": "There's a number of questions there, so  \nhopefully, you can catch them all. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "601b2b17fe85f5ffd83cde17c0f69c24a3de547788e47d65d00270b74024e4ab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa3978b9-e793-4435-bace-738d1606f386", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah, this is Jason, let me go ahead and start.  There's a number of questions there, so  \nhopefully, you can catch them all.  So in terms of the IT enhancements, what we mentioned at the  \nbeginning of the year and is still very consistent with what we've seen roll out is about $80 million of  \nincremental costs that we saw in \u201822 versus \u201821.  And we indicated that would be spread somewhat  \nevenly over the first three quarters of the fiscal year.  So you can kind of think of roughly that one third  \nper quarter is what we've be en experiencing all year.  \n \n First two quarters, we had other actions that drove growth above and beyond that headwind, but that  \nwas with the inflation included in the third quarter, drove that 5% reduction.  As it relates to the fourth  \nquarter, the other unusual item, beyond that lapping, so there's very little year -over-year change as it  \nrelates to the IT enhancements in the four th quarter. ", "original_text": "And we indicated that would be spread somewhat  \nevenly over the first three quarters of the fiscal year. "}, "hash": "be19461a8a36fe7f70439b22343e95582bd39ab089cc99bcbd380bfdbed17727", "class_name": "RelatedNodeInfo"}}, "text": "So in terms of the IT enhancements, what we mentioned at the  \nbeginning of the year and is still very consistent with what we've seen roll out is about $80 million of  \nincremental costs that we saw in \u201822 versus \u201821. ", "start_char_idx": 1539, "end_char_idx": 1758, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa3978b9-e793-4435-bace-738d1606f386": {"__data__": {"id_": "aa3978b9-e793-4435-bace-738d1606f386", "embedding": null, "metadata": {"window": "Jason Hollar:  Yeah, this is Jason, let me go ahead and start.  There's a number of questions there, so  \nhopefully, you can catch them all.  So in terms of the IT enhancements, what we mentioned at the  \nbeginning of the year and is still very consistent with what we've seen roll out is about $80 million of  \nincremental costs that we saw in \u201822 versus \u201821.  And we indicated that would be spread somewhat  \nevenly over the first three quarters of the fiscal year.  So you can kind of think of roughly that one third  \nper quarter is what we've be en experiencing all year.  \n \n First two quarters, we had other actions that drove growth above and beyond that headwind, but that  \nwas with the inflation included in the third quarter, drove that 5% reduction.  As it relates to the fourth  \nquarter, the other unusual item, beyond that lapping, so there's very little year -over-year change as it  \nrelates to the IT enhancements in the four th quarter. ", "original_text": "And we indicated that would be spread somewhat  \nevenly over the first three quarters of the fiscal year. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc02fa27-d1bb-4964-8133-c2eba7f297db", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Jason Hollar:  Yeah, this is Jason, let me go ahead and start.  There's a number of questions there, so  \nhopefully, you can catch them all.  So in terms of the IT enhancements, what we mentioned at the  \nbeginning of the year and is still very consistent with what we've seen roll out is about $80 million of  \nincremental costs that we saw in \u201822 versus \u201821.  And we indicated that would be spread somewhat  \nevenly over the first three quarters of the fiscal year.  So you can kind of think of roughly that one third  \nper quarter is what we've be en experiencing all year.  \n \n First two quarters, we had other actions that drove growth above and beyond that headwind, but that  \nwas with the inflation included in the third quarter, drove that 5% reduction. ", "original_text": "So in terms of the IT enhancements, what we mentioned at the  \nbeginning of the year and is still very consistent with what we've seen roll out is about $80 million of  \nincremental costs that we saw in \u201822 versus \u201821. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "60389656636eaf67b0e9bdfa402621ec1769ae3e8b3761c51b4717acc4f34e25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66ffc7cb-95c9-437d-8332-b3d5a3a2e7f1", "node_type": "1", "metadata": {"window": "There's a number of questions there, so  \nhopefully, you can catch them all.  So in terms of the IT enhancements, what we mentioned at the  \nbeginning of the year and is still very consistent with what we've seen roll out is about $80 million of  \nincremental costs that we saw in \u201822 versus \u201821.  And we indicated that would be spread somewhat  \nevenly over the first three quarters of the fiscal year.  So you can kind of think of roughly that one third  \nper quarter is what we've be en experiencing all year.  \n \n First two quarters, we had other actions that drove growth above and beyond that headwind, but that  \nwas with the inflation included in the third quarter, drove that 5% reduction.  As it relates to the fourth  \nquarter, the other unusual item, beyond that lapping, so there's very little year -over-year change as it  \nrelates to the IT enhancements in the four th quarter.  So that headwind goes away in Q4. ", "original_text": "So you can kind of think of roughly that one third  \nper quarter is what we've be en experiencing all year.  \n \n"}, "hash": "d5cecc0c2d8c46453e121fd69da44ba3c8e4b9a3feb4e30bb3277efa4391d8db", "class_name": "RelatedNodeInfo"}}, "text": "And we indicated that would be spread somewhat  \nevenly over the first three quarters of the fiscal year. ", "start_char_idx": 1758, "end_char_idx": 1864, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66ffc7cb-95c9-437d-8332-b3d5a3a2e7f1": {"__data__": {"id_": "66ffc7cb-95c9-437d-8332-b3d5a3a2e7f1", "embedding": null, "metadata": {"window": "There's a number of questions there, so  \nhopefully, you can catch them all.  So in terms of the IT enhancements, what we mentioned at the  \nbeginning of the year and is still very consistent with what we've seen roll out is about $80 million of  \nincremental costs that we saw in \u201822 versus \u201821.  And we indicated that would be spread somewhat  \nevenly over the first three quarters of the fiscal year.  So you can kind of think of roughly that one third  \nper quarter is what we've be en experiencing all year.  \n \n First two quarters, we had other actions that drove growth above and beyond that headwind, but that  \nwas with the inflation included in the third quarter, drove that 5% reduction.  As it relates to the fourth  \nquarter, the other unusual item, beyond that lapping, so there's very little year -over-year change as it  \nrelates to the IT enhancements in the four th quarter.  So that headwind goes away in Q4. ", "original_text": "So you can kind of think of roughly that one third  \nper quarter is what we've be en experiencing all year.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa3978b9-e793-4435-bace-738d1606f386", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah, this is Jason, let me go ahead and start.  There's a number of questions there, so  \nhopefully, you can catch them all.  So in terms of the IT enhancements, what we mentioned at the  \nbeginning of the year and is still very consistent with what we've seen roll out is about $80 million of  \nincremental costs that we saw in \u201822 versus \u201821.  And we indicated that would be spread somewhat  \nevenly over the first three quarters of the fiscal year.  So you can kind of think of roughly that one third  \nper quarter is what we've be en experiencing all year.  \n \n First two quarters, we had other actions that drove growth above and beyond that headwind, but that  \nwas with the inflation included in the third quarter, drove that 5% reduction.  As it relates to the fourth  \nquarter, the other unusual item, beyond that lapping, so there's very little year -over-year change as it  \nrelates to the IT enhancements in the four th quarter. ", "original_text": "And we indicated that would be spread somewhat  \nevenly over the first three quarters of the fiscal year. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d8f73122ce6f0d431e22b6bebee6581eda11793e5d0aae808c5a09e02a97f120", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c0b0520-8061-414e-b334-bf26bb16d826", "node_type": "1", "metadata": {"window": "So in terms of the IT enhancements, what we mentioned at the  \nbeginning of the year and is still very consistent with what we've seen roll out is about $80 million of  \nincremental costs that we saw in \u201822 versus \u201821.  And we indicated that would be spread somewhat  \nevenly over the first three quarters of the fiscal year.  So you can kind of think of roughly that one third  \nper quarter is what we've be en experiencing all year.  \n \n First two quarters, we had other actions that drove growth above and beyond that headwind, but that  \nwas with the inflation included in the third quarter, drove that 5% reduction.  As it relates to the fourth  \nquarter, the other unusual item, beyond that lapping, so there's very little year -over-year change as it  \nrelates to the IT enhancements in the four th quarter.  So that headwind goes away in Q4.  But we also  \nreferenced last Q4, Q4 of \u201921, that we had some unusual items that were adversely affecting us. ", "original_text": "First two quarters, we had other actions that drove growth above and beyond that headwind, but that  \nwas with the inflation included in the third quarter, drove that 5% reduction. "}, "hash": "c0b0bfcf553870fe3e046561d5b75c898a03d356a88f93ffa0d4468557c15f9e", "class_name": "RelatedNodeInfo"}}, "text": "So you can kind of think of roughly that one third  \nper quarter is what we've be en experiencing all year.  \n \n", "start_char_idx": 1864, "end_char_idx": 1976, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c0b0520-8061-414e-b334-bf26bb16d826": {"__data__": {"id_": "9c0b0520-8061-414e-b334-bf26bb16d826", "embedding": null, "metadata": {"window": "So in terms of the IT enhancements, what we mentioned at the  \nbeginning of the year and is still very consistent with what we've seen roll out is about $80 million of  \nincremental costs that we saw in \u201822 versus \u201821.  And we indicated that would be spread somewhat  \nevenly over the first three quarters of the fiscal year.  So you can kind of think of roughly that one third  \nper quarter is what we've be en experiencing all year.  \n \n First two quarters, we had other actions that drove growth above and beyond that headwind, but that  \nwas with the inflation included in the third quarter, drove that 5% reduction.  As it relates to the fourth  \nquarter, the other unusual item, beyond that lapping, so there's very little year -over-year change as it  \nrelates to the IT enhancements in the four th quarter.  So that headwind goes away in Q4.  But we also  \nreferenced last Q4, Q4 of \u201921, that we had some unusual items that were adversely affecting us. ", "original_text": "First two quarters, we had other actions that drove growth above and beyond that headwind, but that  \nwas with the inflation included in the third quarter, drove that 5% reduction. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66ffc7cb-95c9-437d-8332-b3d5a3a2e7f1", "node_type": "1", "metadata": {"window": "There's a number of questions there, so  \nhopefully, you can catch them all.  So in terms of the IT enhancements, what we mentioned at the  \nbeginning of the year and is still very consistent with what we've seen roll out is about $80 million of  \nincremental costs that we saw in \u201822 versus \u201821.  And we indicated that would be spread somewhat  \nevenly over the first three quarters of the fiscal year.  So you can kind of think of roughly that one third  \nper quarter is what we've be en experiencing all year.  \n \n First two quarters, we had other actions that drove growth above and beyond that headwind, but that  \nwas with the inflation included in the third quarter, drove that 5% reduction.  As it relates to the fourth  \nquarter, the other unusual item, beyond that lapping, so there's very little year -over-year change as it  \nrelates to the IT enhancements in the four th quarter.  So that headwind goes away in Q4. ", "original_text": "So you can kind of think of roughly that one third  \nper quarter is what we've be en experiencing all year.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2776acf3987cdfb1422aff3b6d45b35ea9413729698f7bc4b305dc1bd3291886", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ff89030-7a2a-4bf1-a7c9-6d0f3e2fb034", "node_type": "1", "metadata": {"window": "And we indicated that would be spread somewhat  \nevenly over the first three quarters of the fiscal year.  So you can kind of think of roughly that one third  \nper quarter is what we've be en experiencing all year.  \n \n First two quarters, we had other actions that drove growth above and beyond that headwind, but that  \nwas with the inflation included in the third quarter, drove that 5% reduction.  As it relates to the fourth  \nquarter, the other unusual item, beyond that lapping, so there's very little year -over-year change as it  \nrelates to the IT enhancements in the four th quarter.  So that headwind goes away in Q4.  But we also  \nreferenced last Q4, Q4 of \u201921, that we had some unusual items that were adversely affecting us.  So  \nthat becomes a year -over-year tailwind for us this Q4. ", "original_text": "As it relates to the fourth  \nquarter, the other unusual item, beyond that lapping, so there's very little year -over-year change as it  \nrelates to the IT enhancements in the four th quarter. "}, "hash": "883dce0997b6e5c52dcf4977c59c0ff0aad0e7aaf69794b971eed130365c7c72", "class_name": "RelatedNodeInfo"}}, "text": "First two quarters, we had other actions that drove growth above and beyond that headwind, but that  \nwas with the inflation included in the third quarter, drove that 5% reduction. ", "start_char_idx": 1976, "end_char_idx": 2157, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ff89030-7a2a-4bf1-a7c9-6d0f3e2fb034": {"__data__": {"id_": "0ff89030-7a2a-4bf1-a7c9-6d0f3e2fb034", "embedding": null, "metadata": {"window": "And we indicated that would be spread somewhat  \nevenly over the first three quarters of the fiscal year.  So you can kind of think of roughly that one third  \nper quarter is what we've be en experiencing all year.  \n \n First two quarters, we had other actions that drove growth above and beyond that headwind, but that  \nwas with the inflation included in the third quarter, drove that 5% reduction.  As it relates to the fourth  \nquarter, the other unusual item, beyond that lapping, so there's very little year -over-year change as it  \nrelates to the IT enhancements in the four th quarter.  So that headwind goes away in Q4.  But we also  \nreferenced last Q4, Q4 of \u201921, that we had some unusual items that were adversely affecting us.  So  \nthat becomes a year -over-year tailwind for us this Q4. ", "original_text": "As it relates to the fourth  \nquarter, the other unusual item, beyond that lapping, so there's very little year -over-year change as it  \nrelates to the IT enhancements in the four th quarter. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c0b0520-8061-414e-b334-bf26bb16d826", "node_type": "1", "metadata": {"window": "So in terms of the IT enhancements, what we mentioned at the  \nbeginning of the year and is still very consistent with what we've seen roll out is about $80 million of  \nincremental costs that we saw in \u201822 versus \u201821.  And we indicated that would be spread somewhat  \nevenly over the first three quarters of the fiscal year.  So you can kind of think of roughly that one third  \nper quarter is what we've be en experiencing all year.  \n \n First two quarters, we had other actions that drove growth above and beyond that headwind, but that  \nwas with the inflation included in the third quarter, drove that 5% reduction.  As it relates to the fourth  \nquarter, the other unusual item, beyond that lapping, so there's very little year -over-year change as it  \nrelates to the IT enhancements in the four th quarter.  So that headwind goes away in Q4.  But we also  \nreferenced last Q4, Q4 of \u201921, that we had some unusual items that were adversely affecting us. ", "original_text": "First two quarters, we had other actions that drove growth above and beyond that headwind, but that  \nwas with the inflation included in the third quarter, drove that 5% reduction. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2848a480734c31c44e17c0a79c5a728cd0e887c76d7c40acf706e63da91bd94b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8bf9eb1-5a30-4f45-a449-86436c88b13c", "node_type": "1", "metadata": {"window": "So you can kind of think of roughly that one third  \nper quarter is what we've be en experiencing all year.  \n \n First two quarters, we had other actions that drove growth above and beyond that headwind, but that  \nwas with the inflation included in the third quarter, drove that 5% reduction.  As it relates to the fourth  \nquarter, the other unusual item, beyond that lapping, so there's very little year -over-year change as it  \nrelates to the IT enhancements in the four th quarter.  So that headwind goes away in Q4.  But we also  \nreferenced last Q4, Q4 of \u201921, that we had some unusual items that were adversely affecting us.  So  \nthat becomes a year -over-year tailwind for us this Q4.  And then in addition to that, we indicated  here in  \nthe call today just before this that we are also seeing some volume underlying operational  \nimprovements that are expected for the fourth quarter that then would also continue on at that point.  \n \n", "original_text": "So that headwind goes away in Q4. "}, "hash": "151b740d57206437e1a38c5a416ab228e213dbfde4e87bb29a92f6886d415246", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to the fourth  \nquarter, the other unusual item, beyond that lapping, so there's very little year -over-year change as it  \nrelates to the IT enhancements in the four th quarter. ", "start_char_idx": 2157, "end_char_idx": 2350, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8bf9eb1-5a30-4f45-a449-86436c88b13c": {"__data__": {"id_": "d8bf9eb1-5a30-4f45-a449-86436c88b13c", "embedding": null, "metadata": {"window": "So you can kind of think of roughly that one third  \nper quarter is what we've be en experiencing all year.  \n \n First two quarters, we had other actions that drove growth above and beyond that headwind, but that  \nwas with the inflation included in the third quarter, drove that 5% reduction.  As it relates to the fourth  \nquarter, the other unusual item, beyond that lapping, so there's very little year -over-year change as it  \nrelates to the IT enhancements in the four th quarter.  So that headwind goes away in Q4.  But we also  \nreferenced last Q4, Q4 of \u201921, that we had some unusual items that were adversely affecting us.  So  \nthat becomes a year -over-year tailwind for us this Q4.  And then in addition to that, we indicated  here in  \nthe call today just before this that we are also seeing some volume underlying operational  \nimprovements that are expected for the fourth quarter that then would also continue on at that point.  \n \n", "original_text": "So that headwind goes away in Q4. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ff89030-7a2a-4bf1-a7c9-6d0f3e2fb034", "node_type": "1", "metadata": {"window": "And we indicated that would be spread somewhat  \nevenly over the first three quarters of the fiscal year.  So you can kind of think of roughly that one third  \nper quarter is what we've be en experiencing all year.  \n \n First two quarters, we had other actions that drove growth above and beyond that headwind, but that  \nwas with the inflation included in the third quarter, drove that 5% reduction.  As it relates to the fourth  \nquarter, the other unusual item, beyond that lapping, so there's very little year -over-year change as it  \nrelates to the IT enhancements in the four th quarter.  So that headwind goes away in Q4.  But we also  \nreferenced last Q4, Q4 of \u201921, that we had some unusual items that were adversely affecting us.  So  \nthat becomes a year -over-year tailwind for us this Q4. ", "original_text": "As it relates to the fourth  \nquarter, the other unusual item, beyond that lapping, so there's very little year -over-year change as it  \nrelates to the IT enhancements in the four th quarter. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "32d0d2e5f5dead67054adfd8cfaa353a4f1f0c3f74db0c9c788455a9dc0fceaa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd89f72e-44a5-4a3a-bb52-fab071cd1ddc", "node_type": "1", "metadata": {"window": "First two quarters, we had other actions that drove growth above and beyond that headwind, but that  \nwas with the inflation included in the third quarter, drove that 5% reduction.  As it relates to the fourth  \nquarter, the other unusual item, beyond that lapping, so there's very little year -over-year change as it  \nrelates to the IT enhancements in the four th quarter.  So that headwind goes away in Q4.  But we also  \nreferenced last Q4, Q4 of \u201921, that we had some unusual items that were adversely affecting us.  So  \nthat becomes a year -over-year tailwind for us this Q4.  And then in addition to that, we indicated  here in  \nthe call today just before this that we are also seeing some volume underlying operational  \nimprovements that are expected for the fourth quarter that then would also continue on at that point.  \n \n As it relates to inflation, what we saw here in th e third quarter was elevated. ", "original_text": "But we also  \nreferenced last Q4, Q4 of \u201921, that we had some unusual items that were adversely affecting us. "}, "hash": "577fda6d6c1943a3fb9d83a540ce8c3a81075f77dae680c47be10e8686bdba68", "class_name": "RelatedNodeInfo"}}, "text": "So that headwind goes away in Q4. ", "start_char_idx": 2350, "end_char_idx": 2384, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd89f72e-44a5-4a3a-bb52-fab071cd1ddc": {"__data__": {"id_": "cd89f72e-44a5-4a3a-bb52-fab071cd1ddc", "embedding": null, "metadata": {"window": "First two quarters, we had other actions that drove growth above and beyond that headwind, but that  \nwas with the inflation included in the third quarter, drove that 5% reduction.  As it relates to the fourth  \nquarter, the other unusual item, beyond that lapping, so there's very little year -over-year change as it  \nrelates to the IT enhancements in the four th quarter.  So that headwind goes away in Q4.  But we also  \nreferenced last Q4, Q4 of \u201921, that we had some unusual items that were adversely affecting us.  So  \nthat becomes a year -over-year tailwind for us this Q4.  And then in addition to that, we indicated  here in  \nthe call today just before this that we are also seeing some volume underlying operational  \nimprovements that are expected for the fourth quarter that then would also continue on at that point.  \n \n As it relates to inflation, what we saw here in th e third quarter was elevated. ", "original_text": "But we also  \nreferenced last Q4, Q4 of \u201921, that we had some unusual items that were adversely affecting us. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8bf9eb1-5a30-4f45-a449-86436c88b13c", "node_type": "1", "metadata": {"window": "So you can kind of think of roughly that one third  \nper quarter is what we've be en experiencing all year.  \n \n First two quarters, we had other actions that drove growth above and beyond that headwind, but that  \nwas with the inflation included in the third quarter, drove that 5% reduction.  As it relates to the fourth  \nquarter, the other unusual item, beyond that lapping, so there's very little year -over-year change as it  \nrelates to the IT enhancements in the four th quarter.  So that headwind goes away in Q4.  But we also  \nreferenced last Q4, Q4 of \u201921, that we had some unusual items that were adversely affecting us.  So  \nthat becomes a year -over-year tailwind for us this Q4.  And then in addition to that, we indicated  here in  \nthe call today just before this that we are also seeing some volume underlying operational  \nimprovements that are expected for the fourth quarter that then would also continue on at that point.  \n \n", "original_text": "So that headwind goes away in Q4. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6c14da1084a1aee76f5012f353d45b3692b235d17acf77694d0847d7dea67f11", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6cd05c88-5f20-4f35-99cb-8738307ab90a", "node_type": "1", "metadata": {"window": "As it relates to the fourth  \nquarter, the other unusual item, beyond that lapping, so there's very little year -over-year change as it  \nrelates to the IT enhancements in the four th quarter.  So that headwind goes away in Q4.  But we also  \nreferenced last Q4, Q4 of \u201921, that we had some unusual items that were adversely affecting us.  So  \nthat becomes a year -over-year tailwind for us this Q4.  And then in addition to that, we indicated  here in  \nthe call today just before this that we are also seeing some volume underlying operational  \nimprovements that are expected for the fourth quarter that then would also continue on at that point.  \n \n As it relates to inflation, what we saw here in th e third quarter was elevated.  It was a little bit higher \nthan what we had expected. ", "original_text": "So  \nthat becomes a year -over-year tailwind for us this Q4. "}, "hash": "1c072621f8f7ce7c1796ba4401688b0e7474b287d9c209846c15f8e0665132e6", "class_name": "RelatedNodeInfo"}}, "text": "But we also  \nreferenced last Q4, Q4 of \u201921, that we had some unusual items that were adversely affecting us. ", "start_char_idx": 2384, "end_char_idx": 2494, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6cd05c88-5f20-4f35-99cb-8738307ab90a": {"__data__": {"id_": "6cd05c88-5f20-4f35-99cb-8738307ab90a", "embedding": null, "metadata": {"window": "As it relates to the fourth  \nquarter, the other unusual item, beyond that lapping, so there's very little year -over-year change as it  \nrelates to the IT enhancements in the four th quarter.  So that headwind goes away in Q4.  But we also  \nreferenced last Q4, Q4 of \u201921, that we had some unusual items that were adversely affecting us.  So  \nthat becomes a year -over-year tailwind for us this Q4.  And then in addition to that, we indicated  here in  \nthe call today just before this that we are also seeing some volume underlying operational  \nimprovements that are expected for the fourth quarter that then would also continue on at that point.  \n \n As it relates to inflation, what we saw here in th e third quarter was elevated.  It was a little bit higher \nthan what we had expected. ", "original_text": "So  \nthat becomes a year -over-year tailwind for us this Q4. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd89f72e-44a5-4a3a-bb52-fab071cd1ddc", "node_type": "1", "metadata": {"window": "First two quarters, we had other actions that drove growth above and beyond that headwind, but that  \nwas with the inflation included in the third quarter, drove that 5% reduction.  As it relates to the fourth  \nquarter, the other unusual item, beyond that lapping, so there's very little year -over-year change as it  \nrelates to the IT enhancements in the four th quarter.  So that headwind goes away in Q4.  But we also  \nreferenced last Q4, Q4 of \u201921, that we had some unusual items that were adversely affecting us.  So  \nthat becomes a year -over-year tailwind for us this Q4.  And then in addition to that, we indicated  here in  \nthe call today just before this that we are also seeing some volume underlying operational  \nimprovements that are expected for the fourth quarter that then would also continue on at that point.  \n \n As it relates to inflation, what we saw here in th e third quarter was elevated. ", "original_text": "But we also  \nreferenced last Q4, Q4 of \u201921, that we had some unusual items that were adversely affecting us. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "540c8eb7b898c7534f7a7f8e1c220f7f098a2046d7e665c0943de7666f5bbf9b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e78d5e82-a23a-48a8-b366-1cd184a63cf4", "node_type": "1", "metadata": {"window": "So that headwind goes away in Q4.  But we also  \nreferenced last Q4, Q4 of \u201921, that we had some unusual items that were adversely affecting us.  So  \nthat becomes a year -over-year tailwind for us this Q4.  And then in addition to that, we indicated  here in  \nthe call today just before this that we are also seeing some volume underlying operational  \nimprovements that are expected for the fourth quarter that then would also continue on at that point.  \n \n As it relates to inflation, what we saw here in th e third quarter was elevated.  It was a little bit higher \nthan what we had expected.  It is consistent with the range of our guidance, but nonetheless, it's an item \nthat does impact our Q3 and we're expecting it to impact Q4 and then carry over our comments for the \nfirst half of fiscal \u201823 or just presuming that that cost will continue on at a similar elevated level and be \na year of a year headwind such that by the time we get to the second half of fiscal \u201823, we would then \nlap it at that point in time. ", "original_text": "And then in addition to that, we indicated  here in  \nthe call today just before this that we are also seeing some volume underlying operational  \nimprovements that are expected for the fourth quarter that then would also continue on at that point.  \n \n"}, "hash": "4a218330ecdcd00583bdf6821ab2f7ed787ac6cb51b087477edbaaec027afb1a", "class_name": "RelatedNodeInfo"}}, "text": "So  \nthat becomes a year -over-year tailwind for us this Q4. ", "start_char_idx": 2494, "end_char_idx": 2555, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e78d5e82-a23a-48a8-b366-1cd184a63cf4": {"__data__": {"id_": "e78d5e82-a23a-48a8-b366-1cd184a63cf4", "embedding": null, "metadata": {"window": "So that headwind goes away in Q4.  But we also  \nreferenced last Q4, Q4 of \u201921, that we had some unusual items that were adversely affecting us.  So  \nthat becomes a year -over-year tailwind for us this Q4.  And then in addition to that, we indicated  here in  \nthe call today just before this that we are also seeing some volume underlying operational  \nimprovements that are expected for the fourth quarter that then would also continue on at that point.  \n \n As it relates to inflation, what we saw here in th e third quarter was elevated.  It was a little bit higher \nthan what we had expected.  It is consistent with the range of our guidance, but nonetheless, it's an item \nthat does impact our Q3 and we're expecting it to impact Q4 and then carry over our comments for the \nfirst half of fiscal \u201823 or just presuming that that cost will continue on at a similar elevated level and be \na year of a year headwind such that by the time we get to the second half of fiscal \u201823, we would then \nlap it at that point in time. ", "original_text": "And then in addition to that, we indicated  here in  \nthe call today just before this that we are also seeing some volume underlying operational  \nimprovements that are expected for the fourth quarter that then would also continue on at that point.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6cd05c88-5f20-4f35-99cb-8738307ab90a", "node_type": "1", "metadata": {"window": "As it relates to the fourth  \nquarter, the other unusual item, beyond that lapping, so there's very little year -over-year change as it  \nrelates to the IT enhancements in the four th quarter.  So that headwind goes away in Q4.  But we also  \nreferenced last Q4, Q4 of \u201921, that we had some unusual items that were adversely affecting us.  So  \nthat becomes a year -over-year tailwind for us this Q4.  And then in addition to that, we indicated  here in  \nthe call today just before this that we are also seeing some volume underlying operational  \nimprovements that are expected for the fourth quarter that then would also continue on at that point.  \n \n As it relates to inflation, what we saw here in th e third quarter was elevated.  It was a little bit higher \nthan what we had expected. ", "original_text": "So  \nthat becomes a year -over-year tailwind for us this Q4. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45adcf46c414dcde682e5a777993776ee452dd5236aa7a404087c43e496a08d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5b4e004-cc38-4f7d-96e7-86cad313aa26", "node_type": "1", "metadata": {"window": "But we also  \nreferenced last Q4, Q4 of \u201921, that we had some unusual items that were adversely affecting us.  So  \nthat becomes a year -over-year tailwind for us this Q4.  And then in addition to that, we indicated  here in  \nthe call today just before this that we are also seeing some volume underlying operational  \nimprovements that are expected for the fourth quarter that then would also continue on at that point.  \n \n As it relates to inflation, what we saw here in th e third quarter was elevated.  It was a little bit higher \nthan what we had expected.  It is consistent with the range of our guidance, but nonetheless, it's an item \nthat does impact our Q3 and we're expecting it to impact Q4 and then carry over our comments for the \nfirst half of fiscal \u201823 or just presuming that that cost will continue on at a similar elevated level and be \na year of a year headwind such that by the time we get to the second half of fiscal \u201823, we would then \nlap it at that point in time.  I thi nk I captured all your questions there.  \n \n", "original_text": "As it relates to inflation, what we saw here in th e third quarter was elevated. "}, "hash": "f73ef9c5efc3702df243badc42baa10a07e54ea8ae98416c47219d7c4615575f", "class_name": "RelatedNodeInfo"}}, "text": "And then in addition to that, we indicated  here in  \nthe call today just before this that we are also seeing some volume underlying operational  \nimprovements that are expected for the fourth quarter that then would also continue on at that point.  \n \n", "start_char_idx": 2555, "end_char_idx": 2808, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5b4e004-cc38-4f7d-96e7-86cad313aa26": {"__data__": {"id_": "f5b4e004-cc38-4f7d-96e7-86cad313aa26", "embedding": null, "metadata": {"window": "But we also  \nreferenced last Q4, Q4 of \u201921, that we had some unusual items that were adversely affecting us.  So  \nthat becomes a year -over-year tailwind for us this Q4.  And then in addition to that, we indicated  here in  \nthe call today just before this that we are also seeing some volume underlying operational  \nimprovements that are expected for the fourth quarter that then would also continue on at that point.  \n \n As it relates to inflation, what we saw here in th e third quarter was elevated.  It was a little bit higher \nthan what we had expected.  It is consistent with the range of our guidance, but nonetheless, it's an item \nthat does impact our Q3 and we're expecting it to impact Q4 and then carry over our comments for the \nfirst half of fiscal \u201823 or just presuming that that cost will continue on at a similar elevated level and be \na year of a year headwind such that by the time we get to the second half of fiscal \u201823, we would then \nlap it at that point in time.  I thi nk I captured all your questions there.  \n \n", "original_text": "As it relates to inflation, what we saw here in th e third quarter was elevated. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e78d5e82-a23a-48a8-b366-1cd184a63cf4", "node_type": "1", "metadata": {"window": "So that headwind goes away in Q4.  But we also  \nreferenced last Q4, Q4 of \u201921, that we had some unusual items that were adversely affecting us.  So  \nthat becomes a year -over-year tailwind for us this Q4.  And then in addition to that, we indicated  here in  \nthe call today just before this that we are also seeing some volume underlying operational  \nimprovements that are expected for the fourth quarter that then would also continue on at that point.  \n \n As it relates to inflation, what we saw here in th e third quarter was elevated.  It was a little bit higher \nthan what we had expected.  It is consistent with the range of our guidance, but nonetheless, it's an item \nthat does impact our Q3 and we're expecting it to impact Q4 and then carry over our comments for the \nfirst half of fiscal \u201823 or just presuming that that cost will continue on at a similar elevated level and be \na year of a year headwind such that by the time we get to the second half of fiscal \u201823, we would then \nlap it at that point in time. ", "original_text": "And then in addition to that, we indicated  here in  \nthe call today just before this that we are also seeing some volume underlying operational  \nimprovements that are expected for the fourth quarter that then would also continue on at that point.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "30d1ba623d145c946aab3b94addd39768651d1314c1be5456843d170d2fc26ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab23679d-0343-4be8-825f-be82a151c7a1", "node_type": "1", "metadata": {"window": "So  \nthat becomes a year -over-year tailwind for us this Q4.  And then in addition to that, we indicated  here in  \nthe call today just before this that we are also seeing some volume underlying operational  \nimprovements that are expected for the fourth quarter that then would also continue on at that point.  \n \n As it relates to inflation, what we saw here in th e third quarter was elevated.  It was a little bit higher \nthan what we had expected.  It is consistent with the range of our guidance, but nonetheless, it's an item \nthat does impact our Q3 and we're expecting it to impact Q4 and then carry over our comments for the \nfirst half of fiscal \u201823 or just presuming that that cost will continue on at a similar elevated level and be \na year of a year headwind such that by the time we get to the second half of fiscal \u201823, we would then \nlap it at that point in time.  I thi nk I captured all your questions there.  \n \n Operator:   All right. ", "original_text": "It was a little bit higher \nthan what we had expected. "}, "hash": "617d8dbb0489521312021da3ca81459cced244ea88d6668b22f16392215baf34", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to inflation, what we saw here in th e third quarter was elevated. ", "start_char_idx": 2808, "end_char_idx": 2889, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab23679d-0343-4be8-825f-be82a151c7a1": {"__data__": {"id_": "ab23679d-0343-4be8-825f-be82a151c7a1", "embedding": null, "metadata": {"window": "So  \nthat becomes a year -over-year tailwind for us this Q4.  And then in addition to that, we indicated  here in  \nthe call today just before this that we are also seeing some volume underlying operational  \nimprovements that are expected for the fourth quarter that then would also continue on at that point.  \n \n As it relates to inflation, what we saw here in th e third quarter was elevated.  It was a little bit higher \nthan what we had expected.  It is consistent with the range of our guidance, but nonetheless, it's an item \nthat does impact our Q3 and we're expecting it to impact Q4 and then carry over our comments for the \nfirst half of fiscal \u201823 or just presuming that that cost will continue on at a similar elevated level and be \na year of a year headwind such that by the time we get to the second half of fiscal \u201823, we would then \nlap it at that point in time.  I thi nk I captured all your questions there.  \n \n Operator:   All right. ", "original_text": "It was a little bit higher \nthan what we had expected. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5b4e004-cc38-4f7d-96e7-86cad313aa26", "node_type": "1", "metadata": {"window": "But we also  \nreferenced last Q4, Q4 of \u201921, that we had some unusual items that were adversely affecting us.  So  \nthat becomes a year -over-year tailwind for us this Q4.  And then in addition to that, we indicated  here in  \nthe call today just before this that we are also seeing some volume underlying operational  \nimprovements that are expected for the fourth quarter that then would also continue on at that point.  \n \n As it relates to inflation, what we saw here in th e third quarter was elevated.  It was a little bit higher \nthan what we had expected.  It is consistent with the range of our guidance, but nonetheless, it's an item \nthat does impact our Q3 and we're expecting it to impact Q4 and then carry over our comments for the \nfirst half of fiscal \u201823 or just presuming that that cost will continue on at a similar elevated level and be \na year of a year headwind such that by the time we get to the second half of fiscal \u201823, we would then \nlap it at that point in time.  I thi nk I captured all your questions there.  \n \n", "original_text": "As it relates to inflation, what we saw here in th e third quarter was elevated. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1cad2d4a1bd8ad542614959d52b85ceb997fd527f1ef38168e7da198d7bcf9fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1036cb8c-b7fc-480a-845b-c52650d8d54e", "node_type": "1", "metadata": {"window": "And then in addition to that, we indicated  here in  \nthe call today just before this that we are also seeing some volume underlying operational  \nimprovements that are expected for the fourth quarter that then would also continue on at that point.  \n \n As it relates to inflation, what we saw here in th e third quarter was elevated.  It was a little bit higher \nthan what we had expected.  It is consistent with the range of our guidance, but nonetheless, it's an item \nthat does impact our Q3 and we're expecting it to impact Q4 and then carry over our comments for the \nfirst half of fiscal \u201823 or just presuming that that cost will continue on at a similar elevated level and be \na year of a year headwind such that by the time we get to the second half of fiscal \u201823, we would then \nlap it at that point in time.  I thi nk I captured all your questions there.  \n \n Operator:   All right.  We'll go ahead and take our next question from Eric Percher with Nephron  \nResearch.  \n  \n", "original_text": "It is consistent with the range of our guidance, but nonetheless, it's an item \nthat does impact our Q3 and we're expecting it to impact Q4 and then carry over our comments for the \nfirst half of fiscal \u201823 or just presuming that that cost will continue on at a similar elevated level and be \na year of a year headwind such that by the time we get to the second half of fiscal \u201823, we would then \nlap it at that point in time. "}, "hash": "fe927626ed2ba37a8c806bb29a47e6f8e5547522a9b2cfe7ee96546ecee853b2", "class_name": "RelatedNodeInfo"}}, "text": "It was a little bit higher \nthan what we had expected. ", "start_char_idx": 2889, "end_char_idx": 2944, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1036cb8c-b7fc-480a-845b-c52650d8d54e": {"__data__": {"id_": "1036cb8c-b7fc-480a-845b-c52650d8d54e", "embedding": null, "metadata": {"window": "And then in addition to that, we indicated  here in  \nthe call today just before this that we are also seeing some volume underlying operational  \nimprovements that are expected for the fourth quarter that then would also continue on at that point.  \n \n As it relates to inflation, what we saw here in th e third quarter was elevated.  It was a little bit higher \nthan what we had expected.  It is consistent with the range of our guidance, but nonetheless, it's an item \nthat does impact our Q3 and we're expecting it to impact Q4 and then carry over our comments for the \nfirst half of fiscal \u201823 or just presuming that that cost will continue on at a similar elevated level and be \na year of a year headwind such that by the time we get to the second half of fiscal \u201823, we would then \nlap it at that point in time.  I thi nk I captured all your questions there.  \n \n Operator:   All right.  We'll go ahead and take our next question from Eric Percher with Nephron  \nResearch.  \n  \n", "original_text": "It is consistent with the range of our guidance, but nonetheless, it's an item \nthat does impact our Q3 and we're expecting it to impact Q4 and then carry over our comments for the \nfirst half of fiscal \u201823 or just presuming that that cost will continue on at a similar elevated level and be \na year of a year headwind such that by the time we get to the second half of fiscal \u201823, we would then \nlap it at that point in time. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab23679d-0343-4be8-825f-be82a151c7a1", "node_type": "1", "metadata": {"window": "So  \nthat becomes a year -over-year tailwind for us this Q4.  And then in addition to that, we indicated  here in  \nthe call today just before this that we are also seeing some volume underlying operational  \nimprovements that are expected for the fourth quarter that then would also continue on at that point.  \n \n As it relates to inflation, what we saw here in th e third quarter was elevated.  It was a little bit higher \nthan what we had expected.  It is consistent with the range of our guidance, but nonetheless, it's an item \nthat does impact our Q3 and we're expecting it to impact Q4 and then carry over our comments for the \nfirst half of fiscal \u201823 or just presuming that that cost will continue on at a similar elevated level and be \na year of a year headwind such that by the time we get to the second half of fiscal \u201823, we would then \nlap it at that point in time.  I thi nk I captured all your questions there.  \n \n Operator:   All right. ", "original_text": "It was a little bit higher \nthan what we had expected. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8dcac4f1425363eff7b5ac9a6bd00e543d7525edaee15ab25bf87966cc722d5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56a300be-0848-454c-a89b-3535ab163d2f", "node_type": "1", "metadata": {"window": "As it relates to inflation, what we saw here in th e third quarter was elevated.  It was a little bit higher \nthan what we had expected.  It is consistent with the range of our guidance, but nonetheless, it's an item \nthat does impact our Q3 and we're expecting it to impact Q4 and then carry over our comments for the \nfirst half of fiscal \u201823 or just presuming that that cost will continue on at a similar elevated level and be \na year of a year headwind such that by the time we get to the second half of fiscal \u201823, we would then \nlap it at that point in time.  I thi nk I captured all your questions there.  \n \n Operator:   All right.  We'll go ahead and take our next question from Eric Percher with Nephron  \nResearch.  \n  \n Eric Percher:   Thank you. ", "original_text": "I thi nk I captured all your questions there.  \n \n"}, "hash": "6c9a013fcf964d30eb97af6330b0dc99a1a93e07312010baba003e91f9189209", "class_name": "RelatedNodeInfo"}}, "text": "It is consistent with the range of our guidance, but nonetheless, it's an item \nthat does impact our Q3 and we're expecting it to impact Q4 and then carry over our comments for the \nfirst half of fiscal \u201823 or just presuming that that cost will continue on at a similar elevated level and be \na year of a year headwind such that by the time we get to the second half of fiscal \u201823, we would then \nlap it at that point in time. ", "start_char_idx": 2944, "end_char_idx": 3371, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56a300be-0848-454c-a89b-3535ab163d2f": {"__data__": {"id_": "56a300be-0848-454c-a89b-3535ab163d2f", "embedding": null, "metadata": {"window": "As it relates to inflation, what we saw here in th e third quarter was elevated.  It was a little bit higher \nthan what we had expected.  It is consistent with the range of our guidance, but nonetheless, it's an item \nthat does impact our Q3 and we're expecting it to impact Q4 and then carry over our comments for the \nfirst half of fiscal \u201823 or just presuming that that cost will continue on at a similar elevated level and be \na year of a year headwind such that by the time we get to the second half of fiscal \u201823, we would then \nlap it at that point in time.  I thi nk I captured all your questions there.  \n \n Operator:   All right.  We'll go ahead and take our next question from Eric Percher with Nephron  \nResearch.  \n  \n Eric Percher:   Thank you. ", "original_text": "I thi nk I captured all your questions there.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1036cb8c-b7fc-480a-845b-c52650d8d54e", "node_type": "1", "metadata": {"window": "And then in addition to that, we indicated  here in  \nthe call today just before this that we are also seeing some volume underlying operational  \nimprovements that are expected for the fourth quarter that then would also continue on at that point.  \n \n As it relates to inflation, what we saw here in th e third quarter was elevated.  It was a little bit higher \nthan what we had expected.  It is consistent with the range of our guidance, but nonetheless, it's an item \nthat does impact our Q3 and we're expecting it to impact Q4 and then carry over our comments for the \nfirst half of fiscal \u201823 or just presuming that that cost will continue on at a similar elevated level and be \na year of a year headwind such that by the time we get to the second half of fiscal \u201823, we would then \nlap it at that point in time.  I thi nk I captured all your questions there.  \n \n Operator:   All right.  We'll go ahead and take our next question from Eric Percher with Nephron  \nResearch.  \n  \n", "original_text": "It is consistent with the range of our guidance, but nonetheless, it's an item \nthat does impact our Q3 and we're expecting it to impact Q4 and then carry over our comments for the \nfirst half of fiscal \u201823 or just presuming that that cost will continue on at a similar elevated level and be \na year of a year headwind such that by the time we get to the second half of fiscal \u201823, we would then \nlap it at that point in time. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ed11103ea81bbc5e8a0284811caf97257522fe5ef755018f1ba5ff2e73818710", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73ba0f17-981c-41ef-bf82-5928fe5a8bb0", "node_type": "1", "metadata": {"window": "It was a little bit higher \nthan what we had expected.  It is consistent with the range of our guidance, but nonetheless, it's an item \nthat does impact our Q3 and we're expecting it to impact Q4 and then carry over our comments for the \nfirst half of fiscal \u201823 or just presuming that that cost will continue on at a similar elevated level and be \na year of a year headwind such that by the time we get to the second half of fiscal \u201823, we would then \nlap it at that point in time.  I thi nk I captured all your questions there.  \n \n Operator:   All right.  We'll go ahead and take our next question from Eric Percher with Nephron  \nResearch.  \n  \n Eric Percher:   Thank you.  I recognize you've had some unprecedented headwinds, but throughout the  ", "original_text": "Operator:   All right. "}, "hash": "f2514ef45ca3de13e0104b5550dbd356815254f9d1f0ed0ce564f9b2c75b62ef", "class_name": "RelatedNodeInfo"}}, "text": "I thi nk I captured all your questions there.  \n \n", "start_char_idx": 3371, "end_char_idx": 3421, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73ba0f17-981c-41ef-bf82-5928fe5a8bb0": {"__data__": {"id_": "73ba0f17-981c-41ef-bf82-5928fe5a8bb0", "embedding": null, "metadata": {"window": "It was a little bit higher \nthan what we had expected.  It is consistent with the range of our guidance, but nonetheless, it's an item \nthat does impact our Q3 and we're expecting it to impact Q4 and then carry over our comments for the \nfirst half of fiscal \u201823 or just presuming that that cost will continue on at a similar elevated level and be \na year of a year headwind such that by the time we get to the second half of fiscal \u201823, we would then \nlap it at that point in time.  I thi nk I captured all your questions there.  \n \n Operator:   All right.  We'll go ahead and take our next question from Eric Percher with Nephron  \nResearch.  \n  \n Eric Percher:   Thank you.  I recognize you've had some unprecedented headwinds, but throughout the  ", "original_text": "Operator:   All right. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56a300be-0848-454c-a89b-3535ab163d2f", "node_type": "1", "metadata": {"window": "As it relates to inflation, what we saw here in th e third quarter was elevated.  It was a little bit higher \nthan what we had expected.  It is consistent with the range of our guidance, but nonetheless, it's an item \nthat does impact our Q3 and we're expecting it to impact Q4 and then carry over our comments for the \nfirst half of fiscal \u201823 or just presuming that that cost will continue on at a similar elevated level and be \na year of a year headwind such that by the time we get to the second half of fiscal \u201823, we would then \nlap it at that point in time.  I thi nk I captured all your questions there.  \n \n Operator:   All right.  We'll go ahead and take our next question from Eric Percher with Nephron  \nResearch.  \n  \n Eric Percher:   Thank you. ", "original_text": "I thi nk I captured all your questions there.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3fd872de575eff9b4816c793967bffb0e8e7a2b163727a2d96157c08a44e113", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "438447b6-bdd4-43a4-86e0-ba4888304dd5", "node_type": "1", "metadata": {"window": "It is consistent with the range of our guidance, but nonetheless, it's an item \nthat does impact our Q3 and we're expecting it to impact Q4 and then carry over our comments for the \nfirst half of fiscal \u201823 or just presuming that that cost will continue on at a similar elevated level and be \na year of a year headwind such that by the time we get to the second half of fiscal \u201823, we would then \nlap it at that point in time.  I thi nk I captured all your questions there.  \n \n Operator:   All right.  We'll go ahead and take our next question from Eric Percher with Nephron  \nResearch.  \n  \n Eric Percher:   Thank you.  I recognize you've had some unprecedented headwinds, but throughout the  ", "original_text": "We'll go ahead and take our next question from Eric Percher with Nephron  \nResearch.  \n  \n"}, "hash": "023e268de05a1bc8e1721ccfa741409809a49215d8fd2d915f531f72d78a87cd", "class_name": "RelatedNodeInfo"}}, "text": "Operator:   All right. ", "start_char_idx": 3421, "end_char_idx": 3444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "438447b6-bdd4-43a4-86e0-ba4888304dd5": {"__data__": {"id_": "438447b6-bdd4-43a4-86e0-ba4888304dd5", "embedding": null, "metadata": {"window": "It is consistent with the range of our guidance, but nonetheless, it's an item \nthat does impact our Q3 and we're expecting it to impact Q4 and then carry over our comments for the \nfirst half of fiscal \u201823 or just presuming that that cost will continue on at a similar elevated level and be \na year of a year headwind such that by the time we get to the second half of fiscal \u201823, we would then \nlap it at that point in time.  I thi nk I captured all your questions there.  \n \n Operator:   All right.  We'll go ahead and take our next question from Eric Percher with Nephron  \nResearch.  \n  \n Eric Percher:   Thank you.  I recognize you've had some unprecedented headwinds, but throughout the  ", "original_text": "We'll go ahead and take our next question from Eric Percher with Nephron  \nResearch.  \n  \n", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73ba0f17-981c-41ef-bf82-5928fe5a8bb0", "node_type": "1", "metadata": {"window": "It was a little bit higher \nthan what we had expected.  It is consistent with the range of our guidance, but nonetheless, it's an item \nthat does impact our Q3 and we're expecting it to impact Q4 and then carry over our comments for the \nfirst half of fiscal \u201823 or just presuming that that cost will continue on at a similar elevated level and be \na year of a year headwind such that by the time we get to the second half of fiscal \u201823, we would then \nlap it at that point in time.  I thi nk I captured all your questions there.  \n \n Operator:   All right.  We'll go ahead and take our next question from Eric Percher with Nephron  \nResearch.  \n  \n Eric Percher:   Thank you.  I recognize you've had some unprecedented headwinds, but throughout the  ", "original_text": "Operator:   All right. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f4c4972899317033d2086fb2e7a2006b1fdd0fc05f46a48c03888ab56944f26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1fc2eae5-ed85-4508-a4af-8649020059fc", "node_type": "1", "metadata": {"window": "I thi nk I captured all your questions there.  \n \n Operator:   All right.  We'll go ahead and take our next question from Eric Percher with Nephron  \nResearch.  \n  \n Eric Percher:   Thank you.  I recognize you've had some unprecedented headwinds, but throughout the  ", "original_text": "Eric Percher:   Thank you. "}, "hash": "d82b289e9ae9fab027cc5095a1d9bc9927ed9ebf888366298a93604bf16717b1", "class_name": "RelatedNodeInfo"}}, "text": "We'll go ahead and take our next question from Eric Percher with Nephron  \nResearch.  \n  \n", "start_char_idx": 3444, "end_char_idx": 3534, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1fc2eae5-ed85-4508-a4af-8649020059fc": {"__data__": {"id_": "1fc2eae5-ed85-4508-a4af-8649020059fc", "embedding": null, "metadata": {"window": "I thi nk I captured all your questions there.  \n \n Operator:   All right.  We'll go ahead and take our next question from Eric Percher with Nephron  \nResearch.  \n  \n Eric Percher:   Thank you.  I recognize you've had some unprecedented headwinds, but throughout the  ", "original_text": "Eric Percher:   Thank you. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "438447b6-bdd4-43a4-86e0-ba4888304dd5", "node_type": "1", "metadata": {"window": "It is consistent with the range of our guidance, but nonetheless, it's an item \nthat does impact our Q3 and we're expecting it to impact Q4 and then carry over our comments for the \nfirst half of fiscal \u201823 or just presuming that that cost will continue on at a similar elevated level and be \na year of a year headwind such that by the time we get to the second half of fiscal \u201823, we would then \nlap it at that point in time.  I thi nk I captured all your questions there.  \n \n Operator:   All right.  We'll go ahead and take our next question from Eric Percher with Nephron  \nResearch.  \n  \n Eric Percher:   Thank you.  I recognize you've had some unprecedented headwinds, but throughout the  ", "original_text": "We'll go ahead and take our next question from Eric Percher with Nephron  \nResearch.  \n  \n", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f34a3975fcb66d3ff4b2577d00b6ec40caea99576af7c8d3e0a59d3b42c1e4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41697dc5-53eb-44c4-b4e4-e7d934ebdbf5", "node_type": "1", "metadata": {"window": "Operator:   All right.  We'll go ahead and take our next question from Eric Percher with Nephron  \nResearch.  \n  \n Eric Percher:   Thank you.  I recognize you've had some unprecedented headwinds, but throughout the  ", "original_text": "I recognize you've had some unprecedented headwinds, but throughout the  "}, "hash": "b63de7bd925fb3844dd4d981f5a8cffefc2d6f41a76815dffdd6984544dde9c2", "class_name": "RelatedNodeInfo"}}, "text": "Eric Percher:   Thank you. ", "start_char_idx": 3534, "end_char_idx": 3561, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41697dc5-53eb-44c4-b4e4-e7d934ebdbf5": {"__data__": {"id_": "41697dc5-53eb-44c4-b4e4-e7d934ebdbf5", "embedding": null, "metadata": {"window": "Operator:   All right.  We'll go ahead and take our next question from Eric Percher with Nephron  \nResearch.  \n  \n Eric Percher:   Thank you.  I recognize you've had some unprecedented headwinds, but throughout the  ", "original_text": "I recognize you've had some unprecedented headwinds, but throughout the  ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "665fb122-36ff-4172-8876-0cefc09a4c07", "node_type": "4", "metadata": {"page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e0898a54b9f5b5ab79faf2bafd56522988f52d05c496523f9bfd9913528b848e", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1fc2eae5-ed85-4508-a4af-8649020059fc", "node_type": "1", "metadata": {"window": "I thi nk I captured all your questions there.  \n \n Operator:   All right.  We'll go ahead and take our next question from Eric Percher with Nephron  \nResearch.  \n  \n Eric Percher:   Thank you.  I recognize you've had some unprecedented headwinds, but throughout the  ", "original_text": "Eric Percher:   Thank you. ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a8424cb7114857b49c0df9f7590db91f6555efeb04b203074e1bc42c2897cb2b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebd35188-542d-4770-8606-78dc84331e72", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \nguidance has appeared to assume stabilization or improvement.  And so we've seen step -downs of 100  \nto 125, 150 to 175, and now 300.  It sounds like for \u201823, you're trying to let us know that we're going to  \nsee lapping and it doesn't get better, though there are actions being taken.  Can you give us a feel for  \nwhat actions you would take if it turns out that things continue to get worse? ", "original_text": " \nPage 10 of 15 \n \nguidance has appeared to assume stabilization or improvement. "}, "hash": "0c77d8c595d081bdb191f4f75f48bcf47fbce16868304391652aa02169d37011", "class_name": "RelatedNodeInfo"}}, "text": "I recognize you've had some unprecedented headwinds, but throughout the  ", "start_char_idx": 3561, "end_char_idx": 3634, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebd35188-542d-4770-8606-78dc84331e72": {"__data__": {"id_": "ebd35188-542d-4770-8606-78dc84331e72", "embedding": null, "metadata": {"window": " \nPage 10 of 15 \n \nguidance has appeared to assume stabilization or improvement.  And so we've seen step -downs of 100  \nto 125, 150 to 175, and now 300.  It sounds like for \u201823, you're trying to let us know that we're going to  \nsee lapping and it doesn't get better, though there are actions being taken.  Can you give us a feel for  \nwhat actions you would take if it turns out that things continue to get worse? ", "original_text": " \nPage 10 of 15 \n \nguidance has appeared to assume stabilization or improvement. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41697dc5-53eb-44c4-b4e4-e7d934ebdbf5", "node_type": "1", "metadata": {"window": "Operator:   All right.  We'll go ahead and take our next question from Eric Percher with Nephron  \nResearch.  \n  \n Eric Percher:   Thank you.  I recognize you've had some unprecedented headwinds, but throughout the  ", "original_text": "I recognize you've had some unprecedented headwinds, but throughout the  ", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ae4c77f713c294636c174e60be2022fe390b89b3964a992adc627aa36c88e89e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "368e5b6b-9d6b-4eec-b1bc-4a4f6418c10e", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \nguidance has appeared to assume stabilization or improvement.  And so we've seen step -downs of 100  \nto 125, 150 to 175, and now 300.  It sounds like for \u201823, you're trying to let us know that we're going to  \nsee lapping and it doesn't get better, though there are actions being taken.  Can you give us a feel for  \nwhat actions you would take if it turns out that things continue to get worse?  And have you thought  \nabout the prof itability of elements of the business? ", "original_text": "And so we've seen step -downs of 100  \nto 125, 150 to 175, and now 300. "}, "hash": "d2a3139c4ebac40ee2235e036f24d1de619c2bd4ae4942e1cfdb7e7532cad8ea", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 10 of 15 \n \nguidance has appeared to assume stabilization or improvement. ", "start_char_idx": 0, "end_char_idx": 81, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "368e5b6b-9d6b-4eec-b1bc-4a4f6418c10e": {"__data__": {"id_": "368e5b6b-9d6b-4eec-b1bc-4a4f6418c10e", "embedding": null, "metadata": {"window": " \nPage 10 of 15 \n \nguidance has appeared to assume stabilization or improvement.  And so we've seen step -downs of 100  \nto 125, 150 to 175, and now 300.  It sounds like for \u201823, you're trying to let us know that we're going to  \nsee lapping and it doesn't get better, though there are actions being taken.  Can you give us a feel for  \nwhat actions you would take if it turns out that things continue to get worse?  And have you thought  \nabout the prof itability of elements of the business? ", "original_text": "And so we've seen step -downs of 100  \nto 125, 150 to 175, and now 300. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebd35188-542d-4770-8606-78dc84331e72", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \nguidance has appeared to assume stabilization or improvement.  And so we've seen step -downs of 100  \nto 125, 150 to 175, and now 300.  It sounds like for \u201823, you're trying to let us know that we're going to  \nsee lapping and it doesn't get better, though there are actions being taken.  Can you give us a feel for  \nwhat actions you would take if it turns out that things continue to get worse? ", "original_text": " \nPage 10 of 15 \n \nguidance has appeared to assume stabilization or improvement. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f11120d96b5bfd4964eb924b72e722dc1c3b15235f77d5c73be219872af2be9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a4f2674-243d-4322-8eca-c482a8ca2d7f", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \nguidance has appeared to assume stabilization or improvement.  And so we've seen step -downs of 100  \nto 125, 150 to 175, and now 300.  It sounds like for \u201823, you're trying to let us know that we're going to  \nsee lapping and it doesn't get better, though there are actions being taken.  Can you give us a feel for  \nwhat actions you would take if it turns out that things continue to get worse?  And have you thought  \nabout the prof itability of elements of the business?  What might need to change, or even whether the  \nbusiness might be better positioned for rebound if it's a multi -year rebound under someone else's  \nownership?  \n \n", "original_text": "It sounds like for \u201823, you're trying to let us know that we're going to  \nsee lapping and it doesn't get better, though there are actions being taken. "}, "hash": "dc5ffd0848e9fd1a5639157fd65abe8a9577fafc99db25b374d3f11a55743bbe", "class_name": "RelatedNodeInfo"}}, "text": "And so we've seen step -downs of 100  \nto 125, 150 to 175, and now 300. ", "start_char_idx": 81, "end_char_idx": 153, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a4f2674-243d-4322-8eca-c482a8ca2d7f": {"__data__": {"id_": "3a4f2674-243d-4322-8eca-c482a8ca2d7f", "embedding": null, "metadata": {"window": " \nPage 10 of 15 \n \nguidance has appeared to assume stabilization or improvement.  And so we've seen step -downs of 100  \nto 125, 150 to 175, and now 300.  It sounds like for \u201823, you're trying to let us know that we're going to  \nsee lapping and it doesn't get better, though there are actions being taken.  Can you give us a feel for  \nwhat actions you would take if it turns out that things continue to get worse?  And have you thought  \nabout the prof itability of elements of the business?  What might need to change, or even whether the  \nbusiness might be better positioned for rebound if it's a multi -year rebound under someone else's  \nownership?  \n \n", "original_text": "It sounds like for \u201823, you're trying to let us know that we're going to  \nsee lapping and it doesn't get better, though there are actions being taken. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "368e5b6b-9d6b-4eec-b1bc-4a4f6418c10e", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \nguidance has appeared to assume stabilization or improvement.  And so we've seen step -downs of 100  \nto 125, 150 to 175, and now 300.  It sounds like for \u201823, you're trying to let us know that we're going to  \nsee lapping and it doesn't get better, though there are actions being taken.  Can you give us a feel for  \nwhat actions you would take if it turns out that things continue to get worse?  And have you thought  \nabout the prof itability of elements of the business? ", "original_text": "And so we've seen step -downs of 100  \nto 125, 150 to 175, and now 300. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8735b2109cb3da03ccb8869c0471f9b2287a855e1a2f412a9af93838c532d78d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "14de8a8e-0e50-405b-9c39-e36a2f616b79", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \nguidance has appeared to assume stabilization or improvement.  And so we've seen step -downs of 100  \nto 125, 150 to 175, and now 300.  It sounds like for \u201823, you're trying to let us know that we're going to  \nsee lapping and it doesn't get better, though there are actions being taken.  Can you give us a feel for  \nwhat actions you would take if it turns out that things continue to get worse?  And have you thought  \nabout the prof itability of elements of the business?  What might need to change, or even whether the  \nbusiness might be better positioned for rebound if it's a multi -year rebound under someone else's  \nownership?  \n \n Mike Kaufmann:  Yeah, I'll take that and then Jason can f ill in if I miss any of the components of that.  \n", "original_text": "Can you give us a feel for  \nwhat actions you would take if it turns out that things continue to get worse? "}, "hash": "ad1629d586f1a18b2759361ea045042a5c185a5d23047d3a99d7bc9b1d5f2e9e", "class_name": "RelatedNodeInfo"}}, "text": "It sounds like for \u201823, you're trying to let us know that we're going to  \nsee lapping and it doesn't get better, though there are actions being taken. ", "start_char_idx": 153, "end_char_idx": 305, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "14de8a8e-0e50-405b-9c39-e36a2f616b79": {"__data__": {"id_": "14de8a8e-0e50-405b-9c39-e36a2f616b79", "embedding": null, "metadata": {"window": " \nPage 10 of 15 \n \nguidance has appeared to assume stabilization or improvement.  And so we've seen step -downs of 100  \nto 125, 150 to 175, and now 300.  It sounds like for \u201823, you're trying to let us know that we're going to  \nsee lapping and it doesn't get better, though there are actions being taken.  Can you give us a feel for  \nwhat actions you would take if it turns out that things continue to get worse?  And have you thought  \nabout the prof itability of elements of the business?  What might need to change, or even whether the  \nbusiness might be better positioned for rebound if it's a multi -year rebound under someone else's  \nownership?  \n \n Mike Kaufmann:  Yeah, I'll take that and then Jason can f ill in if I miss any of the components of that.  \n", "original_text": "Can you give us a feel for  \nwhat actions you would take if it turns out that things continue to get worse? ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a4f2674-243d-4322-8eca-c482a8ca2d7f", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \nguidance has appeared to assume stabilization or improvement.  And so we've seen step -downs of 100  \nto 125, 150 to 175, and now 300.  It sounds like for \u201823, you're trying to let us know that we're going to  \nsee lapping and it doesn't get better, though there are actions being taken.  Can you give us a feel for  \nwhat actions you would take if it turns out that things continue to get worse?  And have you thought  \nabout the prof itability of elements of the business?  What might need to change, or even whether the  \nbusiness might be better positioned for rebound if it's a multi -year rebound under someone else's  \nownership?  \n \n", "original_text": "It sounds like for \u201823, you're trying to let us know that we're going to  \nsee lapping and it doesn't get better, though there are actions being taken. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad805425e2ef595c9c17e72e0d00d6e24140c5ebbff2e39abe9eb0bc07dd1bf8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9303b0fa-83c4-4cd6-88a4-3bdd431e9113", "node_type": "1", "metadata": {"window": "And so we've seen step -downs of 100  \nto 125, 150 to 175, and now 300.  It sounds like for \u201823, you're trying to let us know that we're going to  \nsee lapping and it doesn't get better, though there are actions being taken.  Can you give us a feel for  \nwhat actions you would take if it turns out that things continue to get worse?  And have you thought  \nabout the prof itability of elements of the business?  What might need to change, or even whether the  \nbusiness might be better positioned for rebound if it's a multi -year rebound under someone else's  \nownership?  \n \n Mike Kaufmann:  Yeah, I'll take that and then Jason can f ill in if I miss any of the components of that.  \n Thanks for the question. ", "original_text": "And have you thought  \nabout the prof itability of elements of the business? "}, "hash": "9a19341f10c291777dc88fc2eb63af39f0b5e092007f0262c9170321de47620d", "class_name": "RelatedNodeInfo"}}, "text": "Can you give us a feel for  \nwhat actions you would take if it turns out that things continue to get worse? ", "start_char_idx": 305, "end_char_idx": 413, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9303b0fa-83c4-4cd6-88a4-3bdd431e9113": {"__data__": {"id_": "9303b0fa-83c4-4cd6-88a4-3bdd431e9113", "embedding": null, "metadata": {"window": "And so we've seen step -downs of 100  \nto 125, 150 to 175, and now 300.  It sounds like for \u201823, you're trying to let us know that we're going to  \nsee lapping and it doesn't get better, though there are actions being taken.  Can you give us a feel for  \nwhat actions you would take if it turns out that things continue to get worse?  And have you thought  \nabout the prof itability of elements of the business?  What might need to change, or even whether the  \nbusiness might be better positioned for rebound if it's a multi -year rebound under someone else's  \nownership?  \n \n Mike Kaufmann:  Yeah, I'll take that and then Jason can f ill in if I miss any of the components of that.  \n Thanks for the question. ", "original_text": "And have you thought  \nabout the prof itability of elements of the business? ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "14de8a8e-0e50-405b-9c39-e36a2f616b79", "node_type": "1", "metadata": {"window": " \nPage 10 of 15 \n \nguidance has appeared to assume stabilization or improvement.  And so we've seen step -downs of 100  \nto 125, 150 to 175, and now 300.  It sounds like for \u201823, you're trying to let us know that we're going to  \nsee lapping and it doesn't get better, though there are actions being taken.  Can you give us a feel for  \nwhat actions you would take if it turns out that things continue to get worse?  And have you thought  \nabout the prof itability of elements of the business?  What might need to change, or even whether the  \nbusiness might be better positioned for rebound if it's a multi -year rebound under someone else's  \nownership?  \n \n Mike Kaufmann:  Yeah, I'll take that and then Jason can f ill in if I miss any of the components of that.  \n", "original_text": "Can you give us a feel for  \nwhat actions you would take if it turns out that things continue to get worse? ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2997209c3ffd17bbe9620eb92b463323a60a0f7a15ce7adc25d83041c302be62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aba09f55-dc81-4092-a01c-86c42372e43e", "node_type": "1", "metadata": {"window": "It sounds like for \u201823, you're trying to let us know that we're going to  \nsee lapping and it doesn't get better, though there are actions being taken.  Can you give us a feel for  \nwhat actions you would take if it turns out that things continue to get worse?  And have you thought  \nabout the prof itability of elements of the business?  What might need to change, or even whether the  \nbusiness might be better positioned for rebound if it's a multi -year rebound under someone else's  \nownership?  \n \n Mike Kaufmann:  Yeah, I'll take that and then Jason can f ill in if I miss any of the components of that.  \n Thanks for the question.  So yeah, what we had said last quarter, we expected 250 to 300 of incremental  \ncost and now we think it'll be nearly 300. ", "original_text": "What might need to change, or even whether the  \nbusiness might be better positioned for rebound if it's a multi -year rebound under someone else's  \nownership?  \n \n"}, "hash": "051f4943400974c07b71bdea6c41b1334ed4bf0379adfc7231cb860f69d690c8", "class_name": "RelatedNodeInfo"}}, "text": "And have you thought  \nabout the prof itability of elements of the business? ", "start_char_idx": 413, "end_char_idx": 490, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aba09f55-dc81-4092-a01c-86c42372e43e": {"__data__": {"id_": "aba09f55-dc81-4092-a01c-86c42372e43e", "embedding": null, "metadata": {"window": "It sounds like for \u201823, you're trying to let us know that we're going to  \nsee lapping and it doesn't get better, though there are actions being taken.  Can you give us a feel for  \nwhat actions you would take if it turns out that things continue to get worse?  And have you thought  \nabout the prof itability of elements of the business?  What might need to change, or even whether the  \nbusiness might be better positioned for rebound if it's a multi -year rebound under someone else's  \nownership?  \n \n Mike Kaufmann:  Yeah, I'll take that and then Jason can f ill in if I miss any of the components of that.  \n Thanks for the question.  So yeah, what we had said last quarter, we expected 250 to 300 of incremental  \ncost and now we think it'll be nearly 300. ", "original_text": "What might need to change, or even whether the  \nbusiness might be better positioned for rebound if it's a multi -year rebound under someone else's  \nownership?  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9303b0fa-83c4-4cd6-88a4-3bdd431e9113", "node_type": "1", "metadata": {"window": "And so we've seen step -downs of 100  \nto 125, 150 to 175, and now 300.  It sounds like for \u201823, you're trying to let us know that we're going to  \nsee lapping and it doesn't get better, though there are actions being taken.  Can you give us a feel for  \nwhat actions you would take if it turns out that things continue to get worse?  And have you thought  \nabout the prof itability of elements of the business?  What might need to change, or even whether the  \nbusiness might be better positioned for rebound if it's a multi -year rebound under someone else's  \nownership?  \n \n Mike Kaufmann:  Yeah, I'll take that and then Jason can f ill in if I miss any of the components of that.  \n Thanks for the question. ", "original_text": "And have you thought  \nabout the prof itability of elements of the business? ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f65a73f2b715b31c0b4dd02124cba82c28cdbacc016372add632be78d0978b48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b96b28c-db7d-43fc-92d4-795f3c77d197", "node_type": "1", "metadata": {"window": "Can you give us a feel for  \nwhat actions you would take if it turns out that things continue to get worse?  And have you thought  \nabout the prof itability of elements of the business?  What might need to change, or even whether the  \nbusiness might be better positioned for rebound if it's a multi -year rebound under someone else's  \nownership?  \n \n Mike Kaufmann:  Yeah, I'll take that and then Jason can f ill in if I miss any of the components of that.  \n Thanks for the question.  So yeah, what we had said last quarter, we expected 250 to 300 of incremental  \ncost and now we think it'll be nearly 300.  So that's adjusting the inflation component of it up to 300. ", "original_text": "Mike Kaufmann:  Yeah, I'll take that and then Jason can f ill in if I miss any of the components of that.  \n"}, "hash": "a5029785fa72bf71b6252dfe4927fb1c654f74042a64ebe206b99b83c43ab145", "class_name": "RelatedNodeInfo"}}, "text": "What might need to change, or even whether the  \nbusiness might be better positioned for rebound if it's a multi -year rebound under someone else's  \nownership?  \n \n", "start_char_idx": 490, "end_char_idx": 655, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b96b28c-db7d-43fc-92d4-795f3c77d197": {"__data__": {"id_": "3b96b28c-db7d-43fc-92d4-795f3c77d197", "embedding": null, "metadata": {"window": "Can you give us a feel for  \nwhat actions you would take if it turns out that things continue to get worse?  And have you thought  \nabout the prof itability of elements of the business?  What might need to change, or even whether the  \nbusiness might be better positioned for rebound if it's a multi -year rebound under someone else's  \nownership?  \n \n Mike Kaufmann:  Yeah, I'll take that and then Jason can f ill in if I miss any of the components of that.  \n Thanks for the question.  So yeah, what we had said last quarter, we expected 250 to 300 of incremental  \ncost and now we think it'll be nearly 300.  So that's adjusting the inflation component of it up to 300. ", "original_text": "Mike Kaufmann:  Yeah, I'll take that and then Jason can f ill in if I miss any of the components of that.  \n", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aba09f55-dc81-4092-a01c-86c42372e43e", "node_type": "1", "metadata": {"window": "It sounds like for \u201823, you're trying to let us know that we're going to  \nsee lapping and it doesn't get better, though there are actions being taken.  Can you give us a feel for  \nwhat actions you would take if it turns out that things continue to get worse?  And have you thought  \nabout the prof itability of elements of the business?  What might need to change, or even whether the  \nbusiness might be better positioned for rebound if it's a multi -year rebound under someone else's  \nownership?  \n \n Mike Kaufmann:  Yeah, I'll take that and then Jason can f ill in if I miss any of the components of that.  \n Thanks for the question.  So yeah, what we had said last quarter, we expected 250 to 300 of incremental  \ncost and now we think it'll be nearly 300. ", "original_text": "What might need to change, or even whether the  \nbusiness might be better positioned for rebound if it's a multi -year rebound under someone else's  \nownership?  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6cf51bbdf2e5ecdf4f4cefacbca0a303ce0f1a23ea8f3d2fa4fb5ad812cf3d21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29d09f3d-7416-43c8-99a7-03807fceda4a", "node_type": "1", "metadata": {"window": "And have you thought  \nabout the prof itability of elements of the business?  What might need to change, or even whether the  \nbusiness might be better positioned for rebound if it's a multi -year rebound under someone else's  \nownership?  \n \n Mike Kaufmann:  Yeah, I'll take that and then Jason can f ill in if I miss any of the components of that.  \n Thanks for the question.  So yeah, what we had said last quarter, we expected 250 to 300 of incremental  \ncost and now we think it'll be nearly 300.  So that's adjusting the inflation component of it up to 300.  And  \nthen you also heard Jason comment in his comments that we saw some as we look forward into Q4,  \nwe see some PPE cost timing and PPE volume impacts for us in Q4 that will also be an incremental  \nnegative for \u201822. ", "original_text": "Thanks for the question. "}, "hash": "2469052b4f086dd9c44a76180c7163f478b755c8d91b542fcd6f47db7041b406", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yeah, I'll take that and then Jason can f ill in if I miss any of the components of that.  \n", "start_char_idx": 655, "end_char_idx": 763, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29d09f3d-7416-43c8-99a7-03807fceda4a": {"__data__": {"id_": "29d09f3d-7416-43c8-99a7-03807fceda4a", "embedding": null, "metadata": {"window": "And have you thought  \nabout the prof itability of elements of the business?  What might need to change, or even whether the  \nbusiness might be better positioned for rebound if it's a multi -year rebound under someone else's  \nownership?  \n \n Mike Kaufmann:  Yeah, I'll take that and then Jason can f ill in if I miss any of the components of that.  \n Thanks for the question.  So yeah, what we had said last quarter, we expected 250 to 300 of incremental  \ncost and now we think it'll be nearly 300.  So that's adjusting the inflation component of it up to 300.  And  \nthen you also heard Jason comment in his comments that we saw some as we look forward into Q4,  \nwe see some PPE cost timing and PPE volume impacts for us in Q4 that will also be an incremental  \nnegative for \u201822. ", "original_text": "Thanks for the question. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b96b28c-db7d-43fc-92d4-795f3c77d197", "node_type": "1", "metadata": {"window": "Can you give us a feel for  \nwhat actions you would take if it turns out that things continue to get worse?  And have you thought  \nabout the prof itability of elements of the business?  What might need to change, or even whether the  \nbusiness might be better positioned for rebound if it's a multi -year rebound under someone else's  \nownership?  \n \n Mike Kaufmann:  Yeah, I'll take that and then Jason can f ill in if I miss any of the components of that.  \n Thanks for the question.  So yeah, what we had said last quarter, we expected 250 to 300 of incremental  \ncost and now we think it'll be nearly 300.  So that's adjusting the inflation component of it up to 300. ", "original_text": "Mike Kaufmann:  Yeah, I'll take that and then Jason can f ill in if I miss any of the components of that.  \n", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "819f667a07d844901a0ff8b2180dd0f63b03110a619d0d0c93ae1f49d2393d40", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11cceaef-779f-484a-bb55-966c8ebe2851", "node_type": "1", "metadata": {"window": "What might need to change, or even whether the  \nbusiness might be better positioned for rebound if it's a multi -year rebound under someone else's  \nownership?  \n \n Mike Kaufmann:  Yeah, I'll take that and then Jason can f ill in if I miss any of the components of that.  \n Thanks for the question.  So yeah, what we had said last quarter, we expected 250 to 300 of incremental  \ncost and now we think it'll be nearly 300.  So that's adjusting the inflation component of it up to 300.  And  \nthen you also heard Jason comment in his comments that we saw some as we look forward into Q4,  \nwe see some PPE cost timing and PPE volume impacts for us in Q4 that will also be an incremental  \nnegative for \u201822.  So that's what's in our updated guidance to go to the new 45 to 55 down versus where  \nwe were before. ", "original_text": "So yeah, what we had said last quarter, we expected 250 to 300 of incremental  \ncost and now we think it'll be nearly 300. "}, "hash": "65d4912b8e6f57a14046baa33277edaf52dc41f2670b2d5cc59eb5c7c0f9215d", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question. ", "start_char_idx": 763, "end_char_idx": 788, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11cceaef-779f-484a-bb55-966c8ebe2851": {"__data__": {"id_": "11cceaef-779f-484a-bb55-966c8ebe2851", "embedding": null, "metadata": {"window": "What might need to change, or even whether the  \nbusiness might be better positioned for rebound if it's a multi -year rebound under someone else's  \nownership?  \n \n Mike Kaufmann:  Yeah, I'll take that and then Jason can f ill in if I miss any of the components of that.  \n Thanks for the question.  So yeah, what we had said last quarter, we expected 250 to 300 of incremental  \ncost and now we think it'll be nearly 300.  So that's adjusting the inflation component of it up to 300.  And  \nthen you also heard Jason comment in his comments that we saw some as we look forward into Q4,  \nwe see some PPE cost timing and PPE volume impacts for us in Q4 that will also be an incremental  \nnegative for \u201822.  So that's what's in our updated guidance to go to the new 45 to 55 down versus where  \nwe were before. ", "original_text": "So yeah, what we had said last quarter, we expected 250 to 300 of incremental  \ncost and now we think it'll be nearly 300. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29d09f3d-7416-43c8-99a7-03807fceda4a", "node_type": "1", "metadata": {"window": "And have you thought  \nabout the prof itability of elements of the business?  What might need to change, or even whether the  \nbusiness might be better positioned for rebound if it's a multi -year rebound under someone else's  \nownership?  \n \n Mike Kaufmann:  Yeah, I'll take that and then Jason can f ill in if I miss any of the components of that.  \n Thanks for the question.  So yeah, what we had said last quarter, we expected 250 to 300 of incremental  \ncost and now we think it'll be nearly 300.  So that's adjusting the inflation component of it up to 300.  And  \nthen you also heard Jason comment in his comments that we saw some as we look forward into Q4,  \nwe see some PPE cost timing and PPE volume impacts for us in Q4 that will also be an incremental  \nnegative for \u201822. ", "original_text": "Thanks for the question. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "097fc25f1069eb1280b37f686bfc65095d3939ea27061c86c764906af40d35b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75a8c3f2-3bb4-4e61-b063-403cfdfce36b", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yeah, I'll take that and then Jason can f ill in if I miss any of the components of that.  \n Thanks for the question.  So yeah, what we had said last quarter, we expected 250 to 300 of incremental  \ncost and now we think it'll be nearly 300.  So that's adjusting the inflation component of it up to 300.  And  \nthen you also heard Jason comment in his comments that we saw some as we look forward into Q4,  \nwe see some PPE cost timing and PPE volume impacts for us in Q4 that will also be an incremental  \nnegative for \u201822.  So that's what's in our updated guidance to go to the new 45 to 55 down versus where  \nwe were before.  So that's the change. ", "original_text": "So that's adjusting the inflation component of it up to 300. "}, "hash": "3b1638e39a6b384504625be425902ff14729e2fded92a514a40bd2f654e5f163", "class_name": "RelatedNodeInfo"}}, "text": "So yeah, what we had said last quarter, we expected 250 to 300 of incremental  \ncost and now we think it'll be nearly 300. ", "start_char_idx": 788, "end_char_idx": 911, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75a8c3f2-3bb4-4e61-b063-403cfdfce36b": {"__data__": {"id_": "75a8c3f2-3bb4-4e61-b063-403cfdfce36b", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yeah, I'll take that and then Jason can f ill in if I miss any of the components of that.  \n Thanks for the question.  So yeah, what we had said last quarter, we expected 250 to 300 of incremental  \ncost and now we think it'll be nearly 300.  So that's adjusting the inflation component of it up to 300.  And  \nthen you also heard Jason comment in his comments that we saw some as we look forward into Q4,  \nwe see some PPE cost timing and PPE volume impacts for us in Q4 that will also be an incremental  \nnegative for \u201822.  So that's what's in our updated guidance to go to the new 45 to 55 down versus where  \nwe were before.  So that's the change. ", "original_text": "So that's adjusting the inflation component of it up to 300. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11cceaef-779f-484a-bb55-966c8ebe2851", "node_type": "1", "metadata": {"window": "What might need to change, or even whether the  \nbusiness might be better positioned for rebound if it's a multi -year rebound under someone else's  \nownership?  \n \n Mike Kaufmann:  Yeah, I'll take that and then Jason can f ill in if I miss any of the components of that.  \n Thanks for the question.  So yeah, what we had said last quarter, we expected 250 to 300 of incremental  \ncost and now we think it'll be nearly 300.  So that's adjusting the inflation component of it up to 300.  And  \nthen you also heard Jason comment in his comments that we saw some as we look forward into Q4,  \nwe see some PPE cost timing and PPE volume impacts for us in Q4 that will also be an incremental  \nnegative for \u201822.  So that's what's in our updated guidance to go to the new 45 to 55 down versus where  \nwe were before. ", "original_text": "So yeah, what we had said last quarter, we expected 250 to 300 of incremental  \ncost and now we think it'll be nearly 300. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aee035ac2b2351c012ccb75f876afb76349c308e8f2f3cfebfb22a31412a296b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe1958b0-f846-47df-b6f0-a1ae81c6a8b1", "node_type": "1", "metadata": {"window": "Thanks for the question.  So yeah, what we had said last quarter, we expected 250 to 300 of incremental  \ncost and now we think it'll be nearly 300.  So that's adjusting the inflation component of it up to 300.  And  \nthen you also heard Jason comment in his comments that we saw some as we look forward into Q4,  \nwe see some PPE cost timing and PPE volume impacts for us in Q4 that will also be an incremental  \nnegative for \u201822.  So that's what's in our updated guidance to go to the new 45 to 55 down versus where  \nwe were before.  So that's the change.  The two key items that change there. ", "original_text": "And  \nthen you also heard Jason comment in his comments that we saw some as we look forward into Q4,  \nwe see some PPE cost timing and PPE volume impacts for us in Q4 that will also be an incremental  \nnegative for \u201822. "}, "hash": "37bc20c552946c1b14062d67246e56dc6bc140a49b0a4285a4f36e0f233e50cc", "class_name": "RelatedNodeInfo"}}, "text": "So that's adjusting the inflation component of it up to 300. ", "start_char_idx": 911, "end_char_idx": 972, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe1958b0-f846-47df-b6f0-a1ae81c6a8b1": {"__data__": {"id_": "fe1958b0-f846-47df-b6f0-a1ae81c6a8b1", "embedding": null, "metadata": {"window": "Thanks for the question.  So yeah, what we had said last quarter, we expected 250 to 300 of incremental  \ncost and now we think it'll be nearly 300.  So that's adjusting the inflation component of it up to 300.  And  \nthen you also heard Jason comment in his comments that we saw some as we look forward into Q4,  \nwe see some PPE cost timing and PPE volume impacts for us in Q4 that will also be an incremental  \nnegative for \u201822.  So that's what's in our updated guidance to go to the new 45 to 55 down versus where  \nwe were before.  So that's the change.  The two key items that change there. ", "original_text": "And  \nthen you also heard Jason comment in his comments that we saw some as we look forward into Q4,  \nwe see some PPE cost timing and PPE volume impacts for us in Q4 that will also be an incremental  \nnegative for \u201822. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75a8c3f2-3bb4-4e61-b063-403cfdfce36b", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yeah, I'll take that and then Jason can f ill in if I miss any of the components of that.  \n Thanks for the question.  So yeah, what we had said last quarter, we expected 250 to 300 of incremental  \ncost and now we think it'll be nearly 300.  So that's adjusting the inflation component of it up to 300.  And  \nthen you also heard Jason comment in his comments that we saw some as we look forward into Q4,  \nwe see some PPE cost timing and PPE volume impacts for us in Q4 that will also be an incremental  \nnegative for \u201822.  So that's what's in our updated guidance to go to the new 45 to 55 down versus where  \nwe were before.  So that's the change. ", "original_text": "So that's adjusting the inflation component of it up to 300. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d43710813059f1f6f510fe863f10506e456bb598dc4ca860b2d8e8e0184825f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5e905036-5754-4167-93b5-9150d1b74239", "node_type": "1", "metadata": {"window": "So yeah, what we had said last quarter, we expected 250 to 300 of incremental  \ncost and now we think it'll be nearly 300.  So that's adjusting the inflation component of it up to 300.  And  \nthen you also heard Jason comment in his comments that we saw some as we look forward into Q4,  \nwe see some PPE cost timing and PPE volume impacts for us in Q4 that will also be an incremental  \nnegative for \u201822.  So that's what's in our updated guidance to go to the new 45 to 55 down versus where  \nwe were before.  So that's the change.  The two key items that change there.  Again, there was some  \nsmall s tuff we mentioned in Pharma and all that. ", "original_text": "So that's what's in our updated guidance to go to the new 45 to 55 down versus where  \nwe were before. "}, "hash": "324a17d9eaf265265811bb355f1cf795ef5b53a978cd2e97aee1209d07a98ce3", "class_name": "RelatedNodeInfo"}}, "text": "And  \nthen you also heard Jason comment in his comments that we saw some as we look forward into Q4,  \nwe see some PPE cost timing and PPE volume impacts for us in Q4 that will also be an incremental  \nnegative for \u201822. ", "start_char_idx": 972, "end_char_idx": 1192, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5e905036-5754-4167-93b5-9150d1b74239": {"__data__": {"id_": "5e905036-5754-4167-93b5-9150d1b74239", "embedding": null, "metadata": {"window": "So yeah, what we had said last quarter, we expected 250 to 300 of incremental  \ncost and now we think it'll be nearly 300.  So that's adjusting the inflation component of it up to 300.  And  \nthen you also heard Jason comment in his comments that we saw some as we look forward into Q4,  \nwe see some PPE cost timing and PPE volume impacts for us in Q4 that will also be an incremental  \nnegative for \u201822.  So that's what's in our updated guidance to go to the new 45 to 55 down versus where  \nwe were before.  So that's the change.  The two key items that change there.  Again, there was some  \nsmall s tuff we mentioned in Pharma and all that. ", "original_text": "So that's what's in our updated guidance to go to the new 45 to 55 down versus where  \nwe were before. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe1958b0-f846-47df-b6f0-a1ae81c6a8b1", "node_type": "1", "metadata": {"window": "Thanks for the question.  So yeah, what we had said last quarter, we expected 250 to 300 of incremental  \ncost and now we think it'll be nearly 300.  So that's adjusting the inflation component of it up to 300.  And  \nthen you also heard Jason comment in his comments that we saw some as we look forward into Q4,  \nwe see some PPE cost timing and PPE volume impacts for us in Q4 that will also be an incremental  \nnegative for \u201822.  So that's what's in our updated guidance to go to the new 45 to 55 down versus where  \nwe were before.  So that's the change.  The two key items that change there. ", "original_text": "And  \nthen you also heard Jason comment in his comments that we saw some as we look forward into Q4,  \nwe see some PPE cost timing and PPE volume impacts for us in Q4 that will also be an incremental  \nnegative for \u201822. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e4ccaee001079694a9add6bd9d3e6080d88813a2bc9ebe90d70b57750537e1c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c64ac2ca-129e-4309-bdd1-89df4533b020", "node_type": "1", "metadata": {"window": "So that's adjusting the inflation component of it up to 300.  And  \nthen you also heard Jason comment in his comments that we saw some as we look forward into Q4,  \nwe see some PPE cost timing and PPE volume impacts for us in Q4 that will also be an incremental  \nnegative for \u201822.  So that's what's in our updated guidance to go to the new 45 to 55 down versus where  \nwe were before.  So that's the change.  The two key items that change there.  Again, there was some  \nsmall s tuff we mentioned in Pharma and all that.  We believe it's manageable within the guidance  \nfor Pharma. ", "original_text": "So that's the change. "}, "hash": "5395f155b9f9b264ff6e5d198cab18686270ae587e93b94281fcf8e7dea23c91", "class_name": "RelatedNodeInfo"}}, "text": "So that's what's in our updated guidance to go to the new 45 to 55 down versus where  \nwe were before. ", "start_char_idx": 1192, "end_char_idx": 1295, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c64ac2ca-129e-4309-bdd1-89df4533b020": {"__data__": {"id_": "c64ac2ca-129e-4309-bdd1-89df4533b020", "embedding": null, "metadata": {"window": "So that's adjusting the inflation component of it up to 300.  And  \nthen you also heard Jason comment in his comments that we saw some as we look forward into Q4,  \nwe see some PPE cost timing and PPE volume impacts for us in Q4 that will also be an incremental  \nnegative for \u201822.  So that's what's in our updated guidance to go to the new 45 to 55 down versus where  \nwe were before.  So that's the change.  The two key items that change there.  Again, there was some  \nsmall s tuff we mentioned in Pharma and all that.  We believe it's manageable within the guidance  \nfor Pharma. ", "original_text": "So that's the change. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5e905036-5754-4167-93b5-9150d1b74239", "node_type": "1", "metadata": {"window": "So yeah, what we had said last quarter, we expected 250 to 300 of incremental  \ncost and now we think it'll be nearly 300.  So that's adjusting the inflation component of it up to 300.  And  \nthen you also heard Jason comment in his comments that we saw some as we look forward into Q4,  \nwe see some PPE cost timing and PPE volume impacts for us in Q4 that will also be an incremental  \nnegative for \u201822.  So that's what's in our updated guidance to go to the new 45 to 55 down versus where  \nwe were before.  So that's the change.  The two key items that change there.  Again, there was some  \nsmall s tuff we mentioned in Pharma and all that. ", "original_text": "So that's what's in our updated guidance to go to the new 45 to 55 down versus where  \nwe were before. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6a24dc63ab1feab6cde04ea914c92208b677edc15a198e51e6ef1c7adc31c6a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4804ac1d-1b72-4761-bb4b-0a21858e4fdc", "node_type": "1", "metadata": {"window": "And  \nthen you also heard Jason comment in his comments that we saw some as we look forward into Q4,  \nwe see some PPE cost timing and PPE volume impacts for us in Q4 that will also be an incremental  \nnegative for \u201822.  So that's what's in our updated guidance to go to the new 45 to 55 down versus where  \nwe were before.  So that's the change.  The two key items that change there.  Again, there was some  \nsmall s tuff we mentioned in Pharma and all that.  We believe it's manageable within the guidance  \nfor Pharma.  So no call out any change in guidance for Pharma, but that's the drivers for what we chose  \nin Medical. ", "original_text": "The two key items that change there. "}, "hash": "b63c2c905aa0e4d1fde0ffa4891cf92b3708a76a5b1dc9ba2a7738f21fedb8e0", "class_name": "RelatedNodeInfo"}}, "text": "So that's the change. ", "start_char_idx": 1295, "end_char_idx": 1317, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4804ac1d-1b72-4761-bb4b-0a21858e4fdc": {"__data__": {"id_": "4804ac1d-1b72-4761-bb4b-0a21858e4fdc", "embedding": null, "metadata": {"window": "And  \nthen you also heard Jason comment in his comments that we saw some as we look forward into Q4,  \nwe see some PPE cost timing and PPE volume impacts for us in Q4 that will also be an incremental  \nnegative for \u201822.  So that's what's in our updated guidance to go to the new 45 to 55 down versus where  \nwe were before.  So that's the change.  The two key items that change there.  Again, there was some  \nsmall s tuff we mentioned in Pharma and all that.  We believe it's manageable within the guidance  \nfor Pharma.  So no call out any change in guidance for Pharma, but that's the drivers for what we chose  \nin Medical. ", "original_text": "The two key items that change there. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c64ac2ca-129e-4309-bdd1-89df4533b020", "node_type": "1", "metadata": {"window": "So that's adjusting the inflation component of it up to 300.  And  \nthen you also heard Jason comment in his comments that we saw some as we look forward into Q4,  \nwe see some PPE cost timing and PPE volume impacts for us in Q4 that will also be an incremental  \nnegative for \u201822.  So that's what's in our updated guidance to go to the new 45 to 55 down versus where  \nwe were before.  So that's the change.  The two key items that change there.  Again, there was some  \nsmall s tuff we mentioned in Pharma and all that.  We believe it's manageable within the guidance  \nfor Pharma. ", "original_text": "So that's the change. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e62994889ebacf1e2f0dad632fc539115a503fb1a4e7c1aadaec4c4b410da7f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ece819b6-e9eb-4aac-b87e-5f478d69d09b", "node_type": "1", "metadata": {"window": "So that's what's in our updated guidance to go to the new 45 to 55 down versus where  \nwe were before.  So that's the change.  The two key items that change there.  Again, there was some  \nsmall s tuff we mentioned in Pharma and all that.  We believe it's manageable within the guidance  \nfor Pharma.  So no call out any change in guidance for Pharma, but that's the drivers for what we chose  \nin Medical.  As far as looking forward to \u201823, what we were tryi ng to indicate is that we do believe as we  \nannualize, if you think about the inflation increased over the year and it sits in our inventory for a while,  \nso using the $300 million, obviously, we believe that will annualize to a greater number next year. ", "original_text": "Again, there was some  \nsmall s tuff we mentioned in Pharma and all that. "}, "hash": "f5f488c2a4112c7efe52aca61b0ad682fef1fec087f345c73d4bcb81d7c55546", "class_name": "RelatedNodeInfo"}}, "text": "The two key items that change there. ", "start_char_idx": 1317, "end_char_idx": 1354, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ece819b6-e9eb-4aac-b87e-5f478d69d09b": {"__data__": {"id_": "ece819b6-e9eb-4aac-b87e-5f478d69d09b", "embedding": null, "metadata": {"window": "So that's what's in our updated guidance to go to the new 45 to 55 down versus where  \nwe were before.  So that's the change.  The two key items that change there.  Again, there was some  \nsmall s tuff we mentioned in Pharma and all that.  We believe it's manageable within the guidance  \nfor Pharma.  So no call out any change in guidance for Pharma, but that's the drivers for what we chose  \nin Medical.  As far as looking forward to \u201823, what we were tryi ng to indicate is that we do believe as we  \nannualize, if you think about the inflation increased over the year and it sits in our inventory for a while,  \nso using the $300 million, obviously, we believe that will annualize to a greater number next year. ", "original_text": "Again, there was some  \nsmall s tuff we mentioned in Pharma and all that. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4804ac1d-1b72-4761-bb4b-0a21858e4fdc", "node_type": "1", "metadata": {"window": "And  \nthen you also heard Jason comment in his comments that we saw some as we look forward into Q4,  \nwe see some PPE cost timing and PPE volume impacts for us in Q4 that will also be an incremental  \nnegative for \u201822.  So that's what's in our updated guidance to go to the new 45 to 55 down versus where  \nwe were before.  So that's the change.  The two key items that change there.  Again, there was some  \nsmall s tuff we mentioned in Pharma and all that.  We believe it's manageable within the guidance  \nfor Pharma.  So no call out any change in guidance for Pharma, but that's the drivers for what we chose  \nin Medical. ", "original_text": "The two key items that change there. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "621f9bcd2048874a5523814f7916c5cbf28f1a7d7cd7781658c3bdd736b9caad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09df9415-ecdf-4edb-bf62-fb8bacf371d2", "node_type": "1", "metadata": {"window": "So that's the change.  The two key items that change there.  Again, there was some  \nsmall s tuff we mentioned in Pharma and all that.  We believe it's manageable within the guidance  \nfor Pharma.  So no call out any change in guidance for Pharma, but that's the drivers for what we chose  \nin Medical.  As far as looking forward to \u201823, what we were tryi ng to indicate is that we do believe as we  \nannualize, if you think about the inflation increased over the year and it sits in our inventory for a while,  \nso using the $300 million, obviously, we believe that will annualize to a greater number next year.  A nd  \nso the inflation actually on an absolute basis, the total impact of inflation will be greater next year in \u201923  \nthan it was in \u201822. ", "original_text": "We believe it's manageable within the guidance  \nfor Pharma. "}, "hash": "eae79648f6f55f7924290aacdb25b1f987502760d6cca3d08168771cc2550b3b", "class_name": "RelatedNodeInfo"}}, "text": "Again, there was some  \nsmall s tuff we mentioned in Pharma and all that. ", "start_char_idx": 1354, "end_char_idx": 1428, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09df9415-ecdf-4edb-bf62-fb8bacf371d2": {"__data__": {"id_": "09df9415-ecdf-4edb-bf62-fb8bacf371d2", "embedding": null, "metadata": {"window": "So that's the change.  The two key items that change there.  Again, there was some  \nsmall s tuff we mentioned in Pharma and all that.  We believe it's manageable within the guidance  \nfor Pharma.  So no call out any change in guidance for Pharma, but that's the drivers for what we chose  \nin Medical.  As far as looking forward to \u201823, what we were tryi ng to indicate is that we do believe as we  \nannualize, if you think about the inflation increased over the year and it sits in our inventory for a while,  \nso using the $300 million, obviously, we believe that will annualize to a greater number next year.  A nd  \nso the inflation actually on an absolute basis, the total impact of inflation will be greater next year in \u201923  \nthan it was in \u201822. ", "original_text": "We believe it's manageable within the guidance  \nfor Pharma. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ece819b6-e9eb-4aac-b87e-5f478d69d09b", "node_type": "1", "metadata": {"window": "So that's what's in our updated guidance to go to the new 45 to 55 down versus where  \nwe were before.  So that's the change.  The two key items that change there.  Again, there was some  \nsmall s tuff we mentioned in Pharma and all that.  We believe it's manageable within the guidance  \nfor Pharma.  So no call out any change in guidance for Pharma, but that's the drivers for what we chose  \nin Medical.  As far as looking forward to \u201823, what we were tryi ng to indicate is that we do believe as we  \nannualize, if you think about the inflation increased over the year and it sits in our inventory for a while,  \nso using the $300 million, obviously, we believe that will annualize to a greater number next year. ", "original_text": "Again, there was some  \nsmall s tuff we mentioned in Pharma and all that. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2509c13bcb2ef3240a8f31dd4c88ed682a01592b75802e9ff54da42f7585a6fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0dde8dec-8009-4fec-93cc-212b601fd790", "node_type": "1", "metadata": {"window": "The two key items that change there.  Again, there was some  \nsmall s tuff we mentioned in Pharma and all that.  We believe it's manageable within the guidance  \nfor Pharma.  So no call out any change in guidance for Pharma, but that's the drivers for what we chose  \nin Medical.  As far as looking forward to \u201823, what we were tryi ng to indicate is that we do believe as we  \nannualize, if you think about the inflation increased over the year and it sits in our inventory for a while,  \nso using the $300 million, obviously, we believe that will annualize to a greater number next year.  A nd  \nso the inflation actually on an absolute basis, the total impact of inflation will be greater next year in \u201923  \nthan it was in \u201822.  That's what we were talking about there. ", "original_text": "So no call out any change in guidance for Pharma, but that's the drivers for what we chose  \nin Medical. "}, "hash": "d1ca529aeb6d032a123323beb29c00807c3253b731565e7d947d43a4ba0fae9c", "class_name": "RelatedNodeInfo"}}, "text": "We believe it's manageable within the guidance  \nfor Pharma. ", "start_char_idx": 1428, "end_char_idx": 1489, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0dde8dec-8009-4fec-93cc-212b601fd790": {"__data__": {"id_": "0dde8dec-8009-4fec-93cc-212b601fd790", "embedding": null, "metadata": {"window": "The two key items that change there.  Again, there was some  \nsmall s tuff we mentioned in Pharma and all that.  We believe it's manageable within the guidance  \nfor Pharma.  So no call out any change in guidance for Pharma, but that's the drivers for what we chose  \nin Medical.  As far as looking forward to \u201823, what we were tryi ng to indicate is that we do believe as we  \nannualize, if you think about the inflation increased over the year and it sits in our inventory for a while,  \nso using the $300 million, obviously, we believe that will annualize to a greater number next year.  A nd  \nso the inflation actually on an absolute basis, the total impact of inflation will be greater next year in \u201923  \nthan it was in \u201822.  That's what we were talking about there. ", "original_text": "So no call out any change in guidance for Pharma, but that's the drivers for what we chose  \nin Medical. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09df9415-ecdf-4edb-bf62-fb8bacf371d2", "node_type": "1", "metadata": {"window": "So that's the change.  The two key items that change there.  Again, there was some  \nsmall s tuff we mentioned in Pharma and all that.  We believe it's manageable within the guidance  \nfor Pharma.  So no call out any change in guidance for Pharma, but that's the drivers for what we chose  \nin Medical.  As far as looking forward to \u201823, what we were tryi ng to indicate is that we do believe as we  \nannualize, if you think about the inflation increased over the year and it sits in our inventory for a while,  \nso using the $300 million, obviously, we believe that will annualize to a greater number next year.  A nd  \nso the inflation actually on an absolute basis, the total impact of inflation will be greater next year in \u201923  \nthan it was in \u201822. ", "original_text": "We believe it's manageable within the guidance  \nfor Pharma. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "744a73f496754392e88ebd589f0043cc96ede6b1c143fe22d09b763d5fe8b6e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "171b05e7-921f-45e8-af5e-5c198f4a5820", "node_type": "1", "metadata": {"window": "Again, there was some  \nsmall s tuff we mentioned in Pharma and all that.  We believe it's manageable within the guidance  \nfor Pharma.  So no call out any change in guidance for Pharma, but that's the drivers for what we chose  \nin Medical.  As far as looking forward to \u201823, what we were tryi ng to indicate is that we do believe as we  \nannualize, if you think about the inflation increased over the year and it sits in our inventory for a while,  \nso using the $300 million, obviously, we believe that will annualize to a greater number next year.  A nd  \nso the inflation actually on an absolute basis, the total impact of inflation will be greater next year in \u201923  \nthan it was in \u201822.  That's what we were talking about there.  But on the flip side, we also already have  \nimplemented price increases, some i n March and additional ones as I mentioned, that go into effect  \nhere essentially July 1, that as we look at those in additional price increases that we would intend to  \ntake during the year, that we also will see a greater positive impact from price incre ases next year. ", "original_text": "As far as looking forward to \u201823, what we were tryi ng to indicate is that we do believe as we  \nannualize, if you think about the inflation increased over the year and it sits in our inventory for a while,  \nso using the $300 million, obviously, we believe that will annualize to a greater number next year. "}, "hash": "5cbd7071771560a339da658731e4c3d61543b4190d3d2e938688d63788d63d51", "class_name": "RelatedNodeInfo"}}, "text": "So no call out any change in guidance for Pharma, but that's the drivers for what we chose  \nin Medical. ", "start_char_idx": 1489, "end_char_idx": 1594, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "171b05e7-921f-45e8-af5e-5c198f4a5820": {"__data__": {"id_": "171b05e7-921f-45e8-af5e-5c198f4a5820", "embedding": null, "metadata": {"window": "Again, there was some  \nsmall s tuff we mentioned in Pharma and all that.  We believe it's manageable within the guidance  \nfor Pharma.  So no call out any change in guidance for Pharma, but that's the drivers for what we chose  \nin Medical.  As far as looking forward to \u201823, what we were tryi ng to indicate is that we do believe as we  \nannualize, if you think about the inflation increased over the year and it sits in our inventory for a while,  \nso using the $300 million, obviously, we believe that will annualize to a greater number next year.  A nd  \nso the inflation actually on an absolute basis, the total impact of inflation will be greater next year in \u201923  \nthan it was in \u201822.  That's what we were talking about there.  But on the flip side, we also already have  \nimplemented price increases, some i n March and additional ones as I mentioned, that go into effect  \nhere essentially July 1, that as we look at those in additional price increases that we would intend to  \ntake during the year, that we also will see a greater positive impact from price incre ases next year. ", "original_text": "As far as looking forward to \u201823, what we were tryi ng to indicate is that we do believe as we  \nannualize, if you think about the inflation increased over the year and it sits in our inventory for a while,  \nso using the $300 million, obviously, we believe that will annualize to a greater number next year. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0dde8dec-8009-4fec-93cc-212b601fd790", "node_type": "1", "metadata": {"window": "The two key items that change there.  Again, there was some  \nsmall s tuff we mentioned in Pharma and all that.  We believe it's manageable within the guidance  \nfor Pharma.  So no call out any change in guidance for Pharma, but that's the drivers for what we chose  \nin Medical.  As far as looking forward to \u201823, what we were tryi ng to indicate is that we do believe as we  \nannualize, if you think about the inflation increased over the year and it sits in our inventory for a while,  \nso using the $300 million, obviously, we believe that will annualize to a greater number next year.  A nd  \nso the inflation actually on an absolute basis, the total impact of inflation will be greater next year in \u201923  \nthan it was in \u201822.  That's what we were talking about there. ", "original_text": "So no call out any change in guidance for Pharma, but that's the drivers for what we chose  \nin Medical. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "101a134bfeaa55944de06bfde4a9e0afaac9fcacf7ccff4f451f25a9a7245418", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "67ef369f-5db6-4d0a-9899-507171157105", "node_type": "1", "metadata": {"window": "We believe it's manageable within the guidance  \nfor Pharma.  So no call out any change in guidance for Pharma, but that's the drivers for what we chose  \nin Medical.  As far as looking forward to \u201823, what we were tryi ng to indicate is that we do believe as we  \nannualize, if you think about the inflation increased over the year and it sits in our inventory for a while,  \nso using the $300 million, obviously, we believe that will annualize to a greater number next year.  A nd  \nso the inflation actually on an absolute basis, the total impact of inflation will be greater next year in \u201923  \nthan it was in \u201822.  That's what we were talking about there.  But on the flip side, we also already have  \nimplemented price increases, some i n March and additional ones as I mentioned, that go into effect  \nhere essentially July 1, that as we look at those in additional price increases that we would intend to  \ntake during the year, that we also will see a greater positive impact from price incre ases next year.  So  \nwhile inflation on absolute will go up, the positives that we will get from increased pricing will also go  \nup and the two of those will net to a similar to slightly down overall net impact next year in \u201823. ", "original_text": "A nd  \nso the inflation actually on an absolute basis, the total impact of inflation will be greater next year in \u201923  \nthan it was in \u201822. "}, "hash": "f07ad0b32c34ece5b8979470e8fdf4d4f1dba574ab25b89e7a99f4a393f22406", "class_name": "RelatedNodeInfo"}}, "text": "As far as looking forward to \u201823, what we were tryi ng to indicate is that we do believe as we  \nannualize, if you think about the inflation increased over the year and it sits in our inventory for a while,  \nso using the $300 million, obviously, we believe that will annualize to a greater number next year. ", "start_char_idx": 1594, "end_char_idx": 1903, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "67ef369f-5db6-4d0a-9899-507171157105": {"__data__": {"id_": "67ef369f-5db6-4d0a-9899-507171157105", "embedding": null, "metadata": {"window": "We believe it's manageable within the guidance  \nfor Pharma.  So no call out any change in guidance for Pharma, but that's the drivers for what we chose  \nin Medical.  As far as looking forward to \u201823, what we were tryi ng to indicate is that we do believe as we  \nannualize, if you think about the inflation increased over the year and it sits in our inventory for a while,  \nso using the $300 million, obviously, we believe that will annualize to a greater number next year.  A nd  \nso the inflation actually on an absolute basis, the total impact of inflation will be greater next year in \u201923  \nthan it was in \u201822.  That's what we were talking about there.  But on the flip side, we also already have  \nimplemented price increases, some i n March and additional ones as I mentioned, that go into effect  \nhere essentially July 1, that as we look at those in additional price increases that we would intend to  \ntake during the year, that we also will see a greater positive impact from price incre ases next year.  So  \nwhile inflation on absolute will go up, the positives that we will get from increased pricing will also go  \nup and the two of those will net to a similar to slightly down overall net impact next year in \u201823. ", "original_text": "A nd  \nso the inflation actually on an absolute basis, the total impact of inflation will be greater next year in \u201923  \nthan it was in \u201822. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "171b05e7-921f-45e8-af5e-5c198f4a5820", "node_type": "1", "metadata": {"window": "Again, there was some  \nsmall s tuff we mentioned in Pharma and all that.  We believe it's manageable within the guidance  \nfor Pharma.  So no call out any change in guidance for Pharma, but that's the drivers for what we chose  \nin Medical.  As far as looking forward to \u201823, what we were tryi ng to indicate is that we do believe as we  \nannualize, if you think about the inflation increased over the year and it sits in our inventory for a while,  \nso using the $300 million, obviously, we believe that will annualize to a greater number next year.  A nd  \nso the inflation actually on an absolute basis, the total impact of inflation will be greater next year in \u201923  \nthan it was in \u201822.  That's what we were talking about there.  But on the flip side, we also already have  \nimplemented price increases, some i n March and additional ones as I mentioned, that go into effect  \nhere essentially July 1, that as we look at those in additional price increases that we would intend to  \ntake during the year, that we also will see a greater positive impact from price incre ases next year. ", "original_text": "As far as looking forward to \u201823, what we were tryi ng to indicate is that we do believe as we  \nannualize, if you think about the inflation increased over the year and it sits in our inventory for a while,  \nso using the $300 million, obviously, we believe that will annualize to a greater number next year. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8434a296168acaba7b20fd88913658327a23316527400e03662a799e4babdc6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de205405-3e65-4b82-a12f-ccac86a8aa41", "node_type": "1", "metadata": {"window": "So no call out any change in guidance for Pharma, but that's the drivers for what we chose  \nin Medical.  As far as looking forward to \u201823, what we were tryi ng to indicate is that we do believe as we  \nannualize, if you think about the inflation increased over the year and it sits in our inventory for a while,  \nso using the $300 million, obviously, we believe that will annualize to a greater number next year.  A nd  \nso the inflation actually on an absolute basis, the total impact of inflation will be greater next year in \u201923  \nthan it was in \u201822.  That's what we were talking about there.  But on the flip side, we also already have  \nimplemented price increases, some i n March and additional ones as I mentioned, that go into effect  \nhere essentially July 1, that as we look at those in additional price increases that we would intend to  \ntake during the year, that we also will see a greater positive impact from price incre ases next year.  So  \nwhile inflation on absolute will go up, the positives that we will get from increased pricing will also go  \nup and the two of those will net to a similar to slightly down overall net impact next year in \u201823.  So that's  \nhow we're thinkin g about it next year. ", "original_text": "That's what we were talking about there. "}, "hash": "c9cbf5cbaacc5fc59977c264885c69574c608d3bafbcd703864f6f22d1dfeec6", "class_name": "RelatedNodeInfo"}}, "text": "A nd  \nso the inflation actually on an absolute basis, the total impact of inflation will be greater next year in \u201923  \nthan it was in \u201822. ", "start_char_idx": 1903, "end_char_idx": 2043, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de205405-3e65-4b82-a12f-ccac86a8aa41": {"__data__": {"id_": "de205405-3e65-4b82-a12f-ccac86a8aa41", "embedding": null, "metadata": {"window": "So no call out any change in guidance for Pharma, but that's the drivers for what we chose  \nin Medical.  As far as looking forward to \u201823, what we were tryi ng to indicate is that we do believe as we  \nannualize, if you think about the inflation increased over the year and it sits in our inventory for a while,  \nso using the $300 million, obviously, we believe that will annualize to a greater number next year.  A nd  \nso the inflation actually on an absolute basis, the total impact of inflation will be greater next year in \u201923  \nthan it was in \u201822.  That's what we were talking about there.  But on the flip side, we also already have  \nimplemented price increases, some i n March and additional ones as I mentioned, that go into effect  \nhere essentially July 1, that as we look at those in additional price increases that we would intend to  \ntake during the year, that we also will see a greater positive impact from price incre ases next year.  So  \nwhile inflation on absolute will go up, the positives that we will get from increased pricing will also go  \nup and the two of those will net to a similar to slightly down overall net impact next year in \u201823.  So that's  \nhow we're thinkin g about it next year. ", "original_text": "That's what we were talking about there. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "67ef369f-5db6-4d0a-9899-507171157105", "node_type": "1", "metadata": {"window": "We believe it's manageable within the guidance  \nfor Pharma.  So no call out any change in guidance for Pharma, but that's the drivers for what we chose  \nin Medical.  As far as looking forward to \u201823, what we were tryi ng to indicate is that we do believe as we  \nannualize, if you think about the inflation increased over the year and it sits in our inventory for a while,  \nso using the $300 million, obviously, we believe that will annualize to a greater number next year.  A nd  \nso the inflation actually on an absolute basis, the total impact of inflation will be greater next year in \u201923  \nthan it was in \u201822.  That's what we were talking about there.  But on the flip side, we also already have  \nimplemented price increases, some i n March and additional ones as I mentioned, that go into effect  \nhere essentially July 1, that as we look at those in additional price increases that we would intend to  \ntake during the year, that we also will see a greater positive impact from price incre ases next year.  So  \nwhile inflation on absolute will go up, the positives that we will get from increased pricing will also go  \nup and the two of those will net to a similar to slightly down overall net impact next year in \u201823. ", "original_text": "A nd  \nso the inflation actually on an absolute basis, the total impact of inflation will be greater next year in \u201923  \nthan it was in \u201822. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7cb1e4e726c1941354724b16a870ebc22e9f24b69a0d747b0b38f5adeecda796", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f363f80-d6d9-418a-8415-8bd8ebefd085", "node_type": "1", "metadata": {"window": "As far as looking forward to \u201823, what we were tryi ng to indicate is that we do believe as we  \nannualize, if you think about the inflation increased over the year and it sits in our inventory for a while,  \nso using the $300 million, obviously, we believe that will annualize to a greater number next year.  A nd  \nso the inflation actually on an absolute basis, the total impact of inflation will be greater next year in \u201923  \nthan it was in \u201822.  That's what we were talking about there.  But on the flip side, we also already have  \nimplemented price increases, some i n March and additional ones as I mentioned, that go into effect  \nhere essentially July 1, that as we look at those in additional price increases that we would intend to  \ntake during the year, that we also will see a greater positive impact from price incre ases next year.  So  \nwhile inflation on absolute will go up, the positives that we will get from increased pricing will also go  \nup and the two of those will net to a similar to slightly down overall net impact next year in \u201823.  So that's  \nhow we're thinkin g about it next year.  As you can imagine, we're going to continue to focus on those  \nitems and where we have opportunities based on the market, based on the conditions and costing, we  \nwill take more price to market.  \n \n", "original_text": "But on the flip side, we also already have  \nimplemented price increases, some i n March and additional ones as I mentioned, that go into effect  \nhere essentially July 1, that as we look at those in additional price increases that we would intend to  \ntake during the year, that we also will see a greater positive impact from price incre ases next year. "}, "hash": "b6c10b0686d03f34a947fe93c9bf67a6e4e899b7d852058362324d2948d2ecd1", "class_name": "RelatedNodeInfo"}}, "text": "That's what we were talking about there. ", "start_char_idx": 2043, "end_char_idx": 2084, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f363f80-d6d9-418a-8415-8bd8ebefd085": {"__data__": {"id_": "9f363f80-d6d9-418a-8415-8bd8ebefd085", "embedding": null, "metadata": {"window": "As far as looking forward to \u201823, what we were tryi ng to indicate is that we do believe as we  \nannualize, if you think about the inflation increased over the year and it sits in our inventory for a while,  \nso using the $300 million, obviously, we believe that will annualize to a greater number next year.  A nd  \nso the inflation actually on an absolute basis, the total impact of inflation will be greater next year in \u201923  \nthan it was in \u201822.  That's what we were talking about there.  But on the flip side, we also already have  \nimplemented price increases, some i n March and additional ones as I mentioned, that go into effect  \nhere essentially July 1, that as we look at those in additional price increases that we would intend to  \ntake during the year, that we also will see a greater positive impact from price incre ases next year.  So  \nwhile inflation on absolute will go up, the positives that we will get from increased pricing will also go  \nup and the two of those will net to a similar to slightly down overall net impact next year in \u201823.  So that's  \nhow we're thinkin g about it next year.  As you can imagine, we're going to continue to focus on those  \nitems and where we have opportunities based on the market, based on the conditions and costing, we  \nwill take more price to market.  \n \n", "original_text": "But on the flip side, we also already have  \nimplemented price increases, some i n March and additional ones as I mentioned, that go into effect  \nhere essentially July 1, that as we look at those in additional price increases that we would intend to  \ntake during the year, that we also will see a greater positive impact from price incre ases next year. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de205405-3e65-4b82-a12f-ccac86a8aa41", "node_type": "1", "metadata": {"window": "So no call out any change in guidance for Pharma, but that's the drivers for what we chose  \nin Medical.  As far as looking forward to \u201823, what we were tryi ng to indicate is that we do believe as we  \nannualize, if you think about the inflation increased over the year and it sits in our inventory for a while,  \nso using the $300 million, obviously, we believe that will annualize to a greater number next year.  A nd  \nso the inflation actually on an absolute basis, the total impact of inflation will be greater next year in \u201923  \nthan it was in \u201822.  That's what we were talking about there.  But on the flip side, we also already have  \nimplemented price increases, some i n March and additional ones as I mentioned, that go into effect  \nhere essentially July 1, that as we look at those in additional price increases that we would intend to  \ntake during the year, that we also will see a greater positive impact from price incre ases next year.  So  \nwhile inflation on absolute will go up, the positives that we will get from increased pricing will also go  \nup and the two of those will net to a similar to slightly down overall net impact next year in \u201823.  So that's  \nhow we're thinkin g about it next year. ", "original_text": "That's what we were talking about there. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d45493a94fdd164f3f3050fcfc50558f5e66d2d4db93de73a49e892678d78061", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d79def44-e031-41f6-a403-8f74831fb907", "node_type": "1", "metadata": {"window": "A nd  \nso the inflation actually on an absolute basis, the total impact of inflation will be greater next year in \u201923  \nthan it was in \u201822.  That's what we were talking about there.  But on the flip side, we also already have  \nimplemented price increases, some i n March and additional ones as I mentioned, that go into effect  \nhere essentially July 1, that as we look at those in additional price increases that we would intend to  \ntake during the year, that we also will see a greater positive impact from price incre ases next year.  So  \nwhile inflation on absolute will go up, the positives that we will get from increased pricing will also go  \nup and the two of those will net to a similar to slightly down overall net impact next year in \u201823.  So that's  \nhow we're thinkin g about it next year.  As you can imagine, we're going to continue to focus on those  \nitems and where we have opportunities based on the market, based on the conditions and costing, we  \nwill take more price to market.  \n \n And what Jason also said to be helpfu l, our goal is that when we exit the year next year, we plan to \nhave at least 50% of those inflated items offset through either pricing actions that we will have taken, \neither both to manufacturers and to customers, or we will obviously have seen some of t hose costs \ncome back down. ", "original_text": "So  \nwhile inflation on absolute will go up, the positives that we will get from increased pricing will also go  \nup and the two of those will net to a similar to slightly down overall net impact next year in \u201823. "}, "hash": "fcaddad5edf9b15aeccf8a1996761a34ac9156d7f92e76f686b7c09d0a2d522b", "class_name": "RelatedNodeInfo"}}, "text": "But on the flip side, we also already have  \nimplemented price increases, some i n March and additional ones as I mentioned, that go into effect  \nhere essentially July 1, that as we look at those in additional price increases that we would intend to  \ntake during the year, that we also will see a greater positive impact from price incre ases next year. ", "start_char_idx": 2084, "end_char_idx": 2440, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d79def44-e031-41f6-a403-8f74831fb907": {"__data__": {"id_": "d79def44-e031-41f6-a403-8f74831fb907", "embedding": null, "metadata": {"window": "A nd  \nso the inflation actually on an absolute basis, the total impact of inflation will be greater next year in \u201923  \nthan it was in \u201822.  That's what we were talking about there.  But on the flip side, we also already have  \nimplemented price increases, some i n March and additional ones as I mentioned, that go into effect  \nhere essentially July 1, that as we look at those in additional price increases that we would intend to  \ntake during the year, that we also will see a greater positive impact from price incre ases next year.  So  \nwhile inflation on absolute will go up, the positives that we will get from increased pricing will also go  \nup and the two of those will net to a similar to slightly down overall net impact next year in \u201823.  So that's  \nhow we're thinkin g about it next year.  As you can imagine, we're going to continue to focus on those  \nitems and where we have opportunities based on the market, based on the conditions and costing, we  \nwill take more price to market.  \n \n And what Jason also said to be helpfu l, our goal is that when we exit the year next year, we plan to \nhave at least 50% of those inflated items offset through either pricing actions that we will have taken, \neither both to manufacturers and to customers, or we will obviously have seen some of t hose costs \ncome back down. ", "original_text": "So  \nwhile inflation on absolute will go up, the positives that we will get from increased pricing will also go  \nup and the two of those will net to a similar to slightly down overall net impact next year in \u201823. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f363f80-d6d9-418a-8415-8bd8ebefd085", "node_type": "1", "metadata": {"window": "As far as looking forward to \u201823, what we were tryi ng to indicate is that we do believe as we  \nannualize, if you think about the inflation increased over the year and it sits in our inventory for a while,  \nso using the $300 million, obviously, we believe that will annualize to a greater number next year.  A nd  \nso the inflation actually on an absolute basis, the total impact of inflation will be greater next year in \u201923  \nthan it was in \u201822.  That's what we were talking about there.  But on the flip side, we also already have  \nimplemented price increases, some i n March and additional ones as I mentioned, that go into effect  \nhere essentially July 1, that as we look at those in additional price increases that we would intend to  \ntake during the year, that we also will see a greater positive impact from price incre ases next year.  So  \nwhile inflation on absolute will go up, the positives that we will get from increased pricing will also go  \nup and the two of those will net to a similar to slightly down overall net impact next year in \u201823.  So that's  \nhow we're thinkin g about it next year.  As you can imagine, we're going to continue to focus on those  \nitems and where we have opportunities based on the market, based on the conditions and costing, we  \nwill take more price to market.  \n \n", "original_text": "But on the flip side, we also already have  \nimplemented price increases, some i n March and additional ones as I mentioned, that go into effect  \nhere essentially July 1, that as we look at those in additional price increases that we would intend to  \ntake during the year, that we also will see a greater positive impact from price incre ases next year. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1d35b0a5161ef9e7611f32ed0b310cf31263f4d3f42d4f598d89d2740dcc6a5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "599f7948-0f16-4ab5-819d-a96151394eda", "node_type": "1", "metadata": {"window": "That's what we were talking about there.  But on the flip side, we also already have  \nimplemented price increases, some i n March and additional ones as I mentioned, that go into effect  \nhere essentially July 1, that as we look at those in additional price increases that we would intend to  \ntake during the year, that we also will see a greater positive impact from price incre ases next year.  So  \nwhile inflation on absolute will go up, the positives that we will get from increased pricing will also go  \nup and the two of those will net to a similar to slightly down overall net impact next year in \u201823.  So that's  \nhow we're thinkin g about it next year.  As you can imagine, we're going to continue to focus on those  \nitems and where we have opportunities based on the market, based on the conditions and costing, we  \nwill take more price to market.  \n \n And what Jason also said to be helpfu l, our goal is that when we exit the year next year, we plan to \nhave at least 50% of those inflated items offset through either pricing actions that we will have taken, \neither both to manufacturers and to customers, or we will obviously have seen some of t hose costs \ncome back down.  So we do plan to exit at that level. ", "original_text": "So that's  \nhow we're thinkin g about it next year. "}, "hash": "a514767e53cdb8c9ea61853410a43528b7fbf7bce3ef64b556864ea4bf407b8f", "class_name": "RelatedNodeInfo"}}, "text": "So  \nwhile inflation on absolute will go up, the positives that we will get from increased pricing will also go  \nup and the two of those will net to a similar to slightly down overall net impact next year in \u201823. ", "start_char_idx": 2440, "end_char_idx": 2654, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "599f7948-0f16-4ab5-819d-a96151394eda": {"__data__": {"id_": "599f7948-0f16-4ab5-819d-a96151394eda", "embedding": null, "metadata": {"window": "That's what we were talking about there.  But on the flip side, we also already have  \nimplemented price increases, some i n March and additional ones as I mentioned, that go into effect  \nhere essentially July 1, that as we look at those in additional price increases that we would intend to  \ntake during the year, that we also will see a greater positive impact from price incre ases next year.  So  \nwhile inflation on absolute will go up, the positives that we will get from increased pricing will also go  \nup and the two of those will net to a similar to slightly down overall net impact next year in \u201823.  So that's  \nhow we're thinkin g about it next year.  As you can imagine, we're going to continue to focus on those  \nitems and where we have opportunities based on the market, based on the conditions and costing, we  \nwill take more price to market.  \n \n And what Jason also said to be helpfu l, our goal is that when we exit the year next year, we plan to \nhave at least 50% of those inflated items offset through either pricing actions that we will have taken, \neither both to manufacturers and to customers, or we will obviously have seen some of t hose costs \ncome back down.  So we do plan to exit at that level. ", "original_text": "So that's  \nhow we're thinkin g about it next year. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d79def44-e031-41f6-a403-8f74831fb907", "node_type": "1", "metadata": {"window": "A nd  \nso the inflation actually on an absolute basis, the total impact of inflation will be greater next year in \u201923  \nthan it was in \u201822.  That's what we were talking about there.  But on the flip side, we also already have  \nimplemented price increases, some i n March and additional ones as I mentioned, that go into effect  \nhere essentially July 1, that as we look at those in additional price increases that we would intend to  \ntake during the year, that we also will see a greater positive impact from price incre ases next year.  So  \nwhile inflation on absolute will go up, the positives that we will get from increased pricing will also go  \nup and the two of those will net to a similar to slightly down overall net impact next year in \u201823.  So that's  \nhow we're thinkin g about it next year.  As you can imagine, we're going to continue to focus on those  \nitems and where we have opportunities based on the market, based on the conditions and costing, we  \nwill take more price to market.  \n \n And what Jason also said to be helpfu l, our goal is that when we exit the year next year, we plan to \nhave at least 50% of those inflated items offset through either pricing actions that we will have taken, \neither both to manufacturers and to customers, or we will obviously have seen some of t hose costs \ncome back down. ", "original_text": "So  \nwhile inflation on absolute will go up, the positives that we will get from increased pricing will also go  \nup and the two of those will net to a similar to slightly down overall net impact next year in \u201823. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e3301303c4fb208568bdb2f83665def1878b28324c6cd131b7a6ff9112a13c42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ae891c7-79d8-4200-b44e-be7c5c507377", "node_type": "1", "metadata": {"window": "But on the flip side, we also already have  \nimplemented price increases, some i n March and additional ones as I mentioned, that go into effect  \nhere essentially July 1, that as we look at those in additional price increases that we would intend to  \ntake during the year, that we also will see a greater positive impact from price incre ases next year.  So  \nwhile inflation on absolute will go up, the positives that we will get from increased pricing will also go  \nup and the two of those will net to a similar to slightly down overall net impact next year in \u201823.  So that's  \nhow we're thinkin g about it next year.  As you can imagine, we're going to continue to focus on those  \nitems and where we have opportunities based on the market, based on the conditions and costing, we  \nwill take more price to market.  \n \n And what Jason also said to be helpfu l, our goal is that when we exit the year next year, we plan to \nhave at least 50% of those inflated items offset through either pricing actions that we will have taken, \neither both to manufacturers and to customers, or we will obviously have seen some of t hose costs \ncome back down.  So we do plan to exit at that level.  So that's kind of financially I guess, an overall \nsummary of that.  \n \n", "original_text": "As you can imagine, we're going to continue to focus on those  \nitems and where we have opportunities based on the market, based on the conditions and costing, we  \nwill take more price to market.  \n \n"}, "hash": "dbb70d030962f7544504331fe0c2d28798946ee6a641ab071835cd0cc6f37fbc", "class_name": "RelatedNodeInfo"}}, "text": "So that's  \nhow we're thinkin g about it next year. ", "start_char_idx": 2654, "end_char_idx": 2706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ae891c7-79d8-4200-b44e-be7c5c507377": {"__data__": {"id_": "0ae891c7-79d8-4200-b44e-be7c5c507377", "embedding": null, "metadata": {"window": "But on the flip side, we also already have  \nimplemented price increases, some i n March and additional ones as I mentioned, that go into effect  \nhere essentially July 1, that as we look at those in additional price increases that we would intend to  \ntake during the year, that we also will see a greater positive impact from price incre ases next year.  So  \nwhile inflation on absolute will go up, the positives that we will get from increased pricing will also go  \nup and the two of those will net to a similar to slightly down overall net impact next year in \u201823.  So that's  \nhow we're thinkin g about it next year.  As you can imagine, we're going to continue to focus on those  \nitems and where we have opportunities based on the market, based on the conditions and costing, we  \nwill take more price to market.  \n \n And what Jason also said to be helpfu l, our goal is that when we exit the year next year, we plan to \nhave at least 50% of those inflated items offset through either pricing actions that we will have taken, \neither both to manufacturers and to customers, or we will obviously have seen some of t hose costs \ncome back down.  So we do plan to exit at that level.  So that's kind of financially I guess, an overall \nsummary of that.  \n \n", "original_text": "As you can imagine, we're going to continue to focus on those  \nitems and where we have opportunities based on the market, based on the conditions and costing, we  \nwill take more price to market.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "599f7948-0f16-4ab5-819d-a96151394eda", "node_type": "1", "metadata": {"window": "That's what we were talking about there.  But on the flip side, we also already have  \nimplemented price increases, some i n March and additional ones as I mentioned, that go into effect  \nhere essentially July 1, that as we look at those in additional price increases that we would intend to  \ntake during the year, that we also will see a greater positive impact from price incre ases next year.  So  \nwhile inflation on absolute will go up, the positives that we will get from increased pricing will also go  \nup and the two of those will net to a similar to slightly down overall net impact next year in \u201823.  So that's  \nhow we're thinkin g about it next year.  As you can imagine, we're going to continue to focus on those  \nitems and where we have opportunities based on the market, based on the conditions and costing, we  \nwill take more price to market.  \n \n And what Jason also said to be helpfu l, our goal is that when we exit the year next year, we plan to \nhave at least 50% of those inflated items offset through either pricing actions that we will have taken, \neither both to manufacturers and to customers, or we will obviously have seen some of t hose costs \ncome back down.  So we do plan to exit at that level. ", "original_text": "So that's  \nhow we're thinkin g about it next year. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0fbb43a23e08d2c5444fef30d83486672cf840dc2e2a7d0eefa8fb8722b1e76f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b4d3f84c-aff2-4e6f-be8a-448099f38a74", "node_type": "1", "metadata": {"window": "So  \nwhile inflation on absolute will go up, the positives that we will get from increased pricing will also go  \nup and the two of those will net to a similar to slightly down overall net impact next year in \u201823.  So that's  \nhow we're thinkin g about it next year.  As you can imagine, we're going to continue to focus on those  \nitems and where we have opportunities based on the market, based on the conditions and costing, we  \nwill take more price to market.  \n \n And what Jason also said to be helpfu l, our goal is that when we exit the year next year, we plan to \nhave at least 50% of those inflated items offset through either pricing actions that we will have taken, \neither both to manufacturers and to customers, or we will obviously have seen some of t hose costs \ncome back down.  So we do plan to exit at that level.  So that's kind of financially I guess, an overall \nsummary of that.  \n \n To your question around the Medical business, we still continue to feel very good about this business. \n", "original_text": "And what Jason also said to be helpfu l, our goal is that when we exit the year next year, we plan to \nhave at least 50% of those inflated items offset through either pricing actions that we will have taken, \neither both to manufacturers and to customers, or we will obviously have seen some of t hose costs \ncome back down. "}, "hash": "69540a02328d88e64ea9b722c1a1f7f16f1760c6a4c3e0eac150bb1af4b3b2f2", "class_name": "RelatedNodeInfo"}}, "text": "As you can imagine, we're going to continue to focus on those  \nitems and where we have opportunities based on the market, based on the conditions and costing, we  \nwill take more price to market.  \n \n", "start_char_idx": 2706, "end_char_idx": 2907, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b4d3f84c-aff2-4e6f-be8a-448099f38a74": {"__data__": {"id_": "b4d3f84c-aff2-4e6f-be8a-448099f38a74", "embedding": null, "metadata": {"window": "So  \nwhile inflation on absolute will go up, the positives that we will get from increased pricing will also go  \nup and the two of those will net to a similar to slightly down overall net impact next year in \u201823.  So that's  \nhow we're thinkin g about it next year.  As you can imagine, we're going to continue to focus on those  \nitems and where we have opportunities based on the market, based on the conditions and costing, we  \nwill take more price to market.  \n \n And what Jason also said to be helpfu l, our goal is that when we exit the year next year, we plan to \nhave at least 50% of those inflated items offset through either pricing actions that we will have taken, \neither both to manufacturers and to customers, or we will obviously have seen some of t hose costs \ncome back down.  So we do plan to exit at that level.  So that's kind of financially I guess, an overall \nsummary of that.  \n \n To your question around the Medical business, we still continue to feel very good about this business. \n", "original_text": "And what Jason also said to be helpfu l, our goal is that when we exit the year next year, we plan to \nhave at least 50% of those inflated items offset through either pricing actions that we will have taken, \neither both to manufacturers and to customers, or we will obviously have seen some of t hose costs \ncome back down. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ae891c7-79d8-4200-b44e-be7c5c507377", "node_type": "1", "metadata": {"window": "But on the flip side, we also already have  \nimplemented price increases, some i n March and additional ones as I mentioned, that go into effect  \nhere essentially July 1, that as we look at those in additional price increases that we would intend to  \ntake during the year, that we also will see a greater positive impact from price incre ases next year.  So  \nwhile inflation on absolute will go up, the positives that we will get from increased pricing will also go  \nup and the two of those will net to a similar to slightly down overall net impact next year in \u201823.  So that's  \nhow we're thinkin g about it next year.  As you can imagine, we're going to continue to focus on those  \nitems and where we have opportunities based on the market, based on the conditions and costing, we  \nwill take more price to market.  \n \n And what Jason also said to be helpfu l, our goal is that when we exit the year next year, we plan to \nhave at least 50% of those inflated items offset through either pricing actions that we will have taken, \neither both to manufacturers and to customers, or we will obviously have seen some of t hose costs \ncome back down.  So we do plan to exit at that level.  So that's kind of financially I guess, an overall \nsummary of that.  \n \n", "original_text": "As you can imagine, we're going to continue to focus on those  \nitems and where we have opportunities based on the market, based on the conditions and costing, we  \nwill take more price to market.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e7dcf3baa1cabdc8c80acb61068768cc120d28605dfc0c7b97c8ade7d8636b8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "002063be-87e5-4a62-ba25-4c3a457c3d26", "node_type": "1", "metadata": {"window": "So that's  \nhow we're thinkin g about it next year.  As you can imagine, we're going to continue to focus on those  \nitems and where we have opportunities based on the market, based on the conditions and costing, we  \nwill take more price to market.  \n \n And what Jason also said to be helpfu l, our goal is that when we exit the year next year, we plan to \nhave at least 50% of those inflated items offset through either pricing actions that we will have taken, \neither both to manufacturers and to customers, or we will obviously have seen some of t hose costs \ncome back down.  So we do plan to exit at that level.  So that's kind of financially I guess, an overall \nsummary of that.  \n \n To your question around the Medical business, we still continue to feel very good about this business. \n As I look at this bus iness overall yes, our medical products and distribution business is having some \nchallenges, no doubt about it, obviously with lowering guidance three times. ", "original_text": "So we do plan to exit at that level. "}, "hash": "5fe776822a995b2247b686df565b59ef28fa009ccc5c53dc067262725f9380df", "class_name": "RelatedNodeInfo"}}, "text": "And what Jason also said to be helpfu l, our goal is that when we exit the year next year, we plan to \nhave at least 50% of those inflated items offset through either pricing actions that we will have taken, \neither both to manufacturers and to customers, or we will obviously have seen some of t hose costs \ncome back down. ", "start_char_idx": 2907, "end_char_idx": 3232, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "002063be-87e5-4a62-ba25-4c3a457c3d26": {"__data__": {"id_": "002063be-87e5-4a62-ba25-4c3a457c3d26", "embedding": null, "metadata": {"window": "So that's  \nhow we're thinkin g about it next year.  As you can imagine, we're going to continue to focus on those  \nitems and where we have opportunities based on the market, based on the conditions and costing, we  \nwill take more price to market.  \n \n And what Jason also said to be helpfu l, our goal is that when we exit the year next year, we plan to \nhave at least 50% of those inflated items offset through either pricing actions that we will have taken, \neither both to manufacturers and to customers, or we will obviously have seen some of t hose costs \ncome back down.  So we do plan to exit at that level.  So that's kind of financially I guess, an overall \nsummary of that.  \n \n To your question around the Medical business, we still continue to feel very good about this business. \n As I look at this bus iness overall yes, our medical products and distribution business is having some \nchallenges, no doubt about it, obviously with lowering guidance three times. ", "original_text": "So we do plan to exit at that level. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b4d3f84c-aff2-4e6f-be8a-448099f38a74", "node_type": "1", "metadata": {"window": "So  \nwhile inflation on absolute will go up, the positives that we will get from increased pricing will also go  \nup and the two of those will net to a similar to slightly down overall net impact next year in \u201823.  So that's  \nhow we're thinkin g about it next year.  As you can imagine, we're going to continue to focus on those  \nitems and where we have opportunities based on the market, based on the conditions and costing, we  \nwill take more price to market.  \n \n And what Jason also said to be helpfu l, our goal is that when we exit the year next year, we plan to \nhave at least 50% of those inflated items offset through either pricing actions that we will have taken, \neither both to manufacturers and to customers, or we will obviously have seen some of t hose costs \ncome back down.  So we do plan to exit at that level.  So that's kind of financially I guess, an overall \nsummary of that.  \n \n To your question around the Medical business, we still continue to feel very good about this business. \n", "original_text": "And what Jason also said to be helpfu l, our goal is that when we exit the year next year, we plan to \nhave at least 50% of those inflated items offset through either pricing actions that we will have taken, \neither both to manufacturers and to customers, or we will obviously have seen some of t hose costs \ncome back down. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fe60e752be4e1e42d3af970a77f7b5a6c61d68488d35ab41c3f8bd0a10f5127a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fdf68bc6-9588-4ac3-8262-4d8f2537c1af", "node_type": "1", "metadata": {"window": "As you can imagine, we're going to continue to focus on those  \nitems and where we have opportunities based on the market, based on the conditions and costing, we  \nwill take more price to market.  \n \n And what Jason also said to be helpfu l, our goal is that when we exit the year next year, we plan to \nhave at least 50% of those inflated items offset through either pricing actions that we will have taken, \neither both to manufacturers and to customers, or we will obviously have seen some of t hose costs \ncome back down.  So we do plan to exit at that level.  So that's kind of financially I guess, an overall \nsummary of that.  \n \n To your question around the Medical business, we still continue to feel very good about this business. \n As I look at this bus iness overall yes, our medical products and distribution business is having some \nchallenges, no doubt about it, obviously with lowering guidance three times.  But when we look across \nthe rest of the portfolio, whether it be at home, OptiFreight\u00ae, lab, WaveM ark, we continue to see very \nstrong growth from all of those businesses and we feel really good about those. ", "original_text": "So that's kind of financially I guess, an overall \nsummary of that.  \n \n"}, "hash": "f117657b30746109631729b6ecacfa80de285dcbb17c6c5af0931679af824a05", "class_name": "RelatedNodeInfo"}}, "text": "So we do plan to exit at that level. ", "start_char_idx": 3232, "end_char_idx": 3269, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fdf68bc6-9588-4ac3-8262-4d8f2537c1af": {"__data__": {"id_": "fdf68bc6-9588-4ac3-8262-4d8f2537c1af", "embedding": null, "metadata": {"window": "As you can imagine, we're going to continue to focus on those  \nitems and where we have opportunities based on the market, based on the conditions and costing, we  \nwill take more price to market.  \n \n And what Jason also said to be helpfu l, our goal is that when we exit the year next year, we plan to \nhave at least 50% of those inflated items offset through either pricing actions that we will have taken, \neither both to manufacturers and to customers, or we will obviously have seen some of t hose costs \ncome back down.  So we do plan to exit at that level.  So that's kind of financially I guess, an overall \nsummary of that.  \n \n To your question around the Medical business, we still continue to feel very good about this business. \n As I look at this bus iness overall yes, our medical products and distribution business is having some \nchallenges, no doubt about it, obviously with lowering guidance three times.  But when we look across \nthe rest of the portfolio, whether it be at home, OptiFreight\u00ae, lab, WaveM ark, we continue to see very \nstrong growth from all of those businesses and we feel really good about those. ", "original_text": "So that's kind of financially I guess, an overall \nsummary of that.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "002063be-87e5-4a62-ba25-4c3a457c3d26", "node_type": "1", "metadata": {"window": "So that's  \nhow we're thinkin g about it next year.  As you can imagine, we're going to continue to focus on those  \nitems and where we have opportunities based on the market, based on the conditions and costing, we  \nwill take more price to market.  \n \n And what Jason also said to be helpfu l, our goal is that when we exit the year next year, we plan to \nhave at least 50% of those inflated items offset through either pricing actions that we will have taken, \neither both to manufacturers and to customers, or we will obviously have seen some of t hose costs \ncome back down.  So we do plan to exit at that level.  So that's kind of financially I guess, an overall \nsummary of that.  \n \n To your question around the Medical business, we still continue to feel very good about this business. \n As I look at this bus iness overall yes, our medical products and distribution business is having some \nchallenges, no doubt about it, obviously with lowering guidance three times. ", "original_text": "So we do plan to exit at that level. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b7bef969cc41cb9de513e7646518c1164ad0db441dddf9ef4e3c7e47fde9d98", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "958df874-e038-4480-ab01-eeead07d5eff", "node_type": "1", "metadata": {"window": "And what Jason also said to be helpfu l, our goal is that when we exit the year next year, we plan to \nhave at least 50% of those inflated items offset through either pricing actions that we will have taken, \neither both to manufacturers and to customers, or we will obviously have seen some of t hose costs \ncome back down.  So we do plan to exit at that level.  So that's kind of financially I guess, an overall \nsummary of that.  \n \n To your question around the Medical business, we still continue to feel very good about this business. \n As I look at this bus iness overall yes, our medical products and distribution business is having some \nchallenges, no doubt about it, obviously with lowering guidance three times.  But when we look across \nthe rest of the portfolio, whether it be at home, OptiFreight\u00ae, lab, WaveM ark, we continue to see very \nstrong growth from all of those businesses and we feel really good about those.  We feel good about \nthe actions that we're putting in place. ", "original_text": "To your question around the Medical business, we still continue to feel very good about this business. \n"}, "hash": "ca7816a693ce96226779d6d2f0dceed9c81aa053ef33b20c6872a792a1eaaccb", "class_name": "RelatedNodeInfo"}}, "text": "So that's kind of financially I guess, an overall \nsummary of that.  \n \n", "start_char_idx": 3269, "end_char_idx": 3341, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "958df874-e038-4480-ab01-eeead07d5eff": {"__data__": {"id_": "958df874-e038-4480-ab01-eeead07d5eff", "embedding": null, "metadata": {"window": "And what Jason also said to be helpfu l, our goal is that when we exit the year next year, we plan to \nhave at least 50% of those inflated items offset through either pricing actions that we will have taken, \neither both to manufacturers and to customers, or we will obviously have seen some of t hose costs \ncome back down.  So we do plan to exit at that level.  So that's kind of financially I guess, an overall \nsummary of that.  \n \n To your question around the Medical business, we still continue to feel very good about this business. \n As I look at this bus iness overall yes, our medical products and distribution business is having some \nchallenges, no doubt about it, obviously with lowering guidance three times.  But when we look across \nthe rest of the portfolio, whether it be at home, OptiFreight\u00ae, lab, WaveM ark, we continue to see very \nstrong growth from all of those businesses and we feel really good about those.  We feel good about \nthe actions that we're putting in place. ", "original_text": "To your question around the Medical business, we still continue to feel very good about this business. \n", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fdf68bc6-9588-4ac3-8262-4d8f2537c1af", "node_type": "1", "metadata": {"window": "As you can imagine, we're going to continue to focus on those  \nitems and where we have opportunities based on the market, based on the conditions and costing, we  \nwill take more price to market.  \n \n And what Jason also said to be helpfu l, our goal is that when we exit the year next year, we plan to \nhave at least 50% of those inflated items offset through either pricing actions that we will have taken, \neither both to manufacturers and to customers, or we will obviously have seen some of t hose costs \ncome back down.  So we do plan to exit at that level.  So that's kind of financially I guess, an overall \nsummary of that.  \n \n To your question around the Medical business, we still continue to feel very good about this business. \n As I look at this bus iness overall yes, our medical products and distribution business is having some \nchallenges, no doubt about it, obviously with lowering guidance three times.  But when we look across \nthe rest of the portfolio, whether it be at home, OptiFreight\u00ae, lab, WaveM ark, we continue to see very \nstrong growth from all of those businesses and we feel really good about those. ", "original_text": "So that's kind of financially I guess, an overall \nsummary of that.  \n \n", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4f4eae3ea1819093d4485b069dc3aace0f8691203668ffbabdcf90b277d4d59c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0c667db-a07d-4606-b342-73a1d53b1036", "node_type": "1", "metadata": {"window": "So we do plan to exit at that level.  So that's kind of financially I guess, an overall \nsummary of that.  \n \n To your question around the Medical business, we still continue to feel very good about this business. \n As I look at this bus iness overall yes, our medical products and distribution business is having some \nchallenges, no doubt about it, obviously with lowering guidance three times.  But when we look across \nthe rest of the portfolio, whether it be at home, OptiFreight\u00ae, lab, WaveM ark, we continue to see very \nstrong growth from all of those businesses and we feel really good about those.  We feel good about \nthe actions that we're putting in place.  As always, we always constantly look at our portfolio and make \nadjustments as necessary , but we feel good about where we are with Medical at this point in time.  \n ", "original_text": "As I look at this bus iness overall yes, our medical products and distribution business is having some \nchallenges, no doubt about it, obviously with lowering guidance three times. "}, "hash": "694eb28624af9073d5eabdea18c63b4801fad1d679786d262271194fbc2acef6", "class_name": "RelatedNodeInfo"}}, "text": "To your question around the Medical business, we still continue to feel very good about this business. \n", "start_char_idx": 3341, "end_char_idx": 3445, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0c667db-a07d-4606-b342-73a1d53b1036": {"__data__": {"id_": "b0c667db-a07d-4606-b342-73a1d53b1036", "embedding": null, "metadata": {"window": "So we do plan to exit at that level.  So that's kind of financially I guess, an overall \nsummary of that.  \n \n To your question around the Medical business, we still continue to feel very good about this business. \n As I look at this bus iness overall yes, our medical products and distribution business is having some \nchallenges, no doubt about it, obviously with lowering guidance three times.  But when we look across \nthe rest of the portfolio, whether it be at home, OptiFreight\u00ae, lab, WaveM ark, we continue to see very \nstrong growth from all of those businesses and we feel really good about those.  We feel good about \nthe actions that we're putting in place.  As always, we always constantly look at our portfolio and make \nadjustments as necessary , but we feel good about where we are with Medical at this point in time.  \n ", "original_text": "As I look at this bus iness overall yes, our medical products and distribution business is having some \nchallenges, no doubt about it, obviously with lowering guidance three times. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "958df874-e038-4480-ab01-eeead07d5eff", "node_type": "1", "metadata": {"window": "And what Jason also said to be helpfu l, our goal is that when we exit the year next year, we plan to \nhave at least 50% of those inflated items offset through either pricing actions that we will have taken, \neither both to manufacturers and to customers, or we will obviously have seen some of t hose costs \ncome back down.  So we do plan to exit at that level.  So that's kind of financially I guess, an overall \nsummary of that.  \n \n To your question around the Medical business, we still continue to feel very good about this business. \n As I look at this bus iness overall yes, our medical products and distribution business is having some \nchallenges, no doubt about it, obviously with lowering guidance three times.  But when we look across \nthe rest of the portfolio, whether it be at home, OptiFreight\u00ae, lab, WaveM ark, we continue to see very \nstrong growth from all of those businesses and we feel really good about those.  We feel good about \nthe actions that we're putting in place. ", "original_text": "To your question around the Medical business, we still continue to feel very good about this business. \n", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ee0036cac7ca33bc1b28d9a7a363641a405d440c87393ce7395d1dba81dea554", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b9c7156-82f8-4fb5-b724-0aadf5a777f7", "node_type": "1", "metadata": {"window": "So that's kind of financially I guess, an overall \nsummary of that.  \n \n To your question around the Medical business, we still continue to feel very good about this business. \n As I look at this bus iness overall yes, our medical products and distribution business is having some \nchallenges, no doubt about it, obviously with lowering guidance three times.  But when we look across \nthe rest of the portfolio, whether it be at home, OptiFreight\u00ae, lab, WaveM ark, we continue to see very \nstrong growth from all of those businesses and we feel really good about those.  We feel good about \nthe actions that we're putting in place.  As always, we always constantly look at our portfolio and make \nadjustments as necessary , but we feel good about where we are with Medical at this point in time.  \n ", "original_text": "But when we look across \nthe rest of the portfolio, whether it be at home, OptiFreight\u00ae, lab, WaveM ark, we continue to see very \nstrong growth from all of those businesses and we feel really good about those. "}, "hash": "b3b7ebcf9b2e5b72ff3b35938b403872d716d01412eb97f83dc4a9571f9182e4", "class_name": "RelatedNodeInfo"}}, "text": "As I look at this bus iness overall yes, our medical products and distribution business is having some \nchallenges, no doubt about it, obviously with lowering guidance three times. ", "start_char_idx": 3445, "end_char_idx": 3626, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b9c7156-82f8-4fb5-b724-0aadf5a777f7": {"__data__": {"id_": "2b9c7156-82f8-4fb5-b724-0aadf5a777f7", "embedding": null, "metadata": {"window": "So that's kind of financially I guess, an overall \nsummary of that.  \n \n To your question around the Medical business, we still continue to feel very good about this business. \n As I look at this bus iness overall yes, our medical products and distribution business is having some \nchallenges, no doubt about it, obviously with lowering guidance three times.  But when we look across \nthe rest of the portfolio, whether it be at home, OptiFreight\u00ae, lab, WaveM ark, we continue to see very \nstrong growth from all of those businesses and we feel really good about those.  We feel good about \nthe actions that we're putting in place.  As always, we always constantly look at our portfolio and make \nadjustments as necessary , but we feel good about where we are with Medical at this point in time.  \n ", "original_text": "But when we look across \nthe rest of the portfolio, whether it be at home, OptiFreight\u00ae, lab, WaveM ark, we continue to see very \nstrong growth from all of those businesses and we feel really good about those. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0c667db-a07d-4606-b342-73a1d53b1036", "node_type": "1", "metadata": {"window": "So we do plan to exit at that level.  So that's kind of financially I guess, an overall \nsummary of that.  \n \n To your question around the Medical business, we still continue to feel very good about this business. \n As I look at this bus iness overall yes, our medical products and distribution business is having some \nchallenges, no doubt about it, obviously with lowering guidance three times.  But when we look across \nthe rest of the portfolio, whether it be at home, OptiFreight\u00ae, lab, WaveM ark, we continue to see very \nstrong growth from all of those businesses and we feel really good about those.  We feel good about \nthe actions that we're putting in place.  As always, we always constantly look at our portfolio and make \nadjustments as necessary , but we feel good about where we are with Medical at this point in time.  \n ", "original_text": "As I look at this bus iness overall yes, our medical products and distribution business is having some \nchallenges, no doubt about it, obviously with lowering guidance three times. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f51fd5a916536c5cbade256fc382de245e7b4d49ebac7b197c56acda43611a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed5ce0d8-c1bd-43be-b014-91b50962fe75", "node_type": "1", "metadata": {"window": "To your question around the Medical business, we still continue to feel very good about this business. \n As I look at this bus iness overall yes, our medical products and distribution business is having some \nchallenges, no doubt about it, obviously with lowering guidance three times.  But when we look across \nthe rest of the portfolio, whether it be at home, OptiFreight\u00ae, lab, WaveM ark, we continue to see very \nstrong growth from all of those businesses and we feel really good about those.  We feel good about \nthe actions that we're putting in place.  As always, we always constantly look at our portfolio and make \nadjustments as necessary , but we feel good about where we are with Medical at this point in time.  \n ", "original_text": "We feel good about \nthe actions that we're putting in place. "}, "hash": "e5f5d535579dde754ef44937c4301a5dae98251270adc07828fc764014d1cb82", "class_name": "RelatedNodeInfo"}}, "text": "But when we look across \nthe rest of the portfolio, whether it be at home, OptiFreight\u00ae, lab, WaveM ark, we continue to see very \nstrong growth from all of those businesses and we feel really good about those. ", "start_char_idx": 3626, "end_char_idx": 3836, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed5ce0d8-c1bd-43be-b014-91b50962fe75": {"__data__": {"id_": "ed5ce0d8-c1bd-43be-b014-91b50962fe75", "embedding": null, "metadata": {"window": "To your question around the Medical business, we still continue to feel very good about this business. \n As I look at this bus iness overall yes, our medical products and distribution business is having some \nchallenges, no doubt about it, obviously with lowering guidance three times.  But when we look across \nthe rest of the portfolio, whether it be at home, OptiFreight\u00ae, lab, WaveM ark, we continue to see very \nstrong growth from all of those businesses and we feel really good about those.  We feel good about \nthe actions that we're putting in place.  As always, we always constantly look at our portfolio and make \nadjustments as necessary , but we feel good about where we are with Medical at this point in time.  \n ", "original_text": "We feel good about \nthe actions that we're putting in place. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b9c7156-82f8-4fb5-b724-0aadf5a777f7", "node_type": "1", "metadata": {"window": "So that's kind of financially I guess, an overall \nsummary of that.  \n \n To your question around the Medical business, we still continue to feel very good about this business. \n As I look at this bus iness overall yes, our medical products and distribution business is having some \nchallenges, no doubt about it, obviously with lowering guidance three times.  But when we look across \nthe rest of the portfolio, whether it be at home, OptiFreight\u00ae, lab, WaveM ark, we continue to see very \nstrong growth from all of those businesses and we feel really good about those.  We feel good about \nthe actions that we're putting in place.  As always, we always constantly look at our portfolio and make \nadjustments as necessary , but we feel good about where we are with Medical at this point in time.  \n ", "original_text": "But when we look across \nthe rest of the portfolio, whether it be at home, OptiFreight\u00ae, lab, WaveM ark, we continue to see very \nstrong growth from all of those businesses and we feel really good about those. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c838444204c7beefd109e69c58caae8661464566860bdf58b7d4b35367451f42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25d198be-2271-49fc-99a6-9bc7d05861d1", "node_type": "1", "metadata": {"window": "As I look at this bus iness overall yes, our medical products and distribution business is having some \nchallenges, no doubt about it, obviously with lowering guidance three times.  But when we look across \nthe rest of the portfolio, whether it be at home, OptiFreight\u00ae, lab, WaveM ark, we continue to see very \nstrong growth from all of those businesses and we feel really good about those.  We feel good about \nthe actions that we're putting in place.  As always, we always constantly look at our portfolio and make \nadjustments as necessary , but we feel good about where we are with Medical at this point in time.  \n ", "original_text": "As always, we always constantly look at our portfolio and make \nadjustments as necessary , but we feel good about where we are with Medical at this point in time.  \n "}, "hash": "f7dd3c1095e7d8bab447a444e30577de4b664d7b069af9494fae2683803f914c", "class_name": "RelatedNodeInfo"}}, "text": "We feel good about \nthe actions that we're putting in place. ", "start_char_idx": 3836, "end_char_idx": 3897, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25d198be-2271-49fc-99a6-9bc7d05861d1": {"__data__": {"id_": "25d198be-2271-49fc-99a6-9bc7d05861d1", "embedding": null, "metadata": {"window": "As I look at this bus iness overall yes, our medical products and distribution business is having some \nchallenges, no doubt about it, obviously with lowering guidance three times.  But when we look across \nthe rest of the portfolio, whether it be at home, OptiFreight\u00ae, lab, WaveM ark, we continue to see very \nstrong growth from all of those businesses and we feel really good about those.  We feel good about \nthe actions that we're putting in place.  As always, we always constantly look at our portfolio and make \nadjustments as necessary , but we feel good about where we are with Medical at this point in time.  \n ", "original_text": "As always, we always constantly look at our portfolio and make \nadjustments as necessary , but we feel good about where we are with Medical at this point in time.  \n ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "48f73078-3572-4b2e-9c19-4e6845af63db", "node_type": "4", "metadata": {"page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "70159611a458e7607f049616572ec00816c54b304c1dd212dc35d14551535abf", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed5ce0d8-c1bd-43be-b014-91b50962fe75", "node_type": "1", "metadata": {"window": "To your question around the Medical business, we still continue to feel very good about this business. \n As I look at this bus iness overall yes, our medical products and distribution business is having some \nchallenges, no doubt about it, obviously with lowering guidance three times.  But when we look across \nthe rest of the portfolio, whether it be at home, OptiFreight\u00ae, lab, WaveM ark, we continue to see very \nstrong growth from all of those businesses and we feel really good about those.  We feel good about \nthe actions that we're putting in place.  As always, we always constantly look at our portfolio and make \nadjustments as necessary , but we feel good about where we are with Medical at this point in time.  \n ", "original_text": "We feel good about \nthe actions that we're putting in place. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e64558cbabd75fd8fc0e57f7f35266db9385a1e10c3474e30aad4a2a3437354b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d5dbfc5-1eee-4cf7-9990-5a02ff186c4a", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \nOperator:   And we'll go ahead and move on to our next question from Michael Cherny with Bank of  \nAmerica.  \n  \n Michael  Cherny:   Good morning and thanks for all the color.  Mike, I want to dive in a little bit more about   \nthe comments you've made tying into next year on Medical.  As we think about both the fiscal 3Q   \nnumbers and the implied fiscal 4Q guidance. ", "original_text": " \nPage 11 of 15 \n \nOperator:   And we'll go ahead and move on to our next question from Michael Cherny with Bank of  \nAmerica.  \n  \n"}, "hash": "0112af68144c39b8bbaba38189747bb99b69dd2a35ab9dce2507d1f40d8fd010", "class_name": "RelatedNodeInfo"}}, "text": "As always, we always constantly look at our portfolio and make \nadjustments as necessary , but we feel good about where we are with Medical at this point in time.  \n ", "start_char_idx": 3897, "end_char_idx": 4063, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d5dbfc5-1eee-4cf7-9990-5a02ff186c4a": {"__data__": {"id_": "0d5dbfc5-1eee-4cf7-9990-5a02ff186c4a", "embedding": null, "metadata": {"window": " \nPage 11 of 15 \n \nOperator:   And we'll go ahead and move on to our next question from Michael Cherny with Bank of  \nAmerica.  \n  \n Michael  Cherny:   Good morning and thanks for all the color.  Mike, I want to dive in a little bit more about   \nthe comments you've made tying into next year on Medical.  As we think about both the fiscal 3Q   \nnumbers and the implied fiscal 4Q guidance. ", "original_text": " \nPage 11 of 15 \n \nOperator:   And we'll go ahead and move on to our next question from Michael Cherny with Bank of  \nAmerica.  \n  \n", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25d198be-2271-49fc-99a6-9bc7d05861d1", "node_type": "1", "metadata": {"window": "As I look at this bus iness overall yes, our medical products and distribution business is having some \nchallenges, no doubt about it, obviously with lowering guidance three times.  But when we look across \nthe rest of the portfolio, whether it be at home, OptiFreight\u00ae, lab, WaveM ark, we continue to see very \nstrong growth from all of those businesses and we feel really good about those.  We feel good about \nthe actions that we're putting in place.  As always, we always constantly look at our portfolio and make \nadjustments as necessary , but we feel good about where we are with Medical at this point in time.  \n ", "original_text": "As always, we always constantly look at our portfolio and make \nadjustments as necessary , but we feel good about where we are with Medical at this point in time.  \n ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d37f32b0280610e296b41486660aadd08fdfa6f3d52df3b044c8758f88fd04e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84de3e46-a9e8-477a-b711-6d68691a04e7", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \nOperator:   And we'll go ahead and move on to our next question from Michael Cherny with Bank of  \nAmerica.  \n  \n Michael  Cherny:   Good morning and thanks for all the color.  Mike, I want to dive in a little bit more about   \nthe comments you've made tying into next year on Medical.  As we think about both the fiscal 3Q   \nnumbers and the implied fiscal 4Q guidance.  Is that the right annualization and jumping -off point as   \nwe think into next year? ", "original_text": "Michael  Cherny:   Good morning and thanks for all the color. "}, "hash": "b1f281c15d22280d5dbe6e92e15145786fad4965d342caa3acfad6d517ae2742", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 11 of 15 \n \nOperator:   And we'll go ahead and move on to our next question from Michael Cherny with Bank of  \nAmerica.  \n  \n", "start_char_idx": 0, "end_char_idx": 132, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84de3e46-a9e8-477a-b711-6d68691a04e7": {"__data__": {"id_": "84de3e46-a9e8-477a-b711-6d68691a04e7", "embedding": null, "metadata": {"window": " \nPage 11 of 15 \n \nOperator:   And we'll go ahead and move on to our next question from Michael Cherny with Bank of  \nAmerica.  \n  \n Michael  Cherny:   Good morning and thanks for all the color.  Mike, I want to dive in a little bit more about   \nthe comments you've made tying into next year on Medical.  As we think about both the fiscal 3Q   \nnumbers and the implied fiscal 4Q guidance.  Is that the right annualization and jumping -off point as   \nwe think into next year? ", "original_text": "Michael  Cherny:   Good morning and thanks for all the color. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d5dbfc5-1eee-4cf7-9990-5a02ff186c4a", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \nOperator:   And we'll go ahead and move on to our next question from Michael Cherny with Bank of  \nAmerica.  \n  \n Michael  Cherny:   Good morning and thanks for all the color.  Mike, I want to dive in a little bit more about   \nthe comments you've made tying into next year on Medical.  As we think about both the fiscal 3Q   \nnumbers and the implied fiscal 4Q guidance. ", "original_text": " \nPage 11 of 15 \n \nOperator:   And we'll go ahead and move on to our next question from Michael Cherny with Bank of  \nAmerica.  \n  \n", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1afba6b7c65a44cd1b702c41b003e86a7c4e4312dd72a405c91a8705676598fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "422b9354-02cd-478b-aef1-ab0f92a80564", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \nOperator:   And we'll go ahead and move on to our next question from Michael Cherny with Bank of  \nAmerica.  \n  \n Michael  Cherny:   Good morning and thanks for all the color.  Mike, I want to dive in a little bit more about   \nthe comments you've made tying into next year on Medical.  As we think about both the fiscal 3Q   \nnumbers and the implied fiscal 4Q guidance.  Is that the right annualization and jumping -off point as   \nwe think into next year?  And along those lines with the pieces that you've given us, where do you see   \nthe dynamics? ", "original_text": "Mike, I want to dive in a little bit more about   \nthe comments you've made tying into next year on Medical. "}, "hash": "32946af1f9a32cc5deea7525d1e1f9f9dfb2be6ff5fef63aee054d84a7e643e3", "class_name": "RelatedNodeInfo"}}, "text": "Michael  Cherny:   Good morning and thanks for all the color. ", "start_char_idx": 132, "end_char_idx": 194, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "422b9354-02cd-478b-aef1-ab0f92a80564": {"__data__": {"id_": "422b9354-02cd-478b-aef1-ab0f92a80564", "embedding": null, "metadata": {"window": " \nPage 11 of 15 \n \nOperator:   And we'll go ahead and move on to our next question from Michael Cherny with Bank of  \nAmerica.  \n  \n Michael  Cherny:   Good morning and thanks for all the color.  Mike, I want to dive in a little bit more about   \nthe comments you've made tying into next year on Medical.  As we think about both the fiscal 3Q   \nnumbers and the implied fiscal 4Q guidance.  Is that the right annualization and jumping -off point as   \nwe think into next year?  And along those lines with the pieces that you've given us, where do you see   \nthe dynamics? ", "original_text": "Mike, I want to dive in a little bit more about   \nthe comments you've made tying into next year on Medical. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "84de3e46-a9e8-477a-b711-6d68691a04e7", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \nOperator:   And we'll go ahead and move on to our next question from Michael Cherny with Bank of  \nAmerica.  \n  \n Michael  Cherny:   Good morning and thanks for all the color.  Mike, I want to dive in a little bit more about   \nthe comments you've made tying into next year on Medical.  As we think about both the fiscal 3Q   \nnumbers and the implied fiscal 4Q guidance.  Is that the right annualization and jumping -off point as   \nwe think into next year? ", "original_text": "Michael  Cherny:   Good morning and thanks for all the color. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a917ca9b8d602eb836f3a52a72c4a795a2969d27679bb236a7f2ae008dc2cb61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b2c7d08-81ce-4ed4-8066-b9a8da216f69", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \nOperator:   And we'll go ahead and move on to our next question from Michael Cherny with Bank of  \nAmerica.  \n  \n Michael  Cherny:   Good morning and thanks for all the color.  Mike, I want to dive in a little bit more about   \nthe comments you've made tying into next year on Medical.  As we think about both the fiscal 3Q   \nnumbers and the implied fiscal 4Q guidance.  Is that the right annualization and jumping -off point as   \nwe think into next year?  And along those lines with the pieces that you've given us, where do you see   \nthe dynamics?  I know it's early, but around all these pieces coming together towards some level of   \nEPS growth relative to long -range plan, and Jason hinted that you'll be below that. ", "original_text": "As we think about both the fiscal 3Q   \nnumbers and the implied fiscal 4Q guidance. "}, "hash": "f96d18d68492a7a0ada57aaba0f895d10c341505862f26bf5706f47dfe7c4af2", "class_name": "RelatedNodeInfo"}}, "text": "Mike, I want to dive in a little bit more about   \nthe comments you've made tying into next year on Medical. ", "start_char_idx": 194, "end_char_idx": 303, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b2c7d08-81ce-4ed4-8066-b9a8da216f69": {"__data__": {"id_": "3b2c7d08-81ce-4ed4-8066-b9a8da216f69", "embedding": null, "metadata": {"window": " \nPage 11 of 15 \n \nOperator:   And we'll go ahead and move on to our next question from Michael Cherny with Bank of  \nAmerica.  \n  \n Michael  Cherny:   Good morning and thanks for all the color.  Mike, I want to dive in a little bit more about   \nthe comments you've made tying into next year on Medical.  As we think about both the fiscal 3Q   \nnumbers and the implied fiscal 4Q guidance.  Is that the right annualization and jumping -off point as   \nwe think into next year?  And along those lines with the pieces that you've given us, where do you see   \nthe dynamics?  I know it's early, but around all these pieces coming together towards some level of   \nEPS growth relative to long -range plan, and Jason hinted that you'll be below that. ", "original_text": "As we think about both the fiscal 3Q   \nnumbers and the implied fiscal 4Q guidance. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "422b9354-02cd-478b-aef1-ab0f92a80564", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \nOperator:   And we'll go ahead and move on to our next question from Michael Cherny with Bank of  \nAmerica.  \n  \n Michael  Cherny:   Good morning and thanks for all the color.  Mike, I want to dive in a little bit more about   \nthe comments you've made tying into next year on Medical.  As we think about both the fiscal 3Q   \nnumbers and the implied fiscal 4Q guidance.  Is that the right annualization and jumping -off point as   \nwe think into next year?  And along those lines with the pieces that you've given us, where do you see   \nthe dynamics? ", "original_text": "Mike, I want to dive in a little bit more about   \nthe comments you've made tying into next year on Medical. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8fddef665d2aa799544533ebef2902597eed9960d82dba87cea068992830b1ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c7a6f63-c58c-46d7-aeb8-50e0388b3164", "node_type": "1", "metadata": {"window": "Michael  Cherny:   Good morning and thanks for all the color.  Mike, I want to dive in a little bit more about   \nthe comments you've made tying into next year on Medical.  As we think about both the fiscal 3Q   \nnumbers and the implied fiscal 4Q guidance.  Is that the right annualization and jumping -off point as   \nwe think into next year?  And along those lines with the pieces that you've given us, where do you see   \nthe dynamics?  I know it's early, but around all these pieces coming together towards some level of   \nEPS growth relative to long -range plan, and Jason hinted that you'll be below that.  But should we   \nexpect to see EPS growth next year?  \n \n", "original_text": "Is that the right annualization and jumping -off point as   \nwe think into next year? "}, "hash": "97203a59876de1c4e3b7106ce1dc15fe406ffeb4421db51b00ff1c549b91fb93", "class_name": "RelatedNodeInfo"}}, "text": "As we think about both the fiscal 3Q   \nnumbers and the implied fiscal 4Q guidance. ", "start_char_idx": 303, "end_char_idx": 387, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c7a6f63-c58c-46d7-aeb8-50e0388b3164": {"__data__": {"id_": "5c7a6f63-c58c-46d7-aeb8-50e0388b3164", "embedding": null, "metadata": {"window": "Michael  Cherny:   Good morning and thanks for all the color.  Mike, I want to dive in a little bit more about   \nthe comments you've made tying into next year on Medical.  As we think about both the fiscal 3Q   \nnumbers and the implied fiscal 4Q guidance.  Is that the right annualization and jumping -off point as   \nwe think into next year?  And along those lines with the pieces that you've given us, where do you see   \nthe dynamics?  I know it's early, but around all these pieces coming together towards some level of   \nEPS growth relative to long -range plan, and Jason hinted that you'll be below that.  But should we   \nexpect to see EPS growth next year?  \n \n", "original_text": "Is that the right annualization and jumping -off point as   \nwe think into next year? ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b2c7d08-81ce-4ed4-8066-b9a8da216f69", "node_type": "1", "metadata": {"window": " \nPage 11 of 15 \n \nOperator:   And we'll go ahead and move on to our next question from Michael Cherny with Bank of  \nAmerica.  \n  \n Michael  Cherny:   Good morning and thanks for all the color.  Mike, I want to dive in a little bit more about   \nthe comments you've made tying into next year on Medical.  As we think about both the fiscal 3Q   \nnumbers and the implied fiscal 4Q guidance.  Is that the right annualization and jumping -off point as   \nwe think into next year?  And along those lines with the pieces that you've given us, where do you see   \nthe dynamics?  I know it's early, but around all these pieces coming together towards some level of   \nEPS growth relative to long -range plan, and Jason hinted that you'll be below that. ", "original_text": "As we think about both the fiscal 3Q   \nnumbers and the implied fiscal 4Q guidance. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "09c3166ac37a9999b274a6a10db06202e5733ab691a24d2fb81954b76e224cb6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a156381a-4a5f-493b-a499-fc9bcfebe69c", "node_type": "1", "metadata": {"window": "Mike, I want to dive in a little bit more about   \nthe comments you've made tying into next year on Medical.  As we think about both the fiscal 3Q   \nnumbers and the implied fiscal 4Q guidance.  Is that the right annualization and jumping -off point as   \nwe think into next year?  And along those lines with the pieces that you've given us, where do you see   \nthe dynamics?  I know it's early, but around all these pieces coming together towards some level of   \nEPS growth relative to long -range plan, and Jason hinted that you'll be below that.  But should we   \nexpect to see EPS growth next year?  \n \n Jason Hollar:  Yeah. ", "original_text": "And along those lines with the pieces that you've given us, where do you see   \nthe dynamics? "}, "hash": "72cdb3bace8eb109066ae709776de97dc8dbc3b123494cae7fdc64ffe8dda694", "class_name": "RelatedNodeInfo"}}, "text": "Is that the right annualization and jumping -off point as   \nwe think into next year? ", "start_char_idx": 387, "end_char_idx": 473, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a156381a-4a5f-493b-a499-fc9bcfebe69c": {"__data__": {"id_": "a156381a-4a5f-493b-a499-fc9bcfebe69c", "embedding": null, "metadata": {"window": "Mike, I want to dive in a little bit more about   \nthe comments you've made tying into next year on Medical.  As we think about both the fiscal 3Q   \nnumbers and the implied fiscal 4Q guidance.  Is that the right annualization and jumping -off point as   \nwe think into next year?  And along those lines with the pieces that you've given us, where do you see   \nthe dynamics?  I know it's early, but around all these pieces coming together towards some level of   \nEPS growth relative to long -range plan, and Jason hinted that you'll be below that.  But should we   \nexpect to see EPS growth next year?  \n \n Jason Hollar:  Yeah. ", "original_text": "And along those lines with the pieces that you've given us, where do you see   \nthe dynamics? ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c7a6f63-c58c-46d7-aeb8-50e0388b3164", "node_type": "1", "metadata": {"window": "Michael  Cherny:   Good morning and thanks for all the color.  Mike, I want to dive in a little bit more about   \nthe comments you've made tying into next year on Medical.  As we think about both the fiscal 3Q   \nnumbers and the implied fiscal 4Q guidance.  Is that the right annualization and jumping -off point as   \nwe think into next year?  And along those lines with the pieces that you've given us, where do you see   \nthe dynamics?  I know it's early, but around all these pieces coming together towards some level of   \nEPS growth relative to long -range plan, and Jason hinted that you'll be below that.  But should we   \nexpect to see EPS growth next year?  \n \n", "original_text": "Is that the right annualization and jumping -off point as   \nwe think into next year? ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91b4fd38cfc155381ee2fcdedfeb7faf0206eea54e4704d06258b56154306375", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74b8f877-0c7b-414a-9e26-b0e65c7c5f39", "node_type": "1", "metadata": {"window": "As we think about both the fiscal 3Q   \nnumbers and the implied fiscal 4Q guidance.  Is that the right annualization and jumping -off point as   \nwe think into next year?  And along those lines with the pieces that you've given us, where do you see   \nthe dynamics?  I know it's early, but around all these pieces coming together towards some level of   \nEPS growth relative to long -range plan, and Jason hinted that you'll be below that.  But should we   \nexpect to see EPS growth next year?  \n \n Jason Hollar:  Yeah.  Le t me start with that. ", "original_text": "I know it's early, but around all these pieces coming together towards some level of   \nEPS growth relative to long -range plan, and Jason hinted that you'll be below that. "}, "hash": "01c444f321e78dcee395a559e905301ea8fe1ee102ec6be2e7c68ce998cac64c", "class_name": "RelatedNodeInfo"}}, "text": "And along those lines with the pieces that you've given us, where do you see   \nthe dynamics? ", "start_char_idx": 473, "end_char_idx": 567, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74b8f877-0c7b-414a-9e26-b0e65c7c5f39": {"__data__": {"id_": "74b8f877-0c7b-414a-9e26-b0e65c7c5f39", "embedding": null, "metadata": {"window": "As we think about both the fiscal 3Q   \nnumbers and the implied fiscal 4Q guidance.  Is that the right annualization and jumping -off point as   \nwe think into next year?  And along those lines with the pieces that you've given us, where do you see   \nthe dynamics?  I know it's early, but around all these pieces coming together towards some level of   \nEPS growth relative to long -range plan, and Jason hinted that you'll be below that.  But should we   \nexpect to see EPS growth next year?  \n \n Jason Hollar:  Yeah.  Le t me start with that. ", "original_text": "I know it's early, but around all these pieces coming together towards some level of   \nEPS growth relative to long -range plan, and Jason hinted that you'll be below that. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a156381a-4a5f-493b-a499-fc9bcfebe69c", "node_type": "1", "metadata": {"window": "Mike, I want to dive in a little bit more about   \nthe comments you've made tying into next year on Medical.  As we think about both the fiscal 3Q   \nnumbers and the implied fiscal 4Q guidance.  Is that the right annualization and jumping -off point as   \nwe think into next year?  And along those lines with the pieces that you've given us, where do you see   \nthe dynamics?  I know it's early, but around all these pieces coming together towards some level of   \nEPS growth relative to long -range plan, and Jason hinted that you'll be below that.  But should we   \nexpect to see EPS growth next year?  \n \n Jason Hollar:  Yeah. ", "original_text": "And along those lines with the pieces that you've given us, where do you see   \nthe dynamics? ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ade457139c339c9b75b2dc75a6a030539f026a533fa3c30582dc54398abcdda", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ffe41b8-e1ba-4920-80c9-7e8d33b5ca76", "node_type": "1", "metadata": {"window": "Is that the right annualization and jumping -off point as   \nwe think into next year?  And along those lines with the pieces that you've given us, where do you see   \nthe dynamics?  I know it's early, but around all these pieces coming together towards some level of   \nEPS growth relative to long -range plan, and Jason hinted that you'll be below that.  But should we   \nexpect to see EPS growth next year?  \n \n Jason Hollar:  Yeah.  Le t me start with that.  This is Jason. ", "original_text": "But should we   \nexpect to see EPS growth next year?  \n \n"}, "hash": "44ce560d5d2f23f249acd26c91337784f0bd1cc7b50113cbcc88b9e6c24998df", "class_name": "RelatedNodeInfo"}}, "text": "I know it's early, but around all these pieces coming together towards some level of   \nEPS growth relative to long -range plan, and Jason hinted that you'll be below that. ", "start_char_idx": 567, "end_char_idx": 740, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ffe41b8-e1ba-4920-80c9-7e8d33b5ca76": {"__data__": {"id_": "0ffe41b8-e1ba-4920-80c9-7e8d33b5ca76", "embedding": null, "metadata": {"window": "Is that the right annualization and jumping -off point as   \nwe think into next year?  And along those lines with the pieces that you've given us, where do you see   \nthe dynamics?  I know it's early, but around all these pieces coming together towards some level of   \nEPS growth relative to long -range plan, and Jason hinted that you'll be below that.  But should we   \nexpect to see EPS growth next year?  \n \n Jason Hollar:  Yeah.  Le t me start with that.  This is Jason. ", "original_text": "But should we   \nexpect to see EPS growth next year?  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74b8f877-0c7b-414a-9e26-b0e65c7c5f39", "node_type": "1", "metadata": {"window": "As we think about both the fiscal 3Q   \nnumbers and the implied fiscal 4Q guidance.  Is that the right annualization and jumping -off point as   \nwe think into next year?  And along those lines with the pieces that you've given us, where do you see   \nthe dynamics?  I know it's early, but around all these pieces coming together towards some level of   \nEPS growth relative to long -range plan, and Jason hinted that you'll be below that.  But should we   \nexpect to see EPS growth next year?  \n \n Jason Hollar:  Yeah.  Le t me start with that. ", "original_text": "I know it's early, but around all these pieces coming together towards some level of   \nEPS growth relative to long -range plan, and Jason hinted that you'll be below that. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "47a279ff3b52a652e7ce3a9f8793cac8120f3464e0f8a036b5571714687ba18a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28c33c24-5e65-43ea-b4b2-151b9d68ebd1", "node_type": "1", "metadata": {"window": "And along those lines with the pieces that you've given us, where do you see   \nthe dynamics?  I know it's early, but around all these pieces coming together towards some level of   \nEPS growth relative to long -range plan, and Jason hinted that you'll be below that.  But should we   \nexpect to see EPS growth next year?  \n \n Jason Hollar:  Yeah.  Le t me start with that.  This is Jason.  The \u201823 elements that we're providing here   \nfor Medical entirely focused on the inflation component. ", "original_text": "Jason Hollar:  Yeah. "}, "hash": "bedfd57b54f4a767f82913a3dbff1dce3968c64586f26cf1801084ccd6a96805", "class_name": "RelatedNodeInfo"}}, "text": "But should we   \nexpect to see EPS growth next year?  \n \n", "start_char_idx": 740, "end_char_idx": 797, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28c33c24-5e65-43ea-b4b2-151b9d68ebd1": {"__data__": {"id_": "28c33c24-5e65-43ea-b4b2-151b9d68ebd1", "embedding": null, "metadata": {"window": "And along those lines with the pieces that you've given us, where do you see   \nthe dynamics?  I know it's early, but around all these pieces coming together towards some level of   \nEPS growth relative to long -range plan, and Jason hinted that you'll be below that.  But should we   \nexpect to see EPS growth next year?  \n \n Jason Hollar:  Yeah.  Le t me start with that.  This is Jason.  The \u201823 elements that we're providing here   \nfor Medical entirely focused on the inflation component. ", "original_text": "Jason Hollar:  Yeah. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ffe41b8-e1ba-4920-80c9-7e8d33b5ca76", "node_type": "1", "metadata": {"window": "Is that the right annualization and jumping -off point as   \nwe think into next year?  And along those lines with the pieces that you've given us, where do you see   \nthe dynamics?  I know it's early, but around all these pieces coming together towards some level of   \nEPS growth relative to long -range plan, and Jason hinted that you'll be below that.  But should we   \nexpect to see EPS growth next year?  \n \n Jason Hollar:  Yeah.  Le t me start with that.  This is Jason. ", "original_text": "But should we   \nexpect to see EPS growth next year?  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b4b8533c912b626cbe2a1fa0f88982281c970f1bee2e662478d91e6762744687", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e05a909c-8f10-4495-a4c1-469c17a9ff50", "node_type": "1", "metadata": {"window": "I know it's early, but around all these pieces coming together towards some level of   \nEPS growth relative to long -range plan, and Jason hinted that you'll be below that.  But should we   \nexpect to see EPS growth next year?  \n \n Jason Hollar:  Yeah.  Le t me start with that.  This is Jason.  The \u201823 elements that we're providing here   \nfor Medical entirely focused on the inflation component.  That is clearly going to be the most significant   \nitem that we are focused on for both the current year, and what we k now will impact us this next year.   \n", "original_text": "Le t me start with that. "}, "hash": "2fb7f0ad42540cc96314e578b2873038dbcb41ffa9aad1c2e0e39b5b560344cb", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yeah. ", "start_char_idx": 797, "end_char_idx": 818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e05a909c-8f10-4495-a4c1-469c17a9ff50": {"__data__": {"id_": "e05a909c-8f10-4495-a4c1-469c17a9ff50", "embedding": null, "metadata": {"window": "I know it's early, but around all these pieces coming together towards some level of   \nEPS growth relative to long -range plan, and Jason hinted that you'll be below that.  But should we   \nexpect to see EPS growth next year?  \n \n Jason Hollar:  Yeah.  Le t me start with that.  This is Jason.  The \u201823 elements that we're providing here   \nfor Medical entirely focused on the inflation component.  That is clearly going to be the most significant   \nitem that we are focused on for both the current year, and what we k now will impact us this next year.   \n", "original_text": "Le t me start with that. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28c33c24-5e65-43ea-b4b2-151b9d68ebd1", "node_type": "1", "metadata": {"window": "And along those lines with the pieces that you've given us, where do you see   \nthe dynamics?  I know it's early, but around all these pieces coming together towards some level of   \nEPS growth relative to long -range plan, and Jason hinted that you'll be below that.  But should we   \nexpect to see EPS growth next year?  \n \n Jason Hollar:  Yeah.  Le t me start with that.  This is Jason.  The \u201823 elements that we're providing here   \nfor Medical entirely focused on the inflation component. ", "original_text": "Jason Hollar:  Yeah. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "17a3b664577ca5008e8032124ea254609fe018e62fc60ba5391c0bdca1c42b16", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e21d02c-a8d9-49c4-adcf-a98b909b628f", "node_type": "1", "metadata": {"window": "But should we   \nexpect to see EPS growth next year?  \n \n Jason Hollar:  Yeah.  Le t me start with that.  This is Jason.  The \u201823 elements that we're providing here   \nfor Medical entirely focused on the inflation component.  That is clearly going to be the most significant   \nitem that we are focused on for both the current year, and what we k now will impact us this next year.   \n We have not this is not a full comprehensive guidance and this is not meant to be complete with all the   \nmoving pieces. ", "original_text": "This is Jason. "}, "hash": "35344e6c318e399e43f34733acf38d3f8e9e9afe6f4a4fd98b3fe644061db673", "class_name": "RelatedNodeInfo"}}, "text": "Le t me start with that. ", "start_char_idx": 818, "end_char_idx": 843, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e21d02c-a8d9-49c4-adcf-a98b909b628f": {"__data__": {"id_": "3e21d02c-a8d9-49c4-adcf-a98b909b628f", "embedding": null, "metadata": {"window": "But should we   \nexpect to see EPS growth next year?  \n \n Jason Hollar:  Yeah.  Le t me start with that.  This is Jason.  The \u201823 elements that we're providing here   \nfor Medical entirely focused on the inflation component.  That is clearly going to be the most significant   \nitem that we are focused on for both the current year, and what we k now will impact us this next year.   \n We have not this is not a full comprehensive guidance and this is not meant to be complete with all the   \nmoving pieces. ", "original_text": "This is Jason. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e05a909c-8f10-4495-a4c1-469c17a9ff50", "node_type": "1", "metadata": {"window": "I know it's early, but around all these pieces coming together towards some level of   \nEPS growth relative to long -range plan, and Jason hinted that you'll be below that.  But should we   \nexpect to see EPS growth next year?  \n \n Jason Hollar:  Yeah.  Le t me start with that.  This is Jason.  The \u201823 elements that we're providing here   \nfor Medical entirely focused on the inflation component.  That is clearly going to be the most significant   \nitem that we are focused on for both the current year, and what we k now will impact us this next year.   \n", "original_text": "Le t me start with that. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "62db724343947a9ae3979c15b2f4544db271dff4d819ac5c5cfb5028909af305", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ca8a54f2-824d-46a2-8f03-b6eae2365977", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah.  Le t me start with that.  This is Jason.  The \u201823 elements that we're providing here   \nfor Medical entirely focused on the inflation component.  That is clearly going to be the most significant   \nitem that we are focused on for both the current year, and what we k now will impact us this next year.   \n We have not this is not a full comprehensive guidance and this is not meant to be complete with all the   \nmoving pieces.  As Mike indicated, we're very focused on all those growth businesses that he   \nmentioned. ", "original_text": "The \u201823 elements that we're providing here   \nfor Medical entirely focused on the inflation component. "}, "hash": "51c5309a0138b6bb2cdd29541443adad12508ed4c0f0744e37b17a24b339be84", "class_name": "RelatedNodeInfo"}}, "text": "This is Jason. ", "start_char_idx": 843, "end_char_idx": 858, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ca8a54f2-824d-46a2-8f03-b6eae2365977": {"__data__": {"id_": "ca8a54f2-824d-46a2-8f03-b6eae2365977", "embedding": null, "metadata": {"window": "Jason Hollar:  Yeah.  Le t me start with that.  This is Jason.  The \u201823 elements that we're providing here   \nfor Medical entirely focused on the inflation component.  That is clearly going to be the most significant   \nitem that we are focused on for both the current year, and what we k now will impact us this next year.   \n We have not this is not a full comprehensive guidance and this is not meant to be complete with all the   \nmoving pieces.  As Mike indicated, we're very focused on all those growth businesses that he   \nmentioned. ", "original_text": "The \u201823 elements that we're providing here   \nfor Medical entirely focused on the inflation component. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e21d02c-a8d9-49c4-adcf-a98b909b628f", "node_type": "1", "metadata": {"window": "But should we   \nexpect to see EPS growth next year?  \n \n Jason Hollar:  Yeah.  Le t me start with that.  This is Jason.  The \u201823 elements that we're providing here   \nfor Medical entirely focused on the inflation component.  That is clearly going to be the most significant   \nitem that we are focused on for both the current year, and what we k now will impact us this next year.   \n We have not this is not a full comprehensive guidance and this is not meant to be complete with all the   \nmoving pieces. ", "original_text": "This is Jason. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a1f2a84e57a2550bb603918ec068f93b3c3acec4840af3e39eb1eaf692280f47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "716cd97c-bcd7-4cc0-8bb1-88269b7d2b1c", "node_type": "1", "metadata": {"window": "Le t me start with that.  This is Jason.  The \u201823 elements that we're providing here   \nfor Medical entirely focused on the inflation component.  That is clearly going to be the most significant   \nitem that we are focused on for both the current year, and what we k now will impact us this next year.   \n We have not this is not a full comprehensive guidance and this is not meant to be complete with all the   \nmoving pieces.  As Mike indicated, we're very focused on all those growth businesses that he   \nmentioned.  There's going to be other operational elements that will be working through and then we'll   \nprovide more color on. ", "original_text": "That is clearly going to be the most significant   \nitem that we are focused on for both the current year, and what we k now will impact us this next year.   \n"}, "hash": "bee2db66713d4fb57c0c6d66d36f9191a1ccb038cae34ee5e573e150e3799ccd", "class_name": "RelatedNodeInfo"}}, "text": "The \u201823 elements that we're providing here   \nfor Medical entirely focused on the inflation component. ", "start_char_idx": 858, "end_char_idx": 961, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "716cd97c-bcd7-4cc0-8bb1-88269b7d2b1c": {"__data__": {"id_": "716cd97c-bcd7-4cc0-8bb1-88269b7d2b1c", "embedding": null, "metadata": {"window": "Le t me start with that.  This is Jason.  The \u201823 elements that we're providing here   \nfor Medical entirely focused on the inflation component.  That is clearly going to be the most significant   \nitem that we are focused on for both the current year, and what we k now will impact us this next year.   \n We have not this is not a full comprehensive guidance and this is not meant to be complete with all the   \nmoving pieces.  As Mike indicated, we're very focused on all those growth businesses that he   \nmentioned.  There's going to be other operational elements that will be working through and then we'll   \nprovide more color on. ", "original_text": "That is clearly going to be the most significant   \nitem that we are focused on for both the current year, and what we k now will impact us this next year.   \n", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ca8a54f2-824d-46a2-8f03-b6eae2365977", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah.  Le t me start with that.  This is Jason.  The \u201823 elements that we're providing here   \nfor Medical entirely focused on the inflation component.  That is clearly going to be the most significant   \nitem that we are focused on for both the current year, and what we k now will impact us this next year.   \n We have not this is not a full comprehensive guidance and this is not meant to be complete with all the   \nmoving pieces.  As Mike indicated, we're very focused on all those growth businesses that he   \nmentioned. ", "original_text": "The \u201823 elements that we're providing here   \nfor Medical entirely focused on the inflation component. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2ce2d2cabec3a544c8ba054112e79452fecf3cfcbfa09d00dc3fa58a86c8f799", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "465ab7e2-da12-4d9b-9ed8-9b430266c3d4", "node_type": "1", "metadata": {"window": "This is Jason.  The \u201823 elements that we're providing here   \nfor Medical entirely focused on the inflation component.  That is clearly going to be the most significant   \nitem that we are focused on for both the current year, and what we k now will impact us this next year.   \n We have not this is not a full comprehensive guidance and this is not meant to be complete with all the   \nmoving pieces.  As Mike indicated, we're very focused on all those growth businesses that he   \nmentioned.  There's going to be other operational elements that will be working through and then we'll   \nprovide more color on.  As it relates to inflation that $300 million impact this year is by far the most   \nsignificant item. ", "original_text": "We have not this is not a full comprehensive guidance and this is not meant to be complete with all the   \nmoving pieces. "}, "hash": "24972e95e393cd668aa172692969494e9f6d9ebd365defa0b45d4ff80ef37134", "class_name": "RelatedNodeInfo"}}, "text": "That is clearly going to be the most significant   \nitem that we are focused on for both the current year, and what we k now will impact us this next year.   \n", "start_char_idx": 961, "end_char_idx": 1120, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "465ab7e2-da12-4d9b-9ed8-9b430266c3d4": {"__data__": {"id_": "465ab7e2-da12-4d9b-9ed8-9b430266c3d4", "embedding": null, "metadata": {"window": "This is Jason.  The \u201823 elements that we're providing here   \nfor Medical entirely focused on the inflation component.  That is clearly going to be the most significant   \nitem that we are focused on for both the current year, and what we k now will impact us this next year.   \n We have not this is not a full comprehensive guidance and this is not meant to be complete with all the   \nmoving pieces.  As Mike indicated, we're very focused on all those growth businesses that he   \nmentioned.  There's going to be other operational elements that will be working through and then we'll   \nprovide more color on.  As it relates to inflation that $300 million impact this year is by far the most   \nsignificant item. ", "original_text": "We have not this is not a full comprehensive guidance and this is not meant to be complete with all the   \nmoving pieces. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "716cd97c-bcd7-4cc0-8bb1-88269b7d2b1c", "node_type": "1", "metadata": {"window": "Le t me start with that.  This is Jason.  The \u201823 elements that we're providing here   \nfor Medical entirely focused on the inflation component.  That is clearly going to be the most significant   \nitem that we are focused on for both the current year, and what we k now will impact us this next year.   \n We have not this is not a full comprehensive guidance and this is not meant to be complete with all the   \nmoving pieces.  As Mike indicated, we're very focused on all those growth businesses that he   \nmentioned.  There's going to be other operational elements that will be working through and then we'll   \nprovide more color on. ", "original_text": "That is clearly going to be the most significant   \nitem that we are focused on for both the current year, and what we k now will impact us this next year.   \n", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91f5746acb485d7b57c917c693eaa6b0e3ff457bb5f0ddc15fd962b997e79461", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15b8292b-eecc-4beb-9cca-29efc31e5519", "node_type": "1", "metadata": {"window": "The \u201823 elements that we're providing here   \nfor Medical entirely focused on the inflation component.  That is clearly going to be the most significant   \nitem that we are focused on for both the current year, and what we k now will impact us this next year.   \n We have not this is not a full comprehensive guidance and this is not meant to be complete with all the   \nmoving pieces.  As Mike indicated, we're very focused on all those growth businesses that he   \nmentioned.  There's going to be other operational elements that will be working through and then we'll   \nprovide more color on.  As it relates to inflation that $300 million impact this year is by far the most   \nsignificant item.  And when we think about our long -term tar gets, the reason we use the phrase   \nnormalized, is items like that $300 million do need to be adjusted, but as it relates to other moving   \npieces for fiscal \u201823, that will come at our normal guidance update next quarter.  \n \n", "original_text": "As Mike indicated, we're very focused on all those growth businesses that he   \nmentioned. "}, "hash": "ba5bc2c561d03f3559157865c0065ad35bc4c0e8686934d0fce6b2c9229d6d20", "class_name": "RelatedNodeInfo"}}, "text": "We have not this is not a full comprehensive guidance and this is not meant to be complete with all the   \nmoving pieces. ", "start_char_idx": 1120, "end_char_idx": 1242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15b8292b-eecc-4beb-9cca-29efc31e5519": {"__data__": {"id_": "15b8292b-eecc-4beb-9cca-29efc31e5519", "embedding": null, "metadata": {"window": "The \u201823 elements that we're providing here   \nfor Medical entirely focused on the inflation component.  That is clearly going to be the most significant   \nitem that we are focused on for both the current year, and what we k now will impact us this next year.   \n We have not this is not a full comprehensive guidance and this is not meant to be complete with all the   \nmoving pieces.  As Mike indicated, we're very focused on all those growth businesses that he   \nmentioned.  There's going to be other operational elements that will be working through and then we'll   \nprovide more color on.  As it relates to inflation that $300 million impact this year is by far the most   \nsignificant item.  And when we think about our long -term tar gets, the reason we use the phrase   \nnormalized, is items like that $300 million do need to be adjusted, but as it relates to other moving   \npieces for fiscal \u201823, that will come at our normal guidance update next quarter.  \n \n", "original_text": "As Mike indicated, we're very focused on all those growth businesses that he   \nmentioned. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "465ab7e2-da12-4d9b-9ed8-9b430266c3d4", "node_type": "1", "metadata": {"window": "This is Jason.  The \u201823 elements that we're providing here   \nfor Medical entirely focused on the inflation component.  That is clearly going to be the most significant   \nitem that we are focused on for both the current year, and what we k now will impact us this next year.   \n We have not this is not a full comprehensive guidance and this is not meant to be complete with all the   \nmoving pieces.  As Mike indicated, we're very focused on all those growth businesses that he   \nmentioned.  There's going to be other operational elements that will be working through and then we'll   \nprovide more color on.  As it relates to inflation that $300 million impact this year is by far the most   \nsignificant item. ", "original_text": "We have not this is not a full comprehensive guidance and this is not meant to be complete with all the   \nmoving pieces. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "96aac0b86fb6765d5933401d662ad26c5476e7dd41b8532fa139dc21146bf6e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "699fbec6-74c2-4db0-ab4c-558a956363bd", "node_type": "1", "metadata": {"window": "That is clearly going to be the most significant   \nitem that we are focused on for both the current year, and what we k now will impact us this next year.   \n We have not this is not a full comprehensive guidance and this is not meant to be complete with all the   \nmoving pieces.  As Mike indicated, we're very focused on all those growth businesses that he   \nmentioned.  There's going to be other operational elements that will be working through and then we'll   \nprovide more color on.  As it relates to inflation that $300 million impact this year is by far the most   \nsignificant item.  And when we think about our long -term tar gets, the reason we use the phrase   \nnormalized, is items like that $300 million do need to be adjusted, but as it relates to other moving   \npieces for fiscal \u201823, that will come at our normal guidance update next quarter.  \n \n Operator :  All right. ", "original_text": "There's going to be other operational elements that will be working through and then we'll   \nprovide more color on. "}, "hash": "84ab2caff2afa7a5b7292cb66d5907bad17f063f38c668ae67074cc673512ae1", "class_name": "RelatedNodeInfo"}}, "text": "As Mike indicated, we're very focused on all those growth businesses that he   \nmentioned. ", "start_char_idx": 1242, "end_char_idx": 1333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "699fbec6-74c2-4db0-ab4c-558a956363bd": {"__data__": {"id_": "699fbec6-74c2-4db0-ab4c-558a956363bd", "embedding": null, "metadata": {"window": "That is clearly going to be the most significant   \nitem that we are focused on for both the current year, and what we k now will impact us this next year.   \n We have not this is not a full comprehensive guidance and this is not meant to be complete with all the   \nmoving pieces.  As Mike indicated, we're very focused on all those growth businesses that he   \nmentioned.  There's going to be other operational elements that will be working through and then we'll   \nprovide more color on.  As it relates to inflation that $300 million impact this year is by far the most   \nsignificant item.  And when we think about our long -term tar gets, the reason we use the phrase   \nnormalized, is items like that $300 million do need to be adjusted, but as it relates to other moving   \npieces for fiscal \u201823, that will come at our normal guidance update next quarter.  \n \n Operator :  All right. ", "original_text": "There's going to be other operational elements that will be working through and then we'll   \nprovide more color on. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15b8292b-eecc-4beb-9cca-29efc31e5519", "node_type": "1", "metadata": {"window": "The \u201823 elements that we're providing here   \nfor Medical entirely focused on the inflation component.  That is clearly going to be the most significant   \nitem that we are focused on for both the current year, and what we k now will impact us this next year.   \n We have not this is not a full comprehensive guidance and this is not meant to be complete with all the   \nmoving pieces.  As Mike indicated, we're very focused on all those growth businesses that he   \nmentioned.  There's going to be other operational elements that will be working through and then we'll   \nprovide more color on.  As it relates to inflation that $300 million impact this year is by far the most   \nsignificant item.  And when we think about our long -term tar gets, the reason we use the phrase   \nnormalized, is items like that $300 million do need to be adjusted, but as it relates to other moving   \npieces for fiscal \u201823, that will come at our normal guidance update next quarter.  \n \n", "original_text": "As Mike indicated, we're very focused on all those growth businesses that he   \nmentioned. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e9013e314d9a9a95b833a7e013909cbbcda8245885462737c4b6469a862528a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0cc5ec4f-0e43-4919-92a4-b2582c161aa7", "node_type": "1", "metadata": {"window": "We have not this is not a full comprehensive guidance and this is not meant to be complete with all the   \nmoving pieces.  As Mike indicated, we're very focused on all those growth businesses that he   \nmentioned.  There's going to be other operational elements that will be working through and then we'll   \nprovide more color on.  As it relates to inflation that $300 million impact this year is by far the most   \nsignificant item.  And when we think about our long -term tar gets, the reason we use the phrase   \nnormalized, is items like that $300 million do need to be adjusted, but as it relates to other moving   \npieces for fiscal \u201823, that will come at our normal guidance update next quarter.  \n \n Operator :  All right.  We'll go ah ead and take our next question from Lisa Gill, JP Morgan.  \n \n", "original_text": "As it relates to inflation that $300 million impact this year is by far the most   \nsignificant item. "}, "hash": "68639b53bace53ae0b9d465e3e3464ea0fd2e617fb4f4e5ba2a43194d47b7e9f", "class_name": "RelatedNodeInfo"}}, "text": "There's going to be other operational elements that will be working through and then we'll   \nprovide more color on. ", "start_char_idx": 1333, "end_char_idx": 1450, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0cc5ec4f-0e43-4919-92a4-b2582c161aa7": {"__data__": {"id_": "0cc5ec4f-0e43-4919-92a4-b2582c161aa7", "embedding": null, "metadata": {"window": "We have not this is not a full comprehensive guidance and this is not meant to be complete with all the   \nmoving pieces.  As Mike indicated, we're very focused on all those growth businesses that he   \nmentioned.  There's going to be other operational elements that will be working through and then we'll   \nprovide more color on.  As it relates to inflation that $300 million impact this year is by far the most   \nsignificant item.  And when we think about our long -term tar gets, the reason we use the phrase   \nnormalized, is items like that $300 million do need to be adjusted, but as it relates to other moving   \npieces for fiscal \u201823, that will come at our normal guidance update next quarter.  \n \n Operator :  All right.  We'll go ah ead and take our next question from Lisa Gill, JP Morgan.  \n \n", "original_text": "As it relates to inflation that $300 million impact this year is by far the most   \nsignificant item. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "699fbec6-74c2-4db0-ab4c-558a956363bd", "node_type": "1", "metadata": {"window": "That is clearly going to be the most significant   \nitem that we are focused on for both the current year, and what we k now will impact us this next year.   \n We have not this is not a full comprehensive guidance and this is not meant to be complete with all the   \nmoving pieces.  As Mike indicated, we're very focused on all those growth businesses that he   \nmentioned.  There's going to be other operational elements that will be working through and then we'll   \nprovide more color on.  As it relates to inflation that $300 million impact this year is by far the most   \nsignificant item.  And when we think about our long -term tar gets, the reason we use the phrase   \nnormalized, is items like that $300 million do need to be adjusted, but as it relates to other moving   \npieces for fiscal \u201823, that will come at our normal guidance update next quarter.  \n \n Operator :  All right. ", "original_text": "There's going to be other operational elements that will be working through and then we'll   \nprovide more color on. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ad8f27a19f370f8792e7d3883558f987c36e74a5f4dd7b62c412b8e0ac1ffea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "df2a1ffb-4383-412a-9275-79575a2cf97f", "node_type": "1", "metadata": {"window": "As Mike indicated, we're very focused on all those growth businesses that he   \nmentioned.  There's going to be other operational elements that will be working through and then we'll   \nprovide more color on.  As it relates to inflation that $300 million impact this year is by far the most   \nsignificant item.  And when we think about our long -term tar gets, the reason we use the phrase   \nnormalized, is items like that $300 million do need to be adjusted, but as it relates to other moving   \npieces for fiscal \u201823, that will come at our normal guidance update next quarter.  \n \n Operator :  All right.  We'll go ah ead and take our next question from Lisa Gill, JP Morgan.  \n \n Lisa Gill:  Thanks very much. ", "original_text": "And when we think about our long -term tar gets, the reason we use the phrase   \nnormalized, is items like that $300 million do need to be adjusted, but as it relates to other moving   \npieces for fiscal \u201823, that will come at our normal guidance update next quarter.  \n \n"}, "hash": "aec5d5243e70cde09977862030ec6b131de135a1621ed61184e0d76f72a4cc42", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to inflation that $300 million impact this year is by far the most   \nsignificant item. ", "start_char_idx": 1450, "end_char_idx": 1552, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "df2a1ffb-4383-412a-9275-79575a2cf97f": {"__data__": {"id_": "df2a1ffb-4383-412a-9275-79575a2cf97f", "embedding": null, "metadata": {"window": "As Mike indicated, we're very focused on all those growth businesses that he   \nmentioned.  There's going to be other operational elements that will be working through and then we'll   \nprovide more color on.  As it relates to inflation that $300 million impact this year is by far the most   \nsignificant item.  And when we think about our long -term tar gets, the reason we use the phrase   \nnormalized, is items like that $300 million do need to be adjusted, but as it relates to other moving   \npieces for fiscal \u201823, that will come at our normal guidance update next quarter.  \n \n Operator :  All right.  We'll go ah ead and take our next question from Lisa Gill, JP Morgan.  \n \n Lisa Gill:  Thanks very much. ", "original_text": "And when we think about our long -term tar gets, the reason we use the phrase   \nnormalized, is items like that $300 million do need to be adjusted, but as it relates to other moving   \npieces for fiscal \u201823, that will come at our normal guidance update next quarter.  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0cc5ec4f-0e43-4919-92a4-b2582c161aa7", "node_type": "1", "metadata": {"window": "We have not this is not a full comprehensive guidance and this is not meant to be complete with all the   \nmoving pieces.  As Mike indicated, we're very focused on all those growth businesses that he   \nmentioned.  There's going to be other operational elements that will be working through and then we'll   \nprovide more color on.  As it relates to inflation that $300 million impact this year is by far the most   \nsignificant item.  And when we think about our long -term tar gets, the reason we use the phrase   \nnormalized, is items like that $300 million do need to be adjusted, but as it relates to other moving   \npieces for fiscal \u201823, that will come at our normal guidance update next quarter.  \n \n Operator :  All right.  We'll go ah ead and take our next question from Lisa Gill, JP Morgan.  \n \n", "original_text": "As it relates to inflation that $300 million impact this year is by far the most   \nsignificant item. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91361e114e76dad98f89d2cc4272022e6da720287df2813d39bce68d63d682fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45c48ff7-ba8c-4ffa-babb-e79cc693a7e7", "node_type": "1", "metadata": {"window": "There's going to be other operational elements that will be working through and then we'll   \nprovide more color on.  As it relates to inflation that $300 million impact this year is by far the most   \nsignificant item.  And when we think about our long -term tar gets, the reason we use the phrase   \nnormalized, is items like that $300 million do need to be adjusted, but as it relates to other moving   \npieces for fiscal \u201823, that will come at our normal guidance update next quarter.  \n \n Operator :  All right.  We'll go ah ead and take our next question from Lisa Gill, JP Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning. ", "original_text": "Operator :  All right. "}, "hash": "fe4e999aa6a6c9811f423dd2d4917c12558be13fbd1e1efc3911225074aac853", "class_name": "RelatedNodeInfo"}}, "text": "And when we think about our long -term tar gets, the reason we use the phrase   \nnormalized, is items like that $300 million do need to be adjusted, but as it relates to other moving   \npieces for fiscal \u201823, that will come at our normal guidance update next quarter.  \n \n", "start_char_idx": 1552, "end_char_idx": 1824, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45c48ff7-ba8c-4ffa-babb-e79cc693a7e7": {"__data__": {"id_": "45c48ff7-ba8c-4ffa-babb-e79cc693a7e7", "embedding": null, "metadata": {"window": "There's going to be other operational elements that will be working through and then we'll   \nprovide more color on.  As it relates to inflation that $300 million impact this year is by far the most   \nsignificant item.  And when we think about our long -term tar gets, the reason we use the phrase   \nnormalized, is items like that $300 million do need to be adjusted, but as it relates to other moving   \npieces for fiscal \u201823, that will come at our normal guidance update next quarter.  \n \n Operator :  All right.  We'll go ah ead and take our next question from Lisa Gill, JP Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning. ", "original_text": "Operator :  All right. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "df2a1ffb-4383-412a-9275-79575a2cf97f", "node_type": "1", "metadata": {"window": "As Mike indicated, we're very focused on all those growth businesses that he   \nmentioned.  There's going to be other operational elements that will be working through and then we'll   \nprovide more color on.  As it relates to inflation that $300 million impact this year is by far the most   \nsignificant item.  And when we think about our long -term tar gets, the reason we use the phrase   \nnormalized, is items like that $300 million do need to be adjusted, but as it relates to other moving   \npieces for fiscal \u201823, that will come at our normal guidance update next quarter.  \n \n Operator :  All right.  We'll go ah ead and take our next question from Lisa Gill, JP Morgan.  \n \n Lisa Gill:  Thanks very much. ", "original_text": "And when we think about our long -term tar gets, the reason we use the phrase   \nnormalized, is items like that $300 million do need to be adjusted, but as it relates to other moving   \npieces for fiscal \u201823, that will come at our normal guidance update next quarter.  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "73027908cbf9ce600db855d8694ee2d60b6804b8ca5bd8d90a915a150486efc4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e34b61b-14bf-4ceb-8a40-a361298bd6b5", "node_type": "1", "metadata": {"window": "As it relates to inflation that $300 million impact this year is by far the most   \nsignificant item.  And when we think about our long -term tar gets, the reason we use the phrase   \nnormalized, is items like that $300 million do need to be adjusted, but as it relates to other moving   \npieces for fiscal \u201823, that will come at our normal guidance update next quarter.  \n \n Operator :  All right.  We'll go ah ead and take our next question from Lisa Gill, JP Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning.  Staying on the medical supply side of the business, I just  \nwant to better understand just a couple of things. ", "original_text": "We'll go ah ead and take our next question from Lisa Gill, JP Morgan.  \n \n"}, "hash": "6cf18cdad80603643453a2a08666a2c863f0ff7f8874dce8fc5b915cd8d47040", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  All right. ", "start_char_idx": 1824, "end_char_idx": 1847, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e34b61b-14bf-4ceb-8a40-a361298bd6b5": {"__data__": {"id_": "3e34b61b-14bf-4ceb-8a40-a361298bd6b5", "embedding": null, "metadata": {"window": "As it relates to inflation that $300 million impact this year is by far the most   \nsignificant item.  And when we think about our long -term tar gets, the reason we use the phrase   \nnormalized, is items like that $300 million do need to be adjusted, but as it relates to other moving   \npieces for fiscal \u201823, that will come at our normal guidance update next quarter.  \n \n Operator :  All right.  We'll go ah ead and take our next question from Lisa Gill, JP Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning.  Staying on the medical supply side of the business, I just  \nwant to better understand just a couple of things. ", "original_text": "We'll go ah ead and take our next question from Lisa Gill, JP Morgan.  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45c48ff7-ba8c-4ffa-babb-e79cc693a7e7", "node_type": "1", "metadata": {"window": "There's going to be other operational elements that will be working through and then we'll   \nprovide more color on.  As it relates to inflation that $300 million impact this year is by far the most   \nsignificant item.  And when we think about our long -term tar gets, the reason we use the phrase   \nnormalized, is items like that $300 million do need to be adjusted, but as it relates to other moving   \npieces for fiscal \u201823, that will come at our normal guidance update next quarter.  \n \n Operator :  All right.  We'll go ah ead and take our next question from Lisa Gill, JP Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning. ", "original_text": "Operator :  All right. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4882d07f8eb3773d9c5e4e9480e1de9eefaa828d33485ef90f705a9115aab48e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8464a9b2-1a9d-45ed-85aa-8ea949f62da1", "node_type": "1", "metadata": {"window": "And when we think about our long -term tar gets, the reason we use the phrase   \nnormalized, is items like that $300 million do need to be adjusted, but as it relates to other moving   \npieces for fiscal \u201823, that will come at our normal guidance update next quarter.  \n \n Operator :  All right.  We'll go ah ead and take our next question from Lisa Gill, JP Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning.  Staying on the medical supply side of the business, I just  \nwant to better understand just a couple of things.  Mike, you talked about the opportunity now to mitigate  \nsome of this by taking some price increases. ", "original_text": "Lisa Gill:  Thanks very much. "}, "hash": "db57af9442e2b8e5ade3370d5d0c27cb63c817093ac4cfac0ed528e65292ff64", "class_name": "RelatedNodeInfo"}}, "text": "We'll go ah ead and take our next question from Lisa Gill, JP Morgan.  \n \n", "start_char_idx": 1847, "end_char_idx": 1921, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8464a9b2-1a9d-45ed-85aa-8ea949f62da1": {"__data__": {"id_": "8464a9b2-1a9d-45ed-85aa-8ea949f62da1", "embedding": null, "metadata": {"window": "And when we think about our long -term tar gets, the reason we use the phrase   \nnormalized, is items like that $300 million do need to be adjusted, but as it relates to other moving   \npieces for fiscal \u201823, that will come at our normal guidance update next quarter.  \n \n Operator :  All right.  We'll go ah ead and take our next question from Lisa Gill, JP Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning.  Staying on the medical supply side of the business, I just  \nwant to better understand just a couple of things.  Mike, you talked about the opportunity now to mitigate  \nsome of this by taking some price increases. ", "original_text": "Lisa Gill:  Thanks very much. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e34b61b-14bf-4ceb-8a40-a361298bd6b5", "node_type": "1", "metadata": {"window": "As it relates to inflation that $300 million impact this year is by far the most   \nsignificant item.  And when we think about our long -term tar gets, the reason we use the phrase   \nnormalized, is items like that $300 million do need to be adjusted, but as it relates to other moving   \npieces for fiscal \u201823, that will come at our normal guidance update next quarter.  \n \n Operator :  All right.  We'll go ah ead and take our next question from Lisa Gill, JP Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning.  Staying on the medical supply side of the business, I just  \nwant to better understand just a couple of things. ", "original_text": "We'll go ah ead and take our next question from Lisa Gill, JP Morgan.  \n \n", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9d1741acf9980c9ed39e31454e1a077667cb6d55bd3870546db8ea8ac2b6e689", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2591e02b-0f23-4634-8f05-e5822478619b", "node_type": "1", "metadata": {"window": "Operator :  All right.  We'll go ah ead and take our next question from Lisa Gill, JP Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning.  Staying on the medical supply side of the business, I just  \nwant to better understand just a couple of things.  Mike, you talked about the opportunity now to mitigate  \nsome of this by taking some price increases.  Is there any reason we've been talking about all of these  \nheadwinds and pressures for several quarters now? ", "original_text": "Good morning. "}, "hash": "44799d0e28bf6302501011e9e932b675600891b3d9a4c6b577de9894ad507b3d", "class_name": "RelatedNodeInfo"}}, "text": "Lisa Gill:  Thanks very much. ", "start_char_idx": 1921, "end_char_idx": 1951, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2591e02b-0f23-4634-8f05-e5822478619b": {"__data__": {"id_": "2591e02b-0f23-4634-8f05-e5822478619b", "embedding": null, "metadata": {"window": "Operator :  All right.  We'll go ah ead and take our next question from Lisa Gill, JP Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning.  Staying on the medical supply side of the business, I just  \nwant to better understand just a couple of things.  Mike, you talked about the opportunity now to mitigate  \nsome of this by taking some price increases.  Is there any reason we've been talking about all of these  \nheadwinds and pressures for several quarters now? ", "original_text": "Good morning. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8464a9b2-1a9d-45ed-85aa-8ea949f62da1", "node_type": "1", "metadata": {"window": "And when we think about our long -term tar gets, the reason we use the phrase   \nnormalized, is items like that $300 million do need to be adjusted, but as it relates to other moving   \npieces for fiscal \u201823, that will come at our normal guidance update next quarter.  \n \n Operator :  All right.  We'll go ah ead and take our next question from Lisa Gill, JP Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning.  Staying on the medical supply side of the business, I just  \nwant to better understand just a couple of things.  Mike, you talked about the opportunity now to mitigate  \nsome of this by taking some price increases. ", "original_text": "Lisa Gill:  Thanks very much. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ab9a04fddf6cd5f3163f9c27a4c9af62afaccf0c3f24534ae7e2dd8465631c01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e1f0c149-ad10-47b6-80a8-c6deb3ee5095", "node_type": "1", "metadata": {"window": "We'll go ah ead and take our next question from Lisa Gill, JP Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning.  Staying on the medical supply side of the business, I just  \nwant to better understand just a couple of things.  Mike, you talked about the opportunity now to mitigate  \nsome of this by taking some price increases.  Is there any reason we've been talking about all of these  \nheadwinds and pressures for several quarters now?  Is there any reason why one, you haven't been  \nable to do that historically, and why now you'll be able to do it? ", "original_text": "Staying on the medical supply side of the business, I just  \nwant to better understand just a couple of things. "}, "hash": "188387cd74bbfe8c452dad44953dfb166afa98ef96afa9f217c2b65291e29d0a", "class_name": "RelatedNodeInfo"}}, "text": "Good morning. ", "start_char_idx": 1951, "end_char_idx": 1965, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e1f0c149-ad10-47b6-80a8-c6deb3ee5095": {"__data__": {"id_": "e1f0c149-ad10-47b6-80a8-c6deb3ee5095", "embedding": null, "metadata": {"window": "We'll go ah ead and take our next question from Lisa Gill, JP Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning.  Staying on the medical supply side of the business, I just  \nwant to better understand just a couple of things.  Mike, you talked about the opportunity now to mitigate  \nsome of this by taking some price increases.  Is there any reason we've been talking about all of these  \nheadwinds and pressures for several quarters now?  Is there any reason why one, you haven't been  \nable to do that historically, and why now you'll be able to do it? ", "original_text": "Staying on the medical supply side of the business, I just  \nwant to better understand just a couple of things. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2591e02b-0f23-4634-8f05-e5822478619b", "node_type": "1", "metadata": {"window": "Operator :  All right.  We'll go ah ead and take our next question from Lisa Gill, JP Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning.  Staying on the medical supply side of the business, I just  \nwant to better understand just a couple of things.  Mike, you talked about the opportunity now to mitigate  \nsome of this by taking some price increases.  Is there any reason we've been talking about all of these  \nheadwinds and pressures for several quarters now? ", "original_text": "Good morning. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9ffa3d718f35d687ad9b1381dd1a94321089d4304b079ead5e9e34943b4521a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "822ce059-7683-4bad-ba3a-898bac0beba0", "node_type": "1", "metadata": {"window": "Lisa Gill:  Thanks very much.  Good morning.  Staying on the medical supply side of the business, I just  \nwant to better understand just a couple of things.  Mike, you talked about the opportunity now to mitigate  \nsome of this by taking some price increases.  Is there any reason we've been talking about all of these  \nheadwinds and pressures for several quarters now?  Is there any reason why one, you haven't been  \nable to do that historically, and why now you'll be able to do it?  And then secondly, can you maybe just  \ntalk about the competitive landscape? ", "original_text": "Mike, you talked about the opportunity now to mitigate  \nsome of this by taking some price increases. "}, "hash": "82d1597ce03882815fd368cfc91229d1b8db861951b6543e4c83b34149d895ff", "class_name": "RelatedNodeInfo"}}, "text": "Staying on the medical supply side of the business, I just  \nwant to better understand just a couple of things. ", "start_char_idx": 1965, "end_char_idx": 2077, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "822ce059-7683-4bad-ba3a-898bac0beba0": {"__data__": {"id_": "822ce059-7683-4bad-ba3a-898bac0beba0", "embedding": null, "metadata": {"window": "Lisa Gill:  Thanks very much.  Good morning.  Staying on the medical supply side of the business, I just  \nwant to better understand just a couple of things.  Mike, you talked about the opportunity now to mitigate  \nsome of this by taking some price increases.  Is there any reason we've been talking about all of these  \nheadwinds and pressures for several quarters now?  Is there any reason why one, you haven't been  \nable to do that historically, and why now you'll be able to do it?  And then secondly, can you maybe just  \ntalk about the competitive landscape? ", "original_text": "Mike, you talked about the opportunity now to mitigate  \nsome of this by taking some price increases. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e1f0c149-ad10-47b6-80a8-c6deb3ee5095", "node_type": "1", "metadata": {"window": "We'll go ah ead and take our next question from Lisa Gill, JP Morgan.  \n \n Lisa Gill:  Thanks very much.  Good morning.  Staying on the medical supply side of the business, I just  \nwant to better understand just a couple of things.  Mike, you talked about the opportunity now to mitigate  \nsome of this by taking some price increases.  Is there any reason we've been talking about all of these  \nheadwinds and pressures for several quarters now?  Is there any reason why one, you haven't been  \nable to do that historically, and why now you'll be able to do it? ", "original_text": "Staying on the medical supply side of the business, I just  \nwant to better understand just a couple of things. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "cc97bbbb3f9db0ee0ac4fe19237387fc343639d6f4ae52093eaae5a5251277ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5660d13-d154-4a1d-b2d6-45c8b340b80d", "node_type": "1", "metadata": {"window": "Good morning.  Staying on the medical supply side of the business, I just  \nwant to better understand just a couple of things.  Mike, you talked about the opportunity now to mitigate  \nsome of this by taking some price increases.  Is there any reason we've been talking about all of these  \nheadwinds and pressures for several quarters now?  Is there any reason why one, you haven't been  \nable to do that historically, and why now you'll be able to do it?  And then secondly, can you maybe just  \ntalk about the competitive landscape?  Is there anything in the competitive landscape that has prohibited  \nyou from taking mitigating price increases during this time?  \n  \n", "original_text": "Is there any reason we've been talking about all of these  \nheadwinds and pressures for several quarters now? "}, "hash": "7db572241ed20aece17c9ef1a463240e8df1f451f58373ff4735941e6b69daff", "class_name": "RelatedNodeInfo"}}, "text": "Mike, you talked about the opportunity now to mitigate  \nsome of this by taking some price increases. ", "start_char_idx": 2077, "end_char_idx": 2179, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5660d13-d154-4a1d-b2d6-45c8b340b80d": {"__data__": {"id_": "e5660d13-d154-4a1d-b2d6-45c8b340b80d", "embedding": null, "metadata": {"window": "Good morning.  Staying on the medical supply side of the business, I just  \nwant to better understand just a couple of things.  Mike, you talked about the opportunity now to mitigate  \nsome of this by taking some price increases.  Is there any reason we've been talking about all of these  \nheadwinds and pressures for several quarters now?  Is there any reason why one, you haven't been  \nable to do that historically, and why now you'll be able to do it?  And then secondly, can you maybe just  \ntalk about the competitive landscape?  Is there anything in the competitive landscape that has prohibited  \nyou from taking mitigating price increases during this time?  \n  \n", "original_text": "Is there any reason we've been talking about all of these  \nheadwinds and pressures for several quarters now? ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "822ce059-7683-4bad-ba3a-898bac0beba0", "node_type": "1", "metadata": {"window": "Lisa Gill:  Thanks very much.  Good morning.  Staying on the medical supply side of the business, I just  \nwant to better understand just a couple of things.  Mike, you talked about the opportunity now to mitigate  \nsome of this by taking some price increases.  Is there any reason we've been talking about all of these  \nheadwinds and pressures for several quarters now?  Is there any reason why one, you haven't been  \nable to do that historically, and why now you'll be able to do it?  And then secondly, can you maybe just  \ntalk about the competitive landscape? ", "original_text": "Mike, you talked about the opportunity now to mitigate  \nsome of this by taking some price increases. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6259fa4827126a0567386bf0139ba15ecca26841ba7fc225714d3fdbba1791d0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d642a1c3-bfcd-4daf-afd1-b4cbcaab0659", "node_type": "1", "metadata": {"window": "Staying on the medical supply side of the business, I just  \nwant to better understand just a couple of things.  Mike, you talked about the opportunity now to mitigate  \nsome of this by taking some price increases.  Is there any reason we've been talking about all of these  \nheadwinds and pressures for several quarters now?  Is there any reason why one, you haven't been  \nable to do that historically, and why now you'll be able to do it?  And then secondly, can you maybe just  \ntalk about the competitive landscape?  Is there anything in the competitive landscape that has prohibited  \nyou from taking mitigating price increases during this time?  \n  \n Mike  Kaufmann:   Yeah. ", "original_text": "Is there any reason why one, you haven't been  \nable to do that historically, and why now you'll be able to do it? "}, "hash": "5bd74b7a15a2e0adbe825459650966de0fff28821db1c97c46e1b079f7626835", "class_name": "RelatedNodeInfo"}}, "text": "Is there any reason we've been talking about all of these  \nheadwinds and pressures for several quarters now? ", "start_char_idx": 2179, "end_char_idx": 2289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d642a1c3-bfcd-4daf-afd1-b4cbcaab0659": {"__data__": {"id_": "d642a1c3-bfcd-4daf-afd1-b4cbcaab0659", "embedding": null, "metadata": {"window": "Staying on the medical supply side of the business, I just  \nwant to better understand just a couple of things.  Mike, you talked about the opportunity now to mitigate  \nsome of this by taking some price increases.  Is there any reason we've been talking about all of these  \nheadwinds and pressures for several quarters now?  Is there any reason why one, you haven't been  \nable to do that historically, and why now you'll be able to do it?  And then secondly, can you maybe just  \ntalk about the competitive landscape?  Is there anything in the competitive landscape that has prohibited  \nyou from taking mitigating price increases during this time?  \n  \n Mike  Kaufmann:   Yeah. ", "original_text": "Is there any reason why one, you haven't been  \nable to do that historically, and why now you'll be able to do it? ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5660d13-d154-4a1d-b2d6-45c8b340b80d", "node_type": "1", "metadata": {"window": "Good morning.  Staying on the medical supply side of the business, I just  \nwant to better understand just a couple of things.  Mike, you talked about the opportunity now to mitigate  \nsome of this by taking some price increases.  Is there any reason we've been talking about all of these  \nheadwinds and pressures for several quarters now?  Is there any reason why one, you haven't been  \nable to do that historically, and why now you'll be able to do it?  And then secondly, can you maybe just  \ntalk about the competitive landscape?  Is there anything in the competitive landscape that has prohibited  \nyou from taking mitigating price increases during this time?  \n  \n", "original_text": "Is there any reason we've been talking about all of these  \nheadwinds and pressures for several quarters now? ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "687d6820e78b3a5dd18e1ca38cfb4a2396d78bf995ba6b10f91c68010d5ea2d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9931f4bf-e4c3-4f88-94d1-58c3431d4a47", "node_type": "1", "metadata": {"window": "Mike, you talked about the opportunity now to mitigate  \nsome of this by taking some price increases.  Is there any reason we've been talking about all of these  \nheadwinds and pressures for several quarters now?  Is there any reason why one, you haven't been  \nable to do that historically, and why now you'll be able to do it?  And then secondly, can you maybe just  \ntalk about the competitive landscape?  Is there anything in the competitive landscape that has prohibited  \nyou from taking mitigating price increases during this time?  \n  \n Mike  Kaufmann:   Yeah.  Thanks for the question. ", "original_text": "And then secondly, can you maybe just  \ntalk about the competitive landscape? "}, "hash": "45f2551984f5e31e8b08c9d1dc92fa133ce732963cdcc186f63fff4d6768bb36", "class_name": "RelatedNodeInfo"}}, "text": "Is there any reason why one, you haven't been  \nable to do that historically, and why now you'll be able to do it? ", "start_char_idx": 2289, "end_char_idx": 2404, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9931f4bf-e4c3-4f88-94d1-58c3431d4a47": {"__data__": {"id_": "9931f4bf-e4c3-4f88-94d1-58c3431d4a47", "embedding": null, "metadata": {"window": "Mike, you talked about the opportunity now to mitigate  \nsome of this by taking some price increases.  Is there any reason we've been talking about all of these  \nheadwinds and pressures for several quarters now?  Is there any reason why one, you haven't been  \nable to do that historically, and why now you'll be able to do it?  And then secondly, can you maybe just  \ntalk about the competitive landscape?  Is there anything in the competitive landscape that has prohibited  \nyou from taking mitigating price increases during this time?  \n  \n Mike  Kaufmann:   Yeah.  Thanks for the question. ", "original_text": "And then secondly, can you maybe just  \ntalk about the competitive landscape? ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d642a1c3-bfcd-4daf-afd1-b4cbcaab0659", "node_type": "1", "metadata": {"window": "Staying on the medical supply side of the business, I just  \nwant to better understand just a couple of things.  Mike, you talked about the opportunity now to mitigate  \nsome of this by taking some price increases.  Is there any reason we've been talking about all of these  \nheadwinds and pressures for several quarters now?  Is there any reason why one, you haven't been  \nable to do that historically, and why now you'll be able to do it?  And then secondly, can you maybe just  \ntalk about the competitive landscape?  Is there anything in the competitive landscape that has prohibited  \nyou from taking mitigating price increases during this time?  \n  \n Mike  Kaufmann:   Yeah. ", "original_text": "Is there any reason why one, you haven't been  \nable to do that historically, and why now you'll be able to do it? ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "84dad57ead0a75ce23c83fe1967f4c1cfd560a811985ecf31d01ddabe8eacd4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5100769f-d536-47fb-ab58-52da909c683e", "node_type": "1", "metadata": {"window": "Is there any reason we've been talking about all of these  \nheadwinds and pressures for several quarters now?  Is there any reason why one, you haven't been  \nable to do that historically, and why now you'll be able to do it?  And then secondly, can you maybe just  \ntalk about the competitive landscape?  Is there anything in the competitive landscape that has prohibited  \nyou from taking mitigating price increases during this time?  \n  \n Mike  Kaufmann:   Yeah.  Thanks for the question.  So first of all, I would talk abo ut it in two buckets. ", "original_text": "Is there anything in the competitive landscape that has prohibited  \nyou from taking mitigating price increases during this time?  \n  \n"}, "hash": "3a61bb50ae4771d79b14568076330515184ed4d028e79fda1a933f805b60e223", "class_name": "RelatedNodeInfo"}}, "text": "And then secondly, can you maybe just  \ntalk about the competitive landscape? ", "start_char_idx": 2404, "end_char_idx": 2482, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5100769f-d536-47fb-ab58-52da909c683e": {"__data__": {"id_": "5100769f-d536-47fb-ab58-52da909c683e", "embedding": null, "metadata": {"window": "Is there any reason we've been talking about all of these  \nheadwinds and pressures for several quarters now?  Is there any reason why one, you haven't been  \nable to do that historically, and why now you'll be able to do it?  And then secondly, can you maybe just  \ntalk about the competitive landscape?  Is there anything in the competitive landscape that has prohibited  \nyou from taking mitigating price increases during this time?  \n  \n Mike  Kaufmann:   Yeah.  Thanks for the question.  So first of all, I would talk abo ut it in two buckets. ", "original_text": "Is there anything in the competitive landscape that has prohibited  \nyou from taking mitigating price increases during this time?  \n  \n", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9931f4bf-e4c3-4f88-94d1-58c3431d4a47", "node_type": "1", "metadata": {"window": "Mike, you talked about the opportunity now to mitigate  \nsome of this by taking some price increases.  Is there any reason we've been talking about all of these  \nheadwinds and pressures for several quarters now?  Is there any reason why one, you haven't been  \nable to do that historically, and why now you'll be able to do it?  And then secondly, can you maybe just  \ntalk about the competitive landscape?  Is there anything in the competitive landscape that has prohibited  \nyou from taking mitigating price increases during this time?  \n  \n Mike  Kaufmann:   Yeah.  Thanks for the question. ", "original_text": "And then secondly, can you maybe just  \ntalk about the competitive landscape? ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2a65d6b40a98639405dcc11f8de38d6e0af17443700c2bed73187c2d130cd6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7e3e266-f481-46d8-b1d3-744b0dbe2f21", "node_type": "1", "metadata": {"window": "Is there any reason why one, you haven't been  \nable to do that historically, and why now you'll be able to do it?  And then secondly, can you maybe just  \ntalk about the competitive landscape?  Is there anything in the competitive landscape that has prohibited  \nyou from taking mitigating price increases during this time?  \n  \n Mike  Kaufmann:   Yeah.  Thanks for the question.  So first of all, I would talk abo ut it in two buckets.  And  \nas a reminder one, on the branded medical products, when we see price increases from those  \nmanufacturers, we are able to pass those through because it is like you're used to on the Pharma side,  \na cost plus type of model. ", "original_text": "Mike  Kaufmann:   Yeah. "}, "hash": "62187f09eb0ddebf476d0f75d400a527aff5a74fbbf7d20fec1dac3159383e45", "class_name": "RelatedNodeInfo"}}, "text": "Is there anything in the competitive landscape that has prohibited  \nyou from taking mitigating price increases during this time?  \n  \n", "start_char_idx": 2482, "end_char_idx": 2617, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7e3e266-f481-46d8-b1d3-744b0dbe2f21": {"__data__": {"id_": "b7e3e266-f481-46d8-b1d3-744b0dbe2f21", "embedding": null, "metadata": {"window": "Is there any reason why one, you haven't been  \nable to do that historically, and why now you'll be able to do it?  And then secondly, can you maybe just  \ntalk about the competitive landscape?  Is there anything in the competitive landscape that has prohibited  \nyou from taking mitigating price increases during this time?  \n  \n Mike  Kaufmann:   Yeah.  Thanks for the question.  So first of all, I would talk abo ut it in two buckets.  And  \nas a reminder one, on the branded medical products, when we see price increases from those  \nmanufacturers, we are able to pass those through because it is like you're used to on the Pharma side,  \na cost plus type of model. ", "original_text": "Mike  Kaufmann:   Yeah. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5100769f-d536-47fb-ab58-52da909c683e", "node_type": "1", "metadata": {"window": "Is there any reason we've been talking about all of these  \nheadwinds and pressures for several quarters now?  Is there any reason why one, you haven't been  \nable to do that historically, and why now you'll be able to do it?  And then secondly, can you maybe just  \ntalk about the competitive landscape?  Is there anything in the competitive landscape that has prohibited  \nyou from taking mitigating price increases during this time?  \n  \n Mike  Kaufmann:   Yeah.  Thanks for the question.  So first of all, I would talk abo ut it in two buckets. ", "original_text": "Is there anything in the competitive landscape that has prohibited  \nyou from taking mitigating price increases during this time?  \n  \n", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "262982fdb801db59d39355c1743a1d390f2acd011a7bade2d1cf91da9a5f781c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7319d32c-b55f-43a1-bd08-a112d03d1b73", "node_type": "1", "metadata": {"window": "And then secondly, can you maybe just  \ntalk about the competitive landscape?  Is there anything in the competitive landscape that has prohibited  \nyou from taking mitigating price increases during this time?  \n  \n Mike  Kaufmann:   Yeah.  Thanks for the question.  So first of all, I would talk abo ut it in two buckets.  And  \nas a reminder one, on the branded medical products, when we see price increases from those  \nmanufacturers, we are able to pass those through because it is like you're used to on the Pharma side,  \na cost plus type of model.  So wha tever that cost is, we pass it on. ", "original_text": "Thanks for the question. "}, "hash": "df0f7c3182edccd64318793d3908e12860eb505aefae4865affb4b20257098e4", "class_name": "RelatedNodeInfo"}}, "text": "Mike  Kaufmann:   Yeah. ", "start_char_idx": 2617, "end_char_idx": 2641, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7319d32c-b55f-43a1-bd08-a112d03d1b73": {"__data__": {"id_": "7319d32c-b55f-43a1-bd08-a112d03d1b73", "embedding": null, "metadata": {"window": "And then secondly, can you maybe just  \ntalk about the competitive landscape?  Is there anything in the competitive landscape that has prohibited  \nyou from taking mitigating price increases during this time?  \n  \n Mike  Kaufmann:   Yeah.  Thanks for the question.  So first of all, I would talk abo ut it in two buckets.  And  \nas a reminder one, on the branded medical products, when we see price increases from those  \nmanufacturers, we are able to pass those through because it is like you're used to on the Pharma side,  \na cost plus type of model.  So wha tever that cost is, we pass it on. ", "original_text": "Thanks for the question. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7e3e266-f481-46d8-b1d3-744b0dbe2f21", "node_type": "1", "metadata": {"window": "Is there any reason why one, you haven't been  \nable to do that historically, and why now you'll be able to do it?  And then secondly, can you maybe just  \ntalk about the competitive landscape?  Is there anything in the competitive landscape that has prohibited  \nyou from taking mitigating price increases during this time?  \n  \n Mike  Kaufmann:   Yeah.  Thanks for the question.  So first of all, I would talk abo ut it in two buckets.  And  \nas a reminder one, on the branded medical products, when we see price increases from those  \nmanufacturers, we are able to pass those through because it is like you're used to on the Pharma side,  \na cost plus type of model. ", "original_text": "Mike  Kaufmann:   Yeah. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9b99fa851c22f0eb3f423cb4afc213b8d50269d59676dfa9504224ac5f2e8b1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c21e646-1431-408e-a788-7c6768eea05d", "node_type": "1", "metadata": {"window": "Is there anything in the competitive landscape that has prohibited  \nyou from taking mitigating price increases during this time?  \n  \n Mike  Kaufmann:   Yeah.  Thanks for the question.  So first of all, I would talk abo ut it in two buckets.  And  \nas a reminder one, on the branded medical products, when we see price increases from those  \nmanufacturers, we are able to pass those through because it is like you're used to on the Pharma side,  \na cost plus type of model.  So wha tever that cost is, we pass it on.  So what we're talking about  \nspecifically here is the impact on Cardinal branded products, whether it be the Cardinal brand or  \nKendall, Curity, Kangaroo. ", "original_text": "So first of all, I would talk abo ut it in two buckets. "}, "hash": "0a10ec1df2a25fffef89d446f72661af3e63b006d6d541f2e9a56737edf1c690", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question. ", "start_char_idx": 2641, "end_char_idx": 2666, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c21e646-1431-408e-a788-7c6768eea05d": {"__data__": {"id_": "0c21e646-1431-408e-a788-7c6768eea05d", "embedding": null, "metadata": {"window": "Is there anything in the competitive landscape that has prohibited  \nyou from taking mitigating price increases during this time?  \n  \n Mike  Kaufmann:   Yeah.  Thanks for the question.  So first of all, I would talk abo ut it in two buckets.  And  \nas a reminder one, on the branded medical products, when we see price increases from those  \nmanufacturers, we are able to pass those through because it is like you're used to on the Pharma side,  \na cost plus type of model.  So wha tever that cost is, we pass it on.  So what we're talking about  \nspecifically here is the impact on Cardinal branded products, whether it be the Cardinal brand or  \nKendall, Curity, Kangaroo. ", "original_text": "So first of all, I would talk abo ut it in two buckets. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7319d32c-b55f-43a1-bd08-a112d03d1b73", "node_type": "1", "metadata": {"window": "And then secondly, can you maybe just  \ntalk about the competitive landscape?  Is there anything in the competitive landscape that has prohibited  \nyou from taking mitigating price increases during this time?  \n  \n Mike  Kaufmann:   Yeah.  Thanks for the question.  So first of all, I would talk abo ut it in two buckets.  And  \nas a reminder one, on the branded medical products, when we see price increases from those  \nmanufacturers, we are able to pass those through because it is like you're used to on the Pharma side,  \na cost plus type of model.  So wha tever that cost is, we pass it on. ", "original_text": "Thanks for the question. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b726ae2c2dd307921169ded0fa3fe0e1ce13ef75b6141bff3f1d6e8405a85e54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79d643c1-18ee-4bf7-ba28-72f262b9afb3", "node_type": "1", "metadata": {"window": "Mike  Kaufmann:   Yeah.  Thanks for the question.  So first of all, I would talk abo ut it in two buckets.  And  \nas a reminder one, on the branded medical products, when we see price increases from those  \nmanufacturers, we are able to pass those through because it is like you're used to on the Pharma side,  \na cost plus type of model.  So wha tever that cost is, we pass it on.  So what we're talking about  \nspecifically here is the impact on Cardinal branded products, whether it be the Cardinal brand or  \nKendall, Curity, Kangaroo.  All of our brands that we have as we see input costs going up, whe ther that  \nbe transportation, ocean freight, commodities, etc., those are the types of things that are impacting.  \n", "original_text": "And  \nas a reminder one, on the branded medical products, when we see price increases from those  \nmanufacturers, we are able to pass those through because it is like you're used to on the Pharma side,  \na cost plus type of model. "}, "hash": "0bc5d58df7c2559c66f77ccae1af926fe973e6acf3daae7c6fb993b1b256af18", "class_name": "RelatedNodeInfo"}}, "text": "So first of all, I would talk abo ut it in two buckets. ", "start_char_idx": 2666, "end_char_idx": 2722, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79d643c1-18ee-4bf7-ba28-72f262b9afb3": {"__data__": {"id_": "79d643c1-18ee-4bf7-ba28-72f262b9afb3", "embedding": null, "metadata": {"window": "Mike  Kaufmann:   Yeah.  Thanks for the question.  So first of all, I would talk abo ut it in two buckets.  And  \nas a reminder one, on the branded medical products, when we see price increases from those  \nmanufacturers, we are able to pass those through because it is like you're used to on the Pharma side,  \na cost plus type of model.  So wha tever that cost is, we pass it on.  So what we're talking about  \nspecifically here is the impact on Cardinal branded products, whether it be the Cardinal brand or  \nKendall, Curity, Kangaroo.  All of our brands that we have as we see input costs going up, whe ther that  \nbe transportation, ocean freight, commodities, etc., those are the types of things that are impacting.  \n", "original_text": "And  \nas a reminder one, on the branded medical products, when we see price increases from those  \nmanufacturers, we are able to pass those through because it is like you're used to on the Pharma side,  \na cost plus type of model. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c21e646-1431-408e-a788-7c6768eea05d", "node_type": "1", "metadata": {"window": "Is there anything in the competitive landscape that has prohibited  \nyou from taking mitigating price increases during this time?  \n  \n Mike  Kaufmann:   Yeah.  Thanks for the question.  So first of all, I would talk abo ut it in two buckets.  And  \nas a reminder one, on the branded medical products, when we see price increases from those  \nmanufacturers, we are able to pass those through because it is like you're used to on the Pharma side,  \na cost plus type of model.  So wha tever that cost is, we pass it on.  So what we're talking about  \nspecifically here is the impact on Cardinal branded products, whether it be the Cardinal brand or  \nKendall, Curity, Kangaroo. ", "original_text": "So first of all, I would talk abo ut it in two buckets. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fb5491c16251bfbba0bfc4e905bf0abadac7ea669e84a6f05f1391098b718240", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19c956c8-4484-4214-b028-76ec14cfbb7e", "node_type": "1", "metadata": {"window": "Thanks for the question.  So first of all, I would talk abo ut it in two buckets.  And  \nas a reminder one, on the branded medical products, when we see price increases from those  \nmanufacturers, we are able to pass those through because it is like you're used to on the Pharma side,  \na cost plus type of model.  So wha tever that cost is, we pass it on.  So what we're talking about  \nspecifically here is the impact on Cardinal branded products, whether it be the Cardinal brand or  \nKendall, Curity, Kangaroo.  All of our brands that we have as we see input costs going up, whe ther that  \nbe transportation, ocean freight, commodities, etc., those are the types of things that are impacting.  \n And so again, as I think about the entire Medical segment, remember it is highly focused in this one  \narea. ", "original_text": "So wha tever that cost is, we pass it on. "}, "hash": "5ad2838d7f1e235226dd097e894a2078bc0d614b1268ce0199516e1d3d8038a5", "class_name": "RelatedNodeInfo"}}, "text": "And  \nas a reminder one, on the branded medical products, when we see price increases from those  \nmanufacturers, we are able to pass those through because it is like you're used to on the Pharma side,  \na cost plus type of model. ", "start_char_idx": 2722, "end_char_idx": 2953, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19c956c8-4484-4214-b028-76ec14cfbb7e": {"__data__": {"id_": "19c956c8-4484-4214-b028-76ec14cfbb7e", "embedding": null, "metadata": {"window": "Thanks for the question.  So first of all, I would talk abo ut it in two buckets.  And  \nas a reminder one, on the branded medical products, when we see price increases from those  \nmanufacturers, we are able to pass those through because it is like you're used to on the Pharma side,  \na cost plus type of model.  So wha tever that cost is, we pass it on.  So what we're talking about  \nspecifically here is the impact on Cardinal branded products, whether it be the Cardinal brand or  \nKendall, Curity, Kangaroo.  All of our brands that we have as we see input costs going up, whe ther that  \nbe transportation, ocean freight, commodities, etc., those are the types of things that are impacting.  \n And so again, as I think about the entire Medical segment, remember it is highly focused in this one  \narea. ", "original_text": "So wha tever that cost is, we pass it on. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79d643c1-18ee-4bf7-ba28-72f262b9afb3", "node_type": "1", "metadata": {"window": "Mike  Kaufmann:   Yeah.  Thanks for the question.  So first of all, I would talk abo ut it in two buckets.  And  \nas a reminder one, on the branded medical products, when we see price increases from those  \nmanufacturers, we are able to pass those through because it is like you're used to on the Pharma side,  \na cost plus type of model.  So wha tever that cost is, we pass it on.  So what we're talking about  \nspecifically here is the impact on Cardinal branded products, whether it be the Cardinal brand or  \nKendall, Curity, Kangaroo.  All of our brands that we have as we see input costs going up, whe ther that  \nbe transportation, ocean freight, commodities, etc., those are the types of things that are impacting.  \n", "original_text": "And  \nas a reminder one, on the branded medical products, when we see price increases from those  \nmanufacturers, we are able to pass those through because it is like you're used to on the Pharma side,  \na cost plus type of model. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fff1033d7b9bfbc8c3961e2804232b98bd43869fcba4bc31830f611f9c373df8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd61a4dd-c7b1-4706-9013-de1315463eac", "node_type": "1", "metadata": {"window": "So first of all, I would talk abo ut it in two buckets.  And  \nas a reminder one, on the branded medical products, when we see price increases from those  \nmanufacturers, we are able to pass those through because it is like you're used to on the Pharma side,  \na cost plus type of model.  So wha tever that cost is, we pass it on.  So what we're talking about  \nspecifically here is the impact on Cardinal branded products, whether it be the Cardinal brand or  \nKendall, Curity, Kangaroo.  All of our brands that we have as we see input costs going up, whe ther that  \nbe transportation, ocean freight, commodities, etc., those are the types of things that are impacting.  \n And so again, as I think about the entire Medical segment, remember it is highly focused in this one  \narea.  As we look across the rest of the  segment, we see really good progress on our initiatives and the  \nvarious activities that we have going on. ", "original_text": "So what we're talking about  \nspecifically here is the impact on Cardinal branded products, whether it be the Cardinal brand or  \nKendall, Curity, Kangaroo. "}, "hash": "76daf06001e9cd2cee04328a356bd8b45d62b2eb1a2b53e05b1d88a882979fce", "class_name": "RelatedNodeInfo"}}, "text": "So wha tever that cost is, we pass it on. ", "start_char_idx": 2953, "end_char_idx": 2995, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd61a4dd-c7b1-4706-9013-de1315463eac": {"__data__": {"id_": "cd61a4dd-c7b1-4706-9013-de1315463eac", "embedding": null, "metadata": {"window": "So first of all, I would talk abo ut it in two buckets.  And  \nas a reminder one, on the branded medical products, when we see price increases from those  \nmanufacturers, we are able to pass those through because it is like you're used to on the Pharma side,  \na cost plus type of model.  So wha tever that cost is, we pass it on.  So what we're talking about  \nspecifically here is the impact on Cardinal branded products, whether it be the Cardinal brand or  \nKendall, Curity, Kangaroo.  All of our brands that we have as we see input costs going up, whe ther that  \nbe transportation, ocean freight, commodities, etc., those are the types of things that are impacting.  \n And so again, as I think about the entire Medical segment, remember it is highly focused in this one  \narea.  As we look across the rest of the  segment, we see really good progress on our initiatives and the  \nvarious activities that we have going on. ", "original_text": "So what we're talking about  \nspecifically here is the impact on Cardinal branded products, whether it be the Cardinal brand or  \nKendall, Curity, Kangaroo. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19c956c8-4484-4214-b028-76ec14cfbb7e", "node_type": "1", "metadata": {"window": "Thanks for the question.  So first of all, I would talk abo ut it in two buckets.  And  \nas a reminder one, on the branded medical products, when we see price increases from those  \nmanufacturers, we are able to pass those through because it is like you're used to on the Pharma side,  \na cost plus type of model.  So wha tever that cost is, we pass it on.  So what we're talking about  \nspecifically here is the impact on Cardinal branded products, whether it be the Cardinal brand or  \nKendall, Curity, Kangaroo.  All of our brands that we have as we see input costs going up, whe ther that  \nbe transportation, ocean freight, commodities, etc., those are the types of things that are impacting.  \n And so again, as I think about the entire Medical segment, remember it is highly focused in this one  \narea. ", "original_text": "So wha tever that cost is, we pass it on. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e6e72c2410525bcc982386eb81e2185f00d8cabdd1de2228103344568135dddd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bde9167-62c4-4c75-b7dd-14fded756ec8", "node_type": "1", "metadata": {"window": "And  \nas a reminder one, on the branded medical products, when we see price increases from those  \nmanufacturers, we are able to pass those through because it is like you're used to on the Pharma side,  \na cost plus type of model.  So wha tever that cost is, we pass it on.  So what we're talking about  \nspecifically here is the impact on Cardinal branded products, whether it be the Cardinal brand or  \nKendall, Curity, Kangaroo.  All of our brands that we have as we see input costs going up, whe ther that  \nbe transportation, ocean freight, commodities, etc., those are the types of things that are impacting.  \n And so again, as I think about the entire Medical segment, remember it is highly focused in this one  \narea.  As we look across the rest of the  segment, we see really good progress on our initiatives and the  \nvarious activities that we have going on.  Specifically related to this, to your point around taking pricing,  \nas you know, taking pricing in this marketplace is complicated. ", "original_text": "All of our brands that we have as we see input costs going up, whe ther that  \nbe transportation, ocean freight, commodities, etc., those are the types of things that are impacting.  \n"}, "hash": "854f554bb845964265496e83923eb72fc422315d6630f82deab6117d7a8eb85c", "class_name": "RelatedNodeInfo"}}, "text": "So what we're talking about  \nspecifically here is the impact on Cardinal branded products, whether it be the Cardinal brand or  \nKendall, Curity, Kangaroo. ", "start_char_idx": 2995, "end_char_idx": 3152, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bde9167-62c4-4c75-b7dd-14fded756ec8": {"__data__": {"id_": "4bde9167-62c4-4c75-b7dd-14fded756ec8", "embedding": null, "metadata": {"window": "And  \nas a reminder one, on the branded medical products, when we see price increases from those  \nmanufacturers, we are able to pass those through because it is like you're used to on the Pharma side,  \na cost plus type of model.  So wha tever that cost is, we pass it on.  So what we're talking about  \nspecifically here is the impact on Cardinal branded products, whether it be the Cardinal brand or  \nKendall, Curity, Kangaroo.  All of our brands that we have as we see input costs going up, whe ther that  \nbe transportation, ocean freight, commodities, etc., those are the types of things that are impacting.  \n And so again, as I think about the entire Medical segment, remember it is highly focused in this one  \narea.  As we look across the rest of the  segment, we see really good progress on our initiatives and the  \nvarious activities that we have going on.  Specifically related to this, to your point around taking pricing,  \nas you know, taking pricing in this marketplace is complicated. ", "original_text": "All of our brands that we have as we see input costs going up, whe ther that  \nbe transportation, ocean freight, commodities, etc., those are the types of things that are impacting.  \n", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd61a4dd-c7b1-4706-9013-de1315463eac", "node_type": "1", "metadata": {"window": "So first of all, I would talk abo ut it in two buckets.  And  \nas a reminder one, on the branded medical products, when we see price increases from those  \nmanufacturers, we are able to pass those through because it is like you're used to on the Pharma side,  \na cost plus type of model.  So wha tever that cost is, we pass it on.  So what we're talking about  \nspecifically here is the impact on Cardinal branded products, whether it be the Cardinal brand or  \nKendall, Curity, Kangaroo.  All of our brands that we have as we see input costs going up, whe ther that  \nbe transportation, ocean freight, commodities, etc., those are the types of things that are impacting.  \n And so again, as I think about the entire Medical segment, remember it is highly focused in this one  \narea.  As we look across the rest of the  segment, we see really good progress on our initiatives and the  \nvarious activities that we have going on. ", "original_text": "So what we're talking about  \nspecifically here is the impact on Cardinal branded products, whether it be the Cardinal brand or  \nKendall, Curity, Kangaroo. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a16a91f7fd2183c8e81bb904d5967dc03fb4e847309b3ab5591324c3263eb9f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ac803b0e-5276-4ba5-b4af-1ed5b9c7bf0c", "node_type": "1", "metadata": {"window": "So wha tever that cost is, we pass it on.  So what we're talking about  \nspecifically here is the impact on Cardinal branded products, whether it be the Cardinal brand or  \nKendall, Curity, Kangaroo.  All of our brands that we have as we see input costs going up, whe ther that  \nbe transportation, ocean freight, commodities, etc., those are the types of things that are impacting.  \n And so again, as I think about the entire Medical segment, remember it is highly focused in this one  \narea.  As we look across the rest of the  segment, we see really good progress on our initiatives and the  \nvarious activities that we have going on.  Specifically related to this, to your point around taking pricing,  \nas you know, taking pricing in this marketplace is complicated.  First of all, yo u have to work not only  \nwith the actual customers themselves, but you also need to work with the GPOs and make sure that  \nyou are communicating what you intend to do, when you'll do it, you have to give notice. ", "original_text": "And so again, as I think about the entire Medical segment, remember it is highly focused in this one  \narea. "}, "hash": "2d160b876662e2c902212708b32a96805702b2afbfa8cfcae4adaa2e3dbdf62f", "class_name": "RelatedNodeInfo"}}, "text": "All of our brands that we have as we see input costs going up, whe ther that  \nbe transportation, ocean freight, commodities, etc., those are the types of things that are impacting.  \n", "start_char_idx": 3152, "end_char_idx": 3336, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ac803b0e-5276-4ba5-b4af-1ed5b9c7bf0c": {"__data__": {"id_": "ac803b0e-5276-4ba5-b4af-1ed5b9c7bf0c", "embedding": null, "metadata": {"window": "So wha tever that cost is, we pass it on.  So what we're talking about  \nspecifically here is the impact on Cardinal branded products, whether it be the Cardinal brand or  \nKendall, Curity, Kangaroo.  All of our brands that we have as we see input costs going up, whe ther that  \nbe transportation, ocean freight, commodities, etc., those are the types of things that are impacting.  \n And so again, as I think about the entire Medical segment, remember it is highly focused in this one  \narea.  As we look across the rest of the  segment, we see really good progress on our initiatives and the  \nvarious activities that we have going on.  Specifically related to this, to your point around taking pricing,  \nas you know, taking pricing in this marketplace is complicated.  First of all, yo u have to work not only  \nwith the actual customers themselves, but you also need to work with the GPOs and make sure that  \nyou are communicating what you intend to do, when you'll do it, you have to give notice. ", "original_text": "And so again, as I think about the entire Medical segment, remember it is highly focused in this one  \narea. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bde9167-62c4-4c75-b7dd-14fded756ec8", "node_type": "1", "metadata": {"window": "And  \nas a reminder one, on the branded medical products, when we see price increases from those  \nmanufacturers, we are able to pass those through because it is like you're used to on the Pharma side,  \na cost plus type of model.  So wha tever that cost is, we pass it on.  So what we're talking about  \nspecifically here is the impact on Cardinal branded products, whether it be the Cardinal brand or  \nKendall, Curity, Kangaroo.  All of our brands that we have as we see input costs going up, whe ther that  \nbe transportation, ocean freight, commodities, etc., those are the types of things that are impacting.  \n And so again, as I think about the entire Medical segment, remember it is highly focused in this one  \narea.  As we look across the rest of the  segment, we see really good progress on our initiatives and the  \nvarious activities that we have going on.  Specifically related to this, to your point around taking pricing,  \nas you know, taking pricing in this marketplace is complicated. ", "original_text": "All of our brands that we have as we see input costs going up, whe ther that  \nbe transportation, ocean freight, commodities, etc., those are the types of things that are impacting.  \n", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f21dc5c4f3320663a07379f6ead4fab9a201cf9aee618e1535a9af2dacdcbd6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09f1eaa9-9952-42cf-87e1-9d25e3c742cf", "node_type": "1", "metadata": {"window": "So what we're talking about  \nspecifically here is the impact on Cardinal branded products, whether it be the Cardinal brand or  \nKendall, Curity, Kangaroo.  All of our brands that we have as we see input costs going up, whe ther that  \nbe transportation, ocean freight, commodities, etc., those are the types of things that are impacting.  \n And so again, as I think about the entire Medical segment, remember it is highly focused in this one  \narea.  As we look across the rest of the  segment, we see really good progress on our initiatives and the  \nvarious activities that we have going on.  Specifically related to this, to your point around taking pricing,  \nas you know, taking pricing in this marketplace is complicated.  First of all, yo u have to work not only  \nwith the actual customers themselves, but you also need to work with the GPOs and make sure that  \nyou are communicating what you intend to do, when you'll do it, you have to give notice.  Remember,  ", "original_text": "As we look across the rest of the  segment, we see really good progress on our initiatives and the  \nvarious activities that we have going on. "}, "hash": "4038f39a9515c6eff3af1c8cc8457f00eee2005a92b8ca482c1fdb078b79f584", "class_name": "RelatedNodeInfo"}}, "text": "And so again, as I think about the entire Medical segment, remember it is highly focused in this one  \narea. ", "start_char_idx": 3336, "end_char_idx": 3445, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09f1eaa9-9952-42cf-87e1-9d25e3c742cf": {"__data__": {"id_": "09f1eaa9-9952-42cf-87e1-9d25e3c742cf", "embedding": null, "metadata": {"window": "So what we're talking about  \nspecifically here is the impact on Cardinal branded products, whether it be the Cardinal brand or  \nKendall, Curity, Kangaroo.  All of our brands that we have as we see input costs going up, whe ther that  \nbe transportation, ocean freight, commodities, etc., those are the types of things that are impacting.  \n And so again, as I think about the entire Medical segment, remember it is highly focused in this one  \narea.  As we look across the rest of the  segment, we see really good progress on our initiatives and the  \nvarious activities that we have going on.  Specifically related to this, to your point around taking pricing,  \nas you know, taking pricing in this marketplace is complicated.  First of all, yo u have to work not only  \nwith the actual customers themselves, but you also need to work with the GPOs and make sure that  \nyou are communicating what you intend to do, when you'll do it, you have to give notice.  Remember,  ", "original_text": "As we look across the rest of the  segment, we see really good progress on our initiatives and the  \nvarious activities that we have going on. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ac803b0e-5276-4ba5-b4af-1ed5b9c7bf0c", "node_type": "1", "metadata": {"window": "So wha tever that cost is, we pass it on.  So what we're talking about  \nspecifically here is the impact on Cardinal branded products, whether it be the Cardinal brand or  \nKendall, Curity, Kangaroo.  All of our brands that we have as we see input costs going up, whe ther that  \nbe transportation, ocean freight, commodities, etc., those are the types of things that are impacting.  \n And so again, as I think about the entire Medical segment, remember it is highly focused in this one  \narea.  As we look across the rest of the  segment, we see really good progress on our initiatives and the  \nvarious activities that we have going on.  Specifically related to this, to your point around taking pricing,  \nas you know, taking pricing in this marketplace is complicated.  First of all, yo u have to work not only  \nwith the actual customers themselves, but you also need to work with the GPOs and make sure that  \nyou are communicating what you intend to do, when you'll do it, you have to give notice. ", "original_text": "And so again, as I think about the entire Medical segment, remember it is highly focused in this one  \narea. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9683269ca8e627a6a0a63c66ab8a5d40f912ddb5bcf76e8326d9e63a56501c1a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2155e7a-5359-49a3-881d-76b80a8d8a13", "node_type": "1", "metadata": {"window": "All of our brands that we have as we see input costs going up, whe ther that  \nbe transportation, ocean freight, commodities, etc., those are the types of things that are impacting.  \n And so again, as I think about the entire Medical segment, remember it is highly focused in this one  \narea.  As we look across the rest of the  segment, we see really good progress on our initiatives and the  \nvarious activities that we have going on.  Specifically related to this, to your point around taking pricing,  \nas you know, taking pricing in this marketplace is complicated.  First of all, yo u have to work not only  \nwith the actual customers themselves, but you also need to work with the GPOs and make sure that  \nyou are communicating what you intend to do, when you'll do it, you have to give notice.  Remember,  ", "original_text": "Specifically related to this, to your point around taking pricing,  \nas you know, taking pricing in this marketplace is complicated. "}, "hash": "e3072d21bfa55bf138d27a27e4210520802bfcc4229f90d394c4905be326d895", "class_name": "RelatedNodeInfo"}}, "text": "As we look across the rest of the  segment, we see really good progress on our initiatives and the  \nvarious activities that we have going on. ", "start_char_idx": 3445, "end_char_idx": 3588, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2155e7a-5359-49a3-881d-76b80a8d8a13": {"__data__": {"id_": "f2155e7a-5359-49a3-881d-76b80a8d8a13", "embedding": null, "metadata": {"window": "All of our brands that we have as we see input costs going up, whe ther that  \nbe transportation, ocean freight, commodities, etc., those are the types of things that are impacting.  \n And so again, as I think about the entire Medical segment, remember it is highly focused in this one  \narea.  As we look across the rest of the  segment, we see really good progress on our initiatives and the  \nvarious activities that we have going on.  Specifically related to this, to your point around taking pricing,  \nas you know, taking pricing in this marketplace is complicated.  First of all, yo u have to work not only  \nwith the actual customers themselves, but you also need to work with the GPOs and make sure that  \nyou are communicating what you intend to do, when you'll do it, you have to give notice.  Remember,  ", "original_text": "Specifically related to this, to your point around taking pricing,  \nas you know, taking pricing in this marketplace is complicated. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09f1eaa9-9952-42cf-87e1-9d25e3c742cf", "node_type": "1", "metadata": {"window": "So what we're talking about  \nspecifically here is the impact on Cardinal branded products, whether it be the Cardinal brand or  \nKendall, Curity, Kangaroo.  All of our brands that we have as we see input costs going up, whe ther that  \nbe transportation, ocean freight, commodities, etc., those are the types of things that are impacting.  \n And so again, as I think about the entire Medical segment, remember it is highly focused in this one  \narea.  As we look across the rest of the  segment, we see really good progress on our initiatives and the  \nvarious activities that we have going on.  Specifically related to this, to your point around taking pricing,  \nas you know, taking pricing in this marketplace is complicated.  First of all, yo u have to work not only  \nwith the actual customers themselves, but you also need to work with the GPOs and make sure that  \nyou are communicating what you intend to do, when you'll do it, you have to give notice.  Remember,  ", "original_text": "As we look across the rest of the  segment, we see really good progress on our initiatives and the  \nvarious activities that we have going on. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0000270e5945711e118f99b67d79c571bdb5d39661151acb52d78a77d2b2450e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "57f6488e-51d0-424d-8f52-0a1e4dd999e1", "node_type": "1", "metadata": {"window": "And so again, as I think about the entire Medical segment, remember it is highly focused in this one  \narea.  As we look across the rest of the  segment, we see really good progress on our initiatives and the  \nvarious activities that we have going on.  Specifically related to this, to your point around taking pricing,  \nas you know, taking pricing in this marketplace is complicated.  First of all, yo u have to work not only  \nwith the actual customers themselves, but you also need to work with the GPOs and make sure that  \nyou are communicating what you intend to do, when you'll do it, you have to give notice.  Remember,  ", "original_text": "First of all, yo u have to work not only  \nwith the actual customers themselves, but you also need to work with the GPOs and make sure that  \nyou are communicating what you intend to do, when you'll do it, you have to give notice. "}, "hash": "6484348fac6afd98abc59488b4e532991b62a4c260d7917e61cec7af8fd07895", "class_name": "RelatedNodeInfo"}}, "text": "Specifically related to this, to your point around taking pricing,  \nas you know, taking pricing in this marketplace is complicated. ", "start_char_idx": 3588, "end_char_idx": 3721, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "57f6488e-51d0-424d-8f52-0a1e4dd999e1": {"__data__": {"id_": "57f6488e-51d0-424d-8f52-0a1e4dd999e1", "embedding": null, "metadata": {"window": "And so again, as I think about the entire Medical segment, remember it is highly focused in this one  \narea.  As we look across the rest of the  segment, we see really good progress on our initiatives and the  \nvarious activities that we have going on.  Specifically related to this, to your point around taking pricing,  \nas you know, taking pricing in this marketplace is complicated.  First of all, yo u have to work not only  \nwith the actual customers themselves, but you also need to work with the GPOs and make sure that  \nyou are communicating what you intend to do, when you'll do it, you have to give notice.  Remember,  ", "original_text": "First of all, yo u have to work not only  \nwith the actual customers themselves, but you also need to work with the GPOs and make sure that  \nyou are communicating what you intend to do, when you'll do it, you have to give notice. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2155e7a-5359-49a3-881d-76b80a8d8a13", "node_type": "1", "metadata": {"window": "All of our brands that we have as we see input costs going up, whe ther that  \nbe transportation, ocean freight, commodities, etc., those are the types of things that are impacting.  \n And so again, as I think about the entire Medical segment, remember it is highly focused in this one  \narea.  As we look across the rest of the  segment, we see really good progress on our initiatives and the  \nvarious activities that we have going on.  Specifically related to this, to your point around taking pricing,  \nas you know, taking pricing in this marketplace is complicated.  First of all, yo u have to work not only  \nwith the actual customers themselves, but you also need to work with the GPOs and make sure that  \nyou are communicating what you intend to do, when you'll do it, you have to give notice.  Remember,  ", "original_text": "Specifically related to this, to your point around taking pricing,  \nas you know, taking pricing in this marketplace is complicated. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4a39b7dcd6e127dc7726bc0f3bc6f0788dd9ff9f88a339133022dbb720f13a68", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38d1ed3b-cb4d-4491-bb9a-bcecb003818d", "node_type": "1", "metadata": {"window": "As we look across the rest of the  segment, we see really good progress on our initiatives and the  \nvarious activities that we have going on.  Specifically related to this, to your point around taking pricing,  \nas you know, taking pricing in this marketplace is complicated.  First of all, yo u have to work not only  \nwith the actual customers themselves, but you also need to work with the GPOs and make sure that  \nyou are communicating what you intend to do, when you'll do it, you have to give notice.  Remember,  ", "original_text": "Remember,  "}, "hash": "0d0b3fe0edebc79d4d0a64e2e2fddcebec0eb7a1415b04f60320bd5f77637a53", "class_name": "RelatedNodeInfo"}}, "text": "First of all, yo u have to work not only  \nwith the actual customers themselves, but you also need to work with the GPOs and make sure that  \nyou are communicating what you intend to do, when you'll do it, you have to give notice. ", "start_char_idx": 3721, "end_char_idx": 3952, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38d1ed3b-cb4d-4491-bb9a-bcecb003818d": {"__data__": {"id_": "38d1ed3b-cb4d-4491-bb9a-bcecb003818d", "embedding": null, "metadata": {"window": "As we look across the rest of the  segment, we see really good progress on our initiatives and the  \nvarious activities that we have going on.  Specifically related to this, to your point around taking pricing,  \nas you know, taking pricing in this marketplace is complicated.  First of all, yo u have to work not only  \nwith the actual customers themselves, but you also need to work with the GPOs and make sure that  \nyou are communicating what you intend to do, when you'll do it, you have to give notice.  Remember,  ", "original_text": "Remember,  ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4", "node_type": "4", "metadata": {"page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6a44a29a16f76a505d1713ec178da9e93c4ba4a6c58fd367f1b0e001edbcaed", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "57f6488e-51d0-424d-8f52-0a1e4dd999e1", "node_type": "1", "metadata": {"window": "And so again, as I think about the entire Medical segment, remember it is highly focused in this one  \narea.  As we look across the rest of the  segment, we see really good progress on our initiatives and the  \nvarious activities that we have going on.  Specifically related to this, to your point around taking pricing,  \nas you know, taking pricing in this marketplace is complicated.  First of all, yo u have to work not only  \nwith the actual customers themselves, but you also need to work with the GPOs and make sure that  \nyou are communicating what you intend to do, when you'll do it, you have to give notice.  Remember,  ", "original_text": "First of all, yo u have to work not only  \nwith the actual customers themselves, but you also need to work with the GPOs and make sure that  \nyou are communicating what you intend to do, when you'll do it, you have to give notice. ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa46d7274aacda9303525536e923d34dfe5d8ef4d9dc0fe07eb83c1a2ee81c19", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a18cc21a-3a3e-4d0a-b635-5547ff0276a7", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \nin many cases, these are contract s that we have that could be multi -year contracts in place at a fixed  \nprice because this is an industry that has historically not seen large fluctuations in pricing.  It's been  \nrelatively stable.  And while you might see little things here and there, it's generally been very stable.  \n And so the industry itself has been comfortable with doing longer -term pricing. ", "original_text": " \nPage 12 of 15 \n \nin many cases, these are contract s that we have that could be multi -year contracts in place at a fixed  \nprice because this is an industry that has historically not seen large fluctuations in pricing. "}, "hash": "d6b102d9548effbc73360c0261a753d9e9b3d971b25a7b61f0cfb2d276a36d44", "class_name": "RelatedNodeInfo"}}, "text": "Remember,  ", "start_char_idx": 3952, "end_char_idx": 3963, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a18cc21a-3a3e-4d0a-b635-5547ff0276a7": {"__data__": {"id_": "a18cc21a-3a3e-4d0a-b635-5547ff0276a7", "embedding": null, "metadata": {"window": " \nPage 12 of 15 \n \nin many cases, these are contract s that we have that could be multi -year contracts in place at a fixed  \nprice because this is an industry that has historically not seen large fluctuations in pricing.  It's been  \nrelatively stable.  And while you might see little things here and there, it's generally been very stable.  \n And so the industry itself has been comfortable with doing longer -term pricing. ", "original_text": " \nPage 12 of 15 \n \nin many cases, these are contract s that we have that could be multi -year contracts in place at a fixed  \nprice because this is an industry that has historically not seen large fluctuations in pricing. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38d1ed3b-cb4d-4491-bb9a-bcecb003818d", "node_type": "1", "metadata": {"window": "As we look across the rest of the  segment, we see really good progress on our initiatives and the  \nvarious activities that we have going on.  Specifically related to this, to your point around taking pricing,  \nas you know, taking pricing in this marketplace is complicated.  First of all, yo u have to work not only  \nwith the actual customers themselves, but you also need to work with the GPOs and make sure that  \nyou are communicating what you intend to do, when you'll do it, you have to give notice.  Remember,  ", "original_text": "Remember,  ", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "def6e1a1514589e25cc4e43857ab13133a4b05b328361dd113fd7470f3cd24dd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c8a6f691-a284-4b1c-be53-5fbeefa42346", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \nin many cases, these are contract s that we have that could be multi -year contracts in place at a fixed  \nprice because this is an industry that has historically not seen large fluctuations in pricing.  It's been  \nrelatively stable.  And while you might see little things here and there, it's generally been very stable.  \n And so the industry itself has been comfortable with doing longer -term pricing.  Obviously, that model  \nneeds to change going forward based on what we've seen in this hyperinflation environment that we're  \nin that not only has occurred, but seems to be lasting at least a little bit longer. ", "original_text": "It's been  \nrelatively stable. "}, "hash": "e7bcc9a693bf561a6ee439b80a448c996c520bdfdbabcdecc4d42acf4431c192", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 12 of 15 \n \nin many cases, these are contract s that we have that could be multi -year contracts in place at a fixed  \nprice because this is an industry that has historically not seen large fluctuations in pricing. ", "start_char_idx": 0, "end_char_idx": 222, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c8a6f691-a284-4b1c-be53-5fbeefa42346": {"__data__": {"id_": "c8a6f691-a284-4b1c-be53-5fbeefa42346", "embedding": null, "metadata": {"window": " \nPage 12 of 15 \n \nin many cases, these are contract s that we have that could be multi -year contracts in place at a fixed  \nprice because this is an industry that has historically not seen large fluctuations in pricing.  It's been  \nrelatively stable.  And while you might see little things here and there, it's generally been very stable.  \n And so the industry itself has been comfortable with doing longer -term pricing.  Obviously, that model  \nneeds to change going forward based on what we've seen in this hyperinflation environment that we're  \nin that not only has occurred, but seems to be lasting at least a little bit longer. ", "original_text": "It's been  \nrelatively stable. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a18cc21a-3a3e-4d0a-b635-5547ff0276a7", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \nin many cases, these are contract s that we have that could be multi -year contracts in place at a fixed  \nprice because this is an industry that has historically not seen large fluctuations in pricing.  It's been  \nrelatively stable.  And while you might see little things here and there, it's generally been very stable.  \n And so the industry itself has been comfortable with doing longer -term pricing. ", "original_text": " \nPage 12 of 15 \n \nin many cases, these are contract s that we have that could be multi -year contracts in place at a fixed  \nprice because this is an industry that has historically not seen large fluctuations in pricing. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0389bcde8e6f8fedf025c8ac4e47f07ee5e8a4fa9f89daf35e205201980aaa3e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b78c5a95-26c1-4d9d-ab0f-d9ac8372e9fc", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \nin many cases, these are contract s that we have that could be multi -year contracts in place at a fixed  \nprice because this is an industry that has historically not seen large fluctuations in pricing.  It's been  \nrelatively stable.  And while you might see little things here and there, it's generally been very stable.  \n And so the industry itself has been comfortable with doing longer -term pricing.  Obviously, that model  \nneeds to change going forward based on what we've seen in this hyperinflation environment that we're  \nin that not only has occurred, but seems to be lasting at least a little bit longer.  And so this is about  \nworking with customers on redesigning the contr acts, working with the GPOs, working directly with the  \ncustomers. ", "original_text": "And while you might see little things here and there, it's generally been very stable.  \n"}, "hash": "aa5585b5eeac3d20cce8c6019fef07f510efd1ba8f99ef2e57c640e6659dc8ab", "class_name": "RelatedNodeInfo"}}, "text": "It's been  \nrelatively stable. ", "start_char_idx": 222, "end_char_idx": 253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b78c5a95-26c1-4d9d-ab0f-d9ac8372e9fc": {"__data__": {"id_": "b78c5a95-26c1-4d9d-ab0f-d9ac8372e9fc", "embedding": null, "metadata": {"window": " \nPage 12 of 15 \n \nin many cases, these are contract s that we have that could be multi -year contracts in place at a fixed  \nprice because this is an industry that has historically not seen large fluctuations in pricing.  It's been  \nrelatively stable.  And while you might see little things here and there, it's generally been very stable.  \n And so the industry itself has been comfortable with doing longer -term pricing.  Obviously, that model  \nneeds to change going forward based on what we've seen in this hyperinflation environment that we're  \nin that not only has occurred, but seems to be lasting at least a little bit longer.  And so this is about  \nworking with customers on redesigning the contr acts, working with the GPOs, working directly with the  \ncustomers. ", "original_text": "And while you might see little things here and there, it's generally been very stable.  \n", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c8a6f691-a284-4b1c-be53-5fbeefa42346", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \nin many cases, these are contract s that we have that could be multi -year contracts in place at a fixed  \nprice because this is an industry that has historically not seen large fluctuations in pricing.  It's been  \nrelatively stable.  And while you might see little things here and there, it's generally been very stable.  \n And so the industry itself has been comfortable with doing longer -term pricing.  Obviously, that model  \nneeds to change going forward based on what we've seen in this hyperinflation environment that we're  \nin that not only has occurred, but seems to be lasting at least a little bit longer. ", "original_text": "It's been  \nrelatively stable. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1473b5c925db01ba72d942bdac26dde9f62fe66dfcd87daf7ccc458abfe84acb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ff4ab8d-cc54-4bfb-b6ef-a1bce67b6e8a", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \nin many cases, these are contract s that we have that could be multi -year contracts in place at a fixed  \nprice because this is an industry that has historically not seen large fluctuations in pricing.  It's been  \nrelatively stable.  And while you might see little things here and there, it's generally been very stable.  \n And so the industry itself has been comfortable with doing longer -term pricing.  Obviously, that model  \nneeds to change going forward based on what we've seen in this hyperinflation environment that we're  \nin that not only has occurred, but seems to be lasting at least a little bit longer.  And so this is about  \nworking with customers on redesigning the contr acts, working with the GPOs, working directly with the  \ncustomers.  We have been having those conversations. ", "original_text": "And so the industry itself has been comfortable with doing longer -term pricing. "}, "hash": "969979539a06ee5e57f42ea8e81e3a33b02b5c9856d10ad23a01e98567c2f5cc", "class_name": "RelatedNodeInfo"}}, "text": "And while you might see little things here and there, it's generally been very stable.  \n", "start_char_idx": 253, "end_char_idx": 342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ff4ab8d-cc54-4bfb-b6ef-a1bce67b6e8a": {"__data__": {"id_": "8ff4ab8d-cc54-4bfb-b6ef-a1bce67b6e8a", "embedding": null, "metadata": {"window": " \nPage 12 of 15 \n \nin many cases, these are contract s that we have that could be multi -year contracts in place at a fixed  \nprice because this is an industry that has historically not seen large fluctuations in pricing.  It's been  \nrelatively stable.  And while you might see little things here and there, it's generally been very stable.  \n And so the industry itself has been comfortable with doing longer -term pricing.  Obviously, that model  \nneeds to change going forward based on what we've seen in this hyperinflation environment that we're  \nin that not only has occurred, but seems to be lasting at least a little bit longer.  And so this is about  \nworking with customers on redesigning the contr acts, working with the GPOs, working directly with the  \ncustomers.  We have been having those conversations. ", "original_text": "And so the industry itself has been comfortable with doing longer -term pricing. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b78c5a95-26c1-4d9d-ab0f-d9ac8372e9fc", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \nin many cases, these are contract s that we have that could be multi -year contracts in place at a fixed  \nprice because this is an industry that has historically not seen large fluctuations in pricing.  It's been  \nrelatively stable.  And while you might see little things here and there, it's generally been very stable.  \n And so the industry itself has been comfortable with doing longer -term pricing.  Obviously, that model  \nneeds to change going forward based on what we've seen in this hyperinflation environment that we're  \nin that not only has occurred, but seems to be lasting at least a little bit longer.  And so this is about  \nworking with customers on redesigning the contr acts, working with the GPOs, working directly with the  \ncustomers. ", "original_text": "And while you might see little things here and there, it's generally been very stable.  \n", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0f1c871e372bd2cd1b9029da8f0e96aa98359e18cf6b38d2125d951b47869ad2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08801932-7ab2-4f1c-87e8-9ce62857aa39", "node_type": "1", "metadata": {"window": "It's been  \nrelatively stable.  And while you might see little things here and there, it's generally been very stable.  \n And so the industry itself has been comfortable with doing longer -term pricing.  Obviously, that model  \nneeds to change going forward based on what we've seen in this hyperinflation environment that we're  \nin that not only has occurred, but seems to be lasting at least a little bit longer.  And so this is about  \nworking with customers on redesigning the contr acts, working with the GPOs, working directly with the  \ncustomers.  We have been having those conversations.  So we did take price increases on five  \ncategories, effective March 1. ", "original_text": "Obviously, that model  \nneeds to change going forward based on what we've seen in this hyperinflation environment that we're  \nin that not only has occurred, but seems to be lasting at least a little bit longer. "}, "hash": "5cb95509bf75fe4521a19dc81a819e1b963575699983dbb4782c82c391122c32", "class_name": "RelatedNodeInfo"}}, "text": "And so the industry itself has been comfortable with doing longer -term pricing. ", "start_char_idx": 342, "end_char_idx": 423, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08801932-7ab2-4f1c-87e8-9ce62857aa39": {"__data__": {"id_": "08801932-7ab2-4f1c-87e8-9ce62857aa39", "embedding": null, "metadata": {"window": "It's been  \nrelatively stable.  And while you might see little things here and there, it's generally been very stable.  \n And so the industry itself has been comfortable with doing longer -term pricing.  Obviously, that model  \nneeds to change going forward based on what we've seen in this hyperinflation environment that we're  \nin that not only has occurred, but seems to be lasting at least a little bit longer.  And so this is about  \nworking with customers on redesigning the contr acts, working with the GPOs, working directly with the  \ncustomers.  We have been having those conversations.  So we did take price increases on five  \ncategories, effective March 1. ", "original_text": "Obviously, that model  \nneeds to change going forward based on what we've seen in this hyperinflation environment that we're  \nin that not only has occurred, but seems to be lasting at least a little bit longer. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ff4ab8d-cc54-4bfb-b6ef-a1bce67b6e8a", "node_type": "1", "metadata": {"window": " \nPage 12 of 15 \n \nin many cases, these are contract s that we have that could be multi -year contracts in place at a fixed  \nprice because this is an industry that has historically not seen large fluctuations in pricing.  It's been  \nrelatively stable.  And while you might see little things here and there, it's generally been very stable.  \n And so the industry itself has been comfortable with doing longer -term pricing.  Obviously, that model  \nneeds to change going forward based on what we've seen in this hyperinflation environment that we're  \nin that not only has occurred, but seems to be lasting at least a little bit longer.  And so this is about  \nworking with customers on redesigning the contr acts, working with the GPOs, working directly with the  \ncustomers.  We have been having those conversations. ", "original_text": "And so the industry itself has been comfortable with doing longer -term pricing. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "24aca34e613c454323a59ba057c5d45565b99dacec58a3cb70be3e1654b5bfec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e7e0b48-71a3-4f4a-b641-410afbb12af9", "node_type": "1", "metadata": {"window": "And while you might see little things here and there, it's generally been very stable.  \n And so the industry itself has been comfortable with doing longer -term pricing.  Obviously, that model  \nneeds to change going forward based on what we've seen in this hyperinflation environment that we're  \nin that not only has occurred, but seems to be lasting at least a little bit longer.  And so this is about  \nworking with customers on redesigning the contr acts, working with the GPOs, working directly with the  \ncustomers.  We have been having those conversations.  So we did take price increases on five  \ncategories, effective March 1.  We recently added four more categories. ", "original_text": "And so this is about  \nworking with customers on redesigning the contr acts, working with the GPOs, working directly with the  \ncustomers. "}, "hash": "a4a976263dd97fe6d16379019ef31c9d7778799e4cfd3d8d541fa094a5a929d7", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, that model  \nneeds to change going forward based on what we've seen in this hyperinflation environment that we're  \nin that not only has occurred, but seems to be lasting at least a little bit longer. ", "start_char_idx": 423, "end_char_idx": 635, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e7e0b48-71a3-4f4a-b641-410afbb12af9": {"__data__": {"id_": "4e7e0b48-71a3-4f4a-b641-410afbb12af9", "embedding": null, "metadata": {"window": "And while you might see little things here and there, it's generally been very stable.  \n And so the industry itself has been comfortable with doing longer -term pricing.  Obviously, that model  \nneeds to change going forward based on what we've seen in this hyperinflation environment that we're  \nin that not only has occurred, but seems to be lasting at least a little bit longer.  And so this is about  \nworking with customers on redesigning the contr acts, working with the GPOs, working directly with the  \ncustomers.  We have been having those conversations.  So we did take price increases on five  \ncategories, effective March 1.  We recently added four more categories. ", "original_text": "And so this is about  \nworking with customers on redesigning the contr acts, working with the GPOs, working directly with the  \ncustomers. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08801932-7ab2-4f1c-87e8-9ce62857aa39", "node_type": "1", "metadata": {"window": "It's been  \nrelatively stable.  And while you might see little things here and there, it's generally been very stable.  \n And so the industry itself has been comfortable with doing longer -term pricing.  Obviously, that model  \nneeds to change going forward based on what we've seen in this hyperinflation environment that we're  \nin that not only has occurred, but seems to be lasting at least a little bit longer.  And so this is about  \nworking with customers on redesigning the contr acts, working with the GPOs, working directly with the  \ncustomers.  We have been having those conversations.  So we did take price increases on five  \ncategories, effective March 1. ", "original_text": "Obviously, that model  \nneeds to change going forward based on what we've seen in this hyperinflation environment that we're  \nin that not only has occurred, but seems to be lasting at least a little bit longer. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4461fa237388aa9dbf48a86e4a88f341ea38f83126e8b29cda08dc33dadd1bd2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aac43029-e20c-48d6-9695-944b658dedf9", "node_type": "1", "metadata": {"window": "And so the industry itself has been comfortable with doing longer -term pricing.  Obviously, that model  \nneeds to change going forward based on what we've seen in this hyperinflation environment that we're  \nin that not only has occurred, but seems to be lasting at least a little bit longer.  And so this is about  \nworking with customers on redesigning the contr acts, working with the GPOs, working directly with the  \ncustomers.  We have been having those conversations.  So we did take price increases on five  \ncategories, effective March 1.  We recently added four more categories.  This represents thousands of  \nSKUs. ", "original_text": "We have been having those conversations. "}, "hash": "4c23d00c4cb2ecbb46ed9598db474f67cdb81d4d09c60374ca131f71cdb3398b", "class_name": "RelatedNodeInfo"}}, "text": "And so this is about  \nworking with customers on redesigning the contr acts, working with the GPOs, working directly with the  \ncustomers. ", "start_char_idx": 635, "end_char_idx": 774, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aac43029-e20c-48d6-9695-944b658dedf9": {"__data__": {"id_": "aac43029-e20c-48d6-9695-944b658dedf9", "embedding": null, "metadata": {"window": "And so the industry itself has been comfortable with doing longer -term pricing.  Obviously, that model  \nneeds to change going forward based on what we've seen in this hyperinflation environment that we're  \nin that not only has occurred, but seems to be lasting at least a little bit longer.  And so this is about  \nworking with customers on redesigning the contr acts, working with the GPOs, working directly with the  \ncustomers.  We have been having those conversations.  So we did take price increases on five  \ncategories, effective March 1.  We recently added four more categories.  This represents thousands of  \nSKUs. ", "original_text": "We have been having those conversations. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e7e0b48-71a3-4f4a-b641-410afbb12af9", "node_type": "1", "metadata": {"window": "And while you might see little things here and there, it's generally been very stable.  \n And so the industry itself has been comfortable with doing longer -term pricing.  Obviously, that model  \nneeds to change going forward based on what we've seen in this hyperinflation environment that we're  \nin that not only has occurred, but seems to be lasting at least a little bit longer.  And so this is about  \nworking with customers on redesigning the contr acts, working with the GPOs, working directly with the  \ncustomers.  We have been having those conversations.  So we did take price increases on five  \ncategories, effective March 1.  We recently added four more categories. ", "original_text": "And so this is about  \nworking with customers on redesigning the contr acts, working with the GPOs, working directly with the  \ncustomers. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b3257c67e78048999386c248cdad683d879b3f6a453dea5f54016f737c870cfa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "63c46769-d3a6-4c41-a8a7-cb76fee3943a", "node_type": "1", "metadata": {"window": "Obviously, that model  \nneeds to change going forward based on what we've seen in this hyperinflation environment that we're  \nin that not only has occurred, but seems to be lasting at least a little bit longer.  And so this is about  \nworking with customers on redesigning the contr acts, working with the GPOs, working directly with the  \ncustomers.  We have been having those conversations.  So we did take price increases on five  \ncategories, effective March 1.  We recently added four more categories.  This represents thousands of  \nSKUs.  I n fact, it's almost half of our Cardinal Health branded portfolio we have now taken price on. ", "original_text": "So we did take price increases on five  \ncategories, effective March 1. "}, "hash": "6ce4a523841ffab9e5944ad5209d29082ae2d74bd8e1fdf6c93b8a49432f7274", "class_name": "RelatedNodeInfo"}}, "text": "We have been having those conversations. ", "start_char_idx": 774, "end_char_idx": 815, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "63c46769-d3a6-4c41-a8a7-cb76fee3943a": {"__data__": {"id_": "63c46769-d3a6-4c41-a8a7-cb76fee3943a", "embedding": null, "metadata": {"window": "Obviously, that model  \nneeds to change going forward based on what we've seen in this hyperinflation environment that we're  \nin that not only has occurred, but seems to be lasting at least a little bit longer.  And so this is about  \nworking with customers on redesigning the contr acts, working with the GPOs, working directly with the  \ncustomers.  We have been having those conversations.  So we did take price increases on five  \ncategories, effective March 1.  We recently added four more categories.  This represents thousands of  \nSKUs.  I n fact, it's almost half of our Cardinal Health branded portfolio we have now taken price on. ", "original_text": "So we did take price increases on five  \ncategories, effective March 1. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aac43029-e20c-48d6-9695-944b658dedf9", "node_type": "1", "metadata": {"window": "And so the industry itself has been comfortable with doing longer -term pricing.  Obviously, that model  \nneeds to change going forward based on what we've seen in this hyperinflation environment that we're  \nin that not only has occurred, but seems to be lasting at least a little bit longer.  And so this is about  \nworking with customers on redesigning the contr acts, working with the GPOs, working directly with the  \ncustomers.  We have been having those conversations.  So we did take price increases on five  \ncategories, effective March 1.  We recently added four more categories.  This represents thousands of  \nSKUs. ", "original_text": "We have been having those conversations. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "39924f8b06c22e15af19ac091b3c4b5c208eb7cd148e8d9c699abd9ec18aa3fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5724b5e3-29d8-4dd7-9109-3dfc37d3291c", "node_type": "1", "metadata": {"window": "And so this is about  \nworking with customers on redesigning the contr acts, working with the GPOs, working directly with the  \ncustomers.  We have been having those conversations.  So we did take price increases on five  \ncategories, effective March 1.  We recently added four more categories.  This represents thousands of  \nSKUs.  I n fact, it's almost half of our Cardinal Health branded portfolio we have now taken price on.  And  \nto your point, when we compete on products, that's not just against the other distributors. ", "original_text": "We recently added four more categories. "}, "hash": "38316b5a5a674c7b4a91a09bc83ff8db1d40d5aab1d1a0d10d9419193ab9149d", "class_name": "RelatedNodeInfo"}}, "text": "So we did take price increases on five  \ncategories, effective March 1. ", "start_char_idx": 815, "end_char_idx": 887, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5724b5e3-29d8-4dd7-9109-3dfc37d3291c": {"__data__": {"id_": "5724b5e3-29d8-4dd7-9109-3dfc37d3291c", "embedding": null, "metadata": {"window": "And so this is about  \nworking with customers on redesigning the contr acts, working with the GPOs, working directly with the  \ncustomers.  We have been having those conversations.  So we did take price increases on five  \ncategories, effective March 1.  We recently added four more categories.  This represents thousands of  \nSKUs.  I n fact, it's almost half of our Cardinal Health branded portfolio we have now taken price on.  And  \nto your point, when we compete on products, that's not just against the other distributors. ", "original_text": "We recently added four more categories. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "63c46769-d3a6-4c41-a8a7-cb76fee3943a", "node_type": "1", "metadata": {"window": "Obviously, that model  \nneeds to change going forward based on what we've seen in this hyperinflation environment that we're  \nin that not only has occurred, but seems to be lasting at least a little bit longer.  And so this is about  \nworking with customers on redesigning the contr acts, working with the GPOs, working directly with the  \ncustomers.  We have been having those conversations.  So we did take price increases on five  \ncategories, effective March 1.  We recently added four more categories.  This represents thousands of  \nSKUs.  I n fact, it's almost half of our Cardinal Health branded portfolio we have now taken price on. ", "original_text": "So we did take price increases on five  \ncategories, effective March 1. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ada140239fd65dd4e480a5430bb5a4023bb26c50aaa117c9d8221a4adee8e41d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41b30bff-f2cc-4c8b-8438-4b19ef95c8ba", "node_type": "1", "metadata": {"window": "We have been having those conversations.  So we did take price increases on five  \ncategories, effective March 1.  We recently added four more categories.  This represents thousands of  \nSKUs.  I n fact, it's almost half of our Cardinal Health branded portfolio we have now taken price on.  And  \nto your point, when we compete on products, that's not just against the other distributors.  And in fact,  \nin most cases, it's against many other folks in the  marketplace, including some of the branded suppliers.  \n", "original_text": "This represents thousands of  \nSKUs. "}, "hash": "87fc68fa1bc75928737b06c8329a73440bd19c04e77e1a18a9f2dc2e3d1382bb", "class_name": "RelatedNodeInfo"}}, "text": "We recently added four more categories. ", "start_char_idx": 887, "end_char_idx": 927, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41b30bff-f2cc-4c8b-8438-4b19ef95c8ba": {"__data__": {"id_": "41b30bff-f2cc-4c8b-8438-4b19ef95c8ba", "embedding": null, "metadata": {"window": "We have been having those conversations.  So we did take price increases on five  \ncategories, effective March 1.  We recently added four more categories.  This represents thousands of  \nSKUs.  I n fact, it's almost half of our Cardinal Health branded portfolio we have now taken price on.  And  \nto your point, when we compete on products, that's not just against the other distributors.  And in fact,  \nin most cases, it's against many other folks in the  marketplace, including some of the branded suppliers.  \n", "original_text": "This represents thousands of  \nSKUs. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5724b5e3-29d8-4dd7-9109-3dfc37d3291c", "node_type": "1", "metadata": {"window": "And so this is about  \nworking with customers on redesigning the contr acts, working with the GPOs, working directly with the  \ncustomers.  We have been having those conversations.  So we did take price increases on five  \ncategories, effective March 1.  We recently added four more categories.  This represents thousands of  \nSKUs.  I n fact, it's almost half of our Cardinal Health branded portfolio we have now taken price on.  And  \nto your point, when we compete on products, that's not just against the other distributors. ", "original_text": "We recently added four more categories. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "39814e23d343295d091e9432816ba9aef4b99efe2a6d812f6403c1cea5ed3757", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8f634576-27fd-43de-b9b8-795b45fd65a6", "node_type": "1", "metadata": {"window": "So we did take price increases on five  \ncategories, effective March 1.  We recently added four more categories.  This represents thousands of  \nSKUs.  I n fact, it's almost half of our Cardinal Health branded portfolio we have now taken price on.  And  \nto your point, when we compete on products, that's not just against the other distributors.  And in fact,  \nin most cases, it's against many other folks in the  marketplace, including some of the branded suppliers.  \n So we do have to understand what they are doing in the market and understanding how that as we  \nraise price, we still remain competitive in the best option for our customers.  \n \n", "original_text": "I n fact, it's almost half of our Cardinal Health branded portfolio we have now taken price on. "}, "hash": "2824d153f94b7e626926117889044d05c9d49bc5e61b740088d0745c9b6ad6e4", "class_name": "RelatedNodeInfo"}}, "text": "This represents thousands of  \nSKUs. ", "start_char_idx": 927, "end_char_idx": 964, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8f634576-27fd-43de-b9b8-795b45fd65a6": {"__data__": {"id_": "8f634576-27fd-43de-b9b8-795b45fd65a6", "embedding": null, "metadata": {"window": "So we did take price increases on five  \ncategories, effective March 1.  We recently added four more categories.  This represents thousands of  \nSKUs.  I n fact, it's almost half of our Cardinal Health branded portfolio we have now taken price on.  And  \nto your point, when we compete on products, that's not just against the other distributors.  And in fact,  \nin most cases, it's against many other folks in the  marketplace, including some of the branded suppliers.  \n So we do have to understand what they are doing in the market and understanding how that as we  \nraise price, we still remain competitive in the best option for our customers.  \n \n", "original_text": "I n fact, it's almost half of our Cardinal Health branded portfolio we have now taken price on. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41b30bff-f2cc-4c8b-8438-4b19ef95c8ba", "node_type": "1", "metadata": {"window": "We have been having those conversations.  So we did take price increases on five  \ncategories, effective March 1.  We recently added four more categories.  This represents thousands of  \nSKUs.  I n fact, it's almost half of our Cardinal Health branded portfolio we have now taken price on.  And  \nto your point, when we compete on products, that's not just against the other distributors.  And in fact,  \nin most cases, it's against many other folks in the  marketplace, including some of the branded suppliers.  \n", "original_text": "This represents thousands of  \nSKUs. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2b49590f51dc973cce221accbfdb08590f82ed99702156aeba23bf41825938c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "911e584d-6065-4bd5-bcf6-d1244470e7c1", "node_type": "1", "metadata": {"window": "We recently added four more categories.  This represents thousands of  \nSKUs.  I n fact, it's almost half of our Cardinal Health branded portfolio we have now taken price on.  And  \nto your point, when we compete on products, that's not just against the other distributors.  And in fact,  \nin most cases, it's against many other folks in the  marketplace, including some of the branded suppliers.  \n So we do have to understand what they are doing in the market and understanding how that as we  \nraise price, we still remain competitive in the best option for our customers.  \n \n Operator :  And our next  question comes from Ricky Goldwasser with Morgan Stanley.  \n \n", "original_text": "And  \nto your point, when we compete on products, that's not just against the other distributors. "}, "hash": "8fec7cffe2e01cc4cfd89b0620c3a11e730afb65a9ea4d32a1972894643728f3", "class_name": "RelatedNodeInfo"}}, "text": "I n fact, it's almost half of our Cardinal Health branded portfolio we have now taken price on. ", "start_char_idx": 964, "end_char_idx": 1060, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "911e584d-6065-4bd5-bcf6-d1244470e7c1": {"__data__": {"id_": "911e584d-6065-4bd5-bcf6-d1244470e7c1", "embedding": null, "metadata": {"window": "We recently added four more categories.  This represents thousands of  \nSKUs.  I n fact, it's almost half of our Cardinal Health branded portfolio we have now taken price on.  And  \nto your point, when we compete on products, that's not just against the other distributors.  And in fact,  \nin most cases, it's against many other folks in the  marketplace, including some of the branded suppliers.  \n So we do have to understand what they are doing in the market and understanding how that as we  \nraise price, we still remain competitive in the best option for our customers.  \n \n Operator :  And our next  question comes from Ricky Goldwasser with Morgan Stanley.  \n \n", "original_text": "And  \nto your point, when we compete on products, that's not just against the other distributors. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8f634576-27fd-43de-b9b8-795b45fd65a6", "node_type": "1", "metadata": {"window": "So we did take price increases on five  \ncategories, effective March 1.  We recently added four more categories.  This represents thousands of  \nSKUs.  I n fact, it's almost half of our Cardinal Health branded portfolio we have now taken price on.  And  \nto your point, when we compete on products, that's not just against the other distributors.  And in fact,  \nin most cases, it's against many other folks in the  marketplace, including some of the branded suppliers.  \n So we do have to understand what they are doing in the market and understanding how that as we  \nraise price, we still remain competitive in the best option for our customers.  \n \n", "original_text": "I n fact, it's almost half of our Cardinal Health branded portfolio we have now taken price on. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ecc64b3e34878533c17980baca970439b26b1be91a2205841e4c43ba052666e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66c345a9-3547-4af0-a31f-65f281506e14", "node_type": "1", "metadata": {"window": "This represents thousands of  \nSKUs.  I n fact, it's almost half of our Cardinal Health branded portfolio we have now taken price on.  And  \nto your point, when we compete on products, that's not just against the other distributors.  And in fact,  \nin most cases, it's against many other folks in the  marketplace, including some of the branded suppliers.  \n So we do have to understand what they are doing in the market and understanding how that as we  \nraise price, we still remain competitive in the best option for our customers.  \n \n Operator :  And our next  question comes from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yeah, hi. ", "original_text": "And in fact,  \nin most cases, it's against many other folks in the  marketplace, including some of the branded suppliers.  \n"}, "hash": "b8981be0bac4814de6827b8df4b14e3d5fbde96f73f4db4f176cc0591d8c51f5", "class_name": "RelatedNodeInfo"}}, "text": "And  \nto your point, when we compete on products, that's not just against the other distributors. ", "start_char_idx": 1060, "end_char_idx": 1158, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66c345a9-3547-4af0-a31f-65f281506e14": {"__data__": {"id_": "66c345a9-3547-4af0-a31f-65f281506e14", "embedding": null, "metadata": {"window": "This represents thousands of  \nSKUs.  I n fact, it's almost half of our Cardinal Health branded portfolio we have now taken price on.  And  \nto your point, when we compete on products, that's not just against the other distributors.  And in fact,  \nin most cases, it's against many other folks in the  marketplace, including some of the branded suppliers.  \n So we do have to understand what they are doing in the market and understanding how that as we  \nraise price, we still remain competitive in the best option for our customers.  \n \n Operator :  And our next  question comes from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yeah, hi. ", "original_text": "And in fact,  \nin most cases, it's against many other folks in the  marketplace, including some of the branded suppliers.  \n", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "911e584d-6065-4bd5-bcf6-d1244470e7c1", "node_type": "1", "metadata": {"window": "We recently added four more categories.  This represents thousands of  \nSKUs.  I n fact, it's almost half of our Cardinal Health branded portfolio we have now taken price on.  And  \nto your point, when we compete on products, that's not just against the other distributors.  And in fact,  \nin most cases, it's against many other folks in the  marketplace, including some of the branded suppliers.  \n So we do have to understand what they are doing in the market and understanding how that as we  \nraise price, we still remain competitive in the best option for our customers.  \n \n Operator :  And our next  question comes from Ricky Goldwasser with Morgan Stanley.  \n \n", "original_text": "And  \nto your point, when we compete on products, that's not just against the other distributors. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad2c871b9eca61da38451aee3d47e32198ace2e9c269a667d1353c5b51ff614b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce05808e-24af-4a30-982d-84a75b105a75", "node_type": "1", "metadata": {"window": "I n fact, it's almost half of our Cardinal Health branded portfolio we have now taken price on.  And  \nto your point, when we compete on products, that's not just against the other distributors.  And in fact,  \nin most cases, it's against many other folks in the  marketplace, including some of the branded suppliers.  \n So we do have to understand what they are doing in the market and understanding how that as we  \nraise price, we still remain competitive in the best option for our customers.  \n \n Operator :  And our next  question comes from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yeah, hi.  Good morning. ", "original_text": "So we do have to understand what they are doing in the market and understanding how that as we  \nraise price, we still remain competitive in the best option for our customers.  \n \n"}, "hash": "dad55ebc985077d26b727201c0c3ced67caa46418891de921a268907f0fe57d6", "class_name": "RelatedNodeInfo"}}, "text": "And in fact,  \nin most cases, it's against many other folks in the  marketplace, including some of the branded suppliers.  \n", "start_char_idx": 1158, "end_char_idx": 1282, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce05808e-24af-4a30-982d-84a75b105a75": {"__data__": {"id_": "ce05808e-24af-4a30-982d-84a75b105a75", "embedding": null, "metadata": {"window": "I n fact, it's almost half of our Cardinal Health branded portfolio we have now taken price on.  And  \nto your point, when we compete on products, that's not just against the other distributors.  And in fact,  \nin most cases, it's against many other folks in the  marketplace, including some of the branded suppliers.  \n So we do have to understand what they are doing in the market and understanding how that as we  \nraise price, we still remain competitive in the best option for our customers.  \n \n Operator :  And our next  question comes from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yeah, hi.  Good morning. ", "original_text": "So we do have to understand what they are doing in the market and understanding how that as we  \nraise price, we still remain competitive in the best option for our customers.  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66c345a9-3547-4af0-a31f-65f281506e14", "node_type": "1", "metadata": {"window": "This represents thousands of  \nSKUs.  I n fact, it's almost half of our Cardinal Health branded portfolio we have now taken price on.  And  \nto your point, when we compete on products, that's not just against the other distributors.  And in fact,  \nin most cases, it's against many other folks in the  marketplace, including some of the branded suppliers.  \n So we do have to understand what they are doing in the market and understanding how that as we  \nraise price, we still remain competitive in the best option for our customers.  \n \n Operator :  And our next  question comes from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yeah, hi. ", "original_text": "And in fact,  \nin most cases, it's against many other folks in the  marketplace, including some of the branded suppliers.  \n", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aa0997ed8b1543b179bd91cb4c1cf5fa7b952ae708f94a7961367acbf1797f03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99a37b9b-8be1-408f-83ae-13d9bfd03c9d", "node_type": "1", "metadata": {"window": "And  \nto your point, when we compete on products, that's not just against the other distributors.  And in fact,  \nin most cases, it's against many other folks in the  marketplace, including some of the branded suppliers.  \n So we do have to understand what they are doing in the market and understanding how that as we  \nraise price, we still remain competitive in the best option for our customers.  \n \n Operator :  And our next  question comes from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yeah, hi.  Good morning.  So a couple of questions here. ", "original_text": "Operator :  And our next  question comes from Ricky Goldwasser with Morgan Stanley.  \n \n"}, "hash": "5bd5e0aa18f71a076b9a182c93fdf2a2e94c2f248855c2acd3033ca375278033", "class_name": "RelatedNodeInfo"}}, "text": "So we do have to understand what they are doing in the market and understanding how that as we  \nraise price, we still remain competitive in the best option for our customers.  \n \n", "start_char_idx": 1282, "end_char_idx": 1462, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99a37b9b-8be1-408f-83ae-13d9bfd03c9d": {"__data__": {"id_": "99a37b9b-8be1-408f-83ae-13d9bfd03c9d", "embedding": null, "metadata": {"window": "And  \nto your point, when we compete on products, that's not just against the other distributors.  And in fact,  \nin most cases, it's against many other folks in the  marketplace, including some of the branded suppliers.  \n So we do have to understand what they are doing in the market and understanding how that as we  \nraise price, we still remain competitive in the best option for our customers.  \n \n Operator :  And our next  question comes from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yeah, hi.  Good morning.  So a couple of questions here. ", "original_text": "Operator :  And our next  question comes from Ricky Goldwasser with Morgan Stanley.  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce05808e-24af-4a30-982d-84a75b105a75", "node_type": "1", "metadata": {"window": "I n fact, it's almost half of our Cardinal Health branded portfolio we have now taken price on.  And  \nto your point, when we compete on products, that's not just against the other distributors.  And in fact,  \nin most cases, it's against many other folks in the  marketplace, including some of the branded suppliers.  \n So we do have to understand what they are doing in the market and understanding how that as we  \nraise price, we still remain competitive in the best option for our customers.  \n \n Operator :  And our next  question comes from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yeah, hi.  Good morning. ", "original_text": "So we do have to understand what they are doing in the market and understanding how that as we  \nraise price, we still remain competitive in the best option for our customers.  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66c5e83c0c309c25c30b9af0ff501a2b0e45e54f4e2a6276d5b3612264c924c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "66b40f79-8660-45ee-b5b0-f351c90b1621", "node_type": "1", "metadata": {"window": "And in fact,  \nin most cases, it's against many other folks in the  marketplace, including some of the branded suppliers.  \n So we do have to understand what they are doing in the market and understanding how that as we  \nraise price, we still remain competitive in the best option for our customers.  \n \n Operator :  And our next  question comes from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yeah, hi.  Good morning.  So a couple of questions here.  First of all, Mike, if we just  \nstep back, I think you talked in the prepared remarks about investing and building in new  facility in the  \nMedical segment. ", "original_text": "Ricky Goldwasser:  Yeah, hi. "}, "hash": "f9805e2d6a63b71ddc30d89ac79eea74a57804b8b6ce5f1e13a1a1d2264a7846", "class_name": "RelatedNodeInfo"}}, "text": "Operator :  And our next  question comes from Ricky Goldwasser with Morgan Stanley.  \n \n", "start_char_idx": 1462, "end_char_idx": 1550, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "66b40f79-8660-45ee-b5b0-f351c90b1621": {"__data__": {"id_": "66b40f79-8660-45ee-b5b0-f351c90b1621", "embedding": null, "metadata": {"window": "And in fact,  \nin most cases, it's against many other folks in the  marketplace, including some of the branded suppliers.  \n So we do have to understand what they are doing in the market and understanding how that as we  \nraise price, we still remain competitive in the best option for our customers.  \n \n Operator :  And our next  question comes from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yeah, hi.  Good morning.  So a couple of questions here.  First of all, Mike, if we just  \nstep back, I think you talked in the prepared remarks about investing and building in new  facility in the  \nMedical segment. ", "original_text": "Ricky Goldwasser:  Yeah, hi. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99a37b9b-8be1-408f-83ae-13d9bfd03c9d", "node_type": "1", "metadata": {"window": "And  \nto your point, when we compete on products, that's not just against the other distributors.  And in fact,  \nin most cases, it's against many other folks in the  marketplace, including some of the branded suppliers.  \n So we do have to understand what they are doing in the market and understanding how that as we  \nraise price, we still remain competitive in the best option for our customers.  \n \n Operator :  And our next  question comes from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yeah, hi.  Good morning.  So a couple of questions here. ", "original_text": "Operator :  And our next  question comes from Ricky Goldwasser with Morgan Stanley.  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5fcd16a39b0bd0b283b7b99ece188ee3efef04aa20288403e5da92e3ece95263", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03305e7b-fbfc-4ffc-b71d-393206adb158", "node_type": "1", "metadata": {"window": "So we do have to understand what they are doing in the market and understanding how that as we  \nraise price, we still remain competitive in the best option for our customers.  \n \n Operator :  And our next  question comes from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yeah, hi.  Good morning.  So a couple of questions here.  First of all, Mike, if we just  \nstep back, I think you talked in the prepared remarks about investing and building in new  facility in the  \nMedical segment.  But if you really think back and we think about sort of the two segments that you  \nhave, are there any synergies between drug distribution and medical segments? ", "original_text": "Good morning. "}, "hash": "d9dbafa38dd90dab99bed74aed135f29115bdf34b1e09c50bd889cd2d3aa44e3", "class_name": "RelatedNodeInfo"}}, "text": "Ricky Goldwasser:  Yeah, hi. ", "start_char_idx": 1550, "end_char_idx": 1579, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03305e7b-fbfc-4ffc-b71d-393206adb158": {"__data__": {"id_": "03305e7b-fbfc-4ffc-b71d-393206adb158", "embedding": null, "metadata": {"window": "So we do have to understand what they are doing in the market and understanding how that as we  \nraise price, we still remain competitive in the best option for our customers.  \n \n Operator :  And our next  question comes from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yeah, hi.  Good morning.  So a couple of questions here.  First of all, Mike, if we just  \nstep back, I think you talked in the prepared remarks about investing and building in new  facility in the  \nMedical segment.  But if you really think back and we think about sort of the two segments that you  \nhave, are there any synergies between drug distribution and medical segments? ", "original_text": "Good morning. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "66b40f79-8660-45ee-b5b0-f351c90b1621", "node_type": "1", "metadata": {"window": "And in fact,  \nin most cases, it's against many other folks in the  marketplace, including some of the branded suppliers.  \n So we do have to understand what they are doing in the market and understanding how that as we  \nraise price, we still remain competitive in the best option for our customers.  \n \n Operator :  And our next  question comes from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yeah, hi.  Good morning.  So a couple of questions here.  First of all, Mike, if we just  \nstep back, I think you talked in the prepared remarks about investing and building in new  facility in the  \nMedical segment. ", "original_text": "Ricky Goldwasser:  Yeah, hi. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "da9fb16a59a01320a61477a3511464030adcdf5f530b3ed796d095611dc386fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3669f9ad-768d-4f15-afe8-1562c51fb34b", "node_type": "1", "metadata": {"window": "Operator :  And our next  question comes from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yeah, hi.  Good morning.  So a couple of questions here.  First of all, Mike, if we just  \nstep back, I think you talked in the prepared remarks about investing and building in new  facility in the  \nMedical segment.  But if you really think back and we think about sort of the two segments that you  \nhave, are there any synergies between drug distribution and medical segments?  And what is really the  \nrationale to own a business on the M edical side that has been underperforming for a very long time?  \n  \n", "original_text": "So a couple of questions here. "}, "hash": "c65a14a8ebed953f41d0c0f81a81f56077e65f89d39cb637fe00345e020aac83", "class_name": "RelatedNodeInfo"}}, "text": "Good morning. ", "start_char_idx": 1579, "end_char_idx": 1593, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3669f9ad-768d-4f15-afe8-1562c51fb34b": {"__data__": {"id_": "3669f9ad-768d-4f15-afe8-1562c51fb34b", "embedding": null, "metadata": {"window": "Operator :  And our next  question comes from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yeah, hi.  Good morning.  So a couple of questions here.  First of all, Mike, if we just  \nstep back, I think you talked in the prepared remarks about investing and building in new  facility in the  \nMedical segment.  But if you really think back and we think about sort of the two segments that you  \nhave, are there any synergies between drug distribution and medical segments?  And what is really the  \nrationale to own a business on the M edical side that has been underperforming for a very long time?  \n  \n", "original_text": "So a couple of questions here. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03305e7b-fbfc-4ffc-b71d-393206adb158", "node_type": "1", "metadata": {"window": "So we do have to understand what they are doing in the market and understanding how that as we  \nraise price, we still remain competitive in the best option for our customers.  \n \n Operator :  And our next  question comes from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yeah, hi.  Good morning.  So a couple of questions here.  First of all, Mike, if we just  \nstep back, I think you talked in the prepared remarks about investing and building in new  facility in the  \nMedical segment.  But if you really think back and we think about sort of the two segments that you  \nhave, are there any synergies between drug distribution and medical segments? ", "original_text": "Good morning. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6efe8cb8867ee7302cae783a1e34aab3c4592609420966fdada6eea4db6cd1a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56b05c35-f977-40b0-916c-2bfd4d477ad6", "node_type": "1", "metadata": {"window": "Ricky Goldwasser:  Yeah, hi.  Good morning.  So a couple of questions here.  First of all, Mike, if we just  \nstep back, I think you talked in the prepared remarks about investing and building in new  facility in the  \nMedical segment.  But if you really think back and we think about sort of the two segments that you  \nhave, are there any synergies between drug distribution and medical segments?  And what is really the  \nrationale to own a business on the M edical side that has been underperforming for a very long time?  \n  \n Mike  Kaufmann:   Thanks for the question. ", "original_text": "First of all, Mike, if we just  \nstep back, I think you talked in the prepared remarks about investing and building in new  facility in the  \nMedical segment. "}, "hash": "fab35f26e363c4d422a389ffd575fa36b4ef31a69bd57b1323865b11df2124bc", "class_name": "RelatedNodeInfo"}}, "text": "So a couple of questions here. ", "start_char_idx": 1593, "end_char_idx": 1624, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56b05c35-f977-40b0-916c-2bfd4d477ad6": {"__data__": {"id_": "56b05c35-f977-40b0-916c-2bfd4d477ad6", "embedding": null, "metadata": {"window": "Ricky Goldwasser:  Yeah, hi.  Good morning.  So a couple of questions here.  First of all, Mike, if we just  \nstep back, I think you talked in the prepared remarks about investing and building in new  facility in the  \nMedical segment.  But if you really think back and we think about sort of the two segments that you  \nhave, are there any synergies between drug distribution and medical segments?  And what is really the  \nrationale to own a business on the M edical side that has been underperforming for a very long time?  \n  \n Mike  Kaufmann:   Thanks for the question. ", "original_text": "First of all, Mike, if we just  \nstep back, I think you talked in the prepared remarks about investing and building in new  facility in the  \nMedical segment. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3669f9ad-768d-4f15-afe8-1562c51fb34b", "node_type": "1", "metadata": {"window": "Operator :  And our next  question comes from Ricky Goldwasser with Morgan Stanley.  \n \n Ricky Goldwasser:  Yeah, hi.  Good morning.  So a couple of questions here.  First of all, Mike, if we just  \nstep back, I think you talked in the prepared remarks about investing and building in new  facility in the  \nMedical segment.  But if you really think back and we think about sort of the two segments that you  \nhave, are there any synergies between drug distribution and medical segments?  And what is really the  \nrationale to own a business on the M edical side that has been underperforming for a very long time?  \n  \n", "original_text": "So a couple of questions here. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8764f29291c917c19726a9038fad0b335efede529ba271631e35e536019b3fca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b3a80dac-4715-4cb2-a887-2a8ba0ca5198", "node_type": "1", "metadata": {"window": "Good morning.  So a couple of questions here.  First of all, Mike, if we just  \nstep back, I think you talked in the prepared remarks about investing and building in new  facility in the  \nMedical segment.  But if you really think back and we think about sort of the two segments that you  \nhave, are there any synergies between drug distribution and medical segments?  And what is really the  \nrationale to own a business on the M edical side that has been underperforming for a very long time?  \n  \n Mike  Kaufmann:   Thanks for the question.  I appreciate it. ", "original_text": "But if you really think back and we think about sort of the two segments that you  \nhave, are there any synergies between drug distribution and medical segments? "}, "hash": "f50c2977de9a22dbb9c4f7ada31a99af62fcdcd17fab12fbd4c934b11c3c011f", "class_name": "RelatedNodeInfo"}}, "text": "First of all, Mike, if we just  \nstep back, I think you talked in the prepared remarks about investing and building in new  facility in the  \nMedical segment. ", "start_char_idx": 1624, "end_char_idx": 1783, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b3a80dac-4715-4cb2-a887-2a8ba0ca5198": {"__data__": {"id_": "b3a80dac-4715-4cb2-a887-2a8ba0ca5198", "embedding": null, "metadata": {"window": "Good morning.  So a couple of questions here.  First of all, Mike, if we just  \nstep back, I think you talked in the prepared remarks about investing and building in new  facility in the  \nMedical segment.  But if you really think back and we think about sort of the two segments that you  \nhave, are there any synergies between drug distribution and medical segments?  And what is really the  \nrationale to own a business on the M edical side that has been underperforming for a very long time?  \n  \n Mike  Kaufmann:   Thanks for the question.  I appreciate it. ", "original_text": "But if you really think back and we think about sort of the two segments that you  \nhave, are there any synergies between drug distribution and medical segments? ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56b05c35-f977-40b0-916c-2bfd4d477ad6", "node_type": "1", "metadata": {"window": "Ricky Goldwasser:  Yeah, hi.  Good morning.  So a couple of questions here.  First of all, Mike, if we just  \nstep back, I think you talked in the prepared remarks about investing and building in new  facility in the  \nMedical segment.  But if you really think back and we think about sort of the two segments that you  \nhave, are there any synergies between drug distribution and medical segments?  And what is really the  \nrationale to own a business on the M edical side that has been underperforming for a very long time?  \n  \n Mike  Kaufmann:   Thanks for the question. ", "original_text": "First of all, Mike, if we just  \nstep back, I think you talked in the prepared remarks about investing and building in new  facility in the  \nMedical segment. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5f642609090c76556d5d6c80492a58bf529d5a2e10afa1bc6dc8d8e9c9fa444b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91750785-217a-4810-bb52-2f80c65fdbf7", "node_type": "1", "metadata": {"window": "So a couple of questions here.  First of all, Mike, if we just  \nstep back, I think you talked in the prepared remarks about investing and building in new  facility in the  \nMedical segment.  But if you really think back and we think about sort of the two segments that you  \nhave, are there any synergies between drug distribution and medical segments?  And what is really the  \nrationale to own a business on the M edical side that has been underperforming for a very long time?  \n  \n Mike  Kaufmann:   Thanks for the question.  I appreciate it.  A couple of things. ", "original_text": "And what is really the  \nrationale to own a business on the M edical side that has been underperforming for a very long time?  \n  \n"}, "hash": "50865126f594721f6bad46297b5961d71127a15092aaa0b6a86f6dfc3cccc56f", "class_name": "RelatedNodeInfo"}}, "text": "But if you really think back and we think about sort of the two segments that you  \nhave, are there any synergies between drug distribution and medical segments? ", "start_char_idx": 1783, "end_char_idx": 1945, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91750785-217a-4810-bb52-2f80c65fdbf7": {"__data__": {"id_": "91750785-217a-4810-bb52-2f80c65fdbf7", "embedding": null, "metadata": {"window": "So a couple of questions here.  First of all, Mike, if we just  \nstep back, I think you talked in the prepared remarks about investing and building in new  facility in the  \nMedical segment.  But if you really think back and we think about sort of the two segments that you  \nhave, are there any synergies between drug distribution and medical segments?  And what is really the  \nrationale to own a business on the M edical side that has been underperforming for a very long time?  \n  \n Mike  Kaufmann:   Thanks for the question.  I appreciate it.  A couple of things. ", "original_text": "And what is really the  \nrationale to own a business on the M edical side that has been underperforming for a very long time?  \n  \n", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b3a80dac-4715-4cb2-a887-2a8ba0ca5198", "node_type": "1", "metadata": {"window": "Good morning.  So a couple of questions here.  First of all, Mike, if we just  \nstep back, I think you talked in the prepared remarks about investing and building in new  facility in the  \nMedical segment.  But if you really think back and we think about sort of the two segments that you  \nhave, are there any synergies between drug distribution and medical segments?  And what is really the  \nrationale to own a business on the M edical side that has been underperforming for a very long time?  \n  \n Mike  Kaufmann:   Thanks for the question.  I appreciate it. ", "original_text": "But if you really think back and we think about sort of the two segments that you  \nhave, are there any synergies between drug distribution and medical segments? ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6f497628edf328d330c9daad3680f7565831197f35cb0774d3e9628ac62d1285", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "46ed69e3-db5b-4259-b8a1-6d8d3da4fce7", "node_type": "1", "metadata": {"window": "First of all, Mike, if we just  \nstep back, I think you talked in the prepared remarks about investing and building in new  facility in the  \nMedical segment.  But if you really think back and we think about sort of the two segments that you  \nhave, are there any synergies between drug distribution and medical segments?  And what is really the  \nrationale to own a business on the M edical side that has been underperforming for a very long time?  \n  \n Mike  Kaufmann:   Thanks for the question.  I appreciate it.  A couple of things.  As we've said before, we  \ndo see some synergies between M&P. ", "original_text": "Mike  Kaufmann:   Thanks for the question. "}, "hash": "7c695f47c63f1b8c948a7c345853d3378afdc56c0c2400115aedc13346556bc8", "class_name": "RelatedNodeInfo"}}, "text": "And what is really the  \nrationale to own a business on the M edical side that has been underperforming for a very long time?  \n  \n", "start_char_idx": 1945, "end_char_idx": 2076, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "46ed69e3-db5b-4259-b8a1-6d8d3da4fce7": {"__data__": {"id_": "46ed69e3-db5b-4259-b8a1-6d8d3da4fce7", "embedding": null, "metadata": {"window": "First of all, Mike, if we just  \nstep back, I think you talked in the prepared remarks about investing and building in new  facility in the  \nMedical segment.  But if you really think back and we think about sort of the two segments that you  \nhave, are there any synergies between drug distribution and medical segments?  And what is really the  \nrationale to own a business on the M edical side that has been underperforming for a very long time?  \n  \n Mike  Kaufmann:   Thanks for the question.  I appreciate it.  A couple of things.  As we've said before, we  \ndo see some synergies between M&P. ", "original_text": "Mike  Kaufmann:   Thanks for the question. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91750785-217a-4810-bb52-2f80c65fdbf7", "node_type": "1", "metadata": {"window": "So a couple of questions here.  First of all, Mike, if we just  \nstep back, I think you talked in the prepared remarks about investing and building in new  facility in the  \nMedical segment.  But if you really think back and we think about sort of the two segments that you  \nhave, are there any synergies between drug distribution and medical segments?  And what is really the  \nrationale to own a business on the M edical side that has been underperforming for a very long time?  \n  \n Mike  Kaufmann:   Thanks for the question.  I appreciate it.  A couple of things. ", "original_text": "And what is really the  \nrationale to own a business on the M edical side that has been underperforming for a very long time?  \n  \n", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef363c747c8e6ecb1bb1606ef247fa6250a721b4fdff29f17b16885c00ffb134", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ccd6590d-7a89-4519-a1c3-9ed03693d2b0", "node_type": "1", "metadata": {"window": "But if you really think back and we think about sort of the two segments that you  \nhave, are there any synergies between drug distribution and medical segments?  And what is really the  \nrationale to own a business on the M edical side that has been underperforming for a very long time?  \n  \n Mike  Kaufmann:   Thanks for the question.  I appreciate it.  A couple of things.  As we've said before, we  \ndo see some synergies between M&P.  We go to market together with our GPO selling team s, we share  \ncorporate overhead together, we work on our innovation and technology group together. ", "original_text": "I appreciate it. "}, "hash": "5e3d1319bb4317aca58dc6205e958fee059cff5e815566e2fad68717a8045e99", "class_name": "RelatedNodeInfo"}}, "text": "Mike  Kaufmann:   Thanks for the question. ", "start_char_idx": 2076, "end_char_idx": 2119, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ccd6590d-7a89-4519-a1c3-9ed03693d2b0": {"__data__": {"id_": "ccd6590d-7a89-4519-a1c3-9ed03693d2b0", "embedding": null, "metadata": {"window": "But if you really think back and we think about sort of the two segments that you  \nhave, are there any synergies between drug distribution and medical segments?  And what is really the  \nrationale to own a business on the M edical side that has been underperforming for a very long time?  \n  \n Mike  Kaufmann:   Thanks for the question.  I appreciate it.  A couple of things.  As we've said before, we  \ndo see some synergies between M&P.  We go to market together with our GPO selling team s, we share  \ncorporate overhead together, we work on our innovation and technology group together. ", "original_text": "I appreciate it. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "46ed69e3-db5b-4259-b8a1-6d8d3da4fce7", "node_type": "1", "metadata": {"window": "First of all, Mike, if we just  \nstep back, I think you talked in the prepared remarks about investing and building in new  facility in the  \nMedical segment.  But if you really think back and we think about sort of the two segments that you  \nhave, are there any synergies between drug distribution and medical segments?  And what is really the  \nrationale to own a business on the M edical side that has been underperforming for a very long time?  \n  \n Mike  Kaufmann:   Thanks for the question.  I appreciate it.  A couple of things.  As we've said before, we  \ndo see some synergies between M&P. ", "original_text": "Mike  Kaufmann:   Thanks for the question. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0df79987bca0a6e8250f5ff8a13dbe5835927c0745f62d8c5afadbec930a2a6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17b7b498-765e-45e6-b193-1c9ca43e2926", "node_type": "1", "metadata": {"window": "And what is really the  \nrationale to own a business on the M edical side that has been underperforming for a very long time?  \n  \n Mike  Kaufmann:   Thanks for the question.  I appreciate it.  A couple of things.  As we've said before, we  \ndo see some synergies between M&P.  We go to market together with our GPO selling team s, we share  \ncorporate overhead together, we work on our innovation and technology group together.  We work  \ntogether on back -office types of things. ", "original_text": "A couple of things. "}, "hash": "0368ed9124a673aeffad8131743ed3b0205bf20e5de3a48ee1be8cecd7cce1d7", "class_name": "RelatedNodeInfo"}}, "text": "I appreciate it. ", "start_char_idx": 2119, "end_char_idx": 2136, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17b7b498-765e-45e6-b193-1c9ca43e2926": {"__data__": {"id_": "17b7b498-765e-45e6-b193-1c9ca43e2926", "embedding": null, "metadata": {"window": "And what is really the  \nrationale to own a business on the M edical side that has been underperforming for a very long time?  \n  \n Mike  Kaufmann:   Thanks for the question.  I appreciate it.  A couple of things.  As we've said before, we  \ndo see some synergies between M&P.  We go to market together with our GPO selling team s, we share  \ncorporate overhead together, we work on our innovation and technology group together.  We work  \ntogether on back -office types of things. ", "original_text": "A couple of things. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ccd6590d-7a89-4519-a1c3-9ed03693d2b0", "node_type": "1", "metadata": {"window": "But if you really think back and we think about sort of the two segments that you  \nhave, are there any synergies between drug distribution and medical segments?  And what is really the  \nrationale to own a business on the M edical side that has been underperforming for a very long time?  \n  \n Mike  Kaufmann:   Thanks for the question.  I appreciate it.  A couple of things.  As we've said before, we  \ndo see some synergies between M&P.  We go to market together with our GPO selling team s, we share  \ncorporate overhead together, we work on our innovation and technology group together. ", "original_text": "I appreciate it. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8c63c4f13d12874234379b583c57b7acf11875d17211030b4af4cd7c6bbda706", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1050436c-fee6-4e50-87aa-6e7cee01d638", "node_type": "1", "metadata": {"window": "Mike  Kaufmann:   Thanks for the question.  I appreciate it.  A couple of things.  As we've said before, we  \ndo see some synergies between M&P.  We go to market together with our GPO selling team s, we share  \ncorporate overhead together, we work on our innovation and technology group together.  We work  \ntogether on back -office types of things.  Clearly, acute care customers are common to both segments.  \n", "original_text": "As we've said before, we  \ndo see some synergies between M&P. "}, "hash": "2b551a17b2809f0b8d6be1c1f9994a72dc01164040e93badb15e4bc7e0250dec", "class_name": "RelatedNodeInfo"}}, "text": "A couple of things. ", "start_char_idx": 2136, "end_char_idx": 2156, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1050436c-fee6-4e50-87aa-6e7cee01d638": {"__data__": {"id_": "1050436c-fee6-4e50-87aa-6e7cee01d638", "embedding": null, "metadata": {"window": "Mike  Kaufmann:   Thanks for the question.  I appreciate it.  A couple of things.  As we've said before, we  \ndo see some synergies between M&P.  We go to market together with our GPO selling team s, we share  \ncorporate overhead together, we work on our innovation and technology group together.  We work  \ntogether on back -office types of things.  Clearly, acute care customers are common to both segments.  \n", "original_text": "As we've said before, we  \ndo see some synergies between M&P. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17b7b498-765e-45e6-b193-1c9ca43e2926", "node_type": "1", "metadata": {"window": "And what is really the  \nrationale to own a business on the M edical side that has been underperforming for a very long time?  \n  \n Mike  Kaufmann:   Thanks for the question.  I appreciate it.  A couple of things.  As we've said before, we  \ndo see some synergies between M&P.  We go to market together with our GPO selling team s, we share  \ncorporate overhead together, we work on our innovation and technology group together.  We work  \ntogether on back -office types of things. ", "original_text": "A couple of things. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7aead0a1f6002af616332a3f21836d6aa2902405c6be8afe7c7cb6734b1318eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07875912-ef04-4340-96e4-3da1365497a3", "node_type": "1", "metadata": {"window": "I appreciate it.  A couple of things.  As we've said before, we  \ndo see some synergies between M&P.  We go to market together with our GPO selling team s, we share  \ncorporate overhead together, we work on our innovation and technology group together.  We work  \ntogether on back -office types of things.  Clearly, acute care customers are common to both segments.  \n We don't see as much synergy as between the lar ge distribution businesses, obviously because we  \nmaintain separate warehouses and there's different needs for the customers there in terms of specific  \ngo-to-market strategies, but we do see it a lot with our complementary businesses. ", "original_text": "We go to market together with our GPO selling team s, we share  \ncorporate overhead together, we work on our innovation and technology group together. "}, "hash": "d6cf416dd87151ea135c396b3291a9fc8e83f3dba40df64af1b0c486d0bd42c4", "class_name": "RelatedNodeInfo"}}, "text": "As we've said before, we  \ndo see some synergies between M&P. ", "start_char_idx": 2156, "end_char_idx": 2218, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07875912-ef04-4340-96e4-3da1365497a3": {"__data__": {"id_": "07875912-ef04-4340-96e4-3da1365497a3", "embedding": null, "metadata": {"window": "I appreciate it.  A couple of things.  As we've said before, we  \ndo see some synergies between M&P.  We go to market together with our GPO selling team s, we share  \ncorporate overhead together, we work on our innovation and technology group together.  We work  \ntogether on back -office types of things.  Clearly, acute care customers are common to both segments.  \n We don't see as much synergy as between the lar ge distribution businesses, obviously because we  \nmaintain separate warehouses and there's different needs for the customers there in terms of specific  \ngo-to-market strategies, but we do see it a lot with our complementary businesses. ", "original_text": "We go to market together with our GPO selling team s, we share  \ncorporate overhead together, we work on our innovation and technology group together. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1050436c-fee6-4e50-87aa-6e7cee01d638", "node_type": "1", "metadata": {"window": "Mike  Kaufmann:   Thanks for the question.  I appreciate it.  A couple of things.  As we've said before, we  \ndo see some synergies between M&P.  We go to market together with our GPO selling team s, we share  \ncorporate overhead together, we work on our innovation and technology group together.  We work  \ntogether on back -office types of things.  Clearly, acute care customers are common to both segments.  \n", "original_text": "As we've said before, we  \ndo see some synergies between M&P. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5837484c8b4a51f711c7e5c25af2393e5269b5288e3cfa6b426b922779cfd228", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82334f5b-a4d6-43a0-941e-57d03e4a4944", "node_type": "1", "metadata": {"window": "A couple of things.  As we've said before, we  \ndo see some synergies between M&P.  We go to market together with our GPO selling team s, we share  \ncorporate overhead together, we work on our innovation and technology group together.  We work  \ntogether on back -office types of things.  Clearly, acute care customers are common to both segments.  \n We don't see as much synergy as between the lar ge distribution businesses, obviously because we  \nmaintain separate warehouses and there's different needs for the customers there in terms of specific  \ngo-to-market strategies, but we do see it a lot with our complementary businesses.  Our at -Home,  \nbusiness works with our pharma distribution business, our OptiFreight\u00ae business works with them. ", "original_text": "We work  \ntogether on back -office types of things. "}, "hash": "1724d3af709eacf1ad04ee6be4952e814e13d02d0e530021f87ce8fff15cf150", "class_name": "RelatedNodeInfo"}}, "text": "We go to market together with our GPO selling team s, we share  \ncorporate overhead together, we work on our innovation and technology group together. ", "start_char_idx": 2218, "end_char_idx": 2369, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82334f5b-a4d6-43a0-941e-57d03e4a4944": {"__data__": {"id_": "82334f5b-a4d6-43a0-941e-57d03e4a4944", "embedding": null, "metadata": {"window": "A couple of things.  As we've said before, we  \ndo see some synergies between M&P.  We go to market together with our GPO selling team s, we share  \ncorporate overhead together, we work on our innovation and technology group together.  We work  \ntogether on back -office types of things.  Clearly, acute care customers are common to both segments.  \n We don't see as much synergy as between the lar ge distribution businesses, obviously because we  \nmaintain separate warehouses and there's different needs for the customers there in terms of specific  \ngo-to-market strategies, but we do see it a lot with our complementary businesses.  Our at -Home,  \nbusiness works with our pharma distribution business, our OptiFreight\u00ae business works with them. ", "original_text": "We work  \ntogether on back -office types of things. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07875912-ef04-4340-96e4-3da1365497a3", "node_type": "1", "metadata": {"window": "I appreciate it.  A couple of things.  As we've said before, we  \ndo see some synergies between M&P.  We go to market together with our GPO selling team s, we share  \ncorporate overhead together, we work on our innovation and technology group together.  We work  \ntogether on back -office types of things.  Clearly, acute care customers are common to both segments.  \n We don't see as much synergy as between the lar ge distribution businesses, obviously because we  \nmaintain separate warehouses and there's different needs for the customers there in terms of specific  \ngo-to-market strategies, but we do see it a lot with our complementary businesses. ", "original_text": "We go to market together with our GPO selling team s, we share  \ncorporate overhead together, we work on our innovation and technology group together. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f6172793457f7fb73663015546440144324cfc0e1015f215f698317d5a0dbf77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e9214cd6-3a76-4cd8-b9f0-1e49700962be", "node_type": "1", "metadata": {"window": "As we've said before, we  \ndo see some synergies between M&P.  We go to market together with our GPO selling team s, we share  \ncorporate overhead together, we work on our innovation and technology group together.  We work  \ntogether on back -office types of things.  Clearly, acute care customers are common to both segments.  \n We don't see as much synergy as between the lar ge distribution businesses, obviously because we  \nmaintain separate warehouses and there's different needs for the customers there in terms of specific  \ngo-to-market strategies, but we do see it a lot with our complementary businesses.  Our at -Home,  \nbusiness works with our pharma distribution business, our OptiFreight\u00ae business works with them.  So,  \nwe do see working together there. ", "original_text": "Clearly, acute care customers are common to both segments.  \n"}, "hash": "b0d3aa0b7d4d1cb4cc23dd0fd5c395c1dda12ec209ba0243022b043a7941f643", "class_name": "RelatedNodeInfo"}}, "text": "We work  \ntogether on back -office types of things. ", "start_char_idx": 2369, "end_char_idx": 2421, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e9214cd6-3a76-4cd8-b9f0-1e49700962be": {"__data__": {"id_": "e9214cd6-3a76-4cd8-b9f0-1e49700962be", "embedding": null, "metadata": {"window": "As we've said before, we  \ndo see some synergies between M&P.  We go to market together with our GPO selling team s, we share  \ncorporate overhead together, we work on our innovation and technology group together.  We work  \ntogether on back -office types of things.  Clearly, acute care customers are common to both segments.  \n We don't see as much synergy as between the lar ge distribution businesses, obviously because we  \nmaintain separate warehouses and there's different needs for the customers there in terms of specific  \ngo-to-market strategies, but we do see it a lot with our complementary businesses.  Our at -Home,  \nbusiness works with our pharma distribution business, our OptiFreight\u00ae business works with them.  So,  \nwe do see working together there. ", "original_text": "Clearly, acute care customers are common to both segments.  \n", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82334f5b-a4d6-43a0-941e-57d03e4a4944", "node_type": "1", "metadata": {"window": "A couple of things.  As we've said before, we  \ndo see some synergies between M&P.  We go to market together with our GPO selling team s, we share  \ncorporate overhead together, we work on our innovation and technology group together.  We work  \ntogether on back -office types of things.  Clearly, acute care customers are common to both segments.  \n We don't see as much synergy as between the lar ge distribution businesses, obviously because we  \nmaintain separate warehouses and there's different needs for the customers there in terms of specific  \ngo-to-market strategies, but we do see it a lot with our complementary businesses.  Our at -Home,  \nbusiness works with our pharma distribution business, our OptiFreight\u00ae business works with them. ", "original_text": "We work  \ntogether on back -office types of things. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6ffea352773f8dd6efd0e5b4826d6fed7e980db5540662898a84a00002a14cdf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da05d41d-7761-4d5b-8fd9-2407b9092965", "node_type": "1", "metadata": {"window": "We go to market together with our GPO selling team s, we share  \ncorporate overhead together, we work on our innovation and technology group together.  We work  \ntogether on back -office types of things.  Clearly, acute care customers are common to both segments.  \n We don't see as much synergy as between the lar ge distribution businesses, obviously because we  \nmaintain separate warehouses and there's different needs for the customers there in terms of specific  \ngo-to-market strategies, but we do see it a lot with our complementary businesses.  Our at -Home,  \nbusiness works with our pharma distribution business, our OptiFreight\u00ae business works with them.  So,  \nwe do see working together there.  So that being said we d o see opportunities. ", "original_text": "We don't see as much synergy as between the lar ge distribution businesses, obviously because we  \nmaintain separate warehouses and there's different needs for the customers there in terms of specific  \ngo-to-market strategies, but we do see it a lot with our complementary businesses. "}, "hash": "0df8c95a4c922d3ca782da29b73fee891a32237eb83646ed020ae295c26c053a", "class_name": "RelatedNodeInfo"}}, "text": "Clearly, acute care customers are common to both segments.  \n", "start_char_idx": 2421, "end_char_idx": 2482, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da05d41d-7761-4d5b-8fd9-2407b9092965": {"__data__": {"id_": "da05d41d-7761-4d5b-8fd9-2407b9092965", "embedding": null, "metadata": {"window": "We go to market together with our GPO selling team s, we share  \ncorporate overhead together, we work on our innovation and technology group together.  We work  \ntogether on back -office types of things.  Clearly, acute care customers are common to both segments.  \n We don't see as much synergy as between the lar ge distribution businesses, obviously because we  \nmaintain separate warehouses and there's different needs for the customers there in terms of specific  \ngo-to-market strategies, but we do see it a lot with our complementary businesses.  Our at -Home,  \nbusiness works with our pharma distribution business, our OptiFreight\u00ae business works with them.  So,  \nwe do see working together there.  So that being said we d o see opportunities. ", "original_text": "We don't see as much synergy as between the lar ge distribution businesses, obviously because we  \nmaintain separate warehouses and there's different needs for the customers there in terms of specific  \ngo-to-market strategies, but we do see it a lot with our complementary businesses. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e9214cd6-3a76-4cd8-b9f0-1e49700962be", "node_type": "1", "metadata": {"window": "As we've said before, we  \ndo see some synergies between M&P.  We go to market together with our GPO selling team s, we share  \ncorporate overhead together, we work on our innovation and technology group together.  We work  \ntogether on back -office types of things.  Clearly, acute care customers are common to both segments.  \n We don't see as much synergy as between the lar ge distribution businesses, obviously because we  \nmaintain separate warehouses and there's different needs for the customers there in terms of specific  \ngo-to-market strategies, but we do see it a lot with our complementary businesses.  Our at -Home,  \nbusiness works with our pharma distribution business, our OptiFreight\u00ae business works with them.  So,  \nwe do see working together there. ", "original_text": "Clearly, acute care customers are common to both segments.  \n", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6b590b5efe52bb5ff28026d4afda42281d6fb710a90eadc942fae371fd0bc406", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c16f6286-99e9-40b3-b157-8d6e02d669e6", "node_type": "1", "metadata": {"window": "We work  \ntogether on back -office types of things.  Clearly, acute care customers are common to both segments.  \n We don't see as much synergy as between the lar ge distribution businesses, obviously because we  \nmaintain separate warehouses and there's different needs for the customers there in terms of specific  \ngo-to-market strategies, but we do see it a lot with our complementary businesses.  Our at -Home,  \nbusiness works with our pharma distribution business, our OptiFreight\u00ae business works with them.  So,  \nwe do see working together there.  So that being said we d o see opportunities.  But as I've always said,  \nwe will always look at our portfolio, we'll always look to see what is the best opportunity to create  \nshareholder value. ", "original_text": "Our at -Home,  \nbusiness works with our pharma distribution business, our OptiFreight\u00ae business works with them. "}, "hash": "d775fcc0f4feca96b646b8eededaaef764c14649be66b8f26a3d55faf350b4bd", "class_name": "RelatedNodeInfo"}}, "text": "We don't see as much synergy as between the lar ge distribution businesses, obviously because we  \nmaintain separate warehouses and there's different needs for the customers there in terms of specific  \ngo-to-market strategies, but we do see it a lot with our complementary businesses. ", "start_char_idx": 2482, "end_char_idx": 2768, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c16f6286-99e9-40b3-b157-8d6e02d669e6": {"__data__": {"id_": "c16f6286-99e9-40b3-b157-8d6e02d669e6", "embedding": null, "metadata": {"window": "We work  \ntogether on back -office types of things.  Clearly, acute care customers are common to both segments.  \n We don't see as much synergy as between the lar ge distribution businesses, obviously because we  \nmaintain separate warehouses and there's different needs for the customers there in terms of specific  \ngo-to-market strategies, but we do see it a lot with our complementary businesses.  Our at -Home,  \nbusiness works with our pharma distribution business, our OptiFreight\u00ae business works with them.  So,  \nwe do see working together there.  So that being said we d o see opportunities.  But as I've always said,  \nwe will always look at our portfolio, we'll always look to see what is the best opportunity to create  \nshareholder value. ", "original_text": "Our at -Home,  \nbusiness works with our pharma distribution business, our OptiFreight\u00ae business works with them. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da05d41d-7761-4d5b-8fd9-2407b9092965", "node_type": "1", "metadata": {"window": "We go to market together with our GPO selling team s, we share  \ncorporate overhead together, we work on our innovation and technology group together.  We work  \ntogether on back -office types of things.  Clearly, acute care customers are common to both segments.  \n We don't see as much synergy as between the lar ge distribution businesses, obviously because we  \nmaintain separate warehouses and there's different needs for the customers there in terms of specific  \ngo-to-market strategies, but we do see it a lot with our complementary businesses.  Our at -Home,  \nbusiness works with our pharma distribution business, our OptiFreight\u00ae business works with them.  So,  \nwe do see working together there.  So that being said we d o see opportunities. ", "original_text": "We don't see as much synergy as between the lar ge distribution businesses, obviously because we  \nmaintain separate warehouses and there's different needs for the customers there in terms of specific  \ngo-to-market strategies, but we do see it a lot with our complementary businesses. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d842fb0b93951ef2a904b5a8ec80eb374a5d1de9c77c5dd4b9d7888516324858", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b262596-f3cc-44de-b5a4-c4cdd259fd12", "node_type": "1", "metadata": {"window": "Clearly, acute care customers are common to both segments.  \n We don't see as much synergy as between the lar ge distribution businesses, obviously because we  \nmaintain separate warehouses and there's different needs for the customers there in terms of specific  \ngo-to-market strategies, but we do see it a lot with our complementary businesses.  Our at -Home,  \nbusiness works with our pharma distribution business, our OptiFreight\u00ae business works with them.  So,  \nwe do see working together there.  So that being said we d o see opportunities.  But as I've always said,  \nwe will always look at our portfolio, we'll always look to see what is the best opportunity to create  \nshareholder value.  And so at this point in time, we feel good about where we are and where we're  \nheaded, but there's nothing off the table when it comes to looking forward in order to create value for  \nshareholders.  \n \n", "original_text": "So,  \nwe do see working together there. "}, "hash": "e8e9dfe9425eacc5690e780cc186c3ed7d13b42d67115a89055c9034c5187e7d", "class_name": "RelatedNodeInfo"}}, "text": "Our at -Home,  \nbusiness works with our pharma distribution business, our OptiFreight\u00ae business works with them. ", "start_char_idx": 2768, "end_char_idx": 2881, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b262596-f3cc-44de-b5a4-c4cdd259fd12": {"__data__": {"id_": "6b262596-f3cc-44de-b5a4-c4cdd259fd12", "embedding": null, "metadata": {"window": "Clearly, acute care customers are common to both segments.  \n We don't see as much synergy as between the lar ge distribution businesses, obviously because we  \nmaintain separate warehouses and there's different needs for the customers there in terms of specific  \ngo-to-market strategies, but we do see it a lot with our complementary businesses.  Our at -Home,  \nbusiness works with our pharma distribution business, our OptiFreight\u00ae business works with them.  So,  \nwe do see working together there.  So that being said we d o see opportunities.  But as I've always said,  \nwe will always look at our portfolio, we'll always look to see what is the best opportunity to create  \nshareholder value.  And so at this point in time, we feel good about where we are and where we're  \nheaded, but there's nothing off the table when it comes to looking forward in order to create value for  \nshareholders.  \n \n", "original_text": "So,  \nwe do see working together there. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c16f6286-99e9-40b3-b157-8d6e02d669e6", "node_type": "1", "metadata": {"window": "We work  \ntogether on back -office types of things.  Clearly, acute care customers are common to both segments.  \n We don't see as much synergy as between the lar ge distribution businesses, obviously because we  \nmaintain separate warehouses and there's different needs for the customers there in terms of specific  \ngo-to-market strategies, but we do see it a lot with our complementary businesses.  Our at -Home,  \nbusiness works with our pharma distribution business, our OptiFreight\u00ae business works with them.  So,  \nwe do see working together there.  So that being said we d o see opportunities.  But as I've always said,  \nwe will always look at our portfolio, we'll always look to see what is the best opportunity to create  \nshareholder value. ", "original_text": "Our at -Home,  \nbusiness works with our pharma distribution business, our OptiFreight\u00ae business works with them. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "522543bad3751745a31c5ed2df78902bb9916fc913e889089d694db791246cc5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bb6065a-5c20-4e7a-8013-4b6d7b0918c3", "node_type": "1", "metadata": {"window": "We don't see as much synergy as between the lar ge distribution businesses, obviously because we  \nmaintain separate warehouses and there's different needs for the customers there in terms of specific  \ngo-to-market strategies, but we do see it a lot with our complementary businesses.  Our at -Home,  \nbusiness works with our pharma distribution business, our OptiFreight\u00ae business works with them.  So,  \nwe do see working together there.  So that being said we d o see opportunities.  But as I've always said,  \nwe will always look at our portfolio, we'll always look to see what is the best opportunity to create  \nshareholder value.  And so at this point in time, we feel good about where we are and where we're  \nheaded, but there's nothing off the table when it comes to looking forward in order to create value for  \nshareholders.  \n \n Operator:   And our next question comes from Elizabeth Anderson with Evercore ISI.  \n \n", "original_text": "So that being said we d o see opportunities. "}, "hash": "e73f88f1b8f1ef86769045b803d529adfe4157a505117e628077bb68400f4e3d", "class_name": "RelatedNodeInfo"}}, "text": "So,  \nwe do see working together there. ", "start_char_idx": 2881, "end_char_idx": 2921, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bb6065a-5c20-4e7a-8013-4b6d7b0918c3": {"__data__": {"id_": "2bb6065a-5c20-4e7a-8013-4b6d7b0918c3", "embedding": null, "metadata": {"window": "We don't see as much synergy as between the lar ge distribution businesses, obviously because we  \nmaintain separate warehouses and there's different needs for the customers there in terms of specific  \ngo-to-market strategies, but we do see it a lot with our complementary businesses.  Our at -Home,  \nbusiness works with our pharma distribution business, our OptiFreight\u00ae business works with them.  So,  \nwe do see working together there.  So that being said we d o see opportunities.  But as I've always said,  \nwe will always look at our portfolio, we'll always look to see what is the best opportunity to create  \nshareholder value.  And so at this point in time, we feel good about where we are and where we're  \nheaded, but there's nothing off the table when it comes to looking forward in order to create value for  \nshareholders.  \n \n Operator:   And our next question comes from Elizabeth Anderson with Evercore ISI.  \n \n", "original_text": "So that being said we d o see opportunities. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b262596-f3cc-44de-b5a4-c4cdd259fd12", "node_type": "1", "metadata": {"window": "Clearly, acute care customers are common to both segments.  \n We don't see as much synergy as between the lar ge distribution businesses, obviously because we  \nmaintain separate warehouses and there's different needs for the customers there in terms of specific  \ngo-to-market strategies, but we do see it a lot with our complementary businesses.  Our at -Home,  \nbusiness works with our pharma distribution business, our OptiFreight\u00ae business works with them.  So,  \nwe do see working together there.  So that being said we d o see opportunities.  But as I've always said,  \nwe will always look at our portfolio, we'll always look to see what is the best opportunity to create  \nshareholder value.  And so at this point in time, we feel good about where we are and where we're  \nheaded, but there's nothing off the table when it comes to looking forward in order to create value for  \nshareholders.  \n \n", "original_text": "So,  \nwe do see working together there. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4a434e1e78355ee4333747b2269e2e8d960fddd02c0d1a48783c5f92d231ef8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aaef2100-d5e8-4a88-aeaa-0d7503e7e893", "node_type": "1", "metadata": {"window": "Our at -Home,  \nbusiness works with our pharma distribution business, our OptiFreight\u00ae business works with them.  So,  \nwe do see working together there.  So that being said we d o see opportunities.  But as I've always said,  \nwe will always look at our portfolio, we'll always look to see what is the best opportunity to create  \nshareholder value.  And so at this point in time, we feel good about where we are and where we're  \nheaded, but there's nothing off the table when it comes to looking forward in order to create value for  \nshareholders.  \n \n Operator:   And our next question comes from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson:  Hi, guys. ", "original_text": "But as I've always said,  \nwe will always look at our portfolio, we'll always look to see what is the best opportunity to create  \nshareholder value. "}, "hash": "4e53129dab2188d778794f1cc1531eb6939b5e5bb2771b3397382e46619ec28c", "class_name": "RelatedNodeInfo"}}, "text": "So that being said we d o see opportunities. ", "start_char_idx": 2921, "end_char_idx": 2966, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aaef2100-d5e8-4a88-aeaa-0d7503e7e893": {"__data__": {"id_": "aaef2100-d5e8-4a88-aeaa-0d7503e7e893", "embedding": null, "metadata": {"window": "Our at -Home,  \nbusiness works with our pharma distribution business, our OptiFreight\u00ae business works with them.  So,  \nwe do see working together there.  So that being said we d o see opportunities.  But as I've always said,  \nwe will always look at our portfolio, we'll always look to see what is the best opportunity to create  \nshareholder value.  And so at this point in time, we feel good about where we are and where we're  \nheaded, but there's nothing off the table when it comes to looking forward in order to create value for  \nshareholders.  \n \n Operator:   And our next question comes from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson:  Hi, guys. ", "original_text": "But as I've always said,  \nwe will always look at our portfolio, we'll always look to see what is the best opportunity to create  \nshareholder value. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bb6065a-5c20-4e7a-8013-4b6d7b0918c3", "node_type": "1", "metadata": {"window": "We don't see as much synergy as between the lar ge distribution businesses, obviously because we  \nmaintain separate warehouses and there's different needs for the customers there in terms of specific  \ngo-to-market strategies, but we do see it a lot with our complementary businesses.  Our at -Home,  \nbusiness works with our pharma distribution business, our OptiFreight\u00ae business works with them.  So,  \nwe do see working together there.  So that being said we d o see opportunities.  But as I've always said,  \nwe will always look at our portfolio, we'll always look to see what is the best opportunity to create  \nshareholder value.  And so at this point in time, we feel good about where we are and where we're  \nheaded, but there's nothing off the table when it comes to looking forward in order to create value for  \nshareholders.  \n \n Operator:   And our next question comes from Elizabeth Anderson with Evercore ISI.  \n \n", "original_text": "So that being said we d o see opportunities. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "79ef9b183df4f9575e80d30e8ea3624b82943dc0cea5dd5ddc91078e1ca5a775", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c82f30f4-029f-4f2a-97b1-c0a0aca3f28b", "node_type": "1", "metadata": {"window": "So,  \nwe do see working together there.  So that being said we d o see opportunities.  But as I've always said,  \nwe will always look at our portfolio, we'll always look to see what is the best opportunity to create  \nshareholder value.  And so at this point in time, we feel good about where we are and where we're  \nheaded, but there's nothing off the table when it comes to looking forward in order to create value for  \nshareholders.  \n \n Operator:   And our next question comes from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson:  Hi, guys.  Thanks so much for the question. ", "original_text": "And so at this point in time, we feel good about where we are and where we're  \nheaded, but there's nothing off the table when it comes to looking forward in order to create value for  \nshareholders.  \n \n"}, "hash": "d52fcddec3994ef95054be5b06fde4af969c61f0fb612548b06daba0b2566d00", "class_name": "RelatedNodeInfo"}}, "text": "But as I've always said,  \nwe will always look at our portfolio, we'll always look to see what is the best opportunity to create  \nshareholder value. ", "start_char_idx": 2966, "end_char_idx": 3116, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c82f30f4-029f-4f2a-97b1-c0a0aca3f28b": {"__data__": {"id_": "c82f30f4-029f-4f2a-97b1-c0a0aca3f28b", "embedding": null, "metadata": {"window": "So,  \nwe do see working together there.  So that being said we d o see opportunities.  But as I've always said,  \nwe will always look at our portfolio, we'll always look to see what is the best opportunity to create  \nshareholder value.  And so at this point in time, we feel good about where we are and where we're  \nheaded, but there's nothing off the table when it comes to looking forward in order to create value for  \nshareholders.  \n \n Operator:   And our next question comes from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson:  Hi, guys.  Thanks so much for the question. ", "original_text": "And so at this point in time, we feel good about where we are and where we're  \nheaded, but there's nothing off the table when it comes to looking forward in order to create value for  \nshareholders.  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aaef2100-d5e8-4a88-aeaa-0d7503e7e893", "node_type": "1", "metadata": {"window": "Our at -Home,  \nbusiness works with our pharma distribution business, our OptiFreight\u00ae business works with them.  So,  \nwe do see working together there.  So that being said we d o see opportunities.  But as I've always said,  \nwe will always look at our portfolio, we'll always look to see what is the best opportunity to create  \nshareholder value.  And so at this point in time, we feel good about where we are and where we're  \nheaded, but there's nothing off the table when it comes to looking forward in order to create value for  \nshareholders.  \n \n Operator:   And our next question comes from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson:  Hi, guys. ", "original_text": "But as I've always said,  \nwe will always look at our portfolio, we'll always look to see what is the best opportunity to create  \nshareholder value. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8b85aea94b8546ac294f012183e31cd7ae73cf9c556185b81033c3ea20a1f01c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6b9b9412-ed80-4455-8a11-6fd488722be6", "node_type": "1", "metadata": {"window": "So that being said we d o see opportunities.  But as I've always said,  \nwe will always look at our portfolio, we'll always look to see what is the best opportunity to create  \nshareholder value.  And so at this point in time, we feel good about where we are and where we're  \nheaded, but there's nothing off the table when it comes to looking forward in order to create value for  \nshareholders.  \n \n Operator:   And our next question comes from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson:  Hi, guys.  Thanks so much for the question.  I was wondering if you could talk a  \nlittle bit more about the medical utilization assumptions embedded in 4Q, and th en your comments  \nregarding \u201823, both may be on the surgical side and at -home volumes. ", "original_text": "Operator:   And our next question comes from Elizabeth Anderson with Evercore ISI.  \n \n"}, "hash": "abd4829bf9732475785b8d628aed4610088609bcee0e579b9aab5d2711b8c9c4", "class_name": "RelatedNodeInfo"}}, "text": "And so at this point in time, we feel good about where we are and where we're  \nheaded, but there's nothing off the table when it comes to looking forward in order to create value for  \nshareholders.  \n \n", "start_char_idx": 3116, "end_char_idx": 3320, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6b9b9412-ed80-4455-8a11-6fd488722be6": {"__data__": {"id_": "6b9b9412-ed80-4455-8a11-6fd488722be6", "embedding": null, "metadata": {"window": "So that being said we d o see opportunities.  But as I've always said,  \nwe will always look at our portfolio, we'll always look to see what is the best opportunity to create  \nshareholder value.  And so at this point in time, we feel good about where we are and where we're  \nheaded, but there's nothing off the table when it comes to looking forward in order to create value for  \nshareholders.  \n \n Operator:   And our next question comes from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson:  Hi, guys.  Thanks so much for the question.  I was wondering if you could talk a  \nlittle bit more about the medical utilization assumptions embedded in 4Q, and th en your comments  \nregarding \u201823, both may be on the surgical side and at -home volumes. ", "original_text": "Operator:   And our next question comes from Elizabeth Anderson with Evercore ISI.  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c82f30f4-029f-4f2a-97b1-c0a0aca3f28b", "node_type": "1", "metadata": {"window": "So,  \nwe do see working together there.  So that being said we d o see opportunities.  But as I've always said,  \nwe will always look at our portfolio, we'll always look to see what is the best opportunity to create  \nshareholder value.  And so at this point in time, we feel good about where we are and where we're  \nheaded, but there's nothing off the table when it comes to looking forward in order to create value for  \nshareholders.  \n \n Operator:   And our next question comes from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson:  Hi, guys.  Thanks so much for the question. ", "original_text": "And so at this point in time, we feel good about where we are and where we're  \nheaded, but there's nothing off the table when it comes to looking forward in order to create value for  \nshareholders.  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9cfee5098fcce6ad012169b4b397ecbe96de32272087ebe5c91b758e7767a5b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6305d82-fb57-4fca-913c-26f1f329facc", "node_type": "1", "metadata": {"window": "But as I've always said,  \nwe will always look at our portfolio, we'll always look to see what is the best opportunity to create  \nshareholder value.  And so at this point in time, we feel good about where we are and where we're  \nheaded, but there's nothing off the table when it comes to looking forward in order to create value for  \nshareholders.  \n \n Operator:   And our next question comes from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson:  Hi, guys.  Thanks so much for the question.  I was wondering if you could talk a  \nlittle bit more about the medical utilization assumptions embedded in 4Q, and th en your comments  \nregarding \u201823, both may be on the surgical side and at -home volumes.  Thanks.  \n  \n", "original_text": "Elizabeth Anderson:  Hi, guys. "}, "hash": "737e5590df2bd26d9bb78c695306fcc7ff8d0b60701fbdb94a495fe3daa6eb80", "class_name": "RelatedNodeInfo"}}, "text": "Operator:   And our next question comes from Elizabeth Anderson with Evercore ISI.  \n \n", "start_char_idx": 3320, "end_char_idx": 3407, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6305d82-fb57-4fca-913c-26f1f329facc": {"__data__": {"id_": "e6305d82-fb57-4fca-913c-26f1f329facc", "embedding": null, "metadata": {"window": "But as I've always said,  \nwe will always look at our portfolio, we'll always look to see what is the best opportunity to create  \nshareholder value.  And so at this point in time, we feel good about where we are and where we're  \nheaded, but there's nothing off the table when it comes to looking forward in order to create value for  \nshareholders.  \n \n Operator:   And our next question comes from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson:  Hi, guys.  Thanks so much for the question.  I was wondering if you could talk a  \nlittle bit more about the medical utilization assumptions embedded in 4Q, and th en your comments  \nregarding \u201823, both may be on the surgical side and at -home volumes.  Thanks.  \n  \n", "original_text": "Elizabeth Anderson:  Hi, guys. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6b9b9412-ed80-4455-8a11-6fd488722be6", "node_type": "1", "metadata": {"window": "So that being said we d o see opportunities.  But as I've always said,  \nwe will always look at our portfolio, we'll always look to see what is the best opportunity to create  \nshareholder value.  And so at this point in time, we feel good about where we are and where we're  \nheaded, but there's nothing off the table when it comes to looking forward in order to create value for  \nshareholders.  \n \n Operator:   And our next question comes from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson:  Hi, guys.  Thanks so much for the question.  I was wondering if you could talk a  \nlittle bit more about the medical utilization assumptions embedded in 4Q, and th en your comments  \nregarding \u201823, both may be on the surgical side and at -home volumes. ", "original_text": "Operator:   And our next question comes from Elizabeth Anderson with Evercore ISI.  \n \n", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9cb033bb8822f08e5434443f35b48286b4ecb68ab663a7f3e87161edf139e261", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27da4eb7-8d09-4b69-9f98-4cb49f5d81ed", "node_type": "1", "metadata": {"window": "And so at this point in time, we feel good about where we are and where we're  \nheaded, but there's nothing off the table when it comes to looking forward in order to create value for  \nshareholders.  \n \n Operator:   And our next question comes from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson:  Hi, guys.  Thanks so much for the question.  I was wondering if you could talk a  \nlittle bit more about the medical utilization assumptions embedded in 4Q, and th en your comments  \nregarding \u201823, both may be on the surgical side and at -home volumes.  Thanks.  \n  \n Mike Kaufmann:  Yeah. ", "original_text": "Thanks so much for the question. "}, "hash": "527c142015eb64b9df96d9f587349f85e0ead29215990fd68f8eed3c694f78e3", "class_name": "RelatedNodeInfo"}}, "text": "Elizabeth Anderson:  Hi, guys. ", "start_char_idx": 3407, "end_char_idx": 3438, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27da4eb7-8d09-4b69-9f98-4cb49f5d81ed": {"__data__": {"id_": "27da4eb7-8d09-4b69-9f98-4cb49f5d81ed", "embedding": null, "metadata": {"window": "And so at this point in time, we feel good about where we are and where we're  \nheaded, but there's nothing off the table when it comes to looking forward in order to create value for  \nshareholders.  \n \n Operator:   And our next question comes from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson:  Hi, guys.  Thanks so much for the question.  I was wondering if you could talk a  \nlittle bit more about the medical utilization assumptions embedded in 4Q, and th en your comments  \nregarding \u201823, both may be on the surgical side and at -home volumes.  Thanks.  \n  \n Mike Kaufmann:  Yeah. ", "original_text": "Thanks so much for the question. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6305d82-fb57-4fca-913c-26f1f329facc", "node_type": "1", "metadata": {"window": "But as I've always said,  \nwe will always look at our portfolio, we'll always look to see what is the best opportunity to create  \nshareholder value.  And so at this point in time, we feel good about where we are and where we're  \nheaded, but there's nothing off the table when it comes to looking forward in order to create value for  \nshareholders.  \n \n Operator:   And our next question comes from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson:  Hi, guys.  Thanks so much for the question.  I was wondering if you could talk a  \nlittle bit more about the medical utilization assumptions embedded in 4Q, and th en your comments  \nregarding \u201823, both may be on the surgical side and at -home volumes.  Thanks.  \n  \n", "original_text": "Elizabeth Anderson:  Hi, guys. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8f97d9a6c37ba073d2b84f270f5d4dee5bc286db23154a21d916a99a603210eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "855fce69-9f9b-4b87-8f22-bb71f888b672", "node_type": "1", "metadata": {"window": "Operator:   And our next question comes from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson:  Hi, guys.  Thanks so much for the question.  I was wondering if you could talk a  \nlittle bit more about the medical utilization assumptions embedded in 4Q, and th en your comments  \nregarding \u201823, both may be on the surgical side and at -home volumes.  Thanks.  \n  \n Mike Kaufmann:  Yeah.  Right now what we're seeing is we're seeing elective procedures be pretty  \nsimilar to what we would say pre -COVID. ", "original_text": "I was wondering if you could talk a  \nlittle bit more about the medical utilization assumptions embedded in 4Q, and th en your comments  \nregarding \u201823, both may be on the surgical side and at -home volumes. "}, "hash": "a2cf321053c6db59cd342e2e69a418924dd4ab813edc4c4503b717056233fae2", "class_name": "RelatedNodeInfo"}}, "text": "Thanks so much for the question. ", "start_char_idx": 3438, "end_char_idx": 3471, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "855fce69-9f9b-4b87-8f22-bb71f888b672": {"__data__": {"id_": "855fce69-9f9b-4b87-8f22-bb71f888b672", "embedding": null, "metadata": {"window": "Operator:   And our next question comes from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson:  Hi, guys.  Thanks so much for the question.  I was wondering if you could talk a  \nlittle bit more about the medical utilization assumptions embedded in 4Q, and th en your comments  \nregarding \u201823, both may be on the surgical side and at -home volumes.  Thanks.  \n  \n Mike Kaufmann:  Yeah.  Right now what we're seeing is we're seeing elective procedures be pretty  \nsimilar to what we would say pre -COVID. ", "original_text": "I was wondering if you could talk a  \nlittle bit more about the medical utilization assumptions embedded in 4Q, and th en your comments  \nregarding \u201823, both may be on the surgical side and at -home volumes. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27da4eb7-8d09-4b69-9f98-4cb49f5d81ed", "node_type": "1", "metadata": {"window": "And so at this point in time, we feel good about where we are and where we're  \nheaded, but there's nothing off the table when it comes to looking forward in order to create value for  \nshareholders.  \n \n Operator:   And our next question comes from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson:  Hi, guys.  Thanks so much for the question.  I was wondering if you could talk a  \nlittle bit more about the medical utilization assumptions embedded in 4Q, and th en your comments  \nregarding \u201823, both may be on the surgical side and at -home volumes.  Thanks.  \n  \n Mike Kaufmann:  Yeah. ", "original_text": "Thanks so much for the question. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3b985f88f3895feaebc2886a35a43c52c2f92f34668e7ab4183e1de05fc32e57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "796b37cd-a13b-486d-987a-40049924455a", "node_type": "1", "metadata": {"window": "Elizabeth Anderson:  Hi, guys.  Thanks so much for the question.  I was wondering if you could talk a  \nlittle bit more about the medical utilization assumptions embedded in 4Q, and th en your comments  \nregarding \u201823, both may be on the surgical side and at -home volumes.  Thanks.  \n  \n Mike Kaufmann:  Yeah.  Right now what we're seeing is we're seeing elective procedures be pretty  \nsimilar to what we would say pre -COVID.  Now, that's a hard ph rase to use anymore, and it's probably  ", "original_text": "Thanks.  \n  \n"}, "hash": "2d6e84b91f1f1a0e5f88fcf1faece25196b0412294c2008333dca87bb7ce47a3", "class_name": "RelatedNodeInfo"}}, "text": "I was wondering if you could talk a  \nlittle bit more about the medical utilization assumptions embedded in 4Q, and th en your comments  \nregarding \u201823, both may be on the surgical side and at -home volumes. ", "start_char_idx": 3471, "end_char_idx": 3679, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "796b37cd-a13b-486d-987a-40049924455a": {"__data__": {"id_": "796b37cd-a13b-486d-987a-40049924455a", "embedding": null, "metadata": {"window": "Elizabeth Anderson:  Hi, guys.  Thanks so much for the question.  I was wondering if you could talk a  \nlittle bit more about the medical utilization assumptions embedded in 4Q, and th en your comments  \nregarding \u201823, both may be on the surgical side and at -home volumes.  Thanks.  \n  \n Mike Kaufmann:  Yeah.  Right now what we're seeing is we're seeing elective procedures be pretty  \nsimilar to what we would say pre -COVID.  Now, that's a hard ph rase to use anymore, and it's probably  ", "original_text": "Thanks.  \n  \n", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "855fce69-9f9b-4b87-8f22-bb71f888b672", "node_type": "1", "metadata": {"window": "Operator:   And our next question comes from Elizabeth Anderson with Evercore ISI.  \n \n Elizabeth Anderson:  Hi, guys.  Thanks so much for the question.  I was wondering if you could talk a  \nlittle bit more about the medical utilization assumptions embedded in 4Q, and th en your comments  \nregarding \u201823, both may be on the surgical side and at -home volumes.  Thanks.  \n  \n Mike Kaufmann:  Yeah.  Right now what we're seeing is we're seeing elective procedures be pretty  \nsimilar to what we would say pre -COVID. ", "original_text": "I was wondering if you could talk a  \nlittle bit more about the medical utilization assumptions embedded in 4Q, and th en your comments  \nregarding \u201823, both may be on the surgical side and at -home volumes. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "af5b611363b31243f515d2173dd28ada1c7360a714c0ca143ac3a93d2565e077", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "35a89eba-2dfd-4110-b0ef-7845f6ba0f61", "node_type": "1", "metadata": {"window": "Thanks so much for the question.  I was wondering if you could talk a  \nlittle bit more about the medical utilization assumptions embedded in 4Q, and th en your comments  \nregarding \u201823, both may be on the surgical side and at -home volumes.  Thanks.  \n  \n Mike Kaufmann:  Yeah.  Right now what we're seeing is we're seeing elective procedures be pretty  \nsimilar to what we would say pre -COVID.  Now, that's a hard ph rase to use anymore, and it's probably  ", "original_text": "Mike Kaufmann:  Yeah. "}, "hash": "014e06092c8ced9f061feb2ccebddab0225d9e2db33ec53c290c872d5b77a995", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n  \n", "start_char_idx": 3679, "end_char_idx": 3692, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "35a89eba-2dfd-4110-b0ef-7845f6ba0f61": {"__data__": {"id_": "35a89eba-2dfd-4110-b0ef-7845f6ba0f61", "embedding": null, "metadata": {"window": "Thanks so much for the question.  I was wondering if you could talk a  \nlittle bit more about the medical utilization assumptions embedded in 4Q, and th en your comments  \nregarding \u201823, both may be on the surgical side and at -home volumes.  Thanks.  \n  \n Mike Kaufmann:  Yeah.  Right now what we're seeing is we're seeing elective procedures be pretty  \nsimilar to what we would say pre -COVID.  Now, that's a hard ph rase to use anymore, and it's probably  ", "original_text": "Mike Kaufmann:  Yeah. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "796b37cd-a13b-486d-987a-40049924455a", "node_type": "1", "metadata": {"window": "Elizabeth Anderson:  Hi, guys.  Thanks so much for the question.  I was wondering if you could talk a  \nlittle bit more about the medical utilization assumptions embedded in 4Q, and th en your comments  \nregarding \u201823, both may be on the surgical side and at -home volumes.  Thanks.  \n  \n Mike Kaufmann:  Yeah.  Right now what we're seeing is we're seeing elective procedures be pretty  \nsimilar to what we would say pre -COVID.  Now, that's a hard ph rase to use anymore, and it's probably  ", "original_text": "Thanks.  \n  \n", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "244ea065e2c4847014ab87e4f6b91ef96579b5c4a0f4fdf5813f1612675ddc18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee7dbf60-d60b-4800-952b-d9bc924d486c", "node_type": "1", "metadata": {"window": "I was wondering if you could talk a  \nlittle bit more about the medical utilization assumptions embedded in 4Q, and th en your comments  \nregarding \u201823, both may be on the surgical side and at -home volumes.  Thanks.  \n  \n Mike Kaufmann:  Yeah.  Right now what we're seeing is we're seeing elective procedures be pretty  \nsimilar to what we would say pre -COVID.  Now, that's a hard ph rase to use anymore, and it's probably  ", "original_text": "Right now what we're seeing is we're seeing elective procedures be pretty  \nsimilar to what we would say pre -COVID. "}, "hash": "419ae65d103ee422d082a2ef1e42587ebfaf962891034a75437aa709a3afea8d", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yeah. ", "start_char_idx": 3692, "end_char_idx": 3714, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee7dbf60-d60b-4800-952b-d9bc924d486c": {"__data__": {"id_": "ee7dbf60-d60b-4800-952b-d9bc924d486c", "embedding": null, "metadata": {"window": "I was wondering if you could talk a  \nlittle bit more about the medical utilization assumptions embedded in 4Q, and th en your comments  \nregarding \u201823, both may be on the surgical side and at -home volumes.  Thanks.  \n  \n Mike Kaufmann:  Yeah.  Right now what we're seeing is we're seeing elective procedures be pretty  \nsimilar to what we would say pre -COVID.  Now, that's a hard ph rase to use anymore, and it's probably  ", "original_text": "Right now what we're seeing is we're seeing elective procedures be pretty  \nsimilar to what we would say pre -COVID. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "35a89eba-2dfd-4110-b0ef-7845f6ba0f61", "node_type": "1", "metadata": {"window": "Thanks so much for the question.  I was wondering if you could talk a  \nlittle bit more about the medical utilization assumptions embedded in 4Q, and th en your comments  \nregarding \u201823, both may be on the surgical side and at -home volumes.  Thanks.  \n  \n Mike Kaufmann:  Yeah.  Right now what we're seeing is we're seeing elective procedures be pretty  \nsimilar to what we would say pre -COVID.  Now, that's a hard ph rase to use anymore, and it's probably  ", "original_text": "Mike Kaufmann:  Yeah. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4421283dba4ebd24a6312143d6b42c34cd982fdaf2aea0566943f3f36d4cc3c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00a71c21-791f-4fa1-abcb-a23b5970155b", "node_type": "1", "metadata": {"window": "Thanks.  \n  \n Mike Kaufmann:  Yeah.  Right now what we're seeing is we're seeing elective procedures be pretty  \nsimilar to what we would say pre -COVID.  Now, that's a hard ph rase to use anymore, and it's probably  ", "original_text": "Now, that's a hard ph rase to use anymore, and it's probably  "}, "hash": "647397fc57f854f3fc58339a528315dd9638927b583e1d9217cb15fd6aa8a6b9", "class_name": "RelatedNodeInfo"}}, "text": "Right now what we're seeing is we're seeing elective procedures be pretty  \nsimilar to what we would say pre -COVID. ", "start_char_idx": 3714, "end_char_idx": 3831, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00a71c21-791f-4fa1-abcb-a23b5970155b": {"__data__": {"id_": "00a71c21-791f-4fa1-abcb-a23b5970155b", "embedding": null, "metadata": {"window": "Thanks.  \n  \n Mike Kaufmann:  Yeah.  Right now what we're seeing is we're seeing elective procedures be pretty  \nsimilar to what we would say pre -COVID.  Now, that's a hard ph rase to use anymore, and it's probably  ", "original_text": "Now, that's a hard ph rase to use anymore, and it's probably  ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357", "node_type": "4", "metadata": {"page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4fa2a870bfc0a3e90424b3f832b3c2351c00645922b21895f12dc09afddc0d14", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee7dbf60-d60b-4800-952b-d9bc924d486c", "node_type": "1", "metadata": {"window": "I was wondering if you could talk a  \nlittle bit more about the medical utilization assumptions embedded in 4Q, and th en your comments  \nregarding \u201823, both may be on the surgical side and at -home volumes.  Thanks.  \n  \n Mike Kaufmann:  Yeah.  Right now what we're seeing is we're seeing elective procedures be pretty  \nsimilar to what we would say pre -COVID.  Now, that's a hard ph rase to use anymore, and it's probably  ", "original_text": "Right now what we're seeing is we're seeing elective procedures be pretty  \nsimilar to what we would say pre -COVID. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a3ea3c3f65e60e48354814c12d6ae86ae1823daa3b924f3653facbe2fffdbae1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3c0f73d2-5d4b-421d-a4c0-b2ab5dd655bf", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \none will begin getting away from because trying to measure something that's now over two years old  \nwith lots of puts and takes, with new items and changes in the marketplace and everything else, it's a  \nlittle hard to compare to something that old at this point in time.  But roughly what we would say is that,  \nelective procedures in Q3 were pretty similar to the prior couple quarters, prior to and similar levels to  \npre-COVID.  We expect about the same for Q4 and I'm n ot really expecting any differences in \u201823 as far  \nas that goes, in either direction.  We're not expecting that there's a big buildup of unmet needs that are  \ngoing to fly through the system or vice versa, that we should see a significant reduction. ", "original_text": " \nPage 13 of 15 \n \none will begin getting away from because trying to measure something that's now over two years old  \nwith lots of puts and takes, with new items and changes in the marketplace and everything else, it's a  \nlittle hard to compare to something that old at this point in time. "}, "hash": "29410500543f4f41dbdae03d7849a8514bfd1e01eccc9139f6c098c980ca7771", "class_name": "RelatedNodeInfo"}}, "text": "Now, that's a hard ph rase to use anymore, and it's probably  ", "start_char_idx": 3831, "end_char_idx": 3893, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3c0f73d2-5d4b-421d-a4c0-b2ab5dd655bf": {"__data__": {"id_": "3c0f73d2-5d4b-421d-a4c0-b2ab5dd655bf", "embedding": null, "metadata": {"window": " \nPage 13 of 15 \n \none will begin getting away from because trying to measure something that's now over two years old  \nwith lots of puts and takes, with new items and changes in the marketplace and everything else, it's a  \nlittle hard to compare to something that old at this point in time.  But roughly what we would say is that,  \nelective procedures in Q3 were pretty similar to the prior couple quarters, prior to and similar levels to  \npre-COVID.  We expect about the same for Q4 and I'm n ot really expecting any differences in \u201823 as far  \nas that goes, in either direction.  We're not expecting that there's a big buildup of unmet needs that are  \ngoing to fly through the system or vice versa, that we should see a significant reduction. ", "original_text": " \nPage 13 of 15 \n \none will begin getting away from because trying to measure something that's now over two years old  \nwith lots of puts and takes, with new items and changes in the marketplace and everything else, it's a  \nlittle hard to compare to something that old at this point in time. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00a71c21-791f-4fa1-abcb-a23b5970155b", "node_type": "1", "metadata": {"window": "Thanks.  \n  \n Mike Kaufmann:  Yeah.  Right now what we're seeing is we're seeing elective procedures be pretty  \nsimilar to what we would say pre -COVID.  Now, that's a hard ph rase to use anymore, and it's probably  ", "original_text": "Now, that's a hard ph rase to use anymore, and it's probably  ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d3dba4a3ef59f1f43df350cf661177947c3787385fdbf49fd42f096776858a5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82a2e5d0-e492-46b3-8e09-9f7df68ca6f7", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \none will begin getting away from because trying to measure something that's now over two years old  \nwith lots of puts and takes, with new items and changes in the marketplace and everything else, it's a  \nlittle hard to compare to something that old at this point in time.  But roughly what we would say is that,  \nelective procedures in Q3 were pretty similar to the prior couple quarters, prior to and similar levels to  \npre-COVID.  We expect about the same for Q4 and I'm n ot really expecting any differences in \u201823 as far  \nas that goes, in either direction.  We're not expecting that there's a big buildup of unmet needs that are  \ngoing to fly through the system or vice versa, that we should see a significant reduction.  Now, ob viously,  \nthat could change if there's a flare up with COVID or something like that. ", "original_text": "But roughly what we would say is that,  \nelective procedures in Q3 were pretty similar to the prior couple quarters, prior to and similar levels to  \npre-COVID. "}, "hash": "3c91660011cc81cbc5efa53768cb4dc2ee886d57414564f6a81263544cba2576", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 13 of 15 \n \none will begin getting away from because trying to measure something that's now over two years old  \nwith lots of puts and takes, with new items and changes in the marketplace and everything else, it's a  \nlittle hard to compare to something that old at this point in time. ", "start_char_idx": 0, "end_char_idx": 293, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82a2e5d0-e492-46b3-8e09-9f7df68ca6f7": {"__data__": {"id_": "82a2e5d0-e492-46b3-8e09-9f7df68ca6f7", "embedding": null, "metadata": {"window": " \nPage 13 of 15 \n \none will begin getting away from because trying to measure something that's now over two years old  \nwith lots of puts and takes, with new items and changes in the marketplace and everything else, it's a  \nlittle hard to compare to something that old at this point in time.  But roughly what we would say is that,  \nelective procedures in Q3 were pretty similar to the prior couple quarters, prior to and similar levels to  \npre-COVID.  We expect about the same for Q4 and I'm n ot really expecting any differences in \u201823 as far  \nas that goes, in either direction.  We're not expecting that there's a big buildup of unmet needs that are  \ngoing to fly through the system or vice versa, that we should see a significant reduction.  Now, ob viously,  \nthat could change if there's a flare up with COVID or something like that. ", "original_text": "But roughly what we would say is that,  \nelective procedures in Q3 were pretty similar to the prior couple quarters, prior to and similar levels to  \npre-COVID. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3c0f73d2-5d4b-421d-a4c0-b2ab5dd655bf", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \none will begin getting away from because trying to measure something that's now over two years old  \nwith lots of puts and takes, with new items and changes in the marketplace and everything else, it's a  \nlittle hard to compare to something that old at this point in time.  But roughly what we would say is that,  \nelective procedures in Q3 were pretty similar to the prior couple quarters, prior to and similar levels to  \npre-COVID.  We expect about the same for Q4 and I'm n ot really expecting any differences in \u201823 as far  \nas that goes, in either direction.  We're not expecting that there's a big buildup of unmet needs that are  \ngoing to fly through the system or vice versa, that we should see a significant reduction. ", "original_text": " \nPage 13 of 15 \n \none will begin getting away from because trying to measure something that's now over two years old  \nwith lots of puts and takes, with new items and changes in the marketplace and everything else, it's a  \nlittle hard to compare to something that old at this point in time. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80a69dd10e7f5a08e89ac2ac07db3008644d741d7ddbd5ab9fd103616c021a27", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "721499a8-c4bb-4821-a8b5-060c304e1ee6", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \none will begin getting away from because trying to measure something that's now over two years old  \nwith lots of puts and takes, with new items and changes in the marketplace and everything else, it's a  \nlittle hard to compare to something that old at this point in time.  But roughly what we would say is that,  \nelective procedures in Q3 were pretty similar to the prior couple quarters, prior to and similar levels to  \npre-COVID.  We expect about the same for Q4 and I'm n ot really expecting any differences in \u201823 as far  \nas that goes, in either direction.  We're not expecting that there's a big buildup of unmet needs that are  \ngoing to fly through the system or vice versa, that we should see a significant reduction.  Now, ob viously,  \nthat could change if there's a flare up with COVID or something like that.  But right now, we don't see  \nanything at this point in time that we would forecast for the rest of this year and next year as it relates  \nto differences in elective procedures.  \n \n", "original_text": "We expect about the same for Q4 and I'm n ot really expecting any differences in \u201823 as far  \nas that goes, in either direction. "}, "hash": "0d521e2d466fe37e65212b94e985cca4b3d7a4bbc80420e21d2249ea890c6324", "class_name": "RelatedNodeInfo"}}, "text": "But roughly what we would say is that,  \nelective procedures in Q3 were pretty similar to the prior couple quarters, prior to and similar levels to  \npre-COVID. ", "start_char_idx": 293, "end_char_idx": 454, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "721499a8-c4bb-4821-a8b5-060c304e1ee6": {"__data__": {"id_": "721499a8-c4bb-4821-a8b5-060c304e1ee6", "embedding": null, "metadata": {"window": " \nPage 13 of 15 \n \none will begin getting away from because trying to measure something that's now over two years old  \nwith lots of puts and takes, with new items and changes in the marketplace and everything else, it's a  \nlittle hard to compare to something that old at this point in time.  But roughly what we would say is that,  \nelective procedures in Q3 were pretty similar to the prior couple quarters, prior to and similar levels to  \npre-COVID.  We expect about the same for Q4 and I'm n ot really expecting any differences in \u201823 as far  \nas that goes, in either direction.  We're not expecting that there's a big buildup of unmet needs that are  \ngoing to fly through the system or vice versa, that we should see a significant reduction.  Now, ob viously,  \nthat could change if there's a flare up with COVID or something like that.  But right now, we don't see  \nanything at this point in time that we would forecast for the rest of this year and next year as it relates  \nto differences in elective procedures.  \n \n", "original_text": "We expect about the same for Q4 and I'm n ot really expecting any differences in \u201823 as far  \nas that goes, in either direction. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82a2e5d0-e492-46b3-8e09-9f7df68ca6f7", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \none will begin getting away from because trying to measure something that's now over two years old  \nwith lots of puts and takes, with new items and changes in the marketplace and everything else, it's a  \nlittle hard to compare to something that old at this point in time.  But roughly what we would say is that,  \nelective procedures in Q3 were pretty similar to the prior couple quarters, prior to and similar levels to  \npre-COVID.  We expect about the same for Q4 and I'm n ot really expecting any differences in \u201823 as far  \nas that goes, in either direction.  We're not expecting that there's a big buildup of unmet needs that are  \ngoing to fly through the system or vice versa, that we should see a significant reduction.  Now, ob viously,  \nthat could change if there's a flare up with COVID or something like that. ", "original_text": "But roughly what we would say is that,  \nelective procedures in Q3 were pretty similar to the prior couple quarters, prior to and similar levels to  \npre-COVID. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "132506fd364bafe934be27bacd55b5e245ca157733494fc0dbeec7e6e963db65", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "437f6b5b-7b91-4bee-8883-8de77746dbe0", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \none will begin getting away from because trying to measure something that's now over two years old  \nwith lots of puts and takes, with new items and changes in the marketplace and everything else, it's a  \nlittle hard to compare to something that old at this point in time.  But roughly what we would say is that,  \nelective procedures in Q3 were pretty similar to the prior couple quarters, prior to and similar levels to  \npre-COVID.  We expect about the same for Q4 and I'm n ot really expecting any differences in \u201823 as far  \nas that goes, in either direction.  We're not expecting that there's a big buildup of unmet needs that are  \ngoing to fly through the system or vice versa, that we should see a significant reduction.  Now, ob viously,  \nthat could change if there's a flare up with COVID or something like that.  But right now, we don't see  \nanything at this point in time that we would forecast for the rest of this year and next year as it relates  \nto differences in elective procedures.  \n \n Operator:   Then we'll take our next question from George Hill with Deutsche Bank.  \n  \n", "original_text": "We're not expecting that there's a big buildup of unmet needs that are  \ngoing to fly through the system or vice versa, that we should see a significant reduction. "}, "hash": "900b4ca15535dab9826d159d5ef497659386d0d26dde9515a0d88e9bf4e84ced", "class_name": "RelatedNodeInfo"}}, "text": "We expect about the same for Q4 and I'm n ot really expecting any differences in \u201823 as far  \nas that goes, in either direction. ", "start_char_idx": 454, "end_char_idx": 583, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "437f6b5b-7b91-4bee-8883-8de77746dbe0": {"__data__": {"id_": "437f6b5b-7b91-4bee-8883-8de77746dbe0", "embedding": null, "metadata": {"window": " \nPage 13 of 15 \n \none will begin getting away from because trying to measure something that's now over two years old  \nwith lots of puts and takes, with new items and changes in the marketplace and everything else, it's a  \nlittle hard to compare to something that old at this point in time.  But roughly what we would say is that,  \nelective procedures in Q3 were pretty similar to the prior couple quarters, prior to and similar levels to  \npre-COVID.  We expect about the same for Q4 and I'm n ot really expecting any differences in \u201823 as far  \nas that goes, in either direction.  We're not expecting that there's a big buildup of unmet needs that are  \ngoing to fly through the system or vice versa, that we should see a significant reduction.  Now, ob viously,  \nthat could change if there's a flare up with COVID or something like that.  But right now, we don't see  \nanything at this point in time that we would forecast for the rest of this year and next year as it relates  \nto differences in elective procedures.  \n \n Operator:   Then we'll take our next question from George Hill with Deutsche Bank.  \n  \n", "original_text": "We're not expecting that there's a big buildup of unmet needs that are  \ngoing to fly through the system or vice versa, that we should see a significant reduction. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "721499a8-c4bb-4821-a8b5-060c304e1ee6", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \none will begin getting away from because trying to measure something that's now over two years old  \nwith lots of puts and takes, with new items and changes in the marketplace and everything else, it's a  \nlittle hard to compare to something that old at this point in time.  But roughly what we would say is that,  \nelective procedures in Q3 were pretty similar to the prior couple quarters, prior to and similar levels to  \npre-COVID.  We expect about the same for Q4 and I'm n ot really expecting any differences in \u201823 as far  \nas that goes, in either direction.  We're not expecting that there's a big buildup of unmet needs that are  \ngoing to fly through the system or vice versa, that we should see a significant reduction.  Now, ob viously,  \nthat could change if there's a flare up with COVID or something like that.  But right now, we don't see  \nanything at this point in time that we would forecast for the rest of this year and next year as it relates  \nto differences in elective procedures.  \n \n", "original_text": "We expect about the same for Q4 and I'm n ot really expecting any differences in \u201823 as far  \nas that goes, in either direction. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3c045d271abd81dc26d3cae6bec4a117f448e8addd2b73518f3bdbf87eb0ac6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07fb69c7-3fbe-4efc-ae07-b2010e1f885f", "node_type": "1", "metadata": {"window": "But roughly what we would say is that,  \nelective procedures in Q3 were pretty similar to the prior couple quarters, prior to and similar levels to  \npre-COVID.  We expect about the same for Q4 and I'm n ot really expecting any differences in \u201823 as far  \nas that goes, in either direction.  We're not expecting that there's a big buildup of unmet needs that are  \ngoing to fly through the system or vice versa, that we should see a significant reduction.  Now, ob viously,  \nthat could change if there's a flare up with COVID or something like that.  But right now, we don't see  \nanything at this point in time that we would forecast for the rest of this year and next year as it relates  \nto differences in elective procedures.  \n \n Operator:   Then we'll take our next question from George Hill with Deutsche Bank.  \n  \n George  Hill:  Yeah. ", "original_text": "Now, ob viously,  \nthat could change if there's a flare up with COVID or something like that. "}, "hash": "5bb161e64d9fd368da987aa5d781ab622c230124c2b5a149811dd2701bfbe792", "class_name": "RelatedNodeInfo"}}, "text": "We're not expecting that there's a big buildup of unmet needs that are  \ngoing to fly through the system or vice versa, that we should see a significant reduction. ", "start_char_idx": 583, "end_char_idx": 747, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07fb69c7-3fbe-4efc-ae07-b2010e1f885f": {"__data__": {"id_": "07fb69c7-3fbe-4efc-ae07-b2010e1f885f", "embedding": null, "metadata": {"window": "But roughly what we would say is that,  \nelective procedures in Q3 were pretty similar to the prior couple quarters, prior to and similar levels to  \npre-COVID.  We expect about the same for Q4 and I'm n ot really expecting any differences in \u201823 as far  \nas that goes, in either direction.  We're not expecting that there's a big buildup of unmet needs that are  \ngoing to fly through the system or vice versa, that we should see a significant reduction.  Now, ob viously,  \nthat could change if there's a flare up with COVID or something like that.  But right now, we don't see  \nanything at this point in time that we would forecast for the rest of this year and next year as it relates  \nto differences in elective procedures.  \n \n Operator:   Then we'll take our next question from George Hill with Deutsche Bank.  \n  \n George  Hill:  Yeah. ", "original_text": "Now, ob viously,  \nthat could change if there's a flare up with COVID or something like that. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "437f6b5b-7b91-4bee-8883-8de77746dbe0", "node_type": "1", "metadata": {"window": " \nPage 13 of 15 \n \none will begin getting away from because trying to measure something that's now over two years old  \nwith lots of puts and takes, with new items and changes in the marketplace and everything else, it's a  \nlittle hard to compare to something that old at this point in time.  But roughly what we would say is that,  \nelective procedures in Q3 were pretty similar to the prior couple quarters, prior to and similar levels to  \npre-COVID.  We expect about the same for Q4 and I'm n ot really expecting any differences in \u201823 as far  \nas that goes, in either direction.  We're not expecting that there's a big buildup of unmet needs that are  \ngoing to fly through the system or vice versa, that we should see a significant reduction.  Now, ob viously,  \nthat could change if there's a flare up with COVID or something like that.  But right now, we don't see  \nanything at this point in time that we would forecast for the rest of this year and next year as it relates  \nto differences in elective procedures.  \n \n Operator:   Then we'll take our next question from George Hill with Deutsche Bank.  \n  \n", "original_text": "We're not expecting that there's a big buildup of unmet needs that are  \ngoing to fly through the system or vice versa, that we should see a significant reduction. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "36031c57e79234d58863b24386365d5d46c86690558eef866e0b3da17cdb454e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "934625fd-e2b6-4ef9-aa3d-0bf9abf561ea", "node_type": "1", "metadata": {"window": "We expect about the same for Q4 and I'm n ot really expecting any differences in \u201823 as far  \nas that goes, in either direction.  We're not expecting that there's a big buildup of unmet needs that are  \ngoing to fly through the system or vice versa, that we should see a significant reduction.  Now, ob viously,  \nthat could change if there's a flare up with COVID or something like that.  But right now, we don't see  \nanything at this point in time that we would forecast for the rest of this year and next year as it relates  \nto differences in elective procedures.  \n \n Operator:   Then we'll take our next question from George Hill with Deutsche Bank.  \n  \n George  Hill:  Yeah.  Good morning guys and thanks for taking the question. ", "original_text": "But right now, we don't see  \nanything at this point in time that we would forecast for the rest of this year and next year as it relates  \nto differences in elective procedures.  \n \n"}, "hash": "886c643ba5065739f5002359ae3331f695009818a03203e67bd570fb46db7a23", "class_name": "RelatedNodeInfo"}}, "text": "Now, ob viously,  \nthat could change if there's a flare up with COVID or something like that. ", "start_char_idx": 747, "end_char_idx": 841, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "934625fd-e2b6-4ef9-aa3d-0bf9abf561ea": {"__data__": {"id_": "934625fd-e2b6-4ef9-aa3d-0bf9abf561ea", "embedding": null, "metadata": {"window": "We expect about the same for Q4 and I'm n ot really expecting any differences in \u201823 as far  \nas that goes, in either direction.  We're not expecting that there's a big buildup of unmet needs that are  \ngoing to fly through the system or vice versa, that we should see a significant reduction.  Now, ob viously,  \nthat could change if there's a flare up with COVID or something like that.  But right now, we don't see  \nanything at this point in time that we would forecast for the rest of this year and next year as it relates  \nto differences in elective procedures.  \n \n Operator:   Then we'll take our next question from George Hill with Deutsche Bank.  \n  \n George  Hill:  Yeah.  Good morning guys and thanks for taking the question. ", "original_text": "But right now, we don't see  \nanything at this point in time that we would forecast for the rest of this year and next year as it relates  \nto differences in elective procedures.  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07fb69c7-3fbe-4efc-ae07-b2010e1f885f", "node_type": "1", "metadata": {"window": "But roughly what we would say is that,  \nelective procedures in Q3 were pretty similar to the prior couple quarters, prior to and similar levels to  \npre-COVID.  We expect about the same for Q4 and I'm n ot really expecting any differences in \u201823 as far  \nas that goes, in either direction.  We're not expecting that there's a big buildup of unmet needs that are  \ngoing to fly through the system or vice versa, that we should see a significant reduction.  Now, ob viously,  \nthat could change if there's a flare up with COVID or something like that.  But right now, we don't see  \nanything at this point in time that we would forecast for the rest of this year and next year as it relates  \nto differences in elective procedures.  \n \n Operator:   Then we'll take our next question from George Hill with Deutsche Bank.  \n  \n George  Hill:  Yeah. ", "original_text": "Now, ob viously,  \nthat could change if there's a flare up with COVID or something like that. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6d61a4ca1bd1d3f0ceb0c8bcf84c300d0f17f41cf42a5644b449de146ceeaaf4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4fea0aa6-4535-4fd1-ad97-23b57619caed", "node_type": "1", "metadata": {"window": "We're not expecting that there's a big buildup of unmet needs that are  \ngoing to fly through the system or vice versa, that we should see a significant reduction.  Now, ob viously,  \nthat could change if there's a flare up with COVID or something like that.  But right now, we don't see  \nanything at this point in time that we would forecast for the rest of this year and next year as it relates  \nto differences in elective procedures.  \n \n Operator:   Then we'll take our next question from George Hill with Deutsche Bank.  \n  \n George  Hill:  Yeah.  Good morning guys and thanks for taking the question.  Jason, the med surg  \nbusiness, and I'm going to stay on this one, did about 60 million in EBITDA in Q3 and that's kind of the  \nmidpoint of the Q4 guide. ", "original_text": "Operator:   Then we'll take our next question from George Hill with Deutsche Bank.  \n  \n"}, "hash": "0a39ae91616e231124a06404c52becd2b026f6dbacbb228954a8997c9fd9e9c7", "class_name": "RelatedNodeInfo"}}, "text": "But right now, we don't see  \nanything at this point in time that we would forecast for the rest of this year and next year as it relates  \nto differences in elective procedures.  \n \n", "start_char_idx": 841, "end_char_idx": 1024, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4fea0aa6-4535-4fd1-ad97-23b57619caed": {"__data__": {"id_": "4fea0aa6-4535-4fd1-ad97-23b57619caed", "embedding": null, "metadata": {"window": "We're not expecting that there's a big buildup of unmet needs that are  \ngoing to fly through the system or vice versa, that we should see a significant reduction.  Now, ob viously,  \nthat could change if there's a flare up with COVID or something like that.  But right now, we don't see  \nanything at this point in time that we would forecast for the rest of this year and next year as it relates  \nto differences in elective procedures.  \n \n Operator:   Then we'll take our next question from George Hill with Deutsche Bank.  \n  \n George  Hill:  Yeah.  Good morning guys and thanks for taking the question.  Jason, the med surg  \nbusiness, and I'm going to stay on this one, did about 60 million in EBITDA in Q3 and that's kind of the  \nmidpoint of the Q4 guide. ", "original_text": "Operator:   Then we'll take our next question from George Hill with Deutsche Bank.  \n  \n", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "934625fd-e2b6-4ef9-aa3d-0bf9abf561ea", "node_type": "1", "metadata": {"window": "We expect about the same for Q4 and I'm n ot really expecting any differences in \u201823 as far  \nas that goes, in either direction.  We're not expecting that there's a big buildup of unmet needs that are  \ngoing to fly through the system or vice versa, that we should see a significant reduction.  Now, ob viously,  \nthat could change if there's a flare up with COVID or something like that.  But right now, we don't see  \nanything at this point in time that we would forecast for the rest of this year and next year as it relates  \nto differences in elective procedures.  \n \n Operator:   Then we'll take our next question from George Hill with Deutsche Bank.  \n  \n George  Hill:  Yeah.  Good morning guys and thanks for taking the question. ", "original_text": "But right now, we don't see  \nanything at this point in time that we would forecast for the rest of this year and next year as it relates  \nto differences in elective procedures.  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "bae5e81f21642559bfb0729aaae18a20c0a5785bc499aa4cba26dd70b2bd6616", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44c6db32-064e-4818-bb97-c2bb84d410e5", "node_type": "1", "metadata": {"window": "Now, ob viously,  \nthat could change if there's a flare up with COVID or something like that.  But right now, we don't see  \nanything at this point in time that we would forecast for the rest of this year and next year as it relates  \nto differences in elective procedures.  \n \n Operator:   Then we'll take our next question from George Hill with Deutsche Bank.  \n  \n George  Hill:  Yeah.  Good morning guys and thanks for taking the question.  Jason, the med surg  \nbusiness, and I'm going to stay on this one, did about 60 million in EBITDA in Q3 and that's kind of the  \nmidpoint of the Q4 guide.  But as we think about your fiscal \u201823 comments, we know that inflation is  \nbuilding and the impact tends to lag, I guess is the right way to think about med su rge in fiscal \u201923, is   \nthat this is kind of the jumping off the back half of fiscal \u201822 almost overstates the operating earnings  \nrun rate of the business. ", "original_text": "George  Hill:  Yeah. "}, "hash": "1411af9819c7d8220ce83b34ce2a7a6b8b275b15d8ac0e60858d61fde1996a23", "class_name": "RelatedNodeInfo"}}, "text": "Operator:   Then we'll take our next question from George Hill with Deutsche Bank.  \n  \n", "start_char_idx": 1024, "end_char_idx": 1112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44c6db32-064e-4818-bb97-c2bb84d410e5": {"__data__": {"id_": "44c6db32-064e-4818-bb97-c2bb84d410e5", "embedding": null, "metadata": {"window": "Now, ob viously,  \nthat could change if there's a flare up with COVID or something like that.  But right now, we don't see  \nanything at this point in time that we would forecast for the rest of this year and next year as it relates  \nto differences in elective procedures.  \n \n Operator:   Then we'll take our next question from George Hill with Deutsche Bank.  \n  \n George  Hill:  Yeah.  Good morning guys and thanks for taking the question.  Jason, the med surg  \nbusiness, and I'm going to stay on this one, did about 60 million in EBITDA in Q3 and that's kind of the  \nmidpoint of the Q4 guide.  But as we think about your fiscal \u201823 comments, we know that inflation is  \nbuilding and the impact tends to lag, I guess is the right way to think about med su rge in fiscal \u201923, is   \nthat this is kind of the jumping off the back half of fiscal \u201822 almost overstates the operating earnings  \nrun rate of the business. ", "original_text": "George  Hill:  Yeah. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4fea0aa6-4535-4fd1-ad97-23b57619caed", "node_type": "1", "metadata": {"window": "We're not expecting that there's a big buildup of unmet needs that are  \ngoing to fly through the system or vice versa, that we should see a significant reduction.  Now, ob viously,  \nthat could change if there's a flare up with COVID or something like that.  But right now, we don't see  \nanything at this point in time that we would forecast for the rest of this year and next year as it relates  \nto differences in elective procedures.  \n \n Operator:   Then we'll take our next question from George Hill with Deutsche Bank.  \n  \n George  Hill:  Yeah.  Good morning guys and thanks for taking the question.  Jason, the med surg  \nbusiness, and I'm going to stay on this one, did about 60 million in EBITDA in Q3 and that's kind of the  \nmidpoint of the Q4 guide. ", "original_text": "Operator:   Then we'll take our next question from George Hill with Deutsche Bank.  \n  \n", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b1657462693dbc9e97333b5e6aef3b6a3555ff93f7e766cc72bbe18144d36836", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "863883b1-d8ab-434a-bc0d-c04c1944938d", "node_type": "1", "metadata": {"window": "But right now, we don't see  \nanything at this point in time that we would forecast for the rest of this year and next year as it relates  \nto differences in elective procedures.  \n \n Operator:   Then we'll take our next question from George Hill with Deutsche Bank.  \n  \n George  Hill:  Yeah.  Good morning guys and thanks for taking the question.  Jason, the med surg  \nbusiness, and I'm going to stay on this one, did about 60 million in EBITDA in Q3 and that's kind of the  \nmidpoint of the Q4 guide.  But as we think about your fiscal \u201823 comments, we know that inflation is  \nbuilding and the impact tends to lag, I guess is the right way to think about med su rge in fiscal \u201923, is   \nthat this is kind of the jumping off the back half of fiscal \u201822 almost overstates the operating earnings  \nrun rate of the business.  And that I guess I'm trying to get a sense of magnitude of how far down it can  \ngo in fiscal \u201923, a nd to what degree can pricing initiatives kind of offset that?  \n \n", "original_text": "Good morning guys and thanks for taking the question. "}, "hash": "63ffed6e7b350bbea0105a7cde50a198994cf1ec475e72b978f0db172bfd373b", "class_name": "RelatedNodeInfo"}}, "text": "George  Hill:  Yeah. ", "start_char_idx": 1112, "end_char_idx": 1133, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "863883b1-d8ab-434a-bc0d-c04c1944938d": {"__data__": {"id_": "863883b1-d8ab-434a-bc0d-c04c1944938d", "embedding": null, "metadata": {"window": "But right now, we don't see  \nanything at this point in time that we would forecast for the rest of this year and next year as it relates  \nto differences in elective procedures.  \n \n Operator:   Then we'll take our next question from George Hill with Deutsche Bank.  \n  \n George  Hill:  Yeah.  Good morning guys and thanks for taking the question.  Jason, the med surg  \nbusiness, and I'm going to stay on this one, did about 60 million in EBITDA in Q3 and that's kind of the  \nmidpoint of the Q4 guide.  But as we think about your fiscal \u201823 comments, we know that inflation is  \nbuilding and the impact tends to lag, I guess is the right way to think about med su rge in fiscal \u201923, is   \nthat this is kind of the jumping off the back half of fiscal \u201822 almost overstates the operating earnings  \nrun rate of the business.  And that I guess I'm trying to get a sense of magnitude of how far down it can  \ngo in fiscal \u201923, a nd to what degree can pricing initiatives kind of offset that?  \n \n", "original_text": "Good morning guys and thanks for taking the question. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44c6db32-064e-4818-bb97-c2bb84d410e5", "node_type": "1", "metadata": {"window": "Now, ob viously,  \nthat could change if there's a flare up with COVID or something like that.  But right now, we don't see  \nanything at this point in time that we would forecast for the rest of this year and next year as it relates  \nto differences in elective procedures.  \n \n Operator:   Then we'll take our next question from George Hill with Deutsche Bank.  \n  \n George  Hill:  Yeah.  Good morning guys and thanks for taking the question.  Jason, the med surg  \nbusiness, and I'm going to stay on this one, did about 60 million in EBITDA in Q3 and that's kind of the  \nmidpoint of the Q4 guide.  But as we think about your fiscal \u201823 comments, we know that inflation is  \nbuilding and the impact tends to lag, I guess is the right way to think about med su rge in fiscal \u201923, is   \nthat this is kind of the jumping off the back half of fiscal \u201822 almost overstates the operating earnings  \nrun rate of the business. ", "original_text": "George  Hill:  Yeah. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ff680d5f5ee8397446c533b2854ba7a274e0d60361fec269830329f47bbecf5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87d496a4-73de-41c3-ad5f-393b0e94618e", "node_type": "1", "metadata": {"window": "Operator:   Then we'll take our next question from George Hill with Deutsche Bank.  \n  \n George  Hill:  Yeah.  Good morning guys and thanks for taking the question.  Jason, the med surg  \nbusiness, and I'm going to stay on this one, did about 60 million in EBITDA in Q3 and that's kind of the  \nmidpoint of the Q4 guide.  But as we think about your fiscal \u201823 comments, we know that inflation is  \nbuilding and the impact tends to lag, I guess is the right way to think about med su rge in fiscal \u201923, is   \nthat this is kind of the jumping off the back half of fiscal \u201822 almost overstates the operating earnings  \nrun rate of the business.  And that I guess I'm trying to get a sense of magnitude of how far down it can  \ngo in fiscal \u201923, a nd to what degree can pricing initiatives kind of offset that?  \n \n Jason Hollar:  Yeah. ", "original_text": "Jason, the med surg  \nbusiness, and I'm going to stay on this one, did about 60 million in EBITDA in Q3 and that's kind of the  \nmidpoint of the Q4 guide. "}, "hash": "b62c9b67b58bfecb4b3eef1488a4468b7ed266e21c3bc7f6830e1a1635b3ecf1", "class_name": "RelatedNodeInfo"}}, "text": "Good morning guys and thanks for taking the question. ", "start_char_idx": 1133, "end_char_idx": 1187, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87d496a4-73de-41c3-ad5f-393b0e94618e": {"__data__": {"id_": "87d496a4-73de-41c3-ad5f-393b0e94618e", "embedding": null, "metadata": {"window": "Operator:   Then we'll take our next question from George Hill with Deutsche Bank.  \n  \n George  Hill:  Yeah.  Good morning guys and thanks for taking the question.  Jason, the med surg  \nbusiness, and I'm going to stay on this one, did about 60 million in EBITDA in Q3 and that's kind of the  \nmidpoint of the Q4 guide.  But as we think about your fiscal \u201823 comments, we know that inflation is  \nbuilding and the impact tends to lag, I guess is the right way to think about med su rge in fiscal \u201923, is   \nthat this is kind of the jumping off the back half of fiscal \u201822 almost overstates the operating earnings  \nrun rate of the business.  And that I guess I'm trying to get a sense of magnitude of how far down it can  \ngo in fiscal \u201923, a nd to what degree can pricing initiatives kind of offset that?  \n \n Jason Hollar:  Yeah. ", "original_text": "Jason, the med surg  \nbusiness, and I'm going to stay on this one, did about 60 million in EBITDA in Q3 and that's kind of the  \nmidpoint of the Q4 guide. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "863883b1-d8ab-434a-bc0d-c04c1944938d", "node_type": "1", "metadata": {"window": "But right now, we don't see  \nanything at this point in time that we would forecast for the rest of this year and next year as it relates  \nto differences in elective procedures.  \n \n Operator:   Then we'll take our next question from George Hill with Deutsche Bank.  \n  \n George  Hill:  Yeah.  Good morning guys and thanks for taking the question.  Jason, the med surg  \nbusiness, and I'm going to stay on this one, did about 60 million in EBITDA in Q3 and that's kind of the  \nmidpoint of the Q4 guide.  But as we think about your fiscal \u201823 comments, we know that inflation is  \nbuilding and the impact tends to lag, I guess is the right way to think about med su rge in fiscal \u201923, is   \nthat this is kind of the jumping off the back half of fiscal \u201822 almost overstates the operating earnings  \nrun rate of the business.  And that I guess I'm trying to get a sense of magnitude of how far down it can  \ngo in fiscal \u201923, a nd to what degree can pricing initiatives kind of offset that?  \n \n", "original_text": "Good morning guys and thanks for taking the question. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d38e1cad641437859230c5a45e20457b1a742defa5ecd74ae5353f0777c2aca7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28d79f79-679f-496b-95e8-27a1243627c1", "node_type": "1", "metadata": {"window": "George  Hill:  Yeah.  Good morning guys and thanks for taking the question.  Jason, the med surg  \nbusiness, and I'm going to stay on this one, did about 60 million in EBITDA in Q3 and that's kind of the  \nmidpoint of the Q4 guide.  But as we think about your fiscal \u201823 comments, we know that inflation is  \nbuilding and the impact tends to lag, I guess is the right way to think about med su rge in fiscal \u201923, is   \nthat this is kind of the jumping off the back half of fiscal \u201822 almost overstates the operating earnings  \nrun rate of the business.  And that I guess I'm trying to get a sense of magnitude of how far down it can  \ngo in fiscal \u201923, a nd to what degree can pricing initiatives kind of offset that?  \n \n Jason Hollar:  Yeah.  The area I can probably be a little bit more helpful is on the timing associated with  \nthat. ", "original_text": "But as we think about your fiscal \u201823 comments, we know that inflation is  \nbuilding and the impact tends to lag, I guess is the right way to think about med su rge in fiscal \u201923, is   \nthat this is kind of the jumping off the back half of fiscal \u201822 almost overstates the operating earnings  \nrun rate of the business. "}, "hash": "2e503b56bf4332a0cee65ffe0b0d20ef10204386454825c861b2b0764732f33d", "class_name": "RelatedNodeInfo"}}, "text": "Jason, the med surg  \nbusiness, and I'm going to stay on this one, did about 60 million in EBITDA in Q3 and that's kind of the  \nmidpoint of the Q4 guide. ", "start_char_idx": 1187, "end_char_idx": 1342, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28d79f79-679f-496b-95e8-27a1243627c1": {"__data__": {"id_": "28d79f79-679f-496b-95e8-27a1243627c1", "embedding": null, "metadata": {"window": "George  Hill:  Yeah.  Good morning guys and thanks for taking the question.  Jason, the med surg  \nbusiness, and I'm going to stay on this one, did about 60 million in EBITDA in Q3 and that's kind of the  \nmidpoint of the Q4 guide.  But as we think about your fiscal \u201823 comments, we know that inflation is  \nbuilding and the impact tends to lag, I guess is the right way to think about med su rge in fiscal \u201923, is   \nthat this is kind of the jumping off the back half of fiscal \u201822 almost overstates the operating earnings  \nrun rate of the business.  And that I guess I'm trying to get a sense of magnitude of how far down it can  \ngo in fiscal \u201923, a nd to what degree can pricing initiatives kind of offset that?  \n \n Jason Hollar:  Yeah.  The area I can probably be a little bit more helpful is on the timing associated with  \nthat. ", "original_text": "But as we think about your fiscal \u201823 comments, we know that inflation is  \nbuilding and the impact tends to lag, I guess is the right way to think about med su rge in fiscal \u201923, is   \nthat this is kind of the jumping off the back half of fiscal \u201822 almost overstates the operating earnings  \nrun rate of the business. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87d496a4-73de-41c3-ad5f-393b0e94618e", "node_type": "1", "metadata": {"window": "Operator:   Then we'll take our next question from George Hill with Deutsche Bank.  \n  \n George  Hill:  Yeah.  Good morning guys and thanks for taking the question.  Jason, the med surg  \nbusiness, and I'm going to stay on this one, did about 60 million in EBITDA in Q3 and that's kind of the  \nmidpoint of the Q4 guide.  But as we think about your fiscal \u201823 comments, we know that inflation is  \nbuilding and the impact tends to lag, I guess is the right way to think about med su rge in fiscal \u201923, is   \nthat this is kind of the jumping off the back half of fiscal \u201822 almost overstates the operating earnings  \nrun rate of the business.  And that I guess I'm trying to get a sense of magnitude of how far down it can  \ngo in fiscal \u201923, a nd to what degree can pricing initiatives kind of offset that?  \n \n Jason Hollar:  Yeah. ", "original_text": "Jason, the med surg  \nbusiness, and I'm going to stay on this one, did about 60 million in EBITDA in Q3 and that's kind of the  \nmidpoint of the Q4 guide. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b2e0b96a3919f7a4c46d0872fd46ce2e0eac8abca4a0bd62ded80cb96b328e55", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8a5a574-56f3-425f-beed-b9d7750b1c61", "node_type": "1", "metadata": {"window": "Good morning guys and thanks for taking the question.  Jason, the med surg  \nbusiness, and I'm going to stay on this one, did about 60 million in EBITDA in Q3 and that's kind of the  \nmidpoint of the Q4 guide.  But as we think about your fiscal \u201823 comments, we know that inflation is  \nbuilding and the impact tends to lag, I guess is the right way to think about med su rge in fiscal \u201923, is   \nthat this is kind of the jumping off the back half of fiscal \u201822 almost overstates the operating earnings  \nrun rate of the business.  And that I guess I'm trying to get a sense of magnitude of how far down it can  \ngo in fiscal \u201923, a nd to what degree can pricing initiatives kind of offset that?  \n \n Jason Hollar:  Yeah.  The area I can probably be a little bit more helpful is on the timing associated with  \nthat.  The impact of that inflation from a year -over-year perspective will be more u nfavorable in the first  \nhalf of the year. ", "original_text": "And that I guess I'm trying to get a sense of magnitude of how far down it can  \ngo in fiscal \u201923, a nd to what degree can pricing initiatives kind of offset that?  \n \n"}, "hash": "57a7e89c2fd0f9218476230de4a7bd71da593372a08b527042ffcf2f83d956aa", "class_name": "RelatedNodeInfo"}}, "text": "But as we think about your fiscal \u201823 comments, we know that inflation is  \nbuilding and the impact tends to lag, I guess is the right way to think about med su rge in fiscal \u201923, is   \nthat this is kind of the jumping off the back half of fiscal \u201822 almost overstates the operating earnings  \nrun rate of the business. ", "start_char_idx": 1342, "end_char_idx": 1662, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8a5a574-56f3-425f-beed-b9d7750b1c61": {"__data__": {"id_": "b8a5a574-56f3-425f-beed-b9d7750b1c61", "embedding": null, "metadata": {"window": "Good morning guys and thanks for taking the question.  Jason, the med surg  \nbusiness, and I'm going to stay on this one, did about 60 million in EBITDA in Q3 and that's kind of the  \nmidpoint of the Q4 guide.  But as we think about your fiscal \u201823 comments, we know that inflation is  \nbuilding and the impact tends to lag, I guess is the right way to think about med su rge in fiscal \u201923, is   \nthat this is kind of the jumping off the back half of fiscal \u201822 almost overstates the operating earnings  \nrun rate of the business.  And that I guess I'm trying to get a sense of magnitude of how far down it can  \ngo in fiscal \u201923, a nd to what degree can pricing initiatives kind of offset that?  \n \n Jason Hollar:  Yeah.  The area I can probably be a little bit more helpful is on the timing associated with  \nthat.  The impact of that inflation from a year -over-year perspective will be more u nfavorable in the first  \nhalf of the year. ", "original_text": "And that I guess I'm trying to get a sense of magnitude of how far down it can  \ngo in fiscal \u201923, a nd to what degree can pricing initiatives kind of offset that?  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28d79f79-679f-496b-95e8-27a1243627c1", "node_type": "1", "metadata": {"window": "George  Hill:  Yeah.  Good morning guys and thanks for taking the question.  Jason, the med surg  \nbusiness, and I'm going to stay on this one, did about 60 million in EBITDA in Q3 and that's kind of the  \nmidpoint of the Q4 guide.  But as we think about your fiscal \u201823 comments, we know that inflation is  \nbuilding and the impact tends to lag, I guess is the right way to think about med su rge in fiscal \u201923, is   \nthat this is kind of the jumping off the back half of fiscal \u201822 almost overstates the operating earnings  \nrun rate of the business.  And that I guess I'm trying to get a sense of magnitude of how far down it can  \ngo in fiscal \u201923, a nd to what degree can pricing initiatives kind of offset that?  \n \n Jason Hollar:  Yeah.  The area I can probably be a little bit more helpful is on the timing associated with  \nthat. ", "original_text": "But as we think about your fiscal \u201823 comments, we know that inflation is  \nbuilding and the impact tends to lag, I guess is the right way to think about med su rge in fiscal \u201923, is   \nthat this is kind of the jumping off the back half of fiscal \u201822 almost overstates the operating earnings  \nrun rate of the business. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "37259d2858a0ff0e1ffb157224885d6281dd795aa29c90c2c4f3fa274e68dd1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af69265f-7886-44ae-98cd-06406f64e047", "node_type": "1", "metadata": {"window": "Jason, the med surg  \nbusiness, and I'm going to stay on this one, did about 60 million in EBITDA in Q3 and that's kind of the  \nmidpoint of the Q4 guide.  But as we think about your fiscal \u201823 comments, we know that inflation is  \nbuilding and the impact tends to lag, I guess is the right way to think about med su rge in fiscal \u201923, is   \nthat this is kind of the jumping off the back half of fiscal \u201822 almost overstates the operating earnings  \nrun rate of the business.  And that I guess I'm trying to get a sense of magnitude of how far down it can  \ngo in fiscal \u201923, a nd to what degree can pricing initiatives kind of offset that?  \n \n Jason Hollar:  Yeah.  The area I can probably be a little bit more helpful is on the timing associated with  \nthat.  The impact of that inflation from a year -over-year perspective will be more u nfavorable in the first  \nhalf of the year.  If you think about what we had in fiscal \u201822, Q1 had much less of an impact, actually  \nhitting the PNL we had seen the costs start to come start to build in terms of what was procured, but  \nwhat actually hit the P &L escalated much more greatly in the second quarter and has increased from  \nthere in Q3, Q4. ", "original_text": "Jason Hollar:  Yeah. "}, "hash": "985e2dc7fe4a839660f528a6e4970807a7667434ebd37019766742f4f504251e", "class_name": "RelatedNodeInfo"}}, "text": "And that I guess I'm trying to get a sense of magnitude of how far down it can  \ngo in fiscal \u201923, a nd to what degree can pricing initiatives kind of offset that?  \n \n", "start_char_idx": 1662, "end_char_idx": 1830, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af69265f-7886-44ae-98cd-06406f64e047": {"__data__": {"id_": "af69265f-7886-44ae-98cd-06406f64e047", "embedding": null, "metadata": {"window": "Jason, the med surg  \nbusiness, and I'm going to stay on this one, did about 60 million in EBITDA in Q3 and that's kind of the  \nmidpoint of the Q4 guide.  But as we think about your fiscal \u201823 comments, we know that inflation is  \nbuilding and the impact tends to lag, I guess is the right way to think about med su rge in fiscal \u201923, is   \nthat this is kind of the jumping off the back half of fiscal \u201822 almost overstates the operating earnings  \nrun rate of the business.  And that I guess I'm trying to get a sense of magnitude of how far down it can  \ngo in fiscal \u201923, a nd to what degree can pricing initiatives kind of offset that?  \n \n Jason Hollar:  Yeah.  The area I can probably be a little bit more helpful is on the timing associated with  \nthat.  The impact of that inflation from a year -over-year perspective will be more u nfavorable in the first  \nhalf of the year.  If you think about what we had in fiscal \u201822, Q1 had much less of an impact, actually  \nhitting the PNL we had seen the costs start to come start to build in terms of what was procured, but  \nwhat actually hit the P &L escalated much more greatly in the second quarter and has increased from  \nthere in Q3, Q4. ", "original_text": "Jason Hollar:  Yeah. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8a5a574-56f3-425f-beed-b9d7750b1c61", "node_type": "1", "metadata": {"window": "Good morning guys and thanks for taking the question.  Jason, the med surg  \nbusiness, and I'm going to stay on this one, did about 60 million in EBITDA in Q3 and that's kind of the  \nmidpoint of the Q4 guide.  But as we think about your fiscal \u201823 comments, we know that inflation is  \nbuilding and the impact tends to lag, I guess is the right way to think about med su rge in fiscal \u201923, is   \nthat this is kind of the jumping off the back half of fiscal \u201822 almost overstates the operating earnings  \nrun rate of the business.  And that I guess I'm trying to get a sense of magnitude of how far down it can  \ngo in fiscal \u201923, a nd to what degree can pricing initiatives kind of offset that?  \n \n Jason Hollar:  Yeah.  The area I can probably be a little bit more helpful is on the timing associated with  \nthat.  The impact of that inflation from a year -over-year perspective will be more u nfavorable in the first  \nhalf of the year. ", "original_text": "And that I guess I'm trying to get a sense of magnitude of how far down it can  \ngo in fiscal \u201923, a nd to what degree can pricing initiatives kind of offset that?  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "f7334e4bc7b8cf2f8466dc7a38cdac00b42cef717450eacce2e24fa7b27ee8b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ea89404-d666-4e4d-bcb2-78e05d889cc4", "node_type": "1", "metadata": {"window": "But as we think about your fiscal \u201823 comments, we know that inflation is  \nbuilding and the impact tends to lag, I guess is the right way to think about med su rge in fiscal \u201923, is   \nthat this is kind of the jumping off the back half of fiscal \u201822 almost overstates the operating earnings  \nrun rate of the business.  And that I guess I'm trying to get a sense of magnitude of how far down it can  \ngo in fiscal \u201923, a nd to what degree can pricing initiatives kind of offset that?  \n \n Jason Hollar:  Yeah.  The area I can probably be a little bit more helpful is on the timing associated with  \nthat.  The impact of that inflation from a year -over-year perspective will be more u nfavorable in the first  \nhalf of the year.  If you think about what we had in fiscal \u201822, Q1 had much less of an impact, actually  \nhitting the PNL we had seen the costs start to come start to build in terms of what was procured, but  \nwhat actually hit the P &L escalated much more greatly in the second quarter and has increased from  \nthere in Q3, Q4.  So that comparison from a year -over-year perspective, will be unfavorable for those  \nelements, all things being equal. ", "original_text": "The area I can probably be a little bit more helpful is on the timing associated with  \nthat. "}, "hash": "0c657552220737d96eff0925449dc956f12a1f10929ae2ca96f7800929ad7e9c", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yeah. ", "start_char_idx": 1830, "end_char_idx": 1851, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ea89404-d666-4e4d-bcb2-78e05d889cc4": {"__data__": {"id_": "9ea89404-d666-4e4d-bcb2-78e05d889cc4", "embedding": null, "metadata": {"window": "But as we think about your fiscal \u201823 comments, we know that inflation is  \nbuilding and the impact tends to lag, I guess is the right way to think about med su rge in fiscal \u201923, is   \nthat this is kind of the jumping off the back half of fiscal \u201822 almost overstates the operating earnings  \nrun rate of the business.  And that I guess I'm trying to get a sense of magnitude of how far down it can  \ngo in fiscal \u201923, a nd to what degree can pricing initiatives kind of offset that?  \n \n Jason Hollar:  Yeah.  The area I can probably be a little bit more helpful is on the timing associated with  \nthat.  The impact of that inflation from a year -over-year perspective will be more u nfavorable in the first  \nhalf of the year.  If you think about what we had in fiscal \u201822, Q1 had much less of an impact, actually  \nhitting the PNL we had seen the costs start to come start to build in terms of what was procured, but  \nwhat actually hit the P &L escalated much more greatly in the second quarter and has increased from  \nthere in Q3, Q4.  So that comparison from a year -over-year perspective, will be unfavorable for those  \nelements, all things being equal. ", "original_text": "The area I can probably be a little bit more helpful is on the timing associated with  \nthat. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af69265f-7886-44ae-98cd-06406f64e047", "node_type": "1", "metadata": {"window": "Jason, the med surg  \nbusiness, and I'm going to stay on this one, did about 60 million in EBITDA in Q3 and that's kind of the  \nmidpoint of the Q4 guide.  But as we think about your fiscal \u201823 comments, we know that inflation is  \nbuilding and the impact tends to lag, I guess is the right way to think about med su rge in fiscal \u201923, is   \nthat this is kind of the jumping off the back half of fiscal \u201822 almost overstates the operating earnings  \nrun rate of the business.  And that I guess I'm trying to get a sense of magnitude of how far down it can  \ngo in fiscal \u201923, a nd to what degree can pricing initiatives kind of offset that?  \n \n Jason Hollar:  Yeah.  The area I can probably be a little bit more helpful is on the timing associated with  \nthat.  The impact of that inflation from a year -over-year perspective will be more u nfavorable in the first  \nhalf of the year.  If you think about what we had in fiscal \u201822, Q1 had much less of an impact, actually  \nhitting the PNL we had seen the costs start to come start to build in terms of what was procured, but  \nwhat actually hit the P &L escalated much more greatly in the second quarter and has increased from  \nthere in Q3, Q4. ", "original_text": "Jason Hollar:  Yeah. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e03fbd3e6fe4b6b0b27d410a016e0712fd04da346b1f5d88a981a2dfa8e881d9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16ee4255-f258-4e86-9e6c-1048b1bc4ef8", "node_type": "1", "metadata": {"window": "And that I guess I'm trying to get a sense of magnitude of how far down it can  \ngo in fiscal \u201923, a nd to what degree can pricing initiatives kind of offset that?  \n \n Jason Hollar:  Yeah.  The area I can probably be a little bit more helpful is on the timing associated with  \nthat.  The impact of that inflation from a year -over-year perspective will be more u nfavorable in the first  \nhalf of the year.  If you think about what we had in fiscal \u201822, Q1 had much less of an impact, actually  \nhitting the PNL we had seen the costs start to come start to build in terms of what was procured, but  \nwhat actually hit the P &L escalated much more greatly in the second quarter and has increased from  \nthere in Q3, Q4.  So that comparison from a year -over-year perspective, will be unfavorable for those  \nelements, all things being equal.  But given the magnitude of what we're talki ng about, I would expect  \nthat to be one of the more significant items, especially in Q1. ", "original_text": "The impact of that inflation from a year -over-year perspective will be more u nfavorable in the first  \nhalf of the year. "}, "hash": "938b48cf251fbe8b0236d278d380826b7102729c7a4c9efcd011f9b0a2661948", "class_name": "RelatedNodeInfo"}}, "text": "The area I can probably be a little bit more helpful is on the timing associated with  \nthat. ", "start_char_idx": 1851, "end_char_idx": 1945, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16ee4255-f258-4e86-9e6c-1048b1bc4ef8": {"__data__": {"id_": "16ee4255-f258-4e86-9e6c-1048b1bc4ef8", "embedding": null, "metadata": {"window": "And that I guess I'm trying to get a sense of magnitude of how far down it can  \ngo in fiscal \u201923, a nd to what degree can pricing initiatives kind of offset that?  \n \n Jason Hollar:  Yeah.  The area I can probably be a little bit more helpful is on the timing associated with  \nthat.  The impact of that inflation from a year -over-year perspective will be more u nfavorable in the first  \nhalf of the year.  If you think about what we had in fiscal \u201822, Q1 had much less of an impact, actually  \nhitting the PNL we had seen the costs start to come start to build in terms of what was procured, but  \nwhat actually hit the P &L escalated much more greatly in the second quarter and has increased from  \nthere in Q3, Q4.  So that comparison from a year -over-year perspective, will be unfavorable for those  \nelements, all things being equal.  But given the magnitude of what we're talki ng about, I would expect  \nthat to be one of the more significant items, especially in Q1. ", "original_text": "The impact of that inflation from a year -over-year perspective will be more u nfavorable in the first  \nhalf of the year. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ea89404-d666-4e4d-bcb2-78e05d889cc4", "node_type": "1", "metadata": {"window": "But as we think about your fiscal \u201823 comments, we know that inflation is  \nbuilding and the impact tends to lag, I guess is the right way to think about med su rge in fiscal \u201923, is   \nthat this is kind of the jumping off the back half of fiscal \u201822 almost overstates the operating earnings  \nrun rate of the business.  And that I guess I'm trying to get a sense of magnitude of how far down it can  \ngo in fiscal \u201923, a nd to what degree can pricing initiatives kind of offset that?  \n \n Jason Hollar:  Yeah.  The area I can probably be a little bit more helpful is on the timing associated with  \nthat.  The impact of that inflation from a year -over-year perspective will be more u nfavorable in the first  \nhalf of the year.  If you think about what we had in fiscal \u201822, Q1 had much less of an impact, actually  \nhitting the PNL we had seen the costs start to come start to build in terms of what was procured, but  \nwhat actually hit the P &L escalated much more greatly in the second quarter and has increased from  \nthere in Q3, Q4.  So that comparison from a year -over-year perspective, will be unfavorable for those  \nelements, all things being equal. ", "original_text": "The area I can probably be a little bit more helpful is on the timing associated with  \nthat. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0c354fc867c38eaac77c979cc1613c13285bd9acd153abda9153c3c44e340482", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d348abb1-17c8-47ae-9150-18fbf62cac25", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah.  The area I can probably be a little bit more helpful is on the timing associated with  \nthat.  The impact of that inflation from a year -over-year perspective will be more u nfavorable in the first  \nhalf of the year.  If you think about what we had in fiscal \u201822, Q1 had much less of an impact, actually  \nhitting the PNL we had seen the costs start to come start to build in terms of what was procured, but  \nwhat actually hit the P &L escalated much more greatly in the second quarter and has increased from  \nthere in Q3, Q4.  So that comparison from a year -over-year perspective, will be unfavorable for those  \nelements, all things being equal.  But given the magnitude of what we're talki ng about, I would expect  \nthat to be one of the more significant items, especially in Q1.  And then as we get to the back half of the  \nyear, as I indicated in my comments and Mike reiterated a few moments ago, with the expectation that  \nwe are able to offse t about half of the run rate at the end of the fiscal year as we jump into \u201824, that  \nwould imply especially over the second half of the year, that would be trending more favorably and then  \nwe would have much more of a tailwind associated with those items . ", "original_text": "If you think about what we had in fiscal \u201822, Q1 had much less of an impact, actually  \nhitting the PNL we had seen the costs start to come start to build in terms of what was procured, but  \nwhat actually hit the P &L escalated much more greatly in the second quarter and has increased from  \nthere in Q3, Q4. "}, "hash": "743094f7c2f4bede55b9e59964e03cb7a3809daf1c8ce6b31ab20842c30fa050", "class_name": "RelatedNodeInfo"}}, "text": "The impact of that inflation from a year -over-year perspective will be more u nfavorable in the first  \nhalf of the year. ", "start_char_idx": 1945, "end_char_idx": 2068, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d348abb1-17c8-47ae-9150-18fbf62cac25": {"__data__": {"id_": "d348abb1-17c8-47ae-9150-18fbf62cac25", "embedding": null, "metadata": {"window": "Jason Hollar:  Yeah.  The area I can probably be a little bit more helpful is on the timing associated with  \nthat.  The impact of that inflation from a year -over-year perspective will be more u nfavorable in the first  \nhalf of the year.  If you think about what we had in fiscal \u201822, Q1 had much less of an impact, actually  \nhitting the PNL we had seen the costs start to come start to build in terms of what was procured, but  \nwhat actually hit the P &L escalated much more greatly in the second quarter and has increased from  \nthere in Q3, Q4.  So that comparison from a year -over-year perspective, will be unfavorable for those  \nelements, all things being equal.  But given the magnitude of what we're talki ng about, I would expect  \nthat to be one of the more significant items, especially in Q1.  And then as we get to the back half of the  \nyear, as I indicated in my comments and Mike reiterated a few moments ago, with the expectation that  \nwe are able to offse t about half of the run rate at the end of the fiscal year as we jump into \u201824, that  \nwould imply especially over the second half of the year, that would be trending more favorably and then  \nwe would have much more of a tailwind associated with those items . ", "original_text": "If you think about what we had in fiscal \u201822, Q1 had much less of an impact, actually  \nhitting the PNL we had seen the costs start to come start to build in terms of what was procured, but  \nwhat actually hit the P &L escalated much more greatly in the second quarter and has increased from  \nthere in Q3, Q4. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16ee4255-f258-4e86-9e6c-1048b1bc4ef8", "node_type": "1", "metadata": {"window": "And that I guess I'm trying to get a sense of magnitude of how far down it can  \ngo in fiscal \u201923, a nd to what degree can pricing initiatives kind of offset that?  \n \n Jason Hollar:  Yeah.  The area I can probably be a little bit more helpful is on the timing associated with  \nthat.  The impact of that inflation from a year -over-year perspective will be more u nfavorable in the first  \nhalf of the year.  If you think about what we had in fiscal \u201822, Q1 had much less of an impact, actually  \nhitting the PNL we had seen the costs start to come start to build in terms of what was procured, but  \nwhat actually hit the P &L escalated much more greatly in the second quarter and has increased from  \nthere in Q3, Q4.  So that comparison from a year -over-year perspective, will be unfavorable for those  \nelements, all things being equal.  But given the magnitude of what we're talki ng about, I would expect  \nthat to be one of the more significant items, especially in Q1. ", "original_text": "The impact of that inflation from a year -over-year perspective will be more u nfavorable in the first  \nhalf of the year. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8303ccefe048b6b0f9b32686ea9ce72397e0a4b7bf99505a6ce10c0927a586df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db75b57b-670b-40cd-a999-977b88e9847e", "node_type": "1", "metadata": {"window": "The area I can probably be a little bit more helpful is on the timing associated with  \nthat.  The impact of that inflation from a year -over-year perspective will be more u nfavorable in the first  \nhalf of the year.  If you think about what we had in fiscal \u201822, Q1 had much less of an impact, actually  \nhitting the PNL we had seen the costs start to come start to build in terms of what was procured, but  \nwhat actually hit the P &L escalated much more greatly in the second quarter and has increased from  \nthere in Q3, Q4.  So that comparison from a year -over-year perspective, will be unfavorable for those  \nelements, all things being equal.  But given the magnitude of what we're talki ng about, I would expect  \nthat to be one of the more significant items, especially in Q1.  And then as we get to the back half of the  \nyear, as I indicated in my comments and Mike reiterated a few moments ago, with the expectation that  \nwe are able to offse t about half of the run rate at the end of the fiscal year as we jump into \u201824, that  \nwould imply especially over the second half of the year, that would be trending more favorably and then  \nwe would have much more of a tailwind associated with those items .  There are always other moving  \nitems within each year in our guidance. ", "original_text": "So that comparison from a year -over-year perspective, will be unfavorable for those  \nelements, all things being equal. "}, "hash": "3b52127fae861438ce0e34c280191fc48718ac0489d7b3ba900dcd534eb8a238", "class_name": "RelatedNodeInfo"}}, "text": "If you think about what we had in fiscal \u201822, Q1 had much less of an impact, actually  \nhitting the PNL we had seen the costs start to come start to build in terms of what was procured, but  \nwhat actually hit the P &L escalated much more greatly in the second quarter and has increased from  \nthere in Q3, Q4. ", "start_char_idx": 2068, "end_char_idx": 2379, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db75b57b-670b-40cd-a999-977b88e9847e": {"__data__": {"id_": "db75b57b-670b-40cd-a999-977b88e9847e", "embedding": null, "metadata": {"window": "The area I can probably be a little bit more helpful is on the timing associated with  \nthat.  The impact of that inflation from a year -over-year perspective will be more u nfavorable in the first  \nhalf of the year.  If you think about what we had in fiscal \u201822, Q1 had much less of an impact, actually  \nhitting the PNL we had seen the costs start to come start to build in terms of what was procured, but  \nwhat actually hit the P &L escalated much more greatly in the second quarter and has increased from  \nthere in Q3, Q4.  So that comparison from a year -over-year perspective, will be unfavorable for those  \nelements, all things being equal.  But given the magnitude of what we're talki ng about, I would expect  \nthat to be one of the more significant items, especially in Q1.  And then as we get to the back half of the  \nyear, as I indicated in my comments and Mike reiterated a few moments ago, with the expectation that  \nwe are able to offse t about half of the run rate at the end of the fiscal year as we jump into \u201824, that  \nwould imply especially over the second half of the year, that would be trending more favorably and then  \nwe would have much more of a tailwind associated with those items .  There are always other moving  \nitems within each year in our guidance. ", "original_text": "So that comparison from a year -over-year perspective, will be unfavorable for those  \nelements, all things being equal. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d348abb1-17c8-47ae-9150-18fbf62cac25", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah.  The area I can probably be a little bit more helpful is on the timing associated with  \nthat.  The impact of that inflation from a year -over-year perspective will be more u nfavorable in the first  \nhalf of the year.  If you think about what we had in fiscal \u201822, Q1 had much less of an impact, actually  \nhitting the PNL we had seen the costs start to come start to build in terms of what was procured, but  \nwhat actually hit the P &L escalated much more greatly in the second quarter and has increased from  \nthere in Q3, Q4.  So that comparison from a year -over-year perspective, will be unfavorable for those  \nelements, all things being equal.  But given the magnitude of what we're talki ng about, I would expect  \nthat to be one of the more significant items, especially in Q1.  And then as we get to the back half of the  \nyear, as I indicated in my comments and Mike reiterated a few moments ago, with the expectation that  \nwe are able to offse t about half of the run rate at the end of the fiscal year as we jump into \u201824, that  \nwould imply especially over the second half of the year, that would be trending more favorably and then  \nwe would have much more of a tailwind associated with those items . ", "original_text": "If you think about what we had in fiscal \u201822, Q1 had much less of an impact, actually  \nhitting the PNL we had seen the costs start to come start to build in terms of what was procured, but  \nwhat actually hit the P &L escalated much more greatly in the second quarter and has increased from  \nthere in Q3, Q4. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2451c159e02aff2d751cd622d1ebe3960604352a1e98d393fc9d7dd4813e277f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d74d8217-0cb5-4a98-830f-198ee0743782", "node_type": "1", "metadata": {"window": "The impact of that inflation from a year -over-year perspective will be more u nfavorable in the first  \nhalf of the year.  If you think about what we had in fiscal \u201822, Q1 had much less of an impact, actually  \nhitting the PNL we had seen the costs start to come start to build in terms of what was procured, but  \nwhat actually hit the P &L escalated much more greatly in the second quarter and has increased from  \nthere in Q3, Q4.  So that comparison from a year -over-year perspective, will be unfavorable for those  \nelements, all things being equal.  But given the magnitude of what we're talki ng about, I would expect  \nthat to be one of the more significant items, especially in Q1.  And then as we get to the back half of the  \nyear, as I indicated in my comments and Mike reiterated a few moments ago, with the expectation that  \nwe are able to offse t about half of the run rate at the end of the fiscal year as we jump into \u201824, that  \nwould imply especially over the second half of the year, that would be trending more favorably and then  \nwe would have much more of a tailwind associated with those items .  There are always other moving  \nitems within each year in our guidance.  As you go back and look at all of our commentary this year,  \nthere have not been too many significant items referenced other than inflation. ", "original_text": "But given the magnitude of what we're talki ng about, I would expect  \nthat to be one of the more significant items, especially in Q1. "}, "hash": "c6f05279de1884703081acaec1f3c02d075ec0f6136494a1b1a0419872ad406e", "class_name": "RelatedNodeInfo"}}, "text": "So that comparison from a year -over-year perspective, will be unfavorable for those  \nelements, all things being equal. ", "start_char_idx": 2379, "end_char_idx": 2500, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d74d8217-0cb5-4a98-830f-198ee0743782": {"__data__": {"id_": "d74d8217-0cb5-4a98-830f-198ee0743782", "embedding": null, "metadata": {"window": "The impact of that inflation from a year -over-year perspective will be more u nfavorable in the first  \nhalf of the year.  If you think about what we had in fiscal \u201822, Q1 had much less of an impact, actually  \nhitting the PNL we had seen the costs start to come start to build in terms of what was procured, but  \nwhat actually hit the P &L escalated much more greatly in the second quarter and has increased from  \nthere in Q3, Q4.  So that comparison from a year -over-year perspective, will be unfavorable for those  \nelements, all things being equal.  But given the magnitude of what we're talki ng about, I would expect  \nthat to be one of the more significant items, especially in Q1.  And then as we get to the back half of the  \nyear, as I indicated in my comments and Mike reiterated a few moments ago, with the expectation that  \nwe are able to offse t about half of the run rate at the end of the fiscal year as we jump into \u201824, that  \nwould imply especially over the second half of the year, that would be trending more favorably and then  \nwe would have much more of a tailwind associated with those items .  There are always other moving  \nitems within each year in our guidance.  As you go back and look at all of our commentary this year,  \nthere have not been too many significant items referenced other than inflation. ", "original_text": "But given the magnitude of what we're talki ng about, I would expect  \nthat to be one of the more significant items, especially in Q1. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db75b57b-670b-40cd-a999-977b88e9847e", "node_type": "1", "metadata": {"window": "The area I can probably be a little bit more helpful is on the timing associated with  \nthat.  The impact of that inflation from a year -over-year perspective will be more u nfavorable in the first  \nhalf of the year.  If you think about what we had in fiscal \u201822, Q1 had much less of an impact, actually  \nhitting the PNL we had seen the costs start to come start to build in terms of what was procured, but  \nwhat actually hit the P &L escalated much more greatly in the second quarter and has increased from  \nthere in Q3, Q4.  So that comparison from a year -over-year perspective, will be unfavorable for those  \nelements, all things being equal.  But given the magnitude of what we're talki ng about, I would expect  \nthat to be one of the more significant items, especially in Q1.  And then as we get to the back half of the  \nyear, as I indicated in my comments and Mike reiterated a few moments ago, with the expectation that  \nwe are able to offse t about half of the run rate at the end of the fiscal year as we jump into \u201824, that  \nwould imply especially over the second half of the year, that would be trending more favorably and then  \nwe would have much more of a tailwind associated with those items .  There are always other moving  \nitems within each year in our guidance. ", "original_text": "So that comparison from a year -over-year perspective, will be unfavorable for those  \nelements, all things being equal. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7a91b00fbd1be7c49af50a5fec65cf0f8655afcb01bb0a7e0c13e9e4ab33edb4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32847608-19b9-4c6c-bcc7-7467598e8a7e", "node_type": "1", "metadata": {"window": "If you think about what we had in fiscal \u201822, Q1 had much less of an impact, actually  \nhitting the PNL we had seen the costs start to come start to build in terms of what was procured, but  \nwhat actually hit the P &L escalated much more greatly in the second quarter and has increased from  \nthere in Q3, Q4.  So that comparison from a year -over-year perspective, will be unfavorable for those  \nelements, all things being equal.  But given the magnitude of what we're talki ng about, I would expect  \nthat to be one of the more significant items, especially in Q1.  And then as we get to the back half of the  \nyear, as I indicated in my comments and Mike reiterated a few moments ago, with the expectation that  \nwe are able to offse t about half of the run rate at the end of the fiscal year as we jump into \u201824, that  \nwould imply especially over the second half of the year, that would be trending more favorably and then  \nwe would have much more of a tailwind associated with those items .  There are always other moving  \nitems within each year in our guidance.  As you go back and look at all of our commentary this year,  \nthere have not been too many significant items referenced other than inflation.  So this one singular item  \nis going to be the key driver of the year -over-year results for the Medical business next year. ", "original_text": "And then as we get to the back half of the  \nyear, as I indicated in my comments and Mike reiterated a few moments ago, with the expectation that  \nwe are able to offse t about half of the run rate at the end of the fiscal year as we jump into \u201824, that  \nwould imply especially over the second half of the year, that would be trending more favorably and then  \nwe would have much more of a tailwind associated with those items . "}, "hash": "b161c2bf5e7bb25d186f759d76ec0c344735c544250540f42d01f201b950b060", "class_name": "RelatedNodeInfo"}}, "text": "But given the magnitude of what we're talki ng about, I would expect  \nthat to be one of the more significant items, especially in Q1. ", "start_char_idx": 2500, "end_char_idx": 2635, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32847608-19b9-4c6c-bcc7-7467598e8a7e": {"__data__": {"id_": "32847608-19b9-4c6c-bcc7-7467598e8a7e", "embedding": null, "metadata": {"window": "If you think about what we had in fiscal \u201822, Q1 had much less of an impact, actually  \nhitting the PNL we had seen the costs start to come start to build in terms of what was procured, but  \nwhat actually hit the P &L escalated much more greatly in the second quarter and has increased from  \nthere in Q3, Q4.  So that comparison from a year -over-year perspective, will be unfavorable for those  \nelements, all things being equal.  But given the magnitude of what we're talki ng about, I would expect  \nthat to be one of the more significant items, especially in Q1.  And then as we get to the back half of the  \nyear, as I indicated in my comments and Mike reiterated a few moments ago, with the expectation that  \nwe are able to offse t about half of the run rate at the end of the fiscal year as we jump into \u201824, that  \nwould imply especially over the second half of the year, that would be trending more favorably and then  \nwe would have much more of a tailwind associated with those items .  There are always other moving  \nitems within each year in our guidance.  As you go back and look at all of our commentary this year,  \nthere have not been too many significant items referenced other than inflation.  So this one singular item  \nis going to be the key driver of the year -over-year results for the Medical business next year. ", "original_text": "And then as we get to the back half of the  \nyear, as I indicated in my comments and Mike reiterated a few moments ago, with the expectation that  \nwe are able to offse t about half of the run rate at the end of the fiscal year as we jump into \u201824, that  \nwould imply especially over the second half of the year, that would be trending more favorably and then  \nwe would have much more of a tailwind associated with those items . ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d74d8217-0cb5-4a98-830f-198ee0743782", "node_type": "1", "metadata": {"window": "The impact of that inflation from a year -over-year perspective will be more u nfavorable in the first  \nhalf of the year.  If you think about what we had in fiscal \u201822, Q1 had much less of an impact, actually  \nhitting the PNL we had seen the costs start to come start to build in terms of what was procured, but  \nwhat actually hit the P &L escalated much more greatly in the second quarter and has increased from  \nthere in Q3, Q4.  So that comparison from a year -over-year perspective, will be unfavorable for those  \nelements, all things being equal.  But given the magnitude of what we're talki ng about, I would expect  \nthat to be one of the more significant items, especially in Q1.  And then as we get to the back half of the  \nyear, as I indicated in my comments and Mike reiterated a few moments ago, with the expectation that  \nwe are able to offse t about half of the run rate at the end of the fiscal year as we jump into \u201824, that  \nwould imply especially over the second half of the year, that would be trending more favorably and then  \nwe would have much more of a tailwind associated with those items .  There are always other moving  \nitems within each year in our guidance.  As you go back and look at all of our commentary this year,  \nthere have not been too many significant items referenced other than inflation. ", "original_text": "But given the magnitude of what we're talki ng about, I would expect  \nthat to be one of the more significant items, especially in Q1. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45ebc038e48fdafe07c9f02b72b5ccd9ca0624a48ce6ce5ea12691c78d28b543", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "adf41752-492e-40cd-afcb-7cd544d3b158", "node_type": "1", "metadata": {"window": "So that comparison from a year -over-year perspective, will be unfavorable for those  \nelements, all things being equal.  But given the magnitude of what we're talki ng about, I would expect  \nthat to be one of the more significant items, especially in Q1.  And then as we get to the back half of the  \nyear, as I indicated in my comments and Mike reiterated a few moments ago, with the expectation that  \nwe are able to offse t about half of the run rate at the end of the fiscal year as we jump into \u201824, that  \nwould imply especially over the second half of the year, that would be trending more favorably and then  \nwe would have much more of a tailwind associated with those items .  There are always other moving  \nitems within each year in our guidance.  As you go back and look at all of our commentary this year,  \nthere have not been too many significant items referenced other than inflation.  So this one singular item  \nis going to be the key driver of the year -over-year results for the Medical business next year.  There will  \nbe other color of course, back to the gro wth businesses and other changes in underlying assumptions,  \nbut this will be driving the underlying performance for the segment very significantly from a year over  \nyear perspective. ", "original_text": "There are always other moving  \nitems within each year in our guidance. "}, "hash": "09151dfa43f8df14fce7b3f3607288c948e49f1e0455fe5ac6cc18b676c8b76d", "class_name": "RelatedNodeInfo"}}, "text": "And then as we get to the back half of the  \nyear, as I indicated in my comments and Mike reiterated a few moments ago, with the expectation that  \nwe are able to offse t about half of the run rate at the end of the fiscal year as we jump into \u201824, that  \nwould imply especially over the second half of the year, that would be trending more favorably and then  \nwe would have much more of a tailwind associated with those items . ", "start_char_idx": 2635, "end_char_idx": 3065, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "adf41752-492e-40cd-afcb-7cd544d3b158": {"__data__": {"id_": "adf41752-492e-40cd-afcb-7cd544d3b158", "embedding": null, "metadata": {"window": "So that comparison from a year -over-year perspective, will be unfavorable for those  \nelements, all things being equal.  But given the magnitude of what we're talki ng about, I would expect  \nthat to be one of the more significant items, especially in Q1.  And then as we get to the back half of the  \nyear, as I indicated in my comments and Mike reiterated a few moments ago, with the expectation that  \nwe are able to offse t about half of the run rate at the end of the fiscal year as we jump into \u201824, that  \nwould imply especially over the second half of the year, that would be trending more favorably and then  \nwe would have much more of a tailwind associated with those items .  There are always other moving  \nitems within each year in our guidance.  As you go back and look at all of our commentary this year,  \nthere have not been too many significant items referenced other than inflation.  So this one singular item  \nis going to be the key driver of the year -over-year results for the Medical business next year.  There will  \nbe other color of course, back to the gro wth businesses and other changes in underlying assumptions,  \nbut this will be driving the underlying performance for the segment very significantly from a year over  \nyear perspective. ", "original_text": "There are always other moving  \nitems within each year in our guidance. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32847608-19b9-4c6c-bcc7-7467598e8a7e", "node_type": "1", "metadata": {"window": "If you think about what we had in fiscal \u201822, Q1 had much less of an impact, actually  \nhitting the PNL we had seen the costs start to come start to build in terms of what was procured, but  \nwhat actually hit the P &L escalated much more greatly in the second quarter and has increased from  \nthere in Q3, Q4.  So that comparison from a year -over-year perspective, will be unfavorable for those  \nelements, all things being equal.  But given the magnitude of what we're talki ng about, I would expect  \nthat to be one of the more significant items, especially in Q1.  And then as we get to the back half of the  \nyear, as I indicated in my comments and Mike reiterated a few moments ago, with the expectation that  \nwe are able to offse t about half of the run rate at the end of the fiscal year as we jump into \u201824, that  \nwould imply especially over the second half of the year, that would be trending more favorably and then  \nwe would have much more of a tailwind associated with those items .  There are always other moving  \nitems within each year in our guidance.  As you go back and look at all of our commentary this year,  \nthere have not been too many significant items referenced other than inflation.  So this one singular item  \nis going to be the key driver of the year -over-year results for the Medical business next year. ", "original_text": "And then as we get to the back half of the  \nyear, as I indicated in my comments and Mike reiterated a few moments ago, with the expectation that  \nwe are able to offse t about half of the run rate at the end of the fiscal year as we jump into \u201824, that  \nwould imply especially over the second half of the year, that would be trending more favorably and then  \nwe would have much more of a tailwind associated with those items . ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "80fad366b0311e2d5b91d84811a2b75237ac2b01f4bfd51a73c3bad25542dad6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "656c68e4-a18a-48df-8f11-f89d85a85db0", "node_type": "1", "metadata": {"window": "But given the magnitude of what we're talki ng about, I would expect  \nthat to be one of the more significant items, especially in Q1.  And then as we get to the back half of the  \nyear, as I indicated in my comments and Mike reiterated a few moments ago, with the expectation that  \nwe are able to offse t about half of the run rate at the end of the fiscal year as we jump into \u201824, that  \nwould imply especially over the second half of the year, that would be trending more favorably and then  \nwe would have much more of a tailwind associated with those items .  There are always other moving  \nitems within each year in our guidance.  As you go back and look at all of our commentary this year,  \nthere have not been too many significant items referenced other than inflation.  So this one singular item  \nis going to be the key driver of the year -over-year results for the Medical business next year.  There will  \nbe other color of course, back to the gro wth businesses and other changes in underlying assumptions,  \nbut this will be driving the underlying performance for the segment very significantly from a year over  \nyear perspective.  Again, in a general similar magnitude, perhaps a modest headwind associa ted with  \nit based upon those underlying assumptions.  \n \n", "original_text": "As you go back and look at all of our commentary this year,  \nthere have not been too many significant items referenced other than inflation. "}, "hash": "7bfc7e7055963a860b19425af7b966f6d2a1f292afe34d0b448da6db5918ed7e", "class_name": "RelatedNodeInfo"}}, "text": "There are always other moving  \nitems within each year in our guidance. ", "start_char_idx": 3065, "end_char_idx": 3137, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "656c68e4-a18a-48df-8f11-f89d85a85db0": {"__data__": {"id_": "656c68e4-a18a-48df-8f11-f89d85a85db0", "embedding": null, "metadata": {"window": "But given the magnitude of what we're talki ng about, I would expect  \nthat to be one of the more significant items, especially in Q1.  And then as we get to the back half of the  \nyear, as I indicated in my comments and Mike reiterated a few moments ago, with the expectation that  \nwe are able to offse t about half of the run rate at the end of the fiscal year as we jump into \u201824, that  \nwould imply especially over the second half of the year, that would be trending more favorably and then  \nwe would have much more of a tailwind associated with those items .  There are always other moving  \nitems within each year in our guidance.  As you go back and look at all of our commentary this year,  \nthere have not been too many significant items referenced other than inflation.  So this one singular item  \nis going to be the key driver of the year -over-year results for the Medical business next year.  There will  \nbe other color of course, back to the gro wth businesses and other changes in underlying assumptions,  \nbut this will be driving the underlying performance for the segment very significantly from a year over  \nyear perspective.  Again, in a general similar magnitude, perhaps a modest headwind associa ted with  \nit based upon those underlying assumptions.  \n \n", "original_text": "As you go back and look at all of our commentary this year,  \nthere have not been too many significant items referenced other than inflation. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "adf41752-492e-40cd-afcb-7cd544d3b158", "node_type": "1", "metadata": {"window": "So that comparison from a year -over-year perspective, will be unfavorable for those  \nelements, all things being equal.  But given the magnitude of what we're talki ng about, I would expect  \nthat to be one of the more significant items, especially in Q1.  And then as we get to the back half of the  \nyear, as I indicated in my comments and Mike reiterated a few moments ago, with the expectation that  \nwe are able to offse t about half of the run rate at the end of the fiscal year as we jump into \u201824, that  \nwould imply especially over the second half of the year, that would be trending more favorably and then  \nwe would have much more of a tailwind associated with those items .  There are always other moving  \nitems within each year in our guidance.  As you go back and look at all of our commentary this year,  \nthere have not been too many significant items referenced other than inflation.  So this one singular item  \nis going to be the key driver of the year -over-year results for the Medical business next year.  There will  \nbe other color of course, back to the gro wth businesses and other changes in underlying assumptions,  \nbut this will be driving the underlying performance for the segment very significantly from a year over  \nyear perspective. ", "original_text": "There are always other moving  \nitems within each year in our guidance. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3117e93b0c73b820323fb3c92872fca028f027cbd69f0c5e81177639816c745b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "143de87e-a893-4176-85d5-56f810b17fab", "node_type": "1", "metadata": {"window": "And then as we get to the back half of the  \nyear, as I indicated in my comments and Mike reiterated a few moments ago, with the expectation that  \nwe are able to offse t about half of the run rate at the end of the fiscal year as we jump into \u201824, that  \nwould imply especially over the second half of the year, that would be trending more favorably and then  \nwe would have much more of a tailwind associated with those items .  There are always other moving  \nitems within each year in our guidance.  As you go back and look at all of our commentary this year,  \nthere have not been too many significant items referenced other than inflation.  So this one singular item  \nis going to be the key driver of the year -over-year results for the Medical business next year.  There will  \nbe other color of course, back to the gro wth businesses and other changes in underlying assumptions,  \nbut this will be driving the underlying performance for the segment very significantly from a year over  \nyear perspective.  Again, in a general similar magnitude, perhaps a modest headwind associa ted with  \nit based upon those underlying assumptions.  \n \n Operator:   And our next question comes from A.J. ", "original_text": "So this one singular item  \nis going to be the key driver of the year -over-year results for the Medical business next year. "}, "hash": "36023e1e6b62e7a965aa45d6220520338e7550f9dc3b0024878ea29a13037dac", "class_name": "RelatedNodeInfo"}}, "text": "As you go back and look at all of our commentary this year,  \nthere have not been too many significant items referenced other than inflation. ", "start_char_idx": 3137, "end_char_idx": 3279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "143de87e-a893-4176-85d5-56f810b17fab": {"__data__": {"id_": "143de87e-a893-4176-85d5-56f810b17fab", "embedding": null, "metadata": {"window": "And then as we get to the back half of the  \nyear, as I indicated in my comments and Mike reiterated a few moments ago, with the expectation that  \nwe are able to offse t about half of the run rate at the end of the fiscal year as we jump into \u201824, that  \nwould imply especially over the second half of the year, that would be trending more favorably and then  \nwe would have much more of a tailwind associated with those items .  There are always other moving  \nitems within each year in our guidance.  As you go back and look at all of our commentary this year,  \nthere have not been too many significant items referenced other than inflation.  So this one singular item  \nis going to be the key driver of the year -over-year results for the Medical business next year.  There will  \nbe other color of course, back to the gro wth businesses and other changes in underlying assumptions,  \nbut this will be driving the underlying performance for the segment very significantly from a year over  \nyear perspective.  Again, in a general similar magnitude, perhaps a modest headwind associa ted with  \nit based upon those underlying assumptions.  \n \n Operator:   And our next question comes from A.J. ", "original_text": "So this one singular item  \nis going to be the key driver of the year -over-year results for the Medical business next year. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "656c68e4-a18a-48df-8f11-f89d85a85db0", "node_type": "1", "metadata": {"window": "But given the magnitude of what we're talki ng about, I would expect  \nthat to be one of the more significant items, especially in Q1.  And then as we get to the back half of the  \nyear, as I indicated in my comments and Mike reiterated a few moments ago, with the expectation that  \nwe are able to offse t about half of the run rate at the end of the fiscal year as we jump into \u201824, that  \nwould imply especially over the second half of the year, that would be trending more favorably and then  \nwe would have much more of a tailwind associated with those items .  There are always other moving  \nitems within each year in our guidance.  As you go back and look at all of our commentary this year,  \nthere have not been too many significant items referenced other than inflation.  So this one singular item  \nis going to be the key driver of the year -over-year results for the Medical business next year.  There will  \nbe other color of course, back to the gro wth businesses and other changes in underlying assumptions,  \nbut this will be driving the underlying performance for the segment very significantly from a year over  \nyear perspective.  Again, in a general similar magnitude, perhaps a modest headwind associa ted with  \nit based upon those underlying assumptions.  \n \n", "original_text": "As you go back and look at all of our commentary this year,  \nthere have not been too many significant items referenced other than inflation. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9cbeda53a15f0bc2c2c317da5561ed13986a8bbb68493305c5bd15f56059c66d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "87361018-e2ae-4dd4-b667-2bae84a6cc05", "node_type": "1", "metadata": {"window": "There are always other moving  \nitems within each year in our guidance.  As you go back and look at all of our commentary this year,  \nthere have not been too many significant items referenced other than inflation.  So this one singular item  \nis going to be the key driver of the year -over-year results for the Medical business next year.  There will  \nbe other color of course, back to the gro wth businesses and other changes in underlying assumptions,  \nbut this will be driving the underlying performance for the segment very significantly from a year over  \nyear perspective.  Again, in a general similar magnitude, perhaps a modest headwind associa ted with  \nit based upon those underlying assumptions.  \n \n Operator:   And our next question comes from A.J.  Rice with Credit Suisse.  \n  \n", "original_text": "There will  \nbe other color of course, back to the gro wth businesses and other changes in underlying assumptions,  \nbut this will be driving the underlying performance for the segment very significantly from a year over  \nyear perspective. "}, "hash": "420ee7ad5e9a729e20d9ca5eb488b851d0da5318a35bc0751c4774aae6b0e6db", "class_name": "RelatedNodeInfo"}}, "text": "So this one singular item  \nis going to be the key driver of the year -over-year results for the Medical business next year. ", "start_char_idx": 3279, "end_char_idx": 3404, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "87361018-e2ae-4dd4-b667-2bae84a6cc05": {"__data__": {"id_": "87361018-e2ae-4dd4-b667-2bae84a6cc05", "embedding": null, "metadata": {"window": "There are always other moving  \nitems within each year in our guidance.  As you go back and look at all of our commentary this year,  \nthere have not been too many significant items referenced other than inflation.  So this one singular item  \nis going to be the key driver of the year -over-year results for the Medical business next year.  There will  \nbe other color of course, back to the gro wth businesses and other changes in underlying assumptions,  \nbut this will be driving the underlying performance for the segment very significantly from a year over  \nyear perspective.  Again, in a general similar magnitude, perhaps a modest headwind associa ted with  \nit based upon those underlying assumptions.  \n \n Operator:   And our next question comes from A.J.  Rice with Credit Suisse.  \n  \n", "original_text": "There will  \nbe other color of course, back to the gro wth businesses and other changes in underlying assumptions,  \nbut this will be driving the underlying performance for the segment very significantly from a year over  \nyear perspective. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "143de87e-a893-4176-85d5-56f810b17fab", "node_type": "1", "metadata": {"window": "And then as we get to the back half of the  \nyear, as I indicated in my comments and Mike reiterated a few moments ago, with the expectation that  \nwe are able to offse t about half of the run rate at the end of the fiscal year as we jump into \u201824, that  \nwould imply especially over the second half of the year, that would be trending more favorably and then  \nwe would have much more of a tailwind associated with those items .  There are always other moving  \nitems within each year in our guidance.  As you go back and look at all of our commentary this year,  \nthere have not been too many significant items referenced other than inflation.  So this one singular item  \nis going to be the key driver of the year -over-year results for the Medical business next year.  There will  \nbe other color of course, back to the gro wth businesses and other changes in underlying assumptions,  \nbut this will be driving the underlying performance for the segment very significantly from a year over  \nyear perspective.  Again, in a general similar magnitude, perhaps a modest headwind associa ted with  \nit based upon those underlying assumptions.  \n \n Operator:   And our next question comes from A.J. ", "original_text": "So this one singular item  \nis going to be the key driver of the year -over-year results for the Medical business next year. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3ca2763ebeca58b6672ba7453c20c7748e2aeaa19ab4126a18566fc0c39ba9b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6801ae34-2977-4d38-8e6f-f107d6d4266e", "node_type": "1", "metadata": {"window": "As you go back and look at all of our commentary this year,  \nthere have not been too many significant items referenced other than inflation.  So this one singular item  \nis going to be the key driver of the year -over-year results for the Medical business next year.  There will  \nbe other color of course, back to the gro wth businesses and other changes in underlying assumptions,  \nbut this will be driving the underlying performance for the segment very significantly from a year over  \nyear perspective.  Again, in a general similar magnitude, perhaps a modest headwind associa ted with  \nit based upon those underlying assumptions.  \n \n Operator:   And our next question comes from A.J.  Rice with Credit Suisse.  \n  \n A.J Rice:  Hi, everybody. ", "original_text": "Again, in a general similar magnitude, perhaps a modest headwind associa ted with  \nit based upon those underlying assumptions.  \n \n"}, "hash": "9fafb2bf69f6999b862699f35319cb6e63daacf3069d391113f8d3cc908c987c", "class_name": "RelatedNodeInfo"}}, "text": "There will  \nbe other color of course, back to the gro wth businesses and other changes in underlying assumptions,  \nbut this will be driving the underlying performance for the segment very significantly from a year over  \nyear perspective. ", "start_char_idx": 3404, "end_char_idx": 3645, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6801ae34-2977-4d38-8e6f-f107d6d4266e": {"__data__": {"id_": "6801ae34-2977-4d38-8e6f-f107d6d4266e", "embedding": null, "metadata": {"window": "As you go back and look at all of our commentary this year,  \nthere have not been too many significant items referenced other than inflation.  So this one singular item  \nis going to be the key driver of the year -over-year results for the Medical business next year.  There will  \nbe other color of course, back to the gro wth businesses and other changes in underlying assumptions,  \nbut this will be driving the underlying performance for the segment very significantly from a year over  \nyear perspective.  Again, in a general similar magnitude, perhaps a modest headwind associa ted with  \nit based upon those underlying assumptions.  \n \n Operator:   And our next question comes from A.J.  Rice with Credit Suisse.  \n  \n A.J Rice:  Hi, everybody. ", "original_text": "Again, in a general similar magnitude, perhaps a modest headwind associa ted with  \nit based upon those underlying assumptions.  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "87361018-e2ae-4dd4-b667-2bae84a6cc05", "node_type": "1", "metadata": {"window": "There are always other moving  \nitems within each year in our guidance.  As you go back and look at all of our commentary this year,  \nthere have not been too many significant items referenced other than inflation.  So this one singular item  \nis going to be the key driver of the year -over-year results for the Medical business next year.  There will  \nbe other color of course, back to the gro wth businesses and other changes in underlying assumptions,  \nbut this will be driving the underlying performance for the segment very significantly from a year over  \nyear perspective.  Again, in a general similar magnitude, perhaps a modest headwind associa ted with  \nit based upon those underlying assumptions.  \n \n Operator:   And our next question comes from A.J.  Rice with Credit Suisse.  \n  \n", "original_text": "There will  \nbe other color of course, back to the gro wth businesses and other changes in underlying assumptions,  \nbut this will be driving the underlying performance for the segment very significantly from a year over  \nyear perspective. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c4930cd7780f639629cd3f9333fd04883ca2608122f73580b4f0eb8e42b3a914", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b01a0787-25be-44ae-94d5-4bdb2775cbe2", "node_type": "1", "metadata": {"window": "So this one singular item  \nis going to be the key driver of the year -over-year results for the Medical business next year.  There will  \nbe other color of course, back to the gro wth businesses and other changes in underlying assumptions,  \nbut this will be driving the underlying performance for the segment very significantly from a year over  \nyear perspective.  Again, in a general similar magnitude, perhaps a modest headwind associa ted with  \nit based upon those underlying assumptions.  \n \n Operator:   And our next question comes from A.J.  Rice with Credit Suisse.  \n  \n A.J Rice:  Hi, everybody.  Thanks. ", "original_text": "Operator:   And our next question comes from A.J. "}, "hash": "ba36b53e3c5dd97dfdb212df8394da0111b29c96183e7e6e020adc1fd848f86d", "class_name": "RelatedNodeInfo"}}, "text": "Again, in a general similar magnitude, perhaps a modest headwind associa ted with  \nit based upon those underlying assumptions.  \n \n", "start_char_idx": 3645, "end_char_idx": 3777, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b01a0787-25be-44ae-94d5-4bdb2775cbe2": {"__data__": {"id_": "b01a0787-25be-44ae-94d5-4bdb2775cbe2", "embedding": null, "metadata": {"window": "So this one singular item  \nis going to be the key driver of the year -over-year results for the Medical business next year.  There will  \nbe other color of course, back to the gro wth businesses and other changes in underlying assumptions,  \nbut this will be driving the underlying performance for the segment very significantly from a year over  \nyear perspective.  Again, in a general similar magnitude, perhaps a modest headwind associa ted with  \nit based upon those underlying assumptions.  \n \n Operator:   And our next question comes from A.J.  Rice with Credit Suisse.  \n  \n A.J Rice:  Hi, everybody.  Thanks. ", "original_text": "Operator:   And our next question comes from A.J. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6801ae34-2977-4d38-8e6f-f107d6d4266e", "node_type": "1", "metadata": {"window": "As you go back and look at all of our commentary this year,  \nthere have not been too many significant items referenced other than inflation.  So this one singular item  \nis going to be the key driver of the year -over-year results for the Medical business next year.  There will  \nbe other color of course, back to the gro wth businesses and other changes in underlying assumptions,  \nbut this will be driving the underlying performance for the segment very significantly from a year over  \nyear perspective.  Again, in a general similar magnitude, perhaps a modest headwind associa ted with  \nit based upon those underlying assumptions.  \n \n Operator:   And our next question comes from A.J.  Rice with Credit Suisse.  \n  \n A.J Rice:  Hi, everybody. ", "original_text": "Again, in a general similar magnitude, perhaps a modest headwind associa ted with  \nit based upon those underlying assumptions.  \n \n", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "080fe68ca447e227b0cd6d7eaa00fbe2f49413bd548171c1daa40ae9f32a5091", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf6885d8-60c0-4982-bfd7-aa1d65bf8c58", "node_type": "1", "metadata": {"window": "There will  \nbe other color of course, back to the gro wth businesses and other changes in underlying assumptions,  \nbut this will be driving the underlying performance for the segment very significantly from a year over  \nyear perspective.  Again, in a general similar magnitude, perhaps a modest headwind associa ted with  \nit based upon those underlying assumptions.  \n \n Operator:   And our next question comes from A.J.  Rice with Credit Suisse.  \n  \n A.J Rice:  Hi, everybody.  Thanks.  Just on the Medical, I don't think you've given in a while. ", "original_text": "Rice with Credit Suisse.  \n  \n"}, "hash": "f776548a3a53f8a936c4e4f8a42f991e7c7a64dde0e9c301e28839b532784dcb", "class_name": "RelatedNodeInfo"}}, "text": "Operator:   And our next question comes from A.J. ", "start_char_idx": 3777, "end_char_idx": 3827, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf6885d8-60c0-4982-bfd7-aa1d65bf8c58": {"__data__": {"id_": "cf6885d8-60c0-4982-bfd7-aa1d65bf8c58", "embedding": null, "metadata": {"window": "There will  \nbe other color of course, back to the gro wth businesses and other changes in underlying assumptions,  \nbut this will be driving the underlying performance for the segment very significantly from a year over  \nyear perspective.  Again, in a general similar magnitude, perhaps a modest headwind associa ted with  \nit based upon those underlying assumptions.  \n \n Operator:   And our next question comes from A.J.  Rice with Credit Suisse.  \n  \n A.J Rice:  Hi, everybody.  Thanks.  Just on the Medical, I don't think you've given in a while. ", "original_text": "Rice with Credit Suisse.  \n  \n", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b01a0787-25be-44ae-94d5-4bdb2775cbe2", "node_type": "1", "metadata": {"window": "So this one singular item  \nis going to be the key driver of the year -over-year results for the Medical business next year.  There will  \nbe other color of course, back to the gro wth businesses and other changes in underlying assumptions,  \nbut this will be driving the underlying performance for the segment very significantly from a year over  \nyear perspective.  Again, in a general similar magnitude, perhaps a modest headwind associa ted with  \nit based upon those underlying assumptions.  \n \n Operator:   And our next question comes from A.J.  Rice with Credit Suisse.  \n  \n A.J Rice:  Hi, everybody.  Thanks. ", "original_text": "Operator:   And our next question comes from A.J. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "82f9dc226caa5e6850160a03def3790d6956318be48761aa4fa1e0017109134e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a1298b38-9c8b-4dc3-9eff-e3afdf857a39", "node_type": "1", "metadata": {"window": "Again, in a general similar magnitude, perhaps a modest headwind associa ted with  \nit based upon those underlying assumptions.  \n \n Operator:   And our next question comes from A.J.  Rice with Credit Suisse.  \n  \n A.J Rice:  Hi, everybody.  Thanks.  Just on the Medical, I don't think you've given in a while.  How much  \nof the revenues ther e is Cardinal branded products at this point roughly? ", "original_text": "A.J Rice:  Hi, everybody. "}, "hash": "d86695c7ca03f71e1e690cc3d8b417f6d2d5c48647ff74bb966104a7ff18f924", "class_name": "RelatedNodeInfo"}}, "text": "Rice with Credit Suisse.  \n  \n", "start_char_idx": 3827, "end_char_idx": 3857, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a1298b38-9c8b-4dc3-9eff-e3afdf857a39": {"__data__": {"id_": "a1298b38-9c8b-4dc3-9eff-e3afdf857a39", "embedding": null, "metadata": {"window": "Again, in a general similar magnitude, perhaps a modest headwind associa ted with  \nit based upon those underlying assumptions.  \n \n Operator:   And our next question comes from A.J.  Rice with Credit Suisse.  \n  \n A.J Rice:  Hi, everybody.  Thanks.  Just on the Medical, I don't think you've given in a while.  How much  \nof the revenues ther e is Cardinal branded products at this point roughly? ", "original_text": "A.J Rice:  Hi, everybody. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf6885d8-60c0-4982-bfd7-aa1d65bf8c58", "node_type": "1", "metadata": {"window": "There will  \nbe other color of course, back to the gro wth businesses and other changes in underlying assumptions,  \nbut this will be driving the underlying performance for the segment very significantly from a year over  \nyear perspective.  Again, in a general similar magnitude, perhaps a modest headwind associa ted with  \nit based upon those underlying assumptions.  \n \n Operator:   And our next question comes from A.J.  Rice with Credit Suisse.  \n  \n A.J Rice:  Hi, everybody.  Thanks.  Just on the Medical, I don't think you've given in a while. ", "original_text": "Rice with Credit Suisse.  \n  \n", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "59f6b313b7d54ea2d840ed516df73ee6485a6341f42d7cdf87ab56ec363952fa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51eecc6b-cf36-4593-b38d-62035e2cf69e", "node_type": "1", "metadata": {"window": "Operator:   And our next question comes from A.J.  Rice with Credit Suisse.  \n  \n A.J Rice:  Hi, everybody.  Thanks.  Just on the Medical, I don't think you've given in a while.  How much  \nof the revenues ther e is Cardinal branded products at this point roughly?  And then as you're talking  ", "original_text": "Thanks. "}, "hash": "75c8a1fcece89d69cb05b32708b874b259269e50693aa5389ec805da4722131d", "class_name": "RelatedNodeInfo"}}, "text": "A.J Rice:  Hi, everybody. ", "start_char_idx": 3857, "end_char_idx": 3883, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51eecc6b-cf36-4593-b38d-62035e2cf69e": {"__data__": {"id_": "51eecc6b-cf36-4593-b38d-62035e2cf69e", "embedding": null, "metadata": {"window": "Operator:   And our next question comes from A.J.  Rice with Credit Suisse.  \n  \n A.J Rice:  Hi, everybody.  Thanks.  Just on the Medical, I don't think you've given in a while.  How much  \nof the revenues ther e is Cardinal branded products at this point roughly?  And then as you're talking  ", "original_text": "Thanks. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a1298b38-9c8b-4dc3-9eff-e3afdf857a39", "node_type": "1", "metadata": {"window": "Again, in a general similar magnitude, perhaps a modest headwind associa ted with  \nit based upon those underlying assumptions.  \n \n Operator:   And our next question comes from A.J.  Rice with Credit Suisse.  \n  \n A.J Rice:  Hi, everybody.  Thanks.  Just on the Medical, I don't think you've given in a while.  How much  \nof the revenues ther e is Cardinal branded products at this point roughly? ", "original_text": "A.J Rice:  Hi, everybody. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "fae9c640340174fc27a9e9d0a68c909d3d23e418751df3b53e65757941b6dc75", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "96887420-92f5-4f1f-b796-5f9979ab4b04", "node_type": "1", "metadata": {"window": "Rice with Credit Suisse.  \n  \n A.J Rice:  Hi, everybody.  Thanks.  Just on the Medical, I don't think you've given in a while.  How much  \nof the revenues ther e is Cardinal branded products at this point roughly?  And then as you're talking  ", "original_text": "Just on the Medical, I don't think you've given in a while. "}, "hash": "bc5505751c3b8ef27bfcc2a418da9865d035dcba707aaafc262ca5fd01c1621e", "class_name": "RelatedNodeInfo"}}, "text": "Thanks. ", "start_char_idx": 3883, "end_char_idx": 3891, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "96887420-92f5-4f1f-b796-5f9979ab4b04": {"__data__": {"id_": "96887420-92f5-4f1f-b796-5f9979ab4b04", "embedding": null, "metadata": {"window": "Rice with Credit Suisse.  \n  \n A.J Rice:  Hi, everybody.  Thanks.  Just on the Medical, I don't think you've given in a while.  How much  \nof the revenues ther e is Cardinal branded products at this point roughly?  And then as you're talking  ", "original_text": "Just on the Medical, I don't think you've given in a while. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51eecc6b-cf36-4593-b38d-62035e2cf69e", "node_type": "1", "metadata": {"window": "Operator:   And our next question comes from A.J.  Rice with Credit Suisse.  \n  \n A.J Rice:  Hi, everybody.  Thanks.  Just on the Medical, I don't think you've given in a while.  How much  \nof the revenues ther e is Cardinal branded products at this point roughly?  And then as you're talking  ", "original_text": "Thanks. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e3a9abc9e42047fe33c9471ba285db5474f624329e6844e2656b464990d96d53", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9aabf0f2-ba8e-4ddf-933a-6c55cdda28b1", "node_type": "1", "metadata": {"window": "A.J Rice:  Hi, everybody.  Thanks.  Just on the Medical, I don't think you've given in a while.  How much  \nof the revenues ther e is Cardinal branded products at this point roughly?  And then as you're talking  ", "original_text": "How much  \nof the revenues ther e is Cardinal branded products at this point roughly? "}, "hash": "a94162760d1630962bcba9a00cd106f806ecfa623ea84983d231555d2cfe46a8", "class_name": "RelatedNodeInfo"}}, "text": "Just on the Medical, I don't think you've given in a while. ", "start_char_idx": 3891, "end_char_idx": 3951, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9aabf0f2-ba8e-4ddf-933a-6c55cdda28b1": {"__data__": {"id_": "9aabf0f2-ba8e-4ddf-933a-6c55cdda28b1", "embedding": null, "metadata": {"window": "A.J Rice:  Hi, everybody.  Thanks.  Just on the Medical, I don't think you've given in a while.  How much  \nof the revenues ther e is Cardinal branded products at this point roughly?  And then as you're talking  ", "original_text": "How much  \nof the revenues ther e is Cardinal branded products at this point roughly? ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "96887420-92f5-4f1f-b796-5f9979ab4b04", "node_type": "1", "metadata": {"window": "Rice with Credit Suisse.  \n  \n A.J Rice:  Hi, everybody.  Thanks.  Just on the Medical, I don't think you've given in a while.  How much  \nof the revenues ther e is Cardinal branded products at this point roughly?  And then as you're talking  ", "original_text": "Just on the Medical, I don't think you've given in a while. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a5eb13204d3c80d356767393827dd8ba0bdf5e8a16dbd784bcf7b8971dee03fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "793a7ab4-a513-49ef-bef4-81fede520f3f", "node_type": "1", "metadata": {"window": "Thanks.  Just on the Medical, I don't think you've given in a while.  How much  \nof the revenues ther e is Cardinal branded products at this point roughly?  And then as you're talking  ", "original_text": "And then as you're talking  "}, "hash": "33438e172c20dd37bed2e11035a0b21876c59ebbfb801773e6a47d6cd903e986", "class_name": "RelatedNodeInfo"}}, "text": "How much  \nof the revenues ther e is Cardinal branded products at this point roughly? ", "start_char_idx": 3951, "end_char_idx": 4037, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "793a7ab4-a513-49ef-bef4-81fede520f3f": {"__data__": {"id_": "793a7ab4-a513-49ef-bef4-81fede520f3f", "embedding": null, "metadata": {"window": "Thanks.  Just on the Medical, I don't think you've given in a while.  How much  \nof the revenues ther e is Cardinal branded products at this point roughly?  And then as you're talking  ", "original_text": "And then as you're talking  ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3", "node_type": "4", "metadata": {"page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "825d085b433f9a2c165accb4d3ea4a40f409b26f9b643f3488ac2e3eddd3ecab", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9aabf0f2-ba8e-4ddf-933a-6c55cdda28b1", "node_type": "1", "metadata": {"window": "A.J Rice:  Hi, everybody.  Thanks.  Just on the Medical, I don't think you've given in a while.  How much  \nof the revenues ther e is Cardinal branded products at this point roughly?  And then as you're talking  ", "original_text": "How much  \nof the revenues ther e is Cardinal branded products at this point roughly? ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d1151cda14fd122c40c7bdf1ea3d659c2cbcfb74a71f543d6ca5d6c3e6a0f7ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a5f2ba4-a678-4817-acbb-4dd3ff8b9364", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nabout the offset that will come from pricing - your price increases - offsetting about 50% by the end of  \nnext year of fiscal year, are there any other things that are meanin gful that could be impactful?  I don't  \nknow, diversification of sourcing, maybe toggling back and forth in the Cardinal branded products,  \nanything else beyond just pushing for price increases, or do we are we basically waiting for the  \nbackdrop to improve  from a macro perspective?  \n \n Mike Kaufmann:  Yeah.  We've not given any actual mixed percentages in terms of how much of our  \nvolume is Cardinal Health Brand versus others, so I can't do that at this point in time. ", "original_text": " \nPage 14 of 15 \n \nabout the offset that will come from pricing - your price increases - offsetting about 50% by the end of  \nnext year of fiscal year, are there any other things that are meanin gful that could be impactful? "}, "hash": "7effe988ec02eb1bb68550c20bf2d0c96567fe6aa60d027c9607d650767657b2", "class_name": "RelatedNodeInfo"}}, "text": "And then as you're talking  ", "start_char_idx": 4037, "end_char_idx": 4065, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a5f2ba4-a678-4817-acbb-4dd3ff8b9364": {"__data__": {"id_": "9a5f2ba4-a678-4817-acbb-4dd3ff8b9364", "embedding": null, "metadata": {"window": " \nPage 14 of 15 \n \nabout the offset that will come from pricing - your price increases - offsetting about 50% by the end of  \nnext year of fiscal year, are there any other things that are meanin gful that could be impactful?  I don't  \nknow, diversification of sourcing, maybe toggling back and forth in the Cardinal branded products,  \nanything else beyond just pushing for price increases, or do we are we basically waiting for the  \nbackdrop to improve  from a macro perspective?  \n \n Mike Kaufmann:  Yeah.  We've not given any actual mixed percentages in terms of how much of our  \nvolume is Cardinal Health Brand versus others, so I can't do that at this point in time. ", "original_text": " \nPage 14 of 15 \n \nabout the offset that will come from pricing - your price increases - offsetting about 50% by the end of  \nnext year of fiscal year, are there any other things that are meanin gful that could be impactful? ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "793a7ab4-a513-49ef-bef4-81fede520f3f", "node_type": "1", "metadata": {"window": "Thanks.  Just on the Medical, I don't think you've given in a while.  How much  \nof the revenues ther e is Cardinal branded products at this point roughly?  And then as you're talking  ", "original_text": "And then as you're talking  ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0473d967fb00382450e7be01712c4c8330a8046c74455aca950fc9540753c5a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "442d079a-2e6b-4731-b6a9-ac5607abda61", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nabout the offset that will come from pricing - your price increases - offsetting about 50% by the end of  \nnext year of fiscal year, are there any other things that are meanin gful that could be impactful?  I don't  \nknow, diversification of sourcing, maybe toggling back and forth in the Cardinal branded products,  \nanything else beyond just pushing for price increases, or do we are we basically waiting for the  \nbackdrop to improve  from a macro perspective?  \n \n Mike Kaufmann:  Yeah.  We've not given any actual mixed percentages in terms of how much of our  \nvolume is Cardinal Health Brand versus others, so I can't do that at this point in time.  But what I will say  \nis that there's opportunity for growth there. ", "original_text": "I don't  \nknow, diversification of sourcing, maybe toggling back and forth in the Cardinal branded products,  \nanything else beyond just pushing for price increases, or do we are we basically waiting for the  \nbackdrop to improve  from a macro perspective?  \n \n"}, "hash": "6498494478c095e29d437f43e484ddd139c40e7ba2d29b01239a481d240539fa", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 14 of 15 \n \nabout the offset that will come from pricing - your price increases - offsetting about 50% by the end of  \nnext year of fiscal year, are there any other things that are meanin gful that could be impactful? ", "start_char_idx": 0, "end_char_idx": 225, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "442d079a-2e6b-4731-b6a9-ac5607abda61": {"__data__": {"id_": "442d079a-2e6b-4731-b6a9-ac5607abda61", "embedding": null, "metadata": {"window": " \nPage 14 of 15 \n \nabout the offset that will come from pricing - your price increases - offsetting about 50% by the end of  \nnext year of fiscal year, are there any other things that are meanin gful that could be impactful?  I don't  \nknow, diversification of sourcing, maybe toggling back and forth in the Cardinal branded products,  \nanything else beyond just pushing for price increases, or do we are we basically waiting for the  \nbackdrop to improve  from a macro perspective?  \n \n Mike Kaufmann:  Yeah.  We've not given any actual mixed percentages in terms of how much of our  \nvolume is Cardinal Health Brand versus others, so I can't do that at this point in time.  But what I will say  \nis that there's opportunity for growth there. ", "original_text": "I don't  \nknow, diversification of sourcing, maybe toggling back and forth in the Cardinal branded products,  \nanything else beyond just pushing for price increases, or do we are we basically waiting for the  \nbackdrop to improve  from a macro perspective?  \n \n", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a5f2ba4-a678-4817-acbb-4dd3ff8b9364", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nabout the offset that will come from pricing - your price increases - offsetting about 50% by the end of  \nnext year of fiscal year, are there any other things that are meanin gful that could be impactful?  I don't  \nknow, diversification of sourcing, maybe toggling back and forth in the Cardinal branded products,  \nanything else beyond just pushing for price increases, or do we are we basically waiting for the  \nbackdrop to improve  from a macro perspective?  \n \n Mike Kaufmann:  Yeah.  We've not given any actual mixed percentages in terms of how much of our  \nvolume is Cardinal Health Brand versus others, so I can't do that at this point in time. ", "original_text": " \nPage 14 of 15 \n \nabout the offset that will come from pricing - your price increases - offsetting about 50% by the end of  \nnext year of fiscal year, are there any other things that are meanin gful that could be impactful? ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "aeaa17483bf56de0676821b05ac1d78d439a6634e2f6888a86c56230f1100fe7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d56e92c-98b7-44d8-83c3-c3cf236b6039", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nabout the offset that will come from pricing - your price increases - offsetting about 50% by the end of  \nnext year of fiscal year, are there any other things that are meanin gful that could be impactful?  I don't  \nknow, diversification of sourcing, maybe toggling back and forth in the Cardinal branded products,  \nanything else beyond just pushing for price increases, or do we are we basically waiting for the  \nbackdrop to improve  from a macro perspective?  \n \n Mike Kaufmann:  Yeah.  We've not given any actual mixed percentages in terms of how much of our  \nvolume is Cardinal Health Brand versus others, so I can't do that at this point in time.  But what I will say  \nis that there's opportunity for growth there.  We know that that's an area that we're excited about, and  \ncontinue to put things in place, like wor king on our incentives for our sales force, expanding our product  \nline to have more items to drive mix to, which you heard in my comments on our project with Avery  \nDennison and Innara Health. ", "original_text": "Mike Kaufmann:  Yeah. "}, "hash": "c5a4f8f94aad68807f27639890d5df942376950b8f4182028f289acd17f128bd", "class_name": "RelatedNodeInfo"}}, "text": "I don't  \nknow, diversification of sourcing, maybe toggling back and forth in the Cardinal branded products,  \nanything else beyond just pushing for price increases, or do we are we basically waiting for the  \nbackdrop to improve  from a macro perspective?  \n \n", "start_char_idx": 225, "end_char_idx": 486, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d56e92c-98b7-44d8-83c3-c3cf236b6039": {"__data__": {"id_": "2d56e92c-98b7-44d8-83c3-c3cf236b6039", "embedding": null, "metadata": {"window": " \nPage 14 of 15 \n \nabout the offset that will come from pricing - your price increases - offsetting about 50% by the end of  \nnext year of fiscal year, are there any other things that are meanin gful that could be impactful?  I don't  \nknow, diversification of sourcing, maybe toggling back and forth in the Cardinal branded products,  \nanything else beyond just pushing for price increases, or do we are we basically waiting for the  \nbackdrop to improve  from a macro perspective?  \n \n Mike Kaufmann:  Yeah.  We've not given any actual mixed percentages in terms of how much of our  \nvolume is Cardinal Health Brand versus others, so I can't do that at this point in time.  But what I will say  \nis that there's opportunity for growth there.  We know that that's an area that we're excited about, and  \ncontinue to put things in place, like wor king on our incentives for our sales force, expanding our product  \nline to have more items to drive mix to, which you heard in my comments on our project with Avery  \nDennison and Innara Health. ", "original_text": "Mike Kaufmann:  Yeah. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "442d079a-2e6b-4731-b6a9-ac5607abda61", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nabout the offset that will come from pricing - your price increases - offsetting about 50% by the end of  \nnext year of fiscal year, are there any other things that are meanin gful that could be impactful?  I don't  \nknow, diversification of sourcing, maybe toggling back and forth in the Cardinal branded products,  \nanything else beyond just pushing for price increases, or do we are we basically waiting for the  \nbackdrop to improve  from a macro perspective?  \n \n Mike Kaufmann:  Yeah.  We've not given any actual mixed percentages in terms of how much of our  \nvolume is Cardinal Health Brand versus others, so I can't do that at this point in time.  But what I will say  \nis that there's opportunity for growth there. ", "original_text": "I don't  \nknow, diversification of sourcing, maybe toggling back and forth in the Cardinal branded products,  \nanything else beyond just pushing for price increases, or do we are we basically waiting for the  \nbackdrop to improve  from a macro perspective?  \n \n", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "26901164bb3579d26fa21eaa37751f40d7396398439253db8e5bdc72fb67756b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1db6e7a1-4380-4dcb-87b1-1a7b067e91dd", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nabout the offset that will come from pricing - your price increases - offsetting about 50% by the end of  \nnext year of fiscal year, are there any other things that are meanin gful that could be impactful?  I don't  \nknow, diversification of sourcing, maybe toggling back and forth in the Cardinal branded products,  \nanything else beyond just pushing for price increases, or do we are we basically waiting for the  \nbackdrop to improve  from a macro perspective?  \n \n Mike Kaufmann:  Yeah.  We've not given any actual mixed percentages in terms of how much of our  \nvolume is Cardinal Health Brand versus others, so I can't do that at this point in time.  But what I will say  \nis that there's opportunity for growth there.  We know that that's an area that we're excited about, and  \ncontinue to put things in place, like wor king on our incentives for our sales force, expanding our product  \nline to have more items to drive mix to, which you heard in my comments on our project with Avery  \nDennison and Innara Health.  So we're both looking to expand the line, as well as drive the  mix to our  \nsales reps and continuing to work with customers. ", "original_text": "We've not given any actual mixed percentages in terms of how much of our  \nvolume is Cardinal Health Brand versus others, so I can't do that at this point in time. "}, "hash": "2d6beb60379d03b38045a2d50ade7de10790fa3b5c6dd2e7586dd3595415f746", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yeah. ", "start_char_idx": 486, "end_char_idx": 508, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1db6e7a1-4380-4dcb-87b1-1a7b067e91dd": {"__data__": {"id_": "1db6e7a1-4380-4dcb-87b1-1a7b067e91dd", "embedding": null, "metadata": {"window": " \nPage 14 of 15 \n \nabout the offset that will come from pricing - your price increases - offsetting about 50% by the end of  \nnext year of fiscal year, are there any other things that are meanin gful that could be impactful?  I don't  \nknow, diversification of sourcing, maybe toggling back and forth in the Cardinal branded products,  \nanything else beyond just pushing for price increases, or do we are we basically waiting for the  \nbackdrop to improve  from a macro perspective?  \n \n Mike Kaufmann:  Yeah.  We've not given any actual mixed percentages in terms of how much of our  \nvolume is Cardinal Health Brand versus others, so I can't do that at this point in time.  But what I will say  \nis that there's opportunity for growth there.  We know that that's an area that we're excited about, and  \ncontinue to put things in place, like wor king on our incentives for our sales force, expanding our product  \nline to have more items to drive mix to, which you heard in my comments on our project with Avery  \nDennison and Innara Health.  So we're both looking to expand the line, as well as drive the  mix to our  \nsales reps and continuing to work with customers. ", "original_text": "We've not given any actual mixed percentages in terms of how much of our  \nvolume is Cardinal Health Brand versus others, so I can't do that at this point in time. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d56e92c-98b7-44d8-83c3-c3cf236b6039", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nabout the offset that will come from pricing - your price increases - offsetting about 50% by the end of  \nnext year of fiscal year, are there any other things that are meanin gful that could be impactful?  I don't  \nknow, diversification of sourcing, maybe toggling back and forth in the Cardinal branded products,  \nanything else beyond just pushing for price increases, or do we are we basically waiting for the  \nbackdrop to improve  from a macro perspective?  \n \n Mike Kaufmann:  Yeah.  We've not given any actual mixed percentages in terms of how much of our  \nvolume is Cardinal Health Brand versus others, so I can't do that at this point in time.  But what I will say  \nis that there's opportunity for growth there.  We know that that's an area that we're excited about, and  \ncontinue to put things in place, like wor king on our incentives for our sales force, expanding our product  \nline to have more items to drive mix to, which you heard in my comments on our project with Avery  \nDennison and Innara Health. ", "original_text": "Mike Kaufmann:  Yeah. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c1613b1866d7aabcac170bad2720e9cf49fd0b9cc7a93b013d451ebee13e1758", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94c3485a-13c9-4f92-9b6a-d8cd9d71b00d", "node_type": "1", "metadata": {"window": "I don't  \nknow, diversification of sourcing, maybe toggling back and forth in the Cardinal branded products,  \nanything else beyond just pushing for price increases, or do we are we basically waiting for the  \nbackdrop to improve  from a macro perspective?  \n \n Mike Kaufmann:  Yeah.  We've not given any actual mixed percentages in terms of how much of our  \nvolume is Cardinal Health Brand versus others, so I can't do that at this point in time.  But what I will say  \nis that there's opportunity for growth there.  We know that that's an area that we're excited about, and  \ncontinue to put things in place, like wor king on our incentives for our sales force, expanding our product  \nline to have more items to drive mix to, which you heard in my comments on our project with Avery  \nDennison and Innara Health.  So we're both looking to expand the line, as well as drive the  mix to our  \nsales reps and continuing to work with customers.  So while we don't give it, it's an area where we do  \nsee some real opportunity going forward to grow. ", "original_text": "But what I will say  \nis that there's opportunity for growth there. "}, "hash": "4fd8a107a3957942383103c069c74bcaa66ae3c9305db6c1a9af9014cdd02f34", "class_name": "RelatedNodeInfo"}}, "text": "We've not given any actual mixed percentages in terms of how much of our  \nvolume is Cardinal Health Brand versus others, so I can't do that at this point in time. ", "start_char_idx": 508, "end_char_idx": 672, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94c3485a-13c9-4f92-9b6a-d8cd9d71b00d": {"__data__": {"id_": "94c3485a-13c9-4f92-9b6a-d8cd9d71b00d", "embedding": null, "metadata": {"window": "I don't  \nknow, diversification of sourcing, maybe toggling back and forth in the Cardinal branded products,  \nanything else beyond just pushing for price increases, or do we are we basically waiting for the  \nbackdrop to improve  from a macro perspective?  \n \n Mike Kaufmann:  Yeah.  We've not given any actual mixed percentages in terms of how much of our  \nvolume is Cardinal Health Brand versus others, so I can't do that at this point in time.  But what I will say  \nis that there's opportunity for growth there.  We know that that's an area that we're excited about, and  \ncontinue to put things in place, like wor king on our incentives for our sales force, expanding our product  \nline to have more items to drive mix to, which you heard in my comments on our project with Avery  \nDennison and Innara Health.  So we're both looking to expand the line, as well as drive the  mix to our  \nsales reps and continuing to work with customers.  So while we don't give it, it's an area where we do  \nsee some real opportunity going forward to grow. ", "original_text": "But what I will say  \nis that there's opportunity for growth there. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1db6e7a1-4380-4dcb-87b1-1a7b067e91dd", "node_type": "1", "metadata": {"window": " \nPage 14 of 15 \n \nabout the offset that will come from pricing - your price increases - offsetting about 50% by the end of  \nnext year of fiscal year, are there any other things that are meanin gful that could be impactful?  I don't  \nknow, diversification of sourcing, maybe toggling back and forth in the Cardinal branded products,  \nanything else beyond just pushing for price increases, or do we are we basically waiting for the  \nbackdrop to improve  from a macro perspective?  \n \n Mike Kaufmann:  Yeah.  We've not given any actual mixed percentages in terms of how much of our  \nvolume is Cardinal Health Brand versus others, so I can't do that at this point in time.  But what I will say  \nis that there's opportunity for growth there.  We know that that's an area that we're excited about, and  \ncontinue to put things in place, like wor king on our incentives for our sales force, expanding our product  \nline to have more items to drive mix to, which you heard in my comments on our project with Avery  \nDennison and Innara Health.  So we're both looking to expand the line, as well as drive the  mix to our  \nsales reps and continuing to work with customers. ", "original_text": "We've not given any actual mixed percentages in terms of how much of our  \nvolume is Cardinal Health Brand versus others, so I can't do that at this point in time. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4b0434f0376b8eb0888ae4c59cd3d85096319648a3af89a0e832c8a0d2a871c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "811710f1-b05f-4d35-abe9-ca83f74fd84b", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yeah.  We've not given any actual mixed percentages in terms of how much of our  \nvolume is Cardinal Health Brand versus others, so I can't do that at this point in time.  But what I will say  \nis that there's opportunity for growth there.  We know that that's an area that we're excited about, and  \ncontinue to put things in place, like wor king on our incentives for our sales force, expanding our product  \nline to have more items to drive mix to, which you heard in my comments on our project with Avery  \nDennison and Innara Health.  So we're both looking to expand the line, as well as drive the  mix to our  \nsales reps and continuing to work with customers.  So while we don't give it, it's an area where we do  \nsee some real opportunity going forward to grow.  As far as other things to your point. ", "original_text": "We know that that's an area that we're excited about, and  \ncontinue to put things in place, like wor king on our incentives for our sales force, expanding our product  \nline to have more items to drive mix to, which you heard in my comments on our project with Avery  \nDennison and Innara Health. "}, "hash": "49619d70e0ac9fd45d5b04d43dd8c741b5de5d2cdf755fff7b3879a83f47e7aa", "class_name": "RelatedNodeInfo"}}, "text": "But what I will say  \nis that there's opportunity for growth there. ", "start_char_idx": 672, "end_char_idx": 740, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "811710f1-b05f-4d35-abe9-ca83f74fd84b": {"__data__": {"id_": "811710f1-b05f-4d35-abe9-ca83f74fd84b", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yeah.  We've not given any actual mixed percentages in terms of how much of our  \nvolume is Cardinal Health Brand versus others, so I can't do that at this point in time.  But what I will say  \nis that there's opportunity for growth there.  We know that that's an area that we're excited about, and  \ncontinue to put things in place, like wor king on our incentives for our sales force, expanding our product  \nline to have more items to drive mix to, which you heard in my comments on our project with Avery  \nDennison and Innara Health.  So we're both looking to expand the line, as well as drive the  mix to our  \nsales reps and continuing to work with customers.  So while we don't give it, it's an area where we do  \nsee some real opportunity going forward to grow.  As far as other things to your point. ", "original_text": "We know that that's an area that we're excited about, and  \ncontinue to put things in place, like wor king on our incentives for our sales force, expanding our product  \nline to have more items to drive mix to, which you heard in my comments on our project with Avery  \nDennison and Innara Health. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94c3485a-13c9-4f92-9b6a-d8cd9d71b00d", "node_type": "1", "metadata": {"window": "I don't  \nknow, diversification of sourcing, maybe toggling back and forth in the Cardinal branded products,  \nanything else beyond just pushing for price increases, or do we are we basically waiting for the  \nbackdrop to improve  from a macro perspective?  \n \n Mike Kaufmann:  Yeah.  We've not given any actual mixed percentages in terms of how much of our  \nvolume is Cardinal Health Brand versus others, so I can't do that at this point in time.  But what I will say  \nis that there's opportunity for growth there.  We know that that's an area that we're excited about, and  \ncontinue to put things in place, like wor king on our incentives for our sales force, expanding our product  \nline to have more items to drive mix to, which you heard in my comments on our project with Avery  \nDennison and Innara Health.  So we're both looking to expand the line, as well as drive the  mix to our  \nsales reps and continuing to work with customers.  So while we don't give it, it's an area where we do  \nsee some real opportunity going forward to grow. ", "original_text": "But what I will say  \nis that there's opportunity for growth there. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "561c69ab29015a2839ed01270c73b98d97f3b221e43540fd650d46939c7d03d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2cbb92bc-cf50-446a-8b2d-c2aa3a9f16ee", "node_type": "1", "metadata": {"window": "We've not given any actual mixed percentages in terms of how much of our  \nvolume is Cardinal Health Brand versus others, so I can't do that at this point in time.  But what I will say  \nis that there's opportunity for growth there.  We know that that's an area that we're excited about, and  \ncontinue to put things in place, like wor king on our incentives for our sales force, expanding our product  \nline to have more items to drive mix to, which you heard in my comments on our project with Avery  \nDennison and Innara Health.  So we're both looking to expand the line, as well as drive the  mix to our  \nsales reps and continuing to work with customers.  So while we don't give it, it's an area where we do  \nsee some real opportunity going forward to grow.  As far as other things to your point.  So yeah, number  \none is going to be pricing the custo mers. ", "original_text": "So we're both looking to expand the line, as well as drive the  mix to our  \nsales reps and continuing to work with customers. "}, "hash": "fbabb688868a51f3a9ae3bff2866a333aeea8b393f60ef676781a09a8ed9570a", "class_name": "RelatedNodeInfo"}}, "text": "We know that that's an area that we're excited about, and  \ncontinue to put things in place, like wor king on our incentives for our sales force, expanding our product  \nline to have more items to drive mix to, which you heard in my comments on our project with Avery  \nDennison and Innara Health. ", "start_char_idx": 740, "end_char_idx": 1038, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2cbb92bc-cf50-446a-8b2d-c2aa3a9f16ee": {"__data__": {"id_": "2cbb92bc-cf50-446a-8b2d-c2aa3a9f16ee", "embedding": null, "metadata": {"window": "We've not given any actual mixed percentages in terms of how much of our  \nvolume is Cardinal Health Brand versus others, so I can't do that at this point in time.  But what I will say  \nis that there's opportunity for growth there.  We know that that's an area that we're excited about, and  \ncontinue to put things in place, like wor king on our incentives for our sales force, expanding our product  \nline to have more items to drive mix to, which you heard in my comments on our project with Avery  \nDennison and Innara Health.  So we're both looking to expand the line, as well as drive the  mix to our  \nsales reps and continuing to work with customers.  So while we don't give it, it's an area where we do  \nsee some real opportunity going forward to grow.  As far as other things to your point.  So yeah, number  \none is going to be pricing the custo mers. ", "original_text": "So we're both looking to expand the line, as well as drive the  mix to our  \nsales reps and continuing to work with customers. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "811710f1-b05f-4d35-abe9-ca83f74fd84b", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yeah.  We've not given any actual mixed percentages in terms of how much of our  \nvolume is Cardinal Health Brand versus others, so I can't do that at this point in time.  But what I will say  \nis that there's opportunity for growth there.  We know that that's an area that we're excited about, and  \ncontinue to put things in place, like wor king on our incentives for our sales force, expanding our product  \nline to have more items to drive mix to, which you heard in my comments on our project with Avery  \nDennison and Innara Health.  So we're both looking to expand the line, as well as drive the  mix to our  \nsales reps and continuing to work with customers.  So while we don't give it, it's an area where we do  \nsee some real opportunity going forward to grow.  As far as other things to your point. ", "original_text": "We know that that's an area that we're excited about, and  \ncontinue to put things in place, like wor king on our incentives for our sales force, expanding our product  \nline to have more items to drive mix to, which you heard in my comments on our project with Avery  \nDennison and Innara Health. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7e6670e86ffa3b460edd3ee661cc0b26ce26789b5bde75ce742bcff333832ace", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c116be60-f15d-496e-b76b-48dcf4cef8c7", "node_type": "1", "metadata": {"window": "But what I will say  \nis that there's opportunity for growth there.  We know that that's an area that we're excited about, and  \ncontinue to put things in place, like wor king on our incentives for our sales force, expanding our product  \nline to have more items to drive mix to, which you heard in my comments on our project with Avery  \nDennison and Innara Health.  So we're both looking to expand the line, as well as drive the  mix to our  \nsales reps and continuing to work with customers.  So while we don't give it, it's an area where we do  \nsee some real opportunity going forward to grow.  As far as other things to your point.  So yeah, number  \none is going to be pricing the custo mers.  That's going to be initiative. ", "original_text": "So while we don't give it, it's an area where we do  \nsee some real opportunity going forward to grow. "}, "hash": "63ff96e3698bdf2a23a30501e36829818e64e92541611fb644e52ba70a54afab", "class_name": "RelatedNodeInfo"}}, "text": "So we're both looking to expand the line, as well as drive the  mix to our  \nsales reps and continuing to work with customers. ", "start_char_idx": 1038, "end_char_idx": 1165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c116be60-f15d-496e-b76b-48dcf4cef8c7": {"__data__": {"id_": "c116be60-f15d-496e-b76b-48dcf4cef8c7", "embedding": null, "metadata": {"window": "But what I will say  \nis that there's opportunity for growth there.  We know that that's an area that we're excited about, and  \ncontinue to put things in place, like wor king on our incentives for our sales force, expanding our product  \nline to have more items to drive mix to, which you heard in my comments on our project with Avery  \nDennison and Innara Health.  So we're both looking to expand the line, as well as drive the  mix to our  \nsales reps and continuing to work with customers.  So while we don't give it, it's an area where we do  \nsee some real opportunity going forward to grow.  As far as other things to your point.  So yeah, number  \none is going to be pricing the custo mers.  That's going to be initiative. ", "original_text": "So while we don't give it, it's an area where we do  \nsee some real opportunity going forward to grow. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2cbb92bc-cf50-446a-8b2d-c2aa3a9f16ee", "node_type": "1", "metadata": {"window": "We've not given any actual mixed percentages in terms of how much of our  \nvolume is Cardinal Health Brand versus others, so I can't do that at this point in time.  But what I will say  \nis that there's opportunity for growth there.  We know that that's an area that we're excited about, and  \ncontinue to put things in place, like wor king on our incentives for our sales force, expanding our product  \nline to have more items to drive mix to, which you heard in my comments on our project with Avery  \nDennison and Innara Health.  So we're both looking to expand the line, as well as drive the  mix to our  \nsales reps and continuing to work with customers.  So while we don't give it, it's an area where we do  \nsee some real opportunity going forward to grow.  As far as other things to your point.  So yeah, number  \none is going to be pricing the custo mers. ", "original_text": "So we're both looking to expand the line, as well as drive the  mix to our  \nsales reps and continuing to work with customers. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d03b8411c19deccff6e48cbd42eb3fd8bae33e02a33394e8e3e4e21fb8c35e99", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0580d91-704e-4759-bea4-1f5cbd965f4a", "node_type": "1", "metadata": {"window": "We know that that's an area that we're excited about, and  \ncontinue to put things in place, like wor king on our incentives for our sales force, expanding our product  \nline to have more items to drive mix to, which you heard in my comments on our project with Avery  \nDennison and Innara Health.  So we're both looking to expand the line, as well as drive the  mix to our  \nsales reps and continuing to work with customers.  So while we don't give it, it's an area where we do  \nsee some real opportunity going forward to grow.  As far as other things to your point.  So yeah, number  \none is going to be pricing the custo mers.  That's going to be initiative.  I also mentioned that we are  \ntaking fee changes to our manufacturing partners to increase the fees. ", "original_text": "As far as other things to your point. "}, "hash": "ef013faa8e27f0f7d33120fe1dcf36da2bdfcde517ffe8ebc4036adac92070b4", "class_name": "RelatedNodeInfo"}}, "text": "So while we don't give it, it's an area where we do  \nsee some real opportunity going forward to grow. ", "start_char_idx": 1165, "end_char_idx": 1268, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0580d91-704e-4759-bea4-1f5cbd965f4a": {"__data__": {"id_": "d0580d91-704e-4759-bea4-1f5cbd965f4a", "embedding": null, "metadata": {"window": "We know that that's an area that we're excited about, and  \ncontinue to put things in place, like wor king on our incentives for our sales force, expanding our product  \nline to have more items to drive mix to, which you heard in my comments on our project with Avery  \nDennison and Innara Health.  So we're both looking to expand the line, as well as drive the  mix to our  \nsales reps and continuing to work with customers.  So while we don't give it, it's an area where we do  \nsee some real opportunity going forward to grow.  As far as other things to your point.  So yeah, number  \none is going to be pricing the custo mers.  That's going to be initiative.  I also mentioned that we are  \ntaking fee changes to our manufacturing partners to increase the fees. ", "original_text": "As far as other things to your point. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c116be60-f15d-496e-b76b-48dcf4cef8c7", "node_type": "1", "metadata": {"window": "But what I will say  \nis that there's opportunity for growth there.  We know that that's an area that we're excited about, and  \ncontinue to put things in place, like wor king on our incentives for our sales force, expanding our product  \nline to have more items to drive mix to, which you heard in my comments on our project with Avery  \nDennison and Innara Health.  So we're both looking to expand the line, as well as drive the  mix to our  \nsales reps and continuing to work with customers.  So while we don't give it, it's an area where we do  \nsee some real opportunity going forward to grow.  As far as other things to your point.  So yeah, number  \none is going to be pricing the custo mers.  That's going to be initiative. ", "original_text": "So while we don't give it, it's an area where we do  \nsee some real opportunity going forward to grow. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "140939296241bfc461a32a40ab7c9b133d05a0b6ded422e7268c7c1f0d9479f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad8b0370-7c56-4b37-8c07-3419d06e6205", "node_type": "1", "metadata": {"window": "So we're both looking to expand the line, as well as drive the  mix to our  \nsales reps and continuing to work with customers.  So while we don't give it, it's an area where we do  \nsee some real opportunity going forward to grow.  As far as other things to your point.  So yeah, number  \none is going to be pricing the custo mers.  That's going to be initiative.  I also mentioned that we are  \ntaking fee changes to our manufacturing partners to increase the fees.  Our cost, as we said, have gone  \nup. ", "original_text": "So yeah, number  \none is going to be pricing the custo mers. "}, "hash": "1006cfc5a911a00cb3eece89286bd3bce214c627bc2934d22627fe2c72644e1e", "class_name": "RelatedNodeInfo"}}, "text": "As far as other things to your point. ", "start_char_idx": 1268, "end_char_idx": 1306, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad8b0370-7c56-4b37-8c07-3419d06e6205": {"__data__": {"id_": "ad8b0370-7c56-4b37-8c07-3419d06e6205", "embedding": null, "metadata": {"window": "So we're both looking to expand the line, as well as drive the  mix to our  \nsales reps and continuing to work with customers.  So while we don't give it, it's an area where we do  \nsee some real opportunity going forward to grow.  As far as other things to your point.  So yeah, number  \none is going to be pricing the custo mers.  That's going to be initiative.  I also mentioned that we are  \ntaking fee changes to our manufacturing partners to increase the fees.  Our cost, as we said, have gone  \nup. ", "original_text": "So yeah, number  \none is going to be pricing the custo mers. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0580d91-704e-4759-bea4-1f5cbd965f4a", "node_type": "1", "metadata": {"window": "We know that that's an area that we're excited about, and  \ncontinue to put things in place, like wor king on our incentives for our sales force, expanding our product  \nline to have more items to drive mix to, which you heard in my comments on our project with Avery  \nDennison and Innara Health.  So we're both looking to expand the line, as well as drive the  mix to our  \nsales reps and continuing to work with customers.  So while we don't give it, it's an area where we do  \nsee some real opportunity going forward to grow.  As far as other things to your point.  So yeah, number  \none is going to be pricing the custo mers.  That's going to be initiative.  I also mentioned that we are  \ntaking fee changes to our manufacturing partners to increase the fees. ", "original_text": "As far as other things to your point. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7f7b6a0a123c3f0df9a80b8fe905e9d993c856c2c72fb0d220a0623cd65fd3f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "593cea8b-f41c-4ec3-9a3b-44010276ed8a", "node_type": "1", "metadata": {"window": "So while we don't give it, it's an area where we do  \nsee some real opportunity going forward to grow.  As far as other things to your point.  So yeah, number  \none is going to be pricing the custo mers.  That's going to be initiative.  I also mentioned that we are  \ntaking fee changes to our manufacturing partners to increase the fees.  Our cost, as we said, have gone  \nup.  The service that we provide to manufacturers we believe is their best option to b e able to get to  \nmarket and get to the customers that we service. ", "original_text": "That's going to be initiative. "}, "hash": "13e832c11a72447d8a78c86fc5feff69c16672ea27c94a4ce95daf66e11c98d0", "class_name": "RelatedNodeInfo"}}, "text": "So yeah, number  \none is going to be pricing the custo mers. ", "start_char_idx": 1306, "end_char_idx": 1367, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "593cea8b-f41c-4ec3-9a3b-44010276ed8a": {"__data__": {"id_": "593cea8b-f41c-4ec3-9a3b-44010276ed8a", "embedding": null, "metadata": {"window": "So while we don't give it, it's an area where we do  \nsee some real opportunity going forward to grow.  As far as other things to your point.  So yeah, number  \none is going to be pricing the custo mers.  That's going to be initiative.  I also mentioned that we are  \ntaking fee changes to our manufacturing partners to increase the fees.  Our cost, as we said, have gone  \nup.  The service that we provide to manufacturers we believe is their best option to b e able to get to  \nmarket and get to the customers that we service. ", "original_text": "That's going to be initiative. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad8b0370-7c56-4b37-8c07-3419d06e6205", "node_type": "1", "metadata": {"window": "So we're both looking to expand the line, as well as drive the  mix to our  \nsales reps and continuing to work with customers.  So while we don't give it, it's an area where we do  \nsee some real opportunity going forward to grow.  As far as other things to your point.  So yeah, number  \none is going to be pricing the custo mers.  That's going to be initiative.  I also mentioned that we are  \ntaking fee changes to our manufacturing partners to increase the fees.  Our cost, as we said, have gone  \nup. ", "original_text": "So yeah, number  \none is going to be pricing the custo mers. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e1a9d14bcaa1ded935881bf98452827172277b84e5a25cd2f86fd7f8300fc448", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9be4c9c-8421-45b6-99a6-eb692447201f", "node_type": "1", "metadata": {"window": "As far as other things to your point.  So yeah, number  \none is going to be pricing the custo mers.  That's going to be initiative.  I also mentioned that we are  \ntaking fee changes to our manufacturing partners to increase the fees.  Our cost, as we said, have gone  \nup.  The service that we provide to manufacturers we believe is their best option to b e able to get to  \nmarket and get to the customers that we service.  We want to obviously be fair with them and be a great  \nand trusted partner, but we do need to make sure we're charging fairly for our services. ", "original_text": "I also mentioned that we are  \ntaking fee changes to our manufacturing partners to increase the fees. "}, "hash": "7d22138ef506ff0db618420addbfd3f6fdea25a6eea70b74a0bb27b6be4863f2", "class_name": "RelatedNodeInfo"}}, "text": "That's going to be initiative. ", "start_char_idx": 1367, "end_char_idx": 1398, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9be4c9c-8421-45b6-99a6-eb692447201f": {"__data__": {"id_": "d9be4c9c-8421-45b6-99a6-eb692447201f", "embedding": null, "metadata": {"window": "As far as other things to your point.  So yeah, number  \none is going to be pricing the custo mers.  That's going to be initiative.  I also mentioned that we are  \ntaking fee changes to our manufacturing partners to increase the fees.  Our cost, as we said, have gone  \nup.  The service that we provide to manufacturers we believe is their best option to b e able to get to  \nmarket and get to the customers that we service.  We want to obviously be fair with them and be a great  \nand trusted partner, but we do need to make sure we're charging fairly for our services. ", "original_text": "I also mentioned that we are  \ntaking fee changes to our manufacturing partners to increase the fees. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "593cea8b-f41c-4ec3-9a3b-44010276ed8a", "node_type": "1", "metadata": {"window": "So while we don't give it, it's an area where we do  \nsee some real opportunity going forward to grow.  As far as other things to your point.  So yeah, number  \none is going to be pricing the custo mers.  That's going to be initiative.  I also mentioned that we are  \ntaking fee changes to our manufacturing partners to increase the fees.  Our cost, as we said, have gone  \nup.  The service that we provide to manufacturers we believe is their best option to b e able to get to  \nmarket and get to the customers that we service. ", "original_text": "That's going to be initiative. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6542bf434e24a75a5fb077dcdf1e9ec183c2fcad4f6c137b238c9b9f0da0e545", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d7d34932-b0a4-4656-bf48-db8ca75a6f97", "node_type": "1", "metadata": {"window": "So yeah, number  \none is going to be pricing the custo mers.  That's going to be initiative.  I also mentioned that we are  \ntaking fee changes to our manufacturing partners to increase the fees.  Our cost, as we said, have gone  \nup.  The service that we provide to manufacturers we believe is their best option to b e able to get to  \nmarket and get to the customers that we service.  We want to obviously be fair with them and be a great  \nand trusted partner, but we do need to make sure we're charging fairly for our services.  So we have in  \nour taking fee changes to thos e manufacturing partners that we have on the Medical side in order to  \nhelp compensate us for the great service that we drive there. ", "original_text": "Our cost, as we said, have gone  \nup. "}, "hash": "bb18fd139890db8ad187d90f93410705c924b94b866520c72ac50caa91f6cbf8", "class_name": "RelatedNodeInfo"}}, "text": "I also mentioned that we are  \ntaking fee changes to our manufacturing partners to increase the fees. ", "start_char_idx": 1398, "end_char_idx": 1500, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d7d34932-b0a4-4656-bf48-db8ca75a6f97": {"__data__": {"id_": "d7d34932-b0a4-4656-bf48-db8ca75a6f97", "embedding": null, "metadata": {"window": "So yeah, number  \none is going to be pricing the custo mers.  That's going to be initiative.  I also mentioned that we are  \ntaking fee changes to our manufacturing partners to increase the fees.  Our cost, as we said, have gone  \nup.  The service that we provide to manufacturers we believe is their best option to b e able to get to  \nmarket and get to the customers that we service.  We want to obviously be fair with them and be a great  \nand trusted partner, but we do need to make sure we're charging fairly for our services.  So we have in  \nour taking fee changes to thos e manufacturing partners that we have on the Medical side in order to  \nhelp compensate us for the great service that we drive there. ", "original_text": "Our cost, as we said, have gone  \nup. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9be4c9c-8421-45b6-99a6-eb692447201f", "node_type": "1", "metadata": {"window": "As far as other things to your point.  So yeah, number  \none is going to be pricing the custo mers.  That's going to be initiative.  I also mentioned that we are  \ntaking fee changes to our manufacturing partners to increase the fees.  Our cost, as we said, have gone  \nup.  The service that we provide to manufacturers we believe is their best option to b e able to get to  \nmarket and get to the customers that we service.  We want to obviously be fair with them and be a great  \nand trusted partner, but we do need to make sure we're charging fairly for our services. ", "original_text": "I also mentioned that we are  \ntaking fee changes to our manufacturing partners to increase the fees. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9cb505ae53421070086ee4ec8a330ba2b28bd3450c6f53b843d96e1c800b4902", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6939d3d9-7705-4f6e-ae8c-92369a2a6acf", "node_type": "1", "metadata": {"window": "That's going to be initiative.  I also mentioned that we are  \ntaking fee changes to our manufacturing partners to increase the fees.  Our cost, as we said, have gone  \nup.  The service that we provide to manufacturers we believe is their best option to b e able to get to  \nmarket and get to the customers that we service.  We want to obviously be fair with them and be a great  \nand trusted partner, but we do need to make sure we're charging fairly for our services.  So we have in  \nour taking fee changes to thos e manufacturing partners that we have on the Medical side in order to  \nhelp compensate us for the great service that we drive there.  We continue to look at our cost side of  \nthe business. ", "original_text": "The service that we provide to manufacturers we believe is their best option to b e able to get to  \nmarket and get to the customers that we service. "}, "hash": "0e642e5b41f30f4d38f7f7fe81147b8a8b26ff5967988f48becab4f765672d4d", "class_name": "RelatedNodeInfo"}}, "text": "Our cost, as we said, have gone  \nup. ", "start_char_idx": 1500, "end_char_idx": 1538, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6939d3d9-7705-4f6e-ae8c-92369a2a6acf": {"__data__": {"id_": "6939d3d9-7705-4f6e-ae8c-92369a2a6acf", "embedding": null, "metadata": {"window": "That's going to be initiative.  I also mentioned that we are  \ntaking fee changes to our manufacturing partners to increase the fees.  Our cost, as we said, have gone  \nup.  The service that we provide to manufacturers we believe is their best option to b e able to get to  \nmarket and get to the customers that we service.  We want to obviously be fair with them and be a great  \nand trusted partner, but we do need to make sure we're charging fairly for our services.  So we have in  \nour taking fee changes to thos e manufacturing partners that we have on the Medical side in order to  \nhelp compensate us for the great service that we drive there.  We continue to look at our cost side of  \nthe business. ", "original_text": "The service that we provide to manufacturers we believe is their best option to b e able to get to  \nmarket and get to the customers that we service. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d7d34932-b0a4-4656-bf48-db8ca75a6f97", "node_type": "1", "metadata": {"window": "So yeah, number  \none is going to be pricing the custo mers.  That's going to be initiative.  I also mentioned that we are  \ntaking fee changes to our manufacturing partners to increase the fees.  Our cost, as we said, have gone  \nup.  The service that we provide to manufacturers we believe is their best option to b e able to get to  \nmarket and get to the customers that we service.  We want to obviously be fair with them and be a great  \nand trusted partner, but we do need to make sure we're charging fairly for our services.  So we have in  \nour taking fee changes to thos e manufacturing partners that we have on the Medical side in order to  \nhelp compensate us for the great service that we drive there. ", "original_text": "Our cost, as we said, have gone  \nup. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3e43734a22b2f315d86e5d5f830581217d7f9db213aacff1db06a45f274668cf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b43def59-fdf1-4091-a164-b05fb9f6eb5d", "node_type": "1", "metadata": {"window": "I also mentioned that we are  \ntaking fee changes to our manufacturing partners to increase the fees.  Our cost, as we said, have gone  \nup.  The service that we provide to manufacturers we believe is their best option to b e able to get to  \nmarket and get to the customers that we service.  We want to obviously be fair with them and be a great  \nand trusted partner, but we do need to make sure we're charging fairly for our services.  So we have in  \nour taking fee changes to thos e manufacturing partners that we have on the Medical side in order to  \nhelp compensate us for the great service that we drive there.  We continue to look at our cost side of  \nthe business.  We continue to feel good about our $750 million cost takeout, and we 're continuing to  \nlook at opportunities to be even more aggressive on that. ", "original_text": "We want to obviously be fair with them and be a great  \nand trusted partner, but we do need to make sure we're charging fairly for our services. "}, "hash": "895b196791c25e128c58f3bfc20021b33c5aa515c67679af395cb45793df20bc", "class_name": "RelatedNodeInfo"}}, "text": "The service that we provide to manufacturers we believe is their best option to b e able to get to  \nmarket and get to the customers that we service. ", "start_char_idx": 1538, "end_char_idx": 1688, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b43def59-fdf1-4091-a164-b05fb9f6eb5d": {"__data__": {"id_": "b43def59-fdf1-4091-a164-b05fb9f6eb5d", "embedding": null, "metadata": {"window": "I also mentioned that we are  \ntaking fee changes to our manufacturing partners to increase the fees.  Our cost, as we said, have gone  \nup.  The service that we provide to manufacturers we believe is their best option to b e able to get to  \nmarket and get to the customers that we service.  We want to obviously be fair with them and be a great  \nand trusted partner, but we do need to make sure we're charging fairly for our services.  So we have in  \nour taking fee changes to thos e manufacturing partners that we have on the Medical side in order to  \nhelp compensate us for the great service that we drive there.  We continue to look at our cost side of  \nthe business.  We continue to feel good about our $750 million cost takeout, and we 're continuing to  \nlook at opportunities to be even more aggressive on that. ", "original_text": "We want to obviously be fair with them and be a great  \nand trusted partner, but we do need to make sure we're charging fairly for our services. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6939d3d9-7705-4f6e-ae8c-92369a2a6acf", "node_type": "1", "metadata": {"window": "That's going to be initiative.  I also mentioned that we are  \ntaking fee changes to our manufacturing partners to increase the fees.  Our cost, as we said, have gone  \nup.  The service that we provide to manufacturers we believe is their best option to b e able to get to  \nmarket and get to the customers that we service.  We want to obviously be fair with them and be a great  \nand trusted partner, but we do need to make sure we're charging fairly for our services.  So we have in  \nour taking fee changes to thos e manufacturing partners that we have on the Medical side in order to  \nhelp compensate us for the great service that we drive there.  We continue to look at our cost side of  \nthe business. ", "original_text": "The service that we provide to manufacturers we believe is their best option to b e able to get to  \nmarket and get to the customers that we service. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "09ccda25fed32d741546b28c07a23d1bb42d5e65d606a6249f4e7f75bdd76379", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0d4b560e-e18c-44ec-8574-093c6c2a6aee", "node_type": "1", "metadata": {"window": "Our cost, as we said, have gone  \nup.  The service that we provide to manufacturers we believe is their best option to b e able to get to  \nmarket and get to the customers that we service.  We want to obviously be fair with them and be a great  \nand trusted partner, but we do need to make sure we're charging fairly for our services.  So we have in  \nour taking fee changes to thos e manufacturing partners that we have on the Medical side in order to  \nhelp compensate us for the great service that we drive there.  We continue to look at our cost side of  \nthe business.  We continue to feel good about our $750 million cost takeout, and we 're continuing to  \nlook at opportunities to be even more aggressive on that.  And we'll continue to do that going forward.  \n", "original_text": "So we have in  \nour taking fee changes to thos e manufacturing partners that we have on the Medical side in order to  \nhelp compensate us for the great service that we drive there. "}, "hash": "07074ba3cbf3044493b008472185b49223fcd59f3c2079a860cbb40470b4de57", "class_name": "RelatedNodeInfo"}}, "text": "We want to obviously be fair with them and be a great  \nand trusted partner, but we do need to make sure we're charging fairly for our services. ", "start_char_idx": 1688, "end_char_idx": 1833, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0d4b560e-e18c-44ec-8574-093c6c2a6aee": {"__data__": {"id_": "0d4b560e-e18c-44ec-8574-093c6c2a6aee", "embedding": null, "metadata": {"window": "Our cost, as we said, have gone  \nup.  The service that we provide to manufacturers we believe is their best option to b e able to get to  \nmarket and get to the customers that we service.  We want to obviously be fair with them and be a great  \nand trusted partner, but we do need to make sure we're charging fairly for our services.  So we have in  \nour taking fee changes to thos e manufacturing partners that we have on the Medical side in order to  \nhelp compensate us for the great service that we drive there.  We continue to look at our cost side of  \nthe business.  We continue to feel good about our $750 million cost takeout, and we 're continuing to  \nlook at opportunities to be even more aggressive on that.  And we'll continue to do that going forward.  \n", "original_text": "So we have in  \nour taking fee changes to thos e manufacturing partners that we have on the Medical side in order to  \nhelp compensate us for the great service that we drive there. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b43def59-fdf1-4091-a164-b05fb9f6eb5d", "node_type": "1", "metadata": {"window": "I also mentioned that we are  \ntaking fee changes to our manufacturing partners to increase the fees.  Our cost, as we said, have gone  \nup.  The service that we provide to manufacturers we believe is their best option to b e able to get to  \nmarket and get to the customers that we service.  We want to obviously be fair with them and be a great  \nand trusted partner, but we do need to make sure we're charging fairly for our services.  So we have in  \nour taking fee changes to thos e manufacturing partners that we have on the Medical side in order to  \nhelp compensate us for the great service that we drive there.  We continue to look at our cost side of  \nthe business.  We continue to feel good about our $750 million cost takeout, and we 're continuing to  \nlook at opportunities to be even more aggressive on that. ", "original_text": "We want to obviously be fair with them and be a great  \nand trusted partner, but we do need to make sure we're charging fairly for our services. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "1f8642e7118da5cb58cd53c9c004af0d6594a90f4bb3ded04631f7c0fc74cc32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e70791f-ee81-4331-b40c-d70c8a22b029", "node_type": "1", "metadata": {"window": "The service that we provide to manufacturers we believe is their best option to b e able to get to  \nmarket and get to the customers that we service.  We want to obviously be fair with them and be a great  \nand trusted partner, but we do need to make sure we're charging fairly for our services.  So we have in  \nour taking fee changes to thos e manufacturing partners that we have on the Medical side in order to  \nhelp compensate us for the great service that we drive there.  We continue to look at our cost side of  \nthe business.  We continue to feel good about our $750 million cost takeout, and we 're continuing to  \nlook at opportunities to be even more aggressive on that.  And we'll continue to do that going forward.  \n And then in our growth businesses. ", "original_text": "We continue to look at our cost side of  \nthe business. "}, "hash": "390ce767f2eec8ed1d346ce97ef35630d2d980c2104143f11b136bd0b7b23861", "class_name": "RelatedNodeInfo"}}, "text": "So we have in  \nour taking fee changes to thos e manufacturing partners that we have on the Medical side in order to  \nhelp compensate us for the great service that we drive there. ", "start_char_idx": 1833, "end_char_idx": 2014, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e70791f-ee81-4331-b40c-d70c8a22b029": {"__data__": {"id_": "0e70791f-ee81-4331-b40c-d70c8a22b029", "embedding": null, "metadata": {"window": "The service that we provide to manufacturers we believe is their best option to b e able to get to  \nmarket and get to the customers that we service.  We want to obviously be fair with them and be a great  \nand trusted partner, but we do need to make sure we're charging fairly for our services.  So we have in  \nour taking fee changes to thos e manufacturing partners that we have on the Medical side in order to  \nhelp compensate us for the great service that we drive there.  We continue to look at our cost side of  \nthe business.  We continue to feel good about our $750 million cost takeout, and we 're continuing to  \nlook at opportunities to be even more aggressive on that.  And we'll continue to do that going forward.  \n And then in our growth businesses. ", "original_text": "We continue to look at our cost side of  \nthe business. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0d4b560e-e18c-44ec-8574-093c6c2a6aee", "node_type": "1", "metadata": {"window": "Our cost, as we said, have gone  \nup.  The service that we provide to manufacturers we believe is their best option to b e able to get to  \nmarket and get to the customers that we service.  We want to obviously be fair with them and be a great  \nand trusted partner, but we do need to make sure we're charging fairly for our services.  So we have in  \nour taking fee changes to thos e manufacturing partners that we have on the Medical side in order to  \nhelp compensate us for the great service that we drive there.  We continue to look at our cost side of  \nthe business.  We continue to feel good about our $750 million cost takeout, and we 're continuing to  \nlook at opportunities to be even more aggressive on that.  And we'll continue to do that going forward.  \n", "original_text": "So we have in  \nour taking fee changes to thos e manufacturing partners that we have on the Medical side in order to  \nhelp compensate us for the great service that we drive there. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "339dd29c0ceeeb68595e912c15ce784a9c36f6c2f167d2c9f87dbcd743be9ac5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd3ab46d-54aa-4e93-a6f0-f1f241987777", "node_type": "1", "metadata": {"window": "We want to obviously be fair with them and be a great  \nand trusted partner, but we do need to make sure we're charging fairly for our services.  So we have in  \nour taking fee changes to thos e manufacturing partners that we have on the Medical side in order to  \nhelp compensate us for the great service that we drive there.  We continue to look at our cost side of  \nthe business.  We continue to feel good about our $750 million cost takeout, and we 're continuing to  \nlook at opportunities to be even more aggressive on that.  And we'll continue to do that going forward.  \n And then in our growth businesses.  Focusing on those growth businesses, whether it be at -Home, or  \nOptiFreight\u00ae, or lab. ", "original_text": "We continue to feel good about our $750 million cost takeout, and we 're continuing to  \nlook at opportunities to be even more aggressive on that. "}, "hash": "f368eeb2cd3d1c97ae74e9d70cff91a3d90d15acc29eefd97260cbb624b50b82", "class_name": "RelatedNodeInfo"}}, "text": "We continue to look at our cost side of  \nthe business. ", "start_char_idx": 2014, "end_char_idx": 2070, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd3ab46d-54aa-4e93-a6f0-f1f241987777": {"__data__": {"id_": "cd3ab46d-54aa-4e93-a6f0-f1f241987777", "embedding": null, "metadata": {"window": "We want to obviously be fair with them and be a great  \nand trusted partner, but we do need to make sure we're charging fairly for our services.  So we have in  \nour taking fee changes to thos e manufacturing partners that we have on the Medical side in order to  \nhelp compensate us for the great service that we drive there.  We continue to look at our cost side of  \nthe business.  We continue to feel good about our $750 million cost takeout, and we 're continuing to  \nlook at opportunities to be even more aggressive on that.  And we'll continue to do that going forward.  \n And then in our growth businesses.  Focusing on those growth businesses, whether it be at -Home, or  \nOptiFreight\u00ae, or lab. ", "original_text": "We continue to feel good about our $750 million cost takeout, and we 're continuing to  \nlook at opportunities to be even more aggressive on that. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e70791f-ee81-4331-b40c-d70c8a22b029", "node_type": "1", "metadata": {"window": "The service that we provide to manufacturers we believe is their best option to b e able to get to  \nmarket and get to the customers that we service.  We want to obviously be fair with them and be a great  \nand trusted partner, but we do need to make sure we're charging fairly for our services.  So we have in  \nour taking fee changes to thos e manufacturing partners that we have on the Medical side in order to  \nhelp compensate us for the great service that we drive there.  We continue to look at our cost side of  \nthe business.  We continue to feel good about our $750 million cost takeout, and we 're continuing to  \nlook at opportunities to be even more aggressive on that.  And we'll continue to do that going forward.  \n And then in our growth businesses. ", "original_text": "We continue to look at our cost side of  \nthe business. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "83be8ca6fefb537e7888fa7807cf04cf1aa69d6c916489f9da29aa076a8080c2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76d5da46-b5fa-4ca8-bce5-63b15f3fb34a", "node_type": "1", "metadata": {"window": "So we have in  \nour taking fee changes to thos e manufacturing partners that we have on the Medical side in order to  \nhelp compensate us for the great service that we drive there.  We continue to look at our cost side of  \nthe business.  We continue to feel good about our $750 million cost takeout, and we 're continuing to  \nlook at opportunities to be even more aggressive on that.  And we'll continue to do that going forward.  \n And then in our growth businesses.  Focusing on those growth businesses, whether it be at -Home, or  \nOptiFreight\u00ae, or lab.  We're contin uing to make investments, as I noted around where we're doing our  \nlab business in the new facility to grow that, we've got some IP rollout of some new systems in  \nOptiFreight\u00ae and in our at -Home business, that are going to both improve our costs and incre ase our  \nofferings. ", "original_text": "And we'll continue to do that going forward.  \n"}, "hash": "609b38730e7b48b98a206a3e292131998f1e7fa5d8a50c114850b5a4a84985fa", "class_name": "RelatedNodeInfo"}}, "text": "We continue to feel good about our $750 million cost takeout, and we 're continuing to  \nlook at opportunities to be even more aggressive on that. ", "start_char_idx": 2070, "end_char_idx": 2217, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76d5da46-b5fa-4ca8-bce5-63b15f3fb34a": {"__data__": {"id_": "76d5da46-b5fa-4ca8-bce5-63b15f3fb34a", "embedding": null, "metadata": {"window": "So we have in  \nour taking fee changes to thos e manufacturing partners that we have on the Medical side in order to  \nhelp compensate us for the great service that we drive there.  We continue to look at our cost side of  \nthe business.  We continue to feel good about our $750 million cost takeout, and we 're continuing to  \nlook at opportunities to be even more aggressive on that.  And we'll continue to do that going forward.  \n And then in our growth businesses.  Focusing on those growth businesses, whether it be at -Home, or  \nOptiFreight\u00ae, or lab.  We're contin uing to make investments, as I noted around where we're doing our  \nlab business in the new facility to grow that, we've got some IP rollout of some new systems in  \nOptiFreight\u00ae and in our at -Home business, that are going to both improve our costs and incre ase our  \nofferings. ", "original_text": "And we'll continue to do that going forward.  \n", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd3ab46d-54aa-4e93-a6f0-f1f241987777", "node_type": "1", "metadata": {"window": "We want to obviously be fair with them and be a great  \nand trusted partner, but we do need to make sure we're charging fairly for our services.  So we have in  \nour taking fee changes to thos e manufacturing partners that we have on the Medical side in order to  \nhelp compensate us for the great service that we drive there.  We continue to look at our cost side of  \nthe business.  We continue to feel good about our $750 million cost takeout, and we 're continuing to  \nlook at opportunities to be even more aggressive on that.  And we'll continue to do that going forward.  \n And then in our growth businesses.  Focusing on those growth businesses, whether it be at -Home, or  \nOptiFreight\u00ae, or lab. ", "original_text": "We continue to feel good about our $750 million cost takeout, and we 're continuing to  \nlook at opportunities to be even more aggressive on that. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "16f6d01809472f2869a76fac405fb43157372789356ab5d7f12e01a9fd501ef1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d8f1d635-b6c4-4eb0-a5a0-11e330ed81b6", "node_type": "1", "metadata": {"window": "We continue to look at our cost side of  \nthe business.  We continue to feel good about our $750 million cost takeout, and we 're continuing to  \nlook at opportunities to be even more aggressive on that.  And we'll continue to do that going forward.  \n And then in our growth businesses.  Focusing on those growth businesses, whether it be at -Home, or  \nOptiFreight\u00ae, or lab.  We're contin uing to make investments, as I noted around where we're doing our  \nlab business in the new facility to grow that, we've got some IP rollout of some new systems in  \nOptiFreight\u00ae and in our at -Home business, that are going to both improve our costs and incre ase our  \nofferings.  So those are the ways that we're going to be getting after over the next year and over the  \nfollowing years to grow this business.  \n \n", "original_text": "And then in our growth businesses. "}, "hash": "df557a5af3e77dcab024b4cfb1f9623b293641afc74dbb99914bb2049ef927b8", "class_name": "RelatedNodeInfo"}}, "text": "And we'll continue to do that going forward.  \n", "start_char_idx": 2217, "end_char_idx": 2264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d8f1d635-b6c4-4eb0-a5a0-11e330ed81b6": {"__data__": {"id_": "d8f1d635-b6c4-4eb0-a5a0-11e330ed81b6", "embedding": null, "metadata": {"window": "We continue to look at our cost side of  \nthe business.  We continue to feel good about our $750 million cost takeout, and we 're continuing to  \nlook at opportunities to be even more aggressive on that.  And we'll continue to do that going forward.  \n And then in our growth businesses.  Focusing on those growth businesses, whether it be at -Home, or  \nOptiFreight\u00ae, or lab.  We're contin uing to make investments, as I noted around where we're doing our  \nlab business in the new facility to grow that, we've got some IP rollout of some new systems in  \nOptiFreight\u00ae and in our at -Home business, that are going to both improve our costs and incre ase our  \nofferings.  So those are the ways that we're going to be getting after over the next year and over the  \nfollowing years to grow this business.  \n \n", "original_text": "And then in our growth businesses. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76d5da46-b5fa-4ca8-bce5-63b15f3fb34a", "node_type": "1", "metadata": {"window": "So we have in  \nour taking fee changes to thos e manufacturing partners that we have on the Medical side in order to  \nhelp compensate us for the great service that we drive there.  We continue to look at our cost side of  \nthe business.  We continue to feel good about our $750 million cost takeout, and we 're continuing to  \nlook at opportunities to be even more aggressive on that.  And we'll continue to do that going forward.  \n And then in our growth businesses.  Focusing on those growth businesses, whether it be at -Home, or  \nOptiFreight\u00ae, or lab.  We're contin uing to make investments, as I noted around where we're doing our  \nlab business in the new facility to grow that, we've got some IP rollout of some new systems in  \nOptiFreight\u00ae and in our at -Home business, that are going to both improve our costs and incre ase our  \nofferings. ", "original_text": "And we'll continue to do that going forward.  \n", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e66b2d5ce867858ed40f247e9deaec992cb6536ed52f850331fb0334081c5402", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd52d384-e2c4-412e-bbc8-c19b25d62f30", "node_type": "1", "metadata": {"window": "We continue to feel good about our $750 million cost takeout, and we 're continuing to  \nlook at opportunities to be even more aggressive on that.  And we'll continue to do that going forward.  \n And then in our growth businesses.  Focusing on those growth businesses, whether it be at -Home, or  \nOptiFreight\u00ae, or lab.  We're contin uing to make investments, as I noted around where we're doing our  \nlab business in the new facility to grow that, we've got some IP rollout of some new systems in  \nOptiFreight\u00ae and in our at -Home business, that are going to both improve our costs and incre ase our  \nofferings.  So those are the ways that we're going to be getting after over the next year and over the  \nfollowing years to grow this business.  \n \n Operato r:  We will take our next question from Eric Caldwell with Baird.  \n  \n", "original_text": "Focusing on those growth businesses, whether it be at -Home, or  \nOptiFreight\u00ae, or lab. "}, "hash": "894604753430eb7fce15ea6435f44da5a6b25a42923b81ab0e04ca44f2e6ab6a", "class_name": "RelatedNodeInfo"}}, "text": "And then in our growth businesses. ", "start_char_idx": 2264, "end_char_idx": 2299, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd52d384-e2c4-412e-bbc8-c19b25d62f30": {"__data__": {"id_": "fd52d384-e2c4-412e-bbc8-c19b25d62f30", "embedding": null, "metadata": {"window": "We continue to feel good about our $750 million cost takeout, and we 're continuing to  \nlook at opportunities to be even more aggressive on that.  And we'll continue to do that going forward.  \n And then in our growth businesses.  Focusing on those growth businesses, whether it be at -Home, or  \nOptiFreight\u00ae, or lab.  We're contin uing to make investments, as I noted around where we're doing our  \nlab business in the new facility to grow that, we've got some IP rollout of some new systems in  \nOptiFreight\u00ae and in our at -Home business, that are going to both improve our costs and incre ase our  \nofferings.  So those are the ways that we're going to be getting after over the next year and over the  \nfollowing years to grow this business.  \n \n Operato r:  We will take our next question from Eric Caldwell with Baird.  \n  \n", "original_text": "Focusing on those growth businesses, whether it be at -Home, or  \nOptiFreight\u00ae, or lab. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d8f1d635-b6c4-4eb0-a5a0-11e330ed81b6", "node_type": "1", "metadata": {"window": "We continue to look at our cost side of  \nthe business.  We continue to feel good about our $750 million cost takeout, and we 're continuing to  \nlook at opportunities to be even more aggressive on that.  And we'll continue to do that going forward.  \n And then in our growth businesses.  Focusing on those growth businesses, whether it be at -Home, or  \nOptiFreight\u00ae, or lab.  We're contin uing to make investments, as I noted around where we're doing our  \nlab business in the new facility to grow that, we've got some IP rollout of some new systems in  \nOptiFreight\u00ae and in our at -Home business, that are going to both improve our costs and incre ase our  \nofferings.  So those are the ways that we're going to be getting after over the next year and over the  \nfollowing years to grow this business.  \n \n", "original_text": "And then in our growth businesses. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2d41fc6009cc4f1051c83ac163fc13e73d9d48775202411243858aca874a91e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4913d96b-672d-41a9-bcfb-64eeb38f24a5", "node_type": "1", "metadata": {"window": "And we'll continue to do that going forward.  \n And then in our growth businesses.  Focusing on those growth businesses, whether it be at -Home, or  \nOptiFreight\u00ae, or lab.  We're contin uing to make investments, as I noted around where we're doing our  \nlab business in the new facility to grow that, we've got some IP rollout of some new systems in  \nOptiFreight\u00ae and in our at -Home business, that are going to both improve our costs and incre ase our  \nofferings.  So those are the ways that we're going to be getting after over the next year and over the  \nfollowing years to grow this business.  \n \n Operato r:  We will take our next question from Eric Caldwell with Baird.  \n  \n Eric Caldwell:   Hey. ", "original_text": "We're contin uing to make investments, as I noted around where we're doing our  \nlab business in the new facility to grow that, we've got some IP rollout of some new systems in  \nOptiFreight\u00ae and in our at -Home business, that are going to both improve our costs and incre ase our  \nofferings. "}, "hash": "114038bbb1c72561ee0140ea256ca8d7a48e9d1d8360179a85b8daef2244f28c", "class_name": "RelatedNodeInfo"}}, "text": "Focusing on those growth businesses, whether it be at -Home, or  \nOptiFreight\u00ae, or lab. ", "start_char_idx": 2299, "end_char_idx": 2387, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4913d96b-672d-41a9-bcfb-64eeb38f24a5": {"__data__": {"id_": "4913d96b-672d-41a9-bcfb-64eeb38f24a5", "embedding": null, "metadata": {"window": "And we'll continue to do that going forward.  \n And then in our growth businesses.  Focusing on those growth businesses, whether it be at -Home, or  \nOptiFreight\u00ae, or lab.  We're contin uing to make investments, as I noted around where we're doing our  \nlab business in the new facility to grow that, we've got some IP rollout of some new systems in  \nOptiFreight\u00ae and in our at -Home business, that are going to both improve our costs and incre ase our  \nofferings.  So those are the ways that we're going to be getting after over the next year and over the  \nfollowing years to grow this business.  \n \n Operato r:  We will take our next question from Eric Caldwell with Baird.  \n  \n Eric Caldwell:   Hey. ", "original_text": "We're contin uing to make investments, as I noted around where we're doing our  \nlab business in the new facility to grow that, we've got some IP rollout of some new systems in  \nOptiFreight\u00ae and in our at -Home business, that are going to both improve our costs and incre ase our  \nofferings. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd52d384-e2c4-412e-bbc8-c19b25d62f30", "node_type": "1", "metadata": {"window": "We continue to feel good about our $750 million cost takeout, and we 're continuing to  \nlook at opportunities to be even more aggressive on that.  And we'll continue to do that going forward.  \n And then in our growth businesses.  Focusing on those growth businesses, whether it be at -Home, or  \nOptiFreight\u00ae, or lab.  We're contin uing to make investments, as I noted around where we're doing our  \nlab business in the new facility to grow that, we've got some IP rollout of some new systems in  \nOptiFreight\u00ae and in our at -Home business, that are going to both improve our costs and incre ase our  \nofferings.  So those are the ways that we're going to be getting after over the next year and over the  \nfollowing years to grow this business.  \n \n Operato r:  We will take our next question from Eric Caldwell with Baird.  \n  \n", "original_text": "Focusing on those growth businesses, whether it be at -Home, or  \nOptiFreight\u00ae, or lab. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0061ac1a7c1bc873bd4a8414b38918a33f640a9853e8f7a9ac283d975e9e7f69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00083dde-1a5f-426f-b153-b49282ca6951", "node_type": "1", "metadata": {"window": "And then in our growth businesses.  Focusing on those growth businesses, whether it be at -Home, or  \nOptiFreight\u00ae, or lab.  We're contin uing to make investments, as I noted around where we're doing our  \nlab business in the new facility to grow that, we've got some IP rollout of some new systems in  \nOptiFreight\u00ae and in our at -Home business, that are going to both improve our costs and incre ase our  \nofferings.  So those are the ways that we're going to be getting after over the next year and over the  \nfollowing years to grow this business.  \n \n Operato r:  We will take our next question from Eric Caldwell with Baird.  \n  \n Eric Caldwell:   Hey.  Thank you. ", "original_text": "So those are the ways that we're going to be getting after over the next year and over the  \nfollowing years to grow this business.  \n \n"}, "hash": "9bb1735bea334eca1a46ac069c0cc13e0496d6aefc2e5e4c821dc2f4ca23974d", "class_name": "RelatedNodeInfo"}}, "text": "We're contin uing to make investments, as I noted around where we're doing our  \nlab business in the new facility to grow that, we've got some IP rollout of some new systems in  \nOptiFreight\u00ae and in our at -Home business, that are going to both improve our costs and incre ase our  \nofferings. ", "start_char_idx": 2387, "end_char_idx": 2681, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00083dde-1a5f-426f-b153-b49282ca6951": {"__data__": {"id_": "00083dde-1a5f-426f-b153-b49282ca6951", "embedding": null, "metadata": {"window": "And then in our growth businesses.  Focusing on those growth businesses, whether it be at -Home, or  \nOptiFreight\u00ae, or lab.  We're contin uing to make investments, as I noted around where we're doing our  \nlab business in the new facility to grow that, we've got some IP rollout of some new systems in  \nOptiFreight\u00ae and in our at -Home business, that are going to both improve our costs and incre ase our  \nofferings.  So those are the ways that we're going to be getting after over the next year and over the  \nfollowing years to grow this business.  \n \n Operato r:  We will take our next question from Eric Caldwell with Baird.  \n  \n Eric Caldwell:   Hey.  Thank you. ", "original_text": "So those are the ways that we're going to be getting after over the next year and over the  \nfollowing years to grow this business.  \n \n", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4913d96b-672d-41a9-bcfb-64eeb38f24a5", "node_type": "1", "metadata": {"window": "And we'll continue to do that going forward.  \n And then in our growth businesses.  Focusing on those growth businesses, whether it be at -Home, or  \nOptiFreight\u00ae, or lab.  We're contin uing to make investments, as I noted around where we're doing our  \nlab business in the new facility to grow that, we've got some IP rollout of some new systems in  \nOptiFreight\u00ae and in our at -Home business, that are going to both improve our costs and incre ase our  \nofferings.  So those are the ways that we're going to be getting after over the next year and over the  \nfollowing years to grow this business.  \n \n Operato r:  We will take our next question from Eric Caldwell with Baird.  \n  \n Eric Caldwell:   Hey. ", "original_text": "We're contin uing to make investments, as I noted around where we're doing our  \nlab business in the new facility to grow that, we've got some IP rollout of some new systems in  \nOptiFreight\u00ae and in our at -Home business, that are going to both improve our costs and incre ase our  \nofferings. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "975b0eda544a02be1534be79ff7962d7d0ce54245e3cd51e3260a267c10704ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d63346f3-bb59-47b7-a8ce-ded0cf34de57", "node_type": "1", "metadata": {"window": "Focusing on those growth businesses, whether it be at -Home, or  \nOptiFreight\u00ae, or lab.  We're contin uing to make investments, as I noted around where we're doing our  \nlab business in the new facility to grow that, we've got some IP rollout of some new systems in  \nOptiFreight\u00ae and in our at -Home business, that are going to both improve our costs and incre ase our  \nofferings.  So those are the ways that we're going to be getting after over the next year and over the  \nfollowing years to grow this business.  \n \n Operato r:  We will take our next question from Eric Caldwell with Baird.  \n  \n Eric Caldwell:   Hey.  Thank you.  Good morning. ", "original_text": "Operato r:  We will take our next question from Eric Caldwell with Baird.  \n  \n"}, "hash": "bb9ac048d015cd68b0ab28310194e54142e649ea951daee9b8491d5154d298cc", "class_name": "RelatedNodeInfo"}}, "text": "So those are the ways that we're going to be getting after over the next year and over the  \nfollowing years to grow this business.  \n \n", "start_char_idx": 2681, "end_char_idx": 2817, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d63346f3-bb59-47b7-a8ce-ded0cf34de57": {"__data__": {"id_": "d63346f3-bb59-47b7-a8ce-ded0cf34de57", "embedding": null, "metadata": {"window": "Focusing on those growth businesses, whether it be at -Home, or  \nOptiFreight\u00ae, or lab.  We're contin uing to make investments, as I noted around where we're doing our  \nlab business in the new facility to grow that, we've got some IP rollout of some new systems in  \nOptiFreight\u00ae and in our at -Home business, that are going to both improve our costs and incre ase our  \nofferings.  So those are the ways that we're going to be getting after over the next year and over the  \nfollowing years to grow this business.  \n \n Operato r:  We will take our next question from Eric Caldwell with Baird.  \n  \n Eric Caldwell:   Hey.  Thank you.  Good morning. ", "original_text": "Operato r:  We will take our next question from Eric Caldwell with Baird.  \n  \n", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00083dde-1a5f-426f-b153-b49282ca6951", "node_type": "1", "metadata": {"window": "And then in our growth businesses.  Focusing on those growth businesses, whether it be at -Home, or  \nOptiFreight\u00ae, or lab.  We're contin uing to make investments, as I noted around where we're doing our  \nlab business in the new facility to grow that, we've got some IP rollout of some new systems in  \nOptiFreight\u00ae and in our at -Home business, that are going to both improve our costs and incre ase our  \nofferings.  So those are the ways that we're going to be getting after over the next year and over the  \nfollowing years to grow this business.  \n \n Operato r:  We will take our next question from Eric Caldwell with Baird.  \n  \n Eric Caldwell:   Hey.  Thank you. ", "original_text": "So those are the ways that we're going to be getting after over the next year and over the  \nfollowing years to grow this business.  \n \n", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8ea9d21eb387795a4e0be3a0099a385876563c28e806babed1577d0e90b1c36c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c87ac53c-2231-4a9b-ab0f-ab95f369f826", "node_type": "1", "metadata": {"window": "We're contin uing to make investments, as I noted around where we're doing our  \nlab business in the new facility to grow that, we've got some IP rollout of some new systems in  \nOptiFreight\u00ae and in our at -Home business, that are going to both improve our costs and incre ase our  \nofferings.  So those are the ways that we're going to be getting after over the next year and over the  \nfollowing years to grow this business.  \n \n Operato r:  We will take our next question from Eric Caldwell with Baird.  \n  \n Eric Caldwell:   Hey.  Thank you.  Good morning.  I wanted to go back to the first question, I think it was  \nCharles asked. ", "original_text": "Eric Caldwell:   Hey. "}, "hash": "0888002549d73b16136aa1a434224f50b5a201c24b0fd5523456fb1d5d557978", "class_name": "RelatedNodeInfo"}}, "text": "Operato r:  We will take our next question from Eric Caldwell with Baird.  \n  \n", "start_char_idx": 2817, "end_char_idx": 2896, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c87ac53c-2231-4a9b-ab0f-ab95f369f826": {"__data__": {"id_": "c87ac53c-2231-4a9b-ab0f-ab95f369f826", "embedding": null, "metadata": {"window": "We're contin uing to make investments, as I noted around where we're doing our  \nlab business in the new facility to grow that, we've got some IP rollout of some new systems in  \nOptiFreight\u00ae and in our at -Home business, that are going to both improve our costs and incre ase our  \nofferings.  So those are the ways that we're going to be getting after over the next year and over the  \nfollowing years to grow this business.  \n \n Operato r:  We will take our next question from Eric Caldwell with Baird.  \n  \n Eric Caldwell:   Hey.  Thank you.  Good morning.  I wanted to go back to the first question, I think it was  \nCharles asked. ", "original_text": "Eric Caldwell:   Hey. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d63346f3-bb59-47b7-a8ce-ded0cf34de57", "node_type": "1", "metadata": {"window": "Focusing on those growth businesses, whether it be at -Home, or  \nOptiFreight\u00ae, or lab.  We're contin uing to make investments, as I noted around where we're doing our  \nlab business in the new facility to grow that, we've got some IP rollout of some new systems in  \nOptiFreight\u00ae and in our at -Home business, that are going to both improve our costs and incre ase our  \nofferings.  So those are the ways that we're going to be getting after over the next year and over the  \nfollowing years to grow this business.  \n \n Operato r:  We will take our next question from Eric Caldwell with Baird.  \n  \n Eric Caldwell:   Hey.  Thank you.  Good morning. ", "original_text": "Operato r:  We will take our next question from Eric Caldwell with Baird.  \n  \n", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "641b068beca6d6e5a6cd43a6f0abdf45e34175ff6ea8e7cdd7121aff2fa48e12", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5a57089-cfd5-457b-800a-04276e053934", "node_type": "1", "metadata": {"window": "So those are the ways that we're going to be getting after over the next year and over the  \nfollowing years to grow this business.  \n \n Operato r:  We will take our next question from Eric Caldwell with Baird.  \n  \n Eric Caldwell:   Hey.  Thank you.  Good morning.  I wanted to go back to the first question, I think it was  \nCharles asked.  The Pharma comp in 4Q \u201921, you identified some good guys from last year. ", "original_text": "Thank you. "}, "hash": "59a751d3fdbaaccaabeda994539d443f8a63782bcca20367781ab2ad589ef69d", "class_name": "RelatedNodeInfo"}}, "text": "Eric Caldwell:   Hey. ", "start_char_idx": 2896, "end_char_idx": 2918, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5a57089-cfd5-457b-800a-04276e053934": {"__data__": {"id_": "a5a57089-cfd5-457b-800a-04276e053934", "embedding": null, "metadata": {"window": "So those are the ways that we're going to be getting after over the next year and over the  \nfollowing years to grow this business.  \n \n Operato r:  We will take our next question from Eric Caldwell with Baird.  \n  \n Eric Caldwell:   Hey.  Thank you.  Good morning.  I wanted to go back to the first question, I think it was  \nCharles asked.  The Pharma comp in 4Q \u201921, you identified some good guys from last year. ", "original_text": "Thank you. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c87ac53c-2231-4a9b-ab0f-ab95f369f826", "node_type": "1", "metadata": {"window": "We're contin uing to make investments, as I noted around where we're doing our  \nlab business in the new facility to grow that, we've got some IP rollout of some new systems in  \nOptiFreight\u00ae and in our at -Home business, that are going to both improve our costs and incre ase our  \nofferings.  So those are the ways that we're going to be getting after over the next year and over the  \nfollowing years to grow this business.  \n \n Operato r:  We will take our next question from Eric Caldwell with Baird.  \n  \n Eric Caldwell:   Hey.  Thank you.  Good morning.  I wanted to go back to the first question, I think it was  \nCharles asked. ", "original_text": "Eric Caldwell:   Hey. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "47c29a1df181e99d259c53fbf329521c0d76db1e8b117bb5d8dd235a07c4490c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d2fae4ae-05ba-4f7c-8eb0-fa9a47a4a959", "node_type": "1", "metadata": {"window": "Operato r:  We will take our next question from Eric Caldwell with Baird.  \n  \n Eric Caldwell:   Hey.  Thank you.  Good morning.  I wanted to go back to the first question, I think it was  \nCharles asked.  The Pharma comp in 4Q \u201921, you identified some good guys from last year.  You have  \nnot given more specifics today on that those are. ", "original_text": "Good morning. "}, "hash": "708c89cac8f7cfe3c68259a93741acfc1434062fe14ef18e524e335972a36bc2", "class_name": "RelatedNodeInfo"}}, "text": "Thank you. ", "start_char_idx": 2918, "end_char_idx": 2929, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d2fae4ae-05ba-4f7c-8eb0-fa9a47a4a959": {"__data__": {"id_": "d2fae4ae-05ba-4f7c-8eb0-fa9a47a4a959", "embedding": null, "metadata": {"window": "Operato r:  We will take our next question from Eric Caldwell with Baird.  \n  \n Eric Caldwell:   Hey.  Thank you.  Good morning.  I wanted to go back to the first question, I think it was  \nCharles asked.  The Pharma comp in 4Q \u201921, you identified some good guys from last year.  You have  \nnot given more specifics today on that those are. ", "original_text": "Good morning. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5a57089-cfd5-457b-800a-04276e053934", "node_type": "1", "metadata": {"window": "So those are the ways that we're going to be getting after over the next year and over the  \nfollowing years to grow this business.  \n \n Operato r:  We will take our next question from Eric Caldwell with Baird.  \n  \n Eric Caldwell:   Hey.  Thank you.  Good morning.  I wanted to go back to the first question, I think it was  \nCharles asked.  The Pharma comp in 4Q \u201921, you identified some good guys from last year. ", "original_text": "Thank you. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "66806fca712c3bbfcc2f65a2a249396e814b5d8c4724cabc78899a4e08dd29f4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f86fc617-1ac9-4fcb-b592-ba3ae0633edc", "node_type": "1", "metadata": {"window": "Eric Caldwell:   Hey.  Thank you.  Good morning.  I wanted to go back to the first question, I think it was  \nCharles asked.  The Pharma comp in 4Q \u201921, you identified some good guys from last year.  You have  \nnot given more specifics today on that those are.  I think, we're all pretty hectic with earnings and  \neverything else a lot's changed in the last year. ", "original_text": "I wanted to go back to the first question, I think it was  \nCharles asked. "}, "hash": "6c06af0971b19e94b483feb44c352f26ea557880095f74581ffead5319f01150", "class_name": "RelatedNodeInfo"}}, "text": "Good morning. ", "start_char_idx": 2929, "end_char_idx": 2943, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f86fc617-1ac9-4fcb-b592-ba3ae0633edc": {"__data__": {"id_": "f86fc617-1ac9-4fcb-b592-ba3ae0633edc", "embedding": null, "metadata": {"window": "Eric Caldwell:   Hey.  Thank you.  Good morning.  I wanted to go back to the first question, I think it was  \nCharles asked.  The Pharma comp in 4Q \u201921, you identified some good guys from last year.  You have  \nnot given more specifics today on that those are.  I think, we're all pretty hectic with earnings and  \neverything else a lot's changed in the last year. ", "original_text": "I wanted to go back to the first question, I think it was  \nCharles asked. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d2fae4ae-05ba-4f7c-8eb0-fa9a47a4a959", "node_type": "1", "metadata": {"window": "Operato r:  We will take our next question from Eric Caldwell with Baird.  \n  \n Eric Caldwell:   Hey.  Thank you.  Good morning.  I wanted to go back to the first question, I think it was  \nCharles asked.  The Pharma comp in 4Q \u201921, you identified some good guys from last year.  You have  \nnot given more specifics today on that those are. ", "original_text": "Good morning. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "91e88a9503aa87ecb83ea48f694e08228ed6266eb07919893af564f786e1c785", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec2c8eac-8411-4f09-b94b-69f0ca2ef4cd", "node_type": "1", "metadata": {"window": "Thank you.  Good morning.  I wanted to go back to the first question, I think it was  \nCharles asked.  The Pharma comp in 4Q \u201921, you identified some good guys from last year.  You have  \nnot given more specifics today on that those are.  I think, we're all pretty hectic with earnings and  \neverything else a lot's changed in the last year.  Can you just remind us what those items were in the  \nfourth quarter of \u201821 that were bad guys, and how much they were, so we know what the year over year  \ngood guy comp is g oing into this quarter. ", "original_text": "The Pharma comp in 4Q \u201921, you identified some good guys from last year. "}, "hash": "30b19ce72f6ddb01a3078f682f7a6f9bf161e7c992ab43420a83696a65b7ef0b", "class_name": "RelatedNodeInfo"}}, "text": "I wanted to go back to the first question, I think it was  \nCharles asked. ", "start_char_idx": 2943, "end_char_idx": 3018, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec2c8eac-8411-4f09-b94b-69f0ca2ef4cd": {"__data__": {"id_": "ec2c8eac-8411-4f09-b94b-69f0ca2ef4cd", "embedding": null, "metadata": {"window": "Thank you.  Good morning.  I wanted to go back to the first question, I think it was  \nCharles asked.  The Pharma comp in 4Q \u201921, you identified some good guys from last year.  You have  \nnot given more specifics today on that those are.  I think, we're all pretty hectic with earnings and  \neverything else a lot's changed in the last year.  Can you just remind us what those items were in the  \nfourth quarter of \u201821 that were bad guys, and how much they were, so we know what the year over year  \ngood guy comp is g oing into this quarter. ", "original_text": "The Pharma comp in 4Q \u201921, you identified some good guys from last year. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f86fc617-1ac9-4fcb-b592-ba3ae0633edc", "node_type": "1", "metadata": {"window": "Eric Caldwell:   Hey.  Thank you.  Good morning.  I wanted to go back to the first question, I think it was  \nCharles asked.  The Pharma comp in 4Q \u201921, you identified some good guys from last year.  You have  \nnot given more specifics today on that those are.  I think, we're all pretty hectic with earnings and  \neverything else a lot's changed in the last year. ", "original_text": "I wanted to go back to the first question, I think it was  \nCharles asked. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "08fb938d2ab7706610c11d5d1f279280a5c3e000e67ff347d757d1cf846fa222", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c254e113-87de-498f-861e-17f7c3106dca", "node_type": "1", "metadata": {"window": "Good morning.  I wanted to go back to the first question, I think it was  \nCharles asked.  The Pharma comp in 4Q \u201921, you identified some good guys from last year.  You have  \nnot given more specifics today on that those are.  I think, we're all pretty hectic with earnings and  \neverything else a lot's changed in the last year.  Can you just remind us what those items were in the  \nfourth quarter of \u201821 that were bad guys, and how much they were, so we know what the year over year  \ngood guy comp is g oing into this quarter.  And then, are there any new good guys, things the street  \nwouldn't know about, that you know are going to hit in the fourth quarter that get you to your Pharma  \nprofit margin target? ", "original_text": "You have  \nnot given more specifics today on that those are. "}, "hash": "e51344deed0ab1661203bbf68e32a9d1a0f74e412170d3afd70245a4acd0d65e", "class_name": "RelatedNodeInfo"}}, "text": "The Pharma comp in 4Q \u201921, you identified some good guys from last year. ", "start_char_idx": 3018, "end_char_idx": 3091, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c254e113-87de-498f-861e-17f7c3106dca": {"__data__": {"id_": "c254e113-87de-498f-861e-17f7c3106dca", "embedding": null, "metadata": {"window": "Good morning.  I wanted to go back to the first question, I think it was  \nCharles asked.  The Pharma comp in 4Q \u201921, you identified some good guys from last year.  You have  \nnot given more specifics today on that those are.  I think, we're all pretty hectic with earnings and  \neverything else a lot's changed in the last year.  Can you just remind us what those items were in the  \nfourth quarter of \u201821 that were bad guys, and how much they were, so we know what the year over year  \ngood guy comp is g oing into this quarter.  And then, are there any new good guys, things the street  \nwouldn't know about, that you know are going to hit in the fourth quarter that get you to your Pharma  \nprofit margin target? ", "original_text": "You have  \nnot given more specifics today on that those are. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec2c8eac-8411-4f09-b94b-69f0ca2ef4cd", "node_type": "1", "metadata": {"window": "Thank you.  Good morning.  I wanted to go back to the first question, I think it was  \nCharles asked.  The Pharma comp in 4Q \u201921, you identified some good guys from last year.  You have  \nnot given more specifics today on that those are.  I think, we're all pretty hectic with earnings and  \neverything else a lot's changed in the last year.  Can you just remind us what those items were in the  \nfourth quarter of \u201821 that were bad guys, and how much they were, so we know what the year over year  \ngood guy comp is g oing into this quarter. ", "original_text": "The Pharma comp in 4Q \u201921, you identified some good guys from last year. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d41287bb7ca5da52854721d4887585a13d1dc837db0202ac065683752656795c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27978bcd-0b9f-48c6-a2d7-62be469cd07c", "node_type": "1", "metadata": {"window": "I wanted to go back to the first question, I think it was  \nCharles asked.  The Pharma comp in 4Q \u201921, you identified some good guys from last year.  You have  \nnot given more specifics today on that those are.  I think, we're all pretty hectic with earnings and  \neverything else a lot's changed in the last year.  Can you just remind us what those items were in the  \nfourth quarter of \u201821 that were bad guys, and how much they were, so we know what the year over year  \ngood guy comp is g oing into this quarter.  And then, are there any new good guys, things the street  \nwouldn't know about, that you know are going to hit in the fourth quarter that get you to your Pharma  \nprofit margin target?  Thanks very much.  \n \n", "original_text": "I think, we're all pretty hectic with earnings and  \neverything else a lot's changed in the last year. "}, "hash": "05f4e0126b5272cc02ad54e7c12286d689d5aa698b74bcb8715a609eeda99aff", "class_name": "RelatedNodeInfo"}}, "text": "You have  \nnot given more specifics today on that those are. ", "start_char_idx": 3091, "end_char_idx": 3152, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27978bcd-0b9f-48c6-a2d7-62be469cd07c": {"__data__": {"id_": "27978bcd-0b9f-48c6-a2d7-62be469cd07c", "embedding": null, "metadata": {"window": "I wanted to go back to the first question, I think it was  \nCharles asked.  The Pharma comp in 4Q \u201921, you identified some good guys from last year.  You have  \nnot given more specifics today on that those are.  I think, we're all pretty hectic with earnings and  \neverything else a lot's changed in the last year.  Can you just remind us what those items were in the  \nfourth quarter of \u201821 that were bad guys, and how much they were, so we know what the year over year  \ngood guy comp is g oing into this quarter.  And then, are there any new good guys, things the street  \nwouldn't know about, that you know are going to hit in the fourth quarter that get you to your Pharma  \nprofit margin target?  Thanks very much.  \n \n", "original_text": "I think, we're all pretty hectic with earnings and  \neverything else a lot's changed in the last year. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c254e113-87de-498f-861e-17f7c3106dca", "node_type": "1", "metadata": {"window": "Good morning.  I wanted to go back to the first question, I think it was  \nCharles asked.  The Pharma comp in 4Q \u201921, you identified some good guys from last year.  You have  \nnot given more specifics today on that those are.  I think, we're all pretty hectic with earnings and  \neverything else a lot's changed in the last year.  Can you just remind us what those items were in the  \nfourth quarter of \u201821 that were bad guys, and how much they were, so we know what the year over year  \ngood guy comp is g oing into this quarter.  And then, are there any new good guys, things the street  \nwouldn't know about, that you know are going to hit in the fourth quarter that get you to your Pharma  \nprofit margin target? ", "original_text": "You have  \nnot given more specifics today on that those are. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "abde3a3c559ba66f18b1828294994b4c2831b4ea73eac60475f80727a0948b50", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be8114fe-de8c-4433-89a9-b8b00e0de633", "node_type": "1", "metadata": {"window": "The Pharma comp in 4Q \u201921, you identified some good guys from last year.  You have  \nnot given more specifics today on that those are.  I think, we're all pretty hectic with earnings and  \neverything else a lot's changed in the last year.  Can you just remind us what those items were in the  \nfourth quarter of \u201821 that were bad guys, and how much they were, so we know what the year over year  \ngood guy comp is g oing into this quarter.  And then, are there any new good guys, things the street  \nwouldn't know about, that you know are going to hit in the fourth quarter that get you to your Pharma  \nprofit margin target?  Thanks very much.  \n \n Jason Hollar:  Yeah. ", "original_text": "Can you just remind us what those items were in the  \nfourth quarter of \u201821 that were bad guys, and how much they were, so we know what the year over year  \ngood guy comp is g oing into this quarter. "}, "hash": "603c4ca2ae8eab7555064dcb3899a702bab3a1e354bb465266d30307cc2c9fe4", "class_name": "RelatedNodeInfo"}}, "text": "I think, we're all pretty hectic with earnings and  \neverything else a lot's changed in the last year. ", "start_char_idx": 3152, "end_char_idx": 3255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be8114fe-de8c-4433-89a9-b8b00e0de633": {"__data__": {"id_": "be8114fe-de8c-4433-89a9-b8b00e0de633", "embedding": null, "metadata": {"window": "The Pharma comp in 4Q \u201921, you identified some good guys from last year.  You have  \nnot given more specifics today on that those are.  I think, we're all pretty hectic with earnings and  \neverything else a lot's changed in the last year.  Can you just remind us what those items were in the  \nfourth quarter of \u201821 that were bad guys, and how much they were, so we know what the year over year  \ngood guy comp is g oing into this quarter.  And then, are there any new good guys, things the street  \nwouldn't know about, that you know are going to hit in the fourth quarter that get you to your Pharma  \nprofit margin target?  Thanks very much.  \n \n Jason Hollar:  Yeah. ", "original_text": "Can you just remind us what those items were in the  \nfourth quarter of \u201821 that were bad guys, and how much they were, so we know what the year over year  \ngood guy comp is g oing into this quarter. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27978bcd-0b9f-48c6-a2d7-62be469cd07c", "node_type": "1", "metadata": {"window": "I wanted to go back to the first question, I think it was  \nCharles asked.  The Pharma comp in 4Q \u201921, you identified some good guys from last year.  You have  \nnot given more specifics today on that those are.  I think, we're all pretty hectic with earnings and  \neverything else a lot's changed in the last year.  Can you just remind us what those items were in the  \nfourth quarter of \u201821 that were bad guys, and how much they were, so we know what the year over year  \ngood guy comp is g oing into this quarter.  And then, are there any new good guys, things the street  \nwouldn't know about, that you know are going to hit in the fourth quarter that get you to your Pharma  \nprofit margin target?  Thanks very much.  \n \n", "original_text": "I think, we're all pretty hectic with earnings and  \neverything else a lot's changed in the last year. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "39701c9efbb9f57cac6db617824a2c67cf119fb7f09bbab5b8c3f853758452d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eccb05c3-d33f-41ce-ada7-3b3c56cb6e03", "node_type": "1", "metadata": {"window": "You have  \nnot given more specifics today on that those are.  I think, we're all pretty hectic with earnings and  \neverything else a lot's changed in the last year.  Can you just remind us what those items were in the  \nfourth quarter of \u201821 that were bad guys, and how much they were, so we know what the year over year  \ngood guy comp is g oing into this quarter.  And then, are there any new good guys, things the street  \nwouldn't know about, that you know are going to hit in the fourth quarter that get you to your Pharma  \nprofit margin target?  Thanks very much.  \n \n Jason Hollar:  Yeah.  The prim ary item that we referenced last Q4 was inventory adjustments. ", "original_text": "And then, are there any new good guys, things the street  \nwouldn't know about, that you know are going to hit in the fourth quarter that get you to your Pharma  \nprofit margin target? "}, "hash": "f691dbe2c341e11ac37b6da09e2fbceb7f5c299db97425081ffdc66b52a305a1", "class_name": "RelatedNodeInfo"}}, "text": "Can you just remind us what those items were in the  \nfourth quarter of \u201821 that were bad guys, and how much they were, so we know what the year over year  \ngood guy comp is g oing into this quarter. ", "start_char_idx": 3255, "end_char_idx": 3455, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eccb05c3-d33f-41ce-ada7-3b3c56cb6e03": {"__data__": {"id_": "eccb05c3-d33f-41ce-ada7-3b3c56cb6e03", "embedding": null, "metadata": {"window": "You have  \nnot given more specifics today on that those are.  I think, we're all pretty hectic with earnings and  \neverything else a lot's changed in the last year.  Can you just remind us what those items were in the  \nfourth quarter of \u201821 that were bad guys, and how much they were, so we know what the year over year  \ngood guy comp is g oing into this quarter.  And then, are there any new good guys, things the street  \nwouldn't know about, that you know are going to hit in the fourth quarter that get you to your Pharma  \nprofit margin target?  Thanks very much.  \n \n Jason Hollar:  Yeah.  The prim ary item that we referenced last Q4 was inventory adjustments. ", "original_text": "And then, are there any new good guys, things the street  \nwouldn't know about, that you know are going to hit in the fourth quarter that get you to your Pharma  \nprofit margin target? ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be8114fe-de8c-4433-89a9-b8b00e0de633", "node_type": "1", "metadata": {"window": "The Pharma comp in 4Q \u201921, you identified some good guys from last year.  You have  \nnot given more specifics today on that those are.  I think, we're all pretty hectic with earnings and  \neverything else a lot's changed in the last year.  Can you just remind us what those items were in the  \nfourth quarter of \u201821 that were bad guys, and how much they were, so we know what the year over year  \ngood guy comp is g oing into this quarter.  And then, are there any new good guys, things the street  \nwouldn't know about, that you know are going to hit in the fourth quarter that get you to your Pharma  \nprofit margin target?  Thanks very much.  \n \n Jason Hollar:  Yeah. ", "original_text": "Can you just remind us what those items were in the  \nfourth quarter of \u201821 that were bad guys, and how much they were, so we know what the year over year  \ngood guy comp is g oing into this quarter. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ba5cc64c89d93153afb32147fa2772f4e17fba9a8a610186e9ba1dea85f9e589", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3bfbe80b-5806-4d72-904e-448169c29c92", "node_type": "1", "metadata": {"window": "I think, we're all pretty hectic with earnings and  \neverything else a lot's changed in the last year.  Can you just remind us what those items were in the  \nfourth quarter of \u201821 that were bad guys, and how much they were, so we know what the year over year  \ngood guy comp is g oing into this quarter.  And then, are there any new good guys, things the street  \nwouldn't know about, that you know are going to hit in the fourth quarter that get you to your Pharma  \nprofit margin target?  Thanks very much.  \n \n Jason Hollar:  Yeah.  The prim ary item that we referenced last Q4 was inventory adjustments.  We did  \nnot provide any specific number. ", "original_text": "Thanks very much.  \n \n"}, "hash": "2c71332747fbe38cb813ba89c5c41c64ed42729e91ed65418a1ff95c6df8f336", "class_name": "RelatedNodeInfo"}}, "text": "And then, are there any new good guys, things the street  \nwouldn't know about, that you know are going to hit in the fourth quarter that get you to your Pharma  \nprofit margin target? ", "start_char_idx": 3455, "end_char_idx": 3640, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3bfbe80b-5806-4d72-904e-448169c29c92": {"__data__": {"id_": "3bfbe80b-5806-4d72-904e-448169c29c92", "embedding": null, "metadata": {"window": "I think, we're all pretty hectic with earnings and  \neverything else a lot's changed in the last year.  Can you just remind us what those items were in the  \nfourth quarter of \u201821 that were bad guys, and how much they were, so we know what the year over year  \ngood guy comp is g oing into this quarter.  And then, are there any new good guys, things the street  \nwouldn't know about, that you know are going to hit in the fourth quarter that get you to your Pharma  \nprofit margin target?  Thanks very much.  \n \n Jason Hollar:  Yeah.  The prim ary item that we referenced last Q4 was inventory adjustments.  We did  \nnot provide any specific number. ", "original_text": "Thanks very much.  \n \n", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eccb05c3-d33f-41ce-ada7-3b3c56cb6e03", "node_type": "1", "metadata": {"window": "You have  \nnot given more specifics today on that those are.  I think, we're all pretty hectic with earnings and  \neverything else a lot's changed in the last year.  Can you just remind us what those items were in the  \nfourth quarter of \u201821 that were bad guys, and how much they were, so we know what the year over year  \ngood guy comp is g oing into this quarter.  And then, are there any new good guys, things the street  \nwouldn't know about, that you know are going to hit in the fourth quarter that get you to your Pharma  \nprofit margin target?  Thanks very much.  \n \n Jason Hollar:  Yeah.  The prim ary item that we referenced last Q4 was inventory adjustments. ", "original_text": "And then, are there any new good guys, things the street  \nwouldn't know about, that you know are going to hit in the fourth quarter that get you to your Pharma  \nprofit margin target? ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "3824d26549c746f4bcbd7378b03bdc52782a81fe00abe0c9b93af37b73fb39ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e9997a7-6edc-4265-8aa8-277aae55c8dd", "node_type": "1", "metadata": {"window": "Can you just remind us what those items were in the  \nfourth quarter of \u201821 that were bad guys, and how much they were, so we know what the year over year  \ngood guy comp is g oing into this quarter.  And then, are there any new good guys, things the street  \nwouldn't know about, that you know are going to hit in the fourth quarter that get you to your Pharma  \nprofit margin target?  Thanks very much.  \n \n Jason Hollar:  Yeah.  The prim ary item that we referenced last Q4 was inventory adjustments.  We did  \nnot provide any specific number.  I think we might have referenced modest, and so it was a reasonable  \nnumber that you can look at the growth rates there and how that was impacted to pro vide a range. ", "original_text": "Jason Hollar:  Yeah. "}, "hash": "011b1524af69a9c0341678fc93b41114daf27b260d130b58e20f3a4e7c04f683", "class_name": "RelatedNodeInfo"}}, "text": "Thanks very much.  \n \n", "start_char_idx": 3640, "end_char_idx": 3662, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e9997a7-6edc-4265-8aa8-277aae55c8dd": {"__data__": {"id_": "6e9997a7-6edc-4265-8aa8-277aae55c8dd", "embedding": null, "metadata": {"window": "Can you just remind us what those items were in the  \nfourth quarter of \u201821 that were bad guys, and how much they were, so we know what the year over year  \ngood guy comp is g oing into this quarter.  And then, are there any new good guys, things the street  \nwouldn't know about, that you know are going to hit in the fourth quarter that get you to your Pharma  \nprofit margin target?  Thanks very much.  \n \n Jason Hollar:  Yeah.  The prim ary item that we referenced last Q4 was inventory adjustments.  We did  \nnot provide any specific number.  I think we might have referenced modest, and so it was a reasonable  \nnumber that you can look at the growth rates there and how that was impacted to pro vide a range. ", "original_text": "Jason Hollar:  Yeah. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3bfbe80b-5806-4d72-904e-448169c29c92", "node_type": "1", "metadata": {"window": "I think, we're all pretty hectic with earnings and  \neverything else a lot's changed in the last year.  Can you just remind us what those items were in the  \nfourth quarter of \u201821 that were bad guys, and how much they were, so we know what the year over year  \ngood guy comp is g oing into this quarter.  And then, are there any new good guys, things the street  \nwouldn't know about, that you know are going to hit in the fourth quarter that get you to your Pharma  \nprofit margin target?  Thanks very much.  \n \n Jason Hollar:  Yeah.  The prim ary item that we referenced last Q4 was inventory adjustments.  We did  \nnot provide any specific number. ", "original_text": "Thanks very much.  \n \n", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "6520fb70a35ab3d51e3dbab0fc75c594af6c3fb2cd79f22a191696516450b45a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79cd3ce9-2908-4f07-9266-80e5acae4b10", "node_type": "1", "metadata": {"window": "And then, are there any new good guys, things the street  \nwouldn't know about, that you know are going to hit in the fourth quarter that get you to your Pharma  \nprofit margin target?  Thanks very much.  \n \n Jason Hollar:  Yeah.  The prim ary item that we referenced last Q4 was inventory adjustments.  We did  \nnot provide any specific number.  I think we might have referenced modest, and so it was a reasonable  \nnumber that you can look at the growth rates there and how that was impacted to pro vide a range.  The  \nkey again is that we no longer have the headwinds of that 20, 30 million per quarter that we've seen  ", "original_text": "The prim ary item that we referenced last Q4 was inventory adjustments. "}, "hash": "fc88bfd5a11643c5479e62df1e902d32289791786ee016213abc0a954f2024ed", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  Yeah. ", "start_char_idx": 3662, "end_char_idx": 3683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79cd3ce9-2908-4f07-9266-80e5acae4b10": {"__data__": {"id_": "79cd3ce9-2908-4f07-9266-80e5acae4b10", "embedding": null, "metadata": {"window": "And then, are there any new good guys, things the street  \nwouldn't know about, that you know are going to hit in the fourth quarter that get you to your Pharma  \nprofit margin target?  Thanks very much.  \n \n Jason Hollar:  Yeah.  The prim ary item that we referenced last Q4 was inventory adjustments.  We did  \nnot provide any specific number.  I think we might have referenced modest, and so it was a reasonable  \nnumber that you can look at the growth rates there and how that was impacted to pro vide a range.  The  \nkey again is that we no longer have the headwinds of that 20, 30 million per quarter that we've seen  ", "original_text": "The prim ary item that we referenced last Q4 was inventory adjustments. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e9997a7-6edc-4265-8aa8-277aae55c8dd", "node_type": "1", "metadata": {"window": "Can you just remind us what those items were in the  \nfourth quarter of \u201821 that were bad guys, and how much they were, so we know what the year over year  \ngood guy comp is g oing into this quarter.  And then, are there any new good guys, things the street  \nwouldn't know about, that you know are going to hit in the fourth quarter that get you to your Pharma  \nprofit margin target?  Thanks very much.  \n \n Jason Hollar:  Yeah.  The prim ary item that we referenced last Q4 was inventory adjustments.  We did  \nnot provide any specific number.  I think we might have referenced modest, and so it was a reasonable  \nnumber that you can look at the growth rates there and how that was impacted to pro vide a range. ", "original_text": "Jason Hollar:  Yeah. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d8c4e566f28c540bad062033bd76bc50bb6da6dac00b2575809aeef5889d484b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "739feb68-c286-4659-8b8b-a5ecdc4a3a53", "node_type": "1", "metadata": {"window": "Thanks very much.  \n \n Jason Hollar:  Yeah.  The prim ary item that we referenced last Q4 was inventory adjustments.  We did  \nnot provide any specific number.  I think we might have referenced modest, and so it was a reasonable  \nnumber that you can look at the growth rates there and how that was impacted to pro vide a range.  The  \nkey again is that we no longer have the headwinds of that 20, 30 million per quarter that we've seen  ", "original_text": "We did  \nnot provide any specific number. "}, "hash": "390624c7a97d679e87f5bc2c1dc59428a8bc1ede7444bee023117f0270852692", "class_name": "RelatedNodeInfo"}}, "text": "The prim ary item that we referenced last Q4 was inventory adjustments. ", "start_char_idx": 3683, "end_char_idx": 3755, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "739feb68-c286-4659-8b8b-a5ecdc4a3a53": {"__data__": {"id_": "739feb68-c286-4659-8b8b-a5ecdc4a3a53", "embedding": null, "metadata": {"window": "Thanks very much.  \n \n Jason Hollar:  Yeah.  The prim ary item that we referenced last Q4 was inventory adjustments.  We did  \nnot provide any specific number.  I think we might have referenced modest, and so it was a reasonable  \nnumber that you can look at the growth rates there and how that was impacted to pro vide a range.  The  \nkey again is that we no longer have the headwinds of that 20, 30 million per quarter that we've seen  ", "original_text": "We did  \nnot provide any specific number. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79cd3ce9-2908-4f07-9266-80e5acae4b10", "node_type": "1", "metadata": {"window": "And then, are there any new good guys, things the street  \nwouldn't know about, that you know are going to hit in the fourth quarter that get you to your Pharma  \nprofit margin target?  Thanks very much.  \n \n Jason Hollar:  Yeah.  The prim ary item that we referenced last Q4 was inventory adjustments.  We did  \nnot provide any specific number.  I think we might have referenced modest, and so it was a reasonable  \nnumber that you can look at the growth rates there and how that was impacted to pro vide a range.  The  \nkey again is that we no longer have the headwinds of that 20, 30 million per quarter that we've seen  ", "original_text": "The prim ary item that we referenced last Q4 was inventory adjustments. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e07a96321f85220129f96a1766394c06235013770be013354cf8e3a6ca026679", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc15d501-22ba-4320-8a99-acf7243b1a7f", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah.  The prim ary item that we referenced last Q4 was inventory adjustments.  We did  \nnot provide any specific number.  I think we might have referenced modest, and so it was a reasonable  \nnumber that you can look at the growth rates there and how that was impacted to pro vide a range.  The  \nkey again is that we no longer have the headwinds of that 20, 30 million per quarter that we've seen  ", "original_text": "I think we might have referenced modest, and so it was a reasonable  \nnumber that you can look at the growth rates there and how that was impacted to pro vide a range. "}, "hash": "b117ee390c5408e31edde45413ed1823b7ebbd8bdf5133dd8cb00406e2050c41", "class_name": "RelatedNodeInfo"}}, "text": "We did  \nnot provide any specific number. ", "start_char_idx": 3755, "end_char_idx": 3797, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc15d501-22ba-4320-8a99-acf7243b1a7f": {"__data__": {"id_": "cc15d501-22ba-4320-8a99-acf7243b1a7f", "embedding": null, "metadata": {"window": "Jason Hollar:  Yeah.  The prim ary item that we referenced last Q4 was inventory adjustments.  We did  \nnot provide any specific number.  I think we might have referenced modest, and so it was a reasonable  \nnumber that you can look at the growth rates there and how that was impacted to pro vide a range.  The  \nkey again is that we no longer have the headwinds of that 20, 30 million per quarter that we've seen  ", "original_text": "I think we might have referenced modest, and so it was a reasonable  \nnumber that you can look at the growth rates there and how that was impacted to pro vide a range. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "739feb68-c286-4659-8b8b-a5ecdc4a3a53", "node_type": "1", "metadata": {"window": "Thanks very much.  \n \n Jason Hollar:  Yeah.  The prim ary item that we referenced last Q4 was inventory adjustments.  We did  \nnot provide any specific number.  I think we might have referenced modest, and so it was a reasonable  \nnumber that you can look at the growth rates there and how that was impacted to pro vide a range.  The  \nkey again is that we no longer have the headwinds of that 20, 30 million per quarter that we've seen  ", "original_text": "We did  \nnot provide any specific number. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "03e35878823f498d42a4016e44b43e66a008facf448497f23fc0d684325de544", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc3de07f-9b7b-4e6d-9454-3741877b84c9", "node_type": "1", "metadata": {"window": "The prim ary item that we referenced last Q4 was inventory adjustments.  We did  \nnot provide any specific number.  I think we might have referenced modest, and so it was a reasonable  \nnumber that you can look at the growth rates there and how that was impacted to pro vide a range.  The  \nkey again is that we no longer have the headwinds of that 20, 30 million per quarter that we've seen  ", "original_text": "The  \nkey again is that we no longer have the headwinds of that 20, 30 million per quarter that we've seen  "}, "hash": "775b37d3cf4ab24b4beed7910229187ad5b6b9de3f00c73b5889075aa469f193", "class_name": "RelatedNodeInfo"}}, "text": "I think we might have referenced modest, and so it was a reasonable  \nnumber that you can look at the growth rates there and how that was impacted to pro vide a range. ", "start_char_idx": 3797, "end_char_idx": 3965, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc3de07f-9b7b-4e6d-9454-3741877b84c9": {"__data__": {"id_": "dc3de07f-9b7b-4e6d-9454-3741877b84c9", "embedding": null, "metadata": {"window": "The prim ary item that we referenced last Q4 was inventory adjustments.  We did  \nnot provide any specific number.  I think we might have referenced modest, and so it was a reasonable  \nnumber that you can look at the growth rates there and how that was impacted to pro vide a range.  The  \nkey again is that we no longer have the headwinds of that 20, 30 million per quarter that we've seen  ", "original_text": "The  \nkey again is that we no longer have the headwinds of that 20, 30 million per quarter that we've seen  ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "07467b81-a385-40ce-865c-1281c22c7ed9", "node_type": "4", "metadata": {"page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4ad0f908a15aac0b82e80cc18fa3ed30e0efd337c430e530b9193c466eae9c9a", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc15d501-22ba-4320-8a99-acf7243b1a7f", "node_type": "1", "metadata": {"window": "Jason Hollar:  Yeah.  The prim ary item that we referenced last Q4 was inventory adjustments.  We did  \nnot provide any specific number.  I think we might have referenced modest, and so it was a reasonable  \nnumber that you can look at the growth rates there and how that was impacted to pro vide a range.  The  \nkey again is that we no longer have the headwinds of that 20, 30 million per quarter that we've seen  ", "original_text": "I think we might have referenced modest, and so it was a reasonable  \nnumber that you can look at the growth rates there and how that was impacted to pro vide a range. ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "244238b1bd13d03c972211534b5b0aca900c7faf6987c695611415692662a54e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "504e1e25-b638-4473-b2a4-6df478d4e05c", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \nover the first three quarters related to the IT enhancements.  And then we have had some incremental  \nvolume through, we referenced some  net new customer volume within the Pharma business that started  \nto ramp up in the third quarter and is more significant in the fourth quarter, and those would be the most  \nsignificant items that drive that year over year.  \n  \n Operator:   And we'll go ahead  and take our next question from Steven Valiquette with Barclays.  \n Steven  Valiquette:   Great . ", "original_text": " \nPage 15 of 15 \n \nover the first three quarters related to the IT enhancements. "}, "hash": "3ca7b2f57f15a7484426343d0e9e5c345b6f0069eb86bcedc46d81393cdbc8af", "class_name": "RelatedNodeInfo"}}, "text": "The  \nkey again is that we no longer have the headwinds of that 20, 30 million per quarter that we've seen  ", "start_char_idx": 3965, "end_char_idx": 4073, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "504e1e25-b638-4473-b2a4-6df478d4e05c": {"__data__": {"id_": "504e1e25-b638-4473-b2a4-6df478d4e05c", "embedding": null, "metadata": {"window": " \nPage 15 of 15 \n \nover the first three quarters related to the IT enhancements.  And then we have had some incremental  \nvolume through, we referenced some  net new customer volume within the Pharma business that started  \nto ramp up in the third quarter and is more significant in the fourth quarter, and those would be the most  \nsignificant items that drive that year over year.  \n  \n Operator:   And we'll go ahead  and take our next question from Steven Valiquette with Barclays.  \n Steven  Valiquette:   Great . ", "original_text": " \nPage 15 of 15 \n \nover the first three quarters related to the IT enhancements. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc3de07f-9b7b-4e6d-9454-3741877b84c9", "node_type": "1", "metadata": {"window": "The prim ary item that we referenced last Q4 was inventory adjustments.  We did  \nnot provide any specific number.  I think we might have referenced modest, and so it was a reasonable  \nnumber that you can look at the growth rates there and how that was impacted to pro vide a range.  The  \nkey again is that we no longer have the headwinds of that 20, 30 million per quarter that we've seen  ", "original_text": "The  \nkey again is that we no longer have the headwinds of that 20, 30 million per quarter that we've seen  ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7dc05e32ba4cf2a9b82ca7f51f5e759b9d196a7554945e4afa3943162b8184f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1b75414c-ffee-4af9-8215-d8aa4fa7f13b", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \nover the first three quarters related to the IT enhancements.  And then we have had some incremental  \nvolume through, we referenced some  net new customer volume within the Pharma business that started  \nto ramp up in the third quarter and is more significant in the fourth quarter, and those would be the most  \nsignificant items that drive that year over year.  \n  \n Operator:   And we'll go ahead  and take our next question from Steven Valiquette with Barclays.  \n Steven  Valiquette:   Great .  Thanks . ", "original_text": "And then we have had some incremental  \nvolume through, we referenced some  net new customer volume within the Pharma business that started  \nto ramp up in the third quarter and is more significant in the fourth quarter, and those would be the most  \nsignificant items that drive that year over year.  \n  \n"}, "hash": "ba0576b6730ea4b44295da4d4aad00717a2e9b9bfa9ff2471753a377af7c848e", "class_name": "RelatedNodeInfo"}}, "text": " \nPage 15 of 15 \n \nover the first three quarters related to the IT enhancements. ", "start_char_idx": 0, "end_char_idx": 81, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1b75414c-ffee-4af9-8215-d8aa4fa7f13b": {"__data__": {"id_": "1b75414c-ffee-4af9-8215-d8aa4fa7f13b", "embedding": null, "metadata": {"window": " \nPage 15 of 15 \n \nover the first three quarters related to the IT enhancements.  And then we have had some incremental  \nvolume through, we referenced some  net new customer volume within the Pharma business that started  \nto ramp up in the third quarter and is more significant in the fourth quarter, and those would be the most  \nsignificant items that drive that year over year.  \n  \n Operator:   And we'll go ahead  and take our next question from Steven Valiquette with Barclays.  \n Steven  Valiquette:   Great .  Thanks . ", "original_text": "And then we have had some incremental  \nvolume through, we referenced some  net new customer volume within the Pharma business that started  \nto ramp up in the third quarter and is more significant in the fourth quarter, and those would be the most  \nsignificant items that drive that year over year.  \n  \n", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "504e1e25-b638-4473-b2a4-6df478d4e05c", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \nover the first three quarters related to the IT enhancements.  And then we have had some incremental  \nvolume through, we referenced some  net new customer volume within the Pharma business that started  \nto ramp up in the third quarter and is more significant in the fourth quarter, and those would be the most  \nsignificant items that drive that year over year.  \n  \n Operator:   And we'll go ahead  and take our next question from Steven Valiquette with Barclays.  \n Steven  Valiquette:   Great . ", "original_text": " \nPage 15 of 15 \n \nover the first three quarters related to the IT enhancements. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "45b664f47a49b332f17ed076a86d3785cba4ad2323156f6059b3455cfff32107", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1ba49b06-122f-481e-a499-d3ae09d2f471", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \nover the first three quarters related to the IT enhancements.  And then we have had some incremental  \nvolume through, we referenced some  net new customer volume within the Pharma business that started  \nto ramp up in the third quarter and is more significant in the fourth quarter, and those would be the most  \nsignificant items that drive that year over year.  \n  \n Operator:   And we'll go ahead  and take our next question from Steven Valiquette with Barclays.  \n Steven  Valiquette:   Great .  Thanks .  So regarding the elevated operating expenses in the Pharma  \nsegment exiting \u201822 and into the first half of fiscal \u201823, I guess it's still not clear which elevated cost  \ncategories are able to pass through to customers versus which ones you're absorbing in your own  \nmargins. ", "original_text": "Operator:   And we'll go ahead  and take our next question from Steven Valiquette with Barclays.  \n"}, "hash": "e597a57c74dbaa82f5176dd7b55fc66847761b77e1804c5af818f13d56c36802", "class_name": "RelatedNodeInfo"}}, "text": "And then we have had some incremental  \nvolume through, we referenced some  net new customer volume within the Pharma business that started  \nto ramp up in the third quarter and is more significant in the fourth quarter, and those would be the most  \nsignificant items that drive that year over year.  \n  \n", "start_char_idx": 81, "end_char_idx": 387, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1ba49b06-122f-481e-a499-d3ae09d2f471": {"__data__": {"id_": "1ba49b06-122f-481e-a499-d3ae09d2f471", "embedding": null, "metadata": {"window": " \nPage 15 of 15 \n \nover the first three quarters related to the IT enhancements.  And then we have had some incremental  \nvolume through, we referenced some  net new customer volume within the Pharma business that started  \nto ramp up in the third quarter and is more significant in the fourth quarter, and those would be the most  \nsignificant items that drive that year over year.  \n  \n Operator:   And we'll go ahead  and take our next question from Steven Valiquette with Barclays.  \n Steven  Valiquette:   Great .  Thanks .  So regarding the elevated operating expenses in the Pharma  \nsegment exiting \u201822 and into the first half of fiscal \u201823, I guess it's still not clear which elevated cost  \ncategories are able to pass through to customers versus which ones you're absorbing in your own  \nmargins. ", "original_text": "Operator:   And we'll go ahead  and take our next question from Steven Valiquette with Barclays.  \n", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1b75414c-ffee-4af9-8215-d8aa4fa7f13b", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \nover the first three quarters related to the IT enhancements.  And then we have had some incremental  \nvolume through, we referenced some  net new customer volume within the Pharma business that started  \nto ramp up in the third quarter and is more significant in the fourth quarter, and those would be the most  \nsignificant items that drive that year over year.  \n  \n Operator:   And we'll go ahead  and take our next question from Steven Valiquette with Barclays.  \n Steven  Valiquette:   Great .  Thanks . ", "original_text": "And then we have had some incremental  \nvolume through, we referenced some  net new customer volume within the Pharma business that started  \nto ramp up in the third quarter and is more significant in the fourth quarter, and those would be the most  \nsignificant items that drive that year over year.  \n  \n", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "709aad4597398c4dfdd8658015136a92baabb34f78d6b0b0fdba34544693ad1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "73ce99ae-5525-43f6-9526-8d103a2242d4", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \nover the first three quarters related to the IT enhancements.  And then we have had some incremental  \nvolume through, we referenced some  net new customer volume within the Pharma business that started  \nto ramp up in the third quarter and is more significant in the fourth quarter, and those would be the most  \nsignificant items that drive that year over year.  \n  \n Operator:   And we'll go ahead  and take our next question from Steven Valiquette with Barclays.  \n Steven  Valiquette:   Great .  Thanks .  So regarding the elevated operating expenses in the Pharma  \nsegment exiting \u201822 and into the first half of fiscal \u201823, I guess it's still not clear which elevated cost  \ncategories are able to pass through to customers versus which ones you're absorbing in your own  \nmargins.  When thinking about fuel costs, other tra nsportation costs, higher labor expense, etc. ", "original_text": "Steven  Valiquette:   Great . "}, "hash": "d3a6908a988bed1003c7e662a60d2690a8c5ddf5ef293b343ddc9dbc394de959", "class_name": "RelatedNodeInfo"}}, "text": "Operator:   And we'll go ahead  and take our next question from Steven Valiquette with Barclays.  \n", "start_char_idx": 387, "end_char_idx": 486, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "73ce99ae-5525-43f6-9526-8d103a2242d4": {"__data__": {"id_": "73ce99ae-5525-43f6-9526-8d103a2242d4", "embedding": null, "metadata": {"window": " \nPage 15 of 15 \n \nover the first three quarters related to the IT enhancements.  And then we have had some incremental  \nvolume through, we referenced some  net new customer volume within the Pharma business that started  \nto ramp up in the third quarter and is more significant in the fourth quarter, and those would be the most  \nsignificant items that drive that year over year.  \n  \n Operator:   And we'll go ahead  and take our next question from Steven Valiquette with Barclays.  \n Steven  Valiquette:   Great .  Thanks .  So regarding the elevated operating expenses in the Pharma  \nsegment exiting \u201822 and into the first half of fiscal \u201823, I guess it's still not clear which elevated cost  \ncategories are able to pass through to customers versus which ones you're absorbing in your own  \nmargins.  When thinking about fuel costs, other tra nsportation costs, higher labor expense, etc. ", "original_text": "Steven  Valiquette:   Great . ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1ba49b06-122f-481e-a499-d3ae09d2f471", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \nover the first three quarters related to the IT enhancements.  And then we have had some incremental  \nvolume through, we referenced some  net new customer volume within the Pharma business that started  \nto ramp up in the third quarter and is more significant in the fourth quarter, and those would be the most  \nsignificant items that drive that year over year.  \n  \n Operator:   And we'll go ahead  and take our next question from Steven Valiquette with Barclays.  \n Steven  Valiquette:   Great .  Thanks .  So regarding the elevated operating expenses in the Pharma  \nsegment exiting \u201822 and into the first half of fiscal \u201823, I guess it's still not clear which elevated cost  \ncategories are able to pass through to customers versus which ones you're absorbing in your own  \nmargins. ", "original_text": "Operator:   And we'll go ahead  and take our next question from Steven Valiquette with Barclays.  \n", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "92ae71302088eb82eda67ff03521f654301cc05bb3fddbbfb2ddcf01c795b6f1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3044b4f5-7349-4061-bb6f-a62290445e94", "node_type": "1", "metadata": {"window": "And then we have had some incremental  \nvolume through, we referenced some  net new customer volume within the Pharma business that started  \nto ramp up in the third quarter and is more significant in the fourth quarter, and those would be the most  \nsignificant items that drive that year over year.  \n  \n Operator:   And we'll go ahead  and take our next question from Steven Valiquette with Barclays.  \n Steven  Valiquette:   Great .  Thanks .  So regarding the elevated operating expenses in the Pharma  \nsegment exiting \u201822 and into the first half of fiscal \u201823, I guess it's still not clear which elevated cost  \ncategories are able to pass through to customers versus which ones you're absorbing in your own  \nmargins.  When thinking about fuel costs, other tra nsportation costs, higher labor expense, etc.  So I  \nguess just to confirm, in which cost categories are you seeing the greatest increase in operating  \nexpenses that you're not able to pass through to the Pharma customers? ", "original_text": "Thanks . "}, "hash": "cc68425f5b95943e3e2286b4625e8bf6f95837581e63c76573679e95c476d486", "class_name": "RelatedNodeInfo"}}, "text": "Steven  Valiquette:   Great . ", "start_char_idx": 486, "end_char_idx": 516, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3044b4f5-7349-4061-bb6f-a62290445e94": {"__data__": {"id_": "3044b4f5-7349-4061-bb6f-a62290445e94", "embedding": null, "metadata": {"window": "And then we have had some incremental  \nvolume through, we referenced some  net new customer volume within the Pharma business that started  \nto ramp up in the third quarter and is more significant in the fourth quarter, and those would be the most  \nsignificant items that drive that year over year.  \n  \n Operator:   And we'll go ahead  and take our next question from Steven Valiquette with Barclays.  \n Steven  Valiquette:   Great .  Thanks .  So regarding the elevated operating expenses in the Pharma  \nsegment exiting \u201822 and into the first half of fiscal \u201823, I guess it's still not clear which elevated cost  \ncategories are able to pass through to customers versus which ones you're absorbing in your own  \nmargins.  When thinking about fuel costs, other tra nsportation costs, higher labor expense, etc.  So I  \nguess just to confirm, in which cost categories are you seeing the greatest increase in operating  \nexpenses that you're not able to pass through to the Pharma customers? ", "original_text": "Thanks . ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "73ce99ae-5525-43f6-9526-8d103a2242d4", "node_type": "1", "metadata": {"window": " \nPage 15 of 15 \n \nover the first three quarters related to the IT enhancements.  And then we have had some incremental  \nvolume through, we referenced some  net new customer volume within the Pharma business that started  \nto ramp up in the third quarter and is more significant in the fourth quarter, and those would be the most  \nsignificant items that drive that year over year.  \n  \n Operator:   And we'll go ahead  and take our next question from Steven Valiquette with Barclays.  \n Steven  Valiquette:   Great .  Thanks .  So regarding the elevated operating expenses in the Pharma  \nsegment exiting \u201822 and into the first half of fiscal \u201823, I guess it's still not clear which elevated cost  \ncategories are able to pass through to customers versus which ones you're absorbing in your own  \nmargins.  When thinking about fuel costs, other tra nsportation costs, higher labor expense, etc. ", "original_text": "Steven  Valiquette:   Great . ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5cdfc613757afb4707ad8f35f8f5526c7010a772e8c64ea0318b9854c8b15546", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c19c99ec-e97e-4512-8c0e-40068799dbdf", "node_type": "1", "metadata": {"window": "Operator:   And we'll go ahead  and take our next question from Steven Valiquette with Barclays.  \n Steven  Valiquette:   Great .  Thanks .  So regarding the elevated operating expenses in the Pharma  \nsegment exiting \u201822 and into the first half of fiscal \u201823, I guess it's still not clear which elevated cost  \ncategories are able to pass through to customers versus which ones you're absorbing in your own  \nmargins.  When thinking about fuel costs, other tra nsportation costs, higher labor expense, etc.  So I  \nguess just to confirm, in which cost categories are you seeing the greatest increase in operating  \nexpenses that you're not able to pass through to the Pharma customers?  Thanks.  \n \n", "original_text": "So regarding the elevated operating expenses in the Pharma  \nsegment exiting \u201822 and into the first half of fiscal \u201823, I guess it's still not clear which elevated cost  \ncategories are able to pass through to customers versus which ones you're absorbing in your own  \nmargins. "}, "hash": "845fef3fa8bd35440a7c0908413347c79e705ac17739f19bfc674d1073cb5440", "class_name": "RelatedNodeInfo"}}, "text": "Thanks . ", "start_char_idx": 516, "end_char_idx": 525, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c19c99ec-e97e-4512-8c0e-40068799dbdf": {"__data__": {"id_": "c19c99ec-e97e-4512-8c0e-40068799dbdf", "embedding": null, "metadata": {"window": "Operator:   And we'll go ahead  and take our next question from Steven Valiquette with Barclays.  \n Steven  Valiquette:   Great .  Thanks .  So regarding the elevated operating expenses in the Pharma  \nsegment exiting \u201822 and into the first half of fiscal \u201823, I guess it's still not clear which elevated cost  \ncategories are able to pass through to customers versus which ones you're absorbing in your own  \nmargins.  When thinking about fuel costs, other tra nsportation costs, higher labor expense, etc.  So I  \nguess just to confirm, in which cost categories are you seeing the greatest increase in operating  \nexpenses that you're not able to pass through to the Pharma customers?  Thanks.  \n \n", "original_text": "So regarding the elevated operating expenses in the Pharma  \nsegment exiting \u201822 and into the first half of fiscal \u201823, I guess it's still not clear which elevated cost  \ncategories are able to pass through to customers versus which ones you're absorbing in your own  \nmargins. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3044b4f5-7349-4061-bb6f-a62290445e94", "node_type": "1", "metadata": {"window": "And then we have had some incremental  \nvolume through, we referenced some  net new customer volume within the Pharma business that started  \nto ramp up in the third quarter and is more significant in the fourth quarter, and those would be the most  \nsignificant items that drive that year over year.  \n  \n Operator:   And we'll go ahead  and take our next question from Steven Valiquette with Barclays.  \n Steven  Valiquette:   Great .  Thanks .  So regarding the elevated operating expenses in the Pharma  \nsegment exiting \u201822 and into the first half of fiscal \u201823, I guess it's still not clear which elevated cost  \ncategories are able to pass through to customers versus which ones you're absorbing in your own  \nmargins.  When thinking about fuel costs, other tra nsportation costs, higher labor expense, etc.  So I  \nguess just to confirm, in which cost categories are you seeing the greatest increase in operating  \nexpenses that you're not able to pass through to the Pharma customers? ", "original_text": "Thanks . ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "7c554a25aa5d31398cf1657356891fec0d246435bc2fbe73d138c3e11d2a859a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "43cf1f18-edca-4e2e-8d49-eeb03ebbce0a", "node_type": "1", "metadata": {"window": "Steven  Valiquette:   Great .  Thanks .  So regarding the elevated operating expenses in the Pharma  \nsegment exiting \u201822 and into the first half of fiscal \u201823, I guess it's still not clear which elevated cost  \ncategories are able to pass through to customers versus which ones you're absorbing in your own  \nmargins.  When thinking about fuel costs, other tra nsportation costs, higher labor expense, etc.  So I  \nguess just to confirm, in which cost categories are you seeing the greatest increase in operating  \nexpenses that you're not able to pass through to the Pharma customers?  Thanks.  \n \n Mike Kaufmann:  Yeah. ", "original_text": "When thinking about fuel costs, other tra nsportation costs, higher labor expense, etc. "}, "hash": "b72c28d3df414935bd026b18d6c565e8967f35b644217a9a2fc058a5a0cad51c", "class_name": "RelatedNodeInfo"}}, "text": "So regarding the elevated operating expenses in the Pharma  \nsegment exiting \u201822 and into the first half of fiscal \u201823, I guess it's still not clear which elevated cost  \ncategories are able to pass through to customers versus which ones you're absorbing in your own  \nmargins. ", "start_char_idx": 525, "end_char_idx": 803, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "43cf1f18-edca-4e2e-8d49-eeb03ebbce0a": {"__data__": {"id_": "43cf1f18-edca-4e2e-8d49-eeb03ebbce0a", "embedding": null, "metadata": {"window": "Steven  Valiquette:   Great .  Thanks .  So regarding the elevated operating expenses in the Pharma  \nsegment exiting \u201822 and into the first half of fiscal \u201823, I guess it's still not clear which elevated cost  \ncategories are able to pass through to customers versus which ones you're absorbing in your own  \nmargins.  When thinking about fuel costs, other tra nsportation costs, higher labor expense, etc.  So I  \nguess just to confirm, in which cost categories are you seeing the greatest increase in operating  \nexpenses that you're not able to pass through to the Pharma customers?  Thanks.  \n \n Mike Kaufmann:  Yeah. ", "original_text": "When thinking about fuel costs, other tra nsportation costs, higher labor expense, etc. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c19c99ec-e97e-4512-8c0e-40068799dbdf", "node_type": "1", "metadata": {"window": "Operator:   And we'll go ahead  and take our next question from Steven Valiquette with Barclays.  \n Steven  Valiquette:   Great .  Thanks .  So regarding the elevated operating expenses in the Pharma  \nsegment exiting \u201822 and into the first half of fiscal \u201823, I guess it's still not clear which elevated cost  \ncategories are able to pass through to customers versus which ones you're absorbing in your own  \nmargins.  When thinking about fuel costs, other tra nsportation costs, higher labor expense, etc.  So I  \nguess just to confirm, in which cost categories are you seeing the greatest increase in operating  \nexpenses that you're not able to pass through to the Pharma customers?  Thanks.  \n \n", "original_text": "So regarding the elevated operating expenses in the Pharma  \nsegment exiting \u201822 and into the first half of fiscal \u201823, I guess it's still not clear which elevated cost  \ncategories are able to pass through to customers versus which ones you're absorbing in your own  \nmargins. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d66e5724680ba0b62f5208837cbbd572e185ed164d648d78ec9b8e576f88a221", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4cb3e197-955c-4cc6-aa1a-b1b836f22f3a", "node_type": "1", "metadata": {"window": "Thanks .  So regarding the elevated operating expenses in the Pharma  \nsegment exiting \u201822 and into the first half of fiscal \u201823, I guess it's still not clear which elevated cost  \ncategories are able to pass through to customers versus which ones you're absorbing in your own  \nmargins.  When thinking about fuel costs, other tra nsportation costs, higher labor expense, etc.  So I  \nguess just to confirm, in which cost categories are you seeing the greatest increase in operating  \nexpenses that you're not able to pass through to the Pharma customers?  Thanks.  \n \n Mike Kaufmann:  Yeah.  I would say in general, the majority of these are not items that we can pass  \nthrough. ", "original_text": "So I  \nguess just to confirm, in which cost categories are you seeing the greatest increase in operating  \nexpenses that you're not able to pass through to the Pharma customers? "}, "hash": "f699d0dfbf0c1a40a0fe63205dd127f11c19a19ffbaaf17dcc603f7cd8d44bfd", "class_name": "RelatedNodeInfo"}}, "text": "When thinking about fuel costs, other tra nsportation costs, higher labor expense, etc. ", "start_char_idx": 803, "end_char_idx": 891, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4cb3e197-955c-4cc6-aa1a-b1b836f22f3a": {"__data__": {"id_": "4cb3e197-955c-4cc6-aa1a-b1b836f22f3a", "embedding": null, "metadata": {"window": "Thanks .  So regarding the elevated operating expenses in the Pharma  \nsegment exiting \u201822 and into the first half of fiscal \u201823, I guess it's still not clear which elevated cost  \ncategories are able to pass through to customers versus which ones you're absorbing in your own  \nmargins.  When thinking about fuel costs, other tra nsportation costs, higher labor expense, etc.  So I  \nguess just to confirm, in which cost categories are you seeing the greatest increase in operating  \nexpenses that you're not able to pass through to the Pharma customers?  Thanks.  \n \n Mike Kaufmann:  Yeah.  I would say in general, the majority of these are not items that we can pass  \nthrough. ", "original_text": "So I  \nguess just to confirm, in which cost categories are you seeing the greatest increase in operating  \nexpenses that you're not able to pass through to the Pharma customers? ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "43cf1f18-edca-4e2e-8d49-eeb03ebbce0a", "node_type": "1", "metadata": {"window": "Steven  Valiquette:   Great .  Thanks .  So regarding the elevated operating expenses in the Pharma  \nsegment exiting \u201822 and into the first half of fiscal \u201823, I guess it's still not clear which elevated cost  \ncategories are able to pass through to customers versus which ones you're absorbing in your own  \nmargins.  When thinking about fuel costs, other tra nsportation costs, higher labor expense, etc.  So I  \nguess just to confirm, in which cost categories are you seeing the greatest increase in operating  \nexpenses that you're not able to pass through to the Pharma customers?  Thanks.  \n \n Mike Kaufmann:  Yeah. ", "original_text": "When thinking about fuel costs, other tra nsportation costs, higher labor expense, etc. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "243530cfbeefa31159557f20b001807586d124c2e9f7577f2e8c51179a3a5b25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54c99caa-5e52-4e81-b341-574bd7c7ef6f", "node_type": "1", "metadata": {"window": "So regarding the elevated operating expenses in the Pharma  \nsegment exiting \u201822 and into the first half of fiscal \u201823, I guess it's still not clear which elevated cost  \ncategories are able to pass through to customers versus which ones you're absorbing in your own  \nmargins.  When thinking about fuel costs, other tra nsportation costs, higher labor expense, etc.  So I  \nguess just to confirm, in which cost categories are you seeing the greatest increase in operating  \nexpenses that you're not able to pass through to the Pharma customers?  Thanks.  \n \n Mike Kaufmann:  Yeah.  I would say in general, the majority of these are not items that we can pass  \nthrough.  There are opportunities on fuel surcharges for sure, as those remain elevated to pass those  \nthrough. ", "original_text": "Thanks.  \n \n"}, "hash": "24d211e235382bd8031ed957659e23fdc8c584775a7adc2f12989eed3a634124", "class_name": "RelatedNodeInfo"}}, "text": "So I  \nguess just to confirm, in which cost categories are you seeing the greatest increase in operating  \nexpenses that you're not able to pass through to the Pharma customers? ", "start_char_idx": 891, "end_char_idx": 1069, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54c99caa-5e52-4e81-b341-574bd7c7ef6f": {"__data__": {"id_": "54c99caa-5e52-4e81-b341-574bd7c7ef6f", "embedding": null, "metadata": {"window": "So regarding the elevated operating expenses in the Pharma  \nsegment exiting \u201822 and into the first half of fiscal \u201823, I guess it's still not clear which elevated cost  \ncategories are able to pass through to customers versus which ones you're absorbing in your own  \nmargins.  When thinking about fuel costs, other tra nsportation costs, higher labor expense, etc.  So I  \nguess just to confirm, in which cost categories are you seeing the greatest increase in operating  \nexpenses that you're not able to pass through to the Pharma customers?  Thanks.  \n \n Mike Kaufmann:  Yeah.  I would say in general, the majority of these are not items that we can pass  \nthrough.  There are opportunities on fuel surcharges for sure, as those remain elevated to pass those  \nthrough. ", "original_text": "Thanks.  \n \n", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4cb3e197-955c-4cc6-aa1a-b1b836f22f3a", "node_type": "1", "metadata": {"window": "Thanks .  So regarding the elevated operating expenses in the Pharma  \nsegment exiting \u201822 and into the first half of fiscal \u201823, I guess it's still not clear which elevated cost  \ncategories are able to pass through to customers versus which ones you're absorbing in your own  \nmargins.  When thinking about fuel costs, other tra nsportation costs, higher labor expense, etc.  So I  \nguess just to confirm, in which cost categories are you seeing the greatest increase in operating  \nexpenses that you're not able to pass through to the Pharma customers?  Thanks.  \n \n Mike Kaufmann:  Yeah.  I would say in general, the majority of these are not items that we can pass  \nthrough. ", "original_text": "So I  \nguess just to confirm, in which cost categories are you seeing the greatest increase in operating  \nexpenses that you're not able to pass through to the Pharma customers? ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "86bd78ae81afaa4d86525cfb0846b8e17b1a97d4af917b7129912d6ac173e41c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98f03308-dfdc-4677-83cd-faf9d322b65b", "node_type": "1", "metadata": {"window": "When thinking about fuel costs, other tra nsportation costs, higher labor expense, etc.  So I  \nguess just to confirm, in which cost categories are you seeing the greatest increase in operating  \nexpenses that you're not able to pass through to the Pharma customers?  Thanks.  \n \n Mike Kaufmann:  Yeah.  I would say in general, the majority of these are not items that we can pass  \nthrough.  There are opportunities on fuel surcharges for sure, as those remain elevated to pass those  \nthrough.  But I would remind you there was a couple other things. ", "original_text": "Mike Kaufmann:  Yeah. "}, "hash": "3d0567713c37e1e6a9e15321ecdb6934231318708a710bc5070b52535d5ccabd", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n \n", "start_char_idx": 1069, "end_char_idx": 1081, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98f03308-dfdc-4677-83cd-faf9d322b65b": {"__data__": {"id_": "98f03308-dfdc-4677-83cd-faf9d322b65b", "embedding": null, "metadata": {"window": "When thinking about fuel costs, other tra nsportation costs, higher labor expense, etc.  So I  \nguess just to confirm, in which cost categories are you seeing the greatest increase in operating  \nexpenses that you're not able to pass through to the Pharma customers?  Thanks.  \n \n Mike Kaufmann:  Yeah.  I would say in general, the majority of these are not items that we can pass  \nthrough.  There are opportunities on fuel surcharges for sure, as those remain elevated to pass those  \nthrough.  But I would remind you there was a couple other things. ", "original_text": "Mike Kaufmann:  Yeah. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54c99caa-5e52-4e81-b341-574bd7c7ef6f", "node_type": "1", "metadata": {"window": "So regarding the elevated operating expenses in the Pharma  \nsegment exiting \u201822 and into the first half of fiscal \u201823, I guess it's still not clear which elevated cost  \ncategories are able to pass through to customers versus which ones you're absorbing in your own  \nmargins.  When thinking about fuel costs, other tra nsportation costs, higher labor expense, etc.  So I  \nguess just to confirm, in which cost categories are you seeing the greatest increase in operating  \nexpenses that you're not able to pass through to the Pharma customers?  Thanks.  \n \n Mike Kaufmann:  Yeah.  I would say in general, the majority of these are not items that we can pass  \nthrough.  There are opportunities on fuel surcharges for sure, as those remain elevated to pass those  \nthrough. ", "original_text": "Thanks.  \n \n", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c693dc8faa7c7f624721131e85bda26d4798f36703f86b9bf03633f22ce1a375", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ea66318-3fce-430f-8f38-b347a110c6c6", "node_type": "1", "metadata": {"window": "So I  \nguess just to confirm, in which cost categories are you seeing the greatest increase in operating  \nexpenses that you're not able to pass through to the Pharma customers?  Thanks.  \n \n Mike Kaufmann:  Yeah.  I would say in general, the majority of these are not items that we can pass  \nthrough.  There are opportunities on fuel surcharges for sure, as those remain elevated to pass those  \nthrough.  But I would remind you there was a couple other things.  Some of these  costs were also focused  \nmore on the third quarter, such as we did roll out just a few weekends ago, the final rollout of our  \nmultiyear Piedmont project. ", "original_text": "I would say in general, the majority of these are not items that we can pass  \nthrough. "}, "hash": "d4b013ed0d029a84d32ff687eeafc16c89a1af4167de12758c252bc0e216f15d", "class_name": "RelatedNodeInfo"}}, "text": "Mike Kaufmann:  Yeah. ", "start_char_idx": 1081, "end_char_idx": 1103, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ea66318-3fce-430f-8f38-b347a110c6c6": {"__data__": {"id_": "5ea66318-3fce-430f-8f38-b347a110c6c6", "embedding": null, "metadata": {"window": "So I  \nguess just to confirm, in which cost categories are you seeing the greatest increase in operating  \nexpenses that you're not able to pass through to the Pharma customers?  Thanks.  \n \n Mike Kaufmann:  Yeah.  I would say in general, the majority of these are not items that we can pass  \nthrough.  There are opportunities on fuel surcharges for sure, as those remain elevated to pass those  \nthrough.  But I would remind you there was a couple other things.  Some of these  costs were also focused  \nmore on the third quarter, such as we did roll out just a few weekends ago, the final rollout of our  \nmultiyear Piedmont project. ", "original_text": "I would say in general, the majority of these are not items that we can pass  \nthrough. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98f03308-dfdc-4677-83cd-faf9d322b65b", "node_type": "1", "metadata": {"window": "When thinking about fuel costs, other tra nsportation costs, higher labor expense, etc.  So I  \nguess just to confirm, in which cost categories are you seeing the greatest increase in operating  \nexpenses that you're not able to pass through to the Pharma customers?  Thanks.  \n \n Mike Kaufmann:  Yeah.  I would say in general, the majority of these are not items that we can pass  \nthrough.  There are opportunities on fuel surcharges for sure, as those remain elevated to pass those  \nthrough.  But I would remind you there was a couple other things. ", "original_text": "Mike Kaufmann:  Yeah. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e888b29313d5846e764dcffa8e385f52ac95c4a5ae038b3217b939a6573473de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be5e9152-5190-459d-a7eb-8ea5f33fe0c3", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Mike Kaufmann:  Yeah.  I would say in general, the majority of these are not items that we can pass  \nthrough.  There are opportunities on fuel surcharges for sure, as those remain elevated to pass those  \nthrough.  But I would remind you there was a couple other things.  Some of these  costs were also focused  \nmore on the third quarter, such as we did roll out just a few weekends ago, the final rollout of our  \nmultiyear Piedmont project.  So we've had some rollout costs and some making sure that we do that  \nright in the quarter. ", "original_text": "There are opportunities on fuel surcharges for sure, as those remain elevated to pass those  \nthrough. "}, "hash": "d58184b2bc6f945d023501c09005faac79c7cab180e259be43e8f23db5d9446e", "class_name": "RelatedNodeInfo"}}, "text": "I would say in general, the majority of these are not items that we can pass  \nthrough. ", "start_char_idx": 1103, "end_char_idx": 1191, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be5e9152-5190-459d-a7eb-8ea5f33fe0c3": {"__data__": {"id_": "be5e9152-5190-459d-a7eb-8ea5f33fe0c3", "embedding": null, "metadata": {"window": "Thanks.  \n \n Mike Kaufmann:  Yeah.  I would say in general, the majority of these are not items that we can pass  \nthrough.  There are opportunities on fuel surcharges for sure, as those remain elevated to pass those  \nthrough.  But I would remind you there was a couple other things.  Some of these  costs were also focused  \nmore on the third quarter, such as we did roll out just a few weekends ago, the final rollout of our  \nmultiyear Piedmont project.  So we've had some rollout costs and some making sure that we do that  \nright in the quarter. ", "original_text": "There are opportunities on fuel surcharges for sure, as those remain elevated to pass those  \nthrough. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ea66318-3fce-430f-8f38-b347a110c6c6", "node_type": "1", "metadata": {"window": "So I  \nguess just to confirm, in which cost categories are you seeing the greatest increase in operating  \nexpenses that you're not able to pass through to the Pharma customers?  Thanks.  \n \n Mike Kaufmann:  Yeah.  I would say in general, the majority of these are not items that we can pass  \nthrough.  There are opportunities on fuel surcharges for sure, as those remain elevated to pass those  \nthrough.  But I would remind you there was a couple other things.  Some of these  costs were also focused  \nmore on the third quarter, such as we did roll out just a few weekends ago, the final rollout of our  \nmultiyear Piedmont project. ", "original_text": "I would say in general, the majority of these are not items that we can pass  \nthrough. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "43a967a8d6a0638f5b507e932326edfde053bf15073e8c8967876b06e81d4c47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "19cc2716-0083-4fba-8f31-5dfdc9a1164c", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yeah.  I would say in general, the majority of these are not items that we can pass  \nthrough.  There are opportunities on fuel surcharges for sure, as those remain elevated to pass those  \nthrough.  But I would remind you there was a couple other things.  Some of these  costs were also focused  \nmore on the third quarter, such as we did roll out just a few weekends ago, the final rollout of our  \nmultiyear Piedmont project.  So we've had some rollout costs and some making sure that we do that  \nright in the quarter.  We onboa rded some new customers during the quarter and there's some initial  \ncosts there that we also incurred during the quarter. ", "original_text": "But I would remind you there was a couple other things. "}, "hash": "a09b0476ad5a72ada1f8d32612f0541d3214786c8220bce474be6760d9a959b2", "class_name": "RelatedNodeInfo"}}, "text": "There are opportunities on fuel surcharges for sure, as those remain elevated to pass those  \nthrough. ", "start_char_idx": 1191, "end_char_idx": 1294, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "19cc2716-0083-4fba-8f31-5dfdc9a1164c": {"__data__": {"id_": "19cc2716-0083-4fba-8f31-5dfdc9a1164c", "embedding": null, "metadata": {"window": "Mike Kaufmann:  Yeah.  I would say in general, the majority of these are not items that we can pass  \nthrough.  There are opportunities on fuel surcharges for sure, as those remain elevated to pass those  \nthrough.  But I would remind you there was a couple other things.  Some of these  costs were also focused  \nmore on the third quarter, such as we did roll out just a few weekends ago, the final rollout of our  \nmultiyear Piedmont project.  So we've had some rollout costs and some making sure that we do that  \nright in the quarter.  We onboa rded some new customers during the quarter and there's some initial  \ncosts there that we also incurred during the quarter. ", "original_text": "But I would remind you there was a couple other things. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be5e9152-5190-459d-a7eb-8ea5f33fe0c3", "node_type": "1", "metadata": {"window": "Thanks.  \n \n Mike Kaufmann:  Yeah.  I would say in general, the majority of these are not items that we can pass  \nthrough.  There are opportunities on fuel surcharges for sure, as those remain elevated to pass those  \nthrough.  But I would remind you there was a couple other things.  Some of these  costs were also focused  \nmore on the third quarter, such as we did roll out just a few weekends ago, the final rollout of our  \nmultiyear Piedmont project.  So we've had some rollout costs and some making sure that we do that  \nright in the quarter. ", "original_text": "There are opportunities on fuel surcharges for sure, as those remain elevated to pass those  \nthrough. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d09805456ad10245f9842664ff4c20e00b91cf3af35a1361a841e30dfcdc9fd8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7557406-3fbf-47c7-a63d-90aa8a4b1009", "node_type": "1", "metadata": {"window": "I would say in general, the majority of these are not items that we can pass  \nthrough.  There are opportunities on fuel surcharges for sure, as those remain elevated to pass those  \nthrough.  But I would remind you there was a couple other things.  Some of these  costs were also focused  \nmore on the third quarter, such as we did roll out just a few weekends ago, the final rollout of our  \nmultiyear Piedmont project.  So we've had some rollout costs and some making sure that we do that  \nright in the quarter.  We onboa rded some new customers during the quarter and there's some initial  \ncosts there that we also incurred during the quarter.  So I would say that the bucket is there's small  \namount that's passed through to the customers. ", "original_text": "Some of these  costs were also focused  \nmore on the third quarter, such as we did roll out just a few weekends ago, the final rollout of our  \nmultiyear Piedmont project. "}, "hash": "a47f44d7f4395af6e71fc164496a4a8a1d9dc58be15f0470c7bdb0186321ecf9", "class_name": "RelatedNodeInfo"}}, "text": "But I would remind you there was a couple other things. ", "start_char_idx": 1294, "end_char_idx": 1350, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7557406-3fbf-47c7-a63d-90aa8a4b1009": {"__data__": {"id_": "b7557406-3fbf-47c7-a63d-90aa8a4b1009", "embedding": null, "metadata": {"window": "I would say in general, the majority of these are not items that we can pass  \nthrough.  There are opportunities on fuel surcharges for sure, as those remain elevated to pass those  \nthrough.  But I would remind you there was a couple other things.  Some of these  costs were also focused  \nmore on the third quarter, such as we did roll out just a few weekends ago, the final rollout of our  \nmultiyear Piedmont project.  So we've had some rollout costs and some making sure that we do that  \nright in the quarter.  We onboa rded some new customers during the quarter and there's some initial  \ncosts there that we also incurred during the quarter.  So I would say that the bucket is there's small  \namount that's passed through to the customers. ", "original_text": "Some of these  costs were also focused  \nmore on the third quarter, such as we did roll out just a few weekends ago, the final rollout of our  \nmultiyear Piedmont project. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "19cc2716-0083-4fba-8f31-5dfdc9a1164c", "node_type": "1", "metadata": {"window": "Mike Kaufmann:  Yeah.  I would say in general, the majority of these are not items that we can pass  \nthrough.  There are opportunities on fuel surcharges for sure, as those remain elevated to pass those  \nthrough.  But I would remind you there was a couple other things.  Some of these  costs were also focused  \nmore on the third quarter, such as we did roll out just a few weekends ago, the final rollout of our  \nmultiyear Piedmont project.  So we've had some rollout costs and some making sure that we do that  \nright in the quarter.  We onboa rded some new customers during the quarter and there's some initial  \ncosts there that we also incurred during the quarter. ", "original_text": "But I would remind you there was a couple other things. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ec32e1e87c02260ac4a7b79ebcf20eb87919d2591d03ffa0d632491d0d640ada", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "21a183ff-ca27-449c-be30-ce76b303bd75", "node_type": "1", "metadata": {"window": "There are opportunities on fuel surcharges for sure, as those remain elevated to pass those  \nthrough.  But I would remind you there was a couple other things.  Some of these  costs were also focused  \nmore on the third quarter, such as we did roll out just a few weekends ago, the final rollout of our  \nmultiyear Piedmont project.  So we've had some rollout costs and some making sure that we do that  \nright in the quarter.  We onboa rded some new customers during the quarter and there's some initial  \ncosts there that we also incurred during the quarter.  So I would say that the bucket is there's small  \namount that's passed through to the customers.  There's another part that's a little bit I would say,  \ntemporary in the third quarter because they were unique to some work we're doing in the quarter. ", "original_text": "So we've had some rollout costs and some making sure that we do that  \nright in the quarter. "}, "hash": "2389e842eed485c9d9c52a98adfe15945168128620856e6e853f61d95ffd036c", "class_name": "RelatedNodeInfo"}}, "text": "Some of these  costs were also focused  \nmore on the third quarter, such as we did roll out just a few weekends ago, the final rollout of our  \nmultiyear Piedmont project. ", "start_char_idx": 1350, "end_char_idx": 1522, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "21a183ff-ca27-449c-be30-ce76b303bd75": {"__data__": {"id_": "21a183ff-ca27-449c-be30-ce76b303bd75", "embedding": null, "metadata": {"window": "There are opportunities on fuel surcharges for sure, as those remain elevated to pass those  \nthrough.  But I would remind you there was a couple other things.  Some of these  costs were also focused  \nmore on the third quarter, such as we did roll out just a few weekends ago, the final rollout of our  \nmultiyear Piedmont project.  So we've had some rollout costs and some making sure that we do that  \nright in the quarter.  We onboa rded some new customers during the quarter and there's some initial  \ncosts there that we also incurred during the quarter.  So I would say that the bucket is there's small  \namount that's passed through to the customers.  There's another part that's a little bit I would say,  \ntemporary in the third quarter because they were unique to some work we're doing in the quarter. ", "original_text": "So we've had some rollout costs and some making sure that we do that  \nright in the quarter. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7557406-3fbf-47c7-a63d-90aa8a4b1009", "node_type": "1", "metadata": {"window": "I would say in general, the majority of these are not items that we can pass  \nthrough.  There are opportunities on fuel surcharges for sure, as those remain elevated to pass those  \nthrough.  But I would remind you there was a couple other things.  Some of these  costs were also focused  \nmore on the third quarter, such as we did roll out just a few weekends ago, the final rollout of our  \nmultiyear Piedmont project.  So we've had some rollout costs and some making sure that we do that  \nright in the quarter.  We onboa rded some new customers during the quarter and there's some initial  \ncosts there that we also incurred during the quarter.  So I would say that the bucket is there's small  \namount that's passed through to the customers. ", "original_text": "Some of these  costs were also focused  \nmore on the third quarter, such as we did roll out just a few weekends ago, the final rollout of our  \nmultiyear Piedmont project. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ef7a118352950bc2a4e40a8eb25318ea54872d26484d9e58e8d0fb4ace2884dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "791099eb-8060-46a7-beda-d8431690904d", "node_type": "1", "metadata": {"window": "But I would remind you there was a couple other things.  Some of these  costs were also focused  \nmore on the third quarter, such as we did roll out just a few weekends ago, the final rollout of our  \nmultiyear Piedmont project.  So we've had some rollout costs and some making sure that we do that  \nright in the quarter.  We onboa rded some new customers during the quarter and there's some initial  \ncosts there that we also incurred during the quarter.  So I would say that the bucket is there's small  \namount that's passed through to the customers.  There's another part that's a little bit I would say,  \ntemporary in the third quarter because they were unique to some work we're doing in the quarter.  The  \nmajority is elevated transportation costs that we do see more permanent for at least for a while until  \nthey begin to come back down acr oss the portfolio, and those are not able to be passed on. ", "original_text": "We onboa rded some new customers during the quarter and there's some initial  \ncosts there that we also incurred during the quarter. "}, "hash": "b2a930a032b00ca4c13022de1e8fa6c26c7350acf9ec44c485eb872c709e59c2", "class_name": "RelatedNodeInfo"}}, "text": "So we've had some rollout costs and some making sure that we do that  \nright in the quarter. ", "start_char_idx": 1522, "end_char_idx": 1615, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "791099eb-8060-46a7-beda-d8431690904d": {"__data__": {"id_": "791099eb-8060-46a7-beda-d8431690904d", "embedding": null, "metadata": {"window": "But I would remind you there was a couple other things.  Some of these  costs were also focused  \nmore on the third quarter, such as we did roll out just a few weekends ago, the final rollout of our  \nmultiyear Piedmont project.  So we've had some rollout costs and some making sure that we do that  \nright in the quarter.  We onboa rded some new customers during the quarter and there's some initial  \ncosts there that we also incurred during the quarter.  So I would say that the bucket is there's small  \namount that's passed through to the customers.  There's another part that's a little bit I would say,  \ntemporary in the third quarter because they were unique to some work we're doing in the quarter.  The  \nmajority is elevated transportation costs that we do see more permanent for at least for a while until  \nthey begin to come back down acr oss the portfolio, and those are not able to be passed on. ", "original_text": "We onboa rded some new customers during the quarter and there's some initial  \ncosts there that we also incurred during the quarter. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "21a183ff-ca27-449c-be30-ce76b303bd75", "node_type": "1", "metadata": {"window": "There are opportunities on fuel surcharges for sure, as those remain elevated to pass those  \nthrough.  But I would remind you there was a couple other things.  Some of these  costs were also focused  \nmore on the third quarter, such as we did roll out just a few weekends ago, the final rollout of our  \nmultiyear Piedmont project.  So we've had some rollout costs and some making sure that we do that  \nright in the quarter.  We onboa rded some new customers during the quarter and there's some initial  \ncosts there that we also incurred during the quarter.  So I would say that the bucket is there's small  \namount that's passed through to the customers.  There's another part that's a little bit I would say,  \ntemporary in the third quarter because they were unique to some work we're doing in the quarter. ", "original_text": "So we've had some rollout costs and some making sure that we do that  \nright in the quarter. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "a90be84212081d6b1a4c509aff2152557f8befea923935d17a293558c8e1713e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5c8a48d7-cbd4-471c-afb1-ed0e22de9ada", "node_type": "1", "metadata": {"window": "Some of these  costs were also focused  \nmore on the third quarter, such as we did roll out just a few weekends ago, the final rollout of our  \nmultiyear Piedmont project.  So we've had some rollout costs and some making sure that we do that  \nright in the quarter.  We onboa rded some new customers during the quarter and there's some initial  \ncosts there that we also incurred during the quarter.  So I would say that the bucket is there's small  \namount that's passed through to the customers.  There's another part that's a little bit I would say,  \ntemporary in the third quarter because they were unique to some work we're doing in the quarter.  The  \nmajority is elevated transportation costs that we do see more permanent for at least for a while until  \nthey begin to come back down acr oss the portfolio, and those are not able to be passed on.  That being  \nsaid, when we look at the level of those the amount of costs we're taking out of the business, that's why  \nwe're still comfortable with reiterating our overall guidance for Pharma that while they are somewhat  \nelevated in the third quarter, there's something that we would expect and are continuing to address  \ngoing forward to manage the both our guidance for th is year as well as still feel confident about our  \nlonger -term guidance as it relates to pharma.  \n \n", "original_text": "So I would say that the bucket is there's small  \namount that's passed through to the customers. "}, "hash": "728902ee482e73757a57323e005ec27e718c8b1259521c6400703fb874f4a57b", "class_name": "RelatedNodeInfo"}}, "text": "We onboa rded some new customers during the quarter and there's some initial  \ncosts there that we also incurred during the quarter. ", "start_char_idx": 1615, "end_char_idx": 1748, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5c8a48d7-cbd4-471c-afb1-ed0e22de9ada": {"__data__": {"id_": "5c8a48d7-cbd4-471c-afb1-ed0e22de9ada", "embedding": null, "metadata": {"window": "Some of these  costs were also focused  \nmore on the third quarter, such as we did roll out just a few weekends ago, the final rollout of our  \nmultiyear Piedmont project.  So we've had some rollout costs and some making sure that we do that  \nright in the quarter.  We onboa rded some new customers during the quarter and there's some initial  \ncosts there that we also incurred during the quarter.  So I would say that the bucket is there's small  \namount that's passed through to the customers.  There's another part that's a little bit I would say,  \ntemporary in the third quarter because they were unique to some work we're doing in the quarter.  The  \nmajority is elevated transportation costs that we do see more permanent for at least for a while until  \nthey begin to come back down acr oss the portfolio, and those are not able to be passed on.  That being  \nsaid, when we look at the level of those the amount of costs we're taking out of the business, that's why  \nwe're still comfortable with reiterating our overall guidance for Pharma that while they are somewhat  \nelevated in the third quarter, there's something that we would expect and are continuing to address  \ngoing forward to manage the both our guidance for th is year as well as still feel confident about our  \nlonger -term guidance as it relates to pharma.  \n \n", "original_text": "So I would say that the bucket is there's small  \namount that's passed through to the customers. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "791099eb-8060-46a7-beda-d8431690904d", "node_type": "1", "metadata": {"window": "But I would remind you there was a couple other things.  Some of these  costs were also focused  \nmore on the third quarter, such as we did roll out just a few weekends ago, the final rollout of our  \nmultiyear Piedmont project.  So we've had some rollout costs and some making sure that we do that  \nright in the quarter.  We onboa rded some new customers during the quarter and there's some initial  \ncosts there that we also incurred during the quarter.  So I would say that the bucket is there's small  \namount that's passed through to the customers.  There's another part that's a little bit I would say,  \ntemporary in the third quarter because they were unique to some work we're doing in the quarter.  The  \nmajority is elevated transportation costs that we do see more permanent for at least for a while until  \nthey begin to come back down acr oss the portfolio, and those are not able to be passed on. ", "original_text": "We onboa rded some new customers during the quarter and there's some initial  \ncosts there that we also incurred during the quarter. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b00cafd16f8cf9b556e0bdf64fc42d9671ada8b0b8a16f159ab51913c185bed9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38653f16-ddce-407e-9211-bca9fc05f67f", "node_type": "1", "metadata": {"window": "So we've had some rollout costs and some making sure that we do that  \nright in the quarter.  We onboa rded some new customers during the quarter and there's some initial  \ncosts there that we also incurred during the quarter.  So I would say that the bucket is there's small  \namount that's passed through to the customers.  There's another part that's a little bit I would say,  \ntemporary in the third quarter because they were unique to some work we're doing in the quarter.  The  \nmajority is elevated transportation costs that we do see more permanent for at least for a while until  \nthey begin to come back down acr oss the portfolio, and those are not able to be passed on.  That being  \nsaid, when we look at the level of those the amount of costs we're taking out of the business, that's why  \nwe're still comfortable with reiterating our overall guidance for Pharma that while they are somewhat  \nelevated in the third quarter, there's something that we would expect and are continuing to address  \ngoing forward to manage the both our guidance for th is year as well as still feel confident about our  \nlonger -term guidance as it relates to pharma.  \n \n Jason Hollar:  And just to be really clear in this point, we're not talking about any type of product cost  \ninflation that's flowing through for the Pharma b usiness, that is very much captured in the pass -through.  \n  \n", "original_text": "There's another part that's a little bit I would say,  \ntemporary in the third quarter because they were unique to some work we're doing in the quarter. "}, "hash": "dc9066415f7d9901f612dfbac37a2b37d83719504e7386e0b4fbee04d232355f", "class_name": "RelatedNodeInfo"}}, "text": "So I would say that the bucket is there's small  \namount that's passed through to the customers. ", "start_char_idx": 1748, "end_char_idx": 1845, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38653f16-ddce-407e-9211-bca9fc05f67f": {"__data__": {"id_": "38653f16-ddce-407e-9211-bca9fc05f67f", "embedding": null, "metadata": {"window": "So we've had some rollout costs and some making sure that we do that  \nright in the quarter.  We onboa rded some new customers during the quarter and there's some initial  \ncosts there that we also incurred during the quarter.  So I would say that the bucket is there's small  \namount that's passed through to the customers.  There's another part that's a little bit I would say,  \ntemporary in the third quarter because they were unique to some work we're doing in the quarter.  The  \nmajority is elevated transportation costs that we do see more permanent for at least for a while until  \nthey begin to come back down acr oss the portfolio, and those are not able to be passed on.  That being  \nsaid, when we look at the level of those the amount of costs we're taking out of the business, that's why  \nwe're still comfortable with reiterating our overall guidance for Pharma that while they are somewhat  \nelevated in the third quarter, there's something that we would expect and are continuing to address  \ngoing forward to manage the both our guidance for th is year as well as still feel confident about our  \nlonger -term guidance as it relates to pharma.  \n \n Jason Hollar:  And just to be really clear in this point, we're not talking about any type of product cost  \ninflation that's flowing through for the Pharma b usiness, that is very much captured in the pass -through.  \n  \n", "original_text": "There's another part that's a little bit I would say,  \ntemporary in the third quarter because they were unique to some work we're doing in the quarter. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5c8a48d7-cbd4-471c-afb1-ed0e22de9ada", "node_type": "1", "metadata": {"window": "Some of these  costs were also focused  \nmore on the third quarter, such as we did roll out just a few weekends ago, the final rollout of our  \nmultiyear Piedmont project.  So we've had some rollout costs and some making sure that we do that  \nright in the quarter.  We onboa rded some new customers during the quarter and there's some initial  \ncosts there that we also incurred during the quarter.  So I would say that the bucket is there's small  \namount that's passed through to the customers.  There's another part that's a little bit I would say,  \ntemporary in the third quarter because they were unique to some work we're doing in the quarter.  The  \nmajority is elevated transportation costs that we do see more permanent for at least for a while until  \nthey begin to come back down acr oss the portfolio, and those are not able to be passed on.  That being  \nsaid, when we look at the level of those the amount of costs we're taking out of the business, that's why  \nwe're still comfortable with reiterating our overall guidance for Pharma that while they are somewhat  \nelevated in the third quarter, there's something that we would expect and are continuing to address  \ngoing forward to manage the both our guidance for th is year as well as still feel confident about our  \nlonger -term guidance as it relates to pharma.  \n \n", "original_text": "So I would say that the bucket is there's small  \namount that's passed through to the customers. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "b472d027758caf729ecbc5e313ca09e180848b12a6f351cc505c7ba5f71adb7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e2f1a72-b851-44fa-a066-5fb5736ad550", "node_type": "1", "metadata": {"window": "We onboa rded some new customers during the quarter and there's some initial  \ncosts there that we also incurred during the quarter.  So I would say that the bucket is there's small  \namount that's passed through to the customers.  There's another part that's a little bit I would say,  \ntemporary in the third quarter because they were unique to some work we're doing in the quarter.  The  \nmajority is elevated transportation costs that we do see more permanent for at least for a while until  \nthey begin to come back down acr oss the portfolio, and those are not able to be passed on.  That being  \nsaid, when we look at the level of those the amount of costs we're taking out of the business, that's why  \nwe're still comfortable with reiterating our overall guidance for Pharma that while they are somewhat  \nelevated in the third quarter, there's something that we would expect and are continuing to address  \ngoing forward to manage the both our guidance for th is year as well as still feel confident about our  \nlonger -term guidance as it relates to pharma.  \n \n Jason Hollar:  And just to be really clear in this point, we're not talking about any type of product cost  \ninflation that's flowing through for the Pharma b usiness, that is very much captured in the pass -through.  \n  \n Operator:   And it appears there are no further questions at this time. ", "original_text": "The  \nmajority is elevated transportation costs that we do see more permanent for at least for a while until  \nthey begin to come back down acr oss the portfolio, and those are not able to be passed on. "}, "hash": "c1b4c12b3a0350023c18e9ccd44fd2f170b99f73b3d959b2556a12ab9c7c23d6", "class_name": "RelatedNodeInfo"}}, "text": "There's another part that's a little bit I would say,  \ntemporary in the third quarter because they were unique to some work we're doing in the quarter. ", "start_char_idx": 1845, "end_char_idx": 1998, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e2f1a72-b851-44fa-a066-5fb5736ad550": {"__data__": {"id_": "0e2f1a72-b851-44fa-a066-5fb5736ad550", "embedding": null, "metadata": {"window": "We onboa rded some new customers during the quarter and there's some initial  \ncosts there that we also incurred during the quarter.  So I would say that the bucket is there's small  \namount that's passed through to the customers.  There's another part that's a little bit I would say,  \ntemporary in the third quarter because they were unique to some work we're doing in the quarter.  The  \nmajority is elevated transportation costs that we do see more permanent for at least for a while until  \nthey begin to come back down acr oss the portfolio, and those are not able to be passed on.  That being  \nsaid, when we look at the level of those the amount of costs we're taking out of the business, that's why  \nwe're still comfortable with reiterating our overall guidance for Pharma that while they are somewhat  \nelevated in the third quarter, there's something that we would expect and are continuing to address  \ngoing forward to manage the both our guidance for th is year as well as still feel confident about our  \nlonger -term guidance as it relates to pharma.  \n \n Jason Hollar:  And just to be really clear in this point, we're not talking about any type of product cost  \ninflation that's flowing through for the Pharma b usiness, that is very much captured in the pass -through.  \n  \n Operator:   And it appears there are no further questions at this time. ", "original_text": "The  \nmajority is elevated transportation costs that we do see more permanent for at least for a while until  \nthey begin to come back down acr oss the portfolio, and those are not able to be passed on. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38653f16-ddce-407e-9211-bca9fc05f67f", "node_type": "1", "metadata": {"window": "So we've had some rollout costs and some making sure that we do that  \nright in the quarter.  We onboa rded some new customers during the quarter and there's some initial  \ncosts there that we also incurred during the quarter.  So I would say that the bucket is there's small  \namount that's passed through to the customers.  There's another part that's a little bit I would say,  \ntemporary in the third quarter because they were unique to some work we're doing in the quarter.  The  \nmajority is elevated transportation costs that we do see more permanent for at least for a while until  \nthey begin to come back down acr oss the portfolio, and those are not able to be passed on.  That being  \nsaid, when we look at the level of those the amount of costs we're taking out of the business, that's why  \nwe're still comfortable with reiterating our overall guidance for Pharma that while they are somewhat  \nelevated in the third quarter, there's something that we would expect and are continuing to address  \ngoing forward to manage the both our guidance for th is year as well as still feel confident about our  \nlonger -term guidance as it relates to pharma.  \n \n Jason Hollar:  And just to be really clear in this point, we're not talking about any type of product cost  \ninflation that's flowing through for the Pharma b usiness, that is very much captured in the pass -through.  \n  \n", "original_text": "There's another part that's a little bit I would say,  \ntemporary in the third quarter because they were unique to some work we're doing in the quarter. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "d66331b166069b368462fa785dfa44cc3c613334d5977283ce7e069e699036ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e296d52-dfb1-415c-8aa4-5a85699ff492", "node_type": "1", "metadata": {"window": "So I would say that the bucket is there's small  \namount that's passed through to the customers.  There's another part that's a little bit I would say,  \ntemporary in the third quarter because they were unique to some work we're doing in the quarter.  The  \nmajority is elevated transportation costs that we do see more permanent for at least for a while until  \nthey begin to come back down acr oss the portfolio, and those are not able to be passed on.  That being  \nsaid, when we look at the level of those the amount of costs we're taking out of the business, that's why  \nwe're still comfortable with reiterating our overall guidance for Pharma that while they are somewhat  \nelevated in the third quarter, there's something that we would expect and are continuing to address  \ngoing forward to manage the both our guidance for th is year as well as still feel confident about our  \nlonger -term guidance as it relates to pharma.  \n \n Jason Hollar:  And just to be really clear in this point, we're not talking about any type of product cost  \ninflation that's flowing through for the Pharma b usiness, that is very much captured in the pass -through.  \n  \n Operator:   And it appears there are no further questions at this time.  Mr. ", "original_text": "That being  \nsaid, when we look at the level of those the amount of costs we're taking out of the business, that's why  \nwe're still comfortable with reiterating our overall guidance for Pharma that while they are somewhat  \nelevated in the third quarter, there's something that we would expect and are continuing to address  \ngoing forward to manage the both our guidance for th is year as well as still feel confident about our  \nlonger -term guidance as it relates to pharma.  \n \n"}, "hash": "421abc77565ce2c883129daae74c0e6b40f236e3e40c46a23c363ec085ec7c30", "class_name": "RelatedNodeInfo"}}, "text": "The  \nmajority is elevated transportation costs that we do see more permanent for at least for a while until  \nthey begin to come back down acr oss the portfolio, and those are not able to be passed on. ", "start_char_idx": 1998, "end_char_idx": 2201, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e296d52-dfb1-415c-8aa4-5a85699ff492": {"__data__": {"id_": "7e296d52-dfb1-415c-8aa4-5a85699ff492", "embedding": null, "metadata": {"window": "So I would say that the bucket is there's small  \namount that's passed through to the customers.  There's another part that's a little bit I would say,  \ntemporary in the third quarter because they were unique to some work we're doing in the quarter.  The  \nmajority is elevated transportation costs that we do see more permanent for at least for a while until  \nthey begin to come back down acr oss the portfolio, and those are not able to be passed on.  That being  \nsaid, when we look at the level of those the amount of costs we're taking out of the business, that's why  \nwe're still comfortable with reiterating our overall guidance for Pharma that while they are somewhat  \nelevated in the third quarter, there's something that we would expect and are continuing to address  \ngoing forward to manage the both our guidance for th is year as well as still feel confident about our  \nlonger -term guidance as it relates to pharma.  \n \n Jason Hollar:  And just to be really clear in this point, we're not talking about any type of product cost  \ninflation that's flowing through for the Pharma b usiness, that is very much captured in the pass -through.  \n  \n Operator:   And it appears there are no further questions at this time.  Mr. ", "original_text": "That being  \nsaid, when we look at the level of those the amount of costs we're taking out of the business, that's why  \nwe're still comfortable with reiterating our overall guidance for Pharma that while they are somewhat  \nelevated in the third quarter, there's something that we would expect and are continuing to address  \ngoing forward to manage the both our guidance for th is year as well as still feel confident about our  \nlonger -term guidance as it relates to pharma.  \n \n", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e2f1a72-b851-44fa-a066-5fb5736ad550", "node_type": "1", "metadata": {"window": "We onboa rded some new customers during the quarter and there's some initial  \ncosts there that we also incurred during the quarter.  So I would say that the bucket is there's small  \namount that's passed through to the customers.  There's another part that's a little bit I would say,  \ntemporary in the third quarter because they were unique to some work we're doing in the quarter.  The  \nmajority is elevated transportation costs that we do see more permanent for at least for a while until  \nthey begin to come back down acr oss the portfolio, and those are not able to be passed on.  That being  \nsaid, when we look at the level of those the amount of costs we're taking out of the business, that's why  \nwe're still comfortable with reiterating our overall guidance for Pharma that while they are somewhat  \nelevated in the third quarter, there's something that we would expect and are continuing to address  \ngoing forward to manage the both our guidance for th is year as well as still feel confident about our  \nlonger -term guidance as it relates to pharma.  \n \n Jason Hollar:  And just to be really clear in this point, we're not talking about any type of product cost  \ninflation that's flowing through for the Pharma b usiness, that is very much captured in the pass -through.  \n  \n Operator:   And it appears there are no further questions at this time. ", "original_text": "The  \nmajority is elevated transportation costs that we do see more permanent for at least for a while until  \nthey begin to come back down acr oss the portfolio, and those are not able to be passed on. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "85e89d25272bf0584c5f1193e4d7b64885fdb67c6cbe00905c9d1d29bc60171e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ec97ce9-759f-4eb0-98f8-dd36613be68a", "node_type": "1", "metadata": {"window": "There's another part that's a little bit I would say,  \ntemporary in the third quarter because they were unique to some work we're doing in the quarter.  The  \nmajority is elevated transportation costs that we do see more permanent for at least for a while until  \nthey begin to come back down acr oss the portfolio, and those are not able to be passed on.  That being  \nsaid, when we look at the level of those the amount of costs we're taking out of the business, that's why  \nwe're still comfortable with reiterating our overall guidance for Pharma that while they are somewhat  \nelevated in the third quarter, there's something that we would expect and are continuing to address  \ngoing forward to manage the both our guidance for th is year as well as still feel confident about our  \nlonger -term guidance as it relates to pharma.  \n \n Jason Hollar:  And just to be really clear in this point, we're not talking about any type of product cost  \ninflation that's flowing through for the Pharma b usiness, that is very much captured in the pass -through.  \n  \n Operator:   And it appears there are no further questions at this time.  Mr.  Kaufmann, I would like to turn  \nthe conference back to you for any additional or closing remarks.  \n  \n", "original_text": "Jason Hollar:  And just to be really clear in this point, we're not talking about any type of product cost  \ninflation that's flowing through for the Pharma b usiness, that is very much captured in the pass -through.  \n  \n"}, "hash": "3437f728928cd53f806e702455241b2702676e84a1655f7cf1e6dfbf0d9b081c", "class_name": "RelatedNodeInfo"}}, "text": "That being  \nsaid, when we look at the level of those the amount of costs we're taking out of the business, that's why  \nwe're still comfortable with reiterating our overall guidance for Pharma that while they are somewhat  \nelevated in the third quarter, there's something that we would expect and are continuing to address  \ngoing forward to manage the both our guidance for th is year as well as still feel confident about our  \nlonger -term guidance as it relates to pharma.  \n \n", "start_char_idx": 2201, "end_char_idx": 2684, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ec97ce9-759f-4eb0-98f8-dd36613be68a": {"__data__": {"id_": "5ec97ce9-759f-4eb0-98f8-dd36613be68a", "embedding": null, "metadata": {"window": "There's another part that's a little bit I would say,  \ntemporary in the third quarter because they were unique to some work we're doing in the quarter.  The  \nmajority is elevated transportation costs that we do see more permanent for at least for a while until  \nthey begin to come back down acr oss the portfolio, and those are not able to be passed on.  That being  \nsaid, when we look at the level of those the amount of costs we're taking out of the business, that's why  \nwe're still comfortable with reiterating our overall guidance for Pharma that while they are somewhat  \nelevated in the third quarter, there's something that we would expect and are continuing to address  \ngoing forward to manage the both our guidance for th is year as well as still feel confident about our  \nlonger -term guidance as it relates to pharma.  \n \n Jason Hollar:  And just to be really clear in this point, we're not talking about any type of product cost  \ninflation that's flowing through for the Pharma b usiness, that is very much captured in the pass -through.  \n  \n Operator:   And it appears there are no further questions at this time.  Mr.  Kaufmann, I would like to turn  \nthe conference back to you for any additional or closing remarks.  \n  \n", "original_text": "Jason Hollar:  And just to be really clear in this point, we're not talking about any type of product cost  \ninflation that's flowing through for the Pharma b usiness, that is very much captured in the pass -through.  \n  \n", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e296d52-dfb1-415c-8aa4-5a85699ff492", "node_type": "1", "metadata": {"window": "So I would say that the bucket is there's small  \namount that's passed through to the customers.  There's another part that's a little bit I would say,  \ntemporary in the third quarter because they were unique to some work we're doing in the quarter.  The  \nmajority is elevated transportation costs that we do see more permanent for at least for a while until  \nthey begin to come back down acr oss the portfolio, and those are not able to be passed on.  That being  \nsaid, when we look at the level of those the amount of costs we're taking out of the business, that's why  \nwe're still comfortable with reiterating our overall guidance for Pharma that while they are somewhat  \nelevated in the third quarter, there's something that we would expect and are continuing to address  \ngoing forward to manage the both our guidance for th is year as well as still feel confident about our  \nlonger -term guidance as it relates to pharma.  \n \n Jason Hollar:  And just to be really clear in this point, we're not talking about any type of product cost  \ninflation that's flowing through for the Pharma b usiness, that is very much captured in the pass -through.  \n  \n Operator:   And it appears there are no further questions at this time.  Mr. ", "original_text": "That being  \nsaid, when we look at the level of those the amount of costs we're taking out of the business, that's why  \nwe're still comfortable with reiterating our overall guidance for Pharma that while they are somewhat  \nelevated in the third quarter, there's something that we would expect and are continuing to address  \ngoing forward to manage the both our guidance for th is year as well as still feel confident about our  \nlonger -term guidance as it relates to pharma.  \n \n", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "8da50b34573ad4e249b4d3c8301c78fc28211a9b6354f1160c18d0b123a43f8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "332b0114-0663-4132-9489-08300dc3c45e", "node_type": "1", "metadata": {"window": "The  \nmajority is elevated transportation costs that we do see more permanent for at least for a while until  \nthey begin to come back down acr oss the portfolio, and those are not able to be passed on.  That being  \nsaid, when we look at the level of those the amount of costs we're taking out of the business, that's why  \nwe're still comfortable with reiterating our overall guidance for Pharma that while they are somewhat  \nelevated in the third quarter, there's something that we would expect and are continuing to address  \ngoing forward to manage the both our guidance for th is year as well as still feel confident about our  \nlonger -term guidance as it relates to pharma.  \n \n Jason Hollar:  And just to be really clear in this point, we're not talking about any type of product cost  \ninflation that's flowing through for the Pharma b usiness, that is very much captured in the pass -through.  \n  \n Operator:   And it appears there are no further questions at this time.  Mr.  Kaufmann, I would like to turn  \nthe conference back to you for any additional or closing remarks.  \n  \n Mike  Kaufmann:   I just want to thank everybody for their time to be on the call today and I appreciate  \nall the questions. ", "original_text": "Operator:   And it appears there are no further questions at this time. "}, "hash": "1a2382ee68c7833607e2fc3ba43aa2ad0edd2cc7070f5155fea5188acbe6eb3b", "class_name": "RelatedNodeInfo"}}, "text": "Jason Hollar:  And just to be really clear in this point, we're not talking about any type of product cost  \ninflation that's flowing through for the Pharma b usiness, that is very much captured in the pass -through.  \n  \n", "start_char_idx": 2684, "end_char_idx": 2906, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "332b0114-0663-4132-9489-08300dc3c45e": {"__data__": {"id_": "332b0114-0663-4132-9489-08300dc3c45e", "embedding": null, "metadata": {"window": "The  \nmajority is elevated transportation costs that we do see more permanent for at least for a while until  \nthey begin to come back down acr oss the portfolio, and those are not able to be passed on.  That being  \nsaid, when we look at the level of those the amount of costs we're taking out of the business, that's why  \nwe're still comfortable with reiterating our overall guidance for Pharma that while they are somewhat  \nelevated in the third quarter, there's something that we would expect and are continuing to address  \ngoing forward to manage the both our guidance for th is year as well as still feel confident about our  \nlonger -term guidance as it relates to pharma.  \n \n Jason Hollar:  And just to be really clear in this point, we're not talking about any type of product cost  \ninflation that's flowing through for the Pharma b usiness, that is very much captured in the pass -through.  \n  \n Operator:   And it appears there are no further questions at this time.  Mr.  Kaufmann, I would like to turn  \nthe conference back to you for any additional or closing remarks.  \n  \n Mike  Kaufmann:   I just want to thank everybody for their time to be on the call today and I appreciate  \nall the questions. ", "original_text": "Operator:   And it appears there are no further questions at this time. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ec97ce9-759f-4eb0-98f8-dd36613be68a", "node_type": "1", "metadata": {"window": "There's another part that's a little bit I would say,  \ntemporary in the third quarter because they were unique to some work we're doing in the quarter.  The  \nmajority is elevated transportation costs that we do see more permanent for at least for a while until  \nthey begin to come back down acr oss the portfolio, and those are not able to be passed on.  That being  \nsaid, when we look at the level of those the amount of costs we're taking out of the business, that's why  \nwe're still comfortable with reiterating our overall guidance for Pharma that while they are somewhat  \nelevated in the third quarter, there's something that we would expect and are continuing to address  \ngoing forward to manage the both our guidance for th is year as well as still feel confident about our  \nlonger -term guidance as it relates to pharma.  \n \n Jason Hollar:  And just to be really clear in this point, we're not talking about any type of product cost  \ninflation that's flowing through for the Pharma b usiness, that is very much captured in the pass -through.  \n  \n Operator:   And it appears there are no further questions at this time.  Mr.  Kaufmann, I would like to turn  \nthe conference back to you for any additional or closing remarks.  \n  \n", "original_text": "Jason Hollar:  And just to be really clear in this point, we're not talking about any type of product cost  \ninflation that's flowing through for the Pharma b usiness, that is very much captured in the pass -through.  \n  \n", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e5d9d8f403be0e6b6026e2cbae5285f47a27daf2be15b5e9cc53ab8da7f4ddd1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a6ca281-b8d2-4120-a6aa-d2e01f09fffd", "node_type": "1", "metadata": {"window": "That being  \nsaid, when we look at the level of those the amount of costs we're taking out of the business, that's why  \nwe're still comfortable with reiterating our overall guidance for Pharma that while they are somewhat  \nelevated in the third quarter, there's something that we would expect and are continuing to address  \ngoing forward to manage the both our guidance for th is year as well as still feel confident about our  \nlonger -term guidance as it relates to pharma.  \n \n Jason Hollar:  And just to be really clear in this point, we're not talking about any type of product cost  \ninflation that's flowing through for the Pharma b usiness, that is very much captured in the pass -through.  \n  \n Operator:   And it appears there are no further questions at this time.  Mr.  Kaufmann, I would like to turn  \nthe conference back to you for any additional or closing remarks.  \n  \n Mike  Kaufmann:   I just want to thank everybody for their time to be on the call today and I appreciate  \nall the questions.  I'll just reiterate that we are taking action to mitigate these inflationary impacts and  \nglobal supply chain constraints, and we're  focused on driving i mproved performance across all of our  \nbusinesses. ", "original_text": "Mr. "}, "hash": "a04d2d3f33759eddde5758f073a3a8eedc4a2d84cbd17b19d6e7e17902abf537", "class_name": "RelatedNodeInfo"}}, "text": "Operator:   And it appears there are no further questions at this time. ", "start_char_idx": 2906, "end_char_idx": 2978, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a6ca281-b8d2-4120-a6aa-d2e01f09fffd": {"__data__": {"id_": "4a6ca281-b8d2-4120-a6aa-d2e01f09fffd", "embedding": null, "metadata": {"window": "That being  \nsaid, when we look at the level of those the amount of costs we're taking out of the business, that's why  \nwe're still comfortable with reiterating our overall guidance for Pharma that while they are somewhat  \nelevated in the third quarter, there's something that we would expect and are continuing to address  \ngoing forward to manage the both our guidance for th is year as well as still feel confident about our  \nlonger -term guidance as it relates to pharma.  \n \n Jason Hollar:  And just to be really clear in this point, we're not talking about any type of product cost  \ninflation that's flowing through for the Pharma b usiness, that is very much captured in the pass -through.  \n  \n Operator:   And it appears there are no further questions at this time.  Mr.  Kaufmann, I would like to turn  \nthe conference back to you for any additional or closing remarks.  \n  \n Mike  Kaufmann:   I just want to thank everybody for their time to be on the call today and I appreciate  \nall the questions.  I'll just reiterate that we are taking action to mitigate these inflationary impacts and  \nglobal supply chain constraints, and we're  focused on driving i mproved performance across all of our  \nbusinesses. ", "original_text": "Mr. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "332b0114-0663-4132-9489-08300dc3c45e", "node_type": "1", "metadata": {"window": "The  \nmajority is elevated transportation costs that we do see more permanent for at least for a while until  \nthey begin to come back down acr oss the portfolio, and those are not able to be passed on.  That being  \nsaid, when we look at the level of those the amount of costs we're taking out of the business, that's why  \nwe're still comfortable with reiterating our overall guidance for Pharma that while they are somewhat  \nelevated in the third quarter, there's something that we would expect and are continuing to address  \ngoing forward to manage the both our guidance for th is year as well as still feel confident about our  \nlonger -term guidance as it relates to pharma.  \n \n Jason Hollar:  And just to be really clear in this point, we're not talking about any type of product cost  \ninflation that's flowing through for the Pharma b usiness, that is very much captured in the pass -through.  \n  \n Operator:   And it appears there are no further questions at this time.  Mr.  Kaufmann, I would like to turn  \nthe conference back to you for any additional or closing remarks.  \n  \n Mike  Kaufmann:   I just want to thank everybody for their time to be on the call today and I appreciate  \nall the questions. ", "original_text": "Operator:   And it appears there are no further questions at this time. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "0d1816e033abc100b331255d77b2af4b0d7aa706d9df7e94ef55cf6f848744a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be7bbb75-0a7e-4386-bd40-e3a9df0468c7", "node_type": "1", "metadata": {"window": "Jason Hollar:  And just to be really clear in this point, we're not talking about any type of product cost  \ninflation that's flowing through for the Pharma b usiness, that is very much captured in the pass -through.  \n  \n Operator:   And it appears there are no further questions at this time.  Mr.  Kaufmann, I would like to turn  \nthe conference back to you for any additional or closing remarks.  \n  \n Mike  Kaufmann:   I just want to thank everybody for their time to be on the call today and I appreciate  \nall the questions.  I'll just reiterate that we are taking action to mitigate these inflationary impacts and  \nglobal supply chain constraints, and we're  focused on driving i mproved performance across all of our  \nbusinesses.  Take care. ", "original_text": "Kaufmann, I would like to turn  \nthe conference back to you for any additional or closing remarks.  \n  \n"}, "hash": "a6b8c22b4c0ec9c78238d7851accffe5bbcb173605a03389cc0c0d12ea911fbf", "class_name": "RelatedNodeInfo"}}, "text": "Mr. ", "start_char_idx": 2978, "end_char_idx": 2982, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be7bbb75-0a7e-4386-bd40-e3a9df0468c7": {"__data__": {"id_": "be7bbb75-0a7e-4386-bd40-e3a9df0468c7", "embedding": null, "metadata": {"window": "Jason Hollar:  And just to be really clear in this point, we're not talking about any type of product cost  \ninflation that's flowing through for the Pharma b usiness, that is very much captured in the pass -through.  \n  \n Operator:   And it appears there are no further questions at this time.  Mr.  Kaufmann, I would like to turn  \nthe conference back to you for any additional or closing remarks.  \n  \n Mike  Kaufmann:   I just want to thank everybody for their time to be on the call today and I appreciate  \nall the questions.  I'll just reiterate that we are taking action to mitigate these inflationary impacts and  \nglobal supply chain constraints, and we're  focused on driving i mproved performance across all of our  \nbusinesses.  Take care. ", "original_text": "Kaufmann, I would like to turn  \nthe conference back to you for any additional or closing remarks.  \n  \n", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a6ca281-b8d2-4120-a6aa-d2e01f09fffd", "node_type": "1", "metadata": {"window": "That being  \nsaid, when we look at the level of those the amount of costs we're taking out of the business, that's why  \nwe're still comfortable with reiterating our overall guidance for Pharma that while they are somewhat  \nelevated in the third quarter, there's something that we would expect and are continuing to address  \ngoing forward to manage the both our guidance for th is year as well as still feel confident about our  \nlonger -term guidance as it relates to pharma.  \n \n Jason Hollar:  And just to be really clear in this point, we're not talking about any type of product cost  \ninflation that's flowing through for the Pharma b usiness, that is very much captured in the pass -through.  \n  \n Operator:   And it appears there are no further questions at this time.  Mr.  Kaufmann, I would like to turn  \nthe conference back to you for any additional or closing remarks.  \n  \n Mike  Kaufmann:   I just want to thank everybody for their time to be on the call today and I appreciate  \nall the questions.  I'll just reiterate that we are taking action to mitigate these inflationary impacts and  \nglobal supply chain constraints, and we're  focused on driving i mproved performance across all of our  \nbusinesses. ", "original_text": "Mr. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "11aeeb75a3975191ab047b609556043ea21f7c6789120427fc2b69a91f87f478", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "55700999-b378-45bb-b0ad-aa59e9de21ef", "node_type": "1", "metadata": {"window": "Operator:   And it appears there are no further questions at this time.  Mr.  Kaufmann, I would like to turn  \nthe conference back to you for any additional or closing remarks.  \n  \n Mike  Kaufmann:   I just want to thank everybody for their time to be on the call today and I appreciate  \nall the questions.  I'll just reiterate that we are taking action to mitigate these inflationary impacts and  \nglobal supply chain constraints, and we're  focused on driving i mproved performance across all of our  \nbusinesses.  Take care.  And I hope to talk to all of you soon. ", "original_text": "Mike  Kaufmann:   I just want to thank everybody for their time to be on the call today and I appreciate  \nall the questions. "}, "hash": "5c676d3b8b51531204622aa4f075d61963aa64b92f02a9a5ba35beab058bf0e2", "class_name": "RelatedNodeInfo"}}, "text": "Kaufmann, I would like to turn  \nthe conference back to you for any additional or closing remarks.  \n  \n", "start_char_idx": 2982, "end_char_idx": 3086, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "55700999-b378-45bb-b0ad-aa59e9de21ef": {"__data__": {"id_": "55700999-b378-45bb-b0ad-aa59e9de21ef", "embedding": null, "metadata": {"window": "Operator:   And it appears there are no further questions at this time.  Mr.  Kaufmann, I would like to turn  \nthe conference back to you for any additional or closing remarks.  \n  \n Mike  Kaufmann:   I just want to thank everybody for their time to be on the call today and I appreciate  \nall the questions.  I'll just reiterate that we are taking action to mitigate these inflationary impacts and  \nglobal supply chain constraints, and we're  focused on driving i mproved performance across all of our  \nbusinesses.  Take care.  And I hope to talk to all of you soon. ", "original_text": "Mike  Kaufmann:   I just want to thank everybody for their time to be on the call today and I appreciate  \nall the questions. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be7bbb75-0a7e-4386-bd40-e3a9df0468c7", "node_type": "1", "metadata": {"window": "Jason Hollar:  And just to be really clear in this point, we're not talking about any type of product cost  \ninflation that's flowing through for the Pharma b usiness, that is very much captured in the pass -through.  \n  \n Operator:   And it appears there are no further questions at this time.  Mr.  Kaufmann, I would like to turn  \nthe conference back to you for any additional or closing remarks.  \n  \n Mike  Kaufmann:   I just want to thank everybody for their time to be on the call today and I appreciate  \nall the questions.  I'll just reiterate that we are taking action to mitigate these inflationary impacts and  \nglobal supply chain constraints, and we're  focused on driving i mproved performance across all of our  \nbusinesses.  Take care. ", "original_text": "Kaufmann, I would like to turn  \nthe conference back to you for any additional or closing remarks.  \n  \n", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "4bcd2d569d3b7d609dcb012d47291dc1bdb6b54a0b63b810fdfd3ce9a12bc34d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "93d77495-ad52-4911-82b2-a4bad65eabb0", "node_type": "1", "metadata": {"window": "Mr.  Kaufmann, I would like to turn  \nthe conference back to you for any additional or closing remarks.  \n  \n Mike  Kaufmann:   I just want to thank everybody for their time to be on the call today and I appreciate  \nall the questions.  I'll just reiterate that we are taking action to mitigate these inflationary impacts and  \nglobal supply chain constraints, and we're  focused on driving i mproved performance across all of our  \nbusinesses.  Take care.  And I hope to talk to all of you soon.  Bye -bye.  \n  \n", "original_text": "I'll just reiterate that we are taking action to mitigate these inflationary impacts and  \nglobal supply chain constraints, and we're  focused on driving i mproved performance across all of our  \nbusinesses. "}, "hash": "8944a179e2b45a8dce6d36404414a2e74511401b91acf05f8ae10931266857d9", "class_name": "RelatedNodeInfo"}}, "text": "Mike  Kaufmann:   I just want to thank everybody for their time to be on the call today and I appreciate  \nall the questions. ", "start_char_idx": 3086, "end_char_idx": 3212, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "93d77495-ad52-4911-82b2-a4bad65eabb0": {"__data__": {"id_": "93d77495-ad52-4911-82b2-a4bad65eabb0", "embedding": null, "metadata": {"window": "Mr.  Kaufmann, I would like to turn  \nthe conference back to you for any additional or closing remarks.  \n  \n Mike  Kaufmann:   I just want to thank everybody for their time to be on the call today and I appreciate  \nall the questions.  I'll just reiterate that we are taking action to mitigate these inflationary impacts and  \nglobal supply chain constraints, and we're  focused on driving i mproved performance across all of our  \nbusinesses.  Take care.  And I hope to talk to all of you soon.  Bye -bye.  \n  \n", "original_text": "I'll just reiterate that we are taking action to mitigate these inflationary impacts and  \nglobal supply chain constraints, and we're  focused on driving i mproved performance across all of our  \nbusinesses. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "55700999-b378-45bb-b0ad-aa59e9de21ef", "node_type": "1", "metadata": {"window": "Operator:   And it appears there are no further questions at this time.  Mr.  Kaufmann, I would like to turn  \nthe conference back to you for any additional or closing remarks.  \n  \n Mike  Kaufmann:   I just want to thank everybody for their time to be on the call today and I appreciate  \nall the questions.  I'll just reiterate that we are taking action to mitigate these inflationary impacts and  \nglobal supply chain constraints, and we're  focused on driving i mproved performance across all of our  \nbusinesses.  Take care.  And I hope to talk to all of you soon. ", "original_text": "Mike  Kaufmann:   I just want to thank everybody for their time to be on the call today and I appreciate  \nall the questions. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "780e8bddaac624372d9be5ebbb8daade22fd9ea2f3cd46427f24dac69881c77a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "587d1171-fdce-4b74-b67b-1a96aa32e253", "node_type": "1", "metadata": {"window": "Kaufmann, I would like to turn  \nthe conference back to you for any additional or closing remarks.  \n  \n Mike  Kaufmann:   I just want to thank everybody for their time to be on the call today and I appreciate  \nall the questions.  I'll just reiterate that we are taking action to mitigate these inflationary impacts and  \nglobal supply chain constraints, and we're  focused on driving i mproved performance across all of our  \nbusinesses.  Take care.  And I hope to talk to all of you soon.  Bye -bye.  \n  \n Operator:   This concludes today's call. ", "original_text": "Take care. "}, "hash": "dbee4a65b161ba4837ead517be895d8c4192b4d373dca770bf451ea61ab3c103", "class_name": "RelatedNodeInfo"}}, "text": "I'll just reiterate that we are taking action to mitigate these inflationary impacts and  \nglobal supply chain constraints, and we're  focused on driving i mproved performance across all of our  \nbusinesses. ", "start_char_idx": 3212, "end_char_idx": 3420, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "587d1171-fdce-4b74-b67b-1a96aa32e253": {"__data__": {"id_": "587d1171-fdce-4b74-b67b-1a96aa32e253", "embedding": null, "metadata": {"window": "Kaufmann, I would like to turn  \nthe conference back to you for any additional or closing remarks.  \n  \n Mike  Kaufmann:   I just want to thank everybody for their time to be on the call today and I appreciate  \nall the questions.  I'll just reiterate that we are taking action to mitigate these inflationary impacts and  \nglobal supply chain constraints, and we're  focused on driving i mproved performance across all of our  \nbusinesses.  Take care.  And I hope to talk to all of you soon.  Bye -bye.  \n  \n Operator:   This concludes today's call. ", "original_text": "Take care. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "93d77495-ad52-4911-82b2-a4bad65eabb0", "node_type": "1", "metadata": {"window": "Mr.  Kaufmann, I would like to turn  \nthe conference back to you for any additional or closing remarks.  \n  \n Mike  Kaufmann:   I just want to thank everybody for their time to be on the call today and I appreciate  \nall the questions.  I'll just reiterate that we are taking action to mitigate these inflationary impacts and  \nglobal supply chain constraints, and we're  focused on driving i mproved performance across all of our  \nbusinesses.  Take care.  And I hope to talk to all of you soon.  Bye -bye.  \n  \n", "original_text": "I'll just reiterate that we are taking action to mitigate these inflationary impacts and  \nglobal supply chain constraints, and we're  focused on driving i mproved performance across all of our  \nbusinesses. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "e65fa3b3aeeff4e2e9e070950d672afc664c9c607cd6eb5c43886a11234c6cb6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d498ba6-4ab0-4859-b2ca-7d1df145505e", "node_type": "1", "metadata": {"window": "Mike  Kaufmann:   I just want to thank everybody for their time to be on the call today and I appreciate  \nall the questions.  I'll just reiterate that we are taking action to mitigate these inflationary impacts and  \nglobal supply chain constraints, and we're  focused on driving i mproved performance across all of our  \nbusinesses.  Take care.  And I hope to talk to all of you soon.  Bye -bye.  \n  \n Operator:   This concludes today's call.  Thank you for your participation. ", "original_text": "And I hope to talk to all of you soon. "}, "hash": "e9e38110c0b8a9a312416b430edb926a8a22ec0d1ae4fd905bc83354dbe54cac", "class_name": "RelatedNodeInfo"}}, "text": "Take care. ", "start_char_idx": 3420, "end_char_idx": 3431, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d498ba6-4ab0-4859-b2ca-7d1df145505e": {"__data__": {"id_": "6d498ba6-4ab0-4859-b2ca-7d1df145505e", "embedding": null, "metadata": {"window": "Mike  Kaufmann:   I just want to thank everybody for their time to be on the call today and I appreciate  \nall the questions.  I'll just reiterate that we are taking action to mitigate these inflationary impacts and  \nglobal supply chain constraints, and we're  focused on driving i mproved performance across all of our  \nbusinesses.  Take care.  And I hope to talk to all of you soon.  Bye -bye.  \n  \n Operator:   This concludes today's call.  Thank you for your participation. ", "original_text": "And I hope to talk to all of you soon. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "587d1171-fdce-4b74-b67b-1a96aa32e253", "node_type": "1", "metadata": {"window": "Kaufmann, I would like to turn  \nthe conference back to you for any additional or closing remarks.  \n  \n Mike  Kaufmann:   I just want to thank everybody for their time to be on the call today and I appreciate  \nall the questions.  I'll just reiterate that we are taking action to mitigate these inflationary impacts and  \nglobal supply chain constraints, and we're  focused on driving i mproved performance across all of our  \nbusinesses.  Take care.  And I hope to talk to all of you soon.  Bye -bye.  \n  \n Operator:   This concludes today's call. ", "original_text": "Take care. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "9af20302af5fbd05daf29846525dcd21c13f2a0f43e6180ab673c3ee73133c7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38d1fbef-1c90-4886-a365-88d09192d167", "node_type": "1", "metadata": {"window": "I'll just reiterate that we are taking action to mitigate these inflationary impacts and  \nglobal supply chain constraints, and we're  focused on driving i mproved performance across all of our  \nbusinesses.  Take care.  And I hope to talk to all of you soon.  Bye -bye.  \n  \n Operator:   This concludes today's call.  Thank you for your participation.  You may now disconnect.  \n ", "original_text": "Bye -bye.  \n  \n"}, "hash": "000aacf988d3610f32d0b47e98b1e793789294b7806cc53587989cc5233186b8", "class_name": "RelatedNodeInfo"}}, "text": "And I hope to talk to all of you soon. ", "start_char_idx": 3431, "end_char_idx": 3470, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38d1fbef-1c90-4886-a365-88d09192d167": {"__data__": {"id_": "38d1fbef-1c90-4886-a365-88d09192d167", "embedding": null, "metadata": {"window": "I'll just reiterate that we are taking action to mitigate these inflationary impacts and  \nglobal supply chain constraints, and we're  focused on driving i mproved performance across all of our  \nbusinesses.  Take care.  And I hope to talk to all of you soon.  Bye -bye.  \n  \n Operator:   This concludes today's call.  Thank you for your participation.  You may now disconnect.  \n ", "original_text": "Bye -bye.  \n  \n", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d498ba6-4ab0-4859-b2ca-7d1df145505e", "node_type": "1", "metadata": {"window": "Mike  Kaufmann:   I just want to thank everybody for their time to be on the call today and I appreciate  \nall the questions.  I'll just reiterate that we are taking action to mitigate these inflationary impacts and  \nglobal supply chain constraints, and we're  focused on driving i mproved performance across all of our  \nbusinesses.  Take care.  And I hope to talk to all of you soon.  Bye -bye.  \n  \n Operator:   This concludes today's call.  Thank you for your participation. ", "original_text": "And I hope to talk to all of you soon. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "c751345fbcf2473e212b4d3a604f61c57af30bf80e666f2257983cd3bf04be71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "069e58af-170f-48f2-9cab-dd8ad7e426ec", "node_type": "1", "metadata": {"window": "Take care.  And I hope to talk to all of you soon.  Bye -bye.  \n  \n Operator:   This concludes today's call.  Thank you for your participation.  You may now disconnect.  \n ", "original_text": "Operator:   This concludes today's call. "}, "hash": "a079ecbc12feff5375ff808142f4f0fef8b0818f4f434c4bbe56fdc66b0e889f", "class_name": "RelatedNodeInfo"}}, "text": "Bye -bye.  \n  \n", "start_char_idx": 3470, "end_char_idx": 3485, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "069e58af-170f-48f2-9cab-dd8ad7e426ec": {"__data__": {"id_": "069e58af-170f-48f2-9cab-dd8ad7e426ec", "embedding": null, "metadata": {"window": "Take care.  And I hope to talk to all of you soon.  Bye -bye.  \n  \n Operator:   This concludes today's call.  Thank you for your participation.  You may now disconnect.  \n ", "original_text": "Operator:   This concludes today's call. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38d1fbef-1c90-4886-a365-88d09192d167", "node_type": "1", "metadata": {"window": "I'll just reiterate that we are taking action to mitigate these inflationary impacts and  \nglobal supply chain constraints, and we're  focused on driving i mproved performance across all of our  \nbusinesses.  Take care.  And I hope to talk to all of you soon.  Bye -bye.  \n  \n Operator:   This concludes today's call.  Thank you for your participation.  You may now disconnect.  \n ", "original_text": "Bye -bye.  \n  \n", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "ad23ac8084730ef3c7906e7071919766ed49d85078577a870fc6948e817326ff", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "845125e8-769d-4894-bea5-fee9378209e8", "node_type": "1", "metadata": {"window": "And I hope to talk to all of you soon.  Bye -bye.  \n  \n Operator:   This concludes today's call.  Thank you for your participation.  You may now disconnect.  \n ", "original_text": "Thank you for your participation. "}, "hash": "77f30bfae41103c6b0cf7b60677ca15a719413cc21c4796a5a2c33b1e348b6a2", "class_name": "RelatedNodeInfo"}}, "text": "Operator:   This concludes today's call. ", "start_char_idx": 3485, "end_char_idx": 3526, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "845125e8-769d-4894-bea5-fee9378209e8": {"__data__": {"id_": "845125e8-769d-4894-bea5-fee9378209e8", "embedding": null, "metadata": {"window": "And I hope to talk to all of you soon.  Bye -bye.  \n  \n Operator:   This concludes today's call.  Thank you for your participation.  You may now disconnect.  \n ", "original_text": "Thank you for your participation. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "069e58af-170f-48f2-9cab-dd8ad7e426ec", "node_type": "1", "metadata": {"window": "Take care.  And I hope to talk to all of you soon.  Bye -bye.  \n  \n Operator:   This concludes today's call.  Thank you for your participation.  You may now disconnect.  \n ", "original_text": "Operator:   This concludes today's call. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "41b1a64fef5a3e8775bc86592fd56ab44cd4eb175d18a582e4a4f5cbe01704b4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "84a1be93-b8c4-4ec6-8b0f-0ff08c293b57", "node_type": "1", "metadata": {"window": "Bye -bye.  \n  \n Operator:   This concludes today's call.  Thank you for your participation.  You may now disconnect.  \n ", "original_text": "You may now disconnect.  \n "}, "hash": "8fd8acdd6fcab8fedf7e98aa143e474dde48601909995e78166b3cc0def1837a", "class_name": "RelatedNodeInfo"}}, "text": "Thank you for your participation. ", "start_char_idx": 3526, "end_char_idx": 3560, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "84a1be93-b8c4-4ec6-8b0f-0ff08c293b57": {"__data__": {"id_": "84a1be93-b8c4-4ec6-8b0f-0ff08c293b57", "embedding": null, "metadata": {"window": "Bye -bye.  \n  \n Operator:   This concludes today's call.  Thank you for your participation.  You may now disconnect.  \n ", "original_text": "You may now disconnect.  \n ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5", "node_type": "4", "metadata": {"page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "2e6bdfc18e6699a729dd334c9f1a74ffd221b730cb8cb68a6840ee0408c44871", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "845125e8-769d-4894-bea5-fee9378209e8", "node_type": "1", "metadata": {"window": "And I hope to talk to all of you soon.  Bye -bye.  \n  \n Operator:   This concludes today's call.  Thank you for your participation.  You may now disconnect.  \n ", "original_text": "Thank you for your participation. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}, "hash": "5299b11a9ef8e0f94df0f8bb0d3b82cf6c4d45ff4958d4c3789cbaacafeb399d", "class_name": "RelatedNodeInfo"}}, "text": "You may now disconnect.  \n ", "start_char_idx": 3560, "end_char_idx": 3587, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"9861564a-b70a-45d1-a8d3-440b2bf43b82": {"doc_hash": "896c4d285aa7ce61f1985027707432093454d76d12bf4cd8188d9394c287e2cb", "ref_doc_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c"}, "6aab3612-657c-4607-a81f-37c18078577a": {"doc_hash": "7f47fb36442ac3649331587b194a153dfd850454af4a8a5eb364cd6341a961cd", "ref_doc_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c"}, "1e0f3ba3-6964-427c-bec0-c65bf3161363": {"doc_hash": "ddca16fc98f853ec356973b592734084a60e4095483ecc4dec1c241bc5eb7ca8", "ref_doc_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c"}, "f5451f15-5a39-40a1-8060-d001bc39b9eb": {"doc_hash": "be3be9d8495a337032fcd476b76dbea6e53914033be0ff7e5526fbcb020a03a4", "ref_doc_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c"}, "b12e7571-47d5-4063-88a8-bec0885ac20a": {"doc_hash": "c55f68029feeb262be2b7899fda29e2725ddc01ef63c3685276b59963818c1eb", "ref_doc_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c"}, "226dbb9b-725a-4dac-9307-f6fb78c81a4d": {"doc_hash": "21d59bba4892b63fc459059b6464bf9f49accb6899fde4cf8b7bdb3e66a0f69e", "ref_doc_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c"}, "61f2f479-b3ae-4113-a570-ddd7ec89e85c": {"doc_hash": "e86080bda4ca23e42b59d57239dc58e9300fa4f1de7e0e8a83d6b624c51b1596", "ref_doc_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c"}, "2a04914f-e86b-4004-94e9-8e12dae0d039": {"doc_hash": "42814a4953ee35a1ce65bd63b7b3d4298b44f5eb54fef6d4ed81a20ef8c25a5c", "ref_doc_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c"}, "3356a4e6-41ab-41b5-9b56-858737803b51": {"doc_hash": "3c7001b523e63af492f7ff355d5345ef90ddcb884c5da186b0e2a39d0f24a418", "ref_doc_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c"}, "b191f8a7-9b04-4e14-851b-e0fb69333558": {"doc_hash": "46eed298cbc5bb0cb44e12b08894b9cf86136d4d9661e4ff4a4a94ac5942a5d9", "ref_doc_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c"}, "d5d5942f-578e-4009-8a88-0d9fa4e23502": {"doc_hash": "a5f8847da9f5a578ce2db5aa1ae5ea55dbb0d709bccad19f14c2c13d0bc81de3", "ref_doc_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c"}, "c070cc17-29e1-4cc7-a97c-78a375db9e32": {"doc_hash": "977431299182c299d94145e89b6a568313f4aaa27c11e412efa77b7fe2fcb69c", "ref_doc_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c"}, "5953b510-bfa8-44c9-a1b6-9c11cf8a9f7b": {"doc_hash": "529a20d529e8b6e4100a8313008faa5b9236161d0131734708847db26301fee0", "ref_doc_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c"}, "a88196ff-144c-4c7e-a901-8b54d0e35030": {"doc_hash": "40f251e3deac3c4d5ef692e1c2a29ae98e8be9894d685a4836e458ae54948a26", "ref_doc_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c"}, "0498a176-4a8b-4378-8cbd-4ea71576bfee": {"doc_hash": "b1b019f142de14d13d41a3b182d15734cab3ec84f381a7a10f1ea3bb048d032f", "ref_doc_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c"}, "ad088871-518c-4144-b4da-bfe6cf82e5a0": {"doc_hash": "acf28117cf26cc5b630c1f86a4d4047fa587338256d5a197f2002a99e7fba048", "ref_doc_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c"}, "82ef9e54-d236-4694-a3ad-0c632f7fa4ad": {"doc_hash": "0c8d3918d58d2bdc25943d5677aa4bbc2046689103702fb50f757ca1a16667eb", "ref_doc_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c"}, "2c69b1cf-7580-4578-bf13-acf0e6f84109": {"doc_hash": "442313af5499f69960352a0439e1e6a8a3a3c8804d00575ef0685656c1231b21", "ref_doc_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c"}, "2e62478f-8e60-4340-b645-15a550ea1ba5": {"doc_hash": "7482515834d4922d100c3b41666013a1b604e3c9267d63a388c97af8a1edf089", "ref_doc_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c"}, "b5cb5b03-cf22-47ae-b102-1408e6d32026": {"doc_hash": "782017f75c3d19f799c38a1b00fe91abd860a845ee8bd61dec66454932291c70", "ref_doc_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c"}, "d59015fa-1f9f-4c8a-84d2-f8197a5795ed": {"doc_hash": "7fb30d01942380c4966d8663e9db82652049129bd8a1638624b364df6b3b0360", "ref_doc_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c"}, "7cebd692-22e4-4e83-a105-39d39e4cf86a": {"doc_hash": "b22a25e53ebd30634603ea25736dd959c24882b84a21764b34bddac645d980b9", "ref_doc_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c"}, "7559097a-2603-40c2-969e-62a7586e23df": {"doc_hash": "35b2b80f8026b76a4431ba51167347ad121c87ff01bf3ba2088c72a078e530db", "ref_doc_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c"}, "fc7b6a4a-0193-499f-89ae-3781930222e2": {"doc_hash": "888ea3f1e7c743da83fb90f1da1c83fec615a0a37b185e46834147b5f567a4bc", "ref_doc_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c"}, "04154aa0-8f35-45e3-969d-00497c5aef08": {"doc_hash": "3e6d563444da1fd8e10fd44ef7c614edb3e8a9b98a9ce755de2b7d503b67b67c", "ref_doc_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c"}, "31e3833c-1067-45dd-bc8d-57473732b783": {"doc_hash": "e9fba5ecf3c7352356a57d13f06a0d752c578de580bf72e5eb3ada8ce8b775b5", "ref_doc_id": "1b7bc354-8640-46f8-8be4-8d9dca28145c"}, "32d0cc58-70a4-4008-b106-7e6a01f509df": {"doc_hash": "b09fa85e65565b420259af905c3e99db8dab2b4cbe77c49164c2d9e8fc8453a2", "ref_doc_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c"}, "42721dda-8296-4c1b-ad3c-ee45b0e1914a": {"doc_hash": "2a243d289de08c8e90d4196bc14529e5ffb5c7b6370a0ced23c8de275a4c8812", "ref_doc_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c"}, "54a9e66e-a12b-4d9d-aeca-b849838d45d7": {"doc_hash": "6fd396092ddcaf0cafce627454186cf7bce009838c2e965564f6c64b707e084c", "ref_doc_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c"}, "0958599d-8eba-447a-83f6-bc31fe888a31": {"doc_hash": "12890e4766b442e2e285e8388302aa785d84ace491aa423aaf64a7b515ebd9bc", "ref_doc_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c"}, "b2bb5b4c-3f5b-4325-a670-3213763ce4f2": {"doc_hash": "ec9fd06f032dc92be0c886058c3ab7b4fe773fa6dae2c0ab40a34723288edee9", "ref_doc_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c"}, "d981d406-88cb-43e0-93b4-8682b2efbe08": {"doc_hash": "d05f5261b32c9e7b85aeb04145d30a47391b6343310d7bbe581abe8f0c97bfe2", "ref_doc_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c"}, "65e69f90-4d3b-4920-8807-7fa36ffb0455": {"doc_hash": "6de8f6cc3dd2fc21b0bf7627cf0f2a7186e6b4baafabc5f9b760dcf871916fa4", "ref_doc_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c"}, "1b7e229f-4221-4be1-9994-ef2b44054550": {"doc_hash": "f0f515bf207a0121bd83e0d1b838e17259d7860a69d60442614f17e483103ef7", "ref_doc_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c"}, "02b4e416-a019-491b-82c6-982b212afce2": {"doc_hash": "3c5999a5be2d3448b128b1eb8c67b7c78e7ce6c3fac23f2fa78e872e453adb18", "ref_doc_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c"}, "d1c829d4-ebe8-408c-a577-524f42309f36": {"doc_hash": "a255d34c1f9b72c871685ab57e113db39094ef600039bc53f62970795aafc786", "ref_doc_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c"}, "aa1d083b-1725-4351-83b6-1293aa5e9099": {"doc_hash": "6dec8e1ee5194e7de9d5c82dd609ad22b94c4d2e9e05f79f9ec1d78e20cd26e0", "ref_doc_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c"}, "094d0bb6-bfca-4e59-a0e9-e02a806e0b62": {"doc_hash": "aa6f288b773314cae1ffff461f3721a517fe7f7fc0cad6a2b47cc91bfbe24c7d", "ref_doc_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c"}, "839af643-252c-4d9b-b9b8-ff26a787eb09": {"doc_hash": "c5f8dcf80393bb2ce8fec99b23631dd928577c84892185f951e68b39713150d2", "ref_doc_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c"}, "4831a1e1-4d97-4e6f-b374-8304dee7dce6": {"doc_hash": "4e554f4b2941fcda18b00fe6699dc4d15417d30d789c9d9a2aab61eb5ba516ea", "ref_doc_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c"}, "4e90fadb-caab-441e-957f-cdc5653f558f": {"doc_hash": "fe954f62d3ab3c83c130f8217f748bc61c408e86df8ae915587707e0ea82250c", "ref_doc_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c"}, "108ab7a0-30d8-47b6-ad79-7ef2d40cbc2d": {"doc_hash": "bd4f0727ce2c0dbdd41f6507adadb3017257b0228072e1719836ff6a97f84c6b", "ref_doc_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c"}, "89fa0cae-9246-4d29-924a-64e5c3f107b0": {"doc_hash": "481c8b7e778d1afe15e122753521ecac22593ba84b2f8985881ffe228b6fbf36", "ref_doc_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c"}, "0a5a8843-c88a-42ed-9e28-c2bc1a86e6b0": {"doc_hash": "8f4fcbcc84f1c1c9238f17e088db71da075dba50bb3f2da2c0b5b6cae7cf2dc4", "ref_doc_id": "e53884c2-aa9e-4137-ae64-a636c65ae76c"}, "8113da84-d516-46da-8331-ad4d997fffa3": {"doc_hash": "5c1c7291f7fe9f7ce101af11f311e2d0a12c22f1342d3915c47bd3ada775dc46", "ref_doc_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428"}, "5dcb6d96-85fb-422a-8714-42e825b549ca": {"doc_hash": "a2130881ee5950ba3d0d3166676dfdede4b6ea7aa27220394ed9b61c305f0e07", "ref_doc_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428"}, "080cf7ee-82ef-4bf2-bfb3-5ac287442c0a": {"doc_hash": "575b088246343ba530763441ddbb764096d526c165cb22ead4508e83b486b2af", "ref_doc_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428"}, "b03ab9f8-98df-42ef-9919-a6aebd2afa4a": {"doc_hash": "1acd63fef4f5711a736f2297b2fbeada5631e74750d8ebdfe6f9c3add1e2e2a8", "ref_doc_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428"}, "501dc48d-c75e-484a-a273-11432264f642": {"doc_hash": "4c2f6123b0c5cbce5229a2fd61e5fd6d68f48c7150058b242022b808848dbc33", "ref_doc_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428"}, "cb05aaa1-8187-4bc7-8f74-97b4a4a6cace": {"doc_hash": "f00318913f0136c255bdfe73773f5ee0b46f575b0c7ba269ce025bcacc406035", "ref_doc_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428"}, "3857ea75-02f1-441a-bec2-710521da85e8": {"doc_hash": "c13546cec519ca3afa89099e72a4cb2b8e5267eae4a77c32ddd82a9012750c63", "ref_doc_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428"}, "e709a4c8-3c59-4887-bfa8-4dd4bcad1129": {"doc_hash": "a2888d4922681c735c2739972a325873c9caa0ab6e4677f74e59c3af2d77a62a", "ref_doc_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428"}, "9fb0a74f-8b1a-47fe-aa29-9f446dc32900": {"doc_hash": "cb6c9526bdf1b2176c9ae6fb520238631dedeea7335b7a0d21eb313cc662e246", "ref_doc_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428"}, "18d5860e-81bd-4772-acb2-18dee7e45c67": {"doc_hash": "b6ad0583050176f0722d0829100308870dae178e82cdecb50080fa19287c599c", "ref_doc_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428"}, "0db1529a-4f62-4b88-a1a1-0862a29384c8": {"doc_hash": "fb88c2bc9f4d463aaa505067c39c6220fbc2f036582697c3aafaa82361936675", "ref_doc_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428"}, "e09c3658-5a19-4455-9848-1e3c31b8bcca": {"doc_hash": "e448090b4a00beed16665eaad16320606d6e708c7325a1534fc36e02d521556e", "ref_doc_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428"}, "56ca1fc6-3a0c-4722-bf70-073e48a9e59e": {"doc_hash": "d62e579275103809e4700686837a2fc25e55578cb1fba941997517410f2fd024", "ref_doc_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428"}, "7d9ae547-ee60-4220-a19c-27e118511cf3": {"doc_hash": "3bc62633eb74562568ed0cf98df97d95670dca1e033da7eb38885ee46cfd71c3", "ref_doc_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428"}, "f272a3fa-544f-4361-80a9-9182a2e68d66": {"doc_hash": "ed42de7812120e185cbe1b5bc439bcb1a3e5f7cc0782c583b33404591f93acf4", "ref_doc_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428"}, "7229ae2d-0630-4d11-af07-4d725bbea20d": {"doc_hash": "3d28618e5fe6535f5c24e56b24649af39d4a53e08946809a062cae04df584b7b", "ref_doc_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428"}, "967132a2-bb30-4ec7-bb8a-c10c6dbc397e": {"doc_hash": "49b618006812d5c66caeae66ca7a9ea53b481fcdb4538d956938275b59dd08a1", "ref_doc_id": "be79c7a1-50c2-4cb9-bcde-3623a2961428"}, "4a85ab10-a64a-4150-9f87-972ed3be1638": {"doc_hash": "56a33a6cd19ec3d52df59e99933195cfbc9571c4250f80b688158aa5270acf04", "ref_doc_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8"}, "ce5b11fe-765e-4cea-9bea-22d2aa6ac937": {"doc_hash": "46644c92d7fd3522c058fddcfe4f31c2a355fabeee265f8ac2317b534d4ade6d", "ref_doc_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8"}, "3e05a428-97c4-4220-8fcc-c55ff18471f4": {"doc_hash": "893ca48f838d3ee8551c7a102eb8b08c477628b15d4e1dfb2b1e0909148f57e8", "ref_doc_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8"}, "93924e37-6ee9-4f56-a46f-c0715c587de3": {"doc_hash": "54bc5b4a5e4a751a92878ea859ac3ae4838264993150a3ab1f3176155d7f50f0", "ref_doc_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8"}, "1f4b64fc-3b42-41ad-ad5b-6a1059b5630b": {"doc_hash": "5dec63c986ec2ecdcda0f8290197731c703aec511a516235195a02205fb85eca", "ref_doc_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8"}, "d15799ae-b1f8-4f7c-83e8-5f1d1c41cb14": {"doc_hash": "11588cdfc0bea4d05a4a1faa0d86ce734f4061f2414d40dba5271f70a1a20b4b", "ref_doc_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8"}, "17839fd1-a058-44f8-8662-51909ca3db58": {"doc_hash": "30b42052227553ffd6b66406456315304c399f8840add4fa694441b61cb8a9a5", "ref_doc_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8"}, "43957dcb-6239-45ef-b608-0b0230654bfb": {"doc_hash": "4d9312362b4ca522a862aa0db0a84882dae63e98be1ec8cbe8117baf97016ae0", "ref_doc_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8"}, "9ed86934-c1be-4007-a442-28c531e54ab6": {"doc_hash": "b80dcde59f5a3f7e9eaed5a00a10f580ef2c3030bf7a7f563548f8dbd0d355bb", "ref_doc_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8"}, "d0a90130-8552-4ed6-8f9c-e007b61935f4": {"doc_hash": "6ca5b59b12547fe27bd9554e522622eb3a4bea8fdb0cc3dc7492d3686d8b280d", "ref_doc_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8"}, "5235ea24-9b80-48c0-9394-8054a9b6d888": {"doc_hash": "7a2b016b806f8d9db0e0f2c50db10d6b574a71d19d3cb158f88edfb0221facf0", "ref_doc_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8"}, "0d4233c3-c624-45e1-ad85-9120a667415b": {"doc_hash": "dbf220aaf37769a276da3acd42a5ed32cca771846d5e8d6fb5e70bcf5e5574d9", "ref_doc_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8"}, "3bf3d11d-b797-402f-bbab-78a092925771": {"doc_hash": "d105be8680faad0505b3da33baddc293d6883ce4a65deb69ac7f1ce43eacd229", "ref_doc_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8"}, "ea82698d-8c6a-441e-81e8-f80fc4fa01f8": {"doc_hash": "5fad2641cc5b36bb40693406c543cb481ed70bb43ff0389ee38263ad498289ac", "ref_doc_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8"}, "5f63c2ae-a369-48bd-8dde-a40870c8a860": {"doc_hash": "18eb8d91efdcc1acc9996ccd8f2d2b2d7e40d3d791ba51481b63229aef50c80a", "ref_doc_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8"}, "0cc4a662-1fca-4698-9576-41816536bf48": {"doc_hash": "825ed16a592c9dd6e563f55c7ebbf20d3c804706f447e6985af8ba0802b786a5", "ref_doc_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8"}, "261954c1-3e5c-4f90-9c31-bd54d99c9381": {"doc_hash": "d31018f84039ea4c0b6223ab9ca926332dea6ea6c565da4045f082bb14aa21e3", "ref_doc_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8"}, "70eeb967-5220-417b-bc67-e7bdfd9b3830": {"doc_hash": "52031687c596a3cf8223d5538abcc1ee2f52f6742177655c1ba072e2db938f94", "ref_doc_id": "08866547-f0bf-4dc1-ab27-1435a731c9e8"}, "430a1f3f-aefd-473a-abd1-b5f71790776e": {"doc_hash": "038c2cf15449063b7b1ed4a2e268ba90a1e742e999a890cb3f54009d63233e7a", "ref_doc_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5"}, "9b51c219-8a31-412e-9406-0cbb598e6777": {"doc_hash": "cb6f56015ecfe196ac69ed927cb8eacf39416ca99ac2fa8f33c1f638d9ff4b98", "ref_doc_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5"}, "7108691d-6288-46b3-97b7-ce281cf24d07": {"doc_hash": "da2ae57bbe671b2bb7468e34de0deb879fdc28c807c2fec10238549d6e9f1cc1", "ref_doc_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5"}, "581d546e-cc9b-4cc6-8b01-944a4be9a342": {"doc_hash": "9acdb3a8919b6cfde81116ba37010a7d9682cff6ada71474dafc33a7d133655e", "ref_doc_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5"}, "b6d148ce-59c3-4bc0-8481-00116f610f6d": {"doc_hash": "4a8b3e6e19568a32ea2d99fb6ab8aa7ece3c3f290de882ca387b34730f7c7ef4", "ref_doc_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5"}, "da2a0182-687f-4045-8126-37ea0b05dab5": {"doc_hash": "21e02cd6a03f46b28f66fe7c098ee6a3285ce3d6baaa364b886b12f6e4f63c66", "ref_doc_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5"}, "85407112-c2aa-4931-a043-020974083122": {"doc_hash": "1b43f346ea501f6ba5a09f6c5398ad8b8e8ca3b768ca308bb977800750748a26", "ref_doc_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5"}, "76590a9c-6493-460e-85fe-0e5f7fd691ab": {"doc_hash": "aa2218dc56c9ee619fae21a304169c0e50f843841a0c16ef052a6c99a7563ee0", "ref_doc_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5"}, "3a8e33d0-9976-46a5-8f04-7c3ef24c36a1": {"doc_hash": "70f44660588c406e23617bd2a5025d69a89e6e44d24555ad1a57652ef244e7e4", "ref_doc_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5"}, "b3750c08-2d5e-4847-a73d-ec230d52f4f7": {"doc_hash": "66a6fc010d6c5cd828336b8161f1557233a0766a00c04b39fa654e77ddb01222", "ref_doc_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5"}, "844edd1f-0b2d-45e4-baf3-78fd6a0395f6": {"doc_hash": "3d03d7207c81c0758c043abf99a8288625339e10711b5bf5b44ff88f67fd0e4d", "ref_doc_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5"}, "b9ee4045-ef6d-4ff0-a9f1-e62f319454b2": {"doc_hash": "55d74b9d734700463b9c18552b957858c2b967f5ea21b7612bedc624970e1aee", "ref_doc_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5"}, "f44438ce-2bd8-4996-b2da-94fad6042d67": {"doc_hash": "ae806ff588d8249de7eff43fe1f593fd2018d8bcb3f7d2e4450897fd876328d7", "ref_doc_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5"}, "f256a355-3301-4d9e-b132-7611abf6c51c": {"doc_hash": "e4cbde8d4472ef7607aee44a424ad0e461858899d11f5bb8987af65bd035f232", "ref_doc_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5"}, "7dd0e815-f9f1-4496-bd29-e6c00badf645": {"doc_hash": "c06404c3d7154c1ed47cc0c65ed06fa1fbf5863b522fcb3dfabfd937db91382b", "ref_doc_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5"}, "95188c0a-9dd5-44c0-92a0-83397e297501": {"doc_hash": "dc2bf8d3801c0da9915103536d7f3fee54bb6b296f4c7a7ee233e5f39527bd23", "ref_doc_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5"}, "bc4e14e6-b3b4-4036-a7c0-5e7368002a85": {"doc_hash": "1b388089b210bfd9177f82fd94e6cea12c8285bd171683bac0a3a0e5927e4cb1", "ref_doc_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5"}, "70f8eccf-3cd6-41fc-931a-41a8bd8f0cfb": {"doc_hash": "5f3455d3ff37ae6a36755ef53a372c5ca3d20f573be074497d250d10d80de488", "ref_doc_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5"}, "1a4c5154-0f73-450a-8145-ffeb11640f9b": {"doc_hash": "e56f217824b243c5b95d174b9c5c8e19e57a51041f23c99e39b2423b23d47b0a", "ref_doc_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5"}, "bc3ffc41-5602-4435-b2ac-697626c13b61": {"doc_hash": "842f31c223c76d25adbd78d9cb448ee212ca20c754cc032c53bd910816c1c10d", "ref_doc_id": "ffe6f59d-18ff-4d3c-9a1c-b343781737e5"}, "605bb7fe-0bfd-4ac0-9bda-f81bd93e6273": {"doc_hash": "395104c8a329ba5eaaaacae604e515f9aa7aea145fd953c873b4bd5bce5b29f3", "ref_doc_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9"}, "2e2a8f21-decd-405c-9226-2acf33a7b7fb": {"doc_hash": "5bcae296f98f41157d3362c6cd8e6d10f4ba3bb17a5fd944f7e2d4464e4abac4", "ref_doc_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9"}, "c2529853-f67a-48c5-bc55-b09174b24e8e": {"doc_hash": "2c59531130c7bcb88c9a39e1f2a9e8675b03a4e8dfa0b41f86de92174d5892b4", "ref_doc_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9"}, "027e8c4b-bcd3-43fc-973c-2014dae2583f": {"doc_hash": "774ccd2c42d4d994eedf472e15352cf556ce3f9dc5c2a93cdddbd720c4246be0", "ref_doc_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9"}, "c089ef74-fc8e-40fa-b18d-57c384e0e374": {"doc_hash": "6008bc1c7df6060ab537185993f8991c39c2e3b758c5ae4796cfd4fc30bc083d", "ref_doc_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9"}, "070e3616-a37f-42e7-92cc-84f3c9c73398": {"doc_hash": "0edb4abace1b301592aff6286ddeb71813279fc3d6a16ac55666398e8d4711d6", "ref_doc_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9"}, "1a2ecad2-7787-482e-9207-2d508b90051a": {"doc_hash": "fb9bb09285c933e76efd83f18544ddcb2b6c7d453fcbc37ca35be37424acbf43", "ref_doc_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9"}, "40151aaa-aff3-4b8e-8a7e-daafac2c0930": {"doc_hash": "7a29ba079da6b54d68945b8e06d6ee3e05bc6ca48ce2b65378e2078ca2a81f55", "ref_doc_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9"}, "f226b963-5385-469d-9f1f-071d5d8edd06": {"doc_hash": "c22f6761bdc380e226575cf96dae060f4661f52f835a8f875faf2f8a7197898c", "ref_doc_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9"}, "5414619a-04e2-4331-ae8c-f9298754a890": {"doc_hash": "f4230f0e4c8b8076a1e943f2ba0e7cd999ff9c19a29e65822bba8a9cf24bace7", "ref_doc_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9"}, "0f6ca02b-fde3-4949-8abd-d9145328ec9a": {"doc_hash": "06014e808be9489d3646206481c406253e5458737febbef58fe73c7082df49c7", "ref_doc_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9"}, "e05ac319-81c1-4405-9db8-68c32655f164": {"doc_hash": "eb724c5e22e78b2c5f08542bf109a9e24a902f17dcac92b0a9f71e2df78456fe", "ref_doc_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9"}, "ec09fd3b-550c-45ce-b2f8-6ac4d13f832c": {"doc_hash": "4ad2c3ba194be5ec4a32faf455a03ece38ef6028499f46a1d2ba278a586f70ad", "ref_doc_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9"}, "6d916785-c4d2-4407-b562-55cc80253357": {"doc_hash": "f64a5a4879cd866a37aa0695b8495a8211419971914977ff906ce7a72f70ba89", "ref_doc_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9"}, "d3d8d0f1-0aeb-437e-ab3b-326cc243dcd0": {"doc_hash": "8c18a66db200e675a7937119a41d0bdaaaaab1652ce8d19df8465386a8cde8f1", "ref_doc_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9"}, "7b0e4d8d-13ab-448b-8367-83c4af4ee5e6": {"doc_hash": "fc171b7efc93aec342524a90b6680d6b5caa2021a9c59a3e6941867e13a6204f", "ref_doc_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9"}, "6b47b381-f505-4337-ae37-92b5caa91be9": {"doc_hash": "24b573c9aaa56312aebfdab57a8d5b40160b6cd2be7ce33eeeea2b86a41521b2", "ref_doc_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9"}, "76b98b59-e7c1-4ef2-a0ca-c38c769e0fe1": {"doc_hash": "0a7dca56a6c3ea751b4bf9b7d2c2927ccf586f8a7139be69e3784d2a6c808e99", "ref_doc_id": "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9"}, "485fcd1d-ee29-411e-8806-1f79d3552621": {"doc_hash": "cccb54cd75e45b6b468ebfb51416dff6cbd0c02a3f397641796e28d526aa8968", "ref_doc_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042"}, "ffaeead9-2797-4a33-b6d7-403e1b7528c7": {"doc_hash": "aa64a34fa77c3c6ccad883d3d1501843c72850070401a81bb74f42a3cc7cb56c", "ref_doc_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042"}, "c33e6f22-c8c1-437e-a9b9-1b567be2e47e": {"doc_hash": "bc707c0e3a796ea5d8a3b21c4d609d50e04c48c1db087fdc27866a8b422b3996", "ref_doc_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042"}, "9c392311-48ed-4495-81b4-b05150443507": {"doc_hash": "29e59c1543798fa8f887fb8379e7b35e01176d0bbb7a23b31b0c0dd94281d87a", "ref_doc_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042"}, "19934eeb-9f06-470d-8db3-a703dec1e5c6": {"doc_hash": "a49bf025f7dc322a15e54df88b699c7653fe34eb74c6d5bb918091a9dc404a5c", "ref_doc_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042"}, "75e80953-b548-4afa-8766-3efbddba1cfc": {"doc_hash": "ba20fee77a45fa89465df914c926e01162ed04feccb2adf66f8e43876845e282", "ref_doc_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042"}, "3ba627ec-7812-4e20-8fc9-5117d3495605": {"doc_hash": "b333ca4f86351d949f3970ac30393eafc2c086ade7b2a8996bfe63de2e111a86", "ref_doc_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042"}, "d957f2d5-1247-4735-8d0f-97747db3432c": {"doc_hash": "09c5083570de746a949a22073ca3fde34e647e81bfecfccb06b06709a6cfdb24", "ref_doc_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042"}, "1c80b159-113b-4b58-9e08-eb3d9ea55149": {"doc_hash": "1de7a705b207ffe7d24109a285d18b9c222f1c1498bd7c5c8a738ec295585188", "ref_doc_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042"}, "5ed03923-6fb4-4799-9b59-e4687bd881b0": {"doc_hash": "b9dfdb6f1018b938efda3e07e9a4cb06a3b82bf7b0d8ec0064b008cfae5a7bca", "ref_doc_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042"}, "2b3aeb28-18d2-433c-861d-93c630467028": {"doc_hash": "fa5ee44ff47400f4d6f49bedb8a7629f7ca484aa6b004677352799627f69556b", "ref_doc_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042"}, "a9e9f703-72f5-45db-a312-68b6c9a58241": {"doc_hash": "052c59925c37430fa556ca7e173bf7b9f8d773b881f70d97a9a83ed053e52a75", "ref_doc_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042"}, "2aa3006b-50b9-42ce-8db8-0f6473cd71d1": {"doc_hash": "cfadbfee9bd9a9f741c8cdb5b2eae94f346ba1783ba0005712de2d24e4683612", "ref_doc_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042"}, "9236038b-0316-469c-8ba2-b00fc7e1a32b": {"doc_hash": "b663fe37b56251f12cf55e4cdbba548af41869aacfacf3f170283aac55b18643", "ref_doc_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042"}, "4255d71f-0a71-4733-8fe0-8815dc7ce453": {"doc_hash": "5de3761ceae96bc7266090572f30e5dacaa1d1a6d27d019f7f5d04aa6e0cc93c", "ref_doc_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042"}, "aec36554-5df3-428b-be01-75721d468144": {"doc_hash": "9b0aa65811136547c028c7d3ca596485d89f0a57cbee3fc4d2fba10066a94d34", "ref_doc_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042"}, "c22ceccb-da3d-49e7-b90a-80d1c3351431": {"doc_hash": "4d31d9aeab74f3d86a53daa45a6a138f002a7322e88479e4db52736c5bea5bb9", "ref_doc_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042"}, "86a56f91-d08d-46b6-89d5-f23b6c617af1": {"doc_hash": "6900978ba9d1eb6f3b6f8796643fdf4649ade835dfecacc9a0a7b4621e62cb14", "ref_doc_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042"}, "2606b8c4-dd6a-4607-96e9-f3fd176eb08c": {"doc_hash": "6941f8aa1ce73342afe100ad365b05adfb40d2b6791e86afc9ffc30e8ced3dae", "ref_doc_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042"}, "62685d00-6522-488c-b946-3ff8c33ab0d6": {"doc_hash": "1ab7500c9bfa2e5a058ff999f7d651f76e8ebe33872c6a7a0e114e58799ce473", "ref_doc_id": "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042"}, "2e9a39ad-2e5b-405e-9727-a9af2d191ecb": {"doc_hash": "d3b87c173e0dff167e71a4ef89abc39bfd1a09cb16fb42680b8814b9657af4af", "ref_doc_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e"}, "c22dc5e4-13f0-47ce-ba45-be1ea0ab60f8": {"doc_hash": "acca227864b770c0aaf4bdd4ffe245d3034a12555bea9ad7e5c2fcfc72684c2d", "ref_doc_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e"}, "15e44632-45b9-4c32-8287-133ccc99385a": {"doc_hash": "362459e636da60ca756496e54453ac1b2e0f2eaa70f823904759eb68b71ff4f4", "ref_doc_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e"}, "90c3bdbc-03a0-4c73-884a-c27f1afac135": {"doc_hash": "4da03ca20beff07ebec99cfdfb21076421751c83e3ceda45802f055adbb2bb23", "ref_doc_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e"}, "9036003b-7dc6-486f-95bf-383611221c93": {"doc_hash": "e33f5b07926d278a486602d20822d1b91d59f25211b4315df31d310419e86205", "ref_doc_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e"}, "f04198a6-1173-4de4-8f0c-6bf60d5cc451": {"doc_hash": "23e31620c392e74c2d08cdf1261a86f486622a0a34f469f9d7e0d2b07fdc6021", "ref_doc_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e"}, "9b0e5b47-aacb-4765-9eff-4f5973919264": {"doc_hash": "975f1dd6a67b132eeab4dcd99b89594b83c69e37716787343781ff3c80d02b6d", "ref_doc_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e"}, "31617823-033b-4bca-9eb4-ec6a93b390e5": {"doc_hash": "c3bc118e6088b0ce04b393d94ff7e335c1dcd7e624c691fd295ec215cd40a367", "ref_doc_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e"}, "3b0230f9-8a5f-4fc0-ab0e-72c821945ca2": {"doc_hash": "295e79b82a32651510c112f35a464ea97f1bd9b3a74db30cf4048b61baec2da6", "ref_doc_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e"}, "b391213c-79d2-40a3-8eb3-de3bf348730f": {"doc_hash": "5fbdb95e6c543da6c6c28e6f2be62df1757ce4560a52a0220f32088efc902252", "ref_doc_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e"}, "b81448c4-6431-468d-a70b-d5b01956f5e7": {"doc_hash": "0813a41ff620f799e5c680240ae077fb7542c5afe1623afee14e1ca8d36701d4", "ref_doc_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e"}, "b95e763b-f60f-41aa-98a8-710303a85cdd": {"doc_hash": "ed5d0234e9151fad2930a1f209187e432dbe93795af62bac05f0488a491b995d", "ref_doc_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e"}, "0d8ff9f9-3f77-4385-bd65-32f4bc24020b": {"doc_hash": "cc128795c656659060db016f4762940b486f6bf26d4160a71ef0f7b910d3ac35", "ref_doc_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e"}, "e8baa435-44a4-40aa-91c1-d5b7cc6ed784": {"doc_hash": "5e91df2f2c55da013725c19cb38fbefc0e564fcffd01c769358833d134f9c91b", "ref_doc_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e"}, "abdeaa26-759e-4242-9e81-8b3a94035ae4": {"doc_hash": "04860fc71e028002b8cc436894f60c1553b9ccb92ec23e633dbf596534909b7b", "ref_doc_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e"}, "6667823f-b768-4396-8a17-89fc8eca647c": {"doc_hash": "425d37644e4e46b95c0c232f8cfbdceec8f71f81bf8bda1204740658412859cf", "ref_doc_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e"}, "62d6ac93-7909-4633-92aa-3d643083656e": {"doc_hash": "6ed64299430829046f71e8330fe4bad9fc3dbb57567b772f7616e1ff6889e8a3", "ref_doc_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e"}, "cdfc8e8d-548e-49c0-84d3-2ee8b5015ded": {"doc_hash": "80a34d797e0ea5ac78d079dc4869ff1da5e8c7ae260a5241335e04182fbbb09c", "ref_doc_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e"}, "661b2526-b098-4d8f-bf78-7259217f5b8d": {"doc_hash": "1fe0cadc87c258b6f633452015781cdcb04464b85bd530b53993d38f6786ba9d", "ref_doc_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e"}, "8a96a8bf-ac67-41b2-8081-bf8a8ad9963d": {"doc_hash": "79ec5418af979e131d67fd5c1a5d7173c1098a6187e3dce10a0a293d73b0f895", "ref_doc_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e"}, "d8109d82-ffe2-4964-822b-23e52c64d118": {"doc_hash": "8335758968ef60267fc1365372d67daa6703677d04df9a126233e859003b6789", "ref_doc_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e"}, "594187ff-4f0c-4a59-8bef-463e8e6e503c": {"doc_hash": "d709764fab42df70c15eddc973f6776f5e309fb5d86808bdc0cbf08977b4eb8d", "ref_doc_id": "3afcdda6-11be-4418-9147-b2c5a6e2722e"}, "e448cbb6-2a50-40b1-8baa-885ee5c2e998": {"doc_hash": "9c261333ae32044032bf2429750325333ca57ff22a45dd90446b5b5629cf6fa1", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "0ce0134d-b301-46c4-af45-6c2a28303ede": {"doc_hash": "cde038f292b9de8b745d190e781d1ca5043c66362dbc2b46eb2f8c88db22125c", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "4aaccbef-af09-46fd-a8f5-58f5f0b98fe7": {"doc_hash": "adabd06eb62e4a6c6e7741fb279dc43e588d5bba82a795610d46ec95db871c4e", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "5d47c6ff-8970-43ba-8bf7-d3c60c1dd883": {"doc_hash": "db710e121b22ab2ad7ac38fa32c9ec32835d2c518dda762b5a685a72b0e0345c", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "6ceb9de7-ae65-4f20-bd19-90e19e317ebe": {"doc_hash": "eb04850d7b4d8c0dea26b0ac25f0c0596481058a186c5f61aeaffce7b09d2191", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "28cf4a31-14c7-4436-9ff1-9795e257c7ac": {"doc_hash": "c5cc4dae4c68f0b857a29e3de58ae3323d819d86a9b9d2df9f3aae6e2f947f75", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "43ff150e-4c03-4ca6-ae20-c3f742b1e2c7": {"doc_hash": "ed14a36288871805681cde0f59b8cf12fc88ec6b99a90c4594ee2c11b6dda9b2", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "df42005d-e2b8-49c7-a1ea-7725d413df6a": {"doc_hash": "a95b431017c9afaac03b644f8212ddc67e94bce6d06c445afb032e1a27d63ba7", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "5f12e8a1-3440-4115-a305-8759fbe39eea": {"doc_hash": "144afacce85e16fb40b879c3ff56172df1adceec1edf8debb0458d5a298e7ec4", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "f2dcdce6-d897-4358-9eb3-36df32bdc2df": {"doc_hash": "84fe1f7fdb70a32560cfcf6d1dc609cc8a8d8e484d8e988468bf863c7618b729", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "628f0460-858f-49f0-afd3-9511f9ec5e8b": {"doc_hash": "1f4c1a0697e257016dc0ff1d66db40c4d7582ce84e6f656ffb542f6daf5c1938", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "1389b1b8-61bd-4d69-9fe1-2888f3775879": {"doc_hash": "bbe5ddb11b8071a51e1b615b8ed373577e6022721fccf037a19b89d6ab762c9f", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "dd9b935b-2d04-403d-b20d-afdb722b8269": {"doc_hash": "181231c14fe912f3a48b09223207ffe3ebf6d9a3cabf9264ed6bdf0616ab3fd3", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "ac9735c3-b291-4c6d-beea-a07ffaa803ee": {"doc_hash": "2a35e24dfb50c3b73ea849a88c7667dd1067d5ce473cda4388e7aa67621f71c8", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "861358e3-2c87-4d02-b3de-884b41db3086": {"doc_hash": "4210586df62ac834824f8ecef1ad3e0bbdbdcaf42bf5935a6e4e2d0ca1991752", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "c239b1fb-1aaa-491d-a56b-6dde29e8b502": {"doc_hash": "8e86bb9314b9b2bd3493bcf9feabd842cd394148acbf5b14d837d1fefdf3d300", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "5489fb19-b6f2-4087-97ef-9b4731f6cb0e": {"doc_hash": "601b2b17fe85f5ffd83cde17c0f69c24a3de547788e47d65d00270b74024e4ab", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "cc02fa27-d1bb-4964-8133-c2eba7f297db": {"doc_hash": "60389656636eaf67b0e9bdfa402621ec1769ae3e8b3761c51b4717acc4f34e25", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "aa3978b9-e793-4435-bace-738d1606f386": {"doc_hash": "d8f73122ce6f0d431e22b6bebee6581eda11793e5d0aae808c5a09e02a97f120", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "66ffc7cb-95c9-437d-8332-b3d5a3a2e7f1": {"doc_hash": "2776acf3987cdfb1422aff3b6d45b35ea9413729698f7bc4b305dc1bd3291886", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "9c0b0520-8061-414e-b334-bf26bb16d826": {"doc_hash": "2848a480734c31c44e17c0a79c5a728cd0e887c76d7c40acf706e63da91bd94b", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "0ff89030-7a2a-4bf1-a7c9-6d0f3e2fb034": {"doc_hash": "32d0d2e5f5dead67054adfd8cfaa353a4f1f0c3f74db0c9c788455a9dc0fceaa", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "d8bf9eb1-5a30-4f45-a449-86436c88b13c": {"doc_hash": "6c14da1084a1aee76f5012f353d45b3692b235d17acf77694d0847d7dea67f11", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "cd89f72e-44a5-4a3a-bb52-fab071cd1ddc": {"doc_hash": "540c8eb7b898c7534f7a7f8e1c220f7f098a2046d7e665c0943de7666f5bbf9b", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "6cd05c88-5f20-4f35-99cb-8738307ab90a": {"doc_hash": "45adcf46c414dcde682e5a777993776ee452dd5236aa7a404087c43e496a08d9", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "e78d5e82-a23a-48a8-b366-1cd184a63cf4": {"doc_hash": "30d1ba623d145c946aab3b94addd39768651d1314c1be5456843d170d2fc26ae", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "f5b4e004-cc38-4f7d-96e7-86cad313aa26": {"doc_hash": "1cad2d4a1bd8ad542614959d52b85ceb997fd527f1ef38168e7da198d7bcf9fe", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "ab23679d-0343-4be8-825f-be82a151c7a1": {"doc_hash": "8dcac4f1425363eff7b5ac9a6bd00e543d7525edaee15ab25bf87966cc722d5b", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "1036cb8c-b7fc-480a-845b-c52650d8d54e": {"doc_hash": "ed11103ea81bbc5e8a0284811caf97257522fe5ef755018f1ba5ff2e73818710", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "56a300be-0848-454c-a89b-3535ab163d2f": {"doc_hash": "a3fd872de575eff9b4816c793967bffb0e8e7a2b163727a2d96157c08a44e113", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "73ba0f17-981c-41ef-bf82-5928fe5a8bb0": {"doc_hash": "6f4c4972899317033d2086fb2e7a2006b1fdd0fc05f46a48c03888ab56944f26", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "438447b6-bdd4-43a4-86e0-ba4888304dd5": {"doc_hash": "0f34a3975fcb66d3ff4b2577d00b6ec40caea99576af7c8d3e0a59d3b42c1e4d", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "1fc2eae5-ed85-4508-a4af-8649020059fc": {"doc_hash": "a8424cb7114857b49c0df9f7590db91f6555efeb04b203074e1bc42c2897cb2b", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "41697dc5-53eb-44c4-b4e4-e7d934ebdbf5": {"doc_hash": "ae4c77f713c294636c174e60be2022fe390b89b3964a992adc627aa36c88e89e", "ref_doc_id": "665fb122-36ff-4172-8876-0cefc09a4c07"}, "ebd35188-542d-4770-8606-78dc84331e72": {"doc_hash": "0f11120d96b5bfd4964eb924b72e722dc1c3b15235f77d5c73be219872af2be9", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "368e5b6b-9d6b-4eec-b1bc-4a4f6418c10e": {"doc_hash": "8735b2109cb3da03ccb8869c0471f9b2287a855e1a2f412a9af93838c532d78d", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "3a4f2674-243d-4322-8eca-c482a8ca2d7f": {"doc_hash": "ad805425e2ef595c9c17e72e0d00d6e24140c5ebbff2e39abe9eb0bc07dd1bf8", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "14de8a8e-0e50-405b-9c39-e36a2f616b79": {"doc_hash": "2997209c3ffd17bbe9620eb92b463323a60a0f7a15ce7adc25d83041c302be62", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "9303b0fa-83c4-4cd6-88a4-3bdd431e9113": {"doc_hash": "f65a73f2b715b31c0b4dd02124cba82c28cdbacc016372add632be78d0978b48", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "aba09f55-dc81-4092-a01c-86c42372e43e": {"doc_hash": "6cf51bbdf2e5ecdf4f4cefacbca0a303ce0f1a23ea8f3d2fa4fb5ad812cf3d21", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "3b96b28c-db7d-43fc-92d4-795f3c77d197": {"doc_hash": "819f667a07d844901a0ff8b2180dd0f63b03110a619d0d0c93ae1f49d2393d40", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "29d09f3d-7416-43c8-99a7-03807fceda4a": {"doc_hash": "097fc25f1069eb1280b37f686bfc65095d3939ea27061c86c764906af40d35b6", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "11cceaef-779f-484a-bb55-966c8ebe2851": {"doc_hash": "aee035ac2b2351c012ccb75f876afb76349c308e8f2f3cfebfb22a31412a296b", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "75a8c3f2-3bb4-4e61-b063-403cfdfce36b": {"doc_hash": "d43710813059f1f6f510fe863f10506e456bb598dc4ca860b2d8e8e0184825f9", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "fe1958b0-f846-47df-b6f0-a1ae81c6a8b1": {"doc_hash": "e4ccaee001079694a9add6bd9d3e6080d88813a2bc9ebe90d70b57750537e1c8", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "5e905036-5754-4167-93b5-9150d1b74239": {"doc_hash": "6a24dc63ab1feab6cde04ea914c92208b677edc15a198e51e6ef1c7adc31c6a1", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "c64ac2ca-129e-4309-bdd1-89df4533b020": {"doc_hash": "3e62994889ebacf1e2f0dad632fc539115a503fb1a4e7c1aadaec4c4b410da7f", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "4804ac1d-1b72-4761-bb4b-0a21858e4fdc": {"doc_hash": "621f9bcd2048874a5523814f7916c5cbf28f1a7d7cd7781658c3bdd736b9caad", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "ece819b6-e9eb-4aac-b87e-5f478d69d09b": {"doc_hash": "2509c13bcb2ef3240a8f31dd4c88ed682a01592b75802e9ff54da42f7585a6fc", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "09df9415-ecdf-4edb-bf62-fb8bacf371d2": {"doc_hash": "744a73f496754392e88ebd589f0043cc96ede6b1c143fe22d09b763d5fe8b6e2", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "0dde8dec-8009-4fec-93cc-212b601fd790": {"doc_hash": "101a134bfeaa55944de06bfde4a9e0afaac9fcacf7ccff4f451f25a9a7245418", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "171b05e7-921f-45e8-af5e-5c198f4a5820": {"doc_hash": "8434a296168acaba7b20fd88913658327a23316527400e03662a799e4babdc6c", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "67ef369f-5db6-4d0a-9899-507171157105": {"doc_hash": "7cb1e4e726c1941354724b16a870ebc22e9f24b69a0d747b0b38f5adeecda796", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "de205405-3e65-4b82-a12f-ccac86a8aa41": {"doc_hash": "d45493a94fdd164f3f3050fcfc50558f5e66d2d4db93de73a49e892678d78061", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "9f363f80-d6d9-418a-8415-8bd8ebefd085": {"doc_hash": "1d35b0a5161ef9e7611f32ed0b310cf31263f4d3f42d4f598d89d2740dcc6a5b", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "d79def44-e031-41f6-a403-8f74831fb907": {"doc_hash": "e3301303c4fb208568bdb2f83665def1878b28324c6cd131b7a6ff9112a13c42", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "599f7948-0f16-4ab5-819d-a96151394eda": {"doc_hash": "0fbb43a23e08d2c5444fef30d83486672cf840dc2e2a7d0eefa8fb8722b1e76f", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "0ae891c7-79d8-4200-b44e-be7c5c507377": {"doc_hash": "e7dcf3baa1cabdc8c80acb61068768cc120d28605dfc0c7b97c8ade7d8636b8b", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "b4d3f84c-aff2-4e6f-be8a-448099f38a74": {"doc_hash": "fe60e752be4e1e42d3af970a77f7b5a6c61d68488d35ab41c3f8bd0a10f5127a", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "002063be-87e5-4a62-ba25-4c3a457c3d26": {"doc_hash": "2b7bef969cc41cb9de513e7646518c1164ad0db441dddf9ef4e3c7e47fde9d98", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "fdf68bc6-9588-4ac3-8262-4d8f2537c1af": {"doc_hash": "4f4eae3ea1819093d4485b069dc3aace0f8691203668ffbabdcf90b277d4d59c", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "958df874-e038-4480-ab01-eeead07d5eff": {"doc_hash": "ee0036cac7ca33bc1b28d9a7a363641a405d440c87393ce7395d1dba81dea554", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "b0c667db-a07d-4606-b342-73a1d53b1036": {"doc_hash": "6f51fd5a916536c5cbade256fc382de245e7b4d49ebac7b197c56acda43611a1", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "2b9c7156-82f8-4fb5-b724-0aadf5a777f7": {"doc_hash": "c838444204c7beefd109e69c58caae8661464566860bdf58b7d4b35367451f42", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "ed5ce0d8-c1bd-43be-b014-91b50962fe75": {"doc_hash": "e64558cbabd75fd8fc0e57f7f35266db9385a1e10c3474e30aad4a2a3437354b", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "25d198be-2271-49fc-99a6-9bc7d05861d1": {"doc_hash": "d37f32b0280610e296b41486660aadd08fdfa6f3d52df3b044c8758f88fd04e6", "ref_doc_id": "48f73078-3572-4b2e-9c19-4e6845af63db"}, "0d5dbfc5-1eee-4cf7-9990-5a02ff186c4a": {"doc_hash": "1afba6b7c65a44cd1b702c41b003e86a7c4e4312dd72a405c91a8705676598fc", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "84de3e46-a9e8-477a-b711-6d68691a04e7": {"doc_hash": "a917ca9b8d602eb836f3a52a72c4a795a2969d27679bb236a7f2ae008dc2cb61", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "422b9354-02cd-478b-aef1-ab0f92a80564": {"doc_hash": "8fddef665d2aa799544533ebef2902597eed9960d82dba87cea068992830b1ed", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "3b2c7d08-81ce-4ed4-8066-b9a8da216f69": {"doc_hash": "09c3166ac37a9999b274a6a10db06202e5733ab691a24d2fb81954b76e224cb6", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "5c7a6f63-c58c-46d7-aeb8-50e0388b3164": {"doc_hash": "91b4fd38cfc155381ee2fcdedfeb7faf0206eea54e4704d06258b56154306375", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "a156381a-4a5f-493b-a499-fc9bcfebe69c": {"doc_hash": "8ade457139c339c9b75b2dc75a6a030539f026a533fa3c30582dc54398abcdda", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "74b8f877-0c7b-414a-9e26-b0e65c7c5f39": {"doc_hash": "47a279ff3b52a652e7ce3a9f8793cac8120f3464e0f8a036b5571714687ba18a", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "0ffe41b8-e1ba-4920-80c9-7e8d33b5ca76": {"doc_hash": "b4b8533c912b626cbe2a1fa0f88982281c970f1bee2e662478d91e6762744687", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "28c33c24-5e65-43ea-b4b2-151b9d68ebd1": {"doc_hash": "17a3b664577ca5008e8032124ea254609fe018e62fc60ba5391c0bdca1c42b16", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "e05a909c-8f10-4495-a4c1-469c17a9ff50": {"doc_hash": "62db724343947a9ae3979c15b2f4544db271dff4d819ac5c5cfb5028909af305", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "3e21d02c-a8d9-49c4-adcf-a98b909b628f": {"doc_hash": "a1f2a84e57a2550bb603918ec068f93b3c3acec4840af3e39eb1eaf692280f47", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "ca8a54f2-824d-46a2-8f03-b6eae2365977": {"doc_hash": "2ce2d2cabec3a544c8ba054112e79452fecf3cfcbfa09d00dc3fa58a86c8f799", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "716cd97c-bcd7-4cc0-8bb1-88269b7d2b1c": {"doc_hash": "91f5746acb485d7b57c917c693eaa6b0e3ff457bb5f0ddc15fd962b997e79461", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "465ab7e2-da12-4d9b-9ed8-9b430266c3d4": {"doc_hash": "96aac0b86fb6765d5933401d662ad26c5476e7dd41b8532fa139dc21146bf6e8", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "15b8292b-eecc-4beb-9cca-29efc31e5519": {"doc_hash": "e9013e314d9a9a95b833a7e013909cbbcda8245885462737c4b6469a862528a2", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "699fbec6-74c2-4db0-ab4c-558a956363bd": {"doc_hash": "3ad8f27a19f370f8792e7d3883558f987c36e74a5f4dd7b62c412b8e0ac1ffea", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "0cc5ec4f-0e43-4919-92a4-b2582c161aa7": {"doc_hash": "91361e114e76dad98f89d2cc4272022e6da720287df2813d39bce68d63d682fc", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "df2a1ffb-4383-412a-9275-79575a2cf97f": {"doc_hash": "73027908cbf9ce600db855d8694ee2d60b6804b8ca5bd8d90a915a150486efc4", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "45c48ff7-ba8c-4ffa-babb-e79cc693a7e7": {"doc_hash": "4882d07f8eb3773d9c5e4e9480e1de9eefaa828d33485ef90f705a9115aab48e", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "3e34b61b-14bf-4ceb-8a40-a361298bd6b5": {"doc_hash": "9d1741acf9980c9ed39e31454e1a077667cb6d55bd3870546db8ea8ac2b6e689", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "8464a9b2-1a9d-45ed-85aa-8ea949f62da1": {"doc_hash": "ab9a04fddf6cd5f3163f9c27a4c9af62afaccf0c3f24534ae7e2dd8465631c01", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "2591e02b-0f23-4634-8f05-e5822478619b": {"doc_hash": "9ffa3d718f35d687ad9b1381dd1a94321089d4304b079ead5e9e34943b4521a8", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "e1f0c149-ad10-47b6-80a8-c6deb3ee5095": {"doc_hash": "cc97bbbb3f9db0ee0ac4fe19237387fc343639d6f4ae52093eaae5a5251277ae", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "822ce059-7683-4bad-ba3a-898bac0beba0": {"doc_hash": "6259fa4827126a0567386bf0139ba15ecca26841ba7fc225714d3fdbba1791d0", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "e5660d13-d154-4a1d-b2d6-45c8b340b80d": {"doc_hash": "687d6820e78b3a5dd18e1ca38cfb4a2396d78bf995ba6b10f91c68010d5ea2d4", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "d642a1c3-bfcd-4daf-afd1-b4cbcaab0659": {"doc_hash": "84dad57ead0a75ce23c83fe1967f4c1cfd560a811985ecf31d01ddabe8eacd4f", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "9931f4bf-e4c3-4f88-94d1-58c3431d4a47": {"doc_hash": "b2a65d6b40a98639405dcc11f8de38d6e0af17443700c2bed73187c2d130cd6b", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "5100769f-d536-47fb-ab58-52da909c683e": {"doc_hash": "262982fdb801db59d39355c1743a1d390f2acd011a7bade2d1cf91da9a5f781c", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "b7e3e266-f481-46d8-b1d3-744b0dbe2f21": {"doc_hash": "9b99fa851c22f0eb3f423cb4afc213b8d50269d59676dfa9504224ac5f2e8b1f", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "7319d32c-b55f-43a1-bd08-a112d03d1b73": {"doc_hash": "b726ae2c2dd307921169ded0fa3fe0e1ce13ef75b6141bff3f1d6e8405a85e54", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "0c21e646-1431-408e-a788-7c6768eea05d": {"doc_hash": "fb5491c16251bfbba0bfc4e905bf0abadac7ea669e84a6f05f1391098b718240", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "79d643c1-18ee-4bf7-ba28-72f262b9afb3": {"doc_hash": "fff1033d7b9bfbc8c3961e2804232b98bd43869fcba4bc31830f611f9c373df8", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "19c956c8-4484-4214-b028-76ec14cfbb7e": {"doc_hash": "e6e72c2410525bcc982386eb81e2185f00d8cabdd1de2228103344568135dddd", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "cd61a4dd-c7b1-4706-9013-de1315463eac": {"doc_hash": "a16a91f7fd2183c8e81bb904d5967dc03fb4e847309b3ab5591324c3263eb9f9", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "4bde9167-62c4-4c75-b7dd-14fded756ec8": {"doc_hash": "f21dc5c4f3320663a07379f6ead4fab9a201cf9aee618e1535a9af2dacdcbd6c", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "ac803b0e-5276-4ba5-b4af-1ed5b9c7bf0c": {"doc_hash": "9683269ca8e627a6a0a63c66ab8a5d40f912ddb5bcf76e8326d9e63a56501c1a", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "09f1eaa9-9952-42cf-87e1-9d25e3c742cf": {"doc_hash": "0000270e5945711e118f99b67d79c571bdb5d39661151acb52d78a77d2b2450e", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "f2155e7a-5359-49a3-881d-76b80a8d8a13": {"doc_hash": "4a39b7dcd6e127dc7726bc0f3bc6f0788dd9ff9f88a339133022dbb720f13a68", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "57f6488e-51d0-424d-8f52-0a1e4dd999e1": {"doc_hash": "aa46d7274aacda9303525536e923d34dfe5d8ef4d9dc0fe07eb83c1a2ee81c19", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "38d1ed3b-cb4d-4491-bb9a-bcecb003818d": {"doc_hash": "def6e1a1514589e25cc4e43857ab13133a4b05b328361dd113fd7470f3cd24dd", "ref_doc_id": "72af82a0-d5fc-48a9-84ea-1f27daa680d4"}, "a18cc21a-3a3e-4d0a-b635-5547ff0276a7": {"doc_hash": "0389bcde8e6f8fedf025c8ac4e47f07ee5e8a4fa9f89daf35e205201980aaa3e", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "c8a6f691-a284-4b1c-be53-5fbeefa42346": {"doc_hash": "1473b5c925db01ba72d942bdac26dde9f62fe66dfcd87daf7ccc458abfe84acb", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "b78c5a95-26c1-4d9d-ab0f-d9ac8372e9fc": {"doc_hash": "0f1c871e372bd2cd1b9029da8f0e96aa98359e18cf6b38d2125d951b47869ad2", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "8ff4ab8d-cc54-4bfb-b6ef-a1bce67b6e8a": {"doc_hash": "24aca34e613c454323a59ba057c5d45565b99dacec58a3cb70be3e1654b5bfec", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "08801932-7ab2-4f1c-87e8-9ce62857aa39": {"doc_hash": "4461fa237388aa9dbf48a86e4a88f341ea38f83126e8b29cda08dc33dadd1bd2", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "4e7e0b48-71a3-4f4a-b641-410afbb12af9": {"doc_hash": "b3257c67e78048999386c248cdad683d879b3f6a453dea5f54016f737c870cfa", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "aac43029-e20c-48d6-9695-944b658dedf9": {"doc_hash": "39924f8b06c22e15af19ac091b3c4b5c208eb7cd148e8d9c699abd9ec18aa3fe", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "63c46769-d3a6-4c41-a8a7-cb76fee3943a": {"doc_hash": "ada140239fd65dd4e480a5430bb5a4023bb26c50aaa117c9d8221a4adee8e41d", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "5724b5e3-29d8-4dd7-9109-3dfc37d3291c": {"doc_hash": "39814e23d343295d091e9432816ba9aef4b99efe2a6d812f6403c1cea5ed3757", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "41b30bff-f2cc-4c8b-8438-4b19ef95c8ba": {"doc_hash": "2b49590f51dc973cce221accbfdb08590f82ed99702156aeba23bf41825938c2", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "8f634576-27fd-43de-b9b8-795b45fd65a6": {"doc_hash": "6ecc64b3e34878533c17980baca970439b26b1be91a2205841e4c43ba052666e", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "911e584d-6065-4bd5-bcf6-d1244470e7c1": {"doc_hash": "ad2c871b9eca61da38451aee3d47e32198ace2e9c269a667d1353c5b51ff614b", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "66c345a9-3547-4af0-a31f-65f281506e14": {"doc_hash": "aa0997ed8b1543b179bd91cb4c1cf5fa7b952ae708f94a7961367acbf1797f03", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "ce05808e-24af-4a30-982d-84a75b105a75": {"doc_hash": "66c5e83c0c309c25c30b9af0ff501a2b0e45e54f4e2a6276d5b3612264c924c8", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "99a37b9b-8be1-408f-83ae-13d9bfd03c9d": {"doc_hash": "5fcd16a39b0bd0b283b7b99ece188ee3efef04aa20288403e5da92e3ece95263", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "66b40f79-8660-45ee-b5b0-f351c90b1621": {"doc_hash": "da9fb16a59a01320a61477a3511464030adcdf5f530b3ed796d095611dc386fe", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "03305e7b-fbfc-4ffc-b71d-393206adb158": {"doc_hash": "6efe8cb8867ee7302cae783a1e34aab3c4592609420966fdada6eea4db6cd1a4", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "3669f9ad-768d-4f15-afe8-1562c51fb34b": {"doc_hash": "8764f29291c917c19726a9038fad0b335efede529ba271631e35e536019b3fca", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "56b05c35-f977-40b0-916c-2bfd4d477ad6": {"doc_hash": "5f642609090c76556d5d6c80492a58bf529d5a2e10afa1bc6dc8d8e9c9fa444b", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "b3a80dac-4715-4cb2-a887-2a8ba0ca5198": {"doc_hash": "6f497628edf328d330c9daad3680f7565831197f35cb0774d3e9628ac62d1285", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "91750785-217a-4810-bb52-2f80c65fdbf7": {"doc_hash": "ef363c747c8e6ecb1bb1606ef247fa6250a721b4fdff29f17b16885c00ffb134", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "46ed69e3-db5b-4259-b8a1-6d8d3da4fce7": {"doc_hash": "0df79987bca0a6e8250f5ff8a13dbe5835927c0745f62d8c5afadbec930a2a6c", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "ccd6590d-7a89-4519-a1c3-9ed03693d2b0": {"doc_hash": "8c63c4f13d12874234379b583c57b7acf11875d17211030b4af4cd7c6bbda706", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "17b7b498-765e-45e6-b193-1c9ca43e2926": {"doc_hash": "7aead0a1f6002af616332a3f21836d6aa2902405c6be8afe7c7cb6734b1318eb", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "1050436c-fee6-4e50-87aa-6e7cee01d638": {"doc_hash": "5837484c8b4a51f711c7e5c25af2393e5269b5288e3cfa6b426b922779cfd228", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "07875912-ef04-4340-96e4-3da1365497a3": {"doc_hash": "f6172793457f7fb73663015546440144324cfc0e1015f215f698317d5a0dbf77", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "82334f5b-a4d6-43a0-941e-57d03e4a4944": {"doc_hash": "6ffea352773f8dd6efd0e5b4826d6fed7e980db5540662898a84a00002a14cdf", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "e9214cd6-3a76-4cd8-b9f0-1e49700962be": {"doc_hash": "6b590b5efe52bb5ff28026d4afda42281d6fb710a90eadc942fae371fd0bc406", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "da05d41d-7761-4d5b-8fd9-2407b9092965": {"doc_hash": "d842fb0b93951ef2a904b5a8ec80eb374a5d1de9c77c5dd4b9d7888516324858", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "c16f6286-99e9-40b3-b157-8d6e02d669e6": {"doc_hash": "522543bad3751745a31c5ed2df78902bb9916fc913e889089d694db791246cc5", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "6b262596-f3cc-44de-b5a4-c4cdd259fd12": {"doc_hash": "c4a434e1e78355ee4333747b2269e2e8d960fddd02c0d1a48783c5f92d231ef8", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "2bb6065a-5c20-4e7a-8013-4b6d7b0918c3": {"doc_hash": "79ef9b183df4f9575e80d30e8ea3624b82943dc0cea5dd5ddc91078e1ca5a775", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "aaef2100-d5e8-4a88-aeaa-0d7503e7e893": {"doc_hash": "8b85aea94b8546ac294f012183e31cd7ae73cf9c556185b81033c3ea20a1f01c", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "c82f30f4-029f-4f2a-97b1-c0a0aca3f28b": {"doc_hash": "9cfee5098fcce6ad012169b4b397ecbe96de32272087ebe5c91b758e7767a5b1", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "6b9b9412-ed80-4455-8a11-6fd488722be6": {"doc_hash": "9cb033bb8822f08e5434443f35b48286b4ecb68ab663a7f3e87161edf139e261", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "e6305d82-fb57-4fca-913c-26f1f329facc": {"doc_hash": "8f97d9a6c37ba073d2b84f270f5d4dee5bc286db23154a21d916a99a603210eb", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "27da4eb7-8d09-4b69-9f98-4cb49f5d81ed": {"doc_hash": "3b985f88f3895feaebc2886a35a43c52c2f92f34668e7ab4183e1de05fc32e57", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "855fce69-9f9b-4b87-8f22-bb71f888b672": {"doc_hash": "af5b611363b31243f515d2173dd28ada1c7360a714c0ca143ac3a93d2565e077", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "796b37cd-a13b-486d-987a-40049924455a": {"doc_hash": "244ea065e2c4847014ab87e4f6b91ef96579b5c4a0f4fdf5813f1612675ddc18", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "35a89eba-2dfd-4110-b0ef-7845f6ba0f61": {"doc_hash": "4421283dba4ebd24a6312143d6b42c34cd982fdaf2aea0566943f3f36d4cc3c3", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "ee7dbf60-d60b-4800-952b-d9bc924d486c": {"doc_hash": "a3ea3c3f65e60e48354814c12d6ae86ae1823daa3b924f3653facbe2fffdbae1", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "00a71c21-791f-4fa1-abcb-a23b5970155b": {"doc_hash": "d3dba4a3ef59f1f43df350cf661177947c3787385fdbf49fd42f096776858a5c", "ref_doc_id": "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357"}, "3c0f73d2-5d4b-421d-a4c0-b2ab5dd655bf": {"doc_hash": "80a69dd10e7f5a08e89ac2ac07db3008644d741d7ddbd5ab9fd103616c021a27", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "82a2e5d0-e492-46b3-8e09-9f7df68ca6f7": {"doc_hash": "132506fd364bafe934be27bacd55b5e245ca157733494fc0dbeec7e6e963db65", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "721499a8-c4bb-4821-a8b5-060c304e1ee6": {"doc_hash": "3c045d271abd81dc26d3cae6bec4a117f448e8addd2b73518f3bdbf87eb0ac6a", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "437f6b5b-7b91-4bee-8883-8de77746dbe0": {"doc_hash": "36031c57e79234d58863b24386365d5d46c86690558eef866e0b3da17cdb454e", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "07fb69c7-3fbe-4efc-ae07-b2010e1f885f": {"doc_hash": "6d61a4ca1bd1d3f0ceb0c8bcf84c300d0f17f41cf42a5644b449de146ceeaaf4", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "934625fd-e2b6-4ef9-aa3d-0bf9abf561ea": {"doc_hash": "bae5e81f21642559bfb0729aaae18a20c0a5785bc499aa4cba26dd70b2bd6616", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "4fea0aa6-4535-4fd1-ad97-23b57619caed": {"doc_hash": "b1657462693dbc9e97333b5e6aef3b6a3555ff93f7e766cc72bbe18144d36836", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "44c6db32-064e-4818-bb97-c2bb84d410e5": {"doc_hash": "3ff680d5f5ee8397446c533b2854ba7a274e0d60361fec269830329f47bbecf5", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "863883b1-d8ab-434a-bc0d-c04c1944938d": {"doc_hash": "d38e1cad641437859230c5a45e20457b1a742defa5ecd74ae5353f0777c2aca7", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "87d496a4-73de-41c3-ad5f-393b0e94618e": {"doc_hash": "b2e0b96a3919f7a4c46d0872fd46ce2e0eac8abca4a0bd62ded80cb96b328e55", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "28d79f79-679f-496b-95e8-27a1243627c1": {"doc_hash": "37259d2858a0ff0e1ffb157224885d6281dd795aa29c90c2c4f3fa274e68dd1e", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "b8a5a574-56f3-425f-beed-b9d7750b1c61": {"doc_hash": "f7334e4bc7b8cf2f8466dc7a38cdac00b42cef717450eacce2e24fa7b27ee8b2", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "af69265f-7886-44ae-98cd-06406f64e047": {"doc_hash": "e03fbd3e6fe4b6b0b27d410a016e0712fd04da346b1f5d88a981a2dfa8e881d9", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "9ea89404-d666-4e4d-bcb2-78e05d889cc4": {"doc_hash": "0c354fc867c38eaac77c979cc1613c13285bd9acd153abda9153c3c44e340482", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "16ee4255-f258-4e86-9e6c-1048b1bc4ef8": {"doc_hash": "8303ccefe048b6b0f9b32686ea9ce72397e0a4b7bf99505a6ce10c0927a586df", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "d348abb1-17c8-47ae-9150-18fbf62cac25": {"doc_hash": "2451c159e02aff2d751cd622d1ebe3960604352a1e98d393fc9d7dd4813e277f", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "db75b57b-670b-40cd-a999-977b88e9847e": {"doc_hash": "7a91b00fbd1be7c49af50a5fec65cf0f8655afcb01bb0a7e0c13e9e4ab33edb4", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "d74d8217-0cb5-4a98-830f-198ee0743782": {"doc_hash": "45ebc038e48fdafe07c9f02b72b5ccd9ca0624a48ce6ce5ea12691c78d28b543", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "32847608-19b9-4c6c-bcc7-7467598e8a7e": {"doc_hash": "80fad366b0311e2d5b91d84811a2b75237ac2b01f4bfd51a73c3bad25542dad6", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "adf41752-492e-40cd-afcb-7cd544d3b158": {"doc_hash": "3117e93b0c73b820323fb3c92872fca028f027cbd69f0c5e81177639816c745b", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "656c68e4-a18a-48df-8f11-f89d85a85db0": {"doc_hash": "9cbeda53a15f0bc2c2c317da5561ed13986a8bbb68493305c5bd15f56059c66d", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "143de87e-a893-4176-85d5-56f810b17fab": {"doc_hash": "3ca2763ebeca58b6672ba7453c20c7748e2aeaa19ab4126a18566fc0c39ba9b3", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "87361018-e2ae-4dd4-b667-2bae84a6cc05": {"doc_hash": "c4930cd7780f639629cd3f9333fd04883ca2608122f73580b4f0eb8e42b3a914", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "6801ae34-2977-4d38-8e6f-f107d6d4266e": {"doc_hash": "080fe68ca447e227b0cd6d7eaa00fbe2f49413bd548171c1daa40ae9f32a5091", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "b01a0787-25be-44ae-94d5-4bdb2775cbe2": {"doc_hash": "82f9dc226caa5e6850160a03def3790d6956318be48761aa4fa1e0017109134e", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "cf6885d8-60c0-4982-bfd7-aa1d65bf8c58": {"doc_hash": "59f6b313b7d54ea2d840ed516df73ee6485a6341f42d7cdf87ab56ec363952fa", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "a1298b38-9c8b-4dc3-9eff-e3afdf857a39": {"doc_hash": "fae9c640340174fc27a9e9d0a68c909d3d23e418751df3b53e65757941b6dc75", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "51eecc6b-cf36-4593-b38d-62035e2cf69e": {"doc_hash": "e3a9abc9e42047fe33c9471ba285db5474f624329e6844e2656b464990d96d53", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "96887420-92f5-4f1f-b796-5f9979ab4b04": {"doc_hash": "a5eb13204d3c80d356767393827dd8ba0bdf5e8a16dbd784bcf7b8971dee03fb", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "9aabf0f2-ba8e-4ddf-933a-6c55cdda28b1": {"doc_hash": "d1151cda14fd122c40c7bdf1ea3d659c2cbcfb74a71f543d6ca5d6c3e6a0f7ac", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "793a7ab4-a513-49ef-bef4-81fede520f3f": {"doc_hash": "0473d967fb00382450e7be01712c4c8330a8046c74455aca950fc9540753c5a4", "ref_doc_id": "58aefad8-f2a3-4bad-804a-f2885a3994e3"}, "9a5f2ba4-a678-4817-acbb-4dd3ff8b9364": {"doc_hash": "aeaa17483bf56de0676821b05ac1d78d439a6634e2f6888a86c56230f1100fe7", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "442d079a-2e6b-4731-b6a9-ac5607abda61": {"doc_hash": "26901164bb3579d26fa21eaa37751f40d7396398439253db8e5bdc72fb67756b", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "2d56e92c-98b7-44d8-83c3-c3cf236b6039": {"doc_hash": "c1613b1866d7aabcac170bad2720e9cf49fd0b9cc7a93b013d451ebee13e1758", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "1db6e7a1-4380-4dcb-87b1-1a7b067e91dd": {"doc_hash": "4b0434f0376b8eb0888ae4c59cd3d85096319648a3af89a0e832c8a0d2a871c0", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "94c3485a-13c9-4f92-9b6a-d8cd9d71b00d": {"doc_hash": "561c69ab29015a2839ed01270c73b98d97f3b221e43540fd650d46939c7d03d1", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "811710f1-b05f-4d35-abe9-ca83f74fd84b": {"doc_hash": "7e6670e86ffa3b460edd3ee661cc0b26ce26789b5bde75ce742bcff333832ace", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "2cbb92bc-cf50-446a-8b2d-c2aa3a9f16ee": {"doc_hash": "d03b8411c19deccff6e48cbd42eb3fd8bae33e02a33394e8e3e4e21fb8c35e99", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "c116be60-f15d-496e-b76b-48dcf4cef8c7": {"doc_hash": "140939296241bfc461a32a40ab7c9b133d05a0b6ded422e7268c7c1f0d9479f5", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "d0580d91-704e-4759-bea4-1f5cbd965f4a": {"doc_hash": "7f7b6a0a123c3f0df9a80b8fe905e9d993c856c2c72fb0d220a0623cd65fd3f8", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "ad8b0370-7c56-4b37-8c07-3419d06e6205": {"doc_hash": "e1a9d14bcaa1ded935881bf98452827172277b84e5a25cd2f86fd7f8300fc448", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "593cea8b-f41c-4ec3-9a3b-44010276ed8a": {"doc_hash": "6542bf434e24a75a5fb077dcdf1e9ec183c2fcad4f6c137b238c9b9f0da0e545", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "d9be4c9c-8421-45b6-99a6-eb692447201f": {"doc_hash": "9cb505ae53421070086ee4ec8a330ba2b28bd3450c6f53b843d96e1c800b4902", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "d7d34932-b0a4-4656-bf48-db8ca75a6f97": {"doc_hash": "3e43734a22b2f315d86e5d5f830581217d7f9db213aacff1db06a45f274668cf", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "6939d3d9-7705-4f6e-ae8c-92369a2a6acf": {"doc_hash": "09ccda25fed32d741546b28c07a23d1bb42d5e65d606a6249f4e7f75bdd76379", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "b43def59-fdf1-4091-a164-b05fb9f6eb5d": {"doc_hash": "1f8642e7118da5cb58cd53c9c004af0d6594a90f4bb3ded04631f7c0fc74cc32", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "0d4b560e-e18c-44ec-8574-093c6c2a6aee": {"doc_hash": "339dd29c0ceeeb68595e912c15ce784a9c36f6c2f167d2c9f87dbcd743be9ac5", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "0e70791f-ee81-4331-b40c-d70c8a22b029": {"doc_hash": "83be8ca6fefb537e7888fa7807cf04cf1aa69d6c916489f9da29aa076a8080c2", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "cd3ab46d-54aa-4e93-a6f0-f1f241987777": {"doc_hash": "16f6d01809472f2869a76fac405fb43157372789356ab5d7f12e01a9fd501ef1", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "76d5da46-b5fa-4ca8-bce5-63b15f3fb34a": {"doc_hash": "e66b2d5ce867858ed40f247e9deaec992cb6536ed52f850331fb0334081c5402", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "d8f1d635-b6c4-4eb0-a5a0-11e330ed81b6": {"doc_hash": "2d41fc6009cc4f1051c83ac163fc13e73d9d48775202411243858aca874a91e7", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "fd52d384-e2c4-412e-bbc8-c19b25d62f30": {"doc_hash": "0061ac1a7c1bc873bd4a8414b38918a33f640a9853e8f7a9ac283d975e9e7f69", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "4913d96b-672d-41a9-bcfb-64eeb38f24a5": {"doc_hash": "975b0eda544a02be1534be79ff7962d7d0ce54245e3cd51e3260a267c10704ec", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "00083dde-1a5f-426f-b153-b49282ca6951": {"doc_hash": "8ea9d21eb387795a4e0be3a0099a385876563c28e806babed1577d0e90b1c36c", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "d63346f3-bb59-47b7-a8ce-ded0cf34de57": {"doc_hash": "641b068beca6d6e5a6cd43a6f0abdf45e34175ff6ea8e7cdd7121aff2fa48e12", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "c87ac53c-2231-4a9b-ab0f-ab95f369f826": {"doc_hash": "47c29a1df181e99d259c53fbf329521c0d76db1e8b117bb5d8dd235a07c4490c", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "a5a57089-cfd5-457b-800a-04276e053934": {"doc_hash": "66806fca712c3bbfcc2f65a2a249396e814b5d8c4724cabc78899a4e08dd29f4", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "d2fae4ae-05ba-4f7c-8eb0-fa9a47a4a959": {"doc_hash": "91e88a9503aa87ecb83ea48f694e08228ed6266eb07919893af564f786e1c785", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "f86fc617-1ac9-4fcb-b592-ba3ae0633edc": {"doc_hash": "08fb938d2ab7706610c11d5d1f279280a5c3e000e67ff347d757d1cf846fa222", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "ec2c8eac-8411-4f09-b94b-69f0ca2ef4cd": {"doc_hash": "d41287bb7ca5da52854721d4887585a13d1dc837db0202ac065683752656795c", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "c254e113-87de-498f-861e-17f7c3106dca": {"doc_hash": "abde3a3c559ba66f18b1828294994b4c2831b4ea73eac60475f80727a0948b50", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "27978bcd-0b9f-48c6-a2d7-62be469cd07c": {"doc_hash": "39701c9efbb9f57cac6db617824a2c67cf119fb7f09bbab5b8c3f853758452d5", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "be8114fe-de8c-4433-89a9-b8b00e0de633": {"doc_hash": "ba5cc64c89d93153afb32147fa2772f4e17fba9a8a610186e9ba1dea85f9e589", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "eccb05c3-d33f-41ce-ada7-3b3c56cb6e03": {"doc_hash": "3824d26549c746f4bcbd7378b03bdc52782a81fe00abe0c9b93af37b73fb39ca", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "3bfbe80b-5806-4d72-904e-448169c29c92": {"doc_hash": "6520fb70a35ab3d51e3dbab0fc75c594af6c3fb2cd79f22a191696516450b45a", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "6e9997a7-6edc-4265-8aa8-277aae55c8dd": {"doc_hash": "d8c4e566f28c540bad062033bd76bc50bb6da6dac00b2575809aeef5889d484b", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "79cd3ce9-2908-4f07-9266-80e5acae4b10": {"doc_hash": "e07a96321f85220129f96a1766394c06235013770be013354cf8e3a6ca026679", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "739feb68-c286-4659-8b8b-a5ecdc4a3a53": {"doc_hash": "03e35878823f498d42a4016e44b43e66a008facf448497f23fc0d684325de544", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "cc15d501-22ba-4320-8a99-acf7243b1a7f": {"doc_hash": "244238b1bd13d03c972211534b5b0aca900c7faf6987c695611415692662a54e", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "dc3de07f-9b7b-4e6d-9454-3741877b84c9": {"doc_hash": "7dc05e32ba4cf2a9b82ca7f51f5e759b9d196a7554945e4afa3943162b8184f1", "ref_doc_id": "07467b81-a385-40ce-865c-1281c22c7ed9"}, "504e1e25-b638-4473-b2a4-6df478d4e05c": {"doc_hash": "45b664f47a49b332f17ed076a86d3785cba4ad2323156f6059b3455cfff32107", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "1b75414c-ffee-4af9-8215-d8aa4fa7f13b": {"doc_hash": "709aad4597398c4dfdd8658015136a92baabb34f78d6b0b0fdba34544693ad1c", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "1ba49b06-122f-481e-a499-d3ae09d2f471": {"doc_hash": "92ae71302088eb82eda67ff03521f654301cc05bb3fddbbfb2ddcf01c795b6f1", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "73ce99ae-5525-43f6-9526-8d103a2242d4": {"doc_hash": "5cdfc613757afb4707ad8f35f8f5526c7010a772e8c64ea0318b9854c8b15546", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "3044b4f5-7349-4061-bb6f-a62290445e94": {"doc_hash": "7c554a25aa5d31398cf1657356891fec0d246435bc2fbe73d138c3e11d2a859a", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "c19c99ec-e97e-4512-8c0e-40068799dbdf": {"doc_hash": "d66e5724680ba0b62f5208837cbbd572e185ed164d648d78ec9b8e576f88a221", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "43cf1f18-edca-4e2e-8d49-eeb03ebbce0a": {"doc_hash": "243530cfbeefa31159557f20b001807586d124c2e9f7577f2e8c51179a3a5b25", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "4cb3e197-955c-4cc6-aa1a-b1b836f22f3a": {"doc_hash": "86bd78ae81afaa4d86525cfb0846b8e17b1a97d4af917b7129912d6ac173e41c", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "54c99caa-5e52-4e81-b341-574bd7c7ef6f": {"doc_hash": "c693dc8faa7c7f624721131e85bda26d4798f36703f86b9bf03633f22ce1a375", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "98f03308-dfdc-4677-83cd-faf9d322b65b": {"doc_hash": "e888b29313d5846e764dcffa8e385f52ac95c4a5ae038b3217b939a6573473de", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "5ea66318-3fce-430f-8f38-b347a110c6c6": {"doc_hash": "43a967a8d6a0638f5b507e932326edfde053bf15073e8c8967876b06e81d4c47", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "be5e9152-5190-459d-a7eb-8ea5f33fe0c3": {"doc_hash": "d09805456ad10245f9842664ff4c20e00b91cf3af35a1361a841e30dfcdc9fd8", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "19cc2716-0083-4fba-8f31-5dfdc9a1164c": {"doc_hash": "ec32e1e87c02260ac4a7b79ebcf20eb87919d2591d03ffa0d632491d0d640ada", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "b7557406-3fbf-47c7-a63d-90aa8a4b1009": {"doc_hash": "ef7a118352950bc2a4e40a8eb25318ea54872d26484d9e58e8d0fb4ace2884dc", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "21a183ff-ca27-449c-be30-ce76b303bd75": {"doc_hash": "a90be84212081d6b1a4c509aff2152557f8befea923935d17a293558c8e1713e", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "791099eb-8060-46a7-beda-d8431690904d": {"doc_hash": "b00cafd16f8cf9b556e0bdf64fc42d9671ada8b0b8a16f159ab51913c185bed9", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "5c8a48d7-cbd4-471c-afb1-ed0e22de9ada": {"doc_hash": "b472d027758caf729ecbc5e313ca09e180848b12a6f351cc505c7ba5f71adb7a", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "38653f16-ddce-407e-9211-bca9fc05f67f": {"doc_hash": "d66331b166069b368462fa785dfa44cc3c613334d5977283ce7e069e699036ca", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "0e2f1a72-b851-44fa-a066-5fb5736ad550": {"doc_hash": "85e89d25272bf0584c5f1193e4d7b64885fdb67c6cbe00905c9d1d29bc60171e", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "7e296d52-dfb1-415c-8aa4-5a85699ff492": {"doc_hash": "8da50b34573ad4e249b4d3c8301c78fc28211a9b6354f1160c18d0b123a43f8f", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "5ec97ce9-759f-4eb0-98f8-dd36613be68a": {"doc_hash": "e5d9d8f403be0e6b6026e2cbae5285f47a27daf2be15b5e9cc53ab8da7f4ddd1", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "332b0114-0663-4132-9489-08300dc3c45e": {"doc_hash": "0d1816e033abc100b331255d77b2af4b0d7aa706d9df7e94ef55cf6f848744a0", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "4a6ca281-b8d2-4120-a6aa-d2e01f09fffd": {"doc_hash": "11aeeb75a3975191ab047b609556043ea21f7c6789120427fc2b69a91f87f478", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "be7bbb75-0a7e-4386-bd40-e3a9df0468c7": {"doc_hash": "4bcd2d569d3b7d609dcb012d47291dc1bdb6b54a0b63b810fdfd3ce9a12bc34d", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "55700999-b378-45bb-b0ad-aa59e9de21ef": {"doc_hash": "780e8bddaac624372d9be5ebbb8daade22fd9ea2f3cd46427f24dac69881c77a", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "93d77495-ad52-4911-82b2-a4bad65eabb0": {"doc_hash": "e65fa3b3aeeff4e2e9e070950d672afc664c9c607cd6eb5c43886a11234c6cb6", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "587d1171-fdce-4b74-b67b-1a96aa32e253": {"doc_hash": "9af20302af5fbd05daf29846525dcd21c13f2a0f43e6180ab673c3ee73133c7c", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "6d498ba6-4ab0-4859-b2ca-7d1df145505e": {"doc_hash": "c751345fbcf2473e212b4d3a604f61c57af30bf80e666f2257983cd3bf04be71", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "38d1fbef-1c90-4886-a365-88d09192d167": {"doc_hash": "ad23ac8084730ef3c7906e7071919766ed49d85078577a870fc6948e817326ff", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "069e58af-170f-48f2-9cab-dd8ad7e426ec": {"doc_hash": "41b1a64fef5a3e8775bc86592fd56ab44cd4eb175d18a582e4a4f5cbe01704b4", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "845125e8-769d-4894-bea5-fee9378209e8": {"doc_hash": "5299b11a9ef8e0f94df0f8bb0d3b82cf6c4d45ff4958d4c3789cbaacafeb399d", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}, "84a1be93-b8c4-4ec6-8b0f-0ff08c293b57": {"doc_hash": "32c7d9a3fd3c851c85790c0bb6622756af55142161deba3247868cb0fac0b073", "ref_doc_id": "0016ba3c-64f8-480e-89b1-1957d84d5ab5"}}, "docstore/ref_doc_info": {"1b7bc354-8640-46f8-8be4-8d9dca28145c": {"node_ids": ["9861564a-b70a-45d1-a8d3-440b2bf43b82", "6aab3612-657c-4607-a81f-37c18078577a", "1e0f3ba3-6964-427c-bec0-c65bf3161363", "f5451f15-5a39-40a1-8060-d001bc39b9eb", "b12e7571-47d5-4063-88a8-bec0885ac20a", "226dbb9b-725a-4dac-9307-f6fb78c81a4d", "61f2f479-b3ae-4113-a570-ddd7ec89e85c", "2a04914f-e86b-4004-94e9-8e12dae0d039", "3356a4e6-41ab-41b5-9b56-858737803b51", "b191f8a7-9b04-4e14-851b-e0fb69333558", "d5d5942f-578e-4009-8a88-0d9fa4e23502", "c070cc17-29e1-4cc7-a97c-78a375db9e32", "5953b510-bfa8-44c9-a1b6-9c11cf8a9f7b", "a88196ff-144c-4c7e-a901-8b54d0e35030", "0498a176-4a8b-4378-8cbd-4ea71576bfee", "ad088871-518c-4144-b4da-bfe6cf82e5a0", "82ef9e54-d236-4694-a3ad-0c632f7fa4ad", "2c69b1cf-7580-4578-bf13-acf0e6f84109", "2e62478f-8e60-4340-b645-15a550ea1ba5", "b5cb5b03-cf22-47ae-b102-1408e6d32026", "d59015fa-1f9f-4c8a-84d2-f8197a5795ed", "7cebd692-22e4-4e83-a105-39d39e4cf86a", "7559097a-2603-40c2-969e-62a7586e23df", "fc7b6a4a-0193-499f-89ae-3781930222e2", "04154aa0-8f35-45e3-969d-00497c5aef08", "31e3833c-1067-45dd-bc8d-57473732b783"], "metadata": {"window": " \nPage 1 of 15 \n \nQ3 FY22 Cardinal Health, Inc.  Earnings \nConference Call  \nMay 5 , 2022  8:30AM Eastern  \n \nOperator:   Good day , and welcome to the Cardinal Health Inc., Third  Quarter Fiscal Year 2022 \nEarnings Conference Call.  Today's conference is being recorded.  At this time, I would like to  turn the \nconference over to Kevin Moran, Vice President of Investor Relations. ", "original_text": " \nPage 1 of 15 \n \nQ3 FY22 Cardinal Health, Inc. ", "page_label": "1", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "e53884c2-aa9e-4137-ae64-a636c65ae76c": {"node_ids": ["32d0cc58-70a4-4008-b106-7e6a01f509df", "42721dda-8296-4c1b-ad3c-ee45b0e1914a", "54a9e66e-a12b-4d9d-aeca-b849838d45d7", "0958599d-8eba-447a-83f6-bc31fe888a31", "b2bb5b4c-3f5b-4325-a670-3213763ce4f2", "d981d406-88cb-43e0-93b4-8682b2efbe08", "65e69f90-4d3b-4920-8807-7fa36ffb0455", "1b7e229f-4221-4be1-9994-ef2b44054550", "02b4e416-a019-491b-82c6-982b212afce2", "d1c829d4-ebe8-408c-a577-524f42309f36", "aa1d083b-1725-4351-83b6-1293aa5e9099", "094d0bb6-bfca-4e59-a0e9-e02a806e0b62", "839af643-252c-4d9b-b9b8-ff26a787eb09", "4831a1e1-4d97-4e6f-b374-8304dee7dce6", "4e90fadb-caab-441e-957f-cdc5653f558f", "108ab7a0-30d8-47b6-ad79-7ef2d40cbc2d", "89fa0cae-9246-4d29-924a-64e5c3f107b0", "0a5a8843-c88a-42ed-9e28-c2bc1a86e6b0"], "metadata": {"window": " \nPage 2 of 15 \n \nI\u2019ll elaborate on the actions we are taking to drive performance , particularly in Medical , after Jason \nreviews our third quarter results and updated outlook.  \n \n Before turning the discussion over to Jason, it\u2019s important to note that the opioid settlement \nagreement was finalized during the quarter and became effective on April 2nd.  This is an important  \nand significant step forward for our company.  We feel this settlement is the best way to deliver relief \nto communities across the United States and allow our company to move forward by putting \nthousands of lawsuits behind us. ", "original_text": " \nPage 2 of 15 \n \nI\u2019ll elaborate on the actions we are taking to drive performance , particularly in Medical , after Jason \nreviews our third quarter results and updated outlook.  \n \n", "page_label": "2", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "be79c7a1-50c2-4cb9-bcde-3623a2961428": {"node_ids": ["8113da84-d516-46da-8331-ad4d997fffa3", "5dcb6d96-85fb-422a-8714-42e825b549ca", "080cf7ee-82ef-4bf2-bfb3-5ac287442c0a", "b03ab9f8-98df-42ef-9919-a6aebd2afa4a", "501dc48d-c75e-484a-a273-11432264f642", "cb05aaa1-8187-4bc7-8f74-97b4a4a6cace", "3857ea75-02f1-441a-bec2-710521da85e8", "e709a4c8-3c59-4887-bfa8-4dd4bcad1129", "9fb0a74f-8b1a-47fe-aa29-9f446dc32900", "18d5860e-81bd-4772-acb2-18dee7e45c67", "0db1529a-4f62-4b88-a1a1-0862a29384c8", "e09c3658-5a19-4455-9848-1e3c31b8bcca", "56ca1fc6-3a0c-4722-bf70-073e48a9e59e", "7d9ae547-ee60-4220-a19c-27e118511cf3", "f272a3fa-544f-4361-80a9-9182a2e68d66", "7229ae2d-0630-4d11-af07-4d725bbea20d", "967132a2-bb30-4ec7-bb8a-c10c6dbc397e"], "metadata": {"window": " \nPage 3 of 15 \n \nThe net result for the quarter was EPS of $1.45, a decline of 5%.  \n \n In the quarter, we also recorded a $474 million non -cash, pre -tax goodwill impairment charge related \nto the Medical segment, which is excluded from our non -GAAP results.  This accounting charge \nreflects an increase in the discount rate used in our goodwill impairment analysis.  \n \n Third quarter operating cash flow was a use of $419 million, and we ended the quarter with a cash \nbalance of $2.4 billion and no outstanding borrowings under our credit facilities.  \n \n", "original_text": " \nPage 3 of 15 \n \nThe net result for the quarter was EPS of $1.45, a decline of 5%.  \n \n", "page_label": "3", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "08866547-f0bf-4dc1-ab27-1435a731c9e8": {"node_ids": ["4a85ab10-a64a-4150-9f87-972ed3be1638", "ce5b11fe-765e-4cea-9bea-22d2aa6ac937", "3e05a428-97c4-4220-8fcc-c55ff18471f4", "93924e37-6ee9-4f56-a46f-c0715c587de3", "1f4b64fc-3b42-41ad-ad5b-6a1059b5630b", "d15799ae-b1f8-4f7c-83e8-5f1d1c41cb14", "17839fd1-a058-44f8-8662-51909ca3db58", "43957dcb-6239-45ef-b608-0b0230654bfb", "9ed86934-c1be-4007-a442-28c531e54ab6", "d0a90130-8552-4ed6-8f9c-e007b61935f4", "5235ea24-9b80-48c0-9394-8054a9b6d888", "0d4233c3-c624-45e1-ad85-9120a667415b", "3bf3d11d-b797-402f-bbab-78a092925771", "ea82698d-8c6a-441e-81e8-f80fc4fa01f8", "5f63c2ae-a369-48bd-8dde-a40870c8a860", "0cc4a662-1fca-4698-9576-41816536bf48", "261954c1-3e5c-4f90-9c31-bd54d99c9381", "70eeb967-5220-417b-bc67-e7bdfd9b3830"], "metadata": {"window": " \nPage 4 of 15 \n \nTo a lesser extent, the third -quarter decline in segment profit also reflected a lower contribution from \nPPE, as well as the Cordis divestiture.  On PPE, we saw unfavorable price -cost timing in the quarter, \nas well as lower volumes as we exited the quarter.  \n \n We were encouraged, however, by the resiliency in surgical product demand related to elective \nprocedures, which was generally consistent with recent quarters and improved from a year ago.  And, \nwe continued to see strong performance from our Lab business.   \n \n", "original_text": " \nPage 4 of 15 \n \nTo a lesser extent, the third -quarter decline in segment profit also reflected a lower contribution from \nPPE, as well as the Cordis divestiture. ", "page_label": "4", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ffe6f59d-18ff-4d3c-9a1c-b343781737e5": {"node_ids": ["430a1f3f-aefd-473a-abd1-b5f71790776e", "9b51c219-8a31-412e-9406-0cbb598e6777", "7108691d-6288-46b3-97b7-ce281cf24d07", "581d546e-cc9b-4cc6-8b01-944a4be9a342", "b6d148ce-59c3-4bc0-8481-00116f610f6d", "da2a0182-687f-4045-8126-37ea0b05dab5", "85407112-c2aa-4931-a043-020974083122", "76590a9c-6493-460e-85fe-0e5f7fd691ab", "3a8e33d0-9976-46a5-8f04-7c3ef24c36a1", "b3750c08-2d5e-4847-a73d-ec230d52f4f7", "844edd1f-0b2d-45e4-baf3-78fd6a0395f6", "b9ee4045-ef6d-4ff0-a9f1-e62f319454b2", "f44438ce-2bd8-4996-b2da-94fad6042d67", "f256a355-3301-4d9e-b132-7611abf6c51c", "7dd0e815-f9f1-4496-bd29-e6c00badf645", "95188c0a-9dd5-44c0-92a0-83397e297501", "bc4e14e6-b3b4-4036-a7c0-5e7368002a85", "70f8eccf-3cd6-41fc-931a-41a8bd8f0cfb", "1a4c5154-0f73-450a-8145-ffeb11640f9b", "bc3ffc41-5602-4435-b2ac-697626c13b61"], "metadata": {"window": " \nPage 5 of 15 \n \nfirst half of the fiscal year.  Additionally, with the finalization of the global opioid settlement, we \nanticipate lower opioid -related legal costs, partially offset by higher costs for implementat ion of the \nsettlement\u2019s injunctive relief terms.  Together, we expect these litigation items to be a modest net \ntailwind in fiscal \u201823.  For reference, we are currently estimating opioid -related legal costs of \napproximately $115 million in fiscal \u201822. ", "original_text": " \nPage 5 of 15 \n \nfirst half of the fiscal year. ", "page_label": "5", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "a3e841cf-99e5-43d9-a5bf-8c1bda3e72d9": {"node_ids": ["605bb7fe-0bfd-4ac0-9bda-f81bd93e6273", "2e2a8f21-decd-405c-9226-2acf33a7b7fb", "c2529853-f67a-48c5-bc55-b09174b24e8e", "027e8c4b-bcd3-43fc-973c-2014dae2583f", "c089ef74-fc8e-40fa-b18d-57c384e0e374", "070e3616-a37f-42e7-92cc-84f3c9c73398", "1a2ecad2-7787-482e-9207-2d508b90051a", "40151aaa-aff3-4b8e-8a7e-daafac2c0930", "f226b963-5385-469d-9f1f-071d5d8edd06", "5414619a-04e2-4331-ae8c-f9298754a890", "0f6ca02b-fde3-4949-8abd-d9145328ec9a", "e05ac319-81c1-4405-9db8-68c32655f164", "ec09fd3b-550c-45ce-b2f8-6ac4d13f832c", "6d916785-c4d2-4407-b562-55cc80253357", "d3d8d0f1-0aeb-437e-ab3b-326cc243dcd0", "7b0e4d8d-13ab-448b-8367-83c4af4ee5e6", "6b47b381-f505-4337-ae37-92b5caa91be9", "76b98b59-e7c1-4ef2-a0ca-c38c769e0fe1"], "metadata": {"window": " \nPage 6 of 15 \n \nLet me elaborate on the actions we are taking to drive Medical performance and maximize our \ndifferentiated strengths:  \n \nFirst,  we\u2019re taking pricing actions, evolving our commercial contracting strategies, and  focusing on \ndriving mix across our global business.  We have implemented a series of initial customer price \nincreases on nine Cardinal Health brand product categories.  \n \n We\u2019ve also implemented fee increases for certain Medical National brand suppliers to o ffset some of \nthe elevated supply chain costs.  We provide the most efficient and effective way for manufacturers to \nreach our customers and believe these increases help compensate us for the increased cost of \nproviding this value. ", "original_text": " \nPage 6 of 15 \n \nLet me elaborate on the actions we are taking to drive Medical performance and maximize our \ndifferentiated strengths:  \n \nFirst,  we\u2019re taking pricing actions, evolving our commercial contracting strategies, and  focusing on \ndriving mix across our global business. ", "page_label": "6", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "ae540fb1-a3fb-4fd6-b479-96a5c9bf2042": {"node_ids": ["485fcd1d-ee29-411e-8806-1f79d3552621", "ffaeead9-2797-4a33-b6d7-403e1b7528c7", "c33e6f22-c8c1-437e-a9b9-1b567be2e47e", "9c392311-48ed-4495-81b4-b05150443507", "19934eeb-9f06-470d-8db3-a703dec1e5c6", "75e80953-b548-4afa-8766-3efbddba1cfc", "3ba627ec-7812-4e20-8fc9-5117d3495605", "d957f2d5-1247-4735-8d0f-97747db3432c", "1c80b159-113b-4b58-9e08-eb3d9ea55149", "5ed03923-6fb4-4799-9b59-e4687bd881b0", "2b3aeb28-18d2-433c-861d-93c630467028", "a9e9f703-72f5-45db-a312-68b6c9a58241", "2aa3006b-50b9-42ce-8db8-0f6473cd71d1", "9236038b-0316-469c-8ba2-b00fc7e1a32b", "4255d71f-0a71-4733-8fe0-8815dc7ce453", "aec36554-5df3-428b-be01-75721d468144", "c22ceccb-da3d-49e7-b90a-80d1c3351431", "86a56f91-d08d-46b6-89d5-f23b6c617af1", "2606b8c4-dd6a-4607-96e9-f3fd176eb08c", "62685d00-6522-488c-b946-3ff8c33ab0d6"], "metadata": {"window": " \nPage 7 of 15 \n \nAdditionally, our Lab business is consolidating manufacturing and warehouse space into a new, \nlarger 100,000 square foot facility.  This move centra lizes our high -growth lab kitting services and \nsupports significant expansion of our direct -to-consumer kitting capabilities.  \n \n Third,  in addition to investing in our core Medical business, we continue to invest in our growth \nbusinesses, at -Home Solutions and Medical Services, which are aligned with industry trends.  \n \n In at-Home Solutions, we continue to see strong demand as care continue s to shift into the home. ", "original_text": " \nPage 7 of 15 \n \nAdditionally, our Lab business is consolidating manufacturing and warehouse space into a new, \nlarger 100,000 square foot facility. ", "page_label": "7", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "3afcdda6-11be-4418-9147-b2c5a6e2722e": {"node_ids": ["2e9a39ad-2e5b-405e-9727-a9af2d191ecb", "c22dc5e4-13f0-47ce-ba45-be1ea0ab60f8", "15e44632-45b9-4c32-8287-133ccc99385a", "90c3bdbc-03a0-4c73-884a-c27f1afac135", "9036003b-7dc6-486f-95bf-383611221c93", "f04198a6-1173-4de4-8f0c-6bf60d5cc451", "9b0e5b47-aacb-4765-9eff-4f5973919264", "31617823-033b-4bca-9eb4-ec6a93b390e5", "3b0230f9-8a5f-4fc0-ab0e-72c821945ca2", "b391213c-79d2-40a3-8eb3-de3bf348730f", "b81448c4-6431-468d-a70b-d5b01956f5e7", "b95e763b-f60f-41aa-98a8-710303a85cdd", "0d8ff9f9-3f77-4385-bd65-32f4bc24020b", "e8baa435-44a4-40aa-91c1-d5b7cc6ed784", "abdeaa26-759e-4242-9e81-8b3a94035ae4", "6667823f-b768-4396-8a17-89fc8eca647c", "62d6ac93-7909-4633-92aa-3d643083656e", "cdfc8e8d-548e-49c0-84d3-2ee8b5015ded", "661b2526-b098-4d8f-bf78-7259217f5b8d", "8a96a8bf-ac67-41b2-8081-bf8a8ad9963d", "d8109d82-ffe2-4964-822b-23e52c64d118", "594187ff-4f0c-4a59-8bef-463e8e6e503c"], "metadata": {"window": " \nPage 8 of 15 \n \nof growth in the biosimilars market will predominantly come from products with a greater retail or \nspecialty pharmacy presence.  As more retail products with interchangeability come to market, our \nsignificant scale and capabilities designed to support retail pharmacies uniquely positions us to \nsupport and empower those pharmacists as they navigate the important operational complexities of \nmanaging multiple biosimilar launches aga inst major reference products.  \n \n Our Sonexus digital services portal offers tailored solutions to help patients get on, and stay on, \ntherapy.  Patients who interact with our Sonexus portal experience shorter time to therapy for new \npatients and no gaps in th erapy for existing patients. ", "original_text": " \nPage 8 of 15 \n \nof growth in the biosimilars market will predominantly come from products with a greater retail or \nspecialty pharmacy presence. ", "page_label": "8", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "665fb122-36ff-4172-8876-0cefc09a4c07": {"node_ids": ["e448cbb6-2a50-40b1-8baa-885ee5c2e998", "0ce0134d-b301-46c4-af45-6c2a28303ede", "4aaccbef-af09-46fd-a8f5-58f5f0b98fe7", "5d47c6ff-8970-43ba-8bf7-d3c60c1dd883", "6ceb9de7-ae65-4f20-bd19-90e19e317ebe", "28cf4a31-14c7-4436-9ff1-9795e257c7ac", "43ff150e-4c03-4ca6-ae20-c3f742b1e2c7", "df42005d-e2b8-49c7-a1ea-7725d413df6a", "5f12e8a1-3440-4115-a305-8759fbe39eea", "f2dcdce6-d897-4358-9eb3-36df32bdc2df", "628f0460-858f-49f0-afd3-9511f9ec5e8b", "1389b1b8-61bd-4d69-9fe1-2888f3775879", "dd9b935b-2d04-403d-b20d-afdb722b8269", "ac9735c3-b291-4c6d-beea-a07ffaa803ee", "861358e3-2c87-4d02-b3de-884b41db3086", "c239b1fb-1aaa-491d-a56b-6dde29e8b502", "5489fb19-b6f2-4087-97ef-9b4731f6cb0e", "cc02fa27-d1bb-4964-8133-c2eba7f297db", "aa3978b9-e793-4435-bace-738d1606f386", "66ffc7cb-95c9-437d-8332-b3d5a3a2e7f1", "9c0b0520-8061-414e-b334-bf26bb16d826", "0ff89030-7a2a-4bf1-a7c9-6d0f3e2fb034", "d8bf9eb1-5a30-4f45-a449-86436c88b13c", "cd89f72e-44a5-4a3a-bb52-fab071cd1ddc", "6cd05c88-5f20-4f35-99cb-8738307ab90a", "e78d5e82-a23a-48a8-b366-1cd184a63cf4", "f5b4e004-cc38-4f7d-96e7-86cad313aa26", "ab23679d-0343-4be8-825f-be82a151c7a1", "1036cb8c-b7fc-480a-845b-c52650d8d54e", "56a300be-0848-454c-a89b-3535ab163d2f", "73ba0f17-981c-41ef-bf82-5928fe5a8bb0", "438447b6-bdd4-43a4-86e0-ba4888304dd5", "1fc2eae5-ed85-4508-a4af-8649020059fc", "41697dc5-53eb-44c4-b4e4-e7d934ebdbf5"], "metadata": {"window": " \nPage 9 of 15 \n \nAnd now, Jason and I will take your questions.  \n \n Operator:  Thank you.   If you would like to ask a qu estion, please signal by pressing star 1 on your \ntelephone keypad.  If you're using a speakerphone, please make sure your mute function is turned off \nto allow your signal to reach our equipment. ", "original_text": " \nPage 9 of 15 \n \nAnd now, Jason and I will take your questions.  \n \n", "page_label": "9", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "48f73078-3572-4b2e-9c19-4e6845af63db": {"node_ids": ["ebd35188-542d-4770-8606-78dc84331e72", "368e5b6b-9d6b-4eec-b1bc-4a4f6418c10e", "3a4f2674-243d-4322-8eca-c482a8ca2d7f", "14de8a8e-0e50-405b-9c39-e36a2f616b79", "9303b0fa-83c4-4cd6-88a4-3bdd431e9113", "aba09f55-dc81-4092-a01c-86c42372e43e", "3b96b28c-db7d-43fc-92d4-795f3c77d197", "29d09f3d-7416-43c8-99a7-03807fceda4a", "11cceaef-779f-484a-bb55-966c8ebe2851", "75a8c3f2-3bb4-4e61-b063-403cfdfce36b", "fe1958b0-f846-47df-b6f0-a1ae81c6a8b1", "5e905036-5754-4167-93b5-9150d1b74239", "c64ac2ca-129e-4309-bdd1-89df4533b020", "4804ac1d-1b72-4761-bb4b-0a21858e4fdc", "ece819b6-e9eb-4aac-b87e-5f478d69d09b", "09df9415-ecdf-4edb-bf62-fb8bacf371d2", "0dde8dec-8009-4fec-93cc-212b601fd790", "171b05e7-921f-45e8-af5e-5c198f4a5820", "67ef369f-5db6-4d0a-9899-507171157105", "de205405-3e65-4b82-a12f-ccac86a8aa41", "9f363f80-d6d9-418a-8415-8bd8ebefd085", "d79def44-e031-41f6-a403-8f74831fb907", "599f7948-0f16-4ab5-819d-a96151394eda", "0ae891c7-79d8-4200-b44e-be7c5c507377", "b4d3f84c-aff2-4e6f-be8a-448099f38a74", "002063be-87e5-4a62-ba25-4c3a457c3d26", "fdf68bc6-9588-4ac3-8262-4d8f2537c1af", "958df874-e038-4480-ab01-eeead07d5eff", "b0c667db-a07d-4606-b342-73a1d53b1036", "2b9c7156-82f8-4fb5-b724-0aadf5a777f7", "ed5ce0d8-c1bd-43be-b014-91b50962fe75", "25d198be-2271-49fc-99a6-9bc7d05861d1"], "metadata": {"window": " \nPage 10 of 15 \n \nguidance has appeared to assume stabilization or improvement.  And so we've seen step -downs of 100  \nto 125, 150 to 175, and now 300.  It sounds like for \u201823, you're trying to let us know that we're going to  \nsee lapping and it doesn't get better, though there are actions being taken.  Can you give us a feel for  \nwhat actions you would take if it turns out that things continue to get worse? ", "original_text": " \nPage 10 of 15 \n \nguidance has appeared to assume stabilization or improvement. ", "page_label": "10", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "72af82a0-d5fc-48a9-84ea-1f27daa680d4": {"node_ids": ["0d5dbfc5-1eee-4cf7-9990-5a02ff186c4a", "84de3e46-a9e8-477a-b711-6d68691a04e7", "422b9354-02cd-478b-aef1-ab0f92a80564", "3b2c7d08-81ce-4ed4-8066-b9a8da216f69", "5c7a6f63-c58c-46d7-aeb8-50e0388b3164", "a156381a-4a5f-493b-a499-fc9bcfebe69c", "74b8f877-0c7b-414a-9e26-b0e65c7c5f39", "0ffe41b8-e1ba-4920-80c9-7e8d33b5ca76", "28c33c24-5e65-43ea-b4b2-151b9d68ebd1", "e05a909c-8f10-4495-a4c1-469c17a9ff50", "3e21d02c-a8d9-49c4-adcf-a98b909b628f", "ca8a54f2-824d-46a2-8f03-b6eae2365977", "716cd97c-bcd7-4cc0-8bb1-88269b7d2b1c", "465ab7e2-da12-4d9b-9ed8-9b430266c3d4", "15b8292b-eecc-4beb-9cca-29efc31e5519", "699fbec6-74c2-4db0-ab4c-558a956363bd", "0cc5ec4f-0e43-4919-92a4-b2582c161aa7", "df2a1ffb-4383-412a-9275-79575a2cf97f", "45c48ff7-ba8c-4ffa-babb-e79cc693a7e7", "3e34b61b-14bf-4ceb-8a40-a361298bd6b5", "8464a9b2-1a9d-45ed-85aa-8ea949f62da1", "2591e02b-0f23-4634-8f05-e5822478619b", "e1f0c149-ad10-47b6-80a8-c6deb3ee5095", "822ce059-7683-4bad-ba3a-898bac0beba0", "e5660d13-d154-4a1d-b2d6-45c8b340b80d", "d642a1c3-bfcd-4daf-afd1-b4cbcaab0659", "9931f4bf-e4c3-4f88-94d1-58c3431d4a47", "5100769f-d536-47fb-ab58-52da909c683e", "b7e3e266-f481-46d8-b1d3-744b0dbe2f21", "7319d32c-b55f-43a1-bd08-a112d03d1b73", "0c21e646-1431-408e-a788-7c6768eea05d", "79d643c1-18ee-4bf7-ba28-72f262b9afb3", "19c956c8-4484-4214-b028-76ec14cfbb7e", "cd61a4dd-c7b1-4706-9013-de1315463eac", "4bde9167-62c4-4c75-b7dd-14fded756ec8", "ac803b0e-5276-4ba5-b4af-1ed5b9c7bf0c", "09f1eaa9-9952-42cf-87e1-9d25e3c742cf", "f2155e7a-5359-49a3-881d-76b80a8d8a13", "57f6488e-51d0-424d-8f52-0a1e4dd999e1", "38d1ed3b-cb4d-4491-bb9a-bcecb003818d"], "metadata": {"window": " \nPage 11 of 15 \n \nOperator:   And we'll go ahead and move on to our next question from Michael Cherny with Bank of  \nAmerica.  \n  \n Michael  Cherny:   Good morning and thanks for all the color.  Mike, I want to dive in a little bit more about   \nthe comments you've made tying into next year on Medical.  As we think about both the fiscal 3Q   \nnumbers and the implied fiscal 4Q guidance. ", "original_text": " \nPage 11 of 15 \n \nOperator:   And we'll go ahead and move on to our next question from Michael Cherny with Bank of  \nAmerica.  \n  \n", "page_label": "11", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "0e806fa0-c70e-42cd-9a1d-4ca0f78ce357": {"node_ids": ["a18cc21a-3a3e-4d0a-b635-5547ff0276a7", "c8a6f691-a284-4b1c-be53-5fbeefa42346", "b78c5a95-26c1-4d9d-ab0f-d9ac8372e9fc", "8ff4ab8d-cc54-4bfb-b6ef-a1bce67b6e8a", "08801932-7ab2-4f1c-87e8-9ce62857aa39", "4e7e0b48-71a3-4f4a-b641-410afbb12af9", "aac43029-e20c-48d6-9695-944b658dedf9", "63c46769-d3a6-4c41-a8a7-cb76fee3943a", "5724b5e3-29d8-4dd7-9109-3dfc37d3291c", "41b30bff-f2cc-4c8b-8438-4b19ef95c8ba", "8f634576-27fd-43de-b9b8-795b45fd65a6", "911e584d-6065-4bd5-bcf6-d1244470e7c1", "66c345a9-3547-4af0-a31f-65f281506e14", "ce05808e-24af-4a30-982d-84a75b105a75", "99a37b9b-8be1-408f-83ae-13d9bfd03c9d", "66b40f79-8660-45ee-b5b0-f351c90b1621", "03305e7b-fbfc-4ffc-b71d-393206adb158", "3669f9ad-768d-4f15-afe8-1562c51fb34b", "56b05c35-f977-40b0-916c-2bfd4d477ad6", "b3a80dac-4715-4cb2-a887-2a8ba0ca5198", "91750785-217a-4810-bb52-2f80c65fdbf7", "46ed69e3-db5b-4259-b8a1-6d8d3da4fce7", "ccd6590d-7a89-4519-a1c3-9ed03693d2b0", "17b7b498-765e-45e6-b193-1c9ca43e2926", "1050436c-fee6-4e50-87aa-6e7cee01d638", "07875912-ef04-4340-96e4-3da1365497a3", "82334f5b-a4d6-43a0-941e-57d03e4a4944", "e9214cd6-3a76-4cd8-b9f0-1e49700962be", "da05d41d-7761-4d5b-8fd9-2407b9092965", "c16f6286-99e9-40b3-b157-8d6e02d669e6", "6b262596-f3cc-44de-b5a4-c4cdd259fd12", "2bb6065a-5c20-4e7a-8013-4b6d7b0918c3", "aaef2100-d5e8-4a88-aeaa-0d7503e7e893", "c82f30f4-029f-4f2a-97b1-c0a0aca3f28b", "6b9b9412-ed80-4455-8a11-6fd488722be6", "e6305d82-fb57-4fca-913c-26f1f329facc", "27da4eb7-8d09-4b69-9f98-4cb49f5d81ed", "855fce69-9f9b-4b87-8f22-bb71f888b672", "796b37cd-a13b-486d-987a-40049924455a", "35a89eba-2dfd-4110-b0ef-7845f6ba0f61", "ee7dbf60-d60b-4800-952b-d9bc924d486c", "00a71c21-791f-4fa1-abcb-a23b5970155b"], "metadata": {"window": " \nPage 12 of 15 \n \nin many cases, these are contract s that we have that could be multi -year contracts in place at a fixed  \nprice because this is an industry that has historically not seen large fluctuations in pricing.  It's been  \nrelatively stable.  And while you might see little things here and there, it's generally been very stable.  \n And so the industry itself has been comfortable with doing longer -term pricing. ", "original_text": " \nPage 12 of 15 \n \nin many cases, these are contract s that we have that could be multi -year contracts in place at a fixed  \nprice because this is an industry that has historically not seen large fluctuations in pricing. ", "page_label": "12", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "58aefad8-f2a3-4bad-804a-f2885a3994e3": {"node_ids": ["3c0f73d2-5d4b-421d-a4c0-b2ab5dd655bf", "82a2e5d0-e492-46b3-8e09-9f7df68ca6f7", "721499a8-c4bb-4821-a8b5-060c304e1ee6", "437f6b5b-7b91-4bee-8883-8de77746dbe0", "07fb69c7-3fbe-4efc-ae07-b2010e1f885f", "934625fd-e2b6-4ef9-aa3d-0bf9abf561ea", "4fea0aa6-4535-4fd1-ad97-23b57619caed", "44c6db32-064e-4818-bb97-c2bb84d410e5", "863883b1-d8ab-434a-bc0d-c04c1944938d", "87d496a4-73de-41c3-ad5f-393b0e94618e", "28d79f79-679f-496b-95e8-27a1243627c1", "b8a5a574-56f3-425f-beed-b9d7750b1c61", "af69265f-7886-44ae-98cd-06406f64e047", "9ea89404-d666-4e4d-bcb2-78e05d889cc4", "16ee4255-f258-4e86-9e6c-1048b1bc4ef8", "d348abb1-17c8-47ae-9150-18fbf62cac25", "db75b57b-670b-40cd-a999-977b88e9847e", "d74d8217-0cb5-4a98-830f-198ee0743782", "32847608-19b9-4c6c-bcc7-7467598e8a7e", "adf41752-492e-40cd-afcb-7cd544d3b158", "656c68e4-a18a-48df-8f11-f89d85a85db0", "143de87e-a893-4176-85d5-56f810b17fab", "87361018-e2ae-4dd4-b667-2bae84a6cc05", "6801ae34-2977-4d38-8e6f-f107d6d4266e", "b01a0787-25be-44ae-94d5-4bdb2775cbe2", "cf6885d8-60c0-4982-bfd7-aa1d65bf8c58", "a1298b38-9c8b-4dc3-9eff-e3afdf857a39", "51eecc6b-cf36-4593-b38d-62035e2cf69e", "96887420-92f5-4f1f-b796-5f9979ab4b04", "9aabf0f2-ba8e-4ddf-933a-6c55cdda28b1", "793a7ab4-a513-49ef-bef4-81fede520f3f"], "metadata": {"window": " \nPage 13 of 15 \n \none will begin getting away from because trying to measure something that's now over two years old  \nwith lots of puts and takes, with new items and changes in the marketplace and everything else, it's a  \nlittle hard to compare to something that old at this point in time.  But roughly what we would say is that,  \nelective procedures in Q3 were pretty similar to the prior couple quarters, prior to and similar levels to  \npre-COVID.  We expect about the same for Q4 and I'm n ot really expecting any differences in \u201823 as far  \nas that goes, in either direction.  We're not expecting that there's a big buildup of unmet needs that are  \ngoing to fly through the system or vice versa, that we should see a significant reduction. ", "original_text": " \nPage 13 of 15 \n \none will begin getting away from because trying to measure something that's now over two years old  \nwith lots of puts and takes, with new items and changes in the marketplace and everything else, it's a  \nlittle hard to compare to something that old at this point in time. ", "page_label": "13", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "07467b81-a385-40ce-865c-1281c22c7ed9": {"node_ids": ["9a5f2ba4-a678-4817-acbb-4dd3ff8b9364", "442d079a-2e6b-4731-b6a9-ac5607abda61", "2d56e92c-98b7-44d8-83c3-c3cf236b6039", "1db6e7a1-4380-4dcb-87b1-1a7b067e91dd", "94c3485a-13c9-4f92-9b6a-d8cd9d71b00d", "811710f1-b05f-4d35-abe9-ca83f74fd84b", "2cbb92bc-cf50-446a-8b2d-c2aa3a9f16ee", "c116be60-f15d-496e-b76b-48dcf4cef8c7", "d0580d91-704e-4759-bea4-1f5cbd965f4a", "ad8b0370-7c56-4b37-8c07-3419d06e6205", "593cea8b-f41c-4ec3-9a3b-44010276ed8a", "d9be4c9c-8421-45b6-99a6-eb692447201f", "d7d34932-b0a4-4656-bf48-db8ca75a6f97", "6939d3d9-7705-4f6e-ae8c-92369a2a6acf", "b43def59-fdf1-4091-a164-b05fb9f6eb5d", "0d4b560e-e18c-44ec-8574-093c6c2a6aee", "0e70791f-ee81-4331-b40c-d70c8a22b029", "cd3ab46d-54aa-4e93-a6f0-f1f241987777", "76d5da46-b5fa-4ca8-bce5-63b15f3fb34a", "d8f1d635-b6c4-4eb0-a5a0-11e330ed81b6", "fd52d384-e2c4-412e-bbc8-c19b25d62f30", "4913d96b-672d-41a9-bcfb-64eeb38f24a5", "00083dde-1a5f-426f-b153-b49282ca6951", "d63346f3-bb59-47b7-a8ce-ded0cf34de57", "c87ac53c-2231-4a9b-ab0f-ab95f369f826", "a5a57089-cfd5-457b-800a-04276e053934", "d2fae4ae-05ba-4f7c-8eb0-fa9a47a4a959", "f86fc617-1ac9-4fcb-b592-ba3ae0633edc", "ec2c8eac-8411-4f09-b94b-69f0ca2ef4cd", "c254e113-87de-498f-861e-17f7c3106dca", "27978bcd-0b9f-48c6-a2d7-62be469cd07c", "be8114fe-de8c-4433-89a9-b8b00e0de633", "eccb05c3-d33f-41ce-ada7-3b3c56cb6e03", "3bfbe80b-5806-4d72-904e-448169c29c92", "6e9997a7-6edc-4265-8aa8-277aae55c8dd", "79cd3ce9-2908-4f07-9266-80e5acae4b10", "739feb68-c286-4659-8b8b-a5ecdc4a3a53", "cc15d501-22ba-4320-8a99-acf7243b1a7f", "dc3de07f-9b7b-4e6d-9454-3741877b84c9"], "metadata": {"window": " \nPage 14 of 15 \n \nabout the offset that will come from pricing - your price increases - offsetting about 50% by the end of  \nnext year of fiscal year, are there any other things that are meanin gful that could be impactful?  I don't  \nknow, diversification of sourcing, maybe toggling back and forth in the Cardinal branded products,  \nanything else beyond just pushing for price increases, or do we are we basically waiting for the  \nbackdrop to improve  from a macro perspective?  \n \n Mike Kaufmann:  Yeah.  We've not given any actual mixed percentages in terms of how much of our  \nvolume is Cardinal Health Brand versus others, so I can't do that at this point in time. ", "original_text": " \nPage 14 of 15 \n \nabout the offset that will come from pricing - your price increases - offsetting about 50% by the end of  \nnext year of fiscal year, are there any other things that are meanin gful that could be impactful? ", "page_label": "14", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}, "0016ba3c-64f8-480e-89b1-1957d84d5ab5": {"node_ids": ["504e1e25-b638-4473-b2a4-6df478d4e05c", "1b75414c-ffee-4af9-8215-d8aa4fa7f13b", "1ba49b06-122f-481e-a499-d3ae09d2f471", "73ce99ae-5525-43f6-9526-8d103a2242d4", "3044b4f5-7349-4061-bb6f-a62290445e94", "c19c99ec-e97e-4512-8c0e-40068799dbdf", "43cf1f18-edca-4e2e-8d49-eeb03ebbce0a", "4cb3e197-955c-4cc6-aa1a-b1b836f22f3a", "54c99caa-5e52-4e81-b341-574bd7c7ef6f", "98f03308-dfdc-4677-83cd-faf9d322b65b", "5ea66318-3fce-430f-8f38-b347a110c6c6", "be5e9152-5190-459d-a7eb-8ea5f33fe0c3", "19cc2716-0083-4fba-8f31-5dfdc9a1164c", "b7557406-3fbf-47c7-a63d-90aa8a4b1009", "21a183ff-ca27-449c-be30-ce76b303bd75", "791099eb-8060-46a7-beda-d8431690904d", "5c8a48d7-cbd4-471c-afb1-ed0e22de9ada", "38653f16-ddce-407e-9211-bca9fc05f67f", "0e2f1a72-b851-44fa-a066-5fb5736ad550", "7e296d52-dfb1-415c-8aa4-5a85699ff492", "5ec97ce9-759f-4eb0-98f8-dd36613be68a", "332b0114-0663-4132-9489-08300dc3c45e", "4a6ca281-b8d2-4120-a6aa-d2e01f09fffd", "be7bbb75-0a7e-4386-bd40-e3a9df0468c7", "55700999-b378-45bb-b0ad-aa59e9de21ef", "93d77495-ad52-4911-82b2-a4bad65eabb0", "587d1171-fdce-4b74-b67b-1a96aa32e253", "6d498ba6-4ab0-4859-b2ca-7d1df145505e", "38d1fbef-1c90-4886-a365-88d09192d167", "069e58af-170f-48f2-9cab-dd8ad7e426ec", "845125e8-769d-4894-bea5-fee9378209e8", "84a1be93-b8c4-4ec6-8b0f-0ff08c293b57"], "metadata": {"window": " \nPage 15 of 15 \n \nover the first three quarters related to the IT enhancements.  And then we have had some incremental  \nvolume through, we referenced some  net new customer volume within the Pharma business that started  \nto ramp up in the third quarter and is more significant in the fourth quarter, and those would be the most  \nsignificant items that drive that year over year.  \n  \n Operator:   And we'll go ahead  and take our next question from Steven Valiquette with Barclays.  \n Steven  Valiquette:   Great . ", "original_text": " \nPage 15 of 15 \n \nover the first three quarters related to the IT enhancements. ", "page_label": "15", "file_name": "CAH-Q3-FY22-ECT.pdf", "file_path": "pdfs\\CAH-Q3-FY22-ECT.pdf", "file_type": "application/pdf", "file_size": 200256, "creation_date": "2024-07-16", "last_modified_date": "2024-07-16"}}}}